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Preface 
The perioperative period is vitally important in outcomes of patients undergoing 
cardiac surgery. The proper evaluation of preoperative period, as well as 
improvement in standards of perioperative care of these patients have been helping 
to reduce mortality and morbidity rates following the cardiac surgery. Accordingly, 
the content of present textbook mainly covers various topics related to perioperative 
period in cardiac surgery. In order to organize the content, two books have been 
created. The first book focuses on topics both in preoperative and early 
postoperative periods of cardiac surgery. The book covers not only classical chapters 
such as anesthesia for pediatric heart surgery and management of pulmonary 
hypertension in intensive care unit, but also currently “hot” topics consisting of 
strategies of blood conversation and heparin induced thrombocytopenia. The second 
book covers miscellaneous issues such as fungal endocarditis after cardiac surgery, 
off pump versus on pump coronary artery bypass surgery and arrhythmia after 
cardiac surgery.  
This book should prove to be a useful reference for trainees, senior surgeons and 
nurses in cardiac surgery, as well as anesthesiologists, perfusionists, and all the related 
health care workers who are involved in taking care of patients with heart disease 
which require surgical therapy.  
This book aims to improve the knowledge and understanding of readers with regard 
to the background of perioperative period in cardiac surgery.  
I hope these internationally cumulative and diligent efforts will provide patients 
undergoing cardiac surgery with meticulous perioperative care methods. 
Numerous international authors have participated in the creation of this book. I have 
compiled their valuable experiences and contributions about critical issues in the field 
of cardiac surgery. 
I greatly acknowledge the precious assistance of Ms. Molly Kaliman of InTech 
Publisher. I also would like to thank Ilker Kiris, MD, for his productive ideas in the 
course of preparing this book. 
X Preface 
 
Finally, upcoming decades should see even greater advances in the field of care of 
patients undergoing cardiac surgery. I assure that improvements in technologies and 
surgical skills will help to accomplish this goal.  
To my wife, Gokce and to our children, Kaya and Kayra. 
 
Assoc. Prof. Cuneyt Narin, MD 
Department of Cardiovascular Surgery, 
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Intensive Care Management of Patients  
in the First 24 Hours After Cardiac Surgery 
Villalobos J. A. Silva, Aguirre J. Sanchez, Martinez J. Sanchez,  
Franco J. Granillo and Garcia T. Zenón 
Universidad Nacional Autónoma de México (UNAM), Tamaulipas 
México 
1. Introduction 
The cardiac surgery continues having a fundamental roll in the therapeutic arsenal of many 
heart deseases in spite of the spectacular advances that determined drugs or different forms 
of interventionist cardiology have experimented during the past few years. The present 
impact of the heart surgery is due to the constant increase of the cardiovascular risk factors, 
related to the increase in the life expectancy in last the three decades, the clinical approach of 
the ischemic cardiopathy towards the repair has taken to the creation and development of 
techniques and methods at the moment used in the miocardic revascularization surgery; the 
roll of the coronary surgery initiated by Sabiston in 1962 and popularized by Favaloro in 
1967 has had an exponential development with the purpose of to exclude the ill part from 
the artery by placing a bypass to improve the perfusion of the ischemic area. Nevertheless 
the other side of the balance is the pharmacological treatment whose objective is to look for 
the balance between the supply and demands in the ischemic scope at the expense of a 
smaller consumption of oxygen (VO2), diminution of the inflammatory local metabolism, 
control of trombotics phenomena, etc. Now on the basis of the knowledge and acquired 
experience we establish a margin of durability of 90% to 10years in grafts of internal 
mammary  (AMI) and 50-60% of venous grafts (HV), depending on the vascularized area 
and the type of vein, in relation to the arterial grafts the average life is of 90% to 5 years with 
sufficient information of early stenosis problems. Most of the post-operated patients recover 
in a fast and complete form, which depends on the quality of the performed surgery and an 
opportune and suitable handling as all the symptoms of the organism recover of the effects 
of: anesthesia, cardiopulmonary derivation (CEC) and surgical stress. Nevertheless some 
patients who present combinations of indicators of preoperative risk like: age outpost, 
antecedents of miocardic revascularization, recent and acute miocardic heart attack (IAM), 
ejection fraction (EF) low or diabetes, have a much greater surgical risk to the one of the 
habitual patient. At the moment there are certain characteristics that have determined a fast 
recovery as they are the early extubation, to avoid major sedation, the disconnection of the 
support devices and the suspension of drugs as rapidly as possible. A fast treatment before 
a: Low cardiac cost, alteration of the pulmonary function, hemorrhages, coagulopathy and 
fever is essential to be able to obtain a fast recovery of the patients; at the moment the 
surgical indications of the miocardiac revascularization (RVM) have been based in relation 
to the number and degree of affectation of the coronary arteries, decreased ventricular 
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function and more and more by the increase of percutaneous interventions there are patients 
with greater risk and worse diagnosis which has modified the results in the last years, as 
well as a reduction in the number of surgeries per year. Mortality in Europe and the United 
States is lower than 2,5% with a survival that oscillates respectively between 97-80% of 1 
to15 years. Its reduction increased as of the eighth year, is in relation to the average life of 
the grafts, its occlusion, progression of the disease and development of its comorbidities. 1,2,3. 
2. Preoperative surgical risk  
From the antiquity, man has tried to anticipate or predict the facts to come, that is to say the 
prediction of the results in cardiovascular surgery has been and continues being a goal. The 
stratification of the patients in different risk levels, previous to the accomplishment of a 
cardiovascular surgery has diverse intentions, among them the clinical decision making 
with respect to the accomplishment or not of the surgical procedure or the derivation of the 
patient for another type of treatment. It is necessary to establish preoperative conducts that 
can reduce the risk to cost-effectiveness, to establish the stratification of the risk sometimes 
is difficult, being implicit some factors of individual risk that can be interpreted of different 
way and has like objectives:  
1. Identification of patients of high risk with critical allocation, to adapt the perioperatory 
problems.  
2. To diminish the morbidity and mortality, establishing strategies of preoperative, 
intraoperating and post-operative treatment.  
3. It is indispensable to know the heart disease suitably. (Physiopathology, diagnosis, 
treatment, and perioperatory complications).  
4. A suitable evaluation and treatment of the cardiopathy surgical patient, requires a team 
work and communication between: patient-surgeon, cardiologist and intensivist.  
5. Several factors are known that modify the individual risk as they are the age, the sort, 
previous the cardiovascular function, the renal diseases and you will tilt, respiratory 
function and other related factors. 
John and collaborators established 7 fundamental criteria like and 13 important criteria 
which are an influence in the morbi-mortality of the post operated patient. (CHART 1) 
Age 
Every time it is more frequent than patients with age greater to 60 years, are admitted. The 
cardiovascular risk is increased by above of 65 years by the presence of his comorbidities, 
age outpost with cardiac symptoms and a key point is the selection of this type of patients, 
since with this secondary mortality to the surgery is determined. In these patients it is 
frequent the existence of important complications as they are the low cardiac cost, acute 
myocardial infarct of the perioperatory, surgical re-intervention by bleeding, acute renal 
insufficiency, pneumonia, prolonged ventilation, all these increase to the percentage of 
complications and mortality.  
Gender 
Many studies exist that have determined that the woman has a greater risk of mortality after 
the coronary revascularization; because they have minor corporal surface and the size of the 
coronary glasses is smaller. As far as the sort it does not seem to be predictive of mortality in 
valvular procedures, mitral and aortic.  
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Predictors of post-CABG mortality 
Age  
Sex  
Urgency of operation  
Prior heart surgery  
LVEF  
Percent stenosis of LM coronary artery  




PCI during current admission  
Date of most recent MI  











Is the most important aspect of perioperative mortality, the important factors are: severe 
valvular disease, reoperation, left ventricular function, infarct to the myocardium previous, 
cardiac insufficiency, emergency surgery and upheavals of the rate.  
Respiratory function 
The pulmonary disease chronicle is a risk factor to prolong the mechanical ventilation, to 
have a more difficult weaning, and associated to the pulmonary arterial hypertension, its 
extubation requires major care.  
Mortality 
The explanation of the diminution in mortality has been the present methods of myocardic 
protection with retrograde cardioplegia, hypothermia since the ischemia diminishes 
triphosphate of adenosine (ATP), altered sanguineous flow, calcium overload, reduction of 
intracellular calcium sensitivity, sarcoplasmatic dysfunction and the presence of free oxygen 
radicals. The morbidity and mortality fall significantly in spite of being increased the risk 
factors, the tendency of the secondary complications of comorbid sufferings have increased 
until in 30-40%.  
The preoperative cardiovascular evaluation provides recommendations for stratification 
with risk and handling of proposals by the American College of Physicians: Medical history, 
clinical exploration, ECG, X-ray of thorax, laboratories, tests ECG to the exercise, 
ambulatory monitoring (Holter), ventriculography to radio nuclear, heart ultrasound, 
coronary angiography, thallium scintiscanning. 4.5.6.7.8.9 (CHART 2)  
In resistance to indices of multi-factor risk, the functional classification New York Heart 
Association (NYHA) and the American Society of Anesthesiology (HANDLE) are used of 
routine by the anesthesiologist. Nevertheless, these classifications do not designate a 
predicting result after the surgery reason why its predictive ability in operating room is 
limited. 
ASA 
Healthy patient, with a process located without systemic affection.  
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PREOPERATIVE EVALUATION OF CARDIAC SURGERY 
History 
1. History of bleeding: Use of antiplatelet and anticoagulant medication. 
2. Smoking (COPD, bronchospasm). 
3. Alcoholism (cirrhosis) 
4. Diabetes (reactions to protamine, prior infection) 
5. Neurological symptoms. 
6. Venous insufficiency. 
7. Distal vascular reconstruction. 
8. Urologic symptoms. 
9. Gastric ulcer or gastrointestinal bleeding. 
10. Infections (Urol) 
11. Allergies 
Physical Examination. 
1. Skin infection / rash. 
2. Dental Caries (dental) 
3. Vascular examination (carotid, abdominal aneurysm and peripheral pulses) 
4. Heart / Lung (congestive heart failure, new murmur). 
5. Varicose veins. 
Laboratories 
1. Hematologic: PT, PTT, platelets, Hb, Time Ivy. 
2. Chemistry: Electrolytes, BUN, QS, PFHS. 
3. Urinalysis. 
4. Chest X-ray AP and lateral. 
5. Electrocradiogram. 
Chart 2. 
Patient with slight systemic disease.  
Patient with serious, but non incapacitated systemic disease.  
Patient with serious and incapacitated systemic disease, that constitutes a constant threat for 
the life.  
Dying patient, whose life expectancy does not exceed the 24 hours, is realized or not it to his 
surgery.  
NYHA  
Patient with heart disease, without limitations of physical activity.  
Patient with disease, with slight limitation ofordinary physical activity, fatigue, palpitations, 
designs or angina pain.  
Patient with heart disease, with noticeable limitation of physical activity, less than the 
ordinary physical activity, cause tires, palpitations design or pain angina.  
Patient with heart disease, incapacity to walk and physical activity, symptoms of cardiac 
insufficiency, angina.  
There are over 100 studies of perioperatory risk-prognosis stratification that have tried to 
identify adverse predictive factors, the greater limitation of these studies is that they were 
realized in a single institution, small groups, or the cardiac experience of the 
anesthesiologistwas the one taken into account. Between the preoperative risk-prognosis 
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classifying stratification, transoperatory and post-operative factor risks are the following 
scales: Parsonnet, Tumman, Higgins, Tu, Hannan, Connor, Cleveland Clinic, EuroSCORE, 
Ontario Provincial Risk (OPR) among others, which vary in predicting correlation of risk of 
morbidity and mortality in relation to distribution of patients by risk, the average one 
hoped, and the averageobservada.10, 11.12.13 (Chart 3) 
3. Stratification of risk using data base 
The basic information of data is used to improve the clinical practice producing reports with 
validity and application, evaluating the results, optimizing and improving the cares of the 
patient, the high mortality is identified in a small and specific sub-group classified like of 
high risk. The obtained results are used to change institutional programs diminishing 
mortality in patients of high risk like of smaller risk, mainly in patient put under coronary 
revascularization diminishing the mortality from 4,5% to 1,5%.  
The European for System Cardiac Operative Risk Evaluation (EuroSCORE) is a predicting 
logistic model of hospitable mortality in patients submissive cardiac intervention, starting 
off of 18 variables of risk and with a coefficient beta associated to each of them, it provides 
the probability of dying of each individual, this model was created and validated initially in 
across-sectional study of 19,030 European patients in 1999, and it has become, since then, in 
the used model more in the world in this type of patients. Most of the authors agree in 
raising that the Euroscore is a system simple additive that it provides to facultative a tool of 
easy handling to consider the death risk. A variant of the much more simple logistic model, 
denominated Euroscore additive, that awards a weight determined to each factor of risk that 
presents the patient, the sum of these weights exists provides the approximated probability 
to die. 
The interesting exercise to compare logistic Euroscore with additive already has been 
realized, but in fact it contributes certain confusion, and the conclusions that are obtained 
are understood easily observing. 
The preoperative surgical risk models are made on the basis of cardiac surgery using 
cardiopulmonary bypass (CPB). However, it can be applied to off-pump cardiac surgery, as 
evidenced by Vazquez Roque, in a study in 208 patients undergoing bypass surgery without 
cardiopulmonary bypass and found that the mean EuroSCORE was significantly higher in 
patients who died. When comparing patients with and without major complications can see 
that the mean EuroSCORE was also significantly higher in patients with major 
complications. 
Without fatal perioperative morbidity results in an increase of stay in postoperative care 
unit and overall hospital stay, this increases resource consumption and costs per patient. 
The EuroSCORE proved to have a discriminating power and acceptable calibration in 
predicting these events, we can say that Euroscore, despite being designed a risk score based 
on patients who underwent cardiac surgery using CPB may be used to predict the risk of 
death and major complications in patients who are going to be revascularized without the 
use of cardiopulmonary bypass. This is a novel technique that still suffers from risk scores 
based on the preoperative characteristics of their own patients. The study uses databases 
Euroscore retrospective studies, to provide predictive models of morbidity, mortality and 
prolonged stay in the postoperative intensive care unit, which can be used to improve the 
quality of postoperative care in different institutions is a tool to categorize patients for 
cardiac surgery in several subgroups.  
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quality of postoperative care in different institutions is a tool to categorize patients for 
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Risk factors Punctuation 
Female sex 1 
Morbid obesity 3 
Hypertension (p. s.> 140 mmHg) 3 
EJECTION FRACTION  
Good> 50% 0 
Moderate 30-49% 2 
Poor <30% 4 
age years  
70-74  7 
75-79 12 
>80  20 
Reoperation  
Primary 5 
Secundary  10 
Preoperative BIAC 2 
Left Ventricular Aneurysm 5 
Emergency surgery and angioplasty 10 
Dialysis 10 
Catastrophic States 10-50 
Mitral valve surgery 5 
PAP > 60mmHg 8 
Aórtic 5 
Gradient > 120 mmHg  7 
Revascularization + Valve Surgery 2 
Chart 3. 
Due to differences in adult cardiac surgery in the countries of Europe the EuroSCORE is 
responsible for assessing the quality of surgical care, the analysis is performed for each 
individual to individual and predicting mortality among the countries of the study is were: 
Germany, England, Spain, Finland, France and Italy. The EuroSCORE model was 
satisfactory in all countries with a p <0.05, despite epidemiological differences between 
European countries the discriminative power of EuroSCORE was good in Spain and in other 
countries excellent. 14, 15,16,17, 18,19,20. 
4. Cardiac risk evaluation of anesthetic (CARE) 
The scale used most recently is called Cardiac Anesthesia Risk Evaluation Score (CARE), 
prospective studies in cardiac surgery demonstrated a significant number of prognostic 
information was obtained from only a few clinical variables or clinical trial, were validated 
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and compared with 3.548 patients with Parsonet, Tuman, and Tu, the CARE is a simple risk 
classification predicts morbidity and mortality on a scale which means ordinary CARE1 low 
risk, high risk means CARE5 and Care 2-4 as intermediate risk, based on clinical trial 
recognized three variables: 21.22  
Scale of anesthetic Cardiac Risk Assessment (CARE). 
 Heart disease stable without other medical problems, surgery scheduled for a low 
surgical risk. 
 stable heart disease with one or more controlled medical problems, set to a low-risk 
surgery. 
 uncontrolled medical problem, or patient scheduled for surgery high risk. 
 uncontrolled medical problem, scheduled for surgery high risk. 
 advanced or chronic heart disease, scheduled for cardiac surgery that delayed it can 
complicate or improve their lives. 
Cardiopulmonary bypass (CBP) 
On-pump bypass also known as cardiopulmonary bypass is a method used in coronary 
bypass surgery, this device has been used in cardiac surgery since 1960, due to the high 
incidence of perioperative mortality due to low spending, it is increasingly used in the last 
decade, increasing its survival up to 60%. Cardiac surgery and cardiopulmonary bypass 
activate the inflammatory response, characterized by cardiovascular and pulmonary 
disorders, this inflammatory response that occurs during cardiac surgery is presented by 
three processes: 
 Contact of blood with the cardiopulmonary bypass machine. 
 Development of ischemia and reperfusion injury. 
 Release of endotoxins. 
The extent and duration of the inflammatory response depend on many factors including 
the composition of the solution pump, the presence of pulsatile perfusion, pharmacological 
agents used to reduce the response, the use of mechanical filtration, the type of 
extracorporeal circuit and temperature during cardiopulmonary bypass. During CPB flow 
decreased splenic occurs, which induces the crossing of endotoxins by the lumen, activating 
the inflammatory response, endotoxins are potent initiators of the inflammatory cascade, 
which in turn causes production of cytokines and complement activation.  
A frequent complication of systemic inflammatory response is the evolution to multiple 
organ failure (MOF) including respiratory failure, shock and renal failure, development of 
FOM is the most important determinant for the postoperative increases those patients who 
have risk factors such as prolonged mechanical ventilation (intubation ≥ 48 hours), increased 
volumes of lower urinary nitrogenous and persistence of vasopressors, resulting in an 
increase in mortality to 41%. The inflammatory response and also condition FOM 
phenomena of hemolysis, thrombocytopenia and leukopenia, in the first 24 hours of the end 
of cardiopulmonary bypass can be seen that the total count of leukocytes undergoes an 
increase with significant changes in the differential count, the leukocytosis persisted in 72 
hours, in the differential count reports a significant increase in neutrophils and monocytes 
and decreased lymphocyte counts during the first days. Postoperative fever in the second 
and third day in patients undergoing cardiac surgery is accompanied by an increase in 
neutrophils, two times the initial value during cardiopulmonary bypass activation of 
neutrophils is manifested by leukocyte sequestration in the pulmonary circulation at the 
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classification predicts morbidity and mortality on a scale which means ordinary CARE1 low 
risk, high risk means CARE5 and Care 2-4 as intermediate risk, based on clinical trial 
recognized three variables: 21.22  
Scale of anesthetic Cardiac Risk Assessment (CARE). 
 Heart disease stable without other medical problems, surgery scheduled for a low 
surgical risk. 
 stable heart disease with one or more controlled medical problems, set to a low-risk 
surgery. 
 uncontrolled medical problem, or patient scheduled for surgery high risk. 
 uncontrolled medical problem, scheduled for surgery high risk. 
 advanced or chronic heart disease, scheduled for cardiac surgery that delayed it can 
complicate or improve their lives. 
Cardiopulmonary bypass (CBP) 
On-pump bypass also known as cardiopulmonary bypass is a method used in coronary 
bypass surgery, this device has been used in cardiac surgery since 1960, due to the high 
incidence of perioperative mortality due to low spending, it is increasingly used in the last 
decade, increasing its survival up to 60%. Cardiac surgery and cardiopulmonary bypass 
activate the inflammatory response, characterized by cardiovascular and pulmonary 
disorders, this inflammatory response that occurs during cardiac surgery is presented by 
three processes: 
 Contact of blood with the cardiopulmonary bypass machine. 
 Development of ischemia and reperfusion injury. 
 Release of endotoxins. 
The extent and duration of the inflammatory response depend on many factors including 
the composition of the solution pump, the presence of pulsatile perfusion, pharmacological 
agents used to reduce the response, the use of mechanical filtration, the type of 
extracorporeal circuit and temperature during cardiopulmonary bypass. During CPB flow 
decreased splenic occurs, which induces the crossing of endotoxins by the lumen, activating 
the inflammatory response, endotoxins are potent initiators of the inflammatory cascade, 
which in turn causes production of cytokines and complement activation.  
A frequent complication of systemic inflammatory response is the evolution to multiple 
organ failure (MOF) including respiratory failure, shock and renal failure, development of 
FOM is the most important determinant for the postoperative increases those patients who 
have risk factors such as prolonged mechanical ventilation (intubation ≥ 48 hours), increased 
volumes of lower urinary nitrogenous and persistence of vasopressors, resulting in an 
increase in mortality to 41%. The inflammatory response and also condition FOM 
phenomena of hemolysis, thrombocytopenia and leukopenia, in the first 24 hours of the end 
of cardiopulmonary bypass can be seen that the total count of leukocytes undergoes an 
increase with significant changes in the differential count, the leukocytosis persisted in 72 
hours, in the differential count reports a significant increase in neutrophils and monocytes 
and decreased lymphocyte counts during the first days. Postoperative fever in the second 
and third day in patients undergoing cardiac surgery is accompanied by an increase in 
neutrophils, two times the initial value during cardiopulmonary bypass activation of 
neutrophils is manifested by leukocyte sequestration in the pulmonary circulation at the 
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time of reperfusion of the vascular bed can lead to endothelial and parenchymal injury, in 
immunocompromised patients and prolonged intubation favors the development of 
infections. Neutrophils represent the most significant source of oxygen free radicals, which 
is associated with myocardial dysfunction and pulmonar.23, 24,25,26,27. 
The CBP decreased flow causes splenic bacterial translocation which conditions, these cross 
the intestinal lumen and activate the inflammatory response have different degrees of 
hemodynamic compromise, noting in addition sequential elevations of endotoxin followed 
by elevations in levels of cytokines and these correlate the degree of myocardial 
dysfunction. Endotoxins are potent initiators of the inflammatory cascade causing cytokine 
production, production and complement activation, their presence is associated with the 
development of lactic acidosis, decreased peripheral vascular resistance and left ventricular 
dysfunction. The cardiovascular effects of cytokines are mediated by nitric oxide which 
involves interaction between leukocytes and endothelium and the mechanisms that cause 
these effects are the presence of circulating endotoxin, lipopolysaccharide (LPS) of gram-
negative bacterial cell wall that interact with host cells to promote the release of mediators, 
lipopolysaccharide increases because the immune response by binding to protein carriers of 
LPS forms a complex that is a thousand times more potent to induce the release of tumor 
necrosis factor (TNF) and the union lipopolysaccharide occurs between the CD14 receptor of 
macrophages is that the activation of kinases and TNF. The inflammatory response can be 
maintained by several factors including the production of cytokines such as TNF-alpha (α), 
interleukin 1 (IL-1), IL-1 (beta), interleukin 2 (IL-2), interleukin 6 ( IL-6), interleukin 8 (IL-8), 
interleukin 10 (IL-10), interferon and colony stimulating factors, which may be related to 
postoperative complications. The release of cytokines produce clinical manifestations in 
patients with cardiopulmonary bypass, such as fever, altered level of consciousness that 
occurs microembolisms due to encephalopathy. The crystalloid solutions used to prime the 
pump bypass hemodilution while causing turbulence and osmotic pressure during 
cardiopulmonary bypass cause lesions in the cell membrane of erythrocytes and hemolysis 
eventually causing mainly postoperative bleeding and coagulopathy platelet dysfunction. It 
is possible that renal failure during cardiopulmonary bypass is due to changes in renal 
perfusion during periods of hypotension or, for low blood flow, vasoconstriction and 
microembolism, likewise, hemoglobinuria may also cause significant renal dysfunction as a 
result of hemolysis during CPB, cardiopulmonary bypass can also cause susceptibility to 
infections, Sabick et al found that deep sternal infection occurs in 2% in patients undergoing 
extracorporeal pump versus 0.2% in off-pump patients (p <0.04).28 
Intra aortic balloon counterpulsation (BIAC) 
The intra-aortic balloon counterpulsation is the method used in the treatment of severe 
cardiac dysfunction and potentially reversible in the perioperative and postoperative 
cardiac surgery is indicated in the shock associated with myocardial infarction or other 
complications intractable cardiac ischemia, with or without infarction, ventricular failure 
post CPB, and so on. 
There are two main effects of this device, the first is to increase coronary blood flow 
improved myocardial oxygen availability by increasing diastolic perfusion pressure and the 
second is the blood moves during balloon inflation reduces ventricular work by reducing 
afterload with rapid deflation in systole and thus decreasing myocardial oxygen demand, 
this increases the heart rate up to 20%, thus the signs associated with BIAC surgical 
procedure are: 
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Low cardiac output syndrome, perioperative 
As a bridge to cardiac transplantation 
Acute mitral insufficiency 
Perioperative arrhythmias are difficult to control 
Christeson, showed that the use of preoperative IABP reduced hospital costs and length of 
stay in revascularized and reoperation, Dietl, also reported a stay of 10 days vs. 12 days in 
those with BIAC those who did not have it at a cost average hospital stay of $ 4000 per 
paciente. Although minor complications associated with IABP placement has been 
estimated at 6.5% and higher (vascular surgery and requiring transfusion) of 2.1% is greater 
than the benefit conferred on all preoperative placement to reduce mortality significantly vs 
to who are placed in the postoperative period (mortality 8.8% vs 28.2%, p <0.0001) in 
conclusion, the use of BIAC has increased over the past 10 years, significantly as evidenced 
by the record made in 29, 961 patients England and Canada, where the increase in aortic 
counterpulsation in cardiac surgery in the last 6 years is 47%. 29.30. 
Initial assessment and aost-aurgical therapy (TiPQ) 
There should be a systematic evaluation of the patient immediately on arrival to 
postoperative intensive care unit (TiPQ), communication with the surgical team and 
anesthesia should provide an overview of the intervention performed and the response of 
the cardiovascular system and perioperative hemodynamic treatment and handling of 
medication. Although initially it may focus attention on an aspect of patient status (eg, 
existing arrhythmia on arrival), it is essential to develop a systematic approach to 
evaluation. The patient is fully independent and dysfunction of the elements of support 
systems can be fatal quickly. Surgical dressings must be kept intact during the first 24 
hours in order to control the infection. If handling is necessary for diagnostic purposes 
must follow a strict technique. Upon transfer, the patient should continue with the 
pharmacological management started in the operating room and continued monitoring 
that includes at least fan movement, Electrocardiography digital, non-invasive blood 
pressure (PBIN) and pulse oximetry (SO2). Upon arrival to the ICU should be 
corroborated electrocardiographic tracing displayed on the monitor and make an 
immediate transfer line 12-lead ECG or chest circle when necessary. Capnography 
(PECO2) and central venous pressure (CVP) are measures that must be reactivated 
immediately, it also calibrates the transducer invasive blood pressure monitor confirms 
his bed and his blood pressure is checked immediately after the pacemaker (MCP ) 
epicardial and functionality, if the patient arrives with pulmonary catheter also must be 
calibrated immediately and make a hemodynamic profile to assess their cardiovascular 
status at the time and determine current therapeutic recommendations behaviors common 
pulmonary catheter placement are EF <40%, patients with combined valve implantation 
(aortic-mitral) or severe acute heart failure diagnostic doubt its hemodynamic profile. It is 
important to immediately verify the patency of chest tubes and immediately upon arrival 
quantify pleural drainage at 15, 45 minutes and hourly for the first 24 hours, and assess 
their macroscopic features and clot formation. The ventilatory parameters must be set in 
the next 5 minutes upon arrival and assess the degree of de-recruitment and the need for 
alveolar opening Pa02/Fi02 if their relation ship is less than 200 mm Hg and if their 
hemodynamic status is not compromised, the monitoring hypothermia and its 
management is immediate. During the first 15 minutes should be evaluated central 
venous saturation (SvO 2), arterial blood gases, acid-base status, serum electrolytes (ABG) 
and serum examinations required, such as hemoglobin, platelets, hematocrit, serum 
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electrolytes, coagulation, time Ivy, myocardial enzymes, prealbumin, liver function tests 
(LFT), nitrogenous, Cystatin C, urine sediment and start of urine collection for urinary 
urea nitrogen (NUU), subsequent tests are given in the next 6 hours or before be 
necesario.31, 32,33,34,35 
5. Postoperatively not complicated 
At present, the cardiovascular monitoring is noninvasive and invasive integral part of the 
intensive care critically ill cardiac patient. 
Cardiovascular monitoring 
The proper outcome after cardiac surgery depends on preoperative and postoperative 
status of the myocardium rather than coronary anatomy in the postoperative period is 
uniformly diminished contractility compared to the preoperative magnitude and duration 
of this depression depends on the severity of chronic dysfunction, the presence of recent 
ischemic events, efficacy and complications of operative procedures and the 
intraoperative course. All intraoperative events play a significant role in recovery 
processes are the most important anesthetic management, cardioplegia and 
cardiopulmonary bypass duration. Events and preoperative and intraoperative 
interventions vary in magnitude and duration but in characteristic result in reduced 
myocardial contractility and compliance, which affects the postoperative management 
and eventual evolution. Ejection fraction in the preoperative less than 35%, the presence 
of ischemia or infarction in the immediate preoperative have substantial postoperative 
management, patients with outflow tract obstruction by a disease associated with 
hypertrophic chronic hypertension or stenosis aortic present particular difficulties 
postoperatively. It is always important to optimize left ventricular preload in TiPQ 
evaluated through filling pressures but not always filling pressures adequately reflect 
preload, defined as ventricular end-diastolic volume, so that ideally should be monitored 
with end-diastolic volume index and cardiac index continued, ie in real time. Patients 
with chronic volume overload, as in those with mitral regurgitation are dependent on 
adequate volume resuscitation in these patients the response of blood pressure and heart 
rate are usually a better guide to the proper preload because pulmonary occlusion 
pressure and pulmonary artery pressure are insensitive, except at the ends of 
hypovolemia and fluid overload in this situation, blood pressure and cardiac index can 
significantly change before filling pressures. 36.37 
Ventricular work is a crucial element in the postoperative management of heart surgery, the 
hypertrophic ventricular pressure overload or are intolerant to significant changes in heart 
rate when the heart rate is high, the filling time can be shortened enough to compromise the 
volume of end-diastolic volume and thus cardiac output, in contrast, when heart rate is 
below the time needed to develop the maximum end-diastole, cardiac output may decline 
relative to the low frequency. Assuming that the preload is adequate, a heart rate between 
90 and 100 beats per minute is optimal for a hypertrophic myocardium, where compliance is 
significantly diminished synchronized atrioventricular contraction plays a significant role in 
ensuring optimal preload, so these patients require sinus rhythm or a dual-chamber 
pacemaker. The ventricle with volume overload in contrast, is more tolerant of tachycardia 
and loss of atrioventricular synchrony. When ventricular compliance at the end of diastole 
decrease as a result of increased heart rate, systolic emptying may be better in these patients, 
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sinus rhythm below 75 beats per minute tends to be more deleterious to an abnormal 
rhythm frequencies above 90 per minute, with low heart rates, prolonging the diastolic 
filling time committed ventricular ejection fraction because the ventricle is more dilated. 
Ultimately in ventricles with volume overload tachycardia and loss of atrioventricular 
synchrony can be better tolerated than sinus bradycardia. Determining the degree of 
reduction in contractility admission to TiPQ is problematic, the main contributors to the 
decrease in postoperative contractility including ejection fraction before surgery less than 
35%, CPB time, especially if the duration exceeds 120 minutes. In patients undergoing valve 
procedures, it is advisable to perform intraoperative transesophageal echocardiography at 
the end of CPB as this is useful to assess valve function and ventricular dynamics. If the 
preoperative ejection fraction is greater than 35% and the operative course was satisfactory, 
decrease myocardial compliance in the first 4-6 hours in the unit and then quickly returns 
TiPQ values similar to or better than the preoperative values. Patients with an ejection 
fraction before surgery less than 35%, presence of perioperative ischemia or complicated 
operative course may require a longer time to recover or make permanent dysfunction, 
myocardial depression may persist for an extended period of time. These factors may affect 
the withdrawal of ventilatory support and necessitate the use of oxygen in prolonged, the 
tachypnea may be a reflection of compromised perfusion rather than primary respiratory 
failure. 
Maintaining normal blood pressure is critical in the early hours of postoperative necessarily 
invasive measurement must be continued for at least 24 hours for analysis beat to beat but if 
it is non-invasive measurement must be measured regularly every 5 minutes but the 
objectivity of plethysmographic measurements are reliable non-invasive automatic in the 
absence of intense vasoconstriction and a very high frequency. Class I recommendation, 
level of evidence C. The optimal MAP in the first 6 postoperative hours especially in 
revascularized patients should be 65 to 80mmHg, maintaining adequate tissue perfusion to 
all organs and prevent bleeding at the sites of anastomosis of the bypass. The goal of 
hemodynamic monitoring of critically ill patients is to assess the adequate perfusion and 
tissue oxygenation, using intermittent or continuous measurement of oxygen saturation 
both considered acceptable, although the measurement of lactate may be useful lacks 
precision as a measure of status tissue metabolism in patients with mechanical ventilation is 
recommended central venous pressure of 12-14 mm Hg to offset the increase in intrathoracic 
pressure especially those with PEEP> 5mmHg. A similar consideration is the elevation of 
intra-abdominal pressure (IAP is approximately normal. 5-7 mmHg in critically ill patients) 
as it is inversely proportional to tissue perfusion pressure (PPP) and dependent on the mean 
arterial pressure (MAP) ie: PPA = MAP - IAP. 
The good use in the immediate postoperative period of Swan-Ganz implies a broad 
knowledge of hemodynamics by the doctor for a proper training and constant use of the 
device, much of the value of this catheter for monitoring the hemodynamic status is based 
on their ability adequate to measure pulmonary capillary pressure which we take as a 
measure of left ventricular preload. The subsequent interpretation of a good wedge pressure 
curve are not simple things, implies among other things, the tip of the catheter has been 
placed in a part of the lung that the condition of zone 3, the ball was not over-inflated or 
default, the catheter is floating in the right place and has not migrated back, there is no 
strong auto-PEEP and various other things. However there are many more and more data, 
which indicate that the use of postoperative pulmonary catheter in heart depends on many 
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electrolytes, coagulation, time Ivy, myocardial enzymes, prealbumin, liver function tests 
(LFT), nitrogenous, Cystatin C, urine sediment and start of urine collection for urinary 
urea nitrogen (NUU), subsequent tests are given in the next 6 hours or before be 
necesario.31, 32,33,34,35 
5. Postoperatively not complicated 
At present, the cardiovascular monitoring is noninvasive and invasive integral part of the 
intensive care critically ill cardiac patient. 
Cardiovascular monitoring 
The proper outcome after cardiac surgery depends on preoperative and postoperative 
status of the myocardium rather than coronary anatomy in the postoperative period is 
uniformly diminished contractility compared to the preoperative magnitude and duration 
of this depression depends on the severity of chronic dysfunction, the presence of recent 
ischemic events, efficacy and complications of operative procedures and the 
intraoperative course. All intraoperative events play a significant role in recovery 
processes are the most important anesthetic management, cardioplegia and 
cardiopulmonary bypass duration. Events and preoperative and intraoperative 
interventions vary in magnitude and duration but in characteristic result in reduced 
myocardial contractility and compliance, which affects the postoperative management 
and eventual evolution. Ejection fraction in the preoperative less than 35%, the presence 
of ischemia or infarction in the immediate preoperative have substantial postoperative 
management, patients with outflow tract obstruction by a disease associated with 
hypertrophic chronic hypertension or stenosis aortic present particular difficulties 
postoperatively. It is always important to optimize left ventricular preload in TiPQ 
evaluated through filling pressures but not always filling pressures adequately reflect 
preload, defined as ventricular end-diastolic volume, so that ideally should be monitored 
with end-diastolic volume index and cardiac index continued, ie in real time. Patients 
with chronic volume overload, as in those with mitral regurgitation are dependent on 
adequate volume resuscitation in these patients the response of blood pressure and heart 
rate are usually a better guide to the proper preload because pulmonary occlusion 
pressure and pulmonary artery pressure are insensitive, except at the ends of 
hypovolemia and fluid overload in this situation, blood pressure and cardiac index can 
significantly change before filling pressures. 36.37 
Ventricular work is a crucial element in the postoperative management of heart surgery, the 
hypertrophic ventricular pressure overload or are intolerant to significant changes in heart 
rate when the heart rate is high, the filling time can be shortened enough to compromise the 
volume of end-diastolic volume and thus cardiac output, in contrast, when heart rate is 
below the time needed to develop the maximum end-diastole, cardiac output may decline 
relative to the low frequency. Assuming that the preload is adequate, a heart rate between 
90 and 100 beats per minute is optimal for a hypertrophic myocardium, where compliance is 
significantly diminished synchronized atrioventricular contraction plays a significant role in 
ensuring optimal preload, so these patients require sinus rhythm or a dual-chamber 
pacemaker. The ventricle with volume overload in contrast, is more tolerant of tachycardia 
and loss of atrioventricular synchrony. When ventricular compliance at the end of diastole 
decrease as a result of increased heart rate, systolic emptying may be better in these patients, 
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sinus rhythm below 75 beats per minute tends to be more deleterious to an abnormal 
rhythm frequencies above 90 per minute, with low heart rates, prolonging the diastolic 
filling time committed ventricular ejection fraction because the ventricle is more dilated. 
Ultimately in ventricles with volume overload tachycardia and loss of atrioventricular 
synchrony can be better tolerated than sinus bradycardia. Determining the degree of 
reduction in contractility admission to TiPQ is problematic, the main contributors to the 
decrease in postoperative contractility including ejection fraction before surgery less than 
35%, CPB time, especially if the duration exceeds 120 minutes. In patients undergoing valve 
procedures, it is advisable to perform intraoperative transesophageal echocardiography at 
the end of CPB as this is useful to assess valve function and ventricular dynamics. If the 
preoperative ejection fraction is greater than 35% and the operative course was satisfactory, 
decrease myocardial compliance in the first 4-6 hours in the unit and then quickly returns 
TiPQ values similar to or better than the preoperative values. Patients with an ejection 
fraction before surgery less than 35%, presence of perioperative ischemia or complicated 
operative course may require a longer time to recover or make permanent dysfunction, 
myocardial depression may persist for an extended period of time. These factors may affect 
the withdrawal of ventilatory support and necessitate the use of oxygen in prolonged, the 
tachypnea may be a reflection of compromised perfusion rather than primary respiratory 
failure. 
Maintaining normal blood pressure is critical in the early hours of postoperative necessarily 
invasive measurement must be continued for at least 24 hours for analysis beat to beat but if 
it is non-invasive measurement must be measured regularly every 5 minutes but the 
objectivity of plethysmographic measurements are reliable non-invasive automatic in the 
absence of intense vasoconstriction and a very high frequency. Class I recommendation, 
level of evidence C. The optimal MAP in the first 6 postoperative hours especially in 
revascularized patients should be 65 to 80mmHg, maintaining adequate tissue perfusion to 
all organs and prevent bleeding at the sites of anastomosis of the bypass. The goal of 
hemodynamic monitoring of critically ill patients is to assess the adequate perfusion and 
tissue oxygenation, using intermittent or continuous measurement of oxygen saturation 
both considered acceptable, although the measurement of lactate may be useful lacks 
precision as a measure of status tissue metabolism in patients with mechanical ventilation is 
recommended central venous pressure of 12-14 mm Hg to offset the increase in intrathoracic 
pressure especially those with PEEP> 5mmHg. A similar consideration is the elevation of 
intra-abdominal pressure (IAP is approximately normal. 5-7 mmHg in critically ill patients) 
as it is inversely proportional to tissue perfusion pressure (PPP) and dependent on the mean 
arterial pressure (MAP) ie: PPA = MAP - IAP. 
The good use in the immediate postoperative period of Swan-Ganz implies a broad 
knowledge of hemodynamics by the doctor for a proper training and constant use of the 
device, much of the value of this catheter for monitoring the hemodynamic status is based 
on their ability adequate to measure pulmonary capillary pressure which we take as a 
measure of left ventricular preload. The subsequent interpretation of a good wedge pressure 
curve are not simple things, implies among other things, the tip of the catheter has been 
placed in a part of the lung that the condition of zone 3, the ball was not over-inflated or 
default, the catheter is floating in the right place and has not migrated back, there is no 
strong auto-PEEP and various other things. However there are many more and more data, 
which indicate that the use of postoperative pulmonary catheter in heart depends on many 
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factors that have little to do with their true indications or the severity of the patient also has 
serious complications observed in studies presented to the placement of a Swan-Ganz 
pulmonary artery in this group of patients where metabolic changes, hypothermia, 
cardioplegia, ischemia or myocardial stunning favor residual arrhythmias, thromboembolic 
events, infections, pulmonary infarction or to knotting of the catheter, not to mention does 
not improve cardiovascular survival in critically ill patients. 
You must have a central venous line and periodically monitor the central venous saturation 
(SvO2) and good availability in the administration of appropriate fluids for resuscitation in 
the first six hours following the early goals of Rivers and colleagues, as therapy guided by 
objectives has been shown to improve survival in critically ill patients susceptible to revival 
under the supervision of personnel in these areas.  
During the first hours must meet the physiological parameters already discussed, however 
those who do not meet these criteria should be reassessed therapeutic conduct, analyze 
ECG, diuresis, PVC, the need to correct up to 30% hematocrit and evaluate the need for 
inotropic or increase in dosage especially if the central venous saturation is <70%, or GC-
invasive measurements have decreased their acceptable ranges. The SvO 2 is a determinant 
and with greater sensitivity in the postoperative monitoring of oxygenation, perfusion, 
oxygen consumption and microcirculatory level, now has shown that goal-directed 
resuscitation, in which this has been a decisive objectives in the first six hours significantly 
decreased cardiopulmonary morbidity and mortality in patients to assess critical to tissue 
oxygenation indirectly: this is defined as adequate oxygen supply to demand, the supply is 
always greater than consumption (VO2), in cases of circulatory shock and severe hypoxemia 
there is a significant fall in DO2 but the VO2 is maintained by the compensation determined 
by the EO2%, which explains a security mechanism that ensures the proper use until it 
descends DO2 a critical point where consumption becomes dependent on the contribution 
anaeróbico initiating cellular metabolism. 38,39 
The use of PiCCO (press contour cardiac output) can continuously monitor cardiac output, 
the variability of pulse pressure and stroke volume. Likewise, estimates of the severity of 
intermittent pulmonary edema, intravascular volume and intrathoracic cardiac chambers, 
two measures related to ventricular preload.  
Electrocardiographic monitoring or driving is important in the first six hours after a stroke 
thoroughly evaluated on admission electrocardiogram to TiPQ, you need continuous 
monitoring of electrical activity and identify arrhythmias or morphological changes that 
warrant immediate management. You also have to periodically assess the proper 
functioning of epicardial pacemaker generator. Management should be initiated when the 
ventricular rate is above 110lat/min. 
Respiratory monitoring 
First of all clinical assessment remains the mainstay in respiratory monitoring, inspection of 
the chest is important from the patient's arrival to TiPQ is important to assess that there is 
synchrony in movements of both amplexación amplexión and thorax as well as observation 
of permeability each of chest drains and their exact position placed by the surgical team 
must verify proper endotracheal tube position, surely the next step is auscultation of lung 
regions in search of clinical syndromes or abnormal sounds that suggest some clinical 
suspicion is necessary to assess respiratory mechanics measurements in our patient by the 
ventilator as well as scheduling parameters. Sets the following startup parameters: 
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Mode: Assist-control (volume or pressure) 
Respiratory rate = 10-15 L / min; 
Tidal volume = 6-8 ml / kg; 
FiO2 = to maintain SaO2> 90%. 
Over 90% of postoperative patients reach TiPQ Units with mechanical assistance in 
breathing, so the generally invasive respiratory monitoring, however, is always important 
clinical evaluation since joining our service to have an initial assessment and observe its 
evolution in the first 24 hours. Not established the need for routine use of PEEP in patients 
without complications due to decreased functional residual capacity (FRC) in these patients 
and atelectasis appear 5 minutes after the onset of anesthesia are not important and no 
impact on arterial oxygenation postoperatively. However, in the first hour is important to 
evaluate the relationship and consider PaO2/FiO2 lung history to give an appropriate 
value, it is also important to rule out existence of residual pleural effusion or pneumothorax 
because both entities are also involved in lowering the ratio PaO2/FiO 2, and evaluated 
these considerations and having a stable hemodynamic status can be performed alveolar 
recruitment maneuver (ARM) is a technique that uses a sustained increase in airway 
pressure with the aim of recruiting collapsed alveolar units, increasing lung area available 
for gas exchange and consequently arterial oxygenation. Recent studies concern the use of 
MRA after cardiac surgery, during which the authors believe that lung function and 
oxygenation are decreased> 20% with the use of cardiopulmonary bypass and the 
inflammatory response with the exponential growth atelectasis. Cardiac surgery with 
cardiopulmonary bypass includes the complete collapse of the lungs, thus, the move will 
improve oxygenation by opening collapsed lung regions. The results of current work 
suggest that alveolar recruitment maneuvers are safe procedure in patients with 
cardiovascular surgery and reduces the frequency of postoperative atelectasis.  
The decline of ventilatory support should generally be within 24 hours, ideally Fast-track 
implementation of the ventilation is the goal in most patients (Fast-track cardiac anesthesia-
FTCA-). The importance of predicting the timing of weaning is that both the early weaning 
as the unnecessary prolongation of mechanical ventilation is deleterious to the patient. In 
addition only with the clinical trial is difficult to predict how successful disconnection 
accurate (50% positive predictive value and 67% negative predictive value) because these 
results justify the implementation of objectives and accurate methods to identify patients 
who are able to adequately of extubated successfully. 
Early extubation is associated with a significant reduction in costs associated with 
mechanical ventilation, there is now several modalities to a quick and safe extubation, 
spontaneous ventilation with pressure support (VPS) with 2 dual ventilation PEEP levels 
(BiLevel) or that pressure release ventilation (APRV).  
Patients extubated within 24 hrs it has decreased PaO2/FiO2 ratio <200 is recommended the 
use of noninvasive mechanical ventilation for 24 hrs demonstrated by Yoshiyuki Takami et 
al, as it must be part of primary treatment strategy in patients with acute pulmonary edema 
in this group of patients and reduces the need for endotracheal reintubation and lower 
mortality when compared against conventional treatment with oxygen therapy in 
postoperative heart patient.  
Pulse oximetry has been used to transfer the patient to the operating room TiPQ unit and 
required at all times to monitor the state of oxygenation does not replace the determination 
of arterial blood gases, however the devices currently are more sensitive and less margin for 
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factors that have little to do with their true indications or the severity of the patient also has 
serious complications observed in studies presented to the placement of a Swan-Ganz 
pulmonary artery in this group of patients where metabolic changes, hypothermia, 
cardioplegia, ischemia or myocardial stunning favor residual arrhythmias, thromboembolic 
events, infections, pulmonary infarction or to knotting of the catheter, not to mention does 
not improve cardiovascular survival in critically ill patients. 
You must have a central venous line and periodically monitor the central venous saturation 
(SvO2) and good availability in the administration of appropriate fluids for resuscitation in 
the first six hours following the early goals of Rivers and colleagues, as therapy guided by 
objectives has been shown to improve survival in critically ill patients susceptible to revival 
under the supervision of personnel in these areas.  
During the first hours must meet the physiological parameters already discussed, however 
those who do not meet these criteria should be reassessed therapeutic conduct, analyze 
ECG, diuresis, PVC, the need to correct up to 30% hematocrit and evaluate the need for 
inotropic or increase in dosage especially if the central venous saturation is <70%, or GC-
invasive measurements have decreased their acceptable ranges. The SvO 2 is a determinant 
and with greater sensitivity in the postoperative monitoring of oxygenation, perfusion, 
oxygen consumption and microcirculatory level, now has shown that goal-directed 
resuscitation, in which this has been a decisive objectives in the first six hours significantly 
decreased cardiopulmonary morbidity and mortality in patients to assess critical to tissue 
oxygenation indirectly: this is defined as adequate oxygen supply to demand, the supply is 
always greater than consumption (VO2), in cases of circulatory shock and severe hypoxemia 
there is a significant fall in DO2 but the VO2 is maintained by the compensation determined 
by the EO2%, which explains a security mechanism that ensures the proper use until it 
descends DO2 a critical point where consumption becomes dependent on the contribution 
anaeróbico initiating cellular metabolism. 38,39 
The use of PiCCO (press contour cardiac output) can continuously monitor cardiac output, 
the variability of pulse pressure and stroke volume. Likewise, estimates of the severity of 
intermittent pulmonary edema, intravascular volume and intrathoracic cardiac chambers, 
two measures related to ventricular preload.  
Electrocardiographic monitoring or driving is important in the first six hours after a stroke 
thoroughly evaluated on admission electrocardiogram to TiPQ, you need continuous 
monitoring of electrical activity and identify arrhythmias or morphological changes that 
warrant immediate management. You also have to periodically assess the proper 
functioning of epicardial pacemaker generator. Management should be initiated when the 
ventricular rate is above 110lat/min. 
Respiratory monitoring 
First of all clinical assessment remains the mainstay in respiratory monitoring, inspection of 
the chest is important from the patient's arrival to TiPQ is important to assess that there is 
synchrony in movements of both amplexación amplexión and thorax as well as observation 
of permeability each of chest drains and their exact position placed by the surgical team 
must verify proper endotracheal tube position, surely the next step is auscultation of lung 
regions in search of clinical syndromes or abnormal sounds that suggest some clinical 
suspicion is necessary to assess respiratory mechanics measurements in our patient by the 
ventilator as well as scheduling parameters. Sets the following startup parameters: 
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Mode: Assist-control (volume or pressure) 
Respiratory rate = 10-15 L / min; 
Tidal volume = 6-8 ml / kg; 
FiO2 = to maintain SaO2> 90%. 
Over 90% of postoperative patients reach TiPQ Units with mechanical assistance in 
breathing, so the generally invasive respiratory monitoring, however, is always important 
clinical evaluation since joining our service to have an initial assessment and observe its 
evolution in the first 24 hours. Not established the need for routine use of PEEP in patients 
without complications due to decreased functional residual capacity (FRC) in these patients 
and atelectasis appear 5 minutes after the onset of anesthesia are not important and no 
impact on arterial oxygenation postoperatively. However, in the first hour is important to 
evaluate the relationship and consider PaO2/FiO2 lung history to give an appropriate 
value, it is also important to rule out existence of residual pleural effusion or pneumothorax 
because both entities are also involved in lowering the ratio PaO2/FiO 2, and evaluated 
these considerations and having a stable hemodynamic status can be performed alveolar 
recruitment maneuver (ARM) is a technique that uses a sustained increase in airway 
pressure with the aim of recruiting collapsed alveolar units, increasing lung area available 
for gas exchange and consequently arterial oxygenation. Recent studies concern the use of 
MRA after cardiac surgery, during which the authors believe that lung function and 
oxygenation are decreased> 20% with the use of cardiopulmonary bypass and the 
inflammatory response with the exponential growth atelectasis. Cardiac surgery with 
cardiopulmonary bypass includes the complete collapse of the lungs, thus, the move will 
improve oxygenation by opening collapsed lung regions. The results of current work 
suggest that alveolar recruitment maneuvers are safe procedure in patients with 
cardiovascular surgery and reduces the frequency of postoperative atelectasis.  
The decline of ventilatory support should generally be within 24 hours, ideally Fast-track 
implementation of the ventilation is the goal in most patients (Fast-track cardiac anesthesia-
FTCA-). The importance of predicting the timing of weaning is that both the early weaning 
as the unnecessary prolongation of mechanical ventilation is deleterious to the patient. In 
addition only with the clinical trial is difficult to predict how successful disconnection 
accurate (50% positive predictive value and 67% negative predictive value) because these 
results justify the implementation of objectives and accurate methods to identify patients 
who are able to adequately of extubated successfully. 
Early extubation is associated with a significant reduction in costs associated with 
mechanical ventilation, there is now several modalities to a quick and safe extubation, 
spontaneous ventilation with pressure support (VPS) with 2 dual ventilation PEEP levels 
(BiLevel) or that pressure release ventilation (APRV).  
Patients extubated within 24 hrs it has decreased PaO2/FiO2 ratio <200 is recommended the 
use of noninvasive mechanical ventilation for 24 hrs demonstrated by Yoshiyuki Takami et 
al, as it must be part of primary treatment strategy in patients with acute pulmonary edema 
in this group of patients and reduces the need for endotracheal reintubation and lower 
mortality when compared against conventional treatment with oxygen therapy in 
postoperative heart patient.  
Pulse oximetry has been used to transfer the patient to the operating room TiPQ unit and 
required at all times to monitor the state of oxygenation does not replace the determination 
of arterial blood gases, however the devices currently are more sensitive and less margin for 
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error, which has gained considerable ground in noninvasive respiratory monitoring. The 
most common cause of inaccurate readings of SpO2 is movement, affects the ability of light 
to travel from the light-emitting diodes (LED) to the photodetector, parkinsonism, seizures, 
tremors, cause problems with detecting saturation with falsely high measurements in low 
perfusion states, such as low cardiac output, vasoconstriction, hypothermia, hypovolemia, 
severe hypotension, particularly in cardiac surgery, the oximeter reading is difficult, 
however, this noninvasive method provides reliable early the decrease in oxygen saturation 
before they show clinical signs of hypoxemia. 
Capnometry capnography and monitoring is a noninvasive method useful in the 
postoperative cardiovascular since it is constantly evaluating the level of carbon dioxide 
(CO2) exhaled and its graphical representation is undoubtedly an important tool in the 
management of mechanical ventilation in the first hours after surgery. Carbon dioxide the 
patient is transported from the cells into the lungs through the venous blood, mostly in the 
form of bicarbonate (HCO3) and dissolved in small amounts in plasma and bound to 
hemoglobin, the amount of CO2 that comes the alveoli is determined by its production and 
flow of venous blood that is, its perfusion (Q), on the other hand, their removal is an almost 
direct function of alveolar ventilation (V). Therefore, the PaCO2 is the result of the 
relationship between ventilation and perfusion: the ratio = V / Q 
1. In the case where the alveolar ventilation equals pulmonary blood perfusion, PaCO2 is 
very similar to PaCO2 in these cases changes in the PaCO2 almost exactly reflect those 
observed in PaCO2. 
2. In cases where ventilation is inappropriately high with respect to the infusion, ie there 
is a high degree of "dead space" (VD), PaCO2 is considerably lower than PaCO2. 
3. In cases where the ventilation is decreased in relation to infusion, PaCO2 is close to the 
values of PCO2 in venous blood, ie the PvCO2, and results in a V / Q low. This occurs 
in those clinical situations in which the airways or alveolar sick or increased pulmonary 
blood perfusion. 
As evaluated in the above three points the lungs are not physiologically homogeneous and 
therefore carbon dioxide at the end of expiration (ETCO2) is the average of the mixture of all 
different types PaCO2 alveoli. It's called PaCO2-ETCO2 gradient to the difference between 
arterial CO2 pressure and the pressure of CO2 in the alveoli (ETCO2), which normally is 1-5 
mmHg. This small difference is due to the small dead space that exists in normal conditions. 
But knowing the physiological concepts, translation in the immediate postoperative clinic 
may be: 
 A ETCO2 of 0 usually means the patient is not breathing, however, can also be the 
result of a malfunctioning fan or a disconnect from it. 
 The decrease in ETCO2 suggests a decreased production of CO2, hypothermia or a fall 
in transport, low cardiac output, excessive alveolar ventilation, hyperventilation or a 
malfunctioning fan. fig 6 
 Increased ETCO2 may be the result of excessive production of CO2, hyperthermia or 
sepsis or a decrease in alveolar ventilation  
Arterial blood gases are essential to making the postoperative management of blood gases 
were performed on all patients from their initial arrival and subsequent to any adjustment 
or correction fan electrolyte and acid-base status, interpretation of blood gases is sometimes 
difficult; laboratory results must always be studied in light of the clinical picture, by the 
systematic approach to each of the values. In the critically ill patient post-operative heart 
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surgery is also necessary to know the values of venous blood gases. The determination of 
arterial and venous blood gases provides three basic values through direct measurement of 
the respective electrodes: 
1. Partial pressure of oxygen dissolved in plasma, PaO2. 
2. Partial pressure of carbon dioxide dissolved in the plasma, PaCO2. 
3. The degree of acidity or alkalinity of the plasma pH. 
The PaO2 is the rate of oxygenation of the blood an indicator of the intensity of the 
presence of molecular oxygen dissolved in plasma, is the expression of the efficiency of 
alveolar ventilation-perfusion and alveolar capillary diffusion normal to achieve the 
transfer oxygen from inside the alveolus to pulmonary capillary blood. The PaCO2 is a 
ventilation parameter also reflects the respiratory component of acid-base and is a highly 
reliable method that reflects without confusion or error, unless you have a fan failure or 
bad programming environment with respect to individual clinical Patient postoperados.40, 
41,42,43 
Renal monitoring 
The clinical value in the immediate postoperative period is important because the simple 
quantification of urine schedule can objectively evaluate renal function, however there are 
several circumstances where the patient usually attends with minimal deterioration and 
time indicated by decreased urine output, factors are multi-age, prior renal impairment, 
intravascular volume cash cytokines by CBP, controlled hypotension, bleeding, and so on. 
The incidence of acute renal failure (ARF) in cardiac surgery with cardiopulmonary 
bypass, between 1% and 45%, and in most schools in a 1% to 15%. The incidence of severe 
ARF that required renal replacement therapy techniques, the work varies between 1% and 
11.1%, thanks to a study by Charujas and colleagues demonstrate and validate a "ARF 
score" in patients undergoing heart surgery and determine the risk of postoperative renal 
failure in taking a score: 1 to 17 than to predict the risk of acute renal failure expressed in 
percentage.  
The CBP has also been involved for many years in the genesis of renal damage associated 
with cardiac surgery, initially manifested by microscopic or gross hematuria depending on 
the severity, though studies of the last fifteen years, using sensitive techniques to identify 
kidney damage have suggested greater importance of perioperative generator impairment 
and acute renal failure, as opposed to possible damage of CPB. Most of these studies have 
been performed in elective postoperative patients with normal preoperative renal function, 
recent studies comparing off-pump coronary surgery versus conventional coronary surgery, 
show no differences in postoperative renal damage, however the valve patients have been 
considered within the group at high risk of kidney damage. So today in the early hours 24 
hours urine volume remains the most reliable parameter of renal impairment and prayers 
whatever their origin (hypovolemia, nephrotoxicity, ischemia, contrast, etc). 44,45,46,47  
Metabolic monitoring 
Hyperglycemia in the perioperative period is associated with increased morbidity, 
decreased survival and increased costs. A number of observational studies have shown that 
improved control of glucose levels in diabetic patients undergoing coronary 
revascularization improves the outcome. Van den Berghe et al demonstrated in surgical ICU 
patients, 63% of whom were postoperative cardiac surgery, the control of glucose 
concentrations of 80-100 mg / dl was associated with a relative decrease in mortality over 
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error, which has gained considerable ground in noninvasive respiratory monitoring. The 
most common cause of inaccurate readings of SpO2 is movement, affects the ability of light 
to travel from the light-emitting diodes (LED) to the photodetector, parkinsonism, seizures, 
tremors, cause problems with detecting saturation with falsely high measurements in low 
perfusion states, such as low cardiac output, vasoconstriction, hypothermia, hypovolemia, 
severe hypotension, particularly in cardiac surgery, the oximeter reading is difficult, 
however, this noninvasive method provides reliable early the decrease in oxygen saturation 
before they show clinical signs of hypoxemia. 
Capnometry capnography and monitoring is a noninvasive method useful in the 
postoperative cardiovascular since it is constantly evaluating the level of carbon dioxide 
(CO2) exhaled and its graphical representation is undoubtedly an important tool in the 
management of mechanical ventilation in the first hours after surgery. Carbon dioxide the 
patient is transported from the cells into the lungs through the venous blood, mostly in the 
form of bicarbonate (HCO3) and dissolved in small amounts in plasma and bound to 
hemoglobin, the amount of CO2 that comes the alveoli is determined by its production and 
flow of venous blood that is, its perfusion (Q), on the other hand, their removal is an almost 
direct function of alveolar ventilation (V). Therefore, the PaCO2 is the result of the 
relationship between ventilation and perfusion: the ratio = V / Q 
1. In the case where the alveolar ventilation equals pulmonary blood perfusion, PaCO2 is 
very similar to PaCO2 in these cases changes in the PaCO2 almost exactly reflect those 
observed in PaCO2. 
2. In cases where ventilation is inappropriately high with respect to the infusion, ie there 
is a high degree of "dead space" (VD), PaCO2 is considerably lower than PaCO2. 
3. In cases where the ventilation is decreased in relation to infusion, PaCO2 is close to the 
values of PCO2 in venous blood, ie the PvCO2, and results in a V / Q low. This occurs 
in those clinical situations in which the airways or alveolar sick or increased pulmonary 
blood perfusion. 
As evaluated in the above three points the lungs are not physiologically homogeneous and 
therefore carbon dioxide at the end of expiration (ETCO2) is the average of the mixture of all 
different types PaCO2 alveoli. It's called PaCO2-ETCO2 gradient to the difference between 
arterial CO2 pressure and the pressure of CO2 in the alveoli (ETCO2), which normally is 1-5 
mmHg. This small difference is due to the small dead space that exists in normal conditions. 
But knowing the physiological concepts, translation in the immediate postoperative clinic 
may be: 
 A ETCO2 of 0 usually means the patient is not breathing, however, can also be the 
result of a malfunctioning fan or a disconnect from it. 
 The decrease in ETCO2 suggests a decreased production of CO2, hypothermia or a fall 
in transport, low cardiac output, excessive alveolar ventilation, hyperventilation or a 
malfunctioning fan. fig 6 
 Increased ETCO2 may be the result of excessive production of CO2, hyperthermia or 
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or correction fan electrolyte and acid-base status, interpretation of blood gases is sometimes 
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systematic approach to each of the values. In the critically ill patient post-operative heart 
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surgery is also necessary to know the values of venous blood gases. The determination of 
arterial and venous blood gases provides three basic values through direct measurement of 
the respective electrodes: 
1. Partial pressure of oxygen dissolved in plasma, PaO2. 
2. Partial pressure of carbon dioxide dissolved in the plasma, PaCO2. 
3. The degree of acidity or alkalinity of the plasma pH. 
The PaO2 is the rate of oxygenation of the blood an indicator of the intensity of the 
presence of molecular oxygen dissolved in plasma, is the expression of the efficiency of 
alveolar ventilation-perfusion and alveolar capillary diffusion normal to achieve the 
transfer oxygen from inside the alveolus to pulmonary capillary blood. The PaCO2 is a 
ventilation parameter also reflects the respiratory component of acid-base and is a highly 
reliable method that reflects without confusion or error, unless you have a fan failure or 
bad programming environment with respect to individual clinical Patient postoperados.40, 
41,42,43 
Renal monitoring 
The clinical value in the immediate postoperative period is important because the simple 
quantification of urine schedule can objectively evaluate renal function, however there are 
several circumstances where the patient usually attends with minimal deterioration and 
time indicated by decreased urine output, factors are multi-age, prior renal impairment, 
intravascular volume cash cytokines by CBP, controlled hypotension, bleeding, and so on. 
The incidence of acute renal failure (ARF) in cardiac surgery with cardiopulmonary 
bypass, between 1% and 45%, and in most schools in a 1% to 15%. The incidence of severe 
ARF that required renal replacement therapy techniques, the work varies between 1% and 
11.1%, thanks to a study by Charujas and colleagues demonstrate and validate a "ARF 
score" in patients undergoing heart surgery and determine the risk of postoperative renal 
failure in taking a score: 1 to 17 than to predict the risk of acute renal failure expressed in 
percentage.  
The CBP has also been involved for many years in the genesis of renal damage associated 
with cardiac surgery, initially manifested by microscopic or gross hematuria depending on 
the severity, though studies of the last fifteen years, using sensitive techniques to identify 
kidney damage have suggested greater importance of perioperative generator impairment 
and acute renal failure, as opposed to possible damage of CPB. Most of these studies have 
been performed in elective postoperative patients with normal preoperative renal function, 
recent studies comparing off-pump coronary surgery versus conventional coronary surgery, 
show no differences in postoperative renal damage, however the valve patients have been 
considered within the group at high risk of kidney damage. So today in the early hours 24 
hours urine volume remains the most reliable parameter of renal impairment and prayers 
whatever their origin (hypovolemia, nephrotoxicity, ischemia, contrast, etc). 44,45,46,47  
Metabolic monitoring 
Hyperglycemia in the perioperative period is associated with increased morbidity, 
decreased survival and increased costs. A number of observational studies have shown that 
improved control of glucose levels in diabetic patients undergoing coronary 
revascularization improves the outcome. Van den Berghe et al demonstrated in surgical ICU 
patients, 63% of whom were postoperative cardiac surgery, the control of glucose 
concentrations of 80-100 mg / dl was associated with a relative decrease in mortality over 
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40% when compared with controls. This study has been criticized for lack of blind control, 
administration of high doses of glucose control and high incidence of hypoglycemia. The 
current recommendation is to try to keep blood glucose below 150 mg / dl, this was 
secondary to a study called normoglycemia in Intensive Care Evaluation Survival Using 
Glucose Algorithm-Regulation (NICE-SUGAR) used to test the hypothesis that intensive of 
blood sugar reduces mortality 90 days in this study showed higher mortality from severe 
hypoglycemia. Because polyuria in the early hours, the release of antidiuretic hormone and 
hyperaldosteronism that characterizes the patient operated on with CPB, it is common the 
presence of hypokalaemia which must be corrected for values greater than 4.0 mEq / L, just 
as occurs hypomagnesemia should be corrected usually there is usually no changes in 
serum calcium or other ions that require correction. 
The dilutional hyponatremia type being increased total body sodium, the use of mannitol 
and / or furosemide during CPB produces a polyuria in the first two to three hours 
postoperatively INSTANT that can reach 1000 ml / hour, with a tendency to normalize 
within hours, the usual consequence is the need to infuse fluids resulting hypovolemia. 48.49 
Neurological monitoring 
It is essential in the first 24 hours because it is not uncommon to find deficits in different 
degrees and which are generally grouped into cognitive dysfunction, which is the most 
common disorder and unnoticed, and that their identification will be necessary to carry out 
mini-mental and demonstrate an early deficit and time of their higher mental functions. All 
patients coming to the unit with residual sedation TiPQ so within the next 6 hours there is a 
95% elimination of sedatives, since coming patients should be evaluated clinically to assess 
the integrity of the stem bark and well-get a first impression to rule out diagnoses and 
cerebral ischemic event or bleeding. In patients who quickly integrates a focus 
fasciocorporal study should be completed image and a more detailed review to have an 
early management and prevent secondary damage. 50.51 
Moreover, patients with prolonged CPB tend to have greater involvement of 
cardiorespiratory function and hemodynamic instability preoperatively intraoperative 
surgery more complicated, hence the increased incidence of neurological disorders may 
be related to these factors rather than the CPB time, now happens with hypotension and 
cerebral hypoperfusion which is another postulated mechanism of neurological damage. 
The CBP is under hypothermia and anesthesia, both of which lower the cerebral 
metabolism and thus cerebral blood flow as there is less demand on the other hand, 
hemodilution decreases blood viscosity by decreasing its resistance to move, so lower 
blood pressure can keep the same cerebral blood flow. Thus, it alters the autoregulation 
curve of cerebral blood flow may keep it even with blood pressures of 50 to 60 mm Hg, 
studies measuring regional cerebral blood flow in patients during CPB have shown that 
blood pressure can reach 50 mm Hg without altered cerebral blood flow. Moreover, the 
flow can reach 19 cm 3 per 100 grams of tissue per minute without psychometric 
alterations detected between pre and post operative. Glasgow is interpreted evaluation at 
baseline and 6 hours by issuing a neurological assessment, monitoring with bispectral 
index (BIS) in patients who have to initiate a secondary sedation is necessary to identify a 
level of sedation adecuado.52, 53 , 54 
Hematologic monitoring 
Hematologic monitoring after surgery is associated with anemia hemodilution and blood 
loss, the minimum necessary use of blood products has shown improvement in morbidity 
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and mortality in recent years. This consideration has resulted from recent meta-analysis and 
evidence-based medicine, evidence shows the association of adverse effects such as 
increased costs, morbidity and mortality especially in the group <65 years so even 7.5gr 
hemoglobin can be well tolerated and no increased risk increase in elderly patients without 
ischemic but the minimum allowed is 8.5 grams, although a large number of scientific 
publications are those who prefer to have an algorithm in relation to individual patient 
characteristics as shown in the table below . The indications for transfusion in patients with 
coronary disease are valid when hypovolemia has been corrected, optimized hemodynamics 
and oxygenation after correction tachycardia. 55,56,57 
It is common in the postoperative cardiac surgery hours uncomplicated run smoothly. At 
approximately 36 hours the patient can be transferred to a general room with telemetric 
control. 
6. Complicated postoperative 
Cardiovascular 
Hypotension and hypoperfusion injury may condition not directly related to the surgical 
procedure and include cardiac tamponade, a new myocardial ischemia, tension 
pneumothorax, hemothorax or significant bleeding related to arterial cannulation. Rarely 
produce acute thrombosis of a graft or coronary embolization. The electrocardiogram 
(ECG) may be of diagnostic aid because it is expected that the initial postoperative ECG 
changes does not show or reveal abnormalities preoperatively limited ST-T. If there are 
significant changes in ECG repeated, should be thought of an occlusive lesion of one of 
the grafts. 
In the presence of suspected acute ischemia should indicate intravenous nitroglycerin, the 
risk of a perioperative myocardial infarction is present from the preoperative to the hospital 
and even after the diagnosis of acute myocardial infarction (AMI) presents difficulties in the 
perioperative You must have a combination of ECG, cardiac enzymes and echocardiography 
can occasionally make the diagnosis. Frequently observed nonspecific ECG changes a large 
percentage of patients have an increased enzyme and troponin I (TnI) generally exceeds the 
levels observed in AMI unrelated to cardiac surgery. The loss of graft thrombosis has been 
reported in up to 10% of grafts in the first week in the hours following the surgery, aspirin 
and possibly clopidogrel appears to reduce the prevalence of AMI diagnosis although 
postoperative postoperative AMI is difficult itself has a significant effect on morbidity and 
mortality in the long term. 
Arrhythmias 
Low cardiac output syndrome 
The low cardiac output syndrome (LCOS), is characterized by decreased performance of 
cardiac function where the cause may damage myocardial and cardiogenic shock condition 
corresponds to a failure in the balance between central cardiac pump and control 
components peripherals, including: a) the tone of the peripheral circulation and b) 
neurohumoral regulators of vascular tone, with the arrival insufficient oxygenated blood to 
peripheral tissues to meet metabolic needs, their presence is associated with high mortality 
at that requires immediate diagnosis and treatment. The multiple causes can produce or 
aggravate this syndrome can be grouped, for descriptive purposes, the following pathogenic 
mechanisms: 
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index (BIS) in patients who have to initiate a secondary sedation is necessary to identify a 
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and mortality in recent years. This consideration has resulted from recent meta-analysis and 
evidence-based medicine, evidence shows the association of adverse effects such as 
increased costs, morbidity and mortality especially in the group <65 years so even 7.5gr 
hemoglobin can be well tolerated and no increased risk increase in elderly patients without 
ischemic but the minimum allowed is 8.5 grams, although a large number of scientific 
publications are those who prefer to have an algorithm in relation to individual patient 
characteristics as shown in the table below . The indications for transfusion in patients with 
coronary disease are valid when hypovolemia has been corrected, optimized hemodynamics 
and oxygenation after correction tachycardia. 55,56,57 
It is common in the postoperative cardiac surgery hours uncomplicated run smoothly. At 
approximately 36 hours the patient can be transferred to a general room with telemetric 
control. 
6. Complicated postoperative 
Cardiovascular 
Hypotension and hypoperfusion injury may condition not directly related to the surgical 
procedure and include cardiac tamponade, a new myocardial ischemia, tension 
pneumothorax, hemothorax or significant bleeding related to arterial cannulation. Rarely 
produce acute thrombosis of a graft or coronary embolization. The electrocardiogram 
(ECG) may be of diagnostic aid because it is expected that the initial postoperative ECG 
changes does not show or reveal abnormalities preoperatively limited ST-T. If there are 
significant changes in ECG repeated, should be thought of an occlusive lesion of one of 
the grafts. 
In the presence of suspected acute ischemia should indicate intravenous nitroglycerin, the 
risk of a perioperative myocardial infarction is present from the preoperative to the hospital 
and even after the diagnosis of acute myocardial infarction (AMI) presents difficulties in the 
perioperative You must have a combination of ECG, cardiac enzymes and echocardiography 
can occasionally make the diagnosis. Frequently observed nonspecific ECG changes a large 
percentage of patients have an increased enzyme and troponin I (TnI) generally exceeds the 
levels observed in AMI unrelated to cardiac surgery. The loss of graft thrombosis has been 
reported in up to 10% of grafts in the first week in the hours following the surgery, aspirin 
and possibly clopidogrel appears to reduce the prevalence of AMI diagnosis although 
postoperative postoperative AMI is difficult itself has a significant effect on morbidity and 
mortality in the long term. 
Arrhythmias 
Low cardiac output syndrome 
The low cardiac output syndrome (LCOS), is characterized by decreased performance of 
cardiac function where the cause may damage myocardial and cardiogenic shock condition 
corresponds to a failure in the balance between central cardiac pump and control 
components peripherals, including: a) the tone of the peripheral circulation and b) 
neurohumoral regulators of vascular tone, with the arrival insufficient oxygenated blood to 
peripheral tissues to meet metabolic needs, their presence is associated with high mortality 
at that requires immediate diagnosis and treatment. The multiple causes can produce or 
aggravate this syndrome can be grouped, for descriptive purposes, the following pathogenic 
mechanisms: 
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1. Reduced preload. The major cause is the leakage of fluid into the interstitial space, 
excessive bleeding, polyuria, the use of high levels of positive end-expiratory warming 
excessive vasodilator drug use, cardiac tamponade, and so on. 
2. Increase in afterload. It can affect both the left and right ventricle. in the cause of 
increased afterload are systemic hypertension, pulmonary hypertension, the 
replacement of the mitral valve in mitral regurgitation, etc.. 
3. Reduced contractility. The main causes of decreased contractility are perioperative 
AMI, drugs with negative inotropic effect, the phenomena exaggerated ischemia-
reperfusion during aortic clamping, and so on. In relation to the phenomenon of 
ischemia reperfusion is important to note contractile deterioration often not 
immediately apparent to the patient's admission to the ICU. In these cases, there is a 
period of normo-or hyper ventricular early after reperfusion. This period is short 
(hours) and is followed by a gradual depression of systolic function, leading in many 
cases to a false sense of security in the early postoperative hours, when this 
phenomenon is unknown. 
4. Changes in heart rate and heart rate. Are due to extreme bradycardia, supraventricular 
or ventricular tachyarrhythmias and impaired high-risk condition. 
5. Metabolic and electrolyte. Acidosis, hypoxemia, hypo-or hypercapnia, hyperkalemia, 
hypocalcemia and may contribute to the development of this syndrome. 
6. Inadequate surgical management. Sometimes not achieved the expected result from the 
technical point of view and this can generate a low output syndrome, such as poor 
condition can bridge aortocoronary junction in myocardial revascularization surgery, 
prolonged pump time with poor poor systemic perfusion and hypothermia induced, 
the presence of a residual stenosis in mitral commissurotomy, miss-match of prosthetic 
valve replacement or plasty, and so on. 
The diagnosis of low cardiac output syndrome after surgery can be established through the 
clinic or by hemodynamic monitoring. Hypotension is the warning sign and used more 
widely, however, patients with moderate decrease in cardiac index may retain acceptable 
levels of low systemic blood pressure which minute volume is high or normal. Oliguria is 
the most common signs of urinary volume monitoring is time and calculate the minute 
volume through the renal plasma flow and rhythm of diuresis, but lacks specificity. No 
doubt the hypothermia of the extremities and the temperature difference between central 
and extremity: these signs are not very useful in the immediate postoperative period 
because patients usually come to body temperature, cardiovascular recovery with low and 
sometimes remain so for several hour, despite attempts to overheat. In the first hours after 
surgery are patients with marked vasomotor instability (vasoconstriction - vasodilation) for 
which no specific capillary filling. On the other hand in the first hours after surgery can be 
found lactic acidosis, which in many cases does not reflect the present situation, but 
situations of decreased perfusion in the operating room occurred body, markedly 
decreasing the diagnostic and prognostic value with other medical and Finally, the decrease 
in mixed venous saturation, this parameter depends on cardiac output and oxygen 
consumption level of the tissue, so in the first 60 minutes is more specific cardiac output. 
Due to the low sensitivity and specificity of symptoms from the first sign of consensus 
definitions in cardiovascular recovery, recently published, is required to make the clinical 
diagnosis of low cardiac output syndrome, patients present simultaneously at least 2 of the 
following criteria: 
Hypotension (systolic blood pressure below 90 mmHg). 
Oliguria (urine output less than 0.5 ml / kg / hr). 
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The hemodynamic evaluation allows continuous monitoring of cardiac function 
postoperatively, being indispensable implementation in this particular group of patients. 
This is done by direct measurement of cardiac output by thermodilution technique. Authors 
such as J. Kirklin consider being in the presence of low cardiac output when cardiac index 
less than 2.2 L/min/m2 in the early hours after surgery and less than 2.4 L/min/m2 in the 
first postoperative day, other authors consider the value 2.0 L/min/m2 index of heart as the 
limit for the diagnosis of low cardiac output syndrome, with values between 2 and 2.5 
L/min/m2 cardiac index usually require therapeutic intervention, whatever its value must 
be accompanied by systemic vascular resistance values normal or elevated, for 
differentiation vasoplegic syndrome that presents with decreased systemic vascular 
resistance. The radionuclide ventriculography with Technetium 99 is an excellent diagnostic 
tool, with it you can obtain the ejection fraction as much of the left ventricle of the right 
ventricle, and allows cardiac tamponade diagnosed by the presence of pericardial blood or 
clots in relation to Echocardiography its main drawback is to obtain an acceptable acoustic 
window in this group of patients, however these problems have been solved with 
transesophageal echocardiography. LCOS mortality is very high, the study CONAREC III 
mortality of patients suffering from low cardiac output syndrome was 44.7%, compared to 
those patients who did not suffered and whose mortality was only 4.9% in the same study 
when considering all the excuses of death, this syndrome was the most frequent (28.9%) in 
patients undergoing coronary bypass surgery. Another study observed the ESMUCICA 
un12% mortality in CABG and valve surgery in 25-45%) and ESMUCICA II (26% mortality 
in valvular). 
The therapeutic management should follow a similar pattern of the pathogenesis stating: 
a. Optimize preload 
b. Optimizing afterload 
c. Optimizing the pace and heart rate. 
d. Increase inotropy. 
The optimal preload for each patient is different and depends on the heart for each patient 
and how they estimated. When you need to optimize the preload is used intravascular 
volume expansion with either colloids, crystalloids or both, while, as if what is required is a 
decrease in preload is done with diuretics, vasodilators, with predominant effect in the 
venous bed as nitroglycerin, mechanical ventilation with PEEP or hemofiltration if the 
patient is oliguric renal failure. 
Afterload also depends on heart disease for each patient and if you have any other special 
situation. The most commonly used drugs to reduce vascular resistance and therefore 
afterload are vasodilators with predominant effect on the arterioles, such as sodium 
nitroprusside. Another important therapeutic elements are warming persist in hypothermic 
patients, sedation and analgesia in patients who have pain or anxiety they generate strong 
isometric muscle contraction, and oxygen in varying concentrations in those with 
hypoxemia and pulmonary vasoconstriction bed with increased pulmonary vascular 
resistance and consequently the right ventricular afterload. To get the rhythm and heart rate 
can be used atrial pacing in case of a sub-optimal heart rate in sinus rhythm and normal 
atrioventricular conduction, ventricular pacing in cases of atrial fibrillation with low 
ventricular response, and sequential pacing, atrioventricular case of complete 
atrioventricular block. The presence of tachyarrhythmias can be managed with drug 
therapy, over-stimulation or cardioversion shock as appropriate. 
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Commonly used catecholamines such as dopamine, dobutamine, isoproterenol, 
epinephrine, norepinephrine and inotropic catecholamines not milrinone and 
levosimendan, being necessary in many cases the combination of more than one. 
Catecholamines, particularly dopamine are the drugs most often used and indiscriminately 
without taking into account many times the preload. The most important are the 
catecholamines and phosphodiesterase inhibitors, there are few data concerning the use of 
levosimendan. these agents have proven effective in improving myocardial contractility or 
heart rate or both catecholamines are more potent chronotropic and inotropic agents 
determine side effects such as increased myocardial oxygen consumption of the 
myocardium, tachycardia, arrhythmias, and increased in afterload can make your job 
difficult. Β-adrenergic receptors may also be downregulated in patients with previous heart 
failure. This has increased the interest in the use of inhibitors of phosphodiesterase III and 
more recently, the calcium sensitizer levosimendan. In a study by Labriola et al. Nijhawan et 
al.) Drug compared to placebo in patients with low cardiac output syndrome after surgery, 
in which documented an increase in cardiac output and ejection fraction and a decrease 
systemic vascular resistance in patients treated with levosimendan. Gillies et al. Conducted 
a systematic review of the literature on the use of inotropic agents in patients with cardiac 
surgery, in which certain recommendations were documented, each with a particular level 
of evidence. 
Respiratory 
Respiratory dysfunction in postoperative heart surgery patients is a common problem 
that results in a significant increase to 25% mortality and significant morbidity with 
impact on cost and hospital stay, atelectasis is a frequent occurrence in the immediate 
postoperative period The incidence of atelectasis in the postoperative period of 40 to 
cardiac 70%, the term is derived from Greek: Atel and ektasis mean incomplete expansion 
of a segment or lobe is characterized by volume loss and collapse of alveolar region 
manifested radiographically as an area opacified. The severity of atelectasis increases with 
more time to pump, more bridges and prolonged ischemia, the opening of the pleura, 
phrenic nerve injury, intraoperative and very low temperatures. Thoracotomy alters lung 
function by shallow breathing (restrictive functional pattern), and vital capacity may be 
reduced by up to 45 to 70%, the pain diminishes deep breath and a cough can lead to 
ineffective with the consequences in lung mechanics and bronchial hygiene. Another 
important factor is the presence of atelectasis, diaphragmatic paralysis caused possibly by 
phrenic nerve injury caused by surgery or by the use of topical agents or cold 
cardioplegia. Decubitus position maintained, leads to changes in regional distribution of 
ventilation and perfusion of the lung, lung inflation decreases along a vertical axis from 
ventral to dorsal supine and when spontaneous breathing begins immediately after 
surgery and in the supine position ventilation is distributed mainly dependent areas of 
the lung. In contrast, during mechanical ventilation, this pattern changes and the 
distribution of ventilation is primarily aimed at non-dependent areas in both positions, 
therefore, the subsidiaries tend to collapse. Studies have shown that prone position 
ventilation becomes more homogeneous. Mechanical restraint of ventilation is produced 
by several factors explain such as bronchial secretions accumulating in dependent areas, 
pleural effusion or dysfunction of chest drains in the first hours after surgery. Alveolar 
recruitment maneuver is a technique that uses a sustained increase in airway pressure 
with the aim of reducing atelectasis by recruiting collapsed alveolar units, increasing the 
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lung area available for gas exchange and consequently arterial oxygenation. Different 
methods are used alveolar recruitment in the postoperative patient, it is important to 
know that before the maneuver is to have an adequate intravascular volume and residual 
sedation after surgery. Ventilatory strategies proposed to achieve alveolar recruitment in 
surgical patients are based on the use of pressure (PEEP or CPAP) ranging between 20 
and 40 cm H2O for varying periods of time. The effects of positive end-expiratory should 
be monitored continuously, as some of the side effects include decreased venous return by 
increasing the average pressure of the airways, impaired lung perfusion overdistended 
areas (increase dead space), increased pulmonary vascular resistance and right heart 
dysfunction, barotrauma and impaired renal blood flow, which are frequent causes of 
hemodynamic compromise in critically ill patients with cardiovascular disease and those 
with intravascular volume deficit. Pleural effusion is frequently observed in the 
immediate postoperative period, but a considerable percentage persist for more than 30 
days, the incidence is 41-87% in postoperative patients, although most are not significant 
pleural effusions, a study of 602 heart postoperative patients showed pleural effusion in 
63%, more than 30 days but less than 5% need thoracentesis for resolution in those 
patients who had more than 5 days chest drains pleural related to infections associated 
with atelectasis and ipsilateral lung infection, said box by fever, productive cough and an 
alveolar infiltrate on chest radiograph. It is important to differentiate whether it is indeed 
a spill transudate or if there is a pulmonary complication due to an infection with a 
pleural early. To make this distinction using the criteria of Light, which are more sensitive 
at identifying exudates, they meet at least one of the following criteria: (transudates none) 
1. Relationship between pleural fluid protein and serum 0.5, 
2. Relationship between pleural fluid LDH and serum 0.6, 
3. In pleural fluid LDH greater than the 2 / 3 parts of the upper limit of normal for serum 
LDH. 
Other proposed criteria for an exudative pleural effusion are: 
4. Cholesterol> 43 mg / dl, 
5. Gradient-pleural serum albumin less than 1.2 g / dl. 
The thoracic duct that enters the thorax through the right diaphragm and flows into the 
left subclavian vein, has collateral lymphatic sometimes can be injured during surgery 
and result in a chylothorax. This pleural fluid milky-white at times and some colored 
(yellow or red) in other, has high content of lymph (chylomicrons), with a triglyceride 
level above 100 mg / dl and cholesterol below 200 mg / dl , treatment includes not 
remove the chest tubes because the fistula may close spontaneously in the thoracic duct 
short time, starting with parenteral nutrition for 10 to 14 days to reduce the production of 
intestinal lymph and thereby reduce the flow through the thoracic duct. If despite these 
measures fail to control the chylothorax, pleurodesis can be performed. Injury or acute 
progressive respiratory insufficiency (ALI / ARDS) is a multifactorial process of 
respiratory damage from pulmonary or extrapulmonary origin and is defined by the 
European-American consensus.  
In patients with postoperative heart surgery the incidence is 5 to 20% depending on the type 
of surgery, severity, time in surgery, bleeding, age, EuroSCORE, comorbidities, and so on. 
In elderly patients shows the highest incidence due to low physiological reserve and are 
more likely to have postoperative complications, the impact of gender remains 
controversial, although female gender was not shown to be an independent predictor of 
LPA in a large study recent cohort, two small studies identified a strong association between 
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Commonly used catecholamines such as dopamine, dobutamine, isoproterenol, 
epinephrine, norepinephrine and inotropic catecholamines not milrinone and 
levosimendan, being necessary in many cases the combination of more than one. 
Catecholamines, particularly dopamine are the drugs most often used and indiscriminately 
without taking into account many times the preload. The most important are the 
catecholamines and phosphodiesterase inhibitors, there are few data concerning the use of 
levosimendan. these agents have proven effective in improving myocardial contractility or 
heart rate or both catecholamines are more potent chronotropic and inotropic agents 
determine side effects such as increased myocardial oxygen consumption of the 
myocardium, tachycardia, arrhythmias, and increased in afterload can make your job 
difficult. Β-adrenergic receptors may also be downregulated in patients with previous heart 
failure. This has increased the interest in the use of inhibitors of phosphodiesterase III and 
more recently, the calcium sensitizer levosimendan. In a study by Labriola et al. Nijhawan et 
al.) Drug compared to placebo in patients with low cardiac output syndrome after surgery, 
in which documented an increase in cardiac output and ejection fraction and a decrease 
systemic vascular resistance in patients treated with levosimendan. Gillies et al. Conducted 
a systematic review of the literature on the use of inotropic agents in patients with cardiac 
surgery, in which certain recommendations were documented, each with a particular level 
of evidence. 
Respiratory 
Respiratory dysfunction in postoperative heart surgery patients is a common problem 
that results in a significant increase to 25% mortality and significant morbidity with 
impact on cost and hospital stay, atelectasis is a frequent occurrence in the immediate 
postoperative period The incidence of atelectasis in the postoperative period of 40 to 
cardiac 70%, the term is derived from Greek: Atel and ektasis mean incomplete expansion 
of a segment or lobe is characterized by volume loss and collapse of alveolar region 
manifested radiographically as an area opacified. The severity of atelectasis increases with 
more time to pump, more bridges and prolonged ischemia, the opening of the pleura, 
phrenic nerve injury, intraoperative and very low temperatures. Thoracotomy alters lung 
function by shallow breathing (restrictive functional pattern), and vital capacity may be 
reduced by up to 45 to 70%, the pain diminishes deep breath and a cough can lead to 
ineffective with the consequences in lung mechanics and bronchial hygiene. Another 
important factor is the presence of atelectasis, diaphragmatic paralysis caused possibly by 
phrenic nerve injury caused by surgery or by the use of topical agents or cold 
cardioplegia. Decubitus position maintained, leads to changes in regional distribution of 
ventilation and perfusion of the lung, lung inflation decreases along a vertical axis from 
ventral to dorsal supine and when spontaneous breathing begins immediately after 
surgery and in the supine position ventilation is distributed mainly dependent areas of 
the lung. In contrast, during mechanical ventilation, this pattern changes and the 
distribution of ventilation is primarily aimed at non-dependent areas in both positions, 
therefore, the subsidiaries tend to collapse. Studies have shown that prone position 
ventilation becomes more homogeneous. Mechanical restraint of ventilation is produced 
by several factors explain such as bronchial secretions accumulating in dependent areas, 
pleural effusion or dysfunction of chest drains in the first hours after surgery. Alveolar 
recruitment maneuver is a technique that uses a sustained increase in airway pressure 
with the aim of reducing atelectasis by recruiting collapsed alveolar units, increasing the 
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lung area available for gas exchange and consequently arterial oxygenation. Different 
methods are used alveolar recruitment in the postoperative patient, it is important to 
know that before the maneuver is to have an adequate intravascular volume and residual 
sedation after surgery. Ventilatory strategies proposed to achieve alveolar recruitment in 
surgical patients are based on the use of pressure (PEEP or CPAP) ranging between 20 
and 40 cm H2O for varying periods of time. The effects of positive end-expiratory should 
be monitored continuously, as some of the side effects include decreased venous return by 
increasing the average pressure of the airways, impaired lung perfusion overdistended 
areas (increase dead space), increased pulmonary vascular resistance and right heart 
dysfunction, barotrauma and impaired renal blood flow, which are frequent causes of 
hemodynamic compromise in critically ill patients with cardiovascular disease and those 
with intravascular volume deficit. Pleural effusion is frequently observed in the 
immediate postoperative period, but a considerable percentage persist for more than 30 
days, the incidence is 41-87% in postoperative patients, although most are not significant 
pleural effusions, a study of 602 heart postoperative patients showed pleural effusion in 
63%, more than 30 days but less than 5% need thoracentesis for resolution in those 
patients who had more than 5 days chest drains pleural related to infections associated 
with atelectasis and ipsilateral lung infection, said box by fever, productive cough and an 
alveolar infiltrate on chest radiograph. It is important to differentiate whether it is indeed 
a spill transudate or if there is a pulmonary complication due to an infection with a 
pleural early. To make this distinction using the criteria of Light, which are more sensitive 
at identifying exudates, they meet at least one of the following criteria: (transudates none) 
1. Relationship between pleural fluid protein and serum 0.5, 
2. Relationship between pleural fluid LDH and serum 0.6, 
3. In pleural fluid LDH greater than the 2 / 3 parts of the upper limit of normal for serum 
LDH. 
Other proposed criteria for an exudative pleural effusion are: 
4. Cholesterol> 43 mg / dl, 
5. Gradient-pleural serum albumin less than 1.2 g / dl. 
The thoracic duct that enters the thorax through the right diaphragm and flows into the 
left subclavian vein, has collateral lymphatic sometimes can be injured during surgery 
and result in a chylothorax. This pleural fluid milky-white at times and some colored 
(yellow or red) in other, has high content of lymph (chylomicrons), with a triglyceride 
level above 100 mg / dl and cholesterol below 200 mg / dl , treatment includes not 
remove the chest tubes because the fistula may close spontaneously in the thoracic duct 
short time, starting with parenteral nutrition for 10 to 14 days to reduce the production of 
intestinal lymph and thereby reduce the flow through the thoracic duct. If despite these 
measures fail to control the chylothorax, pleurodesis can be performed. Injury or acute 
progressive respiratory insufficiency (ALI / ARDS) is a multifactorial process of 
respiratory damage from pulmonary or extrapulmonary origin and is defined by the 
European-American consensus.  
In patients with postoperative heart surgery the incidence is 5 to 20% depending on the type 
of surgery, severity, time in surgery, bleeding, age, EuroSCORE, comorbidities, and so on. 
In elderly patients shows the highest incidence due to low physiological reserve and are 
more likely to have postoperative complications, the impact of gender remains 
controversial, although female gender was not shown to be an independent predictor of 
LPA in a large study recent cohort, two small studies identified a strong association between 
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female gender and the incidence of ALI after cardiac surgery. Vascular risk factors are 
independent predictors of LPA include diabetes, kidney failure, hypertension. These 
markers of systemic atherosclerotic disease are associated with an increased risk of major 
complications. Preexisting renal insufficiency is a strong predictor of ALI (OR, 2.3), which 
confirms the findings of several studies, increased atherosclerotic burden associated with 
renal failure. Chronic obstructive pulmonary disease (COPD) identified preoperative was 
also an independent risk factor, confirming that patients with COPD who are undergoing 
valve surgery or surgery RVM have two or three times the chance of LPA in severe COPD 
has been associated with excess postoperative mortality in patients with MVR. 
Pathophysiological observed that lung damage is mixed but the most important finding in 
the lungs during the early stages of ALI / ARDS is the presence of severe pulmonary edema 
secondary to increased permeability of capillary endothelium and alveolar epithelial barrier 
of . Simultaneously, increased pulmonary vascular resistance as a result of thromboembolic 
events and reflex vasoconstriction, these morphological characteristics are a complex 
reaction of the lung to different nosological agents and processes and not related to the 
nature of the causal process. During mechanical ventilation in the immediate postoperative 
behavior is rest to follow by pulmonary alveolar protection strategy as ALI / ARDS is a 
syndrome characterized by loss of functional residual capacity, increased lung and short 
circuits refractory hypoxemia FiO2. The standard or optimal tidal volume is difficult to 
determine, because in the inflamed lung or ALI / ARDS alveolar pressures each area has 
specific and requires its own level of PEEP to keep open during expiration. The alveolar 
pressures and volumes that can reach areas not dependent overdistended lung, are often 
insufficient to ensure the recruitment of regions dependent edema and atelectasis by 
maintaining recruitable lung areas open, there is distension of the healthy areas of the lung, 
it is explained that the regional compliance of the lung are different as well as mentioned 
Gattinoni. 
Postoperative bleeding 
One of the most frequent complications encountered in the management of patients, 
approximately 20% of patients present with significant bleeding and only 5% required 
reintervention. Predictive factors for bleeding include age, renal failure, cardiopulmonary 
bypass time, liver failure, hypothermia, secondary fibrinolysis, NSAIDs, etc; bleeding 
contributes to more days of ventilation hospital stay and mortality. 
The definition of excessive bleeding in postoperative patients occurs in 5% -10% 
approximately and only 3% required reoperation, bleeding, and reoperation are 2 
independent predictors of poor prognosis. In those patients with postoperative bleeding can 
be divided into two categories: surgical bleeding (bleeding venous layer anastomosis, 
sternum, anywhere stitches), non-surgical bleeding (caused by coagulopathy). 
Risk factors for bleeding are preoperative such as pharmacologic agents (thrombolytic 
PTCA, antiplatelet drugs, anticoagulation) in the case of ASA should be discontinued 5-7 
days before surgery and anticoagulation is recommended to have INR <1.5, five days prior 
to surgery, vitamin K malabsorption, liver disease due to decreased synthesis of clotting 
factors, SLE, amyloidosis, prior chemotherapy, and so on. 
Intraoperative risk factors are: pump bypass, hypothermia, use of heparin during 
cardiopulmonary bypass generation of fibrinolytic activity and postoperative risk factors 
known are octogenarians, non-elective surgery, low BMI, CPB> 150 min, grafts ≥ 5, surgical 
reintervention. 
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During the first 6 hrs of PO should immediately obtained objective results of platelet count 
and coagulation, for early medical or surgical management, clinical criteria is in relation to 
the following table. 
In the management of patients with heavy bleeding PO should commence administration of 
blood products such as red cell concentrates without doubt the goal is to maintain the 
optimum level in arterial blood content [CaO2 = CaO2 = Hb (g/100ml) x 1.34 (ml O2 / g) 
x% SaO2 + (PaO2 x 0.0031) = ml blood O2/100ml)]. They are prepared with 300 ml volume 
with low WBC (<5x106 cells) to reduce alloimmunization and avoid possible TRALI or lung 
damage. Cell salvage, the process by which collects a patient's own blood during surgery for 
later transfusion in the same patient is a reliable alternative to donor blood transfusion 
when needed. We found 23 studies investigating the effectiveness of cell salvage in cardiac 
surgery, conclude that apparently there is insufficient evidence to support the use of cell 
salvage in cardiac surgery but the methodology in the studies were flawed and may be 
biased. 
Alterations in the number or function of platelets may have effects ranging from a clinically 
insignificant prolongation of bleeding time to large defects of hemostasis, platelet 
transfusion is usually required when it decreases the count: <50,000, is individualized 50-100 
the case and over 100,000 were transfused if the time of Ivy is more than 10 minutes with 
continued bleeding. Can be obtained by platelet concentrates (40-70ml) or platelet apheresis 
(200-300ml). 
The use of fresh frozen plasma in postoperative patients offers all the clotting factors and 
plasma proteins needed to improve the prothrombin time and clotting better ensure 
hemodilution coagulopathy, caution should be exercised in bleeding secondary to heparin, 
as a source ATIII natural and should not be used prophylactically. To replace clotting factors 
to be used a dose of 10 to 20 mL / kg, which could increase the concentration factor by 20% 
immediately after infusion. 58,59,60 
The cryoprecipitate is a concentrate of plasma proteins of high molecular weight cold rush 
its volume is approximately 15 to 20 mL after removing the supernatant plasma containing 
concentrations of factor VIII: C (procoagulant activity), 80 to 120 U; factor VIII: vWF (von 
Willebrand factor), 40 to 70%, fibrinogen, 100 to 250 mg, and Factor XIII, 20 to 30%. 
Most of the work with hemostatic agents were designed to assess the therapeutic efficacy 
and to assess potential toxic effects, so that there are still definite data on the safety of 
hemostatic agents. Many studies on these agents have used perioperative blood loss and 
other parameters with endpoints of little clinical importance, whereas other studies did not 
have enough power to evaluate the clinical outcome of importance, such as mortality or 
need for reoperation. 
Pharmacological agents that decrease postoperative bleeding are desmopressin is a synthetic 
analogue of natural vasopressin, with the advantage of having less vasoconstriction, is 
recommended for use in the immediate postoperative hemostatic, unlike aprotinin has 
fewer side effects such as anaphylaxis, thrombosis and renal failure. Aprotinin has been 
used in recent times but because it is a bovine protein, there is an increased risk of 
anaphylaxis, especially if you already had previous exposure, and its cost is higher. When 
used at low doses acts as antidiuretic hormone and is 10-20 times the dose that increases 
hemostatic function and plasma levels of factor VIII, von Willebrand factor (vWF) and tissue 
plasminogen activator (tPA), releasing these factors endothelium and liver. Also observed 
increased platelet aggregation, the result is the shortening of bleeding time. Administered 
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female gender and the incidence of ALI after cardiac surgery. Vascular risk factors are 
independent predictors of LPA include diabetes, kidney failure, hypertension. These 
markers of systemic atherosclerotic disease are associated with an increased risk of major 
complications. Preexisting renal insufficiency is a strong predictor of ALI (OR, 2.3), which 
confirms the findings of several studies, increased atherosclerotic burden associated with 
renal failure. Chronic obstructive pulmonary disease (COPD) identified preoperative was 
also an independent risk factor, confirming that patients with COPD who are undergoing 
valve surgery or surgery RVM have two or three times the chance of LPA in severe COPD 
has been associated with excess postoperative mortality in patients with MVR. 
Pathophysiological observed that lung damage is mixed but the most important finding in 
the lungs during the early stages of ALI / ARDS is the presence of severe pulmonary edema 
secondary to increased permeability of capillary endothelium and alveolar epithelial barrier 
of . Simultaneously, increased pulmonary vascular resistance as a result of thromboembolic 
events and reflex vasoconstriction, these morphological characteristics are a complex 
reaction of the lung to different nosological agents and processes and not related to the 
nature of the causal process. During mechanical ventilation in the immediate postoperative 
behavior is rest to follow by pulmonary alveolar protection strategy as ALI / ARDS is a 
syndrome characterized by loss of functional residual capacity, increased lung and short 
circuits refractory hypoxemia FiO2. The standard or optimal tidal volume is difficult to 
determine, because in the inflamed lung or ALI / ARDS alveolar pressures each area has 
specific and requires its own level of PEEP to keep open during expiration. The alveolar 
pressures and volumes that can reach areas not dependent overdistended lung, are often 
insufficient to ensure the recruitment of regions dependent edema and atelectasis by 
maintaining recruitable lung areas open, there is distension of the healthy areas of the lung, 
it is explained that the regional compliance of the lung are different as well as mentioned 
Gattinoni. 
Postoperative bleeding 
One of the most frequent complications encountered in the management of patients, 
approximately 20% of patients present with significant bleeding and only 5% required 
reintervention. Predictive factors for bleeding include age, renal failure, cardiopulmonary 
bypass time, liver failure, hypothermia, secondary fibrinolysis, NSAIDs, etc; bleeding 
contributes to more days of ventilation hospital stay and mortality. 
The definition of excessive bleeding in postoperative patients occurs in 5% -10% 
approximately and only 3% required reoperation, bleeding, and reoperation are 2 
independent predictors of poor prognosis. In those patients with postoperative bleeding can 
be divided into two categories: surgical bleeding (bleeding venous layer anastomosis, 
sternum, anywhere stitches), non-surgical bleeding (caused by coagulopathy). 
Risk factors for bleeding are preoperative such as pharmacologic agents (thrombolytic 
PTCA, antiplatelet drugs, anticoagulation) in the case of ASA should be discontinued 5-7 
days before surgery and anticoagulation is recommended to have INR <1.5, five days prior 
to surgery, vitamin K malabsorption, liver disease due to decreased synthesis of clotting 
factors, SLE, amyloidosis, prior chemotherapy, and so on. 
Intraoperative risk factors are: pump bypass, hypothermia, use of heparin during 
cardiopulmonary bypass generation of fibrinolytic activity and postoperative risk factors 
known are octogenarians, non-elective surgery, low BMI, CPB> 150 min, grafts ≥ 5, surgical 
reintervention. 
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During the first 6 hrs of PO should immediately obtained objective results of platelet count 
and coagulation, for early medical or surgical management, clinical criteria is in relation to 
the following table. 
In the management of patients with heavy bleeding PO should commence administration of 
blood products such as red cell concentrates without doubt the goal is to maintain the 
optimum level in arterial blood content [CaO2 = CaO2 = Hb (g/100ml) x 1.34 (ml O2 / g) 
x% SaO2 + (PaO2 x 0.0031) = ml blood O2/100ml)]. They are prepared with 300 ml volume 
with low WBC (<5x106 cells) to reduce alloimmunization and avoid possible TRALI or lung 
damage. Cell salvage, the process by which collects a patient's own blood during surgery for 
later transfusion in the same patient is a reliable alternative to donor blood transfusion 
when needed. We found 23 studies investigating the effectiveness of cell salvage in cardiac 
surgery, conclude that apparently there is insufficient evidence to support the use of cell 
salvage in cardiac surgery but the methodology in the studies were flawed and may be 
biased. 
Alterations in the number or function of platelets may have effects ranging from a clinically 
insignificant prolongation of bleeding time to large defects of hemostasis, platelet 
transfusion is usually required when it decreases the count: <50,000, is individualized 50-100 
the case and over 100,000 were transfused if the time of Ivy is more than 10 minutes with 
continued bleeding. Can be obtained by platelet concentrates (40-70ml) or platelet apheresis 
(200-300ml). 
The use of fresh frozen plasma in postoperative patients offers all the clotting factors and 
plasma proteins needed to improve the prothrombin time and clotting better ensure 
hemodilution coagulopathy, caution should be exercised in bleeding secondary to heparin, 
as a source ATIII natural and should not be used prophylactically. To replace clotting factors 
to be used a dose of 10 to 20 mL / kg, which could increase the concentration factor by 20% 
immediately after infusion. 58,59,60 
The cryoprecipitate is a concentrate of plasma proteins of high molecular weight cold rush 
its volume is approximately 15 to 20 mL after removing the supernatant plasma containing 
concentrations of factor VIII: C (procoagulant activity), 80 to 120 U; factor VIII: vWF (von 
Willebrand factor), 40 to 70%, fibrinogen, 100 to 250 mg, and Factor XIII, 20 to 30%. 
Most of the work with hemostatic agents were designed to assess the therapeutic efficacy 
and to assess potential toxic effects, so that there are still definite data on the safety of 
hemostatic agents. Many studies on these agents have used perioperative blood loss and 
other parameters with endpoints of little clinical importance, whereas other studies did not 
have enough power to evaluate the clinical outcome of importance, such as mortality or 
need for reoperation. 
Pharmacological agents that decrease postoperative bleeding are desmopressin is a synthetic 
analogue of natural vasopressin, with the advantage of having less vasoconstriction, is 
recommended for use in the immediate postoperative hemostatic, unlike aprotinin has 
fewer side effects such as anaphylaxis, thrombosis and renal failure. Aprotinin has been 
used in recent times but because it is a bovine protein, there is an increased risk of 
anaphylaxis, especially if you already had previous exposure, and its cost is higher. When 
used at low doses acts as antidiuretic hormone and is 10-20 times the dose that increases 
hemostatic function and plasma levels of factor VIII, von Willebrand factor (vWF) and tissue 
plasminogen activator (tPA), releasing these factors endothelium and liver. Also observed 
increased platelet aggregation, the result is the shortening of bleeding time. Administered 
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IV (0.3ug/Kg), SC (0.3ug/Kg) but for obvious reasons dministration IV is recommended in 
postoperative patients. The best response is expected between 30-60min after parenteral 
administration. 
Inside are antifibrinolytic drugs: aprotinin (a direct inhibitor of the fibrinolytic enzyme 
plasmin) is the only drug approved by published and the Food and Drug Administration 
(FDA) to minimize transfusion requirements in coronary bypass surgery, directly inhibits 
the fibrinolytic enzyme plasmin, plasma kallikrein, tissue trypsin and activated coagulation 
factor XII, the highest recommended dose is> 700mg. 
 Are also used tranexamic acid and aminocaproic acid, but have not been approved by the 
FDA for this indication, their mechanisms of action are the first to inhibit the binding of 
plasmin to fibrin occupying the binding sites of lysine of the proenzyme plasminogen and 
the second is the same mechanism of action, but 10 times more potent. Doses are 10-30g and 
maintenance 1-3gr/hr and the second 3-10gr with 20-250mg/hr maintenance. 
There are reviews of meta-analysis on the effectiveness of antifibrinolytic agents compared 
with placebo, aprotinin or tranexamic acid, but not aminocaproic acid, reduced the need for 
blood transfusion by 30% and saved about 1 unit of blood per operation. There was no 
difference in efficacy between regimens with high or low doses of aprotinin, while varying 
doses of tranexamic acid and aminocaproic's not possible to assess the relationship between 
dose and efficacy. As for the most relevant clinical events, the relative risk of reoperation for 
excessive bleeding was significantly reduced in patients receiving aprotinin, compared with 
those receiving placebo, although the mortality rate remained unchanged. Both tranexamic 
acid and aminocaproic acid significantly decreased these events. Therefore, the results of the 
work checked and reviews indicate that antifibrinolytic drugs are effective hemostatic 
agents in cardiac surgery. Reductions in transfusion requirements and reoperation for 
bleeding seem to be confirmed by the narrow confidence intervals of likelihood ratios, 
indicators of relative risks. There were no sufficient data on the effectiveness that allow 
definitive conclusions regarding the use of antifibrinolytic agents in other situations. 
61,62,63,64,65,66,67 
While other review reports that aminocaproic acid and tranexamic acid are safe, it is 
noteworthy that the works included were smaller than the jobs studied aprotinin. Therefore, 
the authors say, the safety data are not reliable, especially with regard to thrombosis. 
Currently, the Blood Conservation using Antifibrinolytics: a randomized work in a 
population submitted to cardiac surgery (Randomized Trial in a Cardiac Surgery 
Population) or BART, which is still enrolling patients, is designed to enroll 2970 patients 
with indications for cardiac surgery high risk, to determine whether aprotinin is superior to 
tranexamic acid or aminocaproic acid to reduce the risk of massive postoperative bleeding. 
Secondary endpoints were overall mortality and adverse effects such as cardiovascular 
disease and kidney failure. For all available data, the authors argue that the evidence that 
aprotinin reduces perioperative bleeding and immediate postoperative transfusion 
requirement is sound. However, note that despite the large number of clinical trials that 
have addressed the drug, its effectiveness in reducing the need for reoperation has just 
emerged from reviews and lack of evidence about its effect on mortality. 68,69,70 
Recombinant activated factor VII (rFVIIa) acts locally at the site of tissue injury and 
alterations of the vascular wall by binding to exposed tissue factor, generating small 
amounts of thrombin sufficient to activate platelets. The activated platelet surface can then 
form a template on which rFVIIa half the direct or indirect activation of coagulation to 
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generate thrombin in the end much more and convert fibrinogen to fibrin. The clot is 
stabilized by inhibition of fibrinolysis, secondary to activation of the inhibitor of thrombin-
activatable fibrinolysis mediated by rFVIIa. The availability of rFVIIa has expanded 
treatment options for acute bleeding in hemophilia patients. This drug is not a panacea, but 
it has efficacy in patients with trauma and excessive bleeding resistant to other treatments. 
However, the encouraging results obtained so far must be confirmed by other studies, are 
also necessary cost-effectiveness studies, as it is an expensive drug. The authors recommend 
to take with caution the results of studies recognized even before considering the evidence 
as a guideline. We have tried to increase the power and efficacy of rFVIIa by molecular 
engineering acting on DNA, but no studies. 71,72,73,74,75 
Perioperative myocardial 
Although virtually all patients have some degree of increase in cardiac enzymes after 
surgery. The perioperative myocardial infarction is one of the most serious complications 
after CABG (RVM), an incidence of 5-20%, and is associated with significant morbidity and 
mortality in the post-surgical high. The pathogenesis of IPO vasa in the various mechanisms 
by which the placement of coronary artery bypass bridges leading to myocardial necrosis: 
The most common is acute occlusion of the hemoducto, twist it, subtotal graft stenosis or 
spasm, saying recent articles The presence of collateral arterioles protects perioperative 
stroke patients. 
The perioperative myocardial infarction (IPO) type 5 belongs to heart and is defined 
according to the latest consensus established in 2007 by the AHA / ACC as an increase of at 
least 5 times the baseline or reference biomarkers, along with the emergence of new q waves 
left bundle branch block on electrocardiogram, or coronary angiography showing acute 
occlusion of hemoductos and imaging evidence of recent loss of viable myocardial tissue. 
According to Thielmann, the increase in markers of myocardial damage, can be used to 
discriminate between perioperative stroke related to the placement of coronary artery 
bypass bridge, or another cause. So analyzing 3308 patients with MVR, I conclude that the 
94 who underwent coronary angiography, 56 had stroke related to the placement of 
coronary artery bypass bridges, 38 was not related to the procedure. Levels of troponin I, 
rather than CK / CK-MB rose significantly in the first group with respect to the second, 
considering the troponin I as the best marker to discriminate between IM surgery associated 
with those who are not associate the procedure with a cutoff of 10.5 ng / ml, and those in 
which MI was directly associated with the placement of non-hemoductos with a cutoff of 
35.5 ng / ml. 
In peri-operative myocardial infarction not associated with coronary bypass grafts, is due to 
mechanisms such as inadequate cardioplegic perfusion, incomplete revascularization, distal 
coronary microembolization caused by surgical manipulation, recent unstable angina, poor 
left ventricular function. This early detection of perioperative myocardial infarction plays an 
important role in treating either early coronary angiography and angioplasty, trying to 
preserve left ventricular function as a predictor of long-term survival. Obviously the 
presence of perioperative myocardial infarction is associated with a high rate of heart failure 
and long-term mediately, as evidenced by Steuer, analyzing patients with MVR 7.493 
assessing the number of readmissions for heart failure. Found that 7.7% (576) were 
readmitted for heart failure. Of these, 20% (114) had perioperative myocardial infarction. 
76,77,78,79,80,81 
 
Special Topics in Cardiac Surgery 24
IV (0.3ug/Kg), SC (0.3ug/Kg) but for obvious reasons dministration IV is recommended in 
postoperative patients. The best response is expected between 30-60min after parenteral 
administration. 
Inside are antifibrinolytic drugs: aprotinin (a direct inhibitor of the fibrinolytic enzyme 
plasmin) is the only drug approved by published and the Food and Drug Administration 
(FDA) to minimize transfusion requirements in coronary bypass surgery, directly inhibits 
the fibrinolytic enzyme plasmin, plasma kallikrein, tissue trypsin and activated coagulation 
factor XII, the highest recommended dose is> 700mg. 
 Are also used tranexamic acid and aminocaproic acid, but have not been approved by the 
FDA for this indication, their mechanisms of action are the first to inhibit the binding of 
plasmin to fibrin occupying the binding sites of lysine of the proenzyme plasminogen and 
the second is the same mechanism of action, but 10 times more potent. Doses are 10-30g and 
maintenance 1-3gr/hr and the second 3-10gr with 20-250mg/hr maintenance. 
There are reviews of meta-analysis on the effectiveness of antifibrinolytic agents compared 
with placebo, aprotinin or tranexamic acid, but not aminocaproic acid, reduced the need for 
blood transfusion by 30% and saved about 1 unit of blood per operation. There was no 
difference in efficacy between regimens with high or low doses of aprotinin, while varying 
doses of tranexamic acid and aminocaproic's not possible to assess the relationship between 
dose and efficacy. As for the most relevant clinical events, the relative risk of reoperation for 
excessive bleeding was significantly reduced in patients receiving aprotinin, compared with 
those receiving placebo, although the mortality rate remained unchanged. Both tranexamic 
acid and aminocaproic acid significantly decreased these events. Therefore, the results of the 
work checked and reviews indicate that antifibrinolytic drugs are effective hemostatic 
agents in cardiac surgery. Reductions in transfusion requirements and reoperation for 
bleeding seem to be confirmed by the narrow confidence intervals of likelihood ratios, 
indicators of relative risks. There were no sufficient data on the effectiveness that allow 
definitive conclusions regarding the use of antifibrinolytic agents in other situations. 
61,62,63,64,65,66,67 
While other review reports that aminocaproic acid and tranexamic acid are safe, it is 
noteworthy that the works included were smaller than the jobs studied aprotinin. Therefore, 
the authors say, the safety data are not reliable, especially with regard to thrombosis. 
Currently, the Blood Conservation using Antifibrinolytics: a randomized work in a 
population submitted to cardiac surgery (Randomized Trial in a Cardiac Surgery 
Population) or BART, which is still enrolling patients, is designed to enroll 2970 patients 
with indications for cardiac surgery high risk, to determine whether aprotinin is superior to 
tranexamic acid or aminocaproic acid to reduce the risk of massive postoperative bleeding. 
Secondary endpoints were overall mortality and adverse effects such as cardiovascular 
disease and kidney failure. For all available data, the authors argue that the evidence that 
aprotinin reduces perioperative bleeding and immediate postoperative transfusion 
requirement is sound. However, note that despite the large number of clinical trials that 
have addressed the drug, its effectiveness in reducing the need for reoperation has just 
emerged from reviews and lack of evidence about its effect on mortality. 68,69,70 
Recombinant activated factor VII (rFVIIa) acts locally at the site of tissue injury and 
alterations of the vascular wall by binding to exposed tissue factor, generating small 
amounts of thrombin sufficient to activate platelets. The activated platelet surface can then 
form a template on which rFVIIa half the direct or indirect activation of coagulation to 
 
Intensive Care Management of Patients in the First 24 Hours After Cardiac Surgery 25 
generate thrombin in the end much more and convert fibrinogen to fibrin. The clot is 
stabilized by inhibition of fibrinolysis, secondary to activation of the inhibitor of thrombin-
activatable fibrinolysis mediated by rFVIIa. The availability of rFVIIa has expanded 
treatment options for acute bleeding in hemophilia patients. This drug is not a panacea, but 
it has efficacy in patients with trauma and excessive bleeding resistant to other treatments. 
However, the encouraging results obtained so far must be confirmed by other studies, are 
also necessary cost-effectiveness studies, as it is an expensive drug. The authors recommend 
to take with caution the results of studies recognized even before considering the evidence 
as a guideline. We have tried to increase the power and efficacy of rFVIIa by molecular 
engineering acting on DNA, but no studies. 71,72,73,74,75 
Perioperative myocardial 
Although virtually all patients have some degree of increase in cardiac enzymes after 
surgery. The perioperative myocardial infarction is one of the most serious complications 
after CABG (RVM), an incidence of 5-20%, and is associated with significant morbidity and 
mortality in the post-surgical high. The pathogenesis of IPO vasa in the various mechanisms 
by which the placement of coronary artery bypass bridges leading to myocardial necrosis: 
The most common is acute occlusion of the hemoducto, twist it, subtotal graft stenosis or 
spasm, saying recent articles The presence of collateral arterioles protects perioperative 
stroke patients. 
The perioperative myocardial infarction (IPO) type 5 belongs to heart and is defined 
according to the latest consensus established in 2007 by the AHA / ACC as an increase of at 
least 5 times the baseline or reference biomarkers, along with the emergence of new q waves 
left bundle branch block on electrocardiogram, or coronary angiography showing acute 
occlusion of hemoductos and imaging evidence of recent loss of viable myocardial tissue. 
According to Thielmann, the increase in markers of myocardial damage, can be used to 
discriminate between perioperative stroke related to the placement of coronary artery 
bypass bridge, or another cause. So analyzing 3308 patients with MVR, I conclude that the 
94 who underwent coronary angiography, 56 had stroke related to the placement of 
coronary artery bypass bridges, 38 was not related to the procedure. Levels of troponin I, 
rather than CK / CK-MB rose significantly in the first group with respect to the second, 
considering the troponin I as the best marker to discriminate between IM surgery associated 
with those who are not associate the procedure with a cutoff of 10.5 ng / ml, and those in 
which MI was directly associated with the placement of non-hemoductos with a cutoff of 
35.5 ng / ml. 
In peri-operative myocardial infarction not associated with coronary bypass grafts, is due to 
mechanisms such as inadequate cardioplegic perfusion, incomplete revascularization, distal 
coronary microembolization caused by surgical manipulation, recent unstable angina, poor 
left ventricular function. This early detection of perioperative myocardial infarction plays an 
important role in treating either early coronary angiography and angioplasty, trying to 
preserve left ventricular function as a predictor of long-term survival. Obviously the 
presence of perioperative myocardial infarction is associated with a high rate of heart failure 
and long-term mediately, as evidenced by Steuer, analyzing patients with MVR 7.493 
assessing the number of readmissions for heart failure. Found that 7.7% (576) were 
readmitted for heart failure. Of these, 20% (114) had perioperative myocardial infarction. 
76,77,78,79,80,81 
 
Special Topics in Cardiac Surgery 26
Tamponade 
It is characterized by symptoms and signs of hemodynamic instability due to the restrictive 
effect on cardiac contraction, usually observed within the first 6hrs associated with poor 
permeability of their drains. The prevalence of this complication varies between different 
publications, ranging from 0.8% -8.5%, there are reports in which said one of the most 
frequent causes, to the use of internal mammary artery for coronary artery bypass bridge, on 
the other hand, the use of a single anterior mediastinal tube, instead of 2 tubes (front and 
back) has been associated with a high rate of pericardial fluid and as a result of these 
patients tamponade.La course evaluation should be carried out by echocardiography, and 
not just those with a radiological image suggestive of this entity (heart carafe), since by this 
method because of cardiac surgery postoperative patients identified only 50% of patients. 
This is important because several studies have shown that those patients who develop 
pericardial effusion, even without hemodynamic compromise, increased risk of 
supraventricular arrhythmias, sternal dehiscence, prolonged hospital stay and a significant 
reduction in exercise tolerance. 82,83,84 
Finally, the treatment will be those with hemodynamic compromise, is permeated drains, by 
performing emergency echocardiography and reoperation. 85,86,87,88,89 
Vasoplegic Syndrome 
Vasoplegic syndrome (SV) is a severe form of systemic inflammatory response syndrome 
(SIRS), which ranks its expression on the cardiovascular system. A number of reports 
considered the vasoplegia as a recognized complication of cardiac surgery, the main clinical 
manifestation is the presence of hypotension, usually severe, which features the distinctive 
clinical feature of responding with little or no input from volume. 
In cardiac surgery, the reported incidence is 8 to 10%, even up to 40%, these differences 
often depend on characteristics of the study population (ventricular function), the type of 
intervention assessed (use or not of CPB, type cardioplegia) and mainly from the diagnostic 
criteria used. As mentioned previously, the key point is the presence of hypotension, usually 
with a systolic blood pressure (SBP) <85 mm Hg, and / or mean arterial pressure (MAP) <50 
mm Hg.Un clinical data necessary to consider the diagnosis of Vasoplegia is the lack of 
response to volume expansion. A hypotensive patient in the postoperative period of cardiac 
surgery, central venous pressure (CVP) reduced elevation of the same after the infusion of 
500 or 1000 ml of solutions (even at higher volumes) should lead to the posing of vasoplegia. 
90,91,92,93 
Strict diagnostic confirmation will require the use of hemodynamic monitoring, the presence 
of Swan Ganz catheter will allow a broader determination descended filling pressures, by 
providing values of pulmonary capillary pressure (PCP) reduced. 
Diagnostic criteria 
1. Clinical (only allow them to suspicion) 
Low blood pressure response with little or no volume expansion aapropiada 
2. Hemodynamic 
Hypotension (SBP <85 mm Hg / TAM <50 mm Hg) 
Reduced filling pressures (CVP <5 mm Hg / Wedge <10 mm Hg) 
Minute volume and normal or elevated cardiac index (CI equal to or greater than 2.5 
L/min/m2) 
Reduced systemic vascular resistance (SVR <800 dinas/seg/cm-5) 
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Vasopressor requirement (> 0.5 mcg / kg / min noradrenaline or> 10 mcg / kg / min 
dopamine) 
3. Other 
a. In operating room, with open chest 
PVC hypotension with low (<5 mm Hg) refractory avolumen associated with 
excellent observation of left ventricular contractility. 
b. postoperative 
PVC hypotension with low (<5 mm Hg) refractory avolumen associated with 
echocardiography (bidimensionalcon good window or transesophageal) with 
apreciaciónde good left ventricular contractility. 
The main therapeutic goal is sustain perfusion to vital organs like the kidney, brain, liver 
and heart. This also implies the initial use of volume, the use of two types of drugs, drugs 
with pressor effect, linked to its exclusive or non-selective action on alpha adrenergic 
receptors, such as metaraminol or phenylephrine among the first, and epinephrine, 
norepinephrine or dopamine among the latter. The use of drugs associated with beta-
adrenergic effect, will result in some measure, an increase of myocardial oxygen 
consumption in the same direction, their association with postoperative arrhythmias, has 
also been reported. The second drawback associated with, and probably the most 
important clinical refractoriness to vasopressors is that certain forms of vasoplegia 
postoperative manifest. This refractoriness drugs raises the utility of antagonists or 
inhibitors of NO and the enzyme guanylate cyclase, we consider a rational therapeutic 
approach more physiological. Two drugs are the most studied, methylene blue, and 
vasopressin 94,95,96,97,98 
Methylene Blue (AM): its therapeutic action is based on the inhibitory effect of NO or 
blocking of the enzyme guanylate cyclase. This drug has been considered in several isolated 
reports in a series without a control group and essentially in a randomized control group. 
Leyh et al. reported 54 patients with refractory postoperative vasoplegia the use of 
norepinephrine, treated with 2 mg / kg AM. Fifty-one patients showed favorable 
hemodynamic changes in the course of one hour post-treatment. Three patients died in the 
hospital course of the picture (5.6%). The study lacked a control group. Another key finding 
is the shorter of the table between those treated with AM. In these, vasoplegia resolved 
completely within two hours after the start of infusion, whereas in those managed 
conventionally, the box is extended in time, such extension of time associating with a higher 
incidence of complications and late onset sepsis and multiorgan dysfunction . Several 
authors have agreed with this finding, giving unfavorable prognostic value of the 
persistence over time of the SV, accepting that a breakpoint located between 36 and 48 hours 
is a marker of poor prognosis. 
Vasopressin: Vasopressin (antidiuretic hormone arginine vasopressin), Argenziano et al. 
described the association between the shock with vasodilatation after bypass surgery and 
deficiency of vasopressin. Which is secreted by the neurohypophysis regulates tubular 
permeability to water, typically having limited participation in the control of BP. Under 
conditions of hypotension, such as bleeding or vasoplegia itself is a rapid depletion of 
endogenous. It allows a rapid reversal of hypotension, especially in patients refractory to 
vasopressors. In addition, the hormone increases vascular sensitivity to catecholamines and 
increases urine output, based on its direct action on glomerular efferent arteriole, unlike 
catecholamines, whose site is located on the therapeutic afferent arteriole. The proposed 
dose is 0.05 to 0.1 unit / minute. 
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The use of off-pump surgery was associated with less inflammatory response, with lower 
incidence of postoperative SV. However, the picture is commonly seen and may present a 
favorable course. Vasoplegic syndrome is associated with a poor prognosis, when it is 
resistant norepinerina poorer prognosis with increased morbidity and mortality. The 
reported mortality after cardiac surgery is 24% in series reported by Levin and colleagues, 
and 25% in series reported by Gómez et al, in which case the syndrome persisted for up to 
48hr vasoplegic. 99,100,101,102,103 
7. Drug therapy 
The support with vasopressor, vasodilator and inotropic therapeutic behavior is common in 
the first 24 hours secondary to hemodynamic effects induced hypothermia, myocardial 
stunning, extracorporeal circulation, hypovolemia, sedation, and so on. Despite the 
frequency of use of catecholamines are well known adverse effects such as increased 
myocardial consumption, arrhythmogenic, favor delirium, and so on. 104,105,106 
Dobutamine 
Amine as the structure similar to dopamine is primarily a beta-adrenergic agonist relatively 
selective beta-1. Is much more effective and positive inotropic and positive chronotropic 
capacity less arrhythmogenic than dopamine, has no affinity to dopamine receptors and 
therefore lacks the renal effect. A standard dose (2-15μg/kg/min) positive inotropic 
responses observed with a slight increase in heart rate and decreased peripheral resistance. 
107,108 
In the perioperative setting is used primarily as inotropic, often combined with vasopressor 
either to maintain adequate cardiac output and blood pressure and to achieve a combined 
effect of cardiac output and perfusion. On the other hand as shown by Susana Lobo et. al; 
randomizing 50 patients over 65 high-risk cardiac surgery, receiving IV fluids liquid + vs 
Dobutamine, the largest number of perioperative complications observed was present in 
those who do not use vs those who had dobutamine infusion: 52 % vs 16%, and mortality at 
60 days was 28% vs 8% in the dobutamine group. 109,110,111,112,113,114 
The drug's half life is 3-5 min, one of several effects is the progressive decrease in blood 
pressure and pulmonary wedge has an advantage over the effect of dopamine beta for a 
smaller effect observed tachycardic and arrhythmogenic action and dilation in the 
pulmonary circulation has been confirmed in the peripheral circulation. As observed 
Romson et al; administered dobutamine in varying doses and patients undergoing 
cardiopulmonary bypass the heart rate changes depending on the dose and this is lower in 
individuals over 65 years, there were minimal changes in blood pressure, instead a decrease 
in pulmonary capillary wedge pressure and central venous pressure increased systemic 
vascular resistance remained in a mild and constant left ventricular performance also 
increase due to increased heart rate 115,116 
Phosphodiesterase inhibitors 
They are a family of enzymes involved in cellular physiology by regulating the 
concentration of intracellular second messengers are known at present eight of these 
isoforms of phosphodiesterases, which interests us is the number III. Cyclic AMP, produced 
from the stimulation of beta-adrenergic receptors may have two destinations: the 
culminating with an increase in cardiac contractility, and the other consisting of the 
degradation of cAMP to 5-AMP, produced by phosphodiesterase III . Inhibition of this 
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enzyme protects cAMP, promoting their destination to the increase in contractility. It now 
has a group of inotropic drugs whose mechanism of action is precisely in the inhibition of 
phosphodiesterase-III. Of this group stand amrinone and milrinone for the extensive clinical 
experience has accumulated with its use. These substances belong to the bipyridines, this is 
a positive inotropic effect supplemented by a peripheral vasodilator, which contributes to a 
better ability to emptying of the heart. The hemodynamic effects of milrinone, administered 
as a loading dose of 50 micrograms / kg followed by continuous infusion of 0.35 to 0.75 
micrograms / kg / min is significant reductions in diastolic pressure in the aorta, the mean 
aortic pressure and systemic vascular resistance by about 11% ejection fraction of left 
ventricle is increased by about 14%, these effects are closely related to plasma 
concentrations. 117,118,119,120 
In the postoperative period especially in patients receiving milrinone pump has several 
effects on pulmonary circulation and inotropism as evidenced Mitsunori et al, which 
randomized 30 patients undergoing cardiac surgery treated with milrinone was reported, 
reduced the mean pressure of right atrial pressure in the pulmonary artery wedge, mean 
pulmonary pressure and systemic vascular resistance without making a significant change 
in mean arterial pressure or heart rate. 
On the other hand the use of Milrinone has been shown to be beneficial in patients 
undergoing CSRC bomb and right ventricular dysfunction prior. Jong H. et al analyzed the 
effect of infusion of milrinone in patients undergoing CSRC and right ventricular 
dysfunction (VD) found no increase in cardiac index, heart rate, and decreased systemic 
vascular resistance. Changes in right ventricular ejection fraction were not significant, 
whereas in cardiac output and RV afterload if they were, finally improves graft flow in the 
breast and in the middle cerebral artery during surgery of the CSRC. 
Dopamine 
Dopamine (D) precursor of norepinephrine in the biological synthesis, there are specific 
receptors for this substance, especially in the renal circulation, where it produces a 
vasodilatory effect which favors renal tubular function (Hiberman et.al 1984). At the heart 
there are dopamine receptors, but its function on contractility is weak and little known, this 
effect is not accompanied by an increase in resistance as pronounced as with peripheral 
epinephrine and norepinephrine under in vessels predominantly to dopamine receptor 
stimulation. 
The mechanism of action is dose dependent at relatively low doses (1-5μg/kg/min) 
stimulates dopamine receptors predominantly with subsequent renal and mesenteric 
vasodilation (Szerlip, et. Al 1991). A moderate dose of 5-10 mg / kg / min stimulates beta 
adrenergic receptors leading to positive inotropic effects and high-dose alpha-adrenergic 
stimulation 10-15μg/kg/min carries peripheral vasoconstriction. 
By perioperative is used for its effects on the renal circulation as well as its positive inotropic 
effect can be used in improving the ICC states inotropism significantly, the clinical effect is 
seen immediately as the drug's half life is 3 -4 min. Among its side effects can cause or 
exacerbate tachyarrhythmias, because its effect is mediated by increased levels of 
norepinephrine. At present medical evidence did not show benefit of using low doses of 
dopamine effect of splanchnic vasodilatation and renal function, however, this drug 
increases oxygen consumption at promoting tubular tubular ischemia, in addition there is 
poor correlation between blood levels with dose infused. 
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Dopamine (D) precursor of norepinephrine in the biological synthesis, there are specific 
receptors for this substance, especially in the renal circulation, where it produces a 
vasodilatory effect which favors renal tubular function (Hiberman et.al 1984). At the heart 
there are dopamine receptors, but its function on contractility is weak and little known, this 
effect is not accompanied by an increase in resistance as pronounced as with peripheral 
epinephrine and norepinephrine under in vessels predominantly to dopamine receptor 
stimulation. 
The mechanism of action is dose dependent at relatively low doses (1-5μg/kg/min) 
stimulates dopamine receptors predominantly with subsequent renal and mesenteric 
vasodilation (Szerlip, et. Al 1991). A moderate dose of 5-10 mg / kg / min stimulates beta 
adrenergic receptors leading to positive inotropic effects and high-dose alpha-adrenergic 
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By perioperative is used for its effects on the renal circulation as well as its positive inotropic 
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seen immediately as the drug's half life is 3 -4 min. Among its side effects can cause or 
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increases oxygen consumption at promoting tubular tubular ischemia, in addition there is 
poor correlation between blood levels with dose infused. 
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Norepinephrine 
Its structure is similar to that of epinerfrina is the endogenous neurotransmitter for 
postganglionic sympathetic nervous system, its basic function is to stimulate alpha-1 
receptors and less beta-1 receptors and beta-2. Intravenous administration of 
norepinephrine increases blood pressure by increasing peripheral vascular resistance due to 
this increase, heart rate tends to decrease due to a vagal reflex which overrides the 
stimulation of myocardial beta-1 receptors, their After stimulation of these receptors causes 
a recent positive inotropic effect especially at low doses. 
Under normal conditions this amine decreases renal blood flow (with minimal changes in 
glomerular filtration rate) and mesenteric, splanchnic and liver. The administration of 
norepinephrine should be through a central line to avoid tissue necrosis. Is much more 
convenient administration via infusion and the usual dose is 0.01 to 0.1 mg / kg / min or 2-
15 mcg / min. So perioperative norepinephrine may be used at low doses for its 
chronotropic effect and vasoconstrictive properties (intermediate dose). Especially for its 
effect on the peripheral circulation is indicated in cases where failure is demonstrated in the 
ability of vasoregulation, because it increases blood flow by increasing systemic blood 
pressure especially in shock. It should be used so cautious in patients with MAO inhibitors. 
The tx hypovolemic shock with norepinephrine leads to severe multiorgan hypoperfusion. 
The use of norepinephrine in patients undergoing cardiac surgery is controversial because 
of fear that has regard to the commitment in the function mediated renal vasoconstriction. 
Hiroshi Morimatsu, et. randomized 100 patients to post-operative heart to norepinephrine 
infusion in line and this study was carried out monitoring of renal function with infusion of 
norepinephrine in postsurgical hypotension TAM <70 mmHg. The results was an increase in 
central venous pressure, decreased systemic vascular resistance index with increased heart 
rate will eventually change in serum creatinine of treaties. Kwak Y, showed that one of the 
applications of norepinephrine after surgery is the treatment of hypotension in patients with 
chronic pulmonary hypertension as they are benefiting from the control of blood pressure 
without increasing the PSAP but rather decreases many of them. 
Nitroglycerin 
Its mechanism of action is through biotransformation in vascular smooth muscle by 
activating guanylyl cyclase thereby resulting in an increase of cyclic GMP and thus 
vasodilation. The effectiveness of nitroglycerin decreases after 18-24 hr by a phenomenon of 
tolerance due to decreased formation of nitric oxide in this way. The NTG has the ability to 
vasodilate both beds (arterial and venous) at low doses, dominated by its vasodilatory effect 
and increases venous capacitance and thus decreasing venous pressure and diastolic filling. 
However high doses of nitroglycerin significantly increases venous capacitance and 
systemic arteriolar resistance, thereby decreasing the systolic blood pressure and cardiac 
output. As a mechanism the body responds by reflex sympathetic tachycardia and 
peripheral arteriolar vasoconstriction, despite this effect on the coronary circulation is 
vasodilation of both healthy and affected artery atherosclerosis, and also increase collateral 
circulation areas although its main effect is on the arteries coronary larger caliber and low 
on resistance of lesser caliber. On myocardial oxygen requirements, mainly affects the 
ventricular wall tension by increasing venous capacitance, which in turn decreases venous 
return to the heart leading to a decrease in ventricular wall tension and myocardial oxygen 
consumption. Another beneficial effect is that the decrease in pre-produced increase in LV 
perfusion and favoring the subendocardium. 
 
Intensive Care Management of Patients in the First 24 Hours After Cardiac Surgery 31 
Their metabolism is primarily via hepatic glutathione by organic nitrate reductase. Its effect 
is dissipated in 30-60 min intravenous Its effect is achieved after 90 seconds and is dose 
dependent. The usual dose of 0.5-3 mg is / kg / min infusion or 5-200 g / min and 0.5 mg 
bolus. In post-qx therapy use in peri-and post-qx: 
- Myocardial ischemia associated with ventricular arrhythmias, especially when this is 
caused by halogenated anesthetics. 
- Myocardial ischemia with an increase in pulmonary capillary pressure associated with 
a persistence in the inhalation anesthetics. 
- Coronary Spasm 
- Intravenous administration has been proposed as prophylactic coronary bypass surgery 
to prevent episodes of ischemia by vasospasm 
- Useful for the treatment of hypertension during surgery RVM. 
Sodium nitroprusside 
One of the most commonly used vasodilators in the perioperative period, penetrating the 
endothelium acts to form nitric oxide, this results in the production of guanine 
monophosphate to guanine triphosphate. Thus cyclic GMP is the second messenger that 
triggers calcium binding. Its effect occurs seconds after the start of infusion. The commonly 
used dose is 1-40 mcg / min. 
At low doses predominantly dilated arteries and arterioles, and how the dose increases also 
becomes a venodilators. As with nitroglycerin may occur reflexively tachycardia. And 
increased venous capacitance and thereby reducing cardiac output. On the other hand it is 
important to consider that as an important arteriodilatador can produce the phenomenon of 
coronary steal, mostly because it does not vasodilation in arteries affected by atherosclerosis, 
reducing the flow in the latter. 
Among other effects has the ability to produce dilation of the pulmonary vascular bed 
arriving to produce hypoxia. Another effect is less desirable thiocyanate intoxication, which 
prevent tissue oxygen delivery by blocking the final stages of the respiratory chain. 
Its administration should be in glucose solution covering both the drug and the line 
connecting the infusion pump. The usual dose is 40 - 300 micrograms / min. Going to be 
titrated according to a patient's response. 
Vasopressin 
Vasopressin also known as antidiuretic hormone is a peptide product of the hypothalamus 
and stored in the posterior lobe of the pituitary. Feedback effects in several organs including 
the brain where it acts as a neurotransmitter regulating body temperature, nociception and 
adenocorticotropica hormone release. In the pulmonary vasculature, moderate dose of 
vasopressin causes vasodilatation while high doses produce vasoconstriction. Vasopressin 
also has other effects on thrombosis and hemostasis, including platelet aggregation and 
release of factor VIII and von Willebrand. 
Plasma levels of vasopressin in patients after undergoing bypass surgery ranges from 100 
-200 pg / ml, while the hemorrhagic shock promotes the release of plasma concentrations 
of 1000 pg / ml. Several publications indicate that the usual dose of this drug is between 
0.01 to 0.1 U / min, and is effective in patients with shock vasodilation without adverse 
effects. 
Hypotension refractory to high doses of alpha-adrenergic agonists after cardiac surgery, 
after the use of cardiopulmonary bypass, has been referred to as Sx vasoplegic. This 
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bolus. In post-qx therapy use in peri-and post-qx: 
- Myocardial ischemia associated with ventricular arrhythmias, especially when this is 
caused by halogenated anesthetics. 
- Myocardial ischemia with an increase in pulmonary capillary pressure associated with 
a persistence in the inhalation anesthetics. 
- Coronary Spasm 
- Intravenous administration has been proposed as prophylactic coronary bypass surgery 
to prevent episodes of ischemia by vasospasm 
- Useful for the treatment of hypertension during surgery RVM. 
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One of the most commonly used vasodilators in the perioperative period, penetrating the 
endothelium acts to form nitric oxide, this results in the production of guanine 
monophosphate to guanine triphosphate. Thus cyclic GMP is the second messenger that 
triggers calcium binding. Its effect occurs seconds after the start of infusion. The commonly 
used dose is 1-40 mcg / min. 
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becomes a venodilators. As with nitroglycerin may occur reflexively tachycardia. And 
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important to consider that as an important arteriodilatador can produce the phenomenon of 
coronary steal, mostly because it does not vasodilation in arteries affected by atherosclerosis, 
reducing the flow in the latter. 
Among other effects has the ability to produce dilation of the pulmonary vascular bed 
arriving to produce hypoxia. Another effect is less desirable thiocyanate intoxication, which 
prevent tissue oxygen delivery by blocking the final stages of the respiratory chain. 
Its administration should be in glucose solution covering both the drug and the line 
connecting the infusion pump. The usual dose is 40 - 300 micrograms / min. Going to be 
titrated according to a patient's response. 
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Vasopressin also known as antidiuretic hormone is a peptide product of the hypothalamus 
and stored in the posterior lobe of the pituitary. Feedback effects in several organs including 
the brain where it acts as a neurotransmitter regulating body temperature, nociception and 
adenocorticotropica hormone release. In the pulmonary vasculature, moderate dose of 
vasopressin causes vasodilatation while high doses produce vasoconstriction. Vasopressin 
also has other effects on thrombosis and hemostasis, including platelet aggregation and 
release of factor VIII and von Willebrand. 
Plasma levels of vasopressin in patients after undergoing bypass surgery ranges from 100 
-200 pg / ml, while the hemorrhagic shock promotes the release of plasma concentrations 
of 1000 pg / ml. Several publications indicate that the usual dose of this drug is between 
0.01 to 0.1 U / min, and is effective in patients with shock vasodilation without adverse 
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Hypotension refractory to high doses of alpha-adrenergic agonists after cardiac surgery, 
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vasopressin has been used for this treatment with encouraging results. Masseti and 
colleagues studied 16 patients with intravenous vasopressin (0.1-1 IU / min) for the 
treatment of hypotension refractory to maximum dose of norepinephrine (> 30 mg / kg / 
min). Preoperative ejection fraction was 40.5% and NYHA functional class 3.5. Getting an 
increase in blood pressure of 89 mmHg baseline to 116, increase in SVR from 688 to 1043, 
decreased cardiac index from 2.6 to 2.9 L/min/m2, urine volume increased from 36.8 to 72.8 
ml / h. 
Whereas high doses of vasopressin and effective in the treatment of Sx vasoplegic after 
cardiac surgery with cardiopulmonary bypass. 
In a recent study, Argenziano et al found that about 10% of patients undergoing cardiac 
surgery experienced hypotension by vasodilation after bypass surgery, which not 
necessarily is associated with cardiogenic or septic shock. Interestingly, in situations in 
which hypotension persists after surgery RVM, smooth muscle cells become less sensitive to 
circulating catecholamines. This phenomenon is due to decreased function of adrenergic 
receptors, the study of 50 patients conducted at Columbia Presbyterian Medical Center 
undergoing cardiac surgery were treated with vasopressin in the operating room or 
intensive therapy in the first 24 hr surgery (6). All patients had less than 60 mmHg TAM and 
decreased systemic resistance, despite support with catecholamines. This administration of 
vasopressin infusion of 0.09 U / min increased the TAM from 58 to 75 mmHg, the SVR 
increased from 920 to 1200 dyne s cm and achieving a reduction in the administration of 
norepinephrine in 32%.  
Nesiritide 
Brain natriuretic peptide also known as BNP is a neurohormone secreted by the left 
ventricle in response to increased stress (both pressure and volume in the varga) in the 
ventricular wall. Physiological actions of BNP include natriuresis, vasodilation and 
neurohormonal modulation. So the tx with BNP has emerged as a viable option in the tx 
of acute CHF. Moreover, its determination of serum is currently used to differentiate 
cardiac dyspnea pulmonary dela type. In general, levels of BNP 100pg/ml excludes 
minors 1 decompensated CHF, whereas values greater than 500pg/ml indicates 
decompensation. 
Neseritide is the recombinant form of endogenous human BNP. Has been shown to 
decrease filling pressures, increase cardiac output and improve the clinical condition of 
patients with decompensated CHF. In August 2001 was approved by the FDA for tx of 
CHF in those with decompensated dyspnea at rest or with minimal effort. The 
recommended dose is 2μg/kg initial bolus followed by infusion of 0.01μg/kg/min 
extended to a maximum of 48 hr. 
Several studies have examined the possible application of perioperative neseritide so, in 
patients with left ventricular dysfunction who will undergo heart surgery. In a study 
prospectivco, open, randomized controlled, Brackbill et al examined the use of 
perioperative infusion of neriritide and showed improvement compared with milrinone. 
We included 40 hemodynamically stable patients with LVEF 35% or less that were 
undergoing bypass surgery. And they were randomized to a bolus of nesiritide or 
milrinone intraoperatively followed by an infusion of any of them for 24 hr. The time 
spent in post-qx therapy was the primary outcome measure. The incidence of post-qx ICC, 
the rate of readmission within 30 days, mortality and other clinical parameters were 
compared. Patients receiving nesiritide had a hospital stay of 50.6 + / - 46.8 hours 
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compared with 44.1 + / - 23.5 hours of receiving milrinone (p = 0.57). The incidence of 
post-qx ICC also showed no significant results in both groups (p = 0.25). On the third day 
of follow up, no significant differences in SBP readmission between the two drugs and 
there was no impact on mortality, the authors concluded that nesiritide does not reduce 
hospital stay post-qx like not modify other parameters of disease compared with 
nesiritide in MVR and stable ventricular function. 
In a prospective double-blind (NAPA) Mentzer et al; consider the role nesiritide might play 
in patients with left ventricular dysfunction with MVR with cardiopulmonary bypass. 
Patients with ejection fraction less than or equal to 40% who underwent MVR and DCP 
were randomized to receive nesiritide or placebo for 24-96 hr after induction of anesthesia. 
The post-qx renal function, hemodynamic parameters and drug use (primary endpoints) 
were evaluated in patients with MVR with DCP, mortality and safety (secondary endpoints) 
were evaluated in all patients who received the drug, 303 patients randomized, 279 received 
the drug and 272 underwent MVR with DCP. Compared with placebo, nesiritide was 
associated with a slight increase in serum creatinine (0.15 + / - 0.29 mg / dl versus. 0.34 + / - 
0.48 mg / dl, p <0.001) and a fall in glomerular filtration rate (- 10.8 + / - 19.3 mL/min/1.73 
m (2) versus -17.2 + / - 21.9 mL/min/1.73 m (2), P = 0.001) during hospital stay or stay on 
14. On the other hand, patients treated with nesiritide had a shorter hospital stay (p = 0.043) 
and lower mortality at 180 days. (P = 0.046). The authors concluded that nesiritide in the 
context of RVM with CPB is associated with improved renal function post-qx and possibly 
increased survival.  
8. Medical treatment 
Aspirin 
There are currently a total of 8 studies with more than 2500 patients using aspirin CSRC. The 
doses used 325-1200 mg daily. Two of these studies showed significant benefit of aspirin a 
day after heart surgery. In contrast to the other 6 that saw no difference vs placebo with 
regard to occlusion of the bridges managed belatedly. In conclusion, the evidence so far 
suggests that the use of aspirin to reduce occlusion of coronary artery bypass bridges to 12 
months after CSRC when given the 1st day after surgery, on the other hand is a medicine 
economic which is associated with few adverse effects and is of great benefit for patients 
with coronary artery disease peripheral with that aspirin should be given the most quickly 
as possible after cardiac surgery and continued indefinitely.  
HIipolipemiantes 
There are three studies involving 1900 patients to evaluate the use of these agents on the 
occlusion of coronary artery bypass grafts and the risk of cardiovascular events): The Post-
CABG trial, LOCATE (Lopid Coronary Angiography Trial) and Cholesterol Lowering 
Atherosclerotic Study ( CLAS). All three showed a significant reduction in the progression 
of atherosclerosis in coronary artery bypass bridges. Thus the long-term use of lipid-
lowering drugs prevent the progression of atherosclerosis in both native arteries and in 
coronary bridges and reduces cardiovascular events, it was shown that the use of these 
agents reduces the progression of atherosclerosis after 2 years RVM.  
Pan et al, found that after adjusting the demographic and clinical differences, the 
preoperative use of statins was associated with a 50% reduction in mortality, but showed 
no benefit in the occurrence of AF or IM. Dotan et al, found that statins were associated 
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decompensation. 
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perioperative infusion of neriritide and showed improvement compared with milrinone. 
We included 40 hemodynamically stable patients with LVEF 35% or less that were 
undergoing bypass surgery. And they were randomized to a bolus of nesiritide or 
milrinone intraoperatively followed by an infusion of any of them for 24 hr. The time 
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compared with 44.1 + / - 23.5 hours of receiving milrinone (p = 0.57). The incidence of 
post-qx ICC also showed no significant results in both groups (p = 0.25). On the third day 
of follow up, no significant differences in SBP readmission between the two drugs and 
there was no impact on mortality, the authors concluded that nesiritide does not reduce 
hospital stay post-qx like not modify other parameters of disease compared with 
nesiritide in MVR and stable ventricular function. 
In a prospective double-blind (NAPA) Mentzer et al; consider the role nesiritide might play 
in patients with left ventricular dysfunction with MVR with cardiopulmonary bypass. 
Patients with ejection fraction less than or equal to 40% who underwent MVR and DCP 
were randomized to receive nesiritide or placebo for 24-96 hr after induction of anesthesia. 
The post-qx renal function, hemodynamic parameters and drug use (primary endpoints) 
were evaluated in patients with MVR with DCP, mortality and safety (secondary endpoints) 
were evaluated in all patients who received the drug, 303 patients randomized, 279 received 
the drug and 272 underwent MVR with DCP. Compared with placebo, nesiritide was 
associated with a slight increase in serum creatinine (0.15 + / - 0.29 mg / dl versus. 0.34 + / - 
0.48 mg / dl, p <0.001) and a fall in glomerular filtration rate (- 10.8 + / - 19.3 mL/min/1.73 
m (2) versus -17.2 + / - 21.9 mL/min/1.73 m (2), P = 0.001) during hospital stay or stay on 
14. On the other hand, patients treated with nesiritide had a shorter hospital stay (p = 0.043) 
and lower mortality at 180 days. (P = 0.046). The authors concluded that nesiritide in the 
context of RVM with CPB is associated with improved renal function post-qx and possibly 
increased survival.  
8. Medical treatment 
Aspirin 
There are currently a total of 8 studies with more than 2500 patients using aspirin CSRC. The 
doses used 325-1200 mg daily. Two of these studies showed significant benefit of aspirin a 
day after heart surgery. In contrast to the other 6 that saw no difference vs placebo with 
regard to occlusion of the bridges managed belatedly. In conclusion, the evidence so far 
suggests that the use of aspirin to reduce occlusion of coronary artery bypass bridges to 12 
months after CSRC when given the 1st day after surgery, on the other hand is a medicine 
economic which is associated with few adverse effects and is of great benefit for patients 
with coronary artery disease peripheral with that aspirin should be given the most quickly 
as possible after cardiac surgery and continued indefinitely.  
HIipolipemiantes 
There are three studies involving 1900 patients to evaluate the use of these agents on the 
occlusion of coronary artery bypass grafts and the risk of cardiovascular events): The Post-
CABG trial, LOCATE (Lopid Coronary Angiography Trial) and Cholesterol Lowering 
Atherosclerotic Study ( CLAS). All three showed a significant reduction in the progression 
of atherosclerosis in coronary artery bypass bridges. Thus the long-term use of lipid-
lowering drugs prevent the progression of atherosclerosis in both native arteries and in 
coronary bridges and reduces cardiovascular events, it was shown that the use of these 
agents reduces the progression of atherosclerosis after 2 years RVM.  
Pan et al, found that after adjusting the demographic and clinical differences, the 
preoperative use of statins was associated with a 50% reduction in mortality, but showed 
no benefit in the occurrence of AF or IM. Dotan et al, found that statins were associated 
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with a significant decrease in cardiac mortality, unstable angina and arrhythmias 60 days 
to 1 year.  
Beta blocker 
Its use has been assessed by many studies, but in a perioperative cardiac surgery, Sjölander 
et.al, conducted a controlled double-blind study of 967 patients with MVR. Patients were 
randomized 4 to 21 days after RVM receiving 50 mg of metoprolol 2 times per day x 2 weeks 
and 100 mg of metoprolol per day vs placebo 2 x 2 years. There was no significant difference 
between the 2 study arms with respect to exercise capacity, however cn patients placebo had 
a higher rate of chest pain compared with the metoprolol group. On the other hand no 
significant difference in both groups with regard to revascularization, unstable angina, 
nonfatal MI or death at 2 years of follow-up.  
Finally, Ferguson et al, in a cohort study investigated the use of preoperative B-blocker in 
629 877 patients undergoing CSRC and showed a reduction to 30 days of drug-related 
mortality (OR 0.90, 95% CI0.87-0.93 ). This decrease was consistent with all groups of 
patients except those with LVEF <30% where there was no demonstrated benefit.  
Calcium antagonist 
Only one study has examined the effect of calcium antagonists initiated after surgery RVM, 
Gaudino et al; evaluating the benefits of calcium antagonists after the first year of 
revascularization. A total of 120 patients with normal perfusion function were randomized 
after 1 year of tx with 120 mg diatiazem to continue with or stop. No significant differences 
after 4 years of follow-up among the group of calcium antagonists and those who 
discontinued tx with respect to recurrence of angina (10% vs 12%), residual ischemia, 17% vs 
18%) and cardiac death 2% vs 0%). In short there is little evidence to support the routine use 
of calcium antagonists or nitrates after cardiac surgery.  
ACEI 
Despite the known benefits of ACE inhibitors, only 4 studies examined perioperative 
prophylactic use of ACE inhibitors in patients with MVR. QUO VADIS In the study 149 
patients were randomized to quinapril 40mg/día or placebo for 4 weeks before elective 
surgery RVM, treatment was continued for 1 year. The researchers found that quinapril 
significantly reduced 1-year clinical events, such as death from cardiovascular causes.  
9. Anticoagulants and antithrombotics management 
Thromboembolism and bleeding associated with anticoagulation comprise about 75% of the 
complications associated with prosthetic valves. antithrombotic therapy can reduce but not 
eliminate the possibility of this catrastofe. It is reported that the incidence of perioperative 
arterial thromboembolism is approximately 0.4 to 1.5% and the annual risk of stroke in high 
risk patients without anticoagulation is> 5.6% and <2.0% of major bleeding. 
The risk for thrombus formation with prosthetic heart valves is seven times higher in the 
first month after valve replacement during the following months, years intracardiac 
position independent. The underlying pathophysiology of activation are factors in the 
systems of intrinsic and extrinsic coagulation of synthetic surface extracorporeal 
circulation of blood or from contact with surfaces or tissue devoid of collagen, a 
significant number of surgeons in favor of delaying the anticoagulant because the risk of 
bleeding, the incidence of pericardial tamponade and reoperation is eight times higher in 
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patients treated with high doses of heparin than in those treated with low-dose heparin 
for prevention of venous thrombosis. 
Anticoagulation is recommended in the following cases: 
 Lifetime on all patients with mechanical valves 
 Lifetime in patients with biological valves who have other indications for 
anticoagulation Vgr: atrial fibrillation, heart failure, ventricular ejection fraction less 
than 30% left. 
 For the first three months in patients with bioprostheses after insertion, with a target 
INR of 2.5. No emabrgo strategy with aspirin (low dose-100 mg DE75) is an alternative, 
but there have been no randomized studies supporting the safety of this strategy. 
There is no consensus at the time of initiation of anticoagulation after surgery, but should 
begin during the first days postoperatively. (5 + -2) 
10. References 
[1] Lyons AS, Petruccelli RJ II. Medicine and illustrated history. New York: HN Abrams Inc, 
1978. 
[2] Vesalius A. De humani corporis fabrica. Budapest: Corvina / Magyar Helikon, 1972. 
[3] Rutkow IM. Surgery. An illustrated history. St. Louis, Baltimore, Boston, Chicago, 
London, Madrid, Philadelphia, Sydney, Toronto: Mosby, 1993. 
[4] Casey LC. Roles of cytokines in the pathogenesis of multisystem organ failure induced 
cardiopulmonary. Ann Thorac Surg 1993; S6: S92-S96. 
[5] Huddy SP, Joyce WP. Pepper JR. Gastrointestinal Complications in Patients Who 
underwent cardiopulmonary 4.473 bypass surgery. Br J Surg 1991; 78:293-296. 
[6] CHV Thakar, Jared JP, Worley S, Cotman K, Paganini EP. Renal dysfunction and Serious 
Infections After open-heart surgery. Kidney Int 2003; 64:239-246. 
[7] Laffey J, Boylan J, Cheng D. The systemic inflammatory response to cardiac surgery. 
Anesthesiology 2002; 97:215-252. 
[8] Kollef MH, Wragge T, Pasque Ch Determinants of Mortality and multiorgan dysfunction 
in cardiac surgery Patients Requiring Prolonged mechanical ventilation. Chest 
1995; 107 (5) :1395-1401. 
[9] Kalfin RE, Engelmann RM, Rousseau JA, Flack JE III, Deaton DW, Kreutzer DL, DK 
Dash. Induction of interleukin-8 expression cardiopulmonary bypass DURING. 
Circulation 1993; 88 [Part 2]: 401 - 406. 
[10] Ascione R, Lloyd CT, Underwood MJ, Lotto A, Pitsis AA, Angelini GD. After coronary 
revascularization Inflammatory response With or Without cardiopulmonary 
bypass prospective randomized study. Ann Thorac Surg 2000; 69: 1198-1204. 
[11] Nilsson L, Kulander L, Sven-Olov N, Eriksson O. Endotoxins in cardiopulmonary 
bypass. J Thorac Cardiovasc Surg 1990; 100:777-780. 
[12] Pizzo PA. Empirical therapy and prevention of infections in the immunocompromised 
host. In: Mandell GL, Bennett JE. Dolin R, editors. Principles and practice of 
infectious diseases. 5th edition. New York: Churchill-Livingstone, 2000. pp. 3102-
3112. 
[13] Rossi F. The O2-forming NADPH oxidase of the phagocyte: nature, Mechanisms of 
activating and function. Biochim Biophysics Acta 1984, 853:65-71. 
 
Special Topics in Cardiac Surgery 34
with a significant decrease in cardiac mortality, unstable angina and arrhythmias 60 days 
to 1 year.  
Beta blocker 
Its use has been assessed by many studies, but in a perioperative cardiac surgery, Sjölander 
et.al, conducted a controlled double-blind study of 967 patients with MVR. Patients were 
randomized 4 to 21 days after RVM receiving 50 mg of metoprolol 2 times per day x 2 weeks 
and 100 mg of metoprolol per day vs placebo 2 x 2 years. There was no significant difference 
between the 2 study arms with respect to exercise capacity, however cn patients placebo had 
a higher rate of chest pain compared with the metoprolol group. On the other hand no 
significant difference in both groups with regard to revascularization, unstable angina, 
nonfatal MI or death at 2 years of follow-up.  
Finally, Ferguson et al, in a cohort study investigated the use of preoperative B-blocker in 
629 877 patients undergoing CSRC and showed a reduction to 30 days of drug-related 
mortality (OR 0.90, 95% CI0.87-0.93 ). This decrease was consistent with all groups of 
patients except those with LVEF <30% where there was no demonstrated benefit.  
Calcium antagonist 
Only one study has examined the effect of calcium antagonists initiated after surgery RVM, 
Gaudino et al; evaluating the benefits of calcium antagonists after the first year of 
revascularization. A total of 120 patients with normal perfusion function were randomized 
after 1 year of tx with 120 mg diatiazem to continue with or stop. No significant differences 
after 4 years of follow-up among the group of calcium antagonists and those who 
discontinued tx with respect to recurrence of angina (10% vs 12%), residual ischemia, 17% vs 
18%) and cardiac death 2% vs 0%). In short there is little evidence to support the routine use 
of calcium antagonists or nitrates after cardiac surgery.  
ACEI 
Despite the known benefits of ACE inhibitors, only 4 studies examined perioperative 
prophylactic use of ACE inhibitors in patients with MVR. QUO VADIS In the study 149 
patients were randomized to quinapril 40mg/día or placebo for 4 weeks before elective 
surgery RVM, treatment was continued for 1 year. The researchers found that quinapril 
significantly reduced 1-year clinical events, such as death from cardiovascular causes.  
9. Anticoagulants and antithrombotics management 
Thromboembolism and bleeding associated with anticoagulation comprise about 75% of the 
complications associated with prosthetic valves. antithrombotic therapy can reduce but not 
eliminate the possibility of this catrastofe. It is reported that the incidence of perioperative 
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patients treated with high doses of heparin than in those treated with low-dose heparin 
for prevention of venous thrombosis. 
Anticoagulation is recommended in the following cases: 
 Lifetime on all patients with mechanical valves 
 Lifetime in patients with biological valves who have other indications for 
anticoagulation Vgr: atrial fibrillation, heart failure, ventricular ejection fraction less 
than 30% left. 
 For the first three months in patients with bioprostheses after insertion, with a target 
INR of 2.5. No emabrgo strategy with aspirin (low dose-100 mg DE75) is an alternative, 
but there have been no randomized studies supporting the safety of this strategy. 
There is no consensus at the time of initiation of anticoagulation after surgery, but should 
begin during the first days postoperatively. (5 + -2) 
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1. Introduction 
Several discoveries and inventions in medicine have revolutionized it’s practice. Examples 
would include the discovery of Insulin by Dr William Banting in 1920. The discovery of 
Heparin by Dr Jay McLean and its first clinical use in Toronto in 1933-36, the advent of the 
membrane oxygenator, heart lung machines with progressively smaller footprints, intra 
aortic balloon (IAB) pumps and VAD’s (ventricular assist device) would be some of the 
devices which significantly impacted outcomes in cardiac surgery. 
The fundamentals of IAB technology were first tested by Harken in 1958, who is credited 
with the first use of diastolic augmentation. The pump for Harken’s system was a failure 
due to massive hemolysis. Moulopoulous (in the 1960’s) from the Cleveland Clinic 
developed the first successful prototype of an Intra-aortic balloon pump (IABP) which could 
be timed to the cardiac cycle. 
The IABP device as we know it was reported by Dr Adrian Kantrowitz (Fig 1) and his team 
from Grace Sinai hospital in Detroit. The first clinical implant was performed at Maimonides 
Medical Centre, Brooklyn, NY in Oct 1967 for a 48 yr old woman in cardiogenic shock 
unresponsive to traditional therapy. The IAB was inserted through a cut down of the left 
femoral artery (LFA) and pumping performed for 6 hrs. The shock was reversed and the 
patient discharged. The device was further developed for cardiac surgery by Dr David 
Bregman at New York Presbyterian Hospital in 1976. 
Studying the history of counterpulsation elucidates the great strides in IAB technology and 
its clinical applications. The size of the balloons initially inserted were as large as 15 Fr. Two 
operations were required for balloon usage, one to insert the balloon by cut down in a 
femoral artery, and a second operation to remove the balloon. Advances in technology 
afforded progressively smaller IAB catheter sizes and eventually 8 and 9Fr. balloons were 
developed. Current IAB catheter sizes are 7 and 7.5Fr. 
In 1968 –Kantrowitz and his group began to use the IABP regularly in clinical practice. 
Since 1979 balloon placement utilizes the Seldinger (percutaneous) technique. 
The wrapped IAB was developed in 1985. Advances in technology facilitated graduating 
from cut down insertions to percutaneous and sheathless insertions going from cut down 
insertions to percutaneous and finally sheathless insertions. Smaller diameter catheters 
permitted this along with user friendly consoles with automated and real time timing 
algorithms. 
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Fig. 1. Datascope System 80 
2. Fundamentals of cardiac physiology 
Understanding of counterpulsation, requires a knowledge of relevant cardiovascular 
physiology. The heart works as a series circuit of pumps, the left system and the right 
system.  
The right atrium (RA) receives blood from the inferior and superior vena cava and coronary 
sinus, most of which flows passively into the right ventricle (RV) through the tricuspid 
valve. An additional 20% of ventricular filling occurs through the atrial kick corresponding 
to the “p” wave of the Electrocardiogram (ECG). (Quaal 1993) 
The right system feeds the low pressure pulmonary vasculature which offers little resistance 
to the blood ejected from the right ventricle (RV). Consequently the right ventricular 
musculature is one third the girth of the Left Ventricle. The left atrium receives blood from 
four pulmonary veins and passively empties the blood into the left ventricle through the 
mitral valve. Since there are no valves in the pulmonary veins, elevation of left atrial 
pressure results in an increase in pulmonary vascular resistance (PVR). 
Generation of high pressure is required by the left ventricle, most of the pressure being 
generated occurs during isovolumetric contraction (Fig2-phases of contraction-electrical and 
mechanical) in order to open the aortic valve, and overcome SVR and aortic end diastolic 
pressure (AEDP), which is a function of the systemic vascular resistance.  
The intraventricular septum also contributes to the left ventricular ejection along with the 
thick circular posterior and lateral walls. 
Some of the energy imparted to the blood through ventricular ejection is stored in the 
proximal aorta and large arteries as potential energy during their peak expansion. This is 
known as the Windkessel effect. In diastole, this energy is transformed into kinetic energy 
by the aorta and large arteries causing a recoil, which maintains a pressure head in the aorta. 
This in turn maintains a runoff during diastole into the peripheral arteries. It’s important to 
note that coronary arteries fill during diastole. 
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Fig. 2. Phases of electrical and mechanical contraction 
3. Cardiac output 
Cardiac output is the product of stroke volume and heart rate. Stroke volume is the amount 
of blood ejected by the Left Ventricle with every beat. 
Stroke volume is dependent on 
1. Preload 
2. Afterload 
3. Inotropy or (ventricular contractility) and 
4. Heart rate 
4. Preload 
This concept suggests that the length of ventricular muscle fiber determines the magnitude 
of contraction. The length of the LV muscle fiber in turn is dependent upon the left 
ventricular end diastolic volume (LVEDP). In other words increase in left atrial filling would 
increase the magnitude of LV contraction. The ability of the LV to vary the strength of its 
contraction as a function of the LVEDP and end diastolic muscle fiber length is defined as 
Frank Starling law (fig 3). This gain in contractility is impaired when the stretch goes 
beyond physiological limits. In clinical practice the length of the muscle fiber is proportional 
to the LVEDP ’which is measured indirectly as the pulmonary artery wedge pressure 
(PAWP) by means of a Swan Ganz catheter. In a normal LV, very slight changes in PAWP or 
LVEDP, produces significant increases in stroke volume. 
5. Afterload 
Afterload is defined as the resistance to LV ejection. Major components are SVR and 
AEDP. AEDP is the resistance the LV has to overcome in order to open the aortic valve. 
Ninety percent of myocardial oxygen consumption takes place during the isovolumetric  
 




Fig. 1. Datascope System 80 
2. Fundamentals of cardiac physiology 
Understanding of counterpulsation, requires a knowledge of relevant cardiovascular 
physiology. The heart works as a series circuit of pumps, the left system and the right 
system.  
The right atrium (RA) receives blood from the inferior and superior vena cava and coronary 
sinus, most of which flows passively into the right ventricle (RV) through the tricuspid 
valve. An additional 20% of ventricular filling occurs through the atrial kick corresponding 
to the “p” wave of the Electrocardiogram (ECG). (Quaal 1993) 
The right system feeds the low pressure pulmonary vasculature which offers little resistance 
to the blood ejected from the right ventricle (RV). Consequently the right ventricular 
musculature is one third the girth of the Left Ventricle. The left atrium receives blood from 
four pulmonary veins and passively empties the blood into the left ventricle through the 
mitral valve. Since there are no valves in the pulmonary veins, elevation of left atrial 
pressure results in an increase in pulmonary vascular resistance (PVR). 
Generation of high pressure is required by the left ventricle, most of the pressure being 
generated occurs during isovolumetric contraction (Fig2-phases of contraction-electrical and 
mechanical) in order to open the aortic valve, and overcome SVR and aortic end diastolic 
pressure (AEDP), which is a function of the systemic vascular resistance.  
The intraventricular septum also contributes to the left ventricular ejection along with the 
thick circular posterior and lateral walls. 
Some of the energy imparted to the blood through ventricular ejection is stored in the 
proximal aorta and large arteries as potential energy during their peak expansion. This is 
known as the Windkessel effect. In diastole, this energy is transformed into kinetic energy 
by the aorta and large arteries causing a recoil, which maintains a pressure head in the aorta. 
This in turn maintains a runoff during diastole into the peripheral arteries. It’s important to 
note that coronary arteries fill during diastole. 
Intra-Aortic Balloon Counterpulsation Therapy 




Fig. 2. Phases of electrical and mechanical contraction 
3. Cardiac output 
Cardiac output is the product of stroke volume and heart rate. Stroke volume is the amount 
of blood ejected by the Left Ventricle with every beat. 
Stroke volume is dependent on 
1. Preload 
2. Afterload 
3. Inotropy or (ventricular contractility) and 
4. Heart rate 
4. Preload 
This concept suggests that the length of ventricular muscle fiber determines the magnitude 
of contraction. The length of the LV muscle fiber in turn is dependent upon the left 
ventricular end diastolic volume (LVEDP). In other words increase in left atrial filling would 
increase the magnitude of LV contraction. The ability of the LV to vary the strength of its 
contraction as a function of the LVEDP and end diastolic muscle fiber length is defined as 
Frank Starling law (fig 3). This gain in contractility is impaired when the stretch goes 
beyond physiological limits. In clinical practice the length of the muscle fiber is proportional 
to the LVEDP ’which is measured indirectly as the pulmonary artery wedge pressure 
(PAWP) by means of a Swan Ganz catheter. In a normal LV, very slight changes in PAWP or 
LVEDP, produces significant increases in stroke volume. 
5. Afterload 
Afterload is defined as the resistance to LV ejection. Major components are SVR and 
AEDP. AEDP is the resistance the LV has to overcome in order to open the aortic valve. 
Ninety percent of myocardial oxygen consumption takes place during the isovolumetric  
 




Fig. 3. Starling Law 
contraction phase when the LV is trying to overcome the resistance caused by the AEDP in 
order to open the Aortic valve. The aim of counterpulsation is to lower AEDP, thereby 




Fig. 4. Myocardial Oxygen Supply and Demand 
6. Contractility  
Contractility is defined as the change in the force of contraction, independent of myocardial 
fiber length. Contractility inotropic performance can be increased by endogenous 
production of catecholamines or exogenous administration of vasopressors like 
norepinephrine (NE), dopamine, calcium etc. Myocardial contractility decreases wuth 
hypoxemia and drugs like barbiturates, procainamide, lidocaine, propranolol etc. 
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7. Ventricular function 
In order for us to appreciate the need for the IAB, we need to understand ventricular function, 
end diastolic volume and the Fick equation. Ventricular function in critical care is assessed by 
the Ejection Fraction (EF). EF is defined as the volume of blood ejected per beat (stroke volume 
or SV) divided by the volume in the LV prior to ejection, end diastolic volume (EDV). Stroke 
vol equals EDV minus end systolic volume (ESV). The equation for EF would then be: 
EF = EDV-ESV/EDV= SV/EDV 
Ventricular function is graded into four groups by two dimensional echocardiography 
according to ejection fraction as shown in fig 5 (Conolly HM & Kohl J 2012). 
 
LV Grade Ejection Fraction 
Grade 1 LV ≥ 55% 
Grade 2 LV 45 to 54% 
Grade 3 LV 30 to 44% 
Grade 4 LV ≤ 30% 
Fig. 5. LV Grade and Corresponding Ejection Fraction 
Diastolic volume index: EDV indexed to the patients body surface area (BSA) is another 
measure of ventricular performance. A normal index is considered less than 100ml/m². In 
patients with regurgitant valves and volume overload, the end diastolic volume index 
(EDVI) may be high despite preserved LV function. 
The Fick Equation: Defines the relationship between C.O and oxygen extraction. 
O2 consumption= C.O X O2 content difference (sao2-svo2) 
C.O = O2 consumption/O2 content difference (sao2-svo2) 
Therefore CO is inversely proportional to O2 content difference, assuming that O2 
consumption remains constant. A normal value for arterio-venous oxygen difference would 
be less than 5 ml/dl or 50ml/L. A low cardiac output state would encourage increased 
oxygen extraction, resulting in widening of arterio-venous o2 content of greater than 
5ml/dl. (Hensley et al.,1995 ) 
8. Heart rate 
Increase in the frequency of contraction increases C.O at a given filling pressure. This is 
called the staircase (Bowditch) effect. Reduction in diastolic time can result in reduction of 
ventricular filling, thus limiting C.O increase with tachycardia. An important corollary to 
remember is that the filling of coronary arteries takes place in diastole and tachycardia can 
compromise diastolic coronary filling. 
9. Coronary circulation and anatomy 
The myocardium is perfused during diastole through the coronary system (fig 6).  
The major vessels of the coronary circulation are the left main coronary that divides into left 
anterior descending and circumflex branches, and the right main coronary artery. The left 
and right coronary arteries originate at the base of the aorta from openings called the 
coronary ostia located just distal to the aortic valve leaflets.  
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Fig. 6. The Coronary System 
The left and right coronary arteries and their branches lie on the surface of the heart, and 
therefore are sometimes referred to as the epicardial coronary vessels. These vessels distribute 
blood flow to different regions of the heart muscle. When the vessels are not diseased, they 
have a low vascular resistance relative to their more distal and smaller branches that comprise 
the microvascular network. As in all vascular beds, it is the small arteries and arterioles in the 
microcirculation that are the primary sites of vascular resistance, and therefore the primary site 
for regulation of blood flow. The arterioles branch into numerous capillaries that lie adjacent to 
the cardiac myocytes. A high capillary-to-cardiomyocyte ratio and short diffusion distances 
ensure adequate oxygen delivery to the myocytes and removal of metabolic waste products 
from the cells (e.g., CO2 and H+). Capillary blood flow enters venules that join together to form 
cardiac veins that drain into the coronary sinus located on the posterior side of the heart, 
which in turn drain into the right atrium. There are also anterior cardiac veins and thebesian 
veins that drain directly into the cardiac chambers. The LAD supplies blood to the front 
(anterior-septal) portion of the heart and the LCX supplies the side (anterio-lateral) and back 
(posterior) of the left ventricle. The right coronary artery supplies blood to the ventricles, the 
right atrium (RA), the inferior portion of the myocardium and the sino-atrial node. The LAD 
give rise to various branches called the diagonals and marginal’s while the RCA bifurcates 
into the posterior descending artery (PDA) and the acute marginal artery. The RCA supplies 
blood to the inferior portion of the myocardium. 
10. Heart failure 
Forward heart failure or congestive heart failure is defined as the inability of the heart to keep 
up with its demand. Forward heart failure can lead to backward heart failure. Heart failure 
can be caused by structural heart disease, coronary artery disease, Cardiomyopathy or 
conduction disorders, more often than not requiring surgical correction. Conduction disorder 
can impair C.O by causing a too slow/fast heart rate, loss of atrial kick or loss of conduction. 
Left ventricular failure is directly related to the need for an IAB. Heart failure can be 
manifested as angina, crescendo or unstable angina or exercise induced angina. Heart failure 
causes ischemia and myocardial ischemia can be silent. Ninety seven percent of peri-operative 
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ischemia has been found to be silent (Hensley 1995). Silent ischemia can translate into peri-
operative infarct or ischemia both of which could cause heart failure. Left Ventricular failure 
can be divided into three stages. Stage 1 (fig 7) is manifested as vasoconstriction leading to 
decreased pumping efficiency, increased LV volume and pressure. These physiological events 
activate baroreceptors leading to increased heart rate, increased afterload (SVR), increased 
myocardial oxygen demand and ultimately an increase in preload (LVEDP). 
 
 
Fig. 7. Stage 1 Vasoconstriction 
Stage two (Fig 8) leads to hypervolemia as the heart tries to compensate with the additional 
afterload. There is a decrease in cardiac output and glomerular filtration pressure, further 
activating the Renin-Angiotensisn system. There is an increase in sodium and water 
reabsorption leading to an increase in preload and afterload. There is a decrease in cardiac  
 
 
Fig. 8. Stage 2 - Hypervolemia 
 




Fig. 6. The Coronary System 
The left and right coronary arteries and their branches lie on the surface of the heart, and 
therefore are sometimes referred to as the epicardial coronary vessels. These vessels distribute 
blood flow to different regions of the heart muscle. When the vessels are not diseased, they 
have a low vascular resistance relative to their more distal and smaller branches that comprise 
the microvascular network. As in all vascular beds, it is the small arteries and arterioles in the 
microcirculation that are the primary sites of vascular resistance, and therefore the primary site 
for regulation of blood flow. The arterioles branch into numerous capillaries that lie adjacent to 
the cardiac myocytes. A high capillary-to-cardiomyocyte ratio and short diffusion distances 
ensure adequate oxygen delivery to the myocytes and removal of metabolic waste products 
from the cells (e.g., CO2 and H+). Capillary blood flow enters venules that join together to form 
cardiac veins that drain into the coronary sinus located on the posterior side of the heart, 
which in turn drain into the right atrium. There are also anterior cardiac veins and thebesian 
veins that drain directly into the cardiac chambers. The LAD supplies blood to the front 
(anterior-septal) portion of the heart and the LCX supplies the side (anterio-lateral) and back 
(posterior) of the left ventricle. The right coronary artery supplies blood to the ventricles, the 
right atrium (RA), the inferior portion of the myocardium and the sino-atrial node. The LAD 
give rise to various branches called the diagonals and marginal’s while the RCA bifurcates 
into the posterior descending artery (PDA) and the acute marginal artery. The RCA supplies 
blood to the inferior portion of the myocardium. 
10. Heart failure 
Forward heart failure or congestive heart failure is defined as the inability of the heart to keep 
up with its demand. Forward heart failure can lead to backward heart failure. Heart failure 
can be caused by structural heart disease, coronary artery disease, Cardiomyopathy or 
conduction disorders, more often than not requiring surgical correction. Conduction disorder 
can impair C.O by causing a too slow/fast heart rate, loss of atrial kick or loss of conduction. 
Left ventricular failure is directly related to the need for an IAB. Heart failure can be 
manifested as angina, crescendo or unstable angina or exercise induced angina. Heart failure 
causes ischemia and myocardial ischemia can be silent. Ninety seven percent of peri-operative 
Intra-Aortic Balloon Counterpulsation Therapy 
and Its Role in Optimizing Outcomes in Cardiac Surgery 
 
49 
ischemia has been found to be silent (Hensley 1995). Silent ischemia can translate into peri-
operative infarct or ischemia both of which could cause heart failure. Left Ventricular failure 
can be divided into three stages. Stage 1 (fig 7) is manifested as vasoconstriction leading to 
decreased pumping efficiency, increased LV volume and pressure. These physiological events 
activate baroreceptors leading to increased heart rate, increased afterload (SVR), increased 
myocardial oxygen demand and ultimately an increase in preload (LVEDP). 
 
 
Fig. 7. Stage 1 Vasoconstriction 
Stage two (Fig 8) leads to hypervolemia as the heart tries to compensate with the additional 
afterload. There is a decrease in cardiac output and glomerular filtration pressure, further 
activating the Renin-Angiotensisn system. There is an increase in sodium and water 
reabsorption leading to an increase in preload and afterload. There is a decrease in cardiac  
 
 
Fig. 8. Stage 2 - Hypervolemia 
 
Special Topics in Cardiac Surgery 
 
50
output, decrease in oxygen supply, increase in heart rate and increase in oxygen demand. 
There is an increase in pulmonary artery wedge pressures. 
The final stage of LV failure (Fig 9) is the manifestation of tissue hypoxia. Decreased cardiac 
output, decreased MAP, decreased oxygenation coupled with pulmonary edema causes 
acceleration of anaerobic metabolism, lactic acid production, Tissue anoxia and finally tissue 
death. Its ideal to insert the IAB in stage one or  by stage two, so that we prevent the final 
stage of heart failure. 
 
 
Fig. 9. Stage 3 - Tissue Hypoxia and Apoptosis 
11. Indications for mechanical circulatory support 
Before we cite specific indications for IAB insertion, we should discuss indications for 
mechanical circulatory support. In other words, we should be able to delineate or define 
ventricular failure. LV failure would be defined as cardiac index (CI) of less than 1.8 
L/min/m² with a systolic blood pressure of less than 90 mmhg (ref: Hensley Martin) despite 
maximized preload (mean atrial pressure > 20 mmhg), optimized heart rate (> 80) and 
normalized ionized calcium. This could be extrapolated to RV failure except for the systolic 
blood pressure. RV work is the function of the difference between the RA and PA mean 
pressure. As the difference between the two approaches zero, pulmonary blood flow is passive 
and RV failure is present. RV failure can occur with or without pulmonary hypertension. 
Mechanical support is suggested when the above criteria are present despite maximum 
inotropic support. Maximum inotropic support can be defined as any two or more (High et 
al., 1995) of the following combinations: 
1. > 10 µg/kg/min of Dopamine 
2. > 10 µg/kg/min of Dobutamine 
3. > 0.2 µg/kg/min of Epinephrine 
4. > 0.75 µg/kg/min of Milrinone after loading dose 
5. > 10 µg/kg/min of Nor–epinephrine 
For patients with severe forms of LV failure, ventricular assist devices (VAD) are indicated. 
The initial indicated mechanical support in these scenarios is the IABP. Large and prolonged 
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inotrope infusion will only tend to increase the workload of the ventricle. The IABP does the 
exact opposite, decreases the workload of the heart. 
12. Indications for IAB insertion 
In cardiac surgery the IAB is indicated for the following situations: 
A. Pre-op predictors: 
1. Grade 3 to 4 LV dysfunction or ejection fraction (EF) of less than 0.30 (Dietl CA et 
al.,1996) 
2. Severe and/or multiple valvular disease with end stage myocardial impairment 
not including aortic regurgitation 
3. Anticipated prolonged CPB time 
4. Coronary artery disease (CAD) only partially correctible by grafting with 
concomitant LV dysfunction 
5. Persistent ST Changes before, during or after induction of general anesthesia 
6. Coronary obstruction via clot or otherwise 
B. Intra/post-op predictors: 
1. Pre/post CPB ischemia 
2. Incomplete repair or bypass 
3. Prolonged CPB time 
4. Large ventriculotomy or LV resection for LV aneurysm repair. 
5. Particulate or air embolus in coronary arteries. 
6. Persistent ST changes post CPB. 
Clinical indications for the IAB are listed below (fig 10 showcases benchmarks in 2005 for 
IAB use) 
1. Ventricular failure after myocardial infarction (MI) – (Barron et al., 2001) or acute 
myocardial infarction (AMI). As in all other cases the IAB will would decrease afterload 
and increase coronary perfusion. Early insertion is recommended to ameliorate the 
threatening extension of MI. 
2. Angina- chest pain is usually the initial stages of an MI and here again early insertion is 
recommended 
3. Unstable angina with or without ST segment elevation 
4. Cardiomyopathy- In the majority of cases when cardiomyopathy occurs the patient 
suffers from dilated cardiomyopathy and the IAB assist in raising mean blood pressure 
and reducing afterload. In a very few cases of initial stages of hypertrophic 
cardiomyopathy, where the ventricle tends to be a small volume ventricle (extremely 
thick myocardial wall), a sudden decrease in AEDP would result in insufficient volume 
left to fill the increased capacitance . This would actually result in a drop in MAP and 
systolic blood pressure, especially at an augmentation of 1:1 
5. Acute mitral valve regurgitation (Abid et al.,2002) and/or stenosis with LV rupture 
6. Aortic stenosis without aortic insufficiency (AI) or accompanied by mild AI 
7. Congestive heart failure 
8. Intractable ventricular arrhythmias secondary to ischemia or otherwise. In these cases 
IAB’s with fibre optic technology can be used to track rapid or irregular heart rhythms 
9. Ventricular irritability 
10. Bridge to transplant or destination therapy 
11. Support in the catheterization laboratory (Stone GW et al.,1997) for stenting or PTCA 
(Percutaneous Transluminal Coronary Angioplasty) 
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9. Ventricular irritability 
10. Bridge to transplant or destination therapy 
11. Support in the catheterization laboratory (Stone GW et al.,1997) for stenting or PTCA 
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Fig. 10. BENCHMARK for IAB use (2005) 
12. Myocardial ischemia or stunning of the heart- In this scenario much of the myocardium 
has suffered reversible damage and scarring has occurred only in a portion of the heart. 
13. VSD (ventricular septal defect) - particularly post MI. This may be accompanied by 
papillary muscle rupture and acute mitral regurgitation 
14. Support in the General OR for patients with ongoing heart disease or a history of heart 
disease 
15. Transport (Sinclair TD & Verman HA,2009)for unstable patients 
16. Left main disease 
17. Cardiac contusion and/or trauma 
18. Septic shock or pre-shock syndrome 
19. Pulsatile flow (Onorati F et al.,2009)during CPB 
Freedman coined the term “Myoconservation” (Quaal 1993). It is defined as the 
hemodynamic support provided within the crucial window of opportunity, ensuring that 
enough myocardium remains viable to permit normal function of the heart following 
definitive coronary therapy-whether it be CABG or coronary stenting/PTCA. The IAB is one 
of the very important modalities available to the cardiac surgeon/cardiologist which 
supports myoconservation by supporting the coronary circulation, supporting the systemic 
circulation, reduction in LV stress and reduction in LV workload.  
Miller et al in 1986 summarize “The result of our clinical experience suggest that more 
aggressive use of IAB is likely to save lives of coronary disease patients who develop severe 
complications of their disease. There have been no deaths reported among our patients with 
refractory unstable angina who had an IAB inserted and all evidence suggests that short of 
actually opening the vessel to obtain relief from angina, IAB insertion is the most effective 
method to treat these patients”  
More recent studies (Christenson JT 1999) have confirmed the efficacy of pre-operative IAB 
use in high-risk coronary patients. 
13. Absolute contraindications for IAB insertion 
1. Aortic regurgitation or insufficiency. In this physiology, raising AEDP would result in 
increase of regurgitant factor thereby increasing workload of the heart. In instances of 
mild AI a decision can be made if the benefits outweigh the risks. 
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2. Aortic dissection. Precludes IAB insertion. Attempting to Place an IAB in this situation 
may lead to placement in the false lumen or at the very least increase circulation into 
the false lumen. 
14. Relative contraindications for IAB insertion 
1. Severe peripheral vascular disease (PVD). Although this sometimes precludes insertion, 
we have had some experience with this. A discussion on PVD patients will be 
conducted a little later. 
2. Unresected thoracic, abdominal or thoraco-abdominal aneurysm. An insertion of a 
mechanical device like the IAB and the counterpulsation of such a device against a 
diseased aortic wall may result in aortic dissection 
3. Sepsis or infection 
4. Severe thrombocytopenia 
5. Coagulopathy or coagulopathic disorder 
6. End stage terminal disease 
7. End stage cardiomyopathy unless bridge to transplant/destination therapy 
8. Severe atherosclerosis 
15. Pre-insertion predictors of risks associated with IAB insertion 
1. Age- Increased age appears to be an increased risk. It is probably because of increased 
atherosclerosis associated with increased age (Goldberger 1986). There are other studies 
reporting inconsistent results. 
2. Gender- women tend to have a greater risk of complication due to their smaller stature. 
This is probably due to the smaller lumen size of the femoral artery in women. The IAB 
catheter was expected to occupy greater lumen space in women thereby increasing the 
likelihood of ischemia and/or thrombus formation. Women are 1.6 to 1.8 more likely to 
experience limb ischemia/vascular complications than men (Skillman JJ et al, 1988). 
3. Peripheral vascular disease (PVD) - These patients have higher likelihood for IAB 
complications due to insertion difficulties. Gottlieb suggested a three times likelihood 
for complications (Gottlieb SO et al.,1984), others  have suggested less (Skillman JJ et 
al,.1988). 
4. Type-II diabetes- Due to severe and diffuse atherosclerotic disease, higher incidence of 
hypertension and dampened resistance to bacterial contamination, diabetics tend to 
have a higher risk of complication post IAB. Some investigators found that diabetics 
(Wasfie T et al.,1988) had a 22% incidence of complications post IAB insertion as 
compared to 14% for non-diabetics. For insulin dependent diabetes a higher 
complication rate of 34% (Alderman JD et al., 1987) was suggested. 
5. Duration of IAB therapy- Findings for the duration of safe use of IAB therapy remain 
inconclusive (Quaal 1993) 
16. Complications of IAB insertion 
1. Loss of pedal pulses- Occurs in 15 – 25% of patients (funk M et al.,1989). Asymptomatic 
loss occurs transiently without resulting in limb ischemia and usually returns 
spontaneously or after IAB removal. 
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2. Limb ischemia- Occurs in 12 – 47% patients and is the most frequently reported 
complication (Curtis JJ et al., 1988). This may result from decreased cardiac output 
subsequent to heart failure, elevated SVR, low output syndrome, intimal injury or 
dissection, vessel catheter discrepancy, catheter occlusion or distal thrombo-embolism. 
Limb ischemia usually preceded by pain in the affected limb, change in pallor, cyanotic 
color changes, mottling, decreases in sensation, motor function loss, decrease in 
temperatures in extremity and loss of pedal pulses. Treatment is usually done by 
removal of IAB, thrombectomy, femoro-popiteal grafting and/or papaverine 
administration. 
3. Thromboembolism- Percutaneous insertion/removal of IAB may result in dislodging of 
plaques or clots into the renal, splanchnic, hepatic or peripheral arteries. Clots can be 
seen while removing IAB catheters. It is our institutional policy to have some sort of 
anti-coagulation during IAB therapy. Although Low molecular weight Dextran has 
been used, heparin is preferable as it can be reversed with protamine. Generally 
maintaining the aPTT 1.5 – 2 times normal is sufficient to prevent formation of 
thrombin, thereby protecting from subsequent embolism. It is also recommended to 
flush the IAB catheter with heparinized saline prior to insertion. The only incidence 
where this may not be necessary is when the patient is fully heparinized and on CPB. It 
is always a good practice even in this situation to flush with heparinized saline. At 
Southlake we use pre-mixed heparinized saline bags with 5000 units of heparin in 
500ml of saline. 
4. Compartment syndrome- The legs and thighs of humans are made up of compartments 
containing bone, muscle, nerve tissue and blood vessels, surrounded by a fibrous 
membrane or fascia. Compartment syndrome is caused by an increased pressure within 
the non-distensible fascial space reducing capillary blood flow which in turn 
compromises enclosed fascial tissue. A fasciotomy can be performed to relieve the 
pressure. 
5. Aortic Dissection- Is the most serious of complications from IAB insertion. Often 
unrecognized until removal or until IAB therapy is discontinued resulting in 
hemodynamic instability and death. Diagnosis is confirmed upon autopsy. Isner in 1980 
found an incidence of aortic dissection in 36% of IAB patients (Isner JM et al,. 1980).With 
the advent of smaller French sizes in IAB catheters and better techniques and training, 
incidence of aortic dissection as a direct consequence of IAB insertion has drastically 
reduced .Symptoms of aortic dissection include severe back and/or abdominal pain, 
falling hematocrit and mediastinal enlargement. Aortic Dissection has to be treated 
aggressively and immediately by attempting to repair the dissection in the operating 
room. 
6. Local injury- False aneurysm formation, hematoma, lymphedema, lymph fistula, 
wound hemorrhage, laceration of the femoral/iliac artery or the aorta are common 
complications and can be treated by evacuation and/or arterial repair. 
7. Infective complication- Local wound infection is possible necessitating debridement, 
drainage, systemic antibiotics and rare cases removal. Sterility is very important while 
inserting the IAB whether in the peri-operative setting or otherwise. Generally the thigh 
is prepared by applying betadine prior to insertion and is covered by sterile dressing 
after insertion and anchorage of the catheter by two sutures. 
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8. IAB rupture/entrapment- IAB rupture is rare but immediate removal/replacement is 
required. Rupture is more likely in women and patients with smaller size and usually 
occurs because of the constant contact between IAB membrane and atherosclerotic 
plaque on the femoral arterial/Aorta walls. The most common sign of IAB leak is blood 
in the drive line (fig 11). IAB leak can cause either a helium embolus (in instants of 
patient hypotension where helium pressure within the IAB exceeds blood pressure in 
the aorta) or entrapment of the catheter. The leak can cause a clot to form within the 
catheter resulting in prevention of removal of the catheter at the time of IAB removal. 
This may necessitate a cut down removal of the IAB catheter. 
 
 
Fig. 11. IAB Catheter with Blood in Drive Line and Balloon 
9. Hematologic effects- Long term use of IAB has been associated with increased 
destruction of red cells and thrombocytopenia. The degree of decrease appears to be 
related to the duration of therapy (McCabe 1978) 
10. Malposition of the IAB catheter- If positioned too high, the IAB may occlude blood 
flowing to the head vessels causing cerebral ischemia and or embolism. If positioned 
too low it may occlude the renal arteries thereby causing renal ischemia/perfusion and 
non-optimal coronary perfusion/afterload reduction. 
17. Insertion techniques 
1. Cut down technique- By 1978 the IAB was a 12fr catheter and prior to that year, cut 
down insertion was common. Initially, the common femoral artery is dissected and the 
vascular fascia is opened. With a retractor the femoral artery can be dissected up to a 
length of 5 cms and umbilical tapes are placed around and behind the femoral artery. 
Heparin 5000u is administered and the IAB catheter is introduced at an angle to the 
femoral artery. Placement is confirmed and augmentation initiated. This technique can 
also be used in patients where femoral pulse is not palpable or where difficulty of 
insertion is anticipated as in patients suffering from PVD. 
2. Percutaneous (Seldinger) technique: An 18 gauge cannula is introduced into the 
common femoral artery at a 45 degree angle or less. The guide wire is advanced 
through the needle and the needle removed. The tissue tract around the arterial 
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puncture is then dilated by the dilator provided in the IAB catheter set. The introducer-
dilator set is advanced over the guidewire. Finally the dilator is removed and the IAB 
catheter advanced over the guidewire. The IAB is introduced over the guide wire and 
placed in the second or third intercostal space. It is recommended to maintain a 
continuous flush of the IAB catheter with heparinized saline (1000u in 500ml) after 
placement. It is also recommended to periodically flush the arterial line from the IAB in 
order to prevent clotting of the arterial line coming from the IAB catheter. The 
manufacturer recommends the IAB catheter to be anchored with two sutures to the 
subcutaneous tissue of the thigh (Fig 12) at the anchors provided on the side of the base 
of the catheter or by the sutureless securement device provided. 
 
 
Fig. 12. Proper Anchoring of the IAB Catheter 
3. Sheathless insertion- Initially IAB catheters were enveloped by sheaths with bigger 
French sizes. E.g. The 8Fr IAB catheter has a sheath whose outer diameter is 10Fr. By 
not using the sheath, the practitioner is reducing trauma to the groin and femoral 
artery. Current IAB catheters of 7 and 7.5Fr are inserted in our institution without the 
sheath. Sheathless insertion also reduces the length of catheter indwelling in the tissue, 
thereby reducing limb ischemia. 
4. Subclavian insertion- Currently the manufacturer and FDA (Food and Drug 
Administration) recommends (in their IFU-instruction for use manual) femoral 
insertion of all IAB catheters. IAB catheters have regulatory clearance for femoral 
insertion and are labeled as such. There are situations where the subclavian artery has 
been used in order to avoid an aorto-iliac stenosis. A subclavicular incision is done and 
the subclavian artery isolated via cut down. An IAB catheter is placed antegrade down 
the descending thoracic aorta. 
5. Brachial insertion- The brachial artery can be used as a point of insertion where the 
patients have bilateral obstructive femoral and iliac disease and/or the patient has 
bilateral femoro-popliteal graft. Due to discomfort associated with positioning, the 
authors would recommend only in patients who are intubated and on a ventilator. Care 
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should be taken to insert the IAB on the left rather than the right side. As right sided 
insertion would not give the IAB enough length to cross the aortic arch and lie in the 
descending Aorta. We came across a 74 years female diagnosed with coronary artery 
disease (CAD) and triple vessel disease (TVD) who had aorto-bifemoral grafts inserted 
in 2004. Her risk factors included hypertension, active smoking history, type 2 Diabetes 
and previous MI. Her EF was only 28%, she had moderate MR, moderate PAH and left 
carotid bruit. She was turned down for surgery. She presented in emergency with 
angina. Had a syncopal episode with rapid atrial fibrillation. She was cardioverted 
twice and transported to the cath lab for IAB insertion. An IAB (Fig 13) was initially 
inserted through the right brachial artery and was observed via fluoroscopy to lie in the 
aortic arch. The IAB was then removed and re-inserted via the left brachial artery and 
inserted antegrade down the thoracic aorta. Augmentation was initiated, the patient 




Fig. 13. Transbrachial Insertion 
6. Transthoracic Insertion- In instances where the IAB insertion is precluded due to severe 
PVD or has been tried and failed, The IAB catheter can be introduced down the aorta in 
operative room situations. We had one such patient- a 65 year old male with active 
smoking history, no hypertension/daibetic history and a history of pericarditis in 2003. 
He had a history of severe PVD with bilateral femoral claudication and severe pain in 
his legs. Angiogram was facilitated through the right radial approach. He underwent 
CPB and uneventful CABG to his LAD and PIV (posterior interventricular artery). The 
patient had a hypotensive episode during sternal closure, CPB was re-initiated, 
mammary spasm suspected and a vein graft anastomosed distal to the previous 
mammary artery anastomosis. We were unable to separate from CPB, at this time a 
decision was made to insert an IAB transfemorally. Transfemoral insertion failed and an 
IAB catheter (Fig 14) was placed antegrade down the thoracic aorta. At this point the 
patient was able to separate from CPB. Due to suspicion of myocardial edema, late 
sternal closure was decided upon, the skin closed, dressing placed and patient 
transported to the CVICU. The patient was taken back to the OR post-op day 3, the IAB 
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removed and the chest closed. The patient was extubated post-op day 9 and discharged 
after 25 days. No post-operative morbidity noted other than associate with his history 
of peripheral vascular disease (Datt B 2007) 
 
 
Fig. 14. Trans-thoracic Insertion of IAB Catheter 
18. Mechanics of IAB functioning  
IAB therapy is often referred to as counterpulsation therapy as the balloon inflates in 
diastole or counter to the hearts contraction (systole). The IAB is a polyethylene balloon 
catheter placed percutaneously in the thoracic aorta through the groin (Fig 15). 
 
 
Fig. 15. Femoral Insertion of IAB Catheter 
Balloon inflation actively pushes blood into the coronary arteries, increasing myocardial 
oxygen supply. Balloon deflation decrease AEDP thereby directly reducing myocardial 
work load and myocardial oxygen consumption by reducing the time period for 
isovolumetric contraction. This gives the heart time to rest and gives a chance for 
hibernating myocardium to recover. 
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The IAB is connected by a driveline to a helium chamber or pressurized gas reservoir which 
is connected to the IAB catheter via a solenoid valve. The inflation or helium supply is 
linked to a trigger for the balloon which is usually a synchronized ECG (Electrocardiogram) 
or the patient’s blood pressure. Earlier on in IAB development CO2 was used due to its high 
solubility and safety in case of balloon leak/rupture and gas embolization. Helium started 
being used due to its smaller Reynold’s number (lower density), thereby allowing a smaller 
drive line/catheter. Smaller balloon catheters improved gas shuttle speeds, reduced trauma 
to the groin and resulted in fewer complications post-insertion. 
The balloon is usually placed 2 cms below the subclavian artery in the second to third 
intercostals space. This optimizes coronary perfusion and decreases the chances for renal 




Fig. 16. Chest X-ray Confirmation of IAB Placement 
Synchronization of the IAB is achieved usually by using the R wave of the QRS complex to 
deflate the IAB catheter. In the operating room some practitioners tend to use pressure 
trigger to circumvent electrical interference from the cautery or other devices. If the patient 
is pacer dependent, the pacer spike can also be use to trigger IAB deflation. Correct timing is 
verified by observing the dicrotic notch on the arterial pressure waveform on the balloon 
console and making sure that balloon inflation takes place just after the dicrotic notch (aortic 
valve closure) and deflates prior to LV ejection (R wave on QRS complex-Fig 17 & Fig 18) 
While using the pressure trigger, it’s important to use the dicrotic notch as the marker for 
inflation. This will prevent the balloon from impinging on LV ejection and adding to the 
hearts afterload. 
At Southlake we use the Maquet IAB console (fig 19) CS 100 which has an auto feature for 
timing. Another IAB console which the reader may come across would be the ACAT II 
WAVE console (fig 20) marketed by Arrow international. 
The console uses a unique algorithm to establish the initial timing using the ECG or arterial 
pressure waveforms. It will also automatically readjust the inflation and deflation timing for 
changes in heart rate or rhythm. This allows for ease of nursing care post-operatively and 
decreases the necessity of the perfusionist except for troubleshooting. The IAB has three 
choices for augmentation. 1:1, 1:2 and 1:3. The IAB is generally initiated at 1:2 in order to be 
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removed and the chest closed. The patient was extubated post-op day 9 and discharged 
after 25 days. No post-operative morbidity noted other than associate with his history 
of peripheral vascular disease (Datt B 2007) 
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able to check the timing of the IAB catheter. The timing can be verified by using the inflation 
interval option on the console. Generally at a higher heart rate (>100), a better augmentation 
pressure is achieved by lowering the ratio to 1:2 or 1:3. The (stroke) volume of the balloon 
used is dependent on the size of the balloon and is chosen based on the height of the target 
patient (fig 21). 
Recently, due to the reduction in french size of the IAB catheters to 7Fr, it is possible to 








Fig. 18. Proper IAB Timing 
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Fig. 20. ACAT II WAVE Arrow IABP 
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Fig. 20. ACAT II WAVE Arrow IABP 
 




Fig. 21. Size Selection Criteria for IAB Catheter 
19. Timing errors 
There are four major timing errors with the IAB. The IAB is usually timed at a 1:2 ratio (one 
inflation every second heart beat) and the deflation is triggered off the R wave in the QRS 
complex. If the IAB is timed improperly, it can actually add to the afterload of the heart by 
inflating prior to the closure of the aortic valve. In this situation the cardio-vascular 
hemodynamics can deteriorate quickly and it is important for the practitioner to understand 
and avoid these errors. 
1. Early inflation: The waveform shows inflation of IAB prior to dicrotic notch, diastolic 
augmentation encroaches into systole (fig 22) and is not hard to miss. The physiological 
effects would be potential premature closure of aortic valve, increase in LVEDP, 
LVEDV (Left Ventricular End Diastolic Volume) and PCWP (Pulmonary Capillary 
Wedge Pressure). The net effect would increase afterload, myocardial oxygen 
consumption and possibility of adding to Aortic regurgitation. 
2. Late inflation: Inflation of IAB after the dicrotic notch, indicated by the lack of a sharp 
“V” on the waveform (fig 23). The physiological effects include sub-optimal coronary 
perfusion and decreased diastolic augmentation. 
3. Early deflation: Viewed as a sharp drop in the waveform after diastolic augmentation. 
Assisted AEDP can be equal to the unassisted AEDP (fig 24). There may be little or no 
decrease in assisted systolic pressure. There is an absence of a sharp”v” or pore-systolic 
dip. This error will also lead to sub-optimal coronary perfusion, mvo2 and afterload 
reduction. There is also a potential for causing retrograde coronary and carotid blood 
flow with the latter causing an increase in angina.  
4. Late deflation: Possibly the most dangerous of all timing errors. Rate of rise of assisted 
systolic pressure may be prolonged. Assisted AEDP may be equal to unassisted AEDP. 
Diastolic augmentation waveform may be dampened (fig 25), depending on how late 
Intra-Aortic Balloon Counterpulsation Therapy 
and Its Role in Optimizing Outcomes in Cardiac Surgery 
 
63 
the deflation is. Physiologically, afterload reduction is absent. IAB is actually impeding 
LV ejection and increasing afterload. Isovolumetric contraction phase increases along 













Fig. 23. Late Inflation  
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Fig. 24. Early Deflation  
 
 
Fig. 25. Late Deflation  
20. IAB weaning 
IAB weaning is usually done when the following physiological parameters are observed in 
target patients. 
1. No afterload reduction as seen on balloon waveform 
2. Increased urine output 
3. Improved LV function and hemodynamics 
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4. Cessation and/or improvement of ventricular and/or atrial arrhythmias 
5. Cessation or reduction of angina 
6. When transportation or operative procedure (revascularization of left main or 
aortic/mitral valve repair/replacement) is completed and the patient hemodynamics 
appear to be stable 
7. When the shock phase has been successfully tided over 
The IAB is generally weaned by reducing the ratio from 1:1 to 1:3, after which the 
augmentation volume of the balloon catheter can be reduced. If the IAB volume is being 
decreased as a part of the weaning process, ensure adequate movement of the IAB catheter 
in order to minimize clotting or thrombus formation. The IAB is never turned off when the 
IAB catheter lies in the aorta due to the risk of thrombus formation. Afterload reduction by 
the IAB can be explained via numbers. The stroke volume of an average sized patients in 
normal health is usually 70 to 80 ml. In a patient in compromised cardio-vascular state, this 
stroke volume is reduced to 40 or 50ml. What a 40cc IAB catheter does is to complement the 
native stroke volume of 30-40ml until hibernating myocardium recovery and myocardial 
rest result in an increased stroke volume of that patient. 
21. Advancements in IAB catheter and IAB console technology 
Considerable improvements have been made in IAB catheter and console technology in the 
more than 40 years since counterpulsation was introduced to clinical practice. Early IABP 
consoles required intensive user intervention, as all aspects of console operation were 
manually controlled. Early IAB catheters were 12 Fr. and required surgical insertion via a 
cutdown to the femoral artery. Surgical insertion could take 1-2 hours and complication 
rates were high. In 1979, IAB catheter insertion improved significantly with the 
development of percutaneous IAB insertion. Insertion time was reduced, typically to 15 
minutes. 
Additional improvements to the catheter in the early years included the addition of an inner 
lumen to facilitate wire-guided insertion and the lumen could then be used to monitor the 
arterial blood pressure. Prefolding of the membrane during manufacturing eliminated the 
need for the clinician to wrap the membrane prior to insertion through the introducer 
sheath. Catheters were also made smaller, from 12 Fr. to 10.5 Fr. and then to 9.5 Fr. Catheters 
are now 7 and 7.5 Fr. and this has helped reduce the incidence of limb ischemia to less than 
3%. Reducing the catheter shaft diameter required a significant change to the way catheters 
were designed. With early dual lumen catheters, the inner lumen used for wire guiding the 
insertion and monitoring the arterial pressure was a separate catheter within the balloon 
catheter gas lumen. With the development of a co-lumen design where the two lumens of 
the catheter were extruded together with the inner and outer lumens sharing a common 
wall, the catheter diameter was reduced while maintaining the gas shuttle lumen and 
maximizing the inner lumen to accommodate the largest guide wire possible. The range of 
balloon membrane sizes was also expanded over the years from 40 cc in the early days of 
counterpulsation to 25 cc, 34 cc, 40 cc, and 50 cc IAB membranes. The size of balloon used is 
determined by patient height. The most recent improvement in IAB catheter technology has 
been the addition of a fiber optic pressure sensor to acquire the arterial pressure signal. This 
technology is immune to artifact, resulting in a high fidelity arterial pressure waveform for 
accurate IAB timing. 
While innovations in IAB catheter technology were being developed, improvements in IAB 
console technology were also occurring. Major improvements to the console over the years 
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have been aimed at making the algorithms smarter, the pneumatics faster, and the consoles 
smaller and lighter. Early consoles required constant operator intervention to maintain 
optimal triggering and timing. Improvements to the algorithms in the console resulted in 
the automation of timing so that once the operator established the initial timing, the console 
could adjust the timing for changes in patient heart rate and rhythm. Console pneumatic 
improvements reduced IAB inflation and deflation time, which was important for tracking 
tachycardic rhythms. Consoles were made smaller and lighter to facilitate transport by 
aircraft or ambulance. 
The most significant improvement to console design occurred with the development of fully 
automated operation. With this capability, the console can automatically select the most 
reliable trigger and establish initial timing. It will then automatically readjust timing for 
changes in heart rate and rhythm, using advanced algorithms to track predictable (regular) 
as well as unpredictable (irregular) rhythms. The algorithms will also select an alternate 
trigger if the current trigger is lost. This automation, along with smaller fiber optic catheters 
offers the clinician the most advanced IAB counterpulsation system for optimal patient 
benefit. 
22. Intra-aortic balloon pump use during percutaneous coronary angioplasty 
The Intra-aortic balloon pump (IABP) can also provide important hemodynamic support 
during complex percutaneous coronary intervention (PCI), both in the elective setting, and 
for acute coronary syndromes, including ST segment elevation myocardial infarction. 
Modern coronary interventions can generally be performed to a wide array of patient 
subsets with low risk of procedural complications. However, optimal patient outcomes in 
PCI require identification of higher risk patients, and attempts to modify those risks. One of 
the main predictors of outcomes in PCI is Left Ventricular dysfunction, i.e. Ejection fraction 
<30%. The availability of mechanical support helps provide "backup" or reserve during the 
procedure and decreases the risk of hemodynamic compromise. Typically, mechanical 
support is initiated prior to commencing PCI, and removed shortly after successful PCI. 
Intra-aortic balloon pump use results in the dual benefits of increased peak diastolic 
pressure, while lowering the end-systolic pressure. There is a resultant reduction in after-
load (Perera D et al,2010) and improved coronary perfusion, which leads to improved 
myocardial oxygen supply, with decreased myocardial energy demands.  
The common scenarios for IABP use in PCI include: 
1. Acute Coronary Syndromes (ACS) / ST elevation Myocardial Infarction (STEMI), 
complicated by cardiogenic Shock, due to LV systolic dysfunction or a mechanical 
complications such as acute mitral regurgitation or ventricular septal defect. 
2. PCI in a coronary artery supplying a large territory of myocardium, typically with 
underlying Left ventricular dysfunction (practically speaking, Grade 3 or worse - EF < 
30%). Specific scenarios include i) coronary intervention on a diseased vessel that also 
supplies flow to another occluded vessel (via channels, called collateral arteries, that fill 
that territory in retrograde fashion), ii) unprotected left main stenting, iii) PCI to the 
only patent artery iv) PCI with concomitant valvular disease, if anticipated 
deterioration in the valvular disease (ex. patients with at least moderate ischemic mitral 
regurgitation, and planned PCI that could worsen degree of regurgitation). 
3. If patients have clinical signs of abnormal resting hemodynamics, prior to PCI: low 
systolic blood pressure (SBP) <100, with objective or clinical suspicion of elevated left 
heart filling pressures - pulmonary capillary wedge pressure >20mmHg. 
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4. Survival Dependent vessel: Any one artery supplying a sufficient amount of 
myocardium such that (in the opinion of the cardiologist) closure of the vessel would be 
fatal. 
It should be noted that there is considerable practice variation with Intra-aortic balloon 
support during high risk coronary intervention. Recognizing the higher risk of access 
related and other vascular complications with its insertion, some clinicians prefer to have 
the IABP readily available and use it only if hemodynamic compromise develops. . One trial 
conducted in centers in the United Kingdom, The Balloon Pump-Assisted Coronary 
Intervention Study, assessed whether routine intra-aortic balloon pump insertion, prior to 
PCI, reduced the risk of major adverse cardiac and cardiovascular events in patients with 
severe left ventricular dysfunction and advanced coronary disease. The results of this trial 
involving just over 300 randomized patients did not support routine use, given no 
difference between the groups. Clinical judgment is certainly exercised in situations (such as 
those described above) where the IABP is inserted "pre-emptively", with anticipated 
hemodynamic stress during PCI. 
23. Counterpulsation – An anesthesiologists perspective 
As an anaesthetist, working in the perioperative care of cardiac surgery patients for the last 
20 years, I have observed a significant change in the attitudes and uses of the intra aortic 
balloon pump. I have watched the use of the IABP change from a last resort salvage 
technique for the patient on maximal inotropes with low output syndrome and a dismal 
prognosis, to a first line tool aiming for preservation of myocardial tissue in unstable cardiac 
surgery patients. The presumed IABP’s favorable myocardial oxygen supply/demand 
profile and the ease of percutaneous insertion have been instrumental in this change (Trost 
JC 2006).  
In our institution IABPs are often inserted in preoperative cardiac surgery patients: who are 
experiencing unstable angina, especially post myocardial infarction, not responsive to 
standard non-invasive therapies; that have low output syndrome or congestive heart failure 
secondary to severe left ventricular dysfunction or mechanical complications such as a 
ventricular septal defect or mitral regurgitation induced by a myocardial infarction ; and 
rarely who have acute myocardial ischemia causing intractable arrhythmias. It appears that 
the earlier the balloon is placed in a hemodynamically struggling patient, the more stable 
the patient is in the post-operative period. This practice is consistent with the Task Force on 
Practice Guidelines of the American Heart Association and American College of Cardiology 
(Ryan TJ 1999). Frequently, IABPs are inserted for preoperative cardiac surgery patients with 
symptomatic left main disease. The intention of the IABP is the preservation of viable 
ïschemic myocardial tissue. The mechanism of the preservation may relate more to 
decreased myocardial demand and collateral flow as Kimura showed that in the presence of 
a coronary artery stenosis of greater than 90% the IABP diastolic augmentation did not 
result in an increased post-stenotic pressure (Kimura A 1996). The insertion of the IABP into 
the aforementioned patients facilitates the anaesthetist’s ability to maintain cardiovascular 
stability and a favourable myocardial oxygen supply/delivery ratio at induction, 
maintenance and release from bypass. Replace with" The importance and validity of the 
IABP in maintaining a favorable myocardial oxygen supply/demand ratio is realized in the 
post-operative period (Christenson 1997).  
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rarely who have acute myocardial ischemia causing intractable arrhythmias. It appears that 
the earlier the balloon is placed in a hemodynamically struggling patient, the more stable 
the patient is in the post-operative period. This practice is consistent with the Task Force on 
Practice Guidelines of the American Heart Association and American College of Cardiology 
(Ryan TJ 1999). Frequently, IABPs are inserted for preoperative cardiac surgery patients with 
symptomatic left main disease. The intention of the IABP is the preservation of viable 
ïschemic myocardial tissue. The mechanism of the preservation may relate more to 
decreased myocardial demand and collateral flow as Kimura showed that in the presence of 
a coronary artery stenosis of greater than 90% the IABP diastolic augmentation did not 
result in an increased post-stenotic pressure (Kimura A 1996). The insertion of the IABP into 
the aforementioned patients facilitates the anaesthetist’s ability to maintain cardiovascular 
stability and a favourable myocardial oxygen supply/delivery ratio at induction, 
maintenance and release from bypass. Replace with" The importance and validity of the 
IABP in maintaining a favorable myocardial oxygen supply/demand ratio is realized in the 
post-operative period (Christenson 1997).  
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Intraoperatively, IABPs are inserted into our patients when difficulty to wean from the 
bypass machine is anticipated due to instability in the pre-bypass or bypass period or for 
failure to wean from the bypass machine, once reversible causes for the failure are ruled out. 
There may be a survival advantage to placing the IABP prior to coming off bypass based on 
one review. Delaying insertion of the IABP in the unstable perioperative patient who is 
unresponsive to reasonable doses of inotropes or who has rapidly accelerating inotropic 
requirements may have deleterious effects. Theoretically this is supported by the following 
facts. High inotropic doses increase myocardial inotropy and tension resulting in increased 
myocardial oxygen demands. Impaired diastolic relaxation and increased ectopy and 
afterload, as seen with certain inotropes, may further tip the myocardial supply/demand 
balance in favour of demand (Katz AM 1990). Myocardial injury may be further exacerbated 
by the inotropes increased delivery of calcium to the cell, overcoming the ischemic 
myocardium’s presumed protective attempt at limiting available calcium. Early insertion of 
the IABP in the unstable post-bypass patient appears to theoretically and anecdotally 
improve outcome (Poole Wilson PA 1990).  
Postoperative insertion of the IABP in the majority of our cases is for myocardial failure or 
signs of ischemia. Many times there is a dramatic improvement post balloon insertion. The 
mechanism producing this improvement is often not clear .Possibilities include a heightened 
diastolic pressure overcoming decreased coronary flow secondary to low mean arterial 
pressure, left internal mammary spasm or air within a coronary artery, improved collateral 
flow (Kern MJ 1991), or decreased demands secondary to decreased afterload and preload 
resulting in decreased myocardial wall tension. The IABP often assists in stabilization of the 
patient, although more definitive therapy may be required. The location of the ischemia, as 
visualized by the electrocardiogram and often echocardiogram, the magnitude of the failure, 
the surgical knowledge of the coronary disease and surgery and the response to the IABP 
determine the need for further management.  
We have come to use IABP’s earlier, and the indications have broadened to include all 
stages of the perioperative care. The theoretical protective effect of the IABP with respect to 
the myocardial supply/demand ratio, the ease of insertion of the IABP by the percutaneous 
route clinical observations and limited studies support this practice. 
24. Conclusion 
The IABP since its advent in 1960 has progressively become an indispensable technology 
available to the healthcare team in cardiology and cardiac surgery. Improvements in 
membrane technology have reduced the french sizes required to be used for femoral 
percutaneous insertion. This has minimized trauma caused by femoral insertion of the IAB 
catheter. 
Earlier on in my training as a perfusionist, old school cardiac surgeons always inserted 
IAB’s later rather than sooner. Counterpulsation technology was always thought to be a last 
ditch effort and mortality was thought to be higher once the IAB was inserted. This 
perception has changed radically over the last twenty years. 
The ease of insertion (compared to VAD’s and artificial lungs), ease of removal, low risk of 
complications and availability in the peri/post and pre-operative environment in a hospital 
setting has made counterpulsation an ideal choice to treat acute or chronic heart failure. 
There is no doubt at this point of the positive effects of counterpulsation on early mortality 
and post-operative morbidity in cardiac surgery. In instances where IAB insertion is 
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precluded or insertion has failed, transthoracic (in a peri-operative setting), transbrachial or 
subclavian insertion can also be performed with a positive impact on survival. Morbidity 
and mortality however are higher in these kinds of cases and may have to do with the pre-
operative risk factors these patients come into surgery for. The cardiac surgeon has to tread 
the fine line between deciding the optimal timing for IAB insertion by weighing the benefits 
of counterpulsation vs the low risk of complications. It is increasingly being understood that 
for a poor LV and /or a patient with a risk of peri-operative infarct, it is optimal to insert an 
IAB sooner rather than later. The catheter can easily be removed first or second post-
operative day after the surgery has performed and the risk for infarct been mitigated. 
At Southlake, a 380 bed community hospital, we perform approximately 1000 heart surgeries 
and 3000 PTCA’s annually. In support we insert 250 IAB catheters annually and are the largest 
IAB user in Ontario-Canada. We are a comparatively new heart centre, having started our 
cardiac surgery program in 2004. Aggressive use of counterpulsation reflects the new belief in 
early IAB insertion in cardiac patients at risk of pre, peri or post-operative infarct. Transfusion 
rates at SRHC for CABG in the first half of 2009 approximate 26% (Fig 26). 
 

























Fig. 26. Red Blood Cell Transfusion Rate for 2009 at SRHC. 
Mortality at SRHC for late 2009 (July to Dec 2009) was based on Toronto Risk Score (TRS). 
The observed mortality ranged from 0.5% (TRS 2-4) to 8.5% (TRS >8) as shown in fig 27. 
 
 
Fig. 27. Observed and Expected Mortality at SRHC by Toronto Risk Score 
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It is the opinion of the authors that the above average results in morbidity and mortality for 
our cardiac patients may partly be due to the aggressive use of IAB in cardiac procedures. 
Aggressive use of counterpulsation therapy preempts infarction for the cardiac patient and 
in turn improves outcomes in cardiac surgery. 
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1. Introduction 
The integration of interventional and surgical techniques is demanding a new working 
environment for an interdisciplinary cardiovascular team: the hybrid operating room, where 
angiographic imaging capabilities are integrated in an operating suite. A deep 
understanding of the clinical applications, the current and future technology, and their 
implications on workflows is needed for a sound room design. 
2. Clinical applications in cardiovascular therapy 
2.1 Definition of hybrid procedures  
The definition of hybrid procedures in the literature varies widely. A strict definition of a 
hybrid procedure is a major procedure that combines a conventional surgical part including 
a skin incision with an interventional part using some sort of catheter-based procedure 
guided by fluoroscopic or MRI imaging in a hybrid room without interruption. Wider 
definitions include procedures where the interventional and surgical parts are done in 
sequence, where a surgical part is only necessary in case of emergency or even minor 
procedures as venous cut downs. Sometimes, fluoroscopy guided interventions performed 
by surgeons (e.g. endovascular aortic repair in aortic abdominal aneurysms) are referred to 
as hybrid procedures. The term hybrid procedure in the radiology world may also refer to 
the combination of two imaging modalities for diagnostics or therapeutic purposes. In this 
chapter, the strict definition of hybrid procedures is applied and only procedures with 
fluoroscopic imaging are included, as interventional MRI still is in its very early stage.  
2.2 Pediatric cardiac surgery 
Although surgery remains the treatment of choice for most congenital cardiac 
malformations, interventional cardiology approaches are increasingly being used in simple 
and even complex lesions. The percutaneous approach can be challenging due to low 
patient weight or poor vascular access, induced rhythm disturbances and hemodynamic 
compromise (Bacha et al., 2007). Difficult and complex anatomy as in double-outlet right 
ventricle or transposition of the great arteries, or acute turns or kinks in the pulmonary 
arteries of tetralogy of Fallot patients can make percutaneous procedures challenging if not 
impossible (Sivakumar et al., 2007). However, surgery also has its limitations. Examples are 
operative closure of multiple apical muscular ventricular septal defects, adequate and 
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The definition of hybrid procedures in the literature varies widely. A strict definition of a 
hybrid procedure is a major procedure that combines a conventional surgical part including 
a skin incision with an interventional part using some sort of catheter-based procedure 
guided by fluoroscopic or MRI imaging in a hybrid room without interruption. Wider 
definitions include procedures where the interventional and surgical parts are done in 
sequence, where a surgical part is only necessary in case of emergency or even minor 
procedures as venous cut downs. Sometimes, fluoroscopy guided interventions performed 
by surgeons (e.g. endovascular aortic repair in aortic abdominal aneurysms) are referred to 
as hybrid procedures. The term hybrid procedure in the radiology world may also refer to 
the combination of two imaging modalities for diagnostics or therapeutic purposes. In this 
chapter, the strict definition of hybrid procedures is applied and only procedures with 
fluoroscopic imaging are included, as interventional MRI still is in its very early stage.  
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Although surgery remains the treatment of choice for most congenital cardiac 
malformations, interventional cardiology approaches are increasingly being used in simple 
and even complex lesions. The percutaneous approach can be challenging due to low 
patient weight or poor vascular access, induced rhythm disturbances and hemodynamic 
compromise (Bacha et al., 2007). Difficult and complex anatomy as in double-outlet right 
ventricle or transposition of the great arteries, or acute turns or kinks in the pulmonary 
arteries of tetralogy of Fallot patients can make percutaneous procedures challenging if not 
impossible (Sivakumar et al., 2007). However, surgery also has its limitations. Examples are 
operative closure of multiple apical muscular ventricular septal defects, adequate and 
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lasting relief of peripheral pulmonary artery stenosis, or management of a previously 
implanted stenotic stent. Combining interventions and surgery into a single therapeutic 
procedure potentially leads to reduction of complexity, cardiopulmonary bypass time, risk, 
and to improved outcomes. The hybrid approach to hypoplastic left heart syndrome serves 
as a role model of the hybrid concept for congenital heart disease. Extracorporeal circulation 
and deep hypothermic circulatory arrest in infants can be avoided (or at least shortened), as 
shown in the extensive experience of several groups  (Bacha et al., 2006; see Fig. 1). 
 
 
Fig. 1. Hypoplastic left heart syndrome. Intraoperative post-Fontan evaluation of the 
superior and inferior venae cavae as well as the stented pulmonary arteries. Imaging: 
Courtesy of Prof. Berger, Dr. Ewert German Heart Center, Berlin, Germany (Nollert et al., 
2010) 
Completion angiography in congenital heart diseases is another important concept. Residual 
structural lesions after cardiac surgery for congenital heart disease may complicate the 
postoperative recovery and result in poor outcomes. Therefore, intraoperative assessment of 
the newly created anatomy in 2D with fluoroscopy may help to avoid these complications. 
Rotational angiography with 3D reconstruction of the soft tissues (DynaCT) results in an 
even better delineation of the 3D anatomy and may change surgical strategy in a substantial 
subgroup of patients with CHD. Holzer and colleagues (R.J. Holzer et al., 2009) reported 
their experience with this imaging modality with 31 patients (median age and weight: 7.5 
months and 6.5 kg, respectively) who underwent 32 complex surgical procedures, most of 
them involving pulmonary artery and/or aortic arch reconstructions. The angiograms were 
performed with regular catheters in a dedicated hybrid suite. Unexpected disorder was 
identified in 18 procedures (56%), including right and left pulmonary artery and coronary 
stenoses. The therapeutic strategy was modified in nine of 32 procedures (28%) and 
included surgical revision, hybrid therapy, early catheterization and a change in medical 
management. No major adverse events were noted. These advantages may be achieved in 
the operating room rapidly with fast image processing and even a reduction of contrast 
media and ionizing radiation dose (Pedra et al., 2011). The combination of an angiography 
system in the OR with magnetic resonance imaging may even further reduce dose and 
contrast and add additional functional data (Lurz et al., 2009).  
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2.3 Coronary artery disease 
Routine evaluation of bypass grafts is the first indication for imaging in coronary artery 
bypass grafting. In a study designed and published by the Vanderbilt Heart and Vascular 
Institute (Zhao et al., 2009), routine intraoperative completion angiography performed in a 
fully functional hybrid operation room detected important defects in 97 of 796 (12% of the 
grafts) venous coronary artery bypass grafts in 366 adult patients (14% of the patients) with 
complex coronary artery disease. Their findings in completion angiography at the end of the 
operation included suboptimal anastomoses, poor lie of the venous bypass graft, and 
bypasses to not diseased vessels. The angiography findings led to a change in the 
management, including minor adjustments of the graft, traditional surgical revision or 
percutaneous coronary interventions, resulting in optimal bypass outcomes.  
Surgical bypass grafting and percutaneous coronary artery revascularization are 
traditionally considered isolated options. A simultaneous hybrid approach may allow an 
opportunity to match the best strategy for a particular anatomic lesion. Revascularization of 
the left anterior descending artery with the left internal mammary artery is by far the best 
treatment option in terms of long term results. Integrating this therapy with percutaneous 
coronary angioplasty (hybrid procedure) offers multi-vessel revascularization through a 
mini-thoracotomy. Particularly in high risk patients, morbidity and mortality decreases in 
comparison to conventional surgery (Kon et al., 2008; Bonatti et al., 2008). A study from 
FuWai Hospital in Beijing (Hu et al., 2011) reports on 104 patients with multivessel coronary 
artery disease who were compared with the same sized group of patients undergoing off-
pump surgery matched by propensity scores. The patients treated with the hybrid approach 
had a significantly lower ICU stay and intubation time and experienced less complications 
in terms of bleeding and transfusions needs. At a median follow up of 18 months, patients 
undergoing the hybrid procedure also had a significantly higher freedom from major 
adverse cardiac or cerebrovascular events (99 % vs. 90.4 %; p = 0.03). The hybrid procedure 
was also less costly than an exclusively percutaneous strategy. 
2.4 Transcatheter aortic valve implantation (TAVI) procedures 
Conventional aortic valve replacement for aortic stenosis is based upon standardized 
guidelines with excellent outcomes particularly in younger patients at relatively low-risk 
and will remain the gold standard for aortic valve replacement in the upcoming years. 
However, transcatheter techniques have developed to valid alternatives in high-risk patients 
in whom conventional surgical techniques are considered too invasive and risky. The 
Partner trial (Leon et al., 2010) using the Edwards Sapien valve demonstrated that patients 
with severe aortic stenosis, who are not eligible for conventional aortic valve replacement 
because of too high risk, benefit overwhelmingly from TAVI in comparison to standard 
therapy including valvuloplasty at one year in terms of survival (Cohort B, Leon et al., 
2010). In addition, 700 enrolled very high risk patients undergoing TAVI for severe aortic 
stenosis had comparable mortality rates to those receiving conventional aortic valve 
replacements at one year (Cohort A, 25% vs. 26%). The transfemoral approach was used on 
approximately two-thirds of TAVI patients, while the transapical approach was used in the 
remaining third, unlike Cohort B where only the transfemoral approach was used.  
Joint recommendations of the European Society of Cardiology and the European 
Association of Cardio-thoracic Surgery consider the hybrid operating room the optimal 
environment for these new therapeutic options (Vahanian et al., 2008). In Germany, joint 
recommendations of the German Society of Cardiology and the German Society of Cardiac, 
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Thoracic and Vascular Surgery demand a hybrid operating room or hybrid cathlab as a 
prerequisite for a TAVI program.  
Currently two valves, the Corevalve (Medtronic, Minneapolis, MN) and the Sapien valve 
(Edwards, Irvine, CA) have been granted CE mark in 2007 and are successfully being 
implanted. Several newer generation valves aim to improve the results by more 
sophisticated designs to decrease the common current TAVI complications of aortic 
regurgitation, misplacement, and heart block. Advanced image guidance by dedicated 2D 
and 3D applications (e.g. syngo Aortic Valve guide, Siemens; Heart Navigator, Philips; C-
THV, Paieon) may further simplify navigation and deployment of the devices. Some of the 
upcoming TAVI valves (e.g. Symetis Acurate, Jena Valve, Embracer, Medtronic) have 
dedicated mechanisms to anchor in the sinuses. Therefore, anatomically correct rotation of 
the valve within the aortic annulus is needed to optimally deploy the devices. 3D imaging 
may prove highly valuable to understand the correct relationships between the valve and 
the annulus. 
2.5 Mitral valve repair 
For repair of mitral regurgitation, various devices are currently under investigation and 
await FDA approval. Currently, it is also not quite clear which of the devices will be used in 
a hybrid operating room, because some approaches will most likely be performed in regular 
cathlabs. In Europe, only the MitralClip Mitral valve repair system (Abbott Vascular, Santa 
Clara, CA) has received CE mark in 2008. Studies for FDA clearance are ongoing. The 
MitralClip is creating a double orifice mitral valve by connecting the free edges of the 
anterior and posterior leaflets at the A2 / P2 level. The Everest II trial (Feldman et al., 2011) 
compared the MitralClip with surgical mitral valve with repair in patients with moderate or 
severe mitral valve surgery, who were candidates for mitral valve surgery and 
demonstrated superior safety at the expense of inferior efficacy. Experimentally, prostheses 
for mitral und tricuspid valve replacement are under development and certainly will be 
available within the next years. Complex hybrid procedures may arise where the various 
parts of the mitral valve apparatus (e.g. chordae, leaflet and ring) are repaired on a beating 
heart in combination with purely interventional techniques (e.g. MitralClip). For imaging 
purposes, fluoroscopy will most likely be combined with 2D and 3D ultrasound and a 
fusion of these modalities may become helpful. The reason is that the metal devices are 
optimally imaged without artifacts by fluoroscopy whereas the valve itself is better 
evaluated with ultrasound. As an alternative to transesophageal echocardiography, the use 
of intracardiac 2D and 3D echo (Accunav and Accunav V, Siemens AG Healthcare, 
Montainview, CA) may prove useful, because it would allow avoiding general anesthesia in 
selected patients.  
2.6 Thoracic endovascular aortic repair (TEVAR) 
Thoracic endovascular aortic repair (TEVAR) has become a valid alternative to open repair. 
In selected cases, EVAR, in combination with open surgery, is even applied for pathologies 
of the aortic arch and distal ascending aorta (Walsh et al., 2008). Endoleaks are common 
complications of EVAR and may be missed by angiographic evaluation. CT-like imaging 
with the angiographic C-arm enables the surgeon to diagnose this complication 
intraoperatively and correct it. A group from University of London (Biasi et al., 2009) 
demonstrated in a study of 80 patients undergoing EVAR that 3D imaging with DynaCT in 
the operating room was able to detect endoleaks in 5 patients. These endoleaks were not 
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detected by conventional completion angiography. In addition, conventional CT evaluations 
before discharge did not reveal any endoleak which was not previously seen in DynaCT. In 
addition, the hybrid operating room allowed for immediate treatment of the endoleaks, if 
required. In the near future, off the shelf fenestrated aortic stents will become available for 
the treatment of extensive aortic disease. These fenestrated stents have to be rotated in the 
aorta, such that the fenestrations cover the branches of the aorta. For these highly complex 
procedures, 3D imaging in a hybrid operating room may be extremely helpful for the 
navigation of wires and devices.  
2.7 Hybrid surgery for rhythm disturbances 
The combination of the surgical epicardial approach with the interventional endocardial 
approach for the treatment of rhythm disturbances in particular atrial fibrillation offers 
theoretically advantages over conventional endocardial or epicardial therapy alone. First 
reports emphasized the potential benefit. Krul and coworkers from Amsterdam (Krul et al., 
2011) reported on 31 patients with atrial fibrillation (AF); thereof 13 with persistent and two 
with permanent AF. A minimally-invasive approach combining thoracoscopic pulmonary 
vein isolation (PVI) and ganglionated plexus (GP) ablation with intraoperative 
electrophysiological confirmation of PVI was performed in order to decrease recurrences of 
AF during follow-up. Results at one year follow-up were very encouraging, with 86% of the 
patients without recurrence of AF. A hybrid approach for drug-refractory ventricular 
tachycardia was described by Michowitz (Michowitz et al., 2010). Fourteen patients (most of 
them after previous cardiac surgery) underwent surgical ablation with an epicardial 
approach with concomitant electrophysiological mapping. The authors conclude that the 
surgical access with subxiphoid window and limited anterior thoracotomy in the 
electrophysiology lab is feasible and safe. 
Pacemakers and implantable cardioverter defibrillators (ICD), particularly bi-ventricular 
systems, may be optimally implanted in a hybrid OR environment, because the hybrid 
operating theatre offers the required superior angulation and imaging capabilities in 
comparison to mobile C-arms, and the higher hygienic standards compared to cathlabs. 
DynaCT angiographic 3D imaging may prove useful for imaging the venous system of the 
heart. The coronary sinus can be depicted in 3D and than be overlaid over the fluoroscopy 
image to better guide placement of the left ventricular lead.  
2.8 Other applications outside cardiovascular therapy 
Hybrid operating rooms outside cardiovascular therapies are currently more and more used 
in neurosurgery, traumatology, orthopedics, urology, and general surgery. Interdisciplinary 
usage may be considered. 
The need for hybrid operating theatres is not restricted to cardiac surgery. Vascular 
surgeons and neurosurgeons have equally developed hybrid procedures necessitating 
angiography systems in the OR. Furthermore, hybrid operating rooms are already in use by 
abdominal surgeons, traumatologists, orthopedic surgeons, and even urologists. Imaging 
needs, hygienic requirements, and room set up - particularly for neurosurgery - may be 
considerably different. Other surgical disciplines may want to introduce navigation systems, 
magnetic resonance imaging, endoscopy, biplane angiography systems, or a lateral position 
of anesthesia equipment. However, the hybrid operating rooms are more commonly  
shared with interventionalists including cardiologists, interventional radiologists, 
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electrophysiologists, neuroradiologists, and pediatric cardiologists. Their specific needs 
have to be carefully considered and weighted when planning the hybrid theatre. 
3. Imaging techniques in the hybrid operating room 
The imaging capabilities of modern, fixed C-arms have dramatically changed in the last five 
years. Traditionally, fixed C-arms have been used either for simple 2D fluoroscopy or 3D 
rotational angiography. Nowadays, C-arms, which are able to acquire CT-like 3D images, 
are used for image-based guidance and even provide intra-operative functional imaging, 
like flow analysis.  
3.1 Fluoroscopy 
Traditional fluoroscopy provides real-time, high resolution, low-contrast images in two 
dimensions through the use of an image intensifier. With ultrasound and endoscopy it is the 
main imaging modality to guide devices in real time through the body (see Fig. 2a). Brilliant 
image quality is needed to depict fine anatomic structures and devices. In particular, in cardiac 
interventions, imaging the moving heart requires a high frame rate (30f/s, 50Hz) and high 
power output (at least 80kW). Thus, the image quality needed for cardiac applications can only 
be achieved by high powered fixed angiography systems. In modern fluoroscopy devices image 
intensifiers have been replaced with digital flat panel detectors which enabled fluoroscopy to 
transition into three dimensions, producing CT-like images (see below). Fluoroscopy is 
performed with continuous X-ray to guard the progression of a catheter or other devices within 
the body in live images. To minimize the doses for the patient and the surgeon, dose saving 
measurements are essential in modern fluoroscopy devices (see section 3.4). 
 
 
Fig. 2a. 2D fluoroscopic image 
3.2 Data acquisition 
Angiographic systems provide a so-called acquisition mode, which stores the acquired images 
automatically on the system to be uploaded into an image archive later. While standard 
fluoroscopy is predominantly used to guide devices and to re-position the field of view, 
data acquisition is applied for reporting or diagnostic purposes. In particular, when contrast 
media is injected, a data acquisition is mandatory, because the stored sequences can be 
replayed as often as required without re-injection of contrast media. To achieve a sufficient 
image quality for diagnoses and reporting, the angiographic system uses up to 10 times 
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higher x-ray doses than standard fluoroscopy. Thus, data acquisition is not recommended as 
long as fluoroscopy is sufficient or the images do not need to be stored.  
Data acquisition can be combined with specific imaging protocols, for example, to enhance 
blood vessels while removing background structures (see section 3.3) or to acquire 3D 
images (see section 3.5).  
3.3 Digital subtraction angiography 
Over the past three decades, digital subtraction angiography (DSA) has become a well-
established 2D imaging technique for the visualization of blood vessels in the human body 
(Katzen, 1995). With this technique, a sequence of 2D digital X-ray projection images is 
acquired to show the passage of an injected contrast agent through the vessels of interest. 
Background structures are largely removed by subtracting an image acquired prior to 
injection (usually called the mask image) from the live images (often referred to as contrast 
images). It is obvious that in the resulting subtraction images, background structures are 
completely removed only if these structures are exactly aligned and have equal grey-level 
distributions (see Fig. 2b). Therefore, various motion correction algorithms are applied to 
reduce such artifacts in the image.  
 
 
Fig. 2b. 2D digital subtraction angiography shows the difference between an initial 
fluoroscopic acquisition and a fluoroscopic acquisition after injecting contrast agent. Thus, 
the vessels are clearly depicted in these images. Other remaining structures (white next to 
black structures) caused by motion, are considered artefacts, and can be partly compensated 
by modern angiography devices.  
DSA is clinically used for diagnostic and therapeutic applications of vessel visualization 
throughout the entire body. During complex interventional procedures, DSA is often 
combined with so-called road mapping. In this mode, a DSA sequence is performed and the 
frame with maximum vessel opacification is identified, which becomes the road map mask. 
The road map mask is subtracted from subsequent live fluoroscopic images to produce real-
time subtracted fluoroscopic images overlaid on a static image of the vasculature. Road 
mapping is useful for the placement of catheters and wires in complex and small 
vasculature, because fluoroscopy alone may not adequately show the vessels and may not 
visualize small wires in the distracting underlying tissue. It is also possible to combine the 
road mapping feature with a feature called image fade, which allows the user to manually 
adjust the brightness of the static vessel road-map overlay. 
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Fig. 2a. 2D fluoroscopic image 
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higher x-ray doses than standard fluoroscopy. Thus, data acquisition is not recommended as 
long as fluoroscopy is sufficient or the images do not need to be stored.  
Data acquisition can be combined with specific imaging protocols, for example, to enhance 
blood vessels while removing background structures (see section 3.3) or to acquire 3D 
images (see section 3.5).  
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acquired to show the passage of an injected contrast agent through the vessels of interest. 
Background structures are largely removed by subtracting an image acquired prior to 
injection (usually called the mask image) from the live images (often referred to as contrast 
images). It is obvious that in the resulting subtraction images, background structures are 
completely removed only if these structures are exactly aligned and have equal grey-level 
distributions (see Fig. 2b). Therefore, various motion correction algorithms are applied to 
reduce such artifacts in the image.  
 
 
Fig. 2b. 2D digital subtraction angiography shows the difference between an initial 
fluoroscopic acquisition and a fluoroscopic acquisition after injecting contrast agent. Thus, 
the vessels are clearly depicted in these images. Other remaining structures (white next to 
black structures) caused by motion, are considered artefacts, and can be partly compensated 
by modern angiography devices.  
DSA is clinically used for diagnostic and therapeutic applications of vessel visualization 
throughout the entire body. During complex interventional procedures, DSA is often 
combined with so-called road mapping. In this mode, a DSA sequence is performed and the 
frame with maximum vessel opacification is identified, which becomes the road map mask. 
The road map mask is subtracted from subsequent live fluoroscopic images to produce real-
time subtracted fluoroscopic images overlaid on a static image of the vasculature. Road 
mapping is useful for the placement of catheters and wires in complex and small 
vasculature, because fluoroscopy alone may not adequately show the vessels and may not 
visualize small wires in the distracting underlying tissue. It is also possible to combine the 
road mapping feature with a feature called image fade, which allows the user to manually 
adjust the brightness of the static vessel road-map overlay. 
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3.4 Radiation dose and dose reduction 
Ionizing radiation may, depending on the dose, cause damage to organic tissue. The 
mechanisms by which radiation damages the human body are two-fold: (1) radiation 
directly destroys the DNA of the cells by ionizing atoms in its molecular structure and, (2) 
radiation creates free radicals, which are atoms, molecules, or ions with unpaired electrons. 
These unpaired electrons are usually highly reactive, so radicals are likely to take part in 
chemical reactions that eventually change or harm the DNA of the cells. 
The human body can repair damaged cells to a certain extent, but if exposed to a high 
amount of radiation beyond a given threshold in a short period of time, “deterministic” 
damage will occur. Deterministic radiation damage includes changes of the blood count, 
hair loss, tissue necrosis or cataract. Exposure levels of typical medical diagnostic imaging 
procedures are far below the threshold for deterministic radiation damage. However, 
deterministic effects are an important consideration in external radiation therapy and 
radionuclide therapy. 
In order to assess the risk of radiation exposure, quantitative measurements of dose were 
introduced:   
- Absorbed dose D (also called “energy dose”), measured in Gray (Gy) units, characterizes 
the amount of energy deposited in tissue. It is defined as the amount of radiation 
required to deposit 1 Joule (J) of energy in 1 kilogram of any kind of matter. 
- Equivalent dose H, measured in Sievert (Sv) units, takes in account the damage caused by 
different types of radiation. It is the absorbed dose multiplied by a weighting factor 
characteristic for the particular type of radiation. For X-ray, H = D. 
- Effective dose E, measured in Sievert (Sv) units, includes the sensitivity of different 
organs to radiation. It is the sum of the equivalent doses in all irradiated organs 
multiplied by the respective tissue weighting-factors. 
Determining the effective dose in angiography depends on several factors, primarily on the 
variability in organ sensitivity to radiation. For instance, bone marrow is far more sensitive 
to radiation than the liver. The degree to which organs are affected by radiation also 
depends on the angle of the beams. Because dose distribution in angiography is not as  
“homogeneous” as it is for CT, these factors must be considered when estimating the 
damage caused by irradiation. The effective dose includes the sensitivity to radiation of the 
different organs. It is the sum of the equivalent doses in all irradiated organs multiplied by 
the respective tissue weighting-factors. 
Effective dose provides a good comparison with natural background radiation, which is on 
average about 2.4 mSv per year. Typically, during a cardiac diagnostic intervention with 15 
p/s, the effective dose per minute is 0.6 mSv (Cusma et al., 1999).  
In general, low dose goes hand in hand with less visibility, while higher image quality 
requires, among other factors, a higher dose. To obtain a specific image quality, it is 
necessary to choose the “right” dose for the tissue being penetrated. 
Because guidance of endovascular devices requires continuous X-ray, modern angiographic 
systems include several measures for dose reduction (Balter et al., 2010). There are three 
parameters which can be adapted by the user to reduce the radiation exposure:  
1. Footswitch on-time: footswitch on-time controls how long the body is exposed to X-ray 
beams, thus how long the body is irradiated: less time means less radiation. 
2. Frame rate: high frame rates are used to visualize fast motion without stroboscopic 
effects. However, the higher the frame rate, the more radiation. Therefore, it is best to 
keep the frame rate as low as possible, according to the clinical need. Modern 
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angiographic systems can adjust the frame rate downward in various steps, from 60 
pulses per second (p/s) used in pediatric cardiology to 0.5 p/s in some systems for 
slowly moving objects. A reduction to half pulse rate reduces dose by about half. The 
reduction from 30 p/s to 7.5 p/s results in a dose saving of 75%.  
3. Source-Image- Distance (SID): according to the quadratic law and a requested constant 
dose at the detector, a greater distance between the source and the imager increases the 
skin dose. Rising SID from 105 cm (=SID 1) to 120 cm (=SID 2) increases skin dose (i.e. 
the dose at the IRP) by approximately 30%, if C-arm angles, table position, patient, and 
requested dose at the detector do not change. Fig. 3 illustrates the setup including the 
lower (SID = 105 cm) and the upper (SID = 120 cm) position of the detector. 
 
 
Fig. 3. C-arm, two different SIDs, constant table height, location of the IRP 
Additionally, modern angiographic systems provide some inherent features to reduce dose. 
For example, variable copper filters reduce the skin dose by filtering the low-energy photons 
out of the X-ray, called beam hardening. Some systems adjust the thickness of such filters 
automatically according to the absorption of the patient entrance dose along the path of the 
X-ray beam through the patient. This automatic filter insertion maintains low skin dose 
without degrading image quality and can result in a dose saving of up to 50%.  
Other measurements include radiation-free collimation or radiation-free object positioning. 
Using the last image hold (LIH) as a reference, the system allows radiation-free collimation 
and semitransparent filter parameter setting to precisely target the region of interest (see 
Fig. 4). A similar approach is implemented for optimal patient positioning for imaging: 
graphic display of the outline of the upcoming image allows translation of the table without 
fluoroscopic radiation exposure and provides an indication of which anatomy is in the field-
of-view of the detector. For specific cardiac interventions, such measurements can reduce 
the overall fluoroscopy time by 0.5 to 3 minutes. Under typical fluoroscopy conditions, this 
may result in a dose reduction of 20 to 120 mGy. 
More and more countries and authorities require the reporting of patient exposure to 
radiation following an intervention. To meet current and future regulations, modern 
angiographic systems allow effective reporting of dose exposure, thus enable enhanced in-
house dose reporting and analysis. 
 
Special Topics in Cardiac Surgery 
 
80
3.4 Radiation dose and dose reduction 
Ionizing radiation may, depending on the dose, cause damage to organic tissue. The 
mechanisms by which radiation damages the human body are two-fold: (1) radiation 
directly destroys the DNA of the cells by ionizing atoms in its molecular structure and, (2) 
radiation creates free radicals, which are atoms, molecules, or ions with unpaired electrons. 
These unpaired electrons are usually highly reactive, so radicals are likely to take part in 
chemical reactions that eventually change or harm the DNA of the cells. 
The human body can repair damaged cells to a certain extent, but if exposed to a high 
amount of radiation beyond a given threshold in a short period of time, “deterministic” 
damage will occur. Deterministic radiation damage includes changes of the blood count, 
hair loss, tissue necrosis or cataract. Exposure levels of typical medical diagnostic imaging 
procedures are far below the threshold for deterministic radiation damage. However, 
deterministic effects are an important consideration in external radiation therapy and 
radionuclide therapy. 
In order to assess the risk of radiation exposure, quantitative measurements of dose were 
introduced:   
- Absorbed dose D (also called “energy dose”), measured in Gray (Gy) units, characterizes 
the amount of energy deposited in tissue. It is defined as the amount of radiation 
required to deposit 1 Joule (J) of energy in 1 kilogram of any kind of matter. 
- Equivalent dose H, measured in Sievert (Sv) units, takes in account the damage caused by 
different types of radiation. It is the absorbed dose multiplied by a weighting factor 
characteristic for the particular type of radiation. For X-ray, H = D. 
- Effective dose E, measured in Sievert (Sv) units, includes the sensitivity of different 
organs to radiation. It is the sum of the equivalent doses in all irradiated organs 
multiplied by the respective tissue weighting-factors. 
Determining the effective dose in angiography depends on several factors, primarily on the 
variability in organ sensitivity to radiation. For instance, bone marrow is far more sensitive 
to radiation than the liver. The degree to which organs are affected by radiation also 
depends on the angle of the beams. Because dose distribution in angiography is not as  
“homogeneous” as it is for CT, these factors must be considered when estimating the 
damage caused by irradiation. The effective dose includes the sensitivity to radiation of the 
different organs. It is the sum of the equivalent doses in all irradiated organs multiplied by 
the respective tissue weighting-factors. 
Effective dose provides a good comparison with natural background radiation, which is on 
average about 2.4 mSv per year. Typically, during a cardiac diagnostic intervention with 15 
p/s, the effective dose per minute is 0.6 mSv (Cusma et al., 1999).  
In general, low dose goes hand in hand with less visibility, while higher image quality 
requires, among other factors, a higher dose. To obtain a specific image quality, it is 
necessary to choose the “right” dose for the tissue being penetrated. 
Because guidance of endovascular devices requires continuous X-ray, modern angiographic 
systems include several measures for dose reduction (Balter et al., 2010). There are three 
parameters which can be adapted by the user to reduce the radiation exposure:  
1. Footswitch on-time: footswitch on-time controls how long the body is exposed to X-ray 
beams, thus how long the body is irradiated: less time means less radiation. 
2. Frame rate: high frame rates are used to visualize fast motion without stroboscopic 
effects. However, the higher the frame rate, the more radiation. Therefore, it is best to 
keep the frame rate as low as possible, according to the clinical need. Modern 
 
The Hybrid Operating Room 
 
81 
angiographic systems can adjust the frame rate downward in various steps, from 60 
pulses per second (p/s) used in pediatric cardiology to 0.5 p/s in some systems for 
slowly moving objects. A reduction to half pulse rate reduces dose by about half. The 
reduction from 30 p/s to 7.5 p/s results in a dose saving of 75%.  
3. Source-Image- Distance (SID): according to the quadratic law and a requested constant 
dose at the detector, a greater distance between the source and the imager increases the 
skin dose. Rising SID from 105 cm (=SID 1) to 120 cm (=SID 2) increases skin dose (i.e. 
the dose at the IRP) by approximately 30%, if C-arm angles, table position, patient, and 
requested dose at the detector do not change. Fig. 3 illustrates the setup including the 
lower (SID = 105 cm) and the upper (SID = 120 cm) position of the detector. 
 
 
Fig. 3. C-arm, two different SIDs, constant table height, location of the IRP 
Additionally, modern angiographic systems provide some inherent features to reduce dose. 
For example, variable copper filters reduce the skin dose by filtering the low-energy photons 
out of the X-ray, called beam hardening. Some systems adjust the thickness of such filters 
automatically according to the absorption of the patient entrance dose along the path of the 
X-ray beam through the patient. This automatic filter insertion maintains low skin dose 
without degrading image quality and can result in a dose saving of up to 50%.  
Other measurements include radiation-free collimation or radiation-free object positioning. 
Using the last image hold (LIH) as a reference, the system allows radiation-free collimation 
and semitransparent filter parameter setting to precisely target the region of interest (see 
Fig. 4). A similar approach is implemented for optimal patient positioning for imaging: 
graphic display of the outline of the upcoming image allows translation of the table without 
fluoroscopic radiation exposure and provides an indication of which anatomy is in the field-
of-view of the detector. For specific cardiac interventions, such measurements can reduce 
the overall fluoroscopy time by 0.5 to 3 minutes. Under typical fluoroscopy conditions, this 
may result in a dose reduction of 20 to 120 mGy. 
More and more countries and authorities require the reporting of patient exposure to 
radiation following an intervention. To meet current and future regulations, modern 
angiographic systems allow effective reporting of dose exposure, thus enable enhanced in-
house dose reporting and analysis. 
 




Fig. 4. Radiation-free collimation:  The collimator position is indicated on the last image hold 
(LIH) by a white frame. 
3.5 3D DynaCT imaging 
Three-dimensional (3D) C-arm computed tomography (DynaCT) is a new and innovative 
imaging technique. It uses two-dimensional (2D) X-ray projections acquired with a flat-
panel detector C-arm angiography system to generate CT-like images (Kalender & 
Kyriakou, 2007). The C-arm sweeps around the patient acquiring up to several hundred 2D 
views serving as input for 3D cone-beam reconstruction. Usually, a minimum angular scan 
range of 180 degrees, plus the so-called fan-angle, is required. For typical C-arm CT devices, 
this results in an angular scan range requirement of at least 200 degrees. Resulting voxel 
data sets can be visualized either as cross-sectional images or as 3D data sets using different 
volume rendering techniques. 
Thanks to a detector optimized for high-resolution 2D fluoroscopic and radiographic 
imaging, the spatial resolution provided by DynaCT can be very high. For example, a 
common FD for large-plate C-arm systems, such as the 30 cm × 40 cm Pixium 4700 flat-panel 
detector (Trixell, Moirans, France) offers a native pixel pitch of 154 µm in a 2480 ×1920 
matrix. Due to read-out bandwidth limitations, such detectors are operated in 2 × 2 binning 
mode during DynaCT, which means the smallest high contrast object that can be resolved 
has a size of about 0.2 mm (Strobel et al., 2009). 
 Initially targeted at neuroendovascular imaging of contrast enhanced vascular structures, 
3D C-arm imaging has been continuously improved over the years. It is now possible to 
acquire CT-like soft-tissue images directly in the hybrid OR (see Fig. 5). Beyond their use for 
trans-arterial catheter procedures, these 3D data sets are also valuable for guidance and 
optimization of percutaneous treatments. In combination with 2D fluoroscopic or 
radiographic imaging, information provided by DynaCT can be very valuable for therapy 
planning, guidance, and outcome control – in particular for complicated interventions 
(Doelken et al., 2008). 
There are low-dose DynaCT protocols that achieve acceptable image quality for 
radiosensitive patients, such as pediatric patients, and provide adequate diagnostic image 
quality. In clinical practice, the balance between image quality and dose has to be 
considered. For the prerequisites mentioned above, a five second high contrast DR 
rotational 3D run applying 0.36 μGy/f can be reduced to 0.1 μGy/f resulting, in a dose 
saving of 72%. Low-dose DynaCT can be achieved with an effective dose of 0.3 mSv. 
 




Fig. 5. Cardiac DynaCT image: the C-arm CT results were obtained with syngo DynaCT 
running on a syngo X-workplace (Siemens AG, Healthcare Sector, Forchheim, Germany) 
3.6 Advanced visualization  
Recent post-processing algorithms analyse an entire digital subtraction angiography (DSA) 
sequence at once and represent the sequence in one single colour-coded image. In order to 
obtain a colour-coded image, the algorithm takes the time to maximum opacification of each 
individual pixel, starting with the injection and subsequently visualising the distribution of 
the contrast medium through the vessels. These time measurements are then represented by 
a colour, allowing visualisation of the complete vessel tree in one image. Thus, the colours 
represent the contrast agent from its initial entry into the blood vessels to its flow 
throughout the anatomy of interest in one image. 
Such dynamic flow evaluations provide a greater understanding of the contrast flow within 
the pathology, greater ease in visualizing the success of a procedure, and they assist the 
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Fig. 6. Advanced visualization of an entire DSA sequence (iFlow): Colour-coded pre and 
post-procedural results visualize the improvement of flow  
clinicians in image review by showing a complete Digital Subtraction Angiography (DSA) 
run in a single image (Ahmed et al., 2009). For example, this technology can be used to 
enhance pre-procedural and post-procedural imaging of patients under treatment for 
stenoses of peripheral vessels (see Fig. 6). Flow deviations and the increased utilisation of 
collaterals can more easily be detected prior to intervention, since anomalies more readily 
attract the physician's attention due to their specific colours. Following the intervention, the 
success of a balloon dilatation or stent implantation of a stenosis is readily visible due to the 
improved flow. 
3.7 Fusion imaging and 2D/3D overlay 
Modern angiographic systems are not just used for imaging, but support the surgeon also 
during the procedure by guiding the intervention based on 3D information acquired either 
pre-operatively or intra-operatively. Such guidance requires that the 3D information is 
registered to the patient. The next sections illustrate why 3D images acquired by an 
angiographic system are inherently registered with the patient and show new applications 
based on this fundamental feature of modern angiographic systems.  
3.7.1 Information flow between workstation and angiographic system 
3D DynaCT images are calculated from a set of projections acquired from different angles 
around the patient. The volume is reconstructed on a separate workstation. Even though 
the workstation and the angio system can be considered as separate systems, there is a 
close link and a continuous information flow between these systems. For example, when 
the user virtually rotates the volume on the workstation to view the anatomy from a 
certain perspective, the parameter of this view can be transmitted to the angio system, 
which then drives the C-arm to the exact same perspective for fluoroscopy. In the same 
way, if the C-arm angulation is changed, this angulation can be transmitted to the 
workstation which updates the volume to the same perspective as the fluoroscopic view 
(see Fig. 7).  
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The information flow between the angiographic system and the workstation ensures that an 
anatomical structure in the fluoroscopic image can be related to an anatomical structure in the 
3D image and vice versa: that means the images are registered with each other. Even pre-
operatively acquired images can be related to the patient by image-to-image registration of the 
pre-operative image with the intra-operative acquired DynaCT. Information in the pre-
operative image (e.g. a surgical plan) can be directly overlaid on top of a live fluoroscopy.  
Inherent registration of 3D images of the angiographic systems to the patient triggers new 
applications which go beyond just simple imaging, but towards image-driven guidance 
based on 3D information as illustrated in the next sections. 
3.7.2 Overlay of 3D information on top of 2D fluoroscopy 
Any 3D information extracted from the image in the workstation can be overlaid on the live 
fluoroscopic image. Firstly, the 3D image itself can be overlaid colour-coded on top of the 
fluoroscopic image. For example, in Fig. 8, a 3D angiography is colour-coded in orange and 
overlaid on the live fluoroscopy. Any change of the angulations of the C-arm will cause the 
workstation to re-calculate in real-time the view on the 3D image to match exactly the view 
of the live 2D fluoroscopy image. Without additional contrast agent injection the surgeon 
can observe device movements simultaneously with the 3D overlay of the vessel contours in 
the fluoroscopy image.  
Fig. 7 illustrates an alternative way to add information from the workstation to the 
fluoroscopic image. After either manual or automatic segmentation of the anatomical 
structures of interest in the 3D image, the outline can be overlaid as a contour onto the 
fluoroscopic image. In this example, an AAA aneurysm has been segmented in the DynaCT 
image. The contour of the 3D segmentation is shown in the fluoroscopic view and provides 
additional information which is not visible in the fluoroscopic image. Overlaid landmarks 
do not necessarily need to be extracted from images directly, but might be added by the 
 
 
Fig. 7. Linkage between a modern angio system and its workstation. The corresponding 
information flow guarantees the registration between the 3D DynaCT image in the 
workstation and a 2D fluoroscopic live image and is the prerequisite of true 2D/3D image 
fusion 
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Fig. 8. Overlay of 3D DynaCT image (orange) on top of a fluoroscopic image during cardiac 
resynchronization therapy. Courtesy of K.-J. Gutleben, M.D., G. Nölker, M.D. A. Sinha, 
M.D., J. Brachmann, M.D., Department of Cardiology, Klinikum Coburg, Germany. 
surgeon. For example to place fenestrated stents, a pre-operatively acquired CT image could 
be used to mark the ostia of the visceral arteries manually by the surgeon. By aligning the 
pre-operative CT image with the intra-operatively acquired DynaCT image, the ostia can be 
displayed (beside the contour of the arteries) in the fluoroscopic image. Notably, this truly is 
3D information, i.e. any change in the C-arm position or angulations will update the view on 
the marks to perfectly match the live fluoroscopy image.  
3.7.3 Guidance during Trans-Aortic Valve Implantation (TAVI) 
Trans-Aortic Valve Implantation requires exact positioning of the valve in the aortic root to 
prevent complications. A good fluoroscopic view is essential, whereby  an exact 
perpendicular angle to the aortic root is considered to be optimal for the implantation. 
Recently, applications have been released which support the surgeon in selecting this 
optimal fluoroscopy angulation or even drive the C-arm automatically into the 
perpendicular view to the aortic root (see Fig. 9).  
Some approaches are based on pre-operative CT images, which are used to segment the 
aorta and calculate optimal viewing angles for valve implantations. CT images must be 
registered with DynaCT or fluoroscopic images to transfer the 3D volume to the actual 
angiographic system. Errors during the registration process might result in diversification 
from the optimal angulations of the C-arm and must be manually corrected. Additionally, 
anatomical variations between the acquisition of the pre-operatively CT image and surgery 
are not accounted for. Patients are generally imaged with hands-up in a CT scanner while 
surgery is performed with arms aside the patient, which leads to substantial errors. 
Algorithms purely based on DynaCT images acquired in the OR by the angiographic system 
are inherently registered to the patient and show the present anatomy structures. With such 
an approach, the surgeon does not rely on pre-operative CT images acquired by the 
radiological department which simplifies the workflow in the OR and reduces errors in the 
process.  
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an existing OR suite. All aspects and steps starting with patient transfer from the ward to 
anesthesia and operating room preparation are important. Addiontional aspects for 
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Due to high cost, OR facilities are commonly shared by different disciplines. A very flexible 
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OR configuration (Tomaszewski, 2008). This is especially important with the increasing 
utilization of novel technologies and with space limitations in most OR suites. Layout and 
design should be ergonomic and workflow driven. For the hybrid OR with the addition of 
an angiography system to the room it becomes even more important, because this oftenly 
involves non-standard installations, or non-standard functionality, or non-standard 
products. During the entire planning and implementation process clear, frequent and 
comprehensive communication of all parties involved is vital. 
 
 
Fig. 10. Example of an hybrid OR highlighting relevant major equipment for planning 
4.1 Team 
Hybrid operating rooms are used by different surgical disciplines, interventionalists, 
cardiologists and anesthesiologists. Further staff working in these rooms includes nurses 
and technicians, resulting in a multitude of requirements impacting the room design and 
determining various resources like space, medical, and imaging equipment. Building a 
hybrid operating room needs a team approach with joint effort of customers and vendors 
(Tomaszewski, 2008; Benjamin, 2008). 
Hybrid operating rooms are always individual solutions tailored to the needs and 
preferences of the team and the hospital. Several planning iterations with experienced 
technological support from equipment and imaging vendors lead to an optimal solution. 
Hybrid OR projects involve renovation, new construction, or a little of both. OR equipment 
layout planning and implementation strategies are challenging. A clear understanding of 
the project scope and customer objectives is critical and qualified, multidisciplinary hospital 
team is needed to ensure success of this complex endeavour.  
All team members should be committed to the project. To that end, a clearly defined and 
agreed project organization including all stakeholders with clearly defined roles and 
responsibilities is necessary. 
4.2 Choosing the angiographic system 
Choosing the imaging system for a hybrid OR depends on the intended utilization of the 
room (Bonatti et al., 2007; Ten Cate et al., 2004). 
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Team member Topics 
Surgeon(s) Working positions, clinical applications, 
procedural descriptions, imaging and equipment 
requirements 
Nursing staff (circulating and scrub nurses) Working positions, patient and material logistics 
Surgical technicians (i.e. perfusionist) Working positions, equipment requirements 
Anesthetist Working positions, equipment requirements 
Anesthesia nurses Working positions, equipment requirements, 
material logistics 
OR manager Scheduling, general workflow management 
Biomedical engineers Technical room planning 
Equipment planners, Architects Technical room planning, construction, 
drawings, project management 
Vendors Installation requirements and schedule 
Table 1. Team members of an OR and the issues they care about 
Expert consensus rates the performance of mobile C-arms in hybrid ORs as insufficient and 
recommends floor-mounted systems for hygienic reasons (Bonatti et al., 2007). In fact, some 
hospitals do not allow operating parts directly above the surgical field, because dust may fall 
in the wound and cause infection. Since any ceiling-mounted system includes moving parts 
above the surgical field and impairs the laminar airflow, such systems are not the right option 
for hospitals enforcing highest hygienic standards. Ceiling-mounted systems require 
substantial ceiling space and, therefore, reduce the options to install surgical lights or booms. 
Nonetheless, many hospitals choose ceiling-mounted systems because they cover the whole 
body with more flexibility and – most importantly – without moving the table. The latter is 
sometimes a difficult and dangerous undertaking during surgery with the many lines and 
catheters that must also be moved. Moving from a parking to a working position during 
surgery, however, is easier with a floor-mounted system, because the C-arm just turns in 
from the side and does not interfere with the anesthesiologist. The ceiling-mounted system, 
by contrast, during surgery can hardly move to a parking position at the head end without 
colliding with anesthesia equipment. In an overcrowded environment like the OR, biplane 
systems add to the complexity and interfere with anesthesia, except for neurosurgery, where 
anesthesia is not at the head end. Monoplane systems are therefore clearly recommended for 
rooms mainly used for cardiac surgery. There are certainly exceptions: especially if pediatric 
cardiologists or electrophysiologists are important stakeholders in room usage, a biplane 
system may also be considered (Bonatti et al., 2007; Tomaszewski, 2008).  
3D imaging may become more and more important for OR planning and postoperative 
evaluation of the operative site. Therefore, a large detector would offer greater options, 
including portrait imaging. The preference for a detector may vary, although the majority 
opts for a large detector (Nollert & Wich, 2008). 
In summary, mobile C-arms are generally considered insufficient for cardiovascular 
imaging and do not comply with international standards for cardiac imaging (Bonatti et al., 
2007). For hybrid rooms, fixed monoplane and biplane angiographic systems are available 
which are either mounted on the ceiling or on the floor. Beside conventional C-arm systems, 
a dedicated robotic surgical C-arm is available, which allows maximal flexibility in the 
operating room. 
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The selection of the OR table depends on the primary use of the system. Interventional 
tables with floating table tops and tilt and cradle compete with fully integrated flexible OR 
tables. Identification of the right table is a compromise between interventional and surgical 
requirements (Bonatti et al., 2007; Nollert & Wich, 2008).  
 
 
Fig. 11. Siemens robotic surgical C-Arm system Artis zeego 
Surgical and interventional requirements may be mutually exclusive. Surgeons, especially 
orthopedic, general and neurosurgeons usually expect a table with a segmented tabletop for 
flexible patient positioning. For imaging purposes, a radiolucent tabletop, allowing full 
body coverage, is required. Therefore, non-breakable carbon fibre tabletops are used.  
Interventionalists require a floating tabletop to allow fast and precise movements during 
angiography. Cardiac and vascular surgeons, in general, have less complex positioning 
needs, but based on their interventional experience in angiography may be used to having 
fully motorized movements of the table and the tabletop. For positioning patients on non-
breakable tabletops, positioning aids are available, i.e. inflatable cushions. Truly floating 
tabletops are not available with conventional OR tables. As a compromise, floatable 
angiography tables specifically made for surgery with vertical and lateral tilt are 
recommended (Ten Cate et al., 2004). To further accommodate typical surgical needs, side 
rails for mounting surgical equipment like retractors or limb holders should be available for 
the table. The position of the table in the room also impacts surgical workflow. A diagonal 
position in the OR may be considered in order to gain space and flexibility in the room, as 
well as access to the patient from all sides.  
Alternatively, a conventional surgery table can be combined with an imaging system if the 
vendor offers a corresponding integration. The operating room can then be used either with 
a radiotranslucent but not breakable tabletop that supports 3D imaging, or with a universal 
breakable tabletop that provides enhanced patient positioning, but restricts 3D imaging. The 
latter are particularly suited for neuro- or orthopedic surgery, and these integrated solutions 
recently also became commercially available. If it is planned to share the room for hybrid 
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and open conventional procedures, these are sometimes preferred. They provide greater 
workflow flexibility because the tabletops are dockable and can be easily exchanged, but 
require some compromises with interventional imaging.  
 
 
Fig. 12. Example Siemens OR angiography table with a free floating tabletop 
 
 
Fig. 13. Integrated Trumpf OR table with a radiolucent carbon fibre tabletop 
 
 
Fig. 14. Integrated Trumpf OR table with breakable tabletop and metal parts that impair 
image quality 
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In summary, important aspects to be included considered are the position in the room, 
radiolucency (carbon fiber tabletop), compatibility, and integration of imaging devices with 
the operating table. Further aspects include table load, adjustable table height, and 
horizontal mobility (floating) including vertical and lateral tilt. It is important to also have 
proper accessories available, such as rails for mounting special surgical equipment 
(retractors, camera holder). Free floating angiography tables with tilt and cradle capabilities 
are best suited for cardiovascular hybrid operating rooms.  
4.4 Lights 
Ceiling space in a hybrid OR may be limited, particularly if a ceiling mounted system is 
preferred. Thus, OR lights need special attention, because they may collide with the imaging 
systems, pendants or display booms (Tomaszewski, 2008). 
In general, two different light sources are needed in an operating room: the surgical 
(operating) lights used for open procedures and the ambient lighting for interventional 
procedures. Particular attention should be paid to the possibility to dim the lights. This is 
frequently needed during fluoroscopy or endoscopy. 
For the surgical lights it is most important that they cover the complete area across the 
operating room table. Moreover, they must not interfere with head heights and collision 
paths of other equipment. The most frequent mounting position of OR-lights is centrally 
above the OR table. If a different position is chosen, the lights usually are swivelled in from 
an area outside the OR table. Because one central axis per light head is necessary, this may 
lead to at least two central axes and mounting points in order to ensure sufficient 
illumination of the surgical field. The movement range of the angiography system 
determines the positioning of the OR lights. Central axes must be outside of moving path 
and swivel range. This is especially important as devices have defined room height 
requirements that must be met. In this case, head clearance height for the OR-light may be 
an issue. This makes lights a critical item in the planning and design process (Tomaszewski, 
2008).  
Other aspects in the planning process of OR lights include avoidance of glare and 
reflections. Modern OR lights may have additional features, like build in camera and video 
capabilities. For the illumination of the wound area, a double-arm OR-light system is 
required. Sometimes even a third light may be required, in cases where more than one 
surgical activity takes place at the same time, e.g. vein stripping of the legs.  
In summary, the key topics for planning the surgical light system include: 
- Central location above the OR table (impossible with ceiling mounted systems). 
- Usually three light heads for optimal illumination of multiple surgical fields 
- Suspension accommodating unrestricted, independent movement and stable 
positioning of light heads  
- Modular system with options for extension, e.g. video monitor and/or camera  
4.5 Hygiene 
The operating room has different and stricter hygienic requirements and standards to meet 
than an interventional suite. Recently, hygiene has become a strong focus in addressing 
quality of healthcare delivery (Kerr, 2009; Hirsch, 2008; Sikkink et al., 2008; Peeters et al., 
2008). Several workflow related aspects are crucial for achieving optimal hygienic conditions 
in operating rooms. A surgical scrub facility immediately outside of the OR is mandatory to 
allow proper scrubbing in for all procedures. Hats, gloves, facemasks and proper gowns are 
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mandatory, as well as access sterile processing facilities for the disposal of soiled material 
from open procedures. Finally, clean air, air conditioning and ventilation technologies play 
an important role in achieving these hygienic standards.  
Today, this is mainly achieved with dedicated air-conditioning and ventilation solutions 
that create a limited protection zone, usually called “Laminar Airflow”, even though this 
terminology might sometimes be technically misleading. These ventilation systems need to 
cover the entire aseptic environment of surgery in operating rooms, including the tables for 
materials and instruments. This zone allows for clean-room handovers of sterilized 
materials and shields the surgical team in sterilized garb, usually by a sufficiently large low-
turbulence displacement air flow. Recent guidelines, e.g. in Germany, emphasize the 
importance of low turbulence. To meet the requirements of air cleanliness for operating 
theatres or other surgery rooms with strict hygienic requirements, very high volume flows 
of clean air are necessary. There are different solutions available to do so in an energy-
efficient way. Usually, low-turbulence displacement circulating air canopies are employed.  
Local requirements for the hygienic aspects of Heat, Ventilation, Air Conditioning (HVAC) 
vary significantly. Experts knowing the local requirements need to be involved in order to 
ensure clearance of the hybrid OR at the end of the project. This topic is to be discussed in 
detail with the responsible individuals and authorities in order to avoid non compliance 
with local regulations.  
 
 
Fig. 15. Example for a Laminar Airflow ceiling ensuring a clean environment above the 
surgical area 
4.6 Room layout 
The main objective of OR design is to improve the OR workflow and enhance safety by 
ensuring good access and clear walkways. This sets the stage for equipment and equipment 
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planning in the OR. Devices should be easy and quick to position and park. The limited 
space must be utilized optimally. Ergonomic aspects are to be considered for layout and 
design, which should enable flexible device management to cater to the needs of the various 
users and procedures. A clear floor and optimized cable management allow for efficient 
cleaning and easier maneuvering of devices. Moreover, this avoids tripping hazards. 
Camera and monitor systems for displaying patient data, for educational purposes or for 
telemedicine, may be necessary. Thus, and because of the complex needs for viewing during 
hybrid procedures, a good understanding of the visualization needs is vital. Data 
integration and IT are becoming more and more prominent for documentation, archiving 
and information provision. 
Interventional rooms have excellent imaging capabilities, but frequently lack the 
prerequisites required for formal operating rooms. Operating rooms meet those required 
standards, but usually lack high-level imaging capabilities. Therefore, the hybrid operating 
room has different space requirements. The larger the better should be the basic principle 
for planning. Staff calculations have shown that, in hybrid procedures, up to 18 people are 
in the hybrid room. Current recommendations for hybrid operating rooms suggest > 70 m2 
in comparison to 40-60 m2 for conventional operating rooms (space for a control and a 
technical room has to be added). The room has to fulfill radiation safety requirements as any 
other angiography room. 
A key part of any conceptual design is to visit other institutions that have built a hybrid OR 
(Benjamin, 2008). Thereby, customers learn from best practice and understand what works 
best for others and what other sites would have done differently if they could do it again. 
Topics include type of storage space, type of angiography system, handling of the patient 
flow and anesthesia services, control room concept, sufficiency of space, the type of 
inventory control and storage they have, and usage of barcodes or infrared technology. 
Storage capabilities are especially important. Oftentimes there will be no personnel available 
to fetch devices stored outside the OR. Build-in glass cabinets have proven to be particularly 
useful because they allow the nurses to quickly locate materials. Design includes the 
following steps and activities (Tomaszewski, 2008): 
- Define your current and future workflow and setup 
- Start with a generic standard/sample layout of a hybrid room with the considered 
imaging system as a general guideline 
- Involve all stakeholders (scrub nurses, technicians, surgeons, anesthesiologist, etc.) 
- Cooperate with all vendors involved in the project 
Centres with close proximity of intervention rooms and ORs probably have better 
prerequisites than hospitals with the classic separation of interventional rooms located in 
the internal medicine building and operating theatres located in the surgery building. In this 
situation, we recommend installing the hybrid room in the surgical wing for two reasons: 
1. Immediate readiness of all OR equipment and personnel (e.g., heart-lung machine and 
perfusionists) and access to all surgical supply chain processes, especially in emergency 
situations 
2. Availability of anesthesia and surgical intensive care 
4.7 Planning process 
The standard OR-layout is defined by the centrally positioned OR table and required access 
areas to the patient for anesthesia and surgery. In the hybrid OR the position of the 
angiography system and the table set the stage for the workflow inside the room. Other 
 




















Exemplary layout and equipment for a cardiac Hybrid OR
 
Fig. 16. A schematic room layout and equipment map of a hybrid OR depicts the complexity 
of planning an OR that allows for efficient workflow for all parties involved 
 
 
Fig. 17. Schematic Room layout with important areas for workflow considerations 
highlighted 
equipment follows this framework. Planning should always be done in 2D and with CAD, 
because this is the only way to identify all technical interdependencies and to allow for a 
reliable check of the technical feasibility of the installation. One single master plan across all 
equipment and vendors has to be created in CAD, while each vendor is meant to provide 
proper CAD blocks (Tomaszewski, 2008). However, 2D is usually not easy to “read”, even 
for experienced planners. Fig. 18 and Fig. 19 illustrate this issue. 
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Fig. 18. Example for a 2D drawing of a hybrid OR plan capturing all interdependencies that 
has limited readability for the parties involved 
 
 
Fig. 19. Examples for 3D presentation of a hybrid OR plan, ensuring a common vision of the 
future facility across all parties involved 
3D visualization helps to illustrate the 2D plan, so that full understanding from all parties 
involved is ensured. Most medical equipment suppliers and architects have the ability to 
represent in 3D, such that all elements of the final outcome of the OR can be included in this 
visualization. The following checklist provides an overview of key aspects for consideration 
during the planning and design process: 
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Location and space requirements incl. 
ancillary spaces for technical room, 
storage, etc. 
Workflow and standard room set-up 
Cross-functional team Angiography system 
Surgical versus angiography table Lights and illumination 
Ceiling suspension units and services on 
these units (number of sockets, gases etc.) 
Audio- and video integration including 
visualization and display placement 
Mobile and other equipment, needs and 
position: anesthesia, monitoring and 
hemodynamics, injectors, ultrasound, heart 
and lung machine 
IT-integration (HIS, PACS) 
Table 2. Overview of key aspects to be considered during the planning and design process 
5. Other considerations 
5.1 Training for imaging 
To take advantage of the multiple advanced imaging capabilities of state-of-the-art fixed 
angiography systems, extensive training for physicians, nurses and technicians is crucial. 
Most members of the OR team are not familiar with fixed angiography systems. Only if they 
are well versed in and comfortable using it, they can take full advantage of the imaging and 
workflow capabilities of a hybrid OR.  
Training of the team can be achieved by different concepts. However, at least one member of 
the OR team should be trained in very detail in order to use the system to its full potential. 
This person should serve as a trainer for the other team members and should take 
responsibility for the imaging. A good possibility is to ask colleagues from the radiology 
department to take over the training of the OR team member, since they are very familiar 
with imaging. This specially trained team member should then train several super users, 
who are also very familiar with the system. By ensuring that multiple OR team members can 
operate the system very well, 24/7 coverage can be provided in the hybrid OR - also for 
emergency cases on weekends or during night shifts, if required. 
The individual scope of training depends on the responsibility of the OR staff as well as on 
the workflow set-up. If for example the surgeon himself operates the angiography system, 
he will be among the ones undergoing training in system handling and operation. If, by 
contrast, the system is operated by a radiographer, the surgeon will not need to be trained in 
detail. 
Training possibilities are multiple. Principle training may be achieved by training in the 
hospital’s own hybrid OR by the provider of the imaging system (applications training), at 
other clinical sites by experienced physicians and technicians (mini fellowships), in other 
departments within the hospital, and at hands-on workshops, usually organized by the 
industry.  
5.1.1 Applications training 
When purchasing an angiography system for the hybrid OR, applications training is usually 
provided by the vendor of the imaging system. This training is generally intended for 
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experienced users and offered for approximately three days. Due to limited experience with 
imaging systems in the OR team, however, the training needs in surgery are much higher 
than for example in radiology. 
Duration and content of the application training largely depend on how many different 
clinical disciplines use the system, on their level of experience and on the number of staff to 
be trained. During these trainings, the users are, depending on their scope of responsibility, 
being familiarized with system handling, software usage, image processing and archiving, 
the typical workflow in the hybrid OR and radiation protection. The trainers should be 
present during different clinical procedures in order to provide training and support system 
usage in clinical operation. Fig. 20a and Fig. 20b show an example plan for a three weeks 





Fig. 20a. Typical training schedule of the first week of application training for hybrid OR 
5.1.2 Mini fellowships at clinical sites 
Some experienced clinical sites also offer the possibility to do short fellowships. The fellow 
is being assigned to an experienced team for 3-5 days. During the fellowship the fellow will 
experience the typical workflow in a hybrid OR by accompanying the trainer through the 
different work steps, including treatment decisions and surgery, with the opportunity to 
discuss the workflow with the whole OR team. 
5.1.3 Training in other departments within the hospital 
It has also proven to be very beneficial to send a designated Super User to a department in 
the hospital that is very experienced with angiography systems, for example radiology or 
cardiology. An internship of about one week helps the user to become familiar with system 
usage under the guidance of experienced users. 
 




Fig. 20b. Typical training schedule of the second and third week of applications training in 
the hybrid OR 
5.1.4 Hands-on workshops 
Some device and imaging vendors offer hands-on trainings at conferences or in their 
factories or showrooms for physicians that are just starting to use imaging systems. During 
these trainings, experienced cardiac surgeons and cardiologists train less experienced 
surgeons and fellows on transcatheter procedures and imaging. Corner stone of these 
trainings are the hands-on sessions. The trainee is guided by an experienced cardiologist or 
surgeon while practicing the use of devices like catheters and valves under real image 
guidance by an angiography system. The system and room set-up resembles a real hybrid 
OR or hybrid cathlab (see Fig. 21). 
 
 
Fig. 21. An experienced interventional cardiologist teaches surgeons in basic wire 
techniques. 
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5.2 Financial considerations 
Building a hybrid operating room is a considerable economic investment for every hospital. 
Sound business models and optimal usage of the room are prerequisites to make this 
endeavour a financial success. 
5.2.1 Costs 
The costs for hybrid rooms vary considerably depending on whether or not re- or new 
construction is necessary. 
Furthermore, it may be necessary to hire additional staff such as radiology technicians that 
are familiar with interventional imaging systems. Both new and existing staff may require 
outside training to be able to use the equipment properly. These decisions depend on the 
existing knowledge in the hospital and on what procedures will be performed.  
A recent study (Neumann, 2009) compared the investment necessary for hybrid suites, cath 
labs and standard ORs. Room size, construction requirements, angiography system, other 
equipment, depreciation, maintenance and debt service were taken into account. Overall, 
investment costs for the standard OR were lowest, followed by the cath lab with a 25% 
higher price tag. The costs for a hybrid OR were additional 120% of the costs of the standard 
OR. When comparing the operating costs (maintenance, depreciation, debt service and rent) 
the same relations applied. The costs for the cath lab were 25% higher than for the OR. 
Comparing the OR with the hybrid OR, an additional 90% were required per annum.  
These figures may differ, depending on system choice, building costs and local requirements 
but the above mentioned figures give a good indication on the comparative costs. Taking 
these reasonably high costs into account, the obvious question arises how a hybrid OR can 
be a profitable investment. 
5.2.2 Return on investment 
Several US hospitals reported in detail on return on investment. The Vanderbilt group 
(Greelish, 2009) focused on the growth of a cardiac surgery program through a hybrid room. 
In the year 2004 the annual case volume of adult cardiac cases was 464. 2004 was also the 
year when the institution built their first hybrid OR. In the next 3 years the case load almost 
tripled based upon the hybrid OR set-up.  
A similar case load development as in Vanderbilt Heart is to be seen in Beijing’s Fu Wai 
Hospital. The annual report 2008 shows an increase of over 60% of the hybrid procedures a 
year after their hybrid OR was installed (Fu Wai, 2008). 
In an initial pro forma from St. Vincent Heart Center of Indiana (Cronin & Schroyer, 2010) 
the calculations showed that incremental discharges of 150 patients led to a gross patient 
revenue of $ 6.2m and net patient revenue of $ 2.4m. Deducting total expenses of $ 0.8, the 
excess of revenues over expenses was $ 1.6m. The net present value was calculated to be $ 
0.8m in 2010 and $ 5.4m in 2015, leading to an internal rate of return of 185% in 2010 and 
285% in 2015, respectively. 
Data from Cleveland Clinic Foundation showed the return on investment of their cardiac 
hybrid OR to take only 2 years and 3 months (Cronin & Schroyer, 2010).  
The Advisory Board Company reported a detailed investment calculation for a room 
focusing solely on TAVI procedures in the USA (Katz, 2010). In reality the wide majority of 
rooms will be used for a multitude of procedures, often from different surgical disciplines in 
order to make best use of the room capacity. In the Advisory Board Company’s pro forma, 
focussing only on TAVI cases, the cumulated investment came up to $ 3.4m, consisting of $ 
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1.3m for construction work and $ 2.1 for the equipment. In the first year, starting with a very 
low volume of TAVI patients of 24 and consequently lower revenue of $ 1m, the total net 
revenue was $ 0.9m after reducing bad debt allowance and billing & collection. Annual total 
fixed costs accumulated to $ 0.1m, variable costs for devices, labour etc. to $ 0.9m leading to 
total costs of $ 1m during year one. Consequently the net income was negative by $ 23k in 
the first year. With an increase in patient volume to 37, however, already in year two a net 
income of $ 0.4m could be realized.  
Table 3 gives an overview and comparison of the cost and return situation (by St. Vincent 
Heart Center and the Advisory Board Company). 
 
 St. Vincent Heart Center 
Advisory Board 
Company 
Gross patient revenue in 
year 2010 (St. Vincent) / year 1 (Advisory Board) 6200 1000 
Net revenue 2400 900 
Total expenses 800 1000 
Net Present Value (NPV) in 
year 2010 (St. Vincent) / year 1 (Advisory Board) 800 -23 
Net Present Value (NPV) in 
year 2015 (St. Vincent) / year 5 (Advisory Board) 5400 1300 
Rounded figures in k USD 
Table 3. Financial comparison of pro forma from St. Vincent Heart Center and The Advisory 
Board Company (Cronin & Schroyer, 2010) 
As a general fact, the set-up of hybrid rooms allows for the treatment of previously untreatable 
patients. Good examples are TAVIs. Now, patients previously deemed too old or weak for 
surgery, can be treated by transcatheter valve implantation. With an aging population and 
developments in medicine, the number of octogenarians and nonagenarians to be treated with 
new hybrid and minimally invasive procedures that are best performed in a hybrid OR will 
continue to grow. This will lead to increasing usage of the room capacity and consequently a 
quicker return on investment. Also, with less invasive treatment the necessity to stay in the 
ICU and the hospital for a long time in general decreases, along with the risk of infections. This 
allows discharging patients quicker, which again leads to an improved cost situation in the 
hospital. Furthermore hybrid rooms help to increase efficiency and decrease turnover time 
which can lead to additional cases being performed in the hybrid room as compared to a 
standard OR (Benjamin, 2008). A conventional surgical valve replacement often takes more 
than three hours, whereas a transcatheter valve implantation can be done in one. Calculations 
indicate that the mean incremental operating room profit per procedure is about $ 1,500 per 
hour. If the hospital manages to add only one single hour-long case each day, the hybrid OR 
could help increase profitability by about $ 300k p.a. 
In cardiac surgery, the operating room profit is usually even about 25-30% above the mean 
incremental OR profit (Resnick et al., 2005). 
5.2.3 Positive marketing effects 
Another soft factor that can have a positive financial impact is to use the hybrid OR to 
position the hospital among the technologically most advanced institutions in the area. This 
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helps to both attract the top medical staff to work in the hospital as well as additional 
patients that are searching for the best possible treatment.  
Also many hospitals make use of the increased publicity they can gain by marketing their 
hybrid ORs for the public e.g. in TV reports (see Fig. 22). 
In summary, to justify the substantial investment in the hospital a detailed business plan 
needs to be created, taking into account the specific situation in the hospital. Hospital 
administration usually accepts a start-up phase with a negative margin but will expect 
positive numbers after. A detailed business plan will enable both users and hospital 
administration to base the decision for the hybrid OR on solid grounds and make sure it will 
be used to its full potential. 
5.3 Building a hybrid program 
One key success factor for a hybrid operating room is the team approach of a committed 
interdisciplinary team that takes responsibility for the room. Imaging specialists, cross 
trained physicians, and nurses with the vision to establish new minimally invasive therapies 
are the cornerstones of a blooming hybrid therapy program.  
Bonatti stresses the importance of a dedicated workflow coordinator (Bonatti et al., 2007) to 
direct the workflow. Since the workflow in a hybrid OR has major differences to the one in a 
conventional OR it is mandatory that the whole OR team approaches the new concept open-
mindedly and willing to change traditional processes fundamentally.  
The workflow coordinator or hybrid OR manager takes care of traditional OR management 
topics such as staffing, ancillary support and inventory management. But he also manages 
some new tasks such as prioritizing the cases as in giving true hybrid cases priority over 
standard surgical or cardiologic procedures that can be done in a normal OR or cathlab. He 
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also needs to assure that cross trained physicians are available to work in the new room 
(Katz, 2010). 
A multi-disciplinary approach is necessary to make best use of the hybrid OR and achieve 
the best patient and hospital outcomes. A key factor herein is a good working relationship 
between sometimes competing clinical disciplines. For example, cardiac surgeons and 
interventional cardiologists have to cooperate in numerous cardiac procedures such as 
TAVI. Multi-disciplinary case conferences in order to discuss the best treatment options are 
mandatory. Also, consensus and support from other functions in the hospital, such as 
anesthesia, intensive care, and hospital administration, are essential (Galantowicz & 
Cheatham, 2005).  
However, not only operational integration is necessary, but also financial integration. 
Accounting practice needs to change with the usage of a hybrid OR. To start with, some 
institutions split the charges for hybrid procedures into a percutaneous component 
performed by the interventionist and billed by the cathlab, as well as a surgical component 
executed by the surgeon and billed by the OR department (Katz, 2010). 
Moving forward, full financial integration is of utmost importance in order to avoid 
competition between different clinical disciplines. Consequently, all involved cardiovascular 
departments should be under one profit and loss statement of an integrated cardiovascular 
center (Katz, 2010). 
To support the process of implementing a hybrid program it makes sense to set up best 
practice teams (cardiac and vascular surgery, cardiology, nurses etc.) who jointly develop 
the approach in the hospital. Visiting other institutions with a successful hybrid OR in 
operation is of major help in the planning process. Learning from their experience and 
understanding their mistakes can help shorten the process for all involved staff 
considerably.  
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overload, with all its undesirable consequences. Once the disease has become symptomatic, 
the prognosis without surgical replacement of the valve is dismal: the life expectancy is 
reduced to 2 or 3 years with occurrence of syncope, angina pectoris and certainly with 
dyspnea (5). Age, left ventricular dysfunction and neurologic condition played a major role 
in the denial for AVR (6). Medical treatment and balloon valvotomy (7) do not improve the 
prognosis. Aortic valve replacement (AVR) is the only way to prolong life and improve its 
quality. In spite of technical improvements, the procedure involves a major procedure, with 
all its complications. Moreover, one condition (the valve disease) is replaced by another (the 
prosthetic valve).  
The possible hospital or 30 day complications which can occur after AVR include valve 
related, cardiac non-valve related and non-cardiac events. Identification of their predictors 
could lead to an improved referral pattern and, hence to an improved 30 day outcome, 
provided these predictors are liable to changes. 
2. Methods 
In one centre for cardiac surgery, 1000 patients who underwent AVR with Carpentier-
Edwards cardiac valve, were studied in a retrospective way. The operations were performed 
between the end of 1986 and the end of 2006. In most patients with degenerative aortic valve 
disease, coronary artery disease was also present. Hence, patients who received concomitant 
CABG were also included. Their median age was 75 (71-77) years. The surgical technique 
remained largely unchanged and was performed through a median sternotomy. After 
opening the pericardium, the ascending aorta, the vena cava inferior and superior could be 
accessed for connection to the extracorporeal circulation. The pulmonary artery was ligated 
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order to decompress the left ventricle. Before the extracorporeal circulation was started, the 
patient was fully heparinized. The patient was cooled to 30° Celsius and the heart was 
stopped and topically cooled with sludge ice. Systemic blood pressure, central venous 
pressure and left atrial pressure were continuously monitored. The ascending aorta was 
opened and cold cardioplegia was instilled within the coronary arteries. In case of severe 
coronary artery disease, additional cardioplegia was instilled through the coronary sinus. 
This was repeated after 30 minutes. The calcified aortic valve was inspected and excised. 
The ring was decalcified if necessary. The interrupted sutures were placed as three separate 
series through the aortic annulus, and then through the prosthesis in the same order. The 
valve was lowered into the annulus and the sutures were tied and severed at the desired 
length. If necessary, the great saphenous vein was harvested by another team for 
concomitant CABG. The suturing of the bypass on the coronary arteries were performed 
during the same clamping. The aortotomy was closed with a double running suture and the 
proximal end of the bypasses were also connected. The internal mammary artery was not 
often used. The extracorporeal circulation was stopped stepwise and then disconnected. 
Temporary pacemaker wires were attached to the surface of the ventricles. After thorough 
hemostasis and placement of drains, the chest cavity was closed. The patient was transferred 
to the intensive care unit and kept under sedation for 24 hours. In 1996, the anesthesia 
changed into a “short-track” procedure: the sedation was shortened from one day to 6 hours 
and extubation was performed as soon as possible thereafter. 
The changes is referral pattern were documented by comparison of age and co-morbid 
conditions in four periods of 5 year (1986-1991; 1992-1996; 1997-2001 and 2002-2006). A chi-
square analysis was used as statistical analysis to show significant differences over time.  
Twenty five preoperative and five peri-operative factors were screened in two steps. In a 
first step, the effect on hospital events was studied by an univariate chi-square or a Fisher-
exact analysis. In a second step, the significant factors were entered in a multivariate logistic 
regression analysis in order to identify the predictors.  
The results are presented for each risk factor (first column of the table), n/N (second 
column), p or probability (third column), OR (fourth column) and 95%CI (last column), 
where N is the number of patients at risk (i.e. having the risk factor) and n the number of 
these patients who suffered the complication; OR is the odds ratio and 95%CI is the 95% 
confidence interval.  
These factors were defined or dichotomized if appropriate and numbers are given.  
Octogenarians   186 
Male gender   530 
COPD (chronic obstructive pulmonary disease) 
    235 defined on protocol by pneumologist 
Impaired renal function  109 plasma creatinine over 1.3 mg% 
Previous carcinoma  104 proven by histologic examination and treated  
     with curative intent 
Hypertension   654 blood pressure repeatedly over 140/90 mmHg  
     in resting conditions 
Diabetes    149 treated by diet, peroral antidiabetics or insulin 
Coronary artery disease  631 documented on coronarography  
Myocardial infarction  151 documented by ECG, enzymes (during  
     previous admission) 
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Previous CABG   81 previous admission and operation protocol 
Carotid artery disease  238 stenosis of 40% or more on Doppler-duplex 
History of TIA/CVA (Transient ischemic attack / cerbrovascular accident) 
    40/68 by history and CT (computer tomography),  
     during previous admission 
Left ventricular dysfunction 247 decrease documented by segmental analysis of  
     ventricular wall on echocardiography 
LV ejection fraction<50%  155 calculated by data obtained at  
     echocardiography 
Atrial fibrillation   197 chronic or paroxysmal, documented by ECG 
Ventricular arrhythmias  74 documented by Holter monitoring 
Heart failure   216 at least one previous admission for pulmonary  
     edema 
NYHA (New York Heart Association) class IV 
    251 by anamnesis at admission for AVR 
Need for digitalis   152 by anamnesis at admission for AVR 
Conduction defect  270 documented by ECG: of any type and of any  
     degree 
First degree AV (atrioventricular) block 
    33 ibid  
Previous PaceMaker implant 33 during previous admission  
Previous endocarditis  17 documented by bacteriological analysis during  
     previous admission 
Need for urgent AVR  25 condition needing AVR at the same day in  
     order for the patient to survive 
Cross-clamping>75 min  460 sum of cross clamping time for valve  
     implantation and for additional procedures 
Valve size 19   27 sizes ranging from 19 to 27 
Concomitant CABG  610  
Mitral ring   13  
Aortoplasty   61 enlargement of reduction of the ascending aorta 
Carotid endarterectomy  22  
 
The adverse events under scrutiny were 
- hospital mortality (n=37) 
- valve related events 
 endocarditis, documented by clinical signs, echocardiography and blood samples 
(n=2) 
 thrombo-embolism, with neurological signs (n=25), documented on CT or ischemic 
events on other locations (n=2) 
 bleeding, evident if external or documented on cerebral CT (n=20) 
 ventricular arrhythmias, documented on ECG (n=37) 
- cardiac events not related to the valve 
 congestive heart failure defined by the inability of the heart to maintain an 
adequate circulation without support of inotropics or assist device (n=36) 
 conduction defects (new or progression of an pre-existing defect), documented on 
ECG, of any type and of any degree (n=101) 
 
Special Topics in Cardiac Surgery 
 
108 
order to decompress the left ventricle. Before the extracorporeal circulation was started, the 
patient was fully heparinized. The patient was cooled to 30° Celsius and the heart was 
stopped and topically cooled with sludge ice. Systemic blood pressure, central venous 
pressure and left atrial pressure were continuously monitored. The ascending aorta was 
opened and cold cardioplegia was instilled within the coronary arteries. In case of severe 
coronary artery disease, additional cardioplegia was instilled through the coronary sinus. 
This was repeated after 30 minutes. The calcified aortic valve was inspected and excised. 
The ring was decalcified if necessary. The interrupted sutures were placed as three separate 
series through the aortic annulus, and then through the prosthesis in the same order. The 
valve was lowered into the annulus and the sutures were tied and severed at the desired 
length. If necessary, the great saphenous vein was harvested by another team for 
concomitant CABG. The suturing of the bypass on the coronary arteries were performed 
during the same clamping. The aortotomy was closed with a double running suture and the 
proximal end of the bypasses were also connected. The internal mammary artery was not 
often used. The extracorporeal circulation was stopped stepwise and then disconnected. 
Temporary pacemaker wires were attached to the surface of the ventricles. After thorough 
hemostasis and placement of drains, the chest cavity was closed. The patient was transferred 
to the intensive care unit and kept under sedation for 24 hours. In 1996, the anesthesia 
changed into a “short-track” procedure: the sedation was shortened from one day to 6 hours 
and extubation was performed as soon as possible thereafter. 
The changes is referral pattern were documented by comparison of age and co-morbid 
conditions in four periods of 5 year (1986-1991; 1992-1996; 1997-2001 and 2002-2006). A chi-
square analysis was used as statistical analysis to show significant differences over time.  
Twenty five preoperative and five peri-operative factors were screened in two steps. In a 
first step, the effect on hospital events was studied by an univariate chi-square or a Fisher-
exact analysis. In a second step, the significant factors were entered in a multivariate logistic 
regression analysis in order to identify the predictors.  
The results are presented for each risk factor (first column of the table), n/N (second 
column), p or probability (third column), OR (fourth column) and 95%CI (last column), 
where N is the number of patients at risk (i.e. having the risk factor) and n the number of 
these patients who suffered the complication; OR is the odds ratio and 95%CI is the 95% 
confidence interval.  
These factors were defined or dichotomized if appropriate and numbers are given.  
Octogenarians   186 
Male gender   530 
COPD (chronic obstructive pulmonary disease) 
    235 defined on protocol by pneumologist 
Impaired renal function  109 plasma creatinine over 1.3 mg% 
Previous carcinoma  104 proven by histologic examination and treated  
     with curative intent 
Hypertension   654 blood pressure repeatedly over 140/90 mmHg  
     in resting conditions 
Diabetes    149 treated by diet, peroral antidiabetics or insulin 
Coronary artery disease  631 documented on coronarography  
Myocardial infarction  151 documented by ECG, enzymes (during  
     previous admission) 
The 30 Day Complication Rate After Aortic Valve  
Replacement with a Pericardial Valve in a Mainly Geriatric Population 
 
109 
Previous CABG   81 previous admission and operation protocol 
Carotid artery disease  238 stenosis of 40% or more on Doppler-duplex 
History of TIA/CVA (Transient ischemic attack / cerbrovascular accident) 
    40/68 by history and CT (computer tomography),  
     during previous admission 
Left ventricular dysfunction 247 decrease documented by segmental analysis of  
     ventricular wall on echocardiography 
LV ejection fraction<50%  155 calculated by data obtained at  
     echocardiography 
Atrial fibrillation   197 chronic or paroxysmal, documented by ECG 
Ventricular arrhythmias  74 documented by Holter monitoring 
Heart failure   216 at least one previous admission for pulmonary  
     edema 
NYHA (New York Heart Association) class IV 
    251 by anamnesis at admission for AVR 
Need for digitalis   152 by anamnesis at admission for AVR 
Conduction defect  270 documented by ECG: of any type and of any  
     degree 
First degree AV (atrioventricular) block 
    33 ibid  
Previous PaceMaker implant 33 during previous admission  
Previous endocarditis  17 documented by bacteriological analysis during  
     previous admission 
Need for urgent AVR  25 condition needing AVR at the same day in  
     order for the patient to survive 
Cross-clamping>75 min  460 sum of cross clamping time for valve  
     implantation and for additional procedures 
Valve size 19   27 sizes ranging from 19 to 27 
Concomitant CABG  610  
Mitral ring   13  
Aortoplasty   61 enlargement of reduction of the ascending aorta 
Carotid endarterectomy  22  
 
The adverse events under scrutiny were 
- hospital mortality (n=37) 
- valve related events 
 endocarditis, documented by clinical signs, echocardiography and blood samples 
(n=2) 
 thrombo-embolism, with neurological signs (n=25), documented on CT or ischemic 
events on other locations (n=2) 
 bleeding, evident if external or documented on cerebral CT (n=20) 
 ventricular arrhythmias, documented on ECG (n=37) 
- cardiac events not related to the valve 
 congestive heart failure defined by the inability of the heart to maintain an 
adequate circulation without support of inotropics or assist device (n=36) 
 conduction defects (new or progression of an pre-existing defect), documented on 
ECG, of any type and of any degree (n=101) 
 
Special Topics in Cardiac Surgery 
 
110 
 atrial fibrillation, new or recurrence of a previously paroxysmal atrial fibrillation, 
documented on ECG (n=381) 
- non-cardiac events 
 acute renal function impairment, documented by an increase of plasma creatinine  
with 0.3 mg% (n=53) 
 pulmonary complications: clinical and radiological signs of atelectasis or 
respiratory infection or prolonged intubation (n=58).  
3. Results 
Between the end of 1986 and 1991, 80 patients received a Carpentier-Edwards valve in aortic 
position. This number was 216 between 1992 - 1996, 345 between 1997 - 2001 and 365 
between 2002 and the end of 2006. In our series, the changes in the four 5-year periods 
showed a significant increase in time for 
- patients over 80 (from 6,3% to 25,5%),  
- diabetes: 6.5% to 22.7%;  
- COPD: 6.5% to 36.4%;  
- renal function impairment: 0.9% to 17.7%;  
- carotid artery disease: 2.5% to 40.1%;  
- preoperative period of congestive heart failure: 12,5% to 28.3%;  
- previously performed CABG: 1.3% to 11.3%;  
All increases were highly significant (p<0.001). Only for the need of digitalis, a significant 
decrease was observed: from 39.7% to 9.4% (p<0.001). These results show that patients 
referred for AVR became older and have more co-morbidity. The reduction of use of 
digitalis could be due to the introduction of ACE inhibitors, angiotensin receptor, renin and 
beta blocking agents.  
The hospital results showed a completely different pattern. Only for non-cardiac 
complications, a significant increase (p=0.001) has been found over time, from about 20% in 
the first two five-year periods to about 30% in the last two five-year periods. Mortality and 
major cardiovascular complications rates such as ventricular arrhythmias, bleeding, 
congestive heart failure and thromboembolism all remained well below 5% throughout 
these observation periods, without a noteworthy increase. Atrial fibrillation remained 
between 30 and 40%, without an increase over time.  
Although patients referred for AVR became older and sicker, 30-day postoperative survival 
seemed not affected. Therefore, age and the presence of co-morbid conditions do not 
necessarily represent formal contra-indications for AVR. Nevertheless, an increase of non-
cardiac postoperative complications with concomitant increase in length of stay and use of 
economic resources could be expected if older and sicker patients are operated upon.  
Hospital or 30 day mortality  
Significant preoperative factors for mortality in an unvariate analysis were: 
P<0.001: need for urgent surgery, age over 80, decreased left ventricular function,  
P<0.01: renal function impairment, LVEF below 50%, previous AMI, previous 
heart failure, need for digitalis, 
P<0.05: diabetes, chronic or paroxysmal atrial fibrillation, 
The other risk factors had no significant effect. NYHA functional class II had a protective 
effect (p<0.001) for mortality.  
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Multivariate analysis showed following results 
Factor  n/N  p  OR  95%CI  
Urgent AVR  7/25  <0.001  9.0  2.8-28.7 
Digitalis  12/152  0.002  3.5  1.6-7.7 
Age > 80  17/186  0.005  3.1  1.4-6.6 
 
Mortality in the hospital phase was the most important outcome. It varied between 1.5% (8) 
and 24% (9). These differences were due to large differences in patient characteristics such as 
age and co-morbid conditions. With a time span of almost 20 year between the first and the 
last publication, improvement in surgical techniques and peri-operative care could also be 
responsible for these differences in mortality. 
In most series, the hospital mortality was below 10%. In series where the mortality was over 
10%, several risk factors were usually present. Independent predictors for hospital mortality 
were identified and confirmed that specific co-morbid conditions increased the early 
postoperative risk.  
Most of these factors could be related to the left ventricle and hence to the patient. An 
emergency need for AVR (i.e. to operate on the same day as the admission in order for the 
patient to survive) has been identified as the most important predictor, with a increase of 
mortality of 10 times (10). This has been confirmed in other series (11,12). This indicated to 
an exhaustion of all compensatory mechanisms to maintain an adequate circulation. A need 
for urgent AVR has also been identified as a predictor for early postoperative congestive 
heart failure, which is a highly lethal condition (13). A high preoperative functional class 
NYHA IV (14,15) and a low-flow low-gradient problem also could be related to a protracted 
burden, and hence a decreased left ventricular function. Coronary artery disease, previous 
and the need for concomitant CABG (9,11,12,15) as well as a previous myocardial infarction 
(10,11) and previous CABG (12) could add to a decrease in left ventricular function.  
Valvular factors such as severity of valvular disease and the type and size of valve 
prosthesis implanted also had an effect (15,16). The effect of non-cardiac factors such as 
diabetes (15) and renal disease (11,12,17) was also observed. Remarkably, the effect of age 
over 80 (9,12,18,19), although important, was less compared to the effect of need for urgent 
surgery on mortality(10).  
Thromboembolic events 
TE events were one of the most important and devastating events after AVR, especially if 
permanent neurological deficit was present. One also has to keep in mind that many TE 
events go unnoticed. In one small series, MRI after cardiac surgery could document silent 
events in 6 of 34 patients, which is rather high (20). We found this clinically evident 
thromboembolism in 27 of 1000 patients. In 25 cases, this was neurological. An univariate 
analysis identified a decreased left ventricular function (p<0.01) as sole risk factor.  
This risk factor was confirmed in a multivariate analysis, which showed an ejection fraction 
below 50% as an independent predictor (11/247 patients), with p=0.027, an odds ratio of 2.5 
with a 95% confidence interval between 1.1-5.7.  
Some studies  reported on the predictors for thromboembolism after AVR on long-term and 
none reported on such events on short-term. The short-term thromboembolic events, 
however, have their importance since these are a predictor for future events (21). A 
preoperative CVA seemed to have a comparable significance (21-24) for long-term events.  
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A low ejection fraction also has been identified as predictor (24). Congestive heart failure 
and a dilated ventricle are known risk factors for thromboembolism. Damage to the 
ventricular wall as well as an abnormal flow of blood (and possible stasis) can promote 
intra-ventricular thrombosis and hence embolization. If the LVEF is below 30%, life-long 
anticoagulation is required (25).  
Age also has been identified as an independent predictor (23-27). The age distribution of any 
given patient population should be made known to appreciate fully the effect of this factor. 
Age might be related, however to co-morbid conditions such as diabetes and atheromatosis 
of the aorta and the cerebral vessels (23,24).  
Carotid artery disease could be a matter for debate. In some series (23,24), it was identified 
as a predictor for thromboembolism, in other series, this was not (21). A Doppler-duplex  
investigation is a reliable tool for the detection of lesions and is routinely performed in some 
institutions. It cannot, however, detect atheromatosis of the intracranial vessels.  
A long ECC time (24) might indicate to coronary artery disease (28) and hence, to the need 
for an associated procedure, which mostly is a CABG. This could confirm atheromatous 
vessels as a possible source for thromboembolic events. These cannot be considered entirely 
as valve related. A “smoking gun”, however, is often not found. And CABG itself has never 
been identified as a predictor for thromboembolism.  
AF could also be a matter for debate: it is certainly a risk factor for thromboembolic events. 
However, it is also an indication for anticoagulation, which might cloud the effect of AF. In 
some series, AF was identified as a predictor (28), in others not (21,24).  
It is by no means certain that risk factors for long-term thromboembolic events could be 
used to predict the occurrence of such events on short term. The latter, however, have their 
prognostic significance. Moreover, all these predictors indicate that the sources of 
thromboembolic events are multiple. Hence thromboembolism cannot be considered as 
entirely valve related (21,29), but also as patient related.  
To prevent thromboembolism after AVR with a biological prosthesis, anticoagulant 
medication is given for three months after implantation, after which it can be replaced by 
acetyl salicylic acid, with good results (21), unless anticoagulants are indicated for another 
reason. An RCT to support this strategy does not exist (25), but the general idea is that 
vitamin K antagonists protect against early thromboembolism while re-endothelialization of 
the stent and the sutures is not yet complete. For mechanical heart valves, a life-long 
anticoagulant treatment is necessary. The target level for INR is determined by the valve 
position (for aortic this is lower than for mitral) and by the type of mechanical heart valves. 
Older types such as cage ball devices are more thrombogenic and require deeper 
anticoagulation. A strict classification for thrombogenicity is not available. There are too 
many patient related factors involved (25).  
Bleeding events 
Univariate analysis revealed three factors with a significant effect. This was confirmed by a 
multivariate analysis. The use of vitamin K antagonists could not be included since almost 
all patients received this medication for three months after operation. The three predictors 
were: 
Factor   n/N  p  OR 95%CI  
Concomitant CABG  17/610  0.046  3.6 1.0-12.5 
COPD   8/235  0.051  2.6 1.0-6.6 
Aortoplasty   4/61  0.058  3.5 1.0-12.6 
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Bleeding events could be considered as the other side of the coin of anticoagulation with 
vitamin K antagonists. Effective protection against thromboembolism holds the risk for 
bleeding. A continuous balance should be made. The INR does not only depend on the dose 
of vitamin K antagonists, but also on the adsorption of vitamin K by the mucosa of the colon 
and on its processing by the liver. No other reports concerning predictors for early bleeding 
after valve replacement appeared. Current results indicated that early bleeding seems 
related to the procedure and is different compared to bleeding events at long term, which is 
probably more related to anticoagulation. Nevertheless, other factors such as age and 
increased cardiothoracic index were identified as predictors for bleeding during long-term 
follow-up (26). Fragility in elderly might be an important reason. In other series, no 
predictors or risk factors could be identified (30,31).  
Prosthetic valve endocarditis 
The number of patients with early prosthetic valve endocarditis was low, hence no risk 
factors or predictors (such as preoperative endocarditis) could be identified in our series. 
Literature data only described long-term events.  
The linearized rate for long-term prosthetic valve endocarditis was low and mostly under 
1% per patient year (26,27,32-39). The most event free rates after 5 to 25 year were well over 
90%. This was true for mechanical heart valves (35,40,41) as well as for the different stented 
(30,42) and stentless tissue valves (27,36,43) as for homografts (8). No risk factors could be 
identified, although a previous endocarditis could arouse some suspicion. Prosthetic valve 
endocarditis carried a high risk for mortality, especially if Staphylococcus aureus has been 
detected (44). These micro-organisms often lead to ring abscesses and prosthetic 
paravalvular leak. The occurrence of congestive heart failure with prosthetic valve 
endocarditis has been the main indication for re-operation (45).  
Congestive heart failure 
Univariate analysis identified following risk factors: 
P<0.001: Need for urgent surgery, chronic or paroxysmal atrial fibrillation  
P<0.01: Age over 80, decreased left ventricular function, previous infarction  
P<0.05: COPD, LVEF below 50%, preoperative heart failure, need for digitalis  
NYHA class II had a protective effect (p<0.001) 
Multivariate analysis showed following results 
Factor  n/N  p  OR  95%CI  
Urgent AVR  7/25  <0.001  10.5  3.6-30.8 
Atrial fibr.  16/197  0.001  3.5  1.7-7.4 
EF<50%  10/155  0.055  2.1  1.0-4.4 
 
In-hospital congestive heart failure after AVR is a highly lethal complication (13,46). 
Hospital heart failure occurred in 2.6% of the patients in an earlier series (13), with need for 
urgent AVR as the sole independent predictor. This pointed to an exhaustion of all 
compensatory mechanisms to maintain an adequate circulation and this observation should 
reason not to postpone AVR, once it has become symptomatic. In another study, the level of 
B-type natri-uretic peptide was also identified as a predictor (46). Apoptosis or programmed 
cell death of cardiomyocytes could be an important event in these patients (47). Atrial 
fibrillation could lead to a decreased ventricular filling and cardiac output since the atrial 
contraction is lost. In an earlier series, this was also the case in long-term heart failure (13). 
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Early congestive heart failure should be distinguished from long-term heart failure: the 
latter was diastolic in nature and has some other risk factors such as conduction defects and 
coronary artery disease. An impaired relaxation occurred since after regression of the 
muscle mass, this fibrosis persists for a longer time. This stiffened the LV wall (48). The 
LVEF remained often normal. Hence, this could be labeled as a “diastolic” form of CHF (13).  
Concurrent conduction defects thereby could lead to perfusion defects and wall motion 
abnormalities, even in absence of coronary artery disease (49). Biventricular pacing often 
could correct this condition (50,51). Coronary artery disease could lead to ischemic loss of 
myocardial contractility, adding to the left ventricular function. Concomitant CABG, 
however was not identified as a predictor for postoperative CHF (13).  
A small valve size has not been identified as a predictor for long-term heart failure in a 
previous series (13), neither in the current series for short-term heart failure. Hence, in 
patients with a small aortic root, it seemed not necessary to enlarge the root or to implant a 
stentless valve, which requires a more demanding technique, provided the LVF is normal.  
However, it becomes important in patients with a low ejection fraction. When, in such 
patients, a small valve size leads to an even moderate prosthesis-patient mismatch, this 
might result in heart failure and an increased mortality (52).  
Atrial fibrillation 
Atrial fibrillation and other non-sinusal rhythms occurs in 20% of the postoperative patients 
(32). In other series, this was 40% or more (53,54). The definition and the diagnostic method 
for AF have also an effect on its incidence (54,55). Postoperative AF has not been considered 
as innocent: it could lead to other complications and an increased stay in the hospital. With 
atrial fibrillation, there was a higher incidence of postoperative mortality (54) heart failure, 
renal function impairment, infection and neurologic events (53).  
Univariate analysis showed following risk factors 
P<0.01: Previous PTCA  
P<0.05: LVEF below 50%  
In a multivariate analysis, previous PTCA was the only independent predictor (p=0.006; 
odds ratio 2.7; 95% confidence interval 1.3-5.4) 
The risk factors for postoperative AF in other series were a history of paroxysmal atrial 
fibrillation, a large left atrium, a prolonged P wave, heart failure, high age, low ejection 
fraction and left ventricular hypertrophy (55-57). The effect of age, however remained a 
matter for debate: atrial fibrillation did not occur more frequently in octogenarians after 
AVR (27).  
It seems that postoperative atrial fibrillation was preventable, at least in part. Pacing could 
half the frequency of this event (53). Timely and adequate treatment could increase the 
speed of postoperative rehabilitation and reduce the stay within the hospital (55).  
Conduction defects 
An univariate analysis showed as risk factors:  
P<0.001: preoperative heart failure 
P<0.01:  carotid artery disease, concomitant CABG  
P<0.05: NYHA functional class IV  
An AV block grade 1 showed a trend. A large valve size (27 mm) had no effect.  
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A multivariate analysis showed following results:  
Factor   n/N  p  OR 95%CI  
Preoperative heart failure  32/215  0.001  3.0  1.7-5.4 
Concomitant CABG  69/610  0.007  2.0 1.2-4.2 
NYHA class IV  23/249  0.039  1.9 1.0-3.4 
AV Block grade 1  7/37  0.078  2.4 1.0-5.7 
 
Conduction defects such as complete atrio-ventricular block, and hence permanent 
pacemaker implantation, occurred in almost 10%  of the patients who underwent AVR (58). 
The occurrence of all new conduction defects is reported to be 15% (59). Other reports state a 
lower incidence for permanent pacemaker implantation, since not all conduction defects 
need this treatment. Sometimes, a new conduction defects could be reversible (58). 
Development of a new conduction defects resulted to an increased need for monitoring and 
hence a longer hospital stay (60) 
The main predictor for permanent pace maker implantation in other series were 
preoperative conduction defects (58,61-63). Other predictors were female gender, annular 
calcification, bicuspid aortic valve, hypertension, myocardial infarction, electrolyte 
imbalance and prolonged cross-clamping time (60,64,65). Aortic regurgitation might also 
play a role since this condition usually required implantation of larger valves (58).  
Preoperative changes in the conduction system might be degenerative and due to older age, 
to ischemia and mechanical factors, due to an increased left ventricular pressure (58).  
Some factors such as a calcified annulus could lead to trauma of the conduction system 
during surgery. The link with a congenitally bicuspid aortic valve is less clear. Hypertension 
could lead to calcification but also to increased septal left ventricular hypertrophy, which 
makes the conduction system more difficult to protect during cross-clamping (60). Other 
traumas of the conduction system could be due to impingement by the prosthetic valve or 
by suturing (58).  
Development of a new conduction defects such as left bundle branch block in the 
postoperative period was a marker for future adverse events, such as sudden death (59), 
which illustrates the importance of these defects.  
Non cardiac hospital complications 
Pulmonary complications occurred in 58/1000 patients after AVR (66).  
Univariate analysis showed following risk factors 
P=0.001: postoperative heart failure 
P<0.01: preoperative PM implantation 
P<0.05: COPD 
Multivariate analysis identified following predictors:   
Factor   n/N  p  OR 95%CI  
Pacemaker implant  7/33  0.002  4.4 1.8 – 11.2 
COPD   21/235  0.073  1.7 0.95 – 3.1 
Heart failure   7/34  0.001  4.7 1.8 – 11.9 
 
Respiratory complications after AVR are common (9,66,67) but few reports appeared 
concerning their predictors. Their rate depends largely on the criteria used (need for 
prolonged ventilation, respiratory failure, pulmonary infection).  
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The basic mechanisms of these complications involved a lack of deep inspiration due to 
postoperative pain, with a shallow breathing pattern, a prolonged recumbent positioning, a 
temporary diaphragmatic dysfunction and an impaired mucociliary clearance with a 
decrease in cough effectiveness, increases the risks associated with retained pulmonary 
secretions and bronchial obstruction (68). Atelectasis, infection and prolonged stay within 
the intensive care unit could be the result of such obstruction (69,70).  
The use of an extracorporeal circulation during cardiac operations certainly has side effects 
on the respiratory system, due to inflammation (71,72). With greater hemodilution this effect 
could increase resulting pulmonary edema and pneumonia, especially when endothelial 
cells are injured (73). Pulmonary edema was also a hallmark of postoperative heart failure, 
which has been identified as a clear risk factor for postoperative pulmonary complications. 
Chronic obstructive pulmonary disease could worsen the production of mucus, thereby 
increasing the risk for atelectasis and infection. Early postoperative heart failure, and hence 
pulmonary edema increase the need for ventilator support and prolong the stay on ICU. This 
also could make the patient more vulnerable for postoperative pulmonary problems (66). 
In 58 of 1000 patients, we observed renal function impairment after AVR (17). Renal and 
cardiovascular disease could be linked in two ways. On the one hand, renal function 
impairment, even if this modest, has been an established element in the risk profile for 
atheromatosis (74,75). On the other hand, renal function impairment could also be the result 
of atheromatosis and has certainly been observed after major cardiovascular surgery such as 
AVR. Postoperative decrease of the renal function has been considered a serious 
complication with an increased mortality rate.  
The risk factors in an univariate analysis for this complication were 
Preop. renal impairment  22/108  29/890  <0.001 
Age > 80    22/186  31/814  <0.001 
Preop. atrial fibrillation  22/197  29/803  <0.001 
Preop. pulmonary oedema  22/216  31/781  0.001 
Preop. conduction defect  24/270  28/721  0.002 
Diabetes    15/149  37/851  0.006 
Preop. myocardial infarction  15/151  36/849  0.006 
Postop. heart failure   6/34  47/966  0.007 
CCT >75 min. (complete procedure) 29/460  7/275  0.015 
Previously performed CABG  9/81  42/916  0.018 
concomitant CABG   39/610  14/390  0.031 
LV ejection fraction<0.50  13/155  31/723  0.033 
Previous TIA/CVA   10/108  41/892  0.035 
A multivariate analysis revealed following predictors  
Factor   p  OR  95%CI 
Preop. renal impairment <0.001  5.5  2.9 – 10.4 
Preop. atrial fibrillation 0.010  2.3  1.2 – 4.2 
Age > 80   0.014  2.2  1.2 – 4.1 
Myocardial infarction  0.022  2.2  1.1 – 4.4 
 
Age over 80 has been associated with an increase in atheromatosis and myocardial 
infarction is certainly a marker for it. If atheromatosis also affects the renal arteries, a 
postoperative decrease in renal function could be expected (17).  
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Endothelial dysfunction of patients with CAVS could be a link with renal function 
impairment. This could help explaining the observed association between preoperative AF 
and postoperative renal complications. There are, however, several confounding factors 
(76,77).  
Other risk factors were hypertension, peripheral arterial disease, bypass time over 70 
minutes, severe angina an non-elective surgery (67,78).  
Three difficulties could arise by comparing different series. First, the definition of previous 
renal function impairment as well as of postoperative decrease in renal function varied 
between series. In one series, a level of 2.0 mg/dl was used (78), in another 1.4 mg/dl (17). 
This could account for differences in results. The second difficulty has been the estimation of 
renal function: plasma creatinine , as a routine clinical procedure is not sufficient as estimate 
for glomerular filtration rate. Hence, its results should be interpreted cautiously. The 
estimation of glomerular filtration rate requires a 24-h urine collection, which is liable to 
errors. Third, defining a worsening of renal function by an increase of plasma creatinine  
(79) also had its difficulties: in patients with a plasma creatinine  between 1 and 2 mg and 
hence, a moderate degree in renal function impairment, an additional increase with 0.3% 
could mean a serious additional renal damage. In patients with higher initial plasma 
creatinine , such an increase does not mean necessarily a major change in renal function: the 
slope of the relation between glomerular filtration rate and plasma creatinine  is much less 
compared to the area with low initial plasma creatinine. 
The extracorporeal circulation could have a damaging effect on the glomeruli, especially if 
the kidney already has been injured. Mechanisms inflicting renal damage are non-pulsatile 
perfusion, renal hypoperfusion, hypothermia, and increased levels of circulating 
catecholamines, cytokines, enzymes, free radicals and free hemoglobin (80). Keeping the 
cross-clamp time as short as possible or installing a minimal ECC could be helpful (81,82).  
In spite of increasing age and co-morbid conditions in patients referred for AVR, the 
increase in  hospital complications seemed to be limited to non-cardiac complications, which 
have a lower fatality rate than cardiovascular complications (83). The occurrence of renal 
and pulmonary postoperative events should be taken into account, however, if one chooses 
to operate older and sicker patients with symptomatic aortic valve disease. 
4. Discussion and conclusions 
Postoperative mortality and valve related complications received much attention in most 
patients series. Recently, other cardiac complications such as heart failure, conduction 
defects and atrial fibrillation were also scrutinized. Univariate analysis as screening and 
subsequent multivariate analysis as identification of risk factors for each event could be 
helpful patient selection and, more importantly, improve postoperative results if these risk 
factors are liable for alteration.  
Mortality and congestive heart failure, which was identified as the most lethal cardiac 
complication, were clearly patient related. One might expect a reduction in these events if 
patients are referred early, once aortic valve degeneration has become symptomatic. This 
could avoid the appearance of a major risk factor, i.e. the need for urgent valve replacement. 
This is the clear consequence of a protracted pressure overload on the left ventricle by the 
diseased aortic valve and the ultimate marker for advanced heart valve disease. 
Thromboembolism and bleeding are typically considered as valve related events. The 
former, however, could also be related to patient factors, while the latter could also be 
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The basic mechanisms of these complications involved a lack of deep inspiration due to 
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also could make the patient more vulnerable for postoperative pulmonary problems (66). 
In 58 of 1000 patients, we observed renal function impairment after AVR (17). Renal and 
cardiovascular disease could be linked in two ways. On the one hand, renal function 
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Preop. conduction defect  24/270  28/721  0.002 
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Preop. myocardial infarction  15/151  36/849  0.006 
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Previously performed CABG  9/81  42/916  0.018 
concomitant CABG   39/610  14/390  0.031 
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Age > 80   0.014  2.2  1.2 – 4.1 
Myocardial infarction  0.022  2.2  1.1 – 4.4 
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minutes, severe angina an non-elective surgery (67,78).  
Three difficulties could arise by comparing different series. First, the definition of previous 
renal function impairment as well as of postoperative decrease in renal function varied 
between series. In one series, a level of 2.0 mg/dl was used (78), in another 1.4 mg/dl (17). 
This could account for differences in results. The second difficulty has been the estimation of 
renal function: plasma creatinine , as a routine clinical procedure is not sufficient as estimate 
for glomerular filtration rate. Hence, its results should be interpreted cautiously. The 
estimation of glomerular filtration rate requires a 24-h urine collection, which is liable to 
errors. Third, defining a worsening of renal function by an increase of plasma creatinine  
(79) also had its difficulties: in patients with a plasma creatinine  between 1 and 2 mg and 
hence, a moderate degree in renal function impairment, an additional increase with 0.3% 
could mean a serious additional renal damage. In patients with higher initial plasma 
creatinine , such an increase does not mean necessarily a major change in renal function: the 
slope of the relation between glomerular filtration rate and plasma creatinine  is much less 
compared to the area with low initial plasma creatinine. 
The extracorporeal circulation could have a damaging effect on the glomeruli, especially if 
the kidney already has been injured. Mechanisms inflicting renal damage are non-pulsatile 
perfusion, renal hypoperfusion, hypothermia, and increased levels of circulating 
catecholamines, cytokines, enzymes, free radicals and free hemoglobin (80). Keeping the 
cross-clamp time as short as possible or installing a minimal ECC could be helpful (81,82).  
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have a lower fatality rate than cardiovascular complications (83). The occurrence of renal 
and pulmonary postoperative events should be taken into account, however, if one chooses 
to operate older and sicker patients with symptomatic aortic valve disease. 
4. Discussion and conclusions 
Postoperative mortality and valve related complications received much attention in most 
patients series. Recently, other cardiac complications such as heart failure, conduction 
defects and atrial fibrillation were also scrutinized. Univariate analysis as screening and 
subsequent multivariate analysis as identification of risk factors for each event could be 
helpful patient selection and, more importantly, improve postoperative results if these risk 
factors are liable for alteration.  
Mortality and congestive heart failure, which was identified as the most lethal cardiac 
complication, were clearly patient related. One might expect a reduction in these events if 
patients are referred early, once aortic valve degeneration has become symptomatic. This 
could avoid the appearance of a major risk factor, i.e. the need for urgent valve replacement. 
This is the clear consequence of a protracted pressure overload on the left ventricle by the 
diseased aortic valve and the ultimate marker for advanced heart valve disease. 
Thromboembolism and bleeding are typically considered as valve related events. The 
former, however, could also be related to patient factors, while the latter could also be 
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related to the procedure. Both events could have a significance as risk factor for long-term 
recurrence.  
Occurrence of early postoperative conduction defects and of atrial fibrillation could also be 
considered as markers of advanced valvular heart disease, since some of their risk factors 
might be the result of protracted pressure overload on the left ventricle. Hence, these events 
could be seen as patient related.  
Non-cardiac complications could clearly be related to co-morbid conditions. These, however 
are not always liable to alterations. Hence, the peri- and postoperative care should be 
tailored for each patient. It has also become obvious that age over 80 is not a formal 
contraindication for AVR. Nevertheless, elderly usually have considerable co-morbidity. 
The EUROscore, which was developed for CABG patients overestimates the risk for hospital 
mortality considerably. Low ejection fraction, chronic pulmonary obstructive disease and 
peripheral artery disease have been identified as predictors, although (84). Pulmonary 
function after median sternotomy is reduced in a substantial way, probably by several 
mechanisms such as chest wall restriction, decreased movement of the diaphragm and 
impairment of diffusion across the alveolar membrane (85). 
It seemed worthwhile, therefore, to explore some alternative techniques in valve surgery 
which could reduce the postoperative risk. These could be 1) minimal surgical access, 2) 
minimal extracorporeal circulation and 3) transcatheter aortic valve implantation. 
The first alternative, minimal surgical access by  ministernotomy (85-88) and anterolateral 
minithoracotomy (89-91) could expose the surgical field adequately. Possible indications 
could be obesity, chronic obstructive pulmonary disease (86) and previous chest irratiation 
or CABG with patent left internal mammary artery (91). 
Some advantages have been described such as an economic benefit, improved cosmetic 
result, decrease in postoperative morbidity, length of stay, pain, blood loss and transfusion 
(86-90,92). Cross clamping time had increased, however (88). Two randomized trials have 
appeared, which compared minimal and conventional AVR. The first one, was very small 
and included 20 patients for every group (88). The second one excluded patients with 
obesity and pulmonary disease (85), in spite of previously mentioned indications (86). Pain 
and blood loss were less, but there was no less need for transfusion. No other benefits  such 
as a decrease in renal or pulmonary complications or differences in postoperative 
pulmonary functions could be documented (85,88,93). Results in high risk patients were 
considered as excellent in a recent review, but randomized controlled trials comparing 
minimal with conventional AVR are needed (94). 
The second approach involves the changes in extracorporeal circulation devices. The use of 
an extracorporeal circulation during AVR has the risks of hemodilution and of an 
inflammatory response, which could be reduced by an minimal extracorporeal circulation or 
MECC. This MECC is a closed system with a centrifugal pump, an oxygenator without a 
venous and cardiotomy reservoir. The patient functions as the venous reservoir (95). This 
reduces the contact of blood with artificial surfaces and with air. The risk for hemolysis and 
the need for blood transfusions also decreases (96). With MECC, there is less increase in C-
reactive protein, troponin I level, and better preservation of platelets and renal function. 
Stroke and cerebral injury were also less. The improved biocompatibility of MECC is of 
special advantage in high risk patients (age over 65, renal and pulmonary dysfunction). The 
use of a minimal ECC involves a learning curve, however (82).  
More recently, TAVI or transcatheter aortic valve implantation, either through an artery or 
through the cardiac apex has been developed as third alternative. In patients deemed unfit 
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for conventional AVR, TAVI was compared to balloon valvotomy through a randomized 
controlled (PARTNER) trial. Mortality (30-day and one-year) from any cause and repeat 
hospitalization as well as occurrence of cardiac symptoms (higher NYHA functional class) 
were significantly reduced after TAVI. Major strokes, bleeding events and major vascular 
events occurred more often, however. Balloon valvotomy did not alter the course of aortic 
valve disease. Paravalvular leaks after TAVI were usually mild and did not worsen after one 
year. Postprocedural stroke was troublesome, but might be reduced by developing smaller 
delivering devices. These results cannot be extrapolated to patients in whom conventional 
AVR is an option (7). The trans-apical approach for TAVI is a feasible alternative in high risk 
elderly patients with symptomatic aortic valve disease and peripheral artery disease. There 
is no need for sternotomy or extracorporeal circulation. No post-procedural stroke was 
observed, probably due to the avoidance of an atheromatous aortic arch. Presence of 
preoperative respiratory dysfunction proved to be a risk. The procedural success rate was 
high. Compared to a control group of patients who underwent conventional AVR (by 
propensity score analysis), 30-day and one-year survival superior for trans-apical TAVI, but 
this difference was not significant (97).  
To document the superiority of either of these minimal approaches, RCT on sufficiently 
large scale are needed. For ministernotomy and minithoracotomy, these are feasible, but still 
lacking. For TAVI, it is currently unethical for patients to subject patients to the still 
unknown long-term results of TAVI if these are deemed fit for conventional AVR. 
Conventional AVR still can be considered as the standard therapy for degenerative aortic 
valve disease, with very predictable results, even in the elderly and patients with co-morbid 
condition.  
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related to the procedure. Both events could have a significance as risk factor for long-term 
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1. Introduction 
Venous occlusive disease encompasses a variety of clinical entities that range the spectrum 
from being catastrophic and life threatening, such as massive pulmonary embolism, to 
disease states that may have an occult presentation, such as inferior vena cava occlusion. 
Other examples of veno-occlusive disease states include deep venous thrombosis and right 
atrial masses. When venous occlusion is characterized by an overwhelming volume of 
offending material, clinical therapy may be a significant challenge. This chapter examines 
the historical background of therapy directed at venous occlusion, and outlines a simplified 
technique for addressing the occurrence of major undesirable intravascular material. 
2. Etiology and incidence 
The majority of undesirable material presenting in the major venous circulation have their 
origins in the lower extremity veins. Deep venous thrombosis has an estimated annual 
incidence of over 2 million cases in the United States (Hirsh & Hoak, 1996), and accounts for 
approximately 600,000 hospitalizations per year (Schreiber, 2010). The genesis of venous 
thrombosis continues to be aptly characterized by the observations of Virchow in 1856 
(Virchow, 1998, as cited in Lopez et al., 2004), who is credited with associating the triad of 
(1) venous stasis, (2) endothelial injury and (3) hypercoagulability with the formation of 
intravascular clot. The incidence of pulmonary embolism is closely tied to the occurrence of 
deep venous thrombosis, so much so that the complex of deep venous thrombosis and 
pulmonary embolism is defined by the term “venous thromboembolism”. It is estimated 
that approximately 50% of patients with deep venous thrombosis have detectable 
pulmonary emboli (Hirsh, 1996). Lower extremity deep venous thrombosis in the distal 
vessels, e.g. calf vein thrombosis, has commonly been held to be relatively benign, and 
mostly asymptomatic; however, some studies have shown that propagation of calf vein clot 
above the popliteal level occurs in approximately 15% of patients (Lohr et al., 1991). Upon 
propagation to the popliteal vein, the risk of measurable pulmonary embolism increases to 
approximately 40% (Kakkar et al., 1969, as cited in Hirsch & Hoak, 1996). 
Risk factors for venous thromboembolism are associated with conditions that alter elements 
of Virchow’s triad. These include increasing age, surgery, trauma, hospital or nursing home 
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confinement, malignancy, paralytic neurologic disease, presence of an indwelling venous 
catheter or pacing lead, varicose veins, previous superficial vein thrombosis, pregnancy, and 
oral contraceptive use (Heit, 2002). The recurrence rate for patients with a single episode of 
venous thromboembolism is approximately thirty percent over ten years. 
The incidence of pulmonary embolism in the U.S. is estimated to be 1.35 million cases per 
year (Banovac et al., 2010). Predicted outcomes for patients with pulmonary embolism 
vary greatly with the hemodynamic stability of the patient upon presentation. Patients 
with a systolic arterial blood pressure below 90 mm Hg are deemed to have massive 
pulmonary embolism, while patients with a systolic pressure equal to or above 90 mm Hg 
are categorized as having non-massive pulmonary embolism. In the International 
Cooperative Pulmonary Embolism Registry involving 2,342 patients, the vast majority 
(95.5%) had non-massive pulmonary embolism, while 4.5% had massive pulmonary 
embolism. Patients with massive pulmonary embolism had a 90 day mortality of 52.4%, 
compared with a 90 day mortality of 14.7% in patients with non-massive pulmonary 
embolism (Kucher et al., 2006). In hospital mortality for patients with pulmonary 
embolism rose from 8.1% in clinically stable patients to 25% in unstable patients, and 
increased to 65% in patients requiring cardiopulmonary resuscitation, in a separate study 
of 1,001 patients (Kasper et al., 1997). 
Inferior vena cava thrombosis is also associated with deep venous thrombosis, although to a 
lesser extent than the tie between deep venous thrombosis and pulmonary embolism. The 
frequency of IVC thrombosis in patients with deep venous thrombosis is estimated to be 
between 4 - 15% (Fernandez & Geehan, 2008). Other causes of inferior vena cava thrombosis 
include malignancy, trauma, surgery, abdominal aortic aneurysm, and indwelling venous 
catheters. In one series, carcinoma of the kidney was the most common cause of IVC 
thrombosis, accounting for 31% of cases presenting over a 23 year period (Siqueira-Filho et 
al., 1976). The actual incidence of inferior vena cava thrombosis is difficult to cite, due to the 
variability of its presentation. It is estimated that in patients with IVC thrombosis, over one-
half remain asymptomatic until their initial presentation with pulmonary embolism. 
Iatrogenic causes of inferior vena cava thrombosis are also significant. IVC thrombosis 
maybe a complication of vena cava filter placement, in the treatment of or prophylaxis for 
pulmonary embolism. The occurrence of IVC thrombosis was 2.7% in a 26 year review of 
1731 patients implanted with 1765 vena cava filters (Athanasoulis et al., 2000). Vena cava 
thrombosis may also be caused by indwelling intravascular devices such as pacemaker 
leads, parenteral nutrition catheters, or hemodialysis catheters (Krug & Zerbe, 1980; 
Mulvihill & Fonkalsrud, 1984; Gouge et al., 1988). 
Masses presenting in the cardiac portion of the venous circulation are relatively rare. Most 
of such masses are primary atrial myxomas. A study of 33108 consecutive cardiac surgical 
patients found an incidence of right atrial myxoma to be 0.036%; this incidence represents 
less than 10% of all atrial myxomas, as most atrial myxomas are left sided. Thrombus 
formation on the tumor surface or dislodged tumor fragments may cause pulmonary 
embolism. Thrombus originating in the iliofemoral system or the inferior vena cava may 
propagate into the right atrium (Khurana & Tak, 2004). Once clot presents in the right 
atrium, the prognosis is poor without active thrombectomy. A review of the literature 
involving twenty patients with right atrial thrombus found that the condition was 
uniformly fatal without treatment, while a 50% mortality rate was observed when either 
anticoagulation or thrombolytic therapy was administered. When surgical extraction was 
performed, the mortality rate was reduced to 14% (Armstrong et al., 1985). 
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3. Therapeutic history 
3.1 Medical therapy 
Medical treatment of venous thromboembolism was instituted in 1960 with the first 
randomized clinical trial evaluating the efficacy of anticoagulation in patients with 
pulmonary embolism (Barrett & Jordan, 1960). Anticoagulation therapy does not resolve 
existent thrombus, but prevents its propagation, and significantly reduces the mortality rate 
of pulmonary embolism. Untreated pulmonary embolism carries a mortality rate of 
approximately 30%; this is reduced to approximately 8% when anticoagulation is instituted 
(Banovac et al., 2010). The typical therapeutic approach involves intravenous infusion of 
unfractionated or low molecular weight heparin, followed by oral anticoagulation with 
warfarin , which is continued for a period of several months. It has been suggested that little 
benefit is gained by extending anticoagulation therapy from three to six months in venous 
thromboembolism patients (Campbell et al., 2007). 
Fibrinolytic agents provide active dissolution of clot; they were introduced into clinical 
treatment of venous thromboembolic disease in the 1970s (Tibbutt et al., 1974). 
Streptokinase, urokinase, and recombinant tissue plasminogen activator (rTPA) are 
compounds available for fibrinolytic therapy. All three agents convert plasminogen to 
plasmin, with subsequent enzymatic degradation of fibrin clot. Studies on the efficacy of the 
three available fibrinolytic agents demonstrate no difference in clot resolution after twenty-
four hours (Almoosa, 2002). The positive effect of thrombolytic agents is partially offset by 
their potential for major bleeding complications, including intracerebral hemorrhage. The 
risk of hemorrhage during fibrinolytic therapy varies between 6 – 20% (Harris & Meek, 
2005). A meta-analysis of nine randomized, controlled clinical trials comparing 
anticoagulation alone to anticoagulation plus thrombolysis demonstrated no difference in 
overall mortality between the two treatment regimes in non-selected patients with acute 
pulmonary embolism (Thabut, G. et al., 2002). Therefore, fibrinolytic therapy is indicated for 
patients with massive pulmonary embolism characterized by hypotension, or potentially for 
normotensive pulmonary embolism patients demonstrating right heart dysfunction, as this 
subgroup of patients has been associated with a higher risk of mortality in previous studies 
(Goldhaber, 1993, as cited in Harris & Meeks, 2005). Fibrinolytic agents may be delivered 
intravenously, or selectively into the pulmonary artery at the site of occlusion. A 
prospective, multi-center trial comparing intrapulmonary fibrinolytic infusion with 
intravenous fibrinolytic administration found no significant benefit with intrapulmonary 
catheter therapy (Verstraete et al., 1988). Instead, a prolonged intravenous thrombolytic 
infusion over seven hours appeared to yield a superior benefit to a single infusion over two 
hours. Direct insertion of an infusion catheter into the substrate of the embolus has been 
suggested as a more efficacious method of fibrinolytic delivery. Insufficient clinical data is 
available at this time to establish superiority of intra-embolic infusion over intrapulmonary 
or intravenous fibrinolysis. 
3.2 Surgical therapy 
Patients with massive venous thromboembolism and particularly those with 
contraindications to thrombolytic therapy are candidates for surgical thrombectomy and 
embolectomy. Pulmonary embolectomy is a substantial procedure, necessitating a median 
sternotomy and cardiopulmonary bypass, but without cardioplegic arrest. An arteriotomy 
in the main pulmonary artery is performed to allow instrumental extraction of thrombus 
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3. Therapeutic history 
3.1 Medical therapy 
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pulmonary embolism (Thabut, G. et al., 2002). Therefore, fibrinolytic therapy is indicated for 
patients with massive pulmonary embolism characterized by hypotension, or potentially for 
normotensive pulmonary embolism patients demonstrating right heart dysfunction, as this 
subgroup of patients has been associated with a higher risk of mortality in previous studies 
(Goldhaber, 1993, as cited in Harris & Meeks, 2005). Fibrinolytic agents may be delivered 
intravenously, or selectively into the pulmonary artery at the site of occlusion. A 
prospective, multi-center trial comparing intrapulmonary fibrinolytic infusion with 
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3.2 Surgical therapy 
Patients with massive venous thromboembolism and particularly those with 
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in the main pulmonary artery is performed to allow instrumental extraction of thrombus 
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under direct vision, in an en bloc fashion, if possible. In one surgical series of 29 consecutive 
patients, surgical pulmonary embolectomy was successful in all cases, and the resultant 
survival rate at one month was 89% (Aklog et al., 2002). A review of 1,300 total patients 
undergoing operative pulmonary embolectomy in 46 reported series from 1961 to 2005 
demonstrated an average mortalityof 30% (Stein et al., 2007). Due to its degree of 
invasiveness, surgical embolectomy is generally reserved as the last therapeutic option. 
3.3 Catheter therapy 
Instrumentation for surgical embolectomy dates back to 1963, with the introduction of the 
Fogarty embolectomy balloon catheter (Fogarty, 1963). The venous thrombectomy version of 
the Fogarty balloon is a 6F or 8F catheter with inflated balloon sizes up to 19 mm in 
diameter. The venous thrombectomy catheter is primarily applied to patients with deep 
venous thrombosis. It incorporates a flexible distal tip to facilitate catheter passage through 
venous valves. Procedures are performed in the operating theater, with surgical access used 
to gain vascular control during the thrombectomy process. 
A variety of devices have been devised for a percutaneous approach to thrombectomy. 
Greenfield developed a suction tip catheter for pulmonary embolectomy in 1971 (Greenfield 
et al., 1971). The catheter was previously available in the form of a 10F steerable catheter 
with either a 5 mm or a 7 mm diameter cupped tip. Percutaneous entry was performed in 
either the femoral or jugular vein, and embolectomy conducted under fluoroscopic control. 
Vacuum was established by means of a syringe to aspirate a portion of the embolus into the 
cup, whereupon sustained vacuum was maintained as the catheter was withdrawn to 
remove the clot. Multiple passes of the suction cup catheter were applied until 
improvements in the pulmonary artery pressure and cardiac output denoted a successful 
clinical result. A series of 46 patients undergoing Greenfield suction pulmonary 
embolectomy between 1970 to 1992 demonstrated an overall success rate of 76%, with a one 
month survival rate of 70% (Greenfield et al., 1993). Conventional straight catheter sheaths 
may be employed for percutaneous embolectomy. An approach termed the “Meyerovitz 
technique” applies vacuum via a connected 60 cc syringe to a readily available 8F or 9F 
coronary guiding catheter without distal side holes, advanced through a 10F introducer 
sheath (Goldhaber, 1998). However, limited volumes of clot are extracted, due to the small 
caliber of the guiding catheters used. 
Multiple catheter designs address venous thromboembolism via clot fragmentation. 
Peripheral angioplasty balloon catheters have been applied to restore patency in 
intraluminal occlusion. Dilatation of thrombus in large caliber vessels may result in 
significant distal embolization; therefore, balloon angioplasty may be combined with 
wallstent placement to decrease recurrent embolism resulting from dislodgement of balloon 
dilated endoluminal thrombus. Another approach to fragmentation therapy utilizes manual 
rotation of a pigtail catheter to disrupt clot, with concomitant site specific thrombolytic 
injection to augment the mechanical therapy (Schmitz-Rode et al., 1998). The 5F pigtail 
catheter is ensheathed in a coaxial 5.5F introducer sheath. This device seeks to recanalize an 
occluded vessel, without retrieval of disrupted segments. Treated patients are subjected to 
distal embolization that may potentially be clinically significant. Another specialized 
catheter fragmentation device devised by Amplatz applies high speed rotation of a distal 
impeller on a 7F catheter to draw clot towards the impeller, resulting in disintegration of 
thrombus into tiny particles. Micro thrombi generated by this system are not removed from 
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the circulation. The smaller clot fragments generated by the Amplatz impeller is an 
improvement over pigtail embolectomy; however, the presence of circulating micro-
hemolytic fragments may be of concern, particularly if a substantial volume of debris is 
generated. Clot fragmentation coupled with embolic removal has a theoretic edge over 
fragmentation alone. An 11F Aspirex device integrating high-speed rotation of a distally 
situated spiral with vacuum capability is undergoing clinical trials to evaluate its 
effectiveness in pulmonary arteries between 6 mm and 14 mm in diameter (Kuchar, 2007). 
This device combination of mechanical thrombolysis with vacuum removal addresses 
organized thrombus and seeks the removal of fragmentation byproducts. 
Another approach to clot fragmentation is catheter rheolysis. This class of therapeutic 
catheter utilizes a multi-lumen catheter with separate injection and retrieval ports. High 
pressure fluid infusion through one or more injection ports serve to fragment thrombus 
upon contact. Infusion through the injection port or ports create a Venturi effect, 
establishing a pressure differential between the injection and retrieval ports that create a 
backflow through the retrieval lumen for removal of thrombus fragments and infused fluid. 
Rheolytic catheters are sized in the 6F to 7F range, and are not designed to be used in vessels 
greater than 12 mm in diameter (Kuchar, 2007). Their application in massive pulmonary 
embolism has been described in small clinical series, with resultant limited effectiveness 
(Siablis, 2005, Chiam, 2005, Zeni, 2003, and Koning, 1997, as cited in Kuchar, 2007). 
3.4 En Bloc removal of undesirable intravascular material 
A simplified approach to the en bloc removal of undesirable intravascular material is 
proposed. One of the authors noticed that during surgical embolectomy, it is often possible 
to perform en bloc removal of a large mass of organized thrombus, when a venous drainage 
cannula inserted into the main pulmonary artery gains purchase of the tail of the clot. The 
flow rate established by the cardiopulmonary bypass pump generates significant vacuum 
that in some cases may pull a thrombotic cast of the pulmonary vasculature into the 
extracorporeal circulation, where it is trapped by the in-line filter. In other cases, the large 
caliber of the main pulmonary artery and the subsequent girth of the embolus prevent its 
introduction into the venous outflow cannula; however, it may be grasped by the cannula 
tip and extracted via the pulmonary arteriotomy. The mechanics of thrombectomy gained as 
a result of the open surgical experience suggested a possible technique of percutaneous 
venous extraction. An extracorporeal circuit may be established containing a large bore 
outflow line, a centrifugal pump, an in-line filter, and an inflow line. The distal end of the 
venous outflow cannula is fitted with a balloon-activated funnel tip that expands to the 
luminal diameter of the occluded vessel. The venous outflow cannula is advanced into 
proximity of the obstructing venous material, while the venous inflow cannula is inserted 
into a separate venous entry site. Activation of the centrifugal pump creates a uni-
directional flow that serves two functions: One, it creates a vacuum at the funnel drainage 
side to extract undesirable intravascular material; and two it performs simultaneous 
reinfusion of filtered blood volume to maintain circulatory homeostasis. The extracorporeal 
circuit is placed percutaneously or via femoral venous cutdown. The technique establishes a 
venous to venous bypass circulation without oxygenation, powered by a compact 
centrifugal pump generating a flow rate up to 5 liters per minute. The sizes of both outflow 
and inflow venous cannulae are maximized, to accommodate the large girth of the 
pulmonary vasculature. Whereas previous suction thrombectomy devices extracted clot in 
piecemeal fashion with multiple catheter insertions and removals, due to their limited bore, 
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the extracorporeal veno-venous system strives for en bloc extraction, with intraluminal 
passage of clot in the venous cannulae. 
3.4.1 Instrumentation and technique 
Elements of the funnel drainage cannula and extracorporeal circuit used to extract occluding 
venous material are shown in Figure 1. The funnel cannula (AngioVac® Cannula, Vortex 
Medical Inc., Norwell, MA) contains a 22F body with distal fingers that are balloon 
expandable to generate a maximal funnel diameter of 48F. The funnel drainage cannula is 
connected to ½ inch polyvinyl chloride tubing that leads to the in-line filter with a 90 cc 
capacity. The centrifugal pump is downstream of the filter, and connected to the reinfusion 
cannula, completing the extracorporeal circuit. In preparation for establishment of 
extracorporeal bypass, a 10,000 unit bolus of intravenous heparin is administered to the 
patient, and a constant intravenous infusion of approximately 1,000 units per hour 
continued to maintain the patient’s activated clotting time (ACT) at 300 seconds. If the ACT 
is maintained at 300 or above, use of a heparin coated bypass circuit is unnecessary. Prior to 
use, the circuit is primed with normal saline, yielding a closed system that accomplishes 
vacuum extraction, filtering and reinfusion in concurrent fashion. With use of the Rotaflow 
centrifugal pump (MAQUET Cardiovascular, Wayne, New Jersey), priming of the circuit 
requires approximately 500 cc of saline. In use, venous access is established via the femoral 
or jugular vein, and an angiographic catheter advanced to the site of the occlusion. If 
extraction of pulmonary emboli in a branch vessel is anticipated, cannulation of the target 
vessel is performed using a 5F to 8F pigtail catheter (Andrews, 2004), and an 0.038” 
guidewire left in position. A 26F introducer sheath (Gore® DrySeal Sheath, W.L. Gore & 
Associates, Inc., Medical Products Division, Flagstaff, AZ) is inserted in the femoral or 
jugular venous access site and the drainage cannula fitted with its internal tapered dilator is 
advanced over the emplaced 0.038” guidewire to position the funnel tip approximately 10 
cm proximal to the occlusion. The dilator is removed from the drainage cannula, and the 
balloon inflated with saline to a pressure of 1 atmosphere to expand the collecting funnel. 
The centrifugal pump is activated prior to advancement of the funnel cannula towards the 
occlusion. The rotational speed of the pump is increased in increments of 500 ml/minute 
until thrombus extraction occurs. Flow rate indicated on the pump generally increases as the 
speed is increased. A sudden drop to zero flow may be a signal that a large mass has 
become seated in the funnel. Pump velocity is maintained, and as the mass is compressed 
and extracted through the cannula, flow will be re-established. If the diameter and density 
of a mass of dislodged organized thrombus prevents its passage through the venous 
drainage cannula, the cannula may be removed from the body and its lumen cleared 
externally. Following suction embolectomy, a completion venogram or pulmonary 
arteriogram is performed via the drainage cannula to evaluate the completeness of 
thrombus extraction. 
3.4.2 Functional mechanics of En Bloc intravascular extraction 
Intravascular extraction with the funnel cannula is a flow directed process, with the 
centrifugal pump generating sufficient flow to perform suction embolectomy at one end of 
the circuit and vascular reinfusion at the opposite end of the circuit. The balloon situated at 
the funnel portion of the drainage cannula not only serves to expand the funnel for vessel 
wall apposition and removal of intravascular material, but also provides inflow regulation 
during the extraction procedure (Figure 2). Modulation of antegrade venous flow assists the 
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Fig. 1. Elements of the funnel drainage cannula and extracorporeal circuit 
centrifugal pump in generating the necessary retrograde flow to initiate movement of the 
thrombotic material and its subsequent excursion the length of the drainage cannula. The 
degree of collateralization in the native circulation facilitates intravascular extraction, as it 
preserves the potential for retrograde flow at the treatment site. If retrograde flow at the 
occlusion site is diminished or removed, intravascular extraction may be inhibited. In order 
to delineate the significance of retrograde flow on the dynamics of en bloc extraction, a flow 
model was constructed to allow empirical evaluation of the vacuum extraction process. 
3.4.3 Material and methods 
Branched, tapering vinyl tubing was connected with fittings in a configuration that mimics 
the morphology of the pulmonary vasculature, and a valve was placed immediately distal to 
the site of embolic extraction (Figure 3). Saline was heated to 37 degrees Celsius and 
continuously circulated through the circuit by means of an impeller pump and a peristaltic 
pump in series, at a flow rate of 5.0 L/minute. Organized thrombus was modeled using calf 
liver sectioned into15 mm x 80 mm strips. Calf liver was used to model thrombus, as its 
density is similar to the density of mammalian clot (Nahimyak, 2006 amd Baraislas. 2007), 
and it lacks the propensity for disintegration in a mechanical flow model. With the 
thrombus model placed in the vascular circuit in a position equivalent to the main 
pulmonary artery, the valve proximal to the thrombus model was adjusted to three different 
positions: (1) completely closed position, (2) completely open position, and (3) partially 
closed position. The separation distance at thrombus model capture, centrifugal pump 
speed at capture, and flow rate generated in the funnel drainage cannula at capture were 
measured. 
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Fig. 3. Test fixture to evaluate the mechanics of the vacuum extraction process 
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At a separation distance of 11 cm between the tip of the funnel and the clot model, no 
movement of the clot was noted with the valve closed completely, at all pump flow rates 
increased to a maximum of 6 liters per minute. Advancement of the funnel cannula to the 
proximity of the clot model, at 5 cm of separation, allowed extraction at 4.6 liters per minute 
of pump flow rate. With the valve completely open, allowing ample backflow, the clot 
model was extracted at a separation distance of 11 cm with a pump flow rate of 2.5 liters per 
minute. When the valve was 80% closed, clot extraction did not occur at 11 cm; however, 
removal was observed at 5 cm of separation distance at a pump flow rate of 6 liters per 
minute. 
3.4.5 Clinical experience 
Between December 2009 and May 2011, a total of 49 patients underwent removal of 
undesirable intravascular material using the funnel-tipped venous drainage cannula under 
extracorporeal veno-venous bypass. Procedures were conducted both in the fluoroscopy 
suite, and in the surgical theater under C-arm guidance. Veno-occlusive states addressed by 
these procedures included the following: (1) A retained segment of fibrin sheath from a 
pacemaker lead was extracted from the right atrium of a patient. (2) Vegetation was 
removed from the tricuspid valve of a patient who developed endocarditis from an 
indwelling line. (3) Thrombus and tumor was removed from a patient with an inferior vena 
cava occlusion due to a retroperitoneal malignancy. (4) A saddle embolus was removed 
from a patient with pulmonary embolism. (5) Organized and soft thrombus was removed 
from a patient presenting with bilateral iliofemoral and inferior vena cava occlusion. IVC 
thrombosis and pulmonary embolism accounted for the majority of the procedures, 43% and 
29%, respectively. Seven patients had right atrial thrombus removed via suction 
embolectomy; in four of these patients, the thrombus extended up into the superior vena 
cava, and cannulation of the the SVC was required to remove the occluding clot. Four 
patients had vegetative endocarditic masses removed from their right atria. Several 
representative procedures may be detailed as follows: 
Example 1: 
A 63 year old female presented with severe bilateral lower extremity edema, bordering on 
phlegmasia cerulean dolens. She had an inferior vena cava filter placed two weeks 
previously for deep venous thrombosis, and her history is also significant for a recent 
neurosurgical procedure. The patient’s situation was additionally complicated by a 
documented history of heparin induced thrombocytopenia. A venogram demonstrated 
complete IVC thrombosis extending proximal to the IVC filter and involving both 
iliofemoral systems distally (Figure 4). 
Thrombolytic therapy was contraindicated in this patient, due to the recent neurosurgical 
procedure and the history of heparin induced cytopenia. Rheolytic thrombectomy, applied 
in an attempt to recanalize the vena cava and distal venous circulation, was unsuccessful. 
The patient was brought back to the fluoroscopy suite, where the suction funnel cannula 
was inserted through a 26F introducer sheath via a percutaneous right femoral vein entry 
site. Upon establishment of flow via the centrifugal pump, a large amount of fresh and 
organized thrombus was retrieved in the filter. The suction cannula was advanced into the 
vena cava, as well as the contralateral iliac vein. Two full filter canisters of occluding 
material, totaling 180 cc in volume, was removed from the patient (Figure 5). In addition, the  
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Fig. 3. Test fixture to evaluate the mechanics of the vacuum extraction process 
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Fig. 4. Venogram depicting complete IVC thrombosis 
previously placed IVC filter was removed through the central lumen of the suction cannula, 
while the extracorporeal circulation was maintained to prevent distal embolization from 
occurring during vena caval filter retrieval. Upon completion of the embolectomy 
procedure, a new IVC filter was placed. The post-extraction venogram showed a widely 
patent IVC and iliofemoral vasculature (Figure 6). The patient remained stable throughout 
the procedure. The procedure was conducted under administration of intravenous 
Bivalirudin (Angiomax®, The Medicines Company, Parsippany, NJ), due to the patient 
history of heparin induced thrombocytopenia. 
Example 2: 
A 40kg 23 year old female on renal dialysis via an indwelling right subclavian catheter, with 
a history of end stage renal disease and a failed renal transplant, presented with chest pain. 
She was found to have an embolus in a distal lobar branch of the left pulmonary artery, and 
an echocardiogram and CT scan revealed a fluttering clot at the distal tip of the subclavian 
catheter, and a 3 cm sessile mass on the free wall of the right atrium (Figure 7). Suction 
embolectomy was performed under general anesthesia in the operating room under 
echocardiographic guidance. Due to the small stature of the patient and subsequent limited 
caliber of her vasculature, the left and right femoral veins were exposed via open groin 
incisions. The 22F funnel cannula was introduced directly into the right femoral venotomy, 
and a 17F cannula placed into the left femoral vein for reinfusion. The funnel cannula was 
advanced into the right atrium and positioned in proximity to the subclavian catheter. Flow 
was initiated with the centrifugal pump, and chronic thrombotic material trapped by the 
filter. The subclavian dialysis catheter was removed, and the cannula advanced into the 
superior vena cava while circulating flow was maintained. A large amount of organized 
thrombus was noted in the filter (Figure 8). The echocardiogram showed removal of all 
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Fig. 5. Thrombotic material captured in two filters 
 
 
Fig. 6. Completion venogram demonstrating recanalization of the IVC and iliac veins 
mobile thrombus, and a patent proximal superior vena cava (Figure 9). The sessile mass 
remained attached to the wall of the right atrium; no additional attempts were made to 
detach this immobile mass. A new dialysis catheter was placed, and the patient was 
discharged from the hospital under anticoagulation. 
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Fig. 7. Echocardiogram depicting mobile thrombus and sessile mass in the right atrium 
 
 
Fig. 8. Organized thrombus extracted from right atrium and superior vena cava 
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Fig. 9. Post extraction echocardiogram depicting absence of mobile thrombus  
3.4.6 Clinical results 
Of the 49 total patients in this series, 27 patients were male, and 22 female. The average age 
of the male patients was 53 years with a range between 27 and 88 years, and the average age 
of the female patients was 51 years, with a range between 19 and 82 years. Twelve of the 
procedures were performed in a totally percutaneous manner, while thirty-seven 
procedures were performed via surgical exposure of the femoral veins. Success of an 
extraction procedure is defined as removal of occluding material, fluoroscopic or 
echocardiographic evidence of venous patency, and stabilization of patient hemodynamic 
parameters. Forty of the forty-nine procedures resulted in removal of intravascular material 
for an 80% overall success rate. In 9 cases, minimal or no material was removed. In one case, 
spontaneous fragmentation and distal embolization of the thrombus occurred prior to 
initiation of the suction embolectomy procedure. One perioperative death occurred in a 
hemodialysis patient with a right atrial mass and an inferior vena cava occlusion. 
Hemothorax from a suspected guidewire perforation of the right atrium was noted during 
the procedure. The patient was brought to the operating room, and surgical exploration 
found a substantial fibrotic mass encasing the right atrium and inferior vena cava, 
preventing cannulation for cardiopulmonary bypass. The patient survived the surgery, but 
succumbed within 48 hours in the intensive care unit. No hemolysis or thrombocytopenia 
was observed in any of the patients in this study, and the patients’ hematocrit values 
remained stable post procedure.  
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Fig. 9. Post extraction echocardiogram depicting absence of mobile thrombus  
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The propensity for clot to propagate as well as to organize renders treatment of 
thromboembolic disease difficult. Anticoagulation addresses further propagation of 
thrombus; however, once a patient presents with a significant mass of clot, vascular 
recanalization becomes a formidable task. Complete occlusions in major or great venous 
vessels tend to be unresponsive to thrombolytic therapy, as circulating thrombolytic agents 
are unable to access the inner mass of a substantial body of clot that typifies massive 
pulmonary embolism or total vena cava occlusion. Thrombolytic dissolution occurs at the 
periphery of the occlusion, proceeding progressively inwards with time. Hemodynamic 
instability may curtail the opportunity window for therapeutic intervention, and immediate 
bulk extraction of occlusive material is warranted. Percutaneous interventional devices 
utilizing mechanical or rheolytic fragmentation of clot increase the rate of thrombolysis. 
Dissolution is a function of the amount of interaction achieved by the device with the clot. 
Higher surface contact area between the active components of the device and resident clot 
yields greater thrombolytic activity. Presently available percutaneous devices are limited by 
their size relative to clot in the great vessels. The luminal cross-sectional area of a 7F catheter 
is equal to 3 mm2, which encompasses 0.5% of the surface area of a 30 mm diameter inferior 
vena cava or pulmonary artery with a luminal cross-sectional area of 615 mm2. This means 
that a 7F catheter approaching an occluding thrombus in the vena cava contacts only 0.5% of 
the cross-sectional area of a clot on a single pass. An impractical number of catheter passes 
would be required to clear a total occlusion in the great vessels. 
The large bore of the funnel cannula facilitates material removal from the great vessels. The 
large conduit size also minimizes the potential for hemolysis during vacuum extraction. 
Suction therapy is conducted by a centrifugal pump which generates typical flow rates up to 
5 liters per minute via the 22 F cannula. At this flow rate and cannula size, laminar flow is 
maintained in the extracorporeal circuit, providing atraumatic passage for circulating 
erythrocytes. 
4. Conclusion 
Removal of undesirable intravascular material using extracorporeal recirculation with a 
funnel venous drainage cannula seeks to mimic surgical removal of massive emboli, by 
maximizing physical contact with the leading edge of the occlusion, and conducting en bloc 
removal of substantial embolic masses. The significant flow rates (on the order of 4 or 5 liters 
per minute) established in the drainage cannula while extracting major emboli, are matched 
by simultaneous reinfusion to maintain hemodynamic stability during the embolectomy 
process. A funnel cannula tip that matches the size of the occluded vessel and a high 
circulating flow rate are necessary elements to facilitate embolectomy. Bench top tests 
indicate that backflow must be present to support the level of pump flow rate that generates 
vacuum sufficient to remove large masses. In some of the procedures that yielded little or no 
material extraction, it is possible that a lack of backflow was exhibited due to absent or 
severely limited retrograde collateralization. Guidewire or angiographic catheter passage 
through the thrombotic substrate may yield partial recanalization that provides the requisite 
degree of retrograde flow for successful embolic removal. Another cause of unsuccessful 
extraction may be an advanced degree of fibrotic attachment associated with aged thrombus 
that is not amenable to vacuum dislodgment. Further clinical experience will delineate 
additional associated techniques and define best patient selection criteria for optimal 
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application of vacuum extraction with the funnel cannula. The experience to date generates 
a sense of optimism that suction embolectomy with associated extracorporeal recirculation 
has potential as a functional therapeutic component in the battle against thromboembolic 
disease. Continued research into this and other approaches is certainly warranted. 
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1. Introduction 
Coronary artery bypass grafting (CABG) is one of the most studied operations in medical 
history, but many of the data forming the basis for clinical decisions in patients with 
coronary artery disease (CAD) were derived in the 1970s and 1980s, when the procedure 
and medical therapy were in their relative infancy. Advances in medical therapy (beta 
adrenergic blockers, thienopyridines, statins, and others), percutaneous coronary 
interventions (PCI), and surgical techniques have changed the decision making for patients 
with CAD. In addition, patient populations referred for surgery have changed since the 
original studies documenting advantages of CABG over other forms of therapy. 
Since percutaneous transluminal coronary angioplasty (PTCA) was introduced, significant 
advances have been made in the percutaneous treatment of CAD. When drug-eluting stents 
(DES) were introduced in the early 2000s, many predicted the demise of CABG surgery. 
Enthusiasm for percutaneous treatment of CAD has most recently led to promoting PCI for 
unprotected left main coronary artery (LMCA) disease, an anatomical state typically 
reserved for CABG [1-3]. Percutaneous options have indelibly changed the face of CABG 
surgery and raise questions concerning the “gold standard” of care in coronary 
revascularization. For instance, recent reports document that patients referred for redo 
coronary artery surgery have declined, presumably due to the increased enthusiasm, 
possibly among surgeons themselves, for PCI in this setting [4]. Despite this, few studies 
have actually compared PCI with CABG. Two notable studies are recently available, both 
demonstrating advantages for CABG over PCI for left main CAD and/or three-vessel CAD 
[5, 6].  
Concurrently, details pertaining to short-term outcomes of CABG have been questioned. For 
example, historical saphenous vein graft (SVG) patencies were reported as approximately 
50% at 10 years [7]. However, several studies published in the mid-2000s indicate that early-
term patencies of aorto-coronary SVG conduits are not as good as the historical figures that 
are still often quoted [8-10]. While the long-term patency and performance of the left 
internal mammary artery (LIMA) has not been questioned, the recent poor performance of 
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possibly among surgeons themselves, for PCI in this setting [4]. Despite this, few studies 
have actually compared PCI with CABG. Two notable studies are recently available, both 
demonstrating advantages for CABG over PCI for left main CAD and/or three-vessel CAD 
[5, 6].  
Concurrently, details pertaining to short-term outcomes of CABG have been questioned. For 
example, historical saphenous vein graft (SVG) patencies were reported as approximately 
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are still often quoted [8-10]. While the long-term patency and performance of the left 
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SVG, coupled with increasing enthusiasm and demand for DES has lead to the emergence of 
“hybrid” coronary revascularization, typically consisting of LIMA-to-LAD and PCI of other 
coronary lesions. [11].  
Coronary artery surgery itself has undergone several iterative changes recently. In the 1990s, 
great enthusiasm existed for the “mid-CAB” (minimally-invasive direct coronary artery 
bypass) procedure, an approach integral to “hybrid” revascularizations and primarily 
involving a small left anterior thoracotomy to harvest the LIMA and expose the left anterior 
descending [LAD] coronary artery. However, outside of the context of hybrid procedures, 
mid-CAB has had little widespread applicability, particularly since most patients referred 
for coronary surgery have multivessel disease. Introduction of mid-CAB procedures help 
usher in the era of off-pump CABG, which was heralded as an approach to reduce the risks 
associated with on-pump CABG, particularly myocardial dysfunction and cerebrovascular 
complications [12]. Finally, technology has introduced minimally invasive platforms for 
performing multi-vessel CABG, most recently the introduction of “totally endoscopic” and 
robotic CABG surgery [13]. However, it should be noted that these “improved techniques” 
continue to utilize the same conduit selection and comparative trials with objective evidence 
are lacking. Since minimally invasive strategies for CABG do not routinely incorporate 
changes to the operation known to improve short- and long-term results, there appears little 
reason to suspect that graft patency rates will be improved by less invasive procedures. 
Rather, one could argue that these alterations in approach to CABG are primarily based on 
industry involvement, public demands for less invasive procedures, and as marketing 
strategies by hospital systems. 
Are there alternatives to CABG, which could improve long-term outcomes for graft patency and the 
composite of major adverse coronary events (MACE) particularly when compared with PCI? The 
answer is a resounding “yes,” and it is found in arterial conduits for coronary bypass. CABG 
with multiple arterial grafts have been shown to have improved graft patency, reduced need 
for reoperation or reintervention, and prolonged survival compared with patients 
undergoing CABG with one IMA and SVG [14-17]. For instance, Sabik et al reviewed a 27-
year experience at the Cleveland Clinic with regard to need for reintervention after primary 
CABG and found that the extent of arterial grafting correlated with freedom from 
subsequent reintervention [18]. Specifically, patients who received two IMA grafts at initial 
surgery had approximately 10% risk for reintervention at 10 years; those with one IMA had 
20% risk; and those with no IMA had approximately 30% risk for reintervention at 10 years 
[18].  
However, the surgical community has not fully utilized these assets despite numerous, 
compelling data [19-23]. Jones succinctly summarized the decision point facing 
conventional, open surgery in the face of rapidly advancing technologies, particularly PCI, 
and the impact on referral trends for surgical intervention: “ improve the long-term 
outcome, lessen resources used, or both.” [24]. Therefore, one important philosophic 
principle regarding use of multiple arterial conduits is that the focus is on the long-term 
results, not the short-term.  
The purpose of this chapter is to review the data available for CABG with multiple arterial 
grafts including bilateral IMA use, radial artery, and other conduits. Finally, we will 
demonstrate the advantages of multiple arterial grafting and make the argument that this 
strategy yields superior long-term results compared to any strategy for coronary 
revascularization based on PCI or CABG with traditional conduit selection.  
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2. Percutaneous coronary interventions 
PCI was introduced in 1977 and has undergone consistent improvements in technologies 
and approaches, offering a less invasive treatment modality for CAD [25]. With the 
introduction of DES in 2003, the percentage of CAD patients treated with PCI have 
increased consistently [26, 27]. However, recent studies evaluating long-term outcomes for 
DES have revealed increased morbidity and mortality secondary to late stent thrombosis 
[28-30]. While DES therapy has reduced need for target lesion reintervention [31, 32], there is 
a strict therapeutic requirement for dual anti-platelet therapy (DAPT). Current DAPT 
recommendations are for at least one year after DES therapy, but the ideal length of 
treatment still not yet known [33]. 
3. Comparing coronary bypass surgery and PCI 
Shortly after the emergence of PCI as a reliable and durable therapy for CAD, comparisons 
between angioplasty and CABG were designed in order to determine the relative 
advantages of each modality. The BARI (Bypass Angioplasty Revascularization 
Investigation) trial compared balloon angioplasty with CABG in patients with multivessel 
CAD and severe angina or inducible coronary ischemia. After 5 and 10 years follow-up, no 
difference in long-term survival was demonstrated [34, 35]. Similar results were noted in 
other randomized trials of PTCA versus CABG [36, 37]. It was commonly noted in these 
trials that reintervention for recurrent angina symptoms was significantly more common for 
patients treated with an initial strategy of PTCA [BARI, RITA, GABI]. However, on 
subgroup analysis, survival advantage for CABG was demonstrated among diabetic 
patients in the BARI trial [35]. Finally, a meta-analysis of 13 randomized controlled trials 
comparing CABG with PTCA showed improved survival for CABG at 5-8 years in those 
with multivessel CAD and in diabetic patients [38].  
Even as studies comparing PTCA with CABG were enrolling, bare-metal stents (BMS) were 
introduced, and trials to compare the new technology with CABG emerged. The 
randomized Stent or Surgery (SoS) trial compared multivessel CAD treatment by CABG or 
by PCI with BMS [39]. At a median follow-up of 2 years, these data showed reduced rates of 
coronary reintervention and significantly fewer deaths after CABG. Similar trials comparing 
CABG and PCI with BMS did not demonstrate a survival advantage for either therapy [40], 
although diabetic patients appeared to have improved survival after CABG in the Arterial 
Revascularization Therapies Study (ARTS 1) [41].  
The US Food and Drug Administration approved DES therapy in 2003, stimulating another 
round of comparisons between CABG and PCI with the newer technology. Hannan et al 
reviewed risk-adjusted data from the NY State Dept of Health comparing patients who 
underwent CABG or PCI with DES for multivessel CAD over a 15-month period shortly 
after DES approval [5]. At a mean follow-up of 19 months, CABG patients experienced 
reduced hazard ratio for death, reduced mortality, reduced death/myocardial infarction 
composite, and less need for repeat revascularization [5]. However, the data were not 
acquired in the context of a randomized trial. Finally, the SYNTAX trial, a prospective 
randomized trial conducted across Europe and the US, compared PCI with DES and CABG 
in patients with 3-vessel CAD, left main CAD, or both [6]. The primary outcomes were 
major adverse cardiovascular or cerebrovascular events, and follow-up was provided for 12 
months after intervention. The SYNTAX data demonstrated increased rates of MACE in the 
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answer is a resounding “yes,” and it is found in arterial conduits for coronary bypass. CABG 
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PCI group, primarily related to the increased need for repeat intervention. Death and post-
procedure MI were not significantly different between the two groups, but there was an 
increased stroke rate in the CABG group compared with PCI, which is somewhat offset by 
the fact that surgical patients were not managed with aggressive antiplatelet therapy as 
compared to the PCI group, and many of the cerebrovascular events occurred outside of the 
perioperative period. More recently, three-year follow up SYNTAX data were reported 
confirming advantages of CABG over PCI with regard to MACE. Unlike 12-month data, 
however, composite safety endpoints were no longer different between the two groups, 
including a similar stroke rate [42]. The SYNTAX authors concluded that CABG remains the 
preferred therapy for 3-vessel or left main CAD but recommend longer follow up, as is 
planned for an additional two years [6].  
Despite the favorable data for CABG emanating from carefully designed and conducted 
randomized trials, rates of CABG referral have decreased consistently since the introduction 
of PCI with stent technologies [43]. Preference for PCI appears driven by disparate 
interpretation of PCI-versus-CABG studies, by strong patient preference for less invasive 
procedures with presumed lower periprocedural risk, and by the promise for faster 
recovery. As a result, the percentage of patients referred for CABG with previous PCI has 
increased steadily [44] with higher acuity relative to patients without previous intervention 
[45]. Additionally, technical details of CABG in current surgical practices are considered 
more challenging compared with previous eras due to more diffuse CAD, subjectively 
smaller distal coronary targets, particularly among diabetic patients, and the high incidence 
of prior PCI [46]. Consequently, contemporary results for CABG following PCI are 
characterized by worse perioperative outcomes when compared with CABG patients 
without previous intervention. For example, higher rates of postoperative mortality, MACE, 
and other perioperative complications following CABG in both diabetic and nondiabetic 
patients have been observed [47-50]. More importantly, increased mid-term mortality in 
diabetic patients with prior PCI has been observed after CABG [50], and Rao et al 
demonstrated increased long-term mortality in patients with prior PCI who subsequently 
underwent CABG [51]. 
4. Saphenous vein graft conduits 
Reversed saphenous vein grafts (RSVG) have been utilized for CABG since the procedure’s 
inception [52] and remain an important graft conduit option in the present era and in 
numerous clinical scenarios [53, 54]. Historically, patency rates of RSVG aorto-coronary 
artery grafts have been observed to be approximately 50-60% at 10 years [7, 55]. However, as 
previously noted, recent RSVG patency data are less encouraging [8-10]. For example, the 
PREVENT-IV study evaluated 3,000 patients undergoing CABG with 1-year routine 
angiographic follow-up. At this early time point, 30% of RSVG conduits were occluded and 
over 45% had “failed,” as defined by  75% stenosis [10]. Importantly, study patients with 
vein graft failure had significantly increased rates of perioperative complications including 
MI, death or MI, or MACE relative to the cohort without vein graft complications [10]. 
Similar results have been noted elsewhere [56-59]. Additionally, surprisingly poor early-to-
mid-term RSVG patency rates have been reported elsewhere. The Portland Endoscopic SVG 
Harvest Trial demonstrated 69% [8], patency by angiography at 6-months, while the 
PRAGUE 4 trial showed one-year RSVG patency of 52.5% [9]. The potential impact of poor 
vein graft performance cannot be overstated as RSVG failure is significant contributor to 
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redo coronary surgery [60]. In addition, early vein graft failure is associated with increased 
perioperative myocardial infarction [10, 61], which consequently affects survival after CABG 
[58, 59]. 
Several potential explanations exist for the recently chronicled poor performance of RSVG as 
aorto-coronary conduits including early technical errors, endothelial injury, and early 
thrombosis, which may be related to insufficient biologic reaction to aspirin or inadequate 
antiplatelet effect of aspirin [62-64]. One important contributor to poor RSVG conduit 
performance, receiving significant recent attention, may be the practice of harvesting the 
conduit endoscopically (EVH). This technique was introduced and popularized in the 1990s 
and has been widely adopted due to increased incisional comfort and patient satisfaction, 
and decreased wound complications compared to open vein harvesting [65, 66] such that at 
least 70% of CABG patients undergo EVH based on recent Society of Thoracic Surgeons 
Database reporting [67]. However, EVH has been associated with increased endothelial 
injury, which may have significant negative consequences including graft patency and 
possibly long-term survival [68, 69]. Desai et al recently demonstrated using optical 
coherence tomography that EVH operators had a steep learning curve with regard to subtle 
RSVG injuries and that vein grafts with four or more intimal or medial dissections showed 
significantly worse early patency rates than those with fewer intimal injuries (67% vs. 96%) 
[70].  
In contrast, when RSVGs are harvested using a “no touch” technique, better patency results 
have been noted. The “no touch” method avoids vein stripping, taking surrounding tissue, 
and avoids over-distending the vein conduit as it is being prepared for coronary 
anastomosis [71]. This has also been shown recently to preserve the venous vasa vasorum 
[72]. Perhaps this helps to explain differences in contemporary SVG patency rates versus 
those reported historically, which were always done by an open surgical technique. Other 
predictors of improved vein patency include grafting to the LAD coronary artery versus 
other target sites, smaller venous conduit size, and larger diameter target coronary artery. In 
contrast, young age and low EF reduced long-term patency [60]. The type of distal 
anastomosis (sequential, y- or t-grafts, or other composite grafts) did not affect long-term 
patency [60]. Based on these data, some suggest SVG from the calf/lower leg since size and 
possible thickness of the vein is better [60]. Additionally, EVH is more difficult to perform 
on the lower leg; therefore, programs committed to EVH likely neglect this potentially 
advantageous conduit.  
Current surgical patient cohorts have also been implicated in reduced vein graft patencies. 
For example, it is generally accepted that contemporary patients referred for surgery are 
older and more medically complex [73]. For example, many patients referred for CABG are 
diabetic, a condition that is notorious for more complicated and diffuse CAD [46, 74]. In 
addition, it has been proposed that venous grafts in elderly may be of inferior quality 
relative to younger patients [75]. 
5. General advantages of arterial grafting 
Several advantages to arterial grafting have been demonstrated relative to CABG without 
arterial grafts. Most notably, the LIMA-LAD graft has been shown to be an independent 
predictor of survival after CABG when compared with patients not receiving LIMA-LAD 
[76]. In addition, using more than one IMA graft reduces the need for subsequent 
reintervention and prolongs survival relative to patients receiving only one arterial grafts 
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PCI group, primarily related to the increased need for repeat intervention. Death and post-
procedure MI were not significantly different between the two groups, but there was an 
increased stroke rate in the CABG group compared with PCI, which is somewhat offset by 
the fact that surgical patients were not managed with aggressive antiplatelet therapy as 
compared to the PCI group, and many of the cerebrovascular events occurred outside of the 
perioperative period. More recently, three-year follow up SYNTAX data were reported 
confirming advantages of CABG over PCI with regard to MACE. Unlike 12-month data, 
however, composite safety endpoints were no longer different between the two groups, 
including a similar stroke rate [42]. The SYNTAX authors concluded that CABG remains the 
preferred therapy for 3-vessel or left main CAD but recommend longer follow up, as is 
planned for an additional two years [6].  
Despite the favorable data for CABG emanating from carefully designed and conducted 
randomized trials, rates of CABG referral have decreased consistently since the introduction 
of PCI with stent technologies [43]. Preference for PCI appears driven by disparate 
interpretation of PCI-versus-CABG studies, by strong patient preference for less invasive 
procedures with presumed lower periprocedural risk, and by the promise for faster 
recovery. As a result, the percentage of patients referred for CABG with previous PCI has 
increased steadily [44] with higher acuity relative to patients without previous intervention 
[45]. Additionally, technical details of CABG in current surgical practices are considered 
more challenging compared with previous eras due to more diffuse CAD, subjectively 
smaller distal coronary targets, particularly among diabetic patients, and the high incidence 
of prior PCI [46]. Consequently, contemporary results for CABG following PCI are 
characterized by worse perioperative outcomes when compared with CABG patients 
without previous intervention. For example, higher rates of postoperative mortality, MACE, 
and other perioperative complications following CABG in both diabetic and nondiabetic 
patients have been observed [47-50]. More importantly, increased mid-term mortality in 
diabetic patients with prior PCI has been observed after CABG [50], and Rao et al 
demonstrated increased long-term mortality in patients with prior PCI who subsequently 
underwent CABG [51]. 
4. Saphenous vein graft conduits 
Reversed saphenous vein grafts (RSVG) have been utilized for CABG since the procedure’s 
inception [52] and remain an important graft conduit option in the present era and in 
numerous clinical scenarios [53, 54]. Historically, patency rates of RSVG aorto-coronary 
artery grafts have been observed to be approximately 50-60% at 10 years [7, 55]. However, as 
previously noted, recent RSVG patency data are less encouraging [8-10]. For example, the 
PREVENT-IV study evaluated 3,000 patients undergoing CABG with 1-year routine 
angiographic follow-up. At this early time point, 30% of RSVG conduits were occluded and 
over 45% had “failed,” as defined by  75% stenosis [10]. Importantly, study patients with 
vein graft failure had significantly increased rates of perioperative complications including 
MI, death or MI, or MACE relative to the cohort without vein graft complications [10]. 
Similar results have been noted elsewhere [56-59]. Additionally, surprisingly poor early-to-
mid-term RSVG patency rates have been reported elsewhere. The Portland Endoscopic SVG 
Harvest Trial demonstrated 69% [8], patency by angiography at 6-months, while the 
PRAGUE 4 trial showed one-year RSVG patency of 52.5% [9]. The potential impact of poor 
vein graft performance cannot be overstated as RSVG failure is significant contributor to 
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redo coronary surgery [60]. In addition, early vein graft failure is associated with increased 
perioperative myocardial infarction [10, 61], which consequently affects survival after CABG 
[58, 59]. 
Several potential explanations exist for the recently chronicled poor performance of RSVG as 
aorto-coronary conduits including early technical errors, endothelial injury, and early 
thrombosis, which may be related to insufficient biologic reaction to aspirin or inadequate 
antiplatelet effect of aspirin [62-64]. One important contributor to poor RSVG conduit 
performance, receiving significant recent attention, may be the practice of harvesting the 
conduit endoscopically (EVH). This technique was introduced and popularized in the 1990s 
and has been widely adopted due to increased incisional comfort and patient satisfaction, 
and decreased wound complications compared to open vein harvesting [65, 66] such that at 
least 70% of CABG patients undergo EVH based on recent Society of Thoracic Surgeons 
Database reporting [67]. However, EVH has been associated with increased endothelial 
injury, which may have significant negative consequences including graft patency and 
possibly long-term survival [68, 69]. Desai et al recently demonstrated using optical 
coherence tomography that EVH operators had a steep learning curve with regard to subtle 
RSVG injuries and that vein grafts with four or more intimal or medial dissections showed 
significantly worse early patency rates than those with fewer intimal injuries (67% vs. 96%) 
[70].  
In contrast, when RSVGs are harvested using a “no touch” technique, better patency results 
have been noted. The “no touch” method avoids vein stripping, taking surrounding tissue, 
and avoids over-distending the vein conduit as it is being prepared for coronary 
anastomosis [71]. This has also been shown recently to preserve the venous vasa vasorum 
[72]. Perhaps this helps to explain differences in contemporary SVG patency rates versus 
those reported historically, which were always done by an open surgical technique. Other 
predictors of improved vein patency include grafting to the LAD coronary artery versus 
other target sites, smaller venous conduit size, and larger diameter target coronary artery. In 
contrast, young age and low EF reduced long-term patency [60]. The type of distal 
anastomosis (sequential, y- or t-grafts, or other composite grafts) did not affect long-term 
patency [60]. Based on these data, some suggest SVG from the calf/lower leg since size and 
possible thickness of the vein is better [60]. Additionally, EVH is more difficult to perform 
on the lower leg; therefore, programs committed to EVH likely neglect this potentially 
advantageous conduit.  
Current surgical patient cohorts have also been implicated in reduced vein graft patencies. 
For example, it is generally accepted that contemporary patients referred for surgery are 
older and more medically complex [73]. For example, many patients referred for CABG are 
diabetic, a condition that is notorious for more complicated and diffuse CAD [46, 74]. In 
addition, it has been proposed that venous grafts in elderly may be of inferior quality 
relative to younger patients [75]. 
5. General advantages of arterial grafting 
Several advantages to arterial grafting have been demonstrated relative to CABG without 
arterial grafts. Most notably, the LIMA-LAD graft has been shown to be an independent 
predictor of survival after CABG when compared with patients not receiving LIMA-LAD 
[76]. In addition, using more than one IMA graft reduces the need for subsequent 
reintervention and prolongs survival relative to patients receiving only one arterial grafts 
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[15, 17]. Similarly, Guru et al evaluated the potential benefit of multiple arterial grafting in 
over 53,000 patients undergoing primary CABG between 1991 and 2001. After propensity 
matching, patients receiving  2 arterial grafts had decreased rates of cardiac readmission 
and reduced incidence of the composite of cardiac readmission, death, and repeat 
revascularization relative to those with  one arterial grafts [23]. Furthermore, patients 
receiving  2 arterial grafts had improved survival compared with patients receiving only 
one arterial graft [23]. Similar findings were reported by Nasso, et al, who found no 
differences at 2 years between groups receiving RA, in-situ RIMA, or free RIMA as the 2nd 
arterial graft, although each of these groups was superior to patients receiving only one 
arterial graft (LIMA-LAD) with respect to cardiac event-free survival [77]. Zacharias et al 
also demonstrated advantages of RA grafting as a 2nd arterial conduit on long-term survival 
when compared to RSVG conduits [14]. 
In addition, multiple arterial grafts and their arrangements in all coronary distributions 
have been proven superior to venous grafts with regard to long term patency regardless of 
the anatomic details of the native coronary and distal anastomosis [55]. These results are 
particularly applicable in the context of recurrent angina [16, 55, 78]. Finally, perhaps one of 
the best recent demonstrations of the advantages of arterial grafting over RSVG conduits 
was provided by Gaudino et al, who studied 60 CAD patients who had previously 
undergone PCI and developed in-stent restenosis. After undergoing CABG, patients 
receiving IMA and RA grafts had patency rates of 90% while those undergoing RSVG had 
patency rates of 50% at a mean follow-up of 52 months [79]. 
5.1 Total arterial revascularization 
Since SVG conduits inevitably fail, particularly late [62], there has been increased 
enthusiasm for total arterial revascularization for CABG. Total arterial revascularization 
may obviate the concerns of vein graft failure and has been shown to have good short-
term results [80]. However, little evidence is available to suggest that outcomes are 
improved with “all-arterial” grafting [81]. Zacharias et al have recently demonstrated that 
patients with multi-vessel CAD undergoing all-arterial grafting had improved 12-year 
survival compared with matched patients who underwent standard CABG with LIMA-
LAD and RSVG to other distal targets [82]. Furthermore, complete coronary 
revascularization and use of all-arterial grafting strategy was associated with improved 
12-year survival [82, Figure].  
It has been estimated that all-arterial grafting is possible in 90% of patients using various 
conduits and their configurations [55], and even patients with advanced age have been 
shown to benefit from all-arterial revascularization strategies in terms of freedom from 
recurrent coronary events and improved graft patency [83].  
6. Bilateral internal mammary artery conduits 
In the 1980s, the LIMA-to-LAD graft was shown to be an independent predictor of 
improved short- and long-term results when used as a conduit for CABG compared to 
RSVG-only grafting [76]. Unequivocal advantages of the LIMA-LAD graft include 
prolonged survival relative to use of RSVG to LAD, reduced rates of recurrent angina, 
reduced postoperative MI and other ischemic events, and decreased need for coronary 
reintervention [76, 84]. The superiority of the LIMA in comparison to other CABG conduits  
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Fig. 1. Effects of completeness of revascularization on 12-year old Kaplan-Meier survival in 
triple-vessel disease (3-Ves Dis) patients. (Left) All-arterial patients. (Right) Internal thoracic 
artery/saphenous vein (ITA/Vein) patients. Incomplete - completeness of revascularization 
index (CRI) less than 1, or 2 grafts; complete CRI equal to 1, or 3 grafts; complete plus - CRI 
greater than 1, or 4 or more grafts. All p values by log-rannk (Mantel-Cox) test. (CABG - 
coronary artery bypass graft surgery.) 
may be related to its unique freedom from arteriosclerosis and due to the rich run-off bed 
provided by the LAD coronary and its branches [85]. Since there is no basis for suggesting 
or concluding that the biological and mechanical properties of the right IMA are different 
from the LIMA, successes with the LIMA have prompted investigation of the potential 
benefits of bilateral IMA (BIMA) grafting. 
The original description of BIMA for CABG is credited to Kay in 1969 [86]. Since then, 
multiple centers including our own have investigated the impact of BIMA grafting on long-
term results of CABG. Advantages of BIMA have been somewhat difficult to prove 
definitively without randomized controlled trials in this area, which have not been 
conducted secondary to cost concerns and administrative requirements associated with 
studies inherently requiring significant longitudinal follow-up [87]. Instead, investigation 
and documentation of BIMA benefits have relied on evaluating institutionally maintained 
observational databases to show differences between the “treatment group” and the 
“control group” by way of propensity matching [87]. Analysis of these data show improved 
long-term results for patients receiving BIMA grafting as compared with single IMA 
grafting. However, survival curves do not separate until several years postoperatively, 
which has been a consistent finding [15, 88, 89; Figure]. The demonstrated clinical 
advantages of BIMA grafting strategies include prolonged survival and reduced need for 
coronary reintervention on the basis of recurrent myocardial ischemia, including freedom 
from the need for coronary reintervention [15, 88, 90] which hold true for women as well as 
for men, where it has been demonstrated that use of BIMA had 3-fold improved cardiac-
related survival compared with patients who did not receive an IMA graft [91].  
Reported rates of BIMA use in CABG range from 4.0% to nearly 50% depending upon 
several factors including the contributing authors’ practice preferences and the particular 
patient cohort treated [19-22, 92]. However, it has been estimated that up to 80% would be 
candidates for BIMA grafting [93]. Subjective and potential obstacles to BIMA use include 
increased surgical times, increased technical challenges, especially related to the positioning  
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[15, 17]. Similarly, Guru et al evaluated the potential benefit of multiple arterial grafting in 
over 53,000 patients undergoing primary CABG between 1991 and 2001. After propensity 
matching, patients receiving  2 arterial grafts had decreased rates of cardiac readmission 
and reduced incidence of the composite of cardiac readmission, death, and repeat 
revascularization relative to those with  one arterial grafts [23]. Furthermore, patients 
receiving  2 arterial grafts had improved survival compared with patients receiving only 
one arterial graft [23]. Similar findings were reported by Nasso, et al, who found no 
differences at 2 years between groups receiving RA, in-situ RIMA, or free RIMA as the 2nd 
arterial graft, although each of these groups was superior to patients receiving only one 
arterial graft (LIMA-LAD) with respect to cardiac event-free survival [77]. Zacharias et al 
also demonstrated advantages of RA grafting as a 2nd arterial conduit on long-term survival 
when compared to RSVG conduits [14]. 
In addition, multiple arterial grafts and their arrangements in all coronary distributions 
have been proven superior to venous grafts with regard to long term patency regardless of 
the anatomic details of the native coronary and distal anastomosis [55]. These results are 
particularly applicable in the context of recurrent angina [16, 55, 78]. Finally, perhaps one of 
the best recent demonstrations of the advantages of arterial grafting over RSVG conduits 
was provided by Gaudino et al, who studied 60 CAD patients who had previously 
undergone PCI and developed in-stent restenosis. After undergoing CABG, patients 
receiving IMA and RA grafts had patency rates of 90% while those undergoing RSVG had 
patency rates of 50% at a mean follow-up of 52 months [79]. 
5.1 Total arterial revascularization 
Since SVG conduits inevitably fail, particularly late [62], there has been increased 
enthusiasm for total arterial revascularization for CABG. Total arterial revascularization 
may obviate the concerns of vein graft failure and has been shown to have good short-
term results [80]. However, little evidence is available to suggest that outcomes are 
improved with “all-arterial” grafting [81]. Zacharias et al have recently demonstrated that 
patients with multi-vessel CAD undergoing all-arterial grafting had improved 12-year 
survival compared with matched patients who underwent standard CABG with LIMA-
LAD and RSVG to other distal targets [82]. Furthermore, complete coronary 
revascularization and use of all-arterial grafting strategy was associated with improved 
12-year survival [82, Figure].  
It has been estimated that all-arterial grafting is possible in 90% of patients using various 
conduits and their configurations [55], and even patients with advanced age have been 
shown to benefit from all-arterial revascularization strategies in terms of freedom from 
recurrent coronary events and improved graft patency [83].  
6. Bilateral internal mammary artery conduits 
In the 1980s, the LIMA-to-LAD graft was shown to be an independent predictor of 
improved short- and long-term results when used as a conduit for CABG compared to 
RSVG-only grafting [76]. Unequivocal advantages of the LIMA-LAD graft include 
prolonged survival relative to use of RSVG to LAD, reduced rates of recurrent angina, 
reduced postoperative MI and other ischemic events, and decreased need for coronary 
reintervention [76, 84]. The superiority of the LIMA in comparison to other CABG conduits  
 
Conduit Selection for Improved Outcomes in Coronary Artery Bypass Surgery 149 
 
Fig. 1. Effects of completeness of revascularization on 12-year old Kaplan-Meier survival in 
triple-vessel disease (3-Ves Dis) patients. (Left) All-arterial patients. (Right) Internal thoracic 
artery/saphenous vein (ITA/Vein) patients. Incomplete - completeness of revascularization 
index (CRI) less than 1, or 2 grafts; complete CRI equal to 1, or 3 grafts; complete plus - CRI 
greater than 1, or 4 or more grafts. All p values by log-rannk (Mantel-Cox) test. (CABG - 
coronary artery bypass graft surgery.) 
may be related to its unique freedom from arteriosclerosis and due to the rich run-off bed 
provided by the LAD coronary and its branches [85]. Since there is no basis for suggesting 
or concluding that the biological and mechanical properties of the right IMA are different 
from the LIMA, successes with the LIMA have prompted investigation of the potential 
benefits of bilateral IMA (BIMA) grafting. 
The original description of BIMA for CABG is credited to Kay in 1969 [86]. Since then, 
multiple centers including our own have investigated the impact of BIMA grafting on long-
term results of CABG. Advantages of BIMA have been somewhat difficult to prove 
definitively without randomized controlled trials in this area, which have not been 
conducted secondary to cost concerns and administrative requirements associated with 
studies inherently requiring significant longitudinal follow-up [87]. Instead, investigation 
and documentation of BIMA benefits have relied on evaluating institutionally maintained 
observational databases to show differences between the “treatment group” and the 
“control group” by way of propensity matching [87]. Analysis of these data show improved 
long-term results for patients receiving BIMA grafting as compared with single IMA 
grafting. However, survival curves do not separate until several years postoperatively, 
which has been a consistent finding [15, 88, 89; Figure]. The demonstrated clinical 
advantages of BIMA grafting strategies include prolonged survival and reduced need for 
coronary reintervention on the basis of recurrent myocardial ischemia, including freedom 
from the need for coronary reintervention [15, 88, 90] which hold true for women as well as 
for men, where it has been demonstrated that use of BIMA had 3-fold improved cardiac-
related survival compared with patients who did not receive an IMA graft [91].  
Reported rates of BIMA use in CABG range from 4.0% to nearly 50% depending upon 
several factors including the contributing authors’ practice preferences and the particular 
patient cohort treated [19-22, 92]. However, it has been estimated that up to 80% would be 
candidates for BIMA grafting [93]. Subjective and potential obstacles to BIMA use include 
increased surgical times, increased technical challenges, especially related to the positioning  
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of the non-LIMA-to-LAD graft, and increased rates of sternal wound complications relative 
to patients with one or less IMAs harvested [94]. After 10 years of experience with BIMA 
CABG, Gansera et al noted increased OR and aortic cross clamp times among BIMA patients 
compared with single IMA CABG patients. In addition, patients receiving BIMA grafting 
had higher rates of bleeding requiring postoperative mediastinal reexploration (2.9% vs. 
0.6%) along with increased rates of wound complications [95]. However, they also noted 
that nearly one full additional distal graft was completed when both IMAs were used and, 
most importantly, BIMA grafting was associated with improved 30-day survival, 
particularly among diabetic patients, compared with only one IMA graft. [95]. In this same 
study, a grafting strategy not incorporating 2 IMA conduits was an independent predictor of 
perioperative mortality, directly disputing biases that BIMA grafting is associated with 
increased perioperative complications [95]. Similarly, Kurlansky et al reviewed their 
collective experience with more than 4,500 consecutive CABG procedures (2,369 single IMA; 
2,215 BIMA) and demonstrated that hospital mortality was significantly reduced among 
patients undergoing BIMA grafting compared with controls [92].  
Nevertheless, selection of patients for BIMA grafting should be performed cautiously, 
particularly when performing surgery through a standard median sternotomy incision. This 
is primarily related to the well-demonstrated risk for sternal wound infection after BIMA 
grafting in patients with diabetes, obesity, and other comorbidities [96-100]. However, 
BIMA grafting can be performed safely without significant increased risk for sternal wound 
infection as has been frequently demonstrated [24, 98, 100, 101]. For example, Jones et al 
reviewed their experience with 500 consecutive patients undergoing BIMA CABG over an 
11-year period, excluding only those with proximal coronary stenoses <70% and emergency 
cases with HD instability. Nevertheless, the reported rates of perioperative complications 
were low: operative mortality was 1.8%; deep sternal wound infections were 1%; and 1.8% 
had take back for bleeding. Incredibly, only 2 patients out of the 500 required reoperation 
for myocardial ischemia in the follow-up period. [24]. Interestingly, however, Jones et al 
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point out that if strict criteria for selecting patients for BIMA grafting had been used, nearly 
70% of patients in their series would have been excluded [24].  
As noted previously, RSVG conduits for CABG have not been compared directly to DES, but 
comparisons of BIMA grafting with a strategy primarily employing DES for coronary 
revascularization do exist [102, 103]. After matching for multiple comorbidities, significantly 
improved angina, reduced need for reintervention, and improved reintervention-free 
survival at one year have been observed among patients undergoing BIMA CABG relative 
to PCI [102]. In a similar study, Locker et al examined BIMA CABG versus PCI in diabetic 
patients and demonstrated more complete coronary revascularization, improved angina, 
reduced need for reintervention, and increased cardiovascular event-free survival (80% vs. 
30%, p <0.001) in patients undergoing BIMA CABG [103]. More importantly, 6-year survival 
among patients with left main CAD or 3-vessel CAD was significantly better with BIMA 
revascularization, providing rare evidence for superiority of multiple arterial grafting 
strategy relative to PCI [103]. 
One controversial and often-debated point concerning BIMA CABG relates to the native 
coronary artery planned as a target for the second (right) IMA. Initial opinion considered 
best results of BIMA CABG to occur when the RIMA was grafted to the “next most” 
important coronary bed angiographically, assuming that LIMA to LAD was nearly always 
performed [104]. Schmidt et al found that multiple left-sided grafts lead to improved 
survival relative to a cohort of patients in which the RIMA was placed to the right coronary 
artery distribution along with LIMA-LAD grafting [104]. However, it should be noted that 
graft patency was quite good in both groups (91.7 % vs. 89.6%), as was survival, and 
freedom from heart failure, angina and need for reintervention [104]. They argued that 
maximum long-term benefit from BIMA grafting is realized when the 2nd IMA is placed to 
the coronary distribution subtending the most amount of viable myocardium, which was 
most commonly the circumflex artery distribution. 
The requirement for the 2nd IMA targeted to the left coronary system has been refuted by 
other data. Analysis of Cleveland Clinic data shows that benefits of BIMA CABG are similar 
regardless of the recipient coronary artery for the 2nd IMA graft [89]. Sabik et al found that 
risk-adjusted and unadjusted outcomes did not differ between a strategy for the 2nd IMA 
going to the right coronary or the circumflex coronary artery territory, but several important 
caveats are applicable, particularly with regard to the right coronary artery if the RIMA is to 
be used as an in situ graft to this coronary distribution. For instance, the distal RCA should 
be free of disease, and the proximal RCA stenosis should be  70% in diameter to avoid 
competitive native coronary flow, which may be detrimental to IMA patency. Finally, distal 
viable myocardium should be ensured [105]. More recently, Kurlansky et al reviewed their 
experience in over 2,200 consecutive patients who underwent BIMA grafting. In 2/3 of 
patients, the 2nd IMA was placed to the left coronary system, while in 1/3 of patients, the 2nd 
IMA was placed to the right coronary system. Incredibly, 98% of patients had complete 
coronary revascularization performed with in-situ arterial configurations, that is, avoiding 
free IMA utilization. At a mean follow-up of nearly 13 years, long-term survival was no 
different between groups [106, Figure]. 
Gansera et al recently described their strategy for with BIMA versus single IMA in which 
the RIMA was usually directed anteriorly and to the left as pedicled conduit for the LAD, 
while the LIMA was typically directed for revascularization of the lateral wall (circumflex 
artery distribution) [95]. Importantly, RIMA crossover grafts to the LAD coronary system 
appear to have patency rates that are not different from LIMA-LAD configurations [107]. In  
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of the non-LIMA-to-LAD graft, and increased rates of sternal wound complications relative 
to patients with one or less IMAs harvested [94]. After 10 years of experience with BIMA 
CABG, Gansera et al noted increased OR and aortic cross clamp times among BIMA patients 
compared with single IMA CABG patients. In addition, patients receiving BIMA grafting 
had higher rates of bleeding requiring postoperative mediastinal reexploration (2.9% vs. 
0.6%) along with increased rates of wound complications [95]. However, they also noted 
that nearly one full additional distal graft was completed when both IMAs were used and, 
most importantly, BIMA grafting was associated with improved 30-day survival, 
particularly among diabetic patients, compared with only one IMA graft. [95]. In this same 
study, a grafting strategy not incorporating 2 IMA conduits was an independent predictor of 
perioperative mortality, directly disputing biases that BIMA grafting is associated with 
increased perioperative complications [95]. Similarly, Kurlansky et al reviewed their 
collective experience with more than 4,500 consecutive CABG procedures (2,369 single IMA; 
2,215 BIMA) and demonstrated that hospital mortality was significantly reduced among 
patients undergoing BIMA grafting compared with controls [92].  
Nevertheless, selection of patients for BIMA grafting should be performed cautiously, 
particularly when performing surgery through a standard median sternotomy incision. This 
is primarily related to the well-demonstrated risk for sternal wound infection after BIMA 
grafting in patients with diabetes, obesity, and other comorbidities [96-100]. However, 
BIMA grafting can be performed safely without significant increased risk for sternal wound 
infection as has been frequently demonstrated [24, 98, 100, 101]. For example, Jones et al 
reviewed their experience with 500 consecutive patients undergoing BIMA CABG over an 
11-year period, excluding only those with proximal coronary stenoses <70% and emergency 
cases with HD instability. Nevertheless, the reported rates of perioperative complications 
were low: operative mortality was 1.8%; deep sternal wound infections were 1%; and 1.8% 
had take back for bleeding. Incredibly, only 2 patients out of the 500 required reoperation 
for myocardial ischemia in the follow-up period. [24]. Interestingly, however, Jones et al 
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point out that if strict criteria for selecting patients for BIMA grafting had been used, nearly 
70% of patients in their series would have been excluded [24].  
As noted previously, RSVG conduits for CABG have not been compared directly to DES, but 
comparisons of BIMA grafting with a strategy primarily employing DES for coronary 
revascularization do exist [102, 103]. After matching for multiple comorbidities, significantly 
improved angina, reduced need for reintervention, and improved reintervention-free 
survival at one year have been observed among patients undergoing BIMA CABG relative 
to PCI [102]. In a similar study, Locker et al examined BIMA CABG versus PCI in diabetic 
patients and demonstrated more complete coronary revascularization, improved angina, 
reduced need for reintervention, and increased cardiovascular event-free survival (80% vs. 
30%, p <0.001) in patients undergoing BIMA CABG [103]. More importantly, 6-year survival 
among patients with left main CAD or 3-vessel CAD was significantly better with BIMA 
revascularization, providing rare evidence for superiority of multiple arterial grafting 
strategy relative to PCI [103]. 
One controversial and often-debated point concerning BIMA CABG relates to the native 
coronary artery planned as a target for the second (right) IMA. Initial opinion considered 
best results of BIMA CABG to occur when the RIMA was grafted to the “next most” 
important coronary bed angiographically, assuming that LIMA to LAD was nearly always 
performed [104]. Schmidt et al found that multiple left-sided grafts lead to improved 
survival relative to a cohort of patients in which the RIMA was placed to the right coronary 
artery distribution along with LIMA-LAD grafting [104]. However, it should be noted that 
graft patency was quite good in both groups (91.7 % vs. 89.6%), as was survival, and 
freedom from heart failure, angina and need for reintervention [104]. They argued that 
maximum long-term benefit from BIMA grafting is realized when the 2nd IMA is placed to 
the coronary distribution subtending the most amount of viable myocardium, which was 
most commonly the circumflex artery distribution. 
The requirement for the 2nd IMA targeted to the left coronary system has been refuted by 
other data. Analysis of Cleveland Clinic data shows that benefits of BIMA CABG are similar 
regardless of the recipient coronary artery for the 2nd IMA graft [89]. Sabik et al found that 
risk-adjusted and unadjusted outcomes did not differ between a strategy for the 2nd IMA 
going to the right coronary or the circumflex coronary artery territory, but several important 
caveats are applicable, particularly with regard to the right coronary artery if the RIMA is to 
be used as an in situ graft to this coronary distribution. For instance, the distal RCA should 
be free of disease, and the proximal RCA stenosis should be  70% in diameter to avoid 
competitive native coronary flow, which may be detrimental to IMA patency. Finally, distal 
viable myocardium should be ensured [105]. More recently, Kurlansky et al reviewed their 
experience in over 2,200 consecutive patients who underwent BIMA grafting. In 2/3 of 
patients, the 2nd IMA was placed to the left coronary system, while in 1/3 of patients, the 2nd 
IMA was placed to the right coronary system. Incredibly, 98% of patients had complete 
coronary revascularization performed with in-situ arterial configurations, that is, avoiding 
free IMA utilization. At a mean follow-up of nearly 13 years, long-term survival was no 
different between groups [106, Figure]. 
Gansera et al recently described their strategy for with BIMA versus single IMA in which 
the RIMA was usually directed anteriorly and to the left as pedicled conduit for the LAD, 
while the LIMA was typically directed for revascularization of the lateral wall (circumflex 
artery distribution) [95]. Importantly, RIMA crossover grafts to the LAD coronary system 
appear to have patency rates that are not different from LIMA-LAD configurations [107]. In  
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Fig. 3. Actuarial survival of optimally matched patients who underwent coronary artery 
bypass grafting to the left coronary system (LCS [boxes]) and the right coronary system 
(RCS [triangles]). Number of patients at risk is in parentheses; results are mean = standard 
error of the mean. 
fact, Chow et al reported that RIMA patency was similar to LIMA patency regardless of the 
coronary distribution to which the artery was grafted [108]. However, a “crossover” 
configuration for the RIMA places the RIMA-LAD graft at significant risk for injury during 
subsequent redo sternotomy (as potentially required for aortic valve replacement or other 
procedures). Consequently, when performing this procedure, we often apply a protective 
barrier to the mediastinum prior to sternal closure (Repel-CV, SyntheMed, Inc., Iselin, NJ, 
USA) and often reapproximate the thymic remnant to protect the RIMA-LAD graft [108].  
Therefore, the specific BIMA configuration doesn’t seem to affect MACE, graft patency, or 
morbidity/mortality outcomes [110]. Glineur et al evaluated BIMA grafting with both IMA 
grafts targeted to the left coronary system in either an in-situ or Y-graft configuration, noting 
equivalent patencies and other mid-term results. In addition, the T-graft configuration has 
been shown to be safe and effective in grafting multiple distal coronary targets [111].  
Most results with BIMA grafting are improved by harvesting the conduit as a “skeletonized” 
graft rather than as a pedicled graft, in which the accompanying mammary veins and 
surrounding chest wall muscle and fascia were mobilized along with the artery. Skeletonized 
IMA harvesting preserves sternal perfusion relative to pedicled IMA harvesting [112, 113]. As 
a result, skeletonized IMA harvesting is associated with reduced sternal wound complications 
and longer IMA graft length, allowing more distal coronary targets to be bypassed [Figure, 92, 
98, 100]. Skeletonized IMAs also have increased blood flow through the conduit [114], possible 
as the result of decreased spasm, since skeletonized IMA is typically accomplished without the 
need for electrocautery on the chest wall [100, 106, 115]. 
7. Radial artery 
Professor Alain Carpentier is credited with introducing the radial artery (RA) as an alternative 
conduit for CABG [116], but initial results with the RA were unfavorable, leading Carpentier 
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and others to abandon its use. Subsequently, several RA grafts were empirically observed to 
be patent at follow-up coronary angiography, leading to the concept’s reintroduction in the 
late 1980s [117]. Since then, the RA has since been widely used and aggressively investigated 
as a conduit option for CABG due to ease of use, availability in at least 90% of patients, good 
length allowing reach to any distal target for anastomosis, and it is amenable to concurrent 
harvesting methods (the IMA, SVG, and RA can be harvested simultaneously) [118]. 
Depending upon the details of RA grafting, including the target coronary bed and the 
proximal degree of coronary artery stenosis, long-term RA graft patency approaches 90% and 
can approximate that of pedicled IMA graft patencies [55, 119, 120]. 
Since most coronary grafting strategies employing RA grafts do so to evaluate alternatives 
to SVG conduits, numerous trials comparing RA with SVG for patency and long-term 
outcomes have been conducted recently [14, 78, 121-123]. In general, these data demonstrate 
equivalent or improved patency for the RA compared with SVG. One recent randomized 
controlled trial in the US Veterans Affairs system evaluated RA and SVG as coronary bypass 
grafts to the “best remaining recipient vessel,” with the primary end point of one-year 
angiographic patency [123]. These data demonstrated equivalent graft patencies for RA 
compared with SVG, but one-year patency for both groups approached 90% [123]. This is in 
line with many previous reports on early RA patency, and far exceeds other recent 
estimations of early graft SVG patency for [8-10]. In contrast, the Radial Artery Versus 
Saphenous Vein Patency (RSVP) trial compared 5-year graft patency for RA versus SVG 
when placed to circumflex coronary artery branches that were at least 70% stenotic [121]. 
These data demonstrated a significantly improved patency for RA grafts (98.3%) relative to 
SVG grafts (86.4%) [122].  
Perhaps the most recognized comparison of RA and SVG is provided by the Radial Artery 
Patency Study (RAPS), which randomized 561 patients at 13 centers (Canada, New Zealand) 
to receive a RA graft to the right coronary system or the circumflex coronary system [78]. 
Saphenous vein grafts were placed to the coronary system not receiving the RA graft, and 
all patients underwent LIMA-LAD grafting. One-year angiographic follow-up was 
performed in 440 patients and demonstrated significantly improved patency for RA grafts 
compared with SVG (91.8% vs. 86.4%, p = 0.009). However, angiographic “string sign” was 
significantly increased in RA grafts compared with SVG (7% vs. 0.9%, p = 0.001) [78]. It is 
unclear as to the long-term significance of this finding; as Carpentier originally noted, others 
have since reported that patency of the RA graft with a “string sign” may actually improve 
as the native disease worsens [124]. When patient characteristics and target vessel 
characteristics were considered in the interpretation of the RAPS data, RA grafts were 
protective of graft patency by multivariable analysis, while smaller distal targets, less 
proximal coronary artery stenosis, and diabetes were associated with reduced patency rates 
for SVG or RA grafts [125]. Graft occlusion was significantly more common among diabetics 
with SVG (19%) compared with RA grafts in diabetics (12%). In fact, RA grafting conferred 
even greater protection effect from graft occlusion was among diabetic patients than in the 
study cohort as a whole [125].  
Despite the positive comparisons of RA with SVG patency rates, it has been more difficult to 
ascribe improved clinical outcomes with RA versus SVG [126]. However, some data suggest 
that better long-term survival is seen in those receiving RA conduits as compared with SVG 
(Figure). Zacharias et al evaluated the influence of RA and SVG as a 2nd graft (all patients 
receiving LIMA-LAD) with regard to survival in 2 groups of 925 matched patients each [14]. 
6-year survival was improved in RA patients [14, Figure.].  
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and others to abandon its use. Subsequently, several RA grafts were empirically observed to 
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as a conduit option for CABG due to ease of use, availability in at least 90% of patients, good 
length allowing reach to any distal target for anastomosis, and it is amenable to concurrent 
harvesting methods (the IMA, SVG, and RA can be harvested simultaneously) [118]. 
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proximal degree of coronary artery stenosis, long-term RA graft patency approaches 90% and 
can approximate that of pedicled IMA graft patencies [55, 119, 120]. 
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to SVG conduits, numerous trials comparing RA with SVG for patency and long-term 
outcomes have been conducted recently [14, 78, 121-123]. In general, these data demonstrate 
equivalent or improved patency for the RA compared with SVG. One recent randomized 
controlled trial in the US Veterans Affairs system evaluated RA and SVG as coronary bypass 
grafts to the “best remaining recipient vessel,” with the primary end point of one-year 
angiographic patency [123]. These data demonstrated equivalent graft patencies for RA 
compared with SVG, but one-year patency for both groups approached 90% [123]. This is in 
line with many previous reports on early RA patency, and far exceeds other recent 
estimations of early graft SVG patency for [8-10]. In contrast, the Radial Artery Versus 
Saphenous Vein Patency (RSVP) trial compared 5-year graft patency for RA versus SVG 
when placed to circumflex coronary artery branches that were at least 70% stenotic [121]. 
These data demonstrated a significantly improved patency for RA grafts (98.3%) relative to 
SVG grafts (86.4%) [122].  
Perhaps the most recognized comparison of RA and SVG is provided by the Radial Artery 
Patency Study (RAPS), which randomized 561 patients at 13 centers (Canada, New Zealand) 
to receive a RA graft to the right coronary system or the circumflex coronary system [78]. 
Saphenous vein grafts were placed to the coronary system not receiving the RA graft, and 
all patients underwent LIMA-LAD grafting. One-year angiographic follow-up was 
performed in 440 patients and demonstrated significantly improved patency for RA grafts 
compared with SVG (91.8% vs. 86.4%, p = 0.009). However, angiographic “string sign” was 
significantly increased in RA grafts compared with SVG (7% vs. 0.9%, p = 0.001) [78]. It is 
unclear as to the long-term significance of this finding; as Carpentier originally noted, others 
have since reported that patency of the RA graft with a “string sign” may actually improve 
as the native disease worsens [124]. When patient characteristics and target vessel 
characteristics were considered in the interpretation of the RAPS data, RA grafts were 
protective of graft patency by multivariable analysis, while smaller distal targets, less 
proximal coronary artery stenosis, and diabetes were associated with reduced patency rates 
for SVG or RA grafts [125]. Graft occlusion was significantly more common among diabetics 
with SVG (19%) compared with RA grafts in diabetics (12%). In fact, RA grafting conferred 
even greater protection effect from graft occlusion was among diabetic patients than in the 
study cohort as a whole [125].  
Despite the positive comparisons of RA with SVG patency rates, it has been more difficult to 
ascribe improved clinical outcomes with RA versus SVG [126]. However, some data suggest 
that better long-term survival is seen in those receiving RA conduits as compared with SVG 
(Figure). Zacharias et al evaluated the influence of RA and SVG as a 2nd graft (all patients 
receiving LIMA-LAD) with regard to survival in 2 groups of 925 matched patients each [14]. 
6-year survival was improved in RA patients [14, Figure.].  
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Fig. 4.  
Similar data have been reported by Tranbaugh et al, who compared over 800 patients 
undergoing CABG utilizing LIMA, RA, and SVG with matched patients undergoing CABG 
with LIMA and SVG only [127]. They showed significantly improved survival in the RA 
group in addition to improved patency of RA as compared to SVG (81% vs. 47%) in 
symptomatic patients who subsequently underwent diagnostic angiography after CABG 
(mean time to repeat catheterization 4.3 years) [127]. Importantly, RA use emerged as 
independent predictor of survivalat 14 years when the data were assessed by multivariable 
analysis [127, Figure].  
 
 
Fig. 5. Comparison of Kaplan-Meier survival for propensity-matched patents (p - 0.0011, log 
rank test), CABG - coronary artery bypass graft surgery. 
Conduct of these well-designed trials incorporating angiographic follow-up of RA grafts has 
provided a wealth of insight into features important to successful RA grafting. For example, 
as noted, early graft failures in the form of “string sign” have been noted in randomized 
trials [78], and several explanations for this are possible. For example, RA grafts appear 
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notoriously susceptible to competitive flow within the native coronary circulation, as may 
occur when native coronary stenosis is not severe ( 70%) [128, 129]. Based on this frequent 
observation, use of the RA is not recommended as a conduit for CABG unless the native 
coronary artery stenosis is high grade ( 70%). This strategy has been associated with 
improved patency and reduced “string sign” in the RAPS study [78]. Radial artery graft 
patency is also dependent upon coronary target location, as has been noted for the RIMA 
graft [89]. For instance, Maniar et al found that grafts to the right coronary artery were more 
likely to be occluded compared with those placed to the LAD or to the circumflex coronary 
artery [129], which has been corroborated by others [130].  
Certain inherent, unique characteristics of the RA may also contribute to “string sign” 
formation [131]. Limb arteries such as the RA are known to be more prone to spasm than 
somatic (IMA) or splanchnic arteries [132]. One key difference between the IMA and the RA 
is that the RA is significantly more muscular, leading to increased tendency for spasm 
requiring prolonged vasodilation [133]. Vasodilation of the harvested RA should begin 
intraoperatively by exposing the conduit to papaverine or verapamil/nitroglycerin. 
Verapamil/nitroglycerin may be more effective than papaverine in regards to degree of 
vasodilation and preservation of endothelial function, which can be a problem with 
papaverine (especially if injected intraluminally) and with the alpha-blocking agent 
phenoxybenzamine [118]. Postoperatively, most authors have recommended vasodilation 
with calcium channel blocking agents or long-acting nitrates for at least one month after 
surgery. 
It is debated as to whether the proximal RA graft anastomosis should be performed to the 
ascending aorta or as a composite graft to other conduits. In a study of over 1,500 radial 
artery grafts, Maniar et al found no difference between these two types of grafting strategies 
[129]. Collins et al, reporting the results of the Radial Artery Versus Saphenous Vein Patency 
(RSVP) trial, demonstrated superior patency of RA grafts compared with SVG, and all 
proximal anastomoses were performed to the aorta directly [122]. Jung et al recently 
demonstrated using postoperative CT angiography that RA patency was better when the 
proximal anastomosis was made to the aorta and did not use the IMA as RA inflow [134]. 
However, Desai et al found that at one year, 21% of RA grafts going directly to the aorta had 
“some degree” of angiographic stenosis, which was significantly less than SVG proximal 
anastomoses [78]. 
Testing for appropriateness of RA harvesting to gauge the likelihood of hand ischemia after 
RA harvesting is recommended. The Modified Allen’s Test (MAT) is abnormal in wide 
ranges (<1% to 27%), often attributed to observer variability [135]. When MAT was 
compared with Doppler ultrasonography of the thumb artery, MAT was noted to have a 
sensitivity of 100% and specificity of 97% for thumb ischemia [136]. Various adjuncts to the 
MAT have been proposed, including pulse oximetry, plethysmography, and Doppler 
ultrasonography of the hand [136-138]. However, none of these modalities have been 
proven to add significantly to the diagnostic accuracy of a properly performed MAT, which 
appears to accurately and safely select patients for RA harvesting.  
Harvesting of the RA has been performed traditionally by the open, “no-touch” technique 
[127]. However, more recently, the trend appears to have shifted toward endoscopic RA 
harvesting with demonstrated functional and cosmetic advantages [139] and no increase in 
vasoreactivity or damaged endothelium [140]. However, harvesting the RA as a pedicle with 
harmonic scalpel appears to be less injurious than using electrocautery for tissue dissection 
[140]. Patency rates are similar regardless of method of harvesting [142]. 
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8. Summary 
Coronary artery bypass grafting remains one of the most frequently performed major 
operations worldwide. Even in the burgeoning era of percutaneous approaches to coronary 
heart disease, the indications for CABG continue to be based on relief of angina, prevention 
of myocardial damage from ischemic complications, and prolonged expected survival in 
select patients. In order to provide the best results for CABG patients, the surgeon’s chief 
focus should be on improved long-term outcomes. Based on the information available, the 
best long-term outcomes of CABG are achieved when incorporating a strategy of grafting 
with arterial conduits.  
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Denmark 
1. Introduction 
Conventional coronary artery by-pass grafting (CCABG) performed using cardioplegic 
arrest and cardiopulmonary by-pass is a very well documented treatment for ischemic heart 
disease. The operation often relieves chest pain and it improves survival for patients with 
triple- vessel disease and left main coronary artery disease. 
Since it was introduced in the late 1960´es, CCABG has become one of the most commonly 
performed operations. In 2007, an estimated 408.000 surgical coronary revascularizations 
were performed in the United States alone (1) 
Given the ageing populations in large parts of the world, CCABG is also increasingly being 
offered to elderly patients and to patients with co-morbidities. As a consequence, a 
significant number of operated patients suffer major or minor complications. Concerns have 
been raised that the use of cardiopulmonary by-pass (CPB) could cause neuro-cognitive 
dysfunction. Also, CPB has been linked to myocardial, renal and pulmonary damage. 
Several mechanisms have been suggested: Manipulation of the aorta during cannulation 
and clamping may cause dislodgment and embolization of atherosclerotic deposits, cardiac 
arrest may induce myocardial damage, and the long-lasting and repeated contact of blood 
with the non-biological surfaces of filters and tubing of the heart- lung- machine induce 
mechanical wearing of the formed elements and biochemical over-activation of the immune- 
and coagulation systems 
Development of the Off-pump Coronary Artery By-pass (OPCAB) technique has been 
driven by concerns of these possible side-effects from CPB. On the other hand, concerns 
have been raised about whether the quality of anastomoses constructed “on the beating 
heart” - i.e. without cardiopulmonary by-pass and cardioplegic arrest – would be as good 
as that of the anastomoses performed during CCABG. The question remains controversial. 
Best estimates of the proportion of surgical coronary revascularizations performed as 
OPCAB in the United States is around 25%. Some surgical centres perform almost all 
coronary by-pass operations off-pump, while others hardly or never use this technique. 
Tradition and economy dictate that OPCAB is the preferred method in some parts of the 
developing world. In the beginning of the OPCAB-experience, evidence was limited to 
small, published series by individual surgeons (2-3). Although seemingly providing good 
results, these observations were hampered by the lack of a control group. Later studies 
from databases were difficult to interpret because the original intention-to-treat was not 
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1. Introduction 
Conventional coronary artery by-pass grafting (CCABG) performed using cardioplegic 
arrest and cardiopulmonary by-pass is a very well documented treatment for ischemic heart 
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Since it was introduced in the late 1960´es, CCABG has become one of the most commonly 
performed operations. In 2007, an estimated 408.000 surgical coronary revascularizations 
were performed in the United States alone (1) 
Given the ageing populations in large parts of the world, CCABG is also increasingly being 
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significant number of operated patients suffer major or minor complications. Concerns have 
been raised that the use of cardiopulmonary by-pass (CPB) could cause neuro-cognitive 
dysfunction. Also, CPB has been linked to myocardial, renal and pulmonary damage. 
Several mechanisms have been suggested: Manipulation of the aorta during cannulation 
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arrest may induce myocardial damage, and the long-lasting and repeated contact of blood 
with the non-biological surfaces of filters and tubing of the heart- lung- machine induce 
mechanical wearing of the formed elements and biochemical over-activation of the immune- 
and coagulation systems 
Development of the Off-pump Coronary Artery By-pass (OPCAB) technique has been 
driven by concerns of these possible side-effects from CPB. On the other hand, concerns 
have been raised about whether the quality of anastomoses constructed “on the beating 
heart” - i.e. without cardiopulmonary by-pass and cardioplegic arrest – would be as good 
as that of the anastomoses performed during CCABG. The question remains controversial. 
Best estimates of the proportion of surgical coronary revascularizations performed as 
OPCAB in the United States is around 25%. Some surgical centres perform almost all 
coronary by-pass operations off-pump, while others hardly or never use this technique. 
Tradition and economy dictate that OPCAB is the preferred method in some parts of the 
developing world. In the beginning of the OPCAB-experience, evidence was limited to 
small, published series by individual surgeons (2-3). Although seemingly providing good 
results, these observations were hampered by the lack of a control group. Later studies 
from databases were difficult to interpret because the original intention-to-treat was not 
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recorded. This may have caused high-risk patients to be moved from one treatment group 
to the other (4-5). 
From the late 1990ies to 2002 a significant technical development in stabilizing equipment 
led to a fast rise in the number of OPCAB procedures. From 2002 results from the first 
randomized studies failed to show a clear benefit and interest has cooled somewhat. A 
significant number of randomized studies have been conducted comparing very different 
end-points after OPCAB and CCABG. This chapter aims to review the results of these 
studies to assess the comparative effectiveness and safety of the two techniques.  
2. Methods 
Searching MEDLINE and Cochrane library using the terms » OPCAB «, » off-pump «, » 
offpump « OR »MIDCAB«, limited to English language june 23rd, 2010, provided 4788 
abstracts that were read manually to find randomized, controlled trials. Two-hundred and 
twenty nine papers were retrieved and read before 90 papers, reporting results from 61 
individual randomized, controlled trials, were identified. 
3. Results 
3.1 Effectiveness 
Long term survival 
The comparative long-term survival of OPCAB and CCABG is not well evaluated. The 
longest follow-up is in the OCTOPUS-study (6). Five years postoperatively 130/142 
OPCAB-patients and 130/139 CCABG patients were alive (p=ns). Other studies with up to 
twelve months follow-up also failed to show any difference (7-13). Due to the relatively low 
risk of mortality associated with either operation, however, the statistical strength to detect 
any difference is not present in any of these studies. 
 The largest randomized study, the ROOBY-trial (14) showed a trend towards higher 
mortality in the OPCAB group at one year follow-up (4.1% vs. 2.9%, p=0.15) and a 
significant difference in cardiac deaths only (2.7% vs. 1.3%, p=0.03). On the other hand, 
another study with a mean 3.8 years follow-up of 300 patients showed a trend in the 
opposite direction with 5 deaths in the OPCAB-group and 10 in the CCABG-group (15).  
Graft patency 
Even with the use of contemporary cardiac stabilizers and intracoronary shunts, OPCAB 
remains more technically challenging than CCABG. Difficulties with positioning the heart 
may cause the surgeon to graft a less favourable part of the coronary artery. Performing the 
anastomosis is more difficult and may lead to stenosis at the anastomosis site. Furthermore, 
the coagulability of blood is increased after OPCAB compared to CCABG (16-20). Hence, a 
serious concern when introducing the OPCAB technique has been whether the number and 
quality of the grafts would be equivalent to what could be achieved using CPB. 
In the vast majority of randomized, controlled trials, the OPCAB-patients tended to receive a 
lower number of grafts than the patients operated using CPB. In the largest studies and in a 
meta-analysis this difference was statistically significant (13-14, 21, 22) with a mean 
difference of 0.1-0.3 grafts. Several studies compared the number of grafts compared to a 
preoperative plan. In most of these studies, no difference was found (8-9,12, 14, 23), a few 
studies showed a difference in favour of CCABG, and one study found a difference in 
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favour of OPCAB (24). In this study, however, the absolute number of grafts was 0.2 lower 
in the OPCAB-group. 
Allmost all of the earlier studies showed a trend towards poorer graft patency in OPCAB 
patients. A single, smaller study found this difference to be statistically significant (25). Also, 
the proportion of patent grafts in the largest study, the ROOBY-trial, was 82.6% in the 
OPCAB group and 87.8% in the CCABG group (p<0.01) (14). This difference, however, did 
not result in a higher number of myocardial infarctions in the OPCAB group. 
In studies performed by few, dedicated OPCAB surgeons, the difference in number of grafts 
was very small and not statistically significant (12, 24). The study by Khan (25), the SMART 
study (14), and the Best Bypass Surgery Study (26) differentiated the findings and found a 
higher proportion of occluded grafts at right and circumflex territories and fewer occlusions 
in the LAD territory. Lingaas et al only found differences in graft patency between OPCAB 
and CCABG to be significantly different when comparing vein grafts as opposed to internal 
mammary artery grafts (10). 
Recurrent or persistent chest pain 
An important parameter is freedom from chest pain. In the Octopus trial (6, 24), 89.0% 
experienced freedom from chest pain in the OPCAB group compared to 89.3% in the 
CCABG-group (p=ns). At five years follow-up, these numbers were down to 82.3% and 
87.7%, respectively (p=ns). At one year follow-up, ergometer testing was performed in 81% 
of the patients. It was found to be negative in 79.8% of CCABG patients and 83.1% of 
OPCAB patients (p=ns). In the SMART-study, chest pain was present at one-year follow-up 
in 0% of CCABG and 3% of OPCAB patients, respectively (p=ns) (12). In a separate 
publication, using a specific questionnaire on chest pain in the 400 patients involved in the 
BHACAS1 and BHACAS2-studies, no difference was found after a median follow-up of 
three years (27). 
Reintervention 
Given the lower number of patent grafts in the OPCAB groups, a greater need for coronary 
re-intervention might be expected. Only few of the published trials have had long enough 
follow-up for this question to be evaluated. In the BHACAS-1 study, three percent of both 
OPCAB and CCABG patients had had a reintervention – either percutaneous or surgical – 
within a median three years follow-up (7). The longest follow-up, which was published by 
the Octopus trialists, reported 7.7% of OPCAB-patients and 5% of CCABG patients to have 
undergone reintervention after five years (6). In the ROOBY-trial, the proportion 
undergoing reintervention was 4.6% in the OPCAB group and 3.4% in the CCABG group at 
one year follow-up. Neither individual studies nor metanalyses found thiese differences to 
be statistically significant (21, 26).   
Quality of life 
A number of studies compare self-reported, health related quality of life after OPCAB and 
CCABG. Medical Outcomes Study-Short Form 36 (MOS SF-36) is the most commonly used 
tool. In this questionnaire eight scales cover physical, mental, and social well-being (28). One 
study found a significantly higher score among CCABG-patients in one of the eight scales 
(“Role emotional”) in contrast to another study who favoured OPCAB patients in the 
dimension “Social Relationships”, using another questionnaire (29,30). In general, few 
significant inter-group differences have been found, given the multiple tests being 
performed.  
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On the other hand, a significant increase in self-reported, health related quality of life is 




Most of the randomized trials have included either consecutive patients or patients with low 
perioperative risk due to young age, few comorbidities, and need for relatively few grafts. 
The expected operative mortality for this group of patients is too low for any of the 
randomized trials to have sufficient statistical strength to detect a difference between 
treatment groups. This is also true for metaanalyses of randomized trials. 
Among the larger non-randomized studies, Cleveland et al. analyzed data from the Society 
of Thoracic Surgeons (STS) database (4). They included operations performed in 1998 and 
1999 in 126 centers with experience in OPCAB surgery. A total of 118.140 CCABG and 
11.717 OPCAB procedures were included. The risk adjusted mortality in this comparison 
was 2.94% in the CCABG group and 2.32% in the OPCAB group (p < 0.0001). Magee and co-
workers compared the results of 6.466 CCABG and 1.983 OPCAB procedures in two 
American centres in 1998-2000 (5). In spite of a significantly higher preoperative morbidity 
in the OPCAB-group, mortality in the OPCAB group was 1.8% against 3.5% in the CCABG-
group (p = 0.002). However, these comparisons were not performed according to the 
principle of intention–to-treat. This is a significant drawback, since patients who were 
converted to CCABG during the operation after initially attempting to perform OPCAB are 
analyzed as belonging to the CCABG group. Hence, the complications of the most 
complicated OPCAB-procedures were exported to the CCABG-group.  
It is worth noting that one of the few randomized studies that specifically included high-risk 
patients who received an acute operation, found a significantly higher mortality in the 
CCABG group than in the OPCAB group (7.7% vs. 1.6%, p=0.04) (32). However, this study 
exclusively included patients who only needed grafting the LAD territory, which would be 
expected to favour OPCAB. 
3.3 Other cardiac complications 
Myocardial damage 
None of the randomized studies or meta-analyses has documented any significant difference 
in the incidence of clinical peri-operative myocardial infarction. However, many randomized 
studies provide evidence of a lower, subclinical release of biochemical markers of myocardial 
damage among patient operated using OPCAB (12, 25, 32-42). This tendency is very robust 
across the different studies, and it is even preset in a study that showed a significantly higher 
proportion of graft occlusions in the OPCAB group (25). These differences are ascribed to 
ischemia and reperfusion with cardioplegia. Apart from creatinine-kinase type B (CK-MB) and 
Troponine T, also atrial natriuretic peptide and heart type fatty-acid binding protein tend to 
exhibit a higher raise after CCABG than after OPCAB (36). All of these differences, are, 
however in an order of magnitude smaller than what has so far been considered clinically 
relevant. By detailed measurement of left ventricular ejection fraction between groups, no 
inter-group differences were found (42). On the other hand, the long term follow-up of the 
OCTOPUS-study showed that the patients with the highest release of CK-MB had the highest 
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risk of experiencing a clinical myocardial infarction during the following year (43). A number 
of confounding issues may, however, be relevant. 
In a study of myocardial biopsies, it was found that the concentration of reduced glutathion 
recovered more rapidly in CCABG than OPCAB patients (38). For the OPCAB-operations, a 
proximal snare was used for occlusion of the vessel while performing the anastomosis. This 
finding suggests that cardioplegia is better tolerated than occlusion. Still, a higher increase in 
CK-MB was found in the CCABG-group. Together, these findings suggest that the 
myocardium in the territory of the occluded vessel suffers more from occlusion but a less 
profound damage to the entire myocardium is caused by ischemia and reperfusion. Which of 
these two situations pose the largest threat to heart function is not clear. Gadolinium contrast 
enhanced magnetic resonance perfusion imaging, reflecting permanent damage to the 
myocardium, failed to detect a difference between treatment groups despite a higher release of 
Troponine- I in the CCABG-group (39). On this background, it was speculated whether some 
of the Troponine leak represented protein release from non-structurally bound cytosolic pools, 
rather than true myocardial necrosis. In another study, micro-dialysis was used to sample 
myocardial interstitial fluid during and after surgery (44). More abnormal values were found 
during CCABG than during OPCAB. It was not stated in the paper whether samples were 
taken within or outside the area of the temporally occluded vessel during OPCAB. 
Atrial fibrillation 
In the BHACAS-1 study, Heart rate and rhythm were continuously monitored for 72 
postoperative hours. The incidence of postoperative atrial fibrillation was found to be 45% 
among CCABG patients as compared to 8% among patients operated with OPCAB (p<0.001) 
(45). A large number of  later studies, including the BHACAS-2 study, have confirmed this 
tendency but with a much smaller difference between groups. The tendency is statistically 
significant in some of these studies and in meta-analyses (21). 
Postoperative inotropic support and low cardiac output syndrome 
Need for inotropic drugs after the operation may reflect either transient or permanent heart 
failure. Several, larger studies do not report this end-point (13-14), but among the ones that 
do, there is a trend towards a higher incidence in patients operated using cardiopulmonary 
by-pass. A meta-analysis of 16 studies including 1655 patients found a need for inotropic 
support postoperatively in 23.6% of CCABG and 15.1% of OPCAB patients (p=0.04)(21). 
Other studies report the incidence of “low cardiac output syndrome”, defined as need for 
intra-aortic balloon pump, need for inotropic drugs or pressor drugs. One of the larger 
studies reports a significant difference (12), while others do not (13, 46). 
3.4 Neurological complications 
Stroke 
Theoretically, the use of cardiopulmonary by-pass may cause stroke by a number of 
different mechanisms. These include the manipulation of the ascending aorta for 
cannulation and clamping, gaseous or particulate emboli formed in the by-pass circuit, and 
accidental interruption of flow. 
Also, post-operative atrial fibrillation may cause strokes in spite of adequate antithrombotic 
treatment. For these reasons, an important argument for favouring OPCAB has been the 
intention to reduce the rate of peri-operative strokes.  
In low risk patients, the risk of suffering a peri-operative stroke is between 1 and 1.5%. 
Hence, none of the individual, randomized, controlled trials have had the statistical strength 
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intention to reduce the rate of peri-operative strokes.  
In low risk patients, the risk of suffering a peri-operative stroke is between 1 and 1.5%. 
Hence, none of the individual, randomized, controlled trials have had the statistical strength 
 
Special Topics in Cardiac Surgery 
 
170 
to prove a difference. A single meta-analysis only just managed to show a significant 
difference (47), but other analyses, comprising just as many or more trials and patients, 
failed to prove OPCAB superior (21). Therefore, until the time of the publication of the 
ROOBY-trial (14), evidence was ambiguous. In the ROOBY trial, however, the trend was 
opposite that of most earlier studies with 1.3% strokes in the OPCAB-group and 0.7% in the 
CCABG-group (p=0.28). In view of the large volume of this trial compared to all the other 
trials, it can no longer be stated that there is a clear trend in favour of OPCAB to reduce the 
rate of peri-operative strokes in younger, low-risk patients. It is, however, worth noting, that 
the OPCAB technique is still being developed in order to reduce stroke rate. An increasing 
number of surgeons favour a “no-touch-aorta” technique, placing proximal anastomoses 
end-to-side in a mammary artery graft rather than on the aorta itself. In addition, some 
centers aim to reduce the risk of embolisation due to atrial fibrillation by ligating the left 
atrial appendage. Excellent results have been produced, but not tested in randomized trials. 
Neurocognitive dysfunction 
Several randomized trials have used neuro-psychological or neuro-cognitive tests to detect 
perioperative cerebral damage lesser than overt stroke. In some of these studies, early 
postoperative testing favoured OPCAB (48-49) while others found no significant difference 
(50-53). Zamvar and coworkers, only including patients with triple-vessel disease, performed a 
battery of neuro-cognitive tests one week and ten weeks postoperatively, comparing with pre-
operative test results. At both occasions, they found a significantly higher degree of neuro-
cognitive dysfunction in CCABG-patients than in OPCAB-patients (54). 
In the Octopus trial (6, 41, 49), a significant  difference in favour of OPCAB was found after 
three months but not after one year nor after five years of follow-up. At five years follow-up, 
a more than fifty per cent decline in scores at neuro-cognitive testing was found in both 
groups, illustrating the fact that patients with ischemic heart disease in general have an 
increased risk of neurocognitive decline. A similar decline has been documented after three 
years in a non- surgical control group (55). 
Surrogate end-points of brain damage are often used in randomized trials comparing 
OPCAB with CCABG. These include release of the S-100 peptide and detection of High 
Intensity Transcranial Doppler Signals (HITS) as well as changes in serum concentrations of 
different hormones. 
When S-100 is detected in peripheral blood, it is seen as a marker of damage to, and 
increased permeability of, the blood-brain barrier. There is good evidence from randomized 
controlled trials that the increase of S-100 is higher after CCABG than after OPCAB  (48, 51, 
56). In two out of three studies these increases are compared to the results of postoperative, 
neurocognitive tests, but none of the studies showed any correlation between S-100 levels 
and neurocognitive function. In one of the studies one patient suffered a major stroke 
resulting in paralysis of an arm and a leg without a major increase in blood concentrations 
of S-100. Hence, the clinical significance of relase of S-100 is uncertain. 
Characteristic high-intensity signals – HITS - can be detected by trans-cranial measurement 
of Doppler signals from the medial cerebral artery. The amount of HITS increase during 
manipulation of the aorta, especially during cannulation, clamping, and declamping. A 
lower number of HITS are observed at the beginning of cardiopulmonary by-pass. It is not 
clear, to what extent HITS represent particulate emboli being released from vessel walls, 
tubes or filters and what proportion of HITS are being generated by gaseous microemboli 
and turbulence. Several studies have demonstrated a larger amount of HITS in patients 
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undergoing CCABG than in patients undergoing OPCAB (48, 53). One study showed a 
correlation between the number of HITS detected in the CCABG-group and the results of 
one out of three neurocognitive tests. This correlation, however, according to a figure in the 
publication, relies heavily on the results from one patient (48). No correlation was found 
with the results of any of the other two tests nor, in the OPCAB group,  between the number 
of HITS and the results of any of the three tests. In a larger study, a lower neuro-cognitive 
score was found at discharge from hospital in patients who had undergone CCABG 
compared to patients operated with OPCAB-tecghnique (53). This difference was not found 
at six weeks and six months follow-up and no correlation was found between number of 
HITS and postoperative cognitive function.  
To summarize, there is strong evidence of more HITS when performing CCABG than 
OPCAB. There is, however, no evidence that these HITS represent emboli or that they have 
any significance with regard to early or late postoperative cognitive dysfunction. 
In another study, cerebral SPECT-scans revealed more evidence of microemboli after CCABG 
than after OPCAB (50). However, like in the case of HITS and S-100 release, this finding could 
not be shown to correlate with the performance of patients in neuro-cognitive tests. 
One study suggests that changes in neuro-cognitive function and tendency to mental 
depression after both CCABG and OPCAB are related to disturbance of the circadian rhytms 
of cortisol and melatonine release (57). These disturbances are, though, also susceptible to 
other factors and they occur after both types of procedures. The clinical significance of this 
finding is not clear.  
3.5 Renal function 
Transient or permanent renal impairment are well known complications to cardiac surgery 
(58). This risk has be attributed to the systemic, inflammatory response, hypoperfusion of 
the kidneys during operation and, possibly, the non-pulsatile nature of flow during 
cardiopulmonary by-pass (59). 
Clinically significant, new onset renal failure – defined either as need for dialysis or by 
increase in biochemical markers to pathological levels – occur at a rate of approximately 1-2 
per cent of the low-risk patients typically included in randomized, controlled trials. None of 
these studies have, therefore, had the statistical strength to detect a difference in the 
incidence of this end-point between patients operated with OPCAB or CCABG. Even in a 
large meta-analysis by Cheng et al (21) showing an odds ratio of 0.58 in favour of OPCAB 
the confidence limits were too wide to allow statistical significance. 
On the other hand, when comparing biochemical markers of sub-clinical renal damage, 
evidence from several clinical trials is in favour of OPCAB (11, 60-61). This difference is clear 
whether glomerular or tubular damage is compared (60). In one study, the difference between 
creatinine clearance after CCABG compared to OPCAB was especially high in patients with 
diabetes, hypertension and heart failure (11). In one trial, comparing patients operated using 
pulsatile flow in the cardiopulmonary by-pass circuit, no difference in postoperative renal 
function was found between patients operated with OPCAB and CCABG. This finding seems 
to confirm the theory that non-pulsatile flow contributes to the subclinical renal impairment 
often seen after cardiac surgery using cardiopulmonary by-pass (61). 
3.6 Lung function 
During cardiopulmonary by-pass, ventilation is commonly stopped to prevent the motion of 
the lungs interfering with surgery. During the early postoperative period patients who have 
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undergoing CCABG than in patients undergoing OPCAB (48, 53). One study showed a 
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one out of three neurocognitive tests. This correlation, however, according to a figure in the 
publication, relies heavily on the results from one patient (48). No correlation was found 
with the results of any of the other two tests nor, in the OPCAB group,  between the number 
of HITS and the results of any of the three tests. In a larger study, a lower neuro-cognitive 
score was found at discharge from hospital in patients who had undergone CCABG 
compared to patients operated with OPCAB-tecghnique (53). This difference was not found 
at six weeks and six months follow-up and no correlation was found between number of 
HITS and postoperative cognitive function.  
To summarize, there is strong evidence of more HITS when performing CCABG than 
OPCAB. There is, however, no evidence that these HITS represent emboli or that they have 
any significance with regard to early or late postoperative cognitive dysfunction. 
In another study, cerebral SPECT-scans revealed more evidence of microemboli after CCABG 
than after OPCAB (50). However, like in the case of HITS and S-100 release, this finding could 
not be shown to correlate with the performance of patients in neuro-cognitive tests. 
One study suggests that changes in neuro-cognitive function and tendency to mental 
depression after both CCABG and OPCAB are related to disturbance of the circadian rhytms 
of cortisol and melatonine release (57). These disturbances are, though, also susceptible to 
other factors and they occur after both types of procedures. The clinical significance of this 
finding is not clear.  
3.5 Renal function 
Transient or permanent renal impairment are well known complications to cardiac surgery 
(58). This risk has be attributed to the systemic, inflammatory response, hypoperfusion of 
the kidneys during operation and, possibly, the non-pulsatile nature of flow during 
cardiopulmonary by-pass (59). 
Clinically significant, new onset renal failure – defined either as need for dialysis or by 
increase in biochemical markers to pathological levels – occur at a rate of approximately 1-2 
per cent of the low-risk patients typically included in randomized, controlled trials. None of 
these studies have, therefore, had the statistical strength to detect a difference in the 
incidence of this end-point between patients operated with OPCAB or CCABG. Even in a 
large meta-analysis by Cheng et al (21) showing an odds ratio of 0.58 in favour of OPCAB 
the confidence limits were too wide to allow statistical significance. 
On the other hand, when comparing biochemical markers of sub-clinical renal damage, 
evidence from several clinical trials is in favour of OPCAB (11, 60-61). This difference is clear 
whether glomerular or tubular damage is compared (60). In one study, the difference between 
creatinine clearance after CCABG compared to OPCAB was especially high in patients with 
diabetes, hypertension and heart failure (11). In one trial, comparing patients operated using 
pulsatile flow in the cardiopulmonary by-pass circuit, no difference in postoperative renal 
function was found between patients operated with OPCAB and CCABG. This finding seems 
to confirm the theory that non-pulsatile flow contributes to the subclinical renal impairment 
often seen after cardiac surgery using cardiopulmonary by-pass (61). 
3.6 Lung function 
During cardiopulmonary by-pass, ventilation is commonly stopped to prevent the motion of 
the lungs interfering with surgery. During the early postoperative period patients who have 
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undergone cardiac surgery are prone to develop atelectasis. Theoretically, this may be 
prevented by OPCAB where the lungs are continuously ventilated. 
Most of the authors addressing this question, found that postoperative ventilation times were 
longer for patients who underwent CCABG than for those who underwent OPCAB. There is 
good evidence from a meta-analysis for a lower incidence of chest infections and shorter 
postoperative need for ventilator assistance after OPCAB (21), although one study of low-risk 
patients contradicts this finding (23). Most of these studies may be biased by the fact that the 
staff members deciding the time when the patients should be weaned from the ventilator were 
not blinded with regard to the type of operation that had been performed. On the other hand, 
evidence is strengthened by the fact that the one study in which the staff was indeed blinded 
also found a shorter postoperative need of ventilation in the OPCAB group (12). 
In two trials, patients with chronic obstructive pulmonary disease were studied specifically. 
In one of these studies, a significantly higher postoperative decrease in lung function was 
found among post-CCABG patients (62). In the other study, a shorter time to extubation and 
shorter stay in intensive care unit was found among OPCAB patients (63). Also, in a study 
of patients with recent myocardial infarction, a shorter ventilation time was documented for 
OPCAB-patients compared to CCABG-patients (32). 
It has been suggested, that the mechanism behind impaired lung function after CCABG was 
changes in alveolar gas exchange as a result of increased interstitial oedema. This effect has, 
however, been specifically addressed by several studies finding that this effect is 
comparable in OPCAB and CCABG-patients and most significant during the first few 
postoperative hours (23, 42, 64-65).In a randomized comparison of patients with single- and 
double-vessel disease, a significantly higher veno-arterial shunting was found after cardio-
pulmonary by-pass (23). It is still unknown whether this result can be generalized to 
patients with triple vessel disease where the OPCAB-technique is complicated by the need 
to manipulate the heart. 
3.7 Gastro-intestinal complications 
There is evidence from a single, large, randomized trial that the risk of gastro-intestinal 
complications - including ischaemic bowel, hepatic failure, gastric bleeding, perforated 
duodenal ulcer, acute cholecystitis, and acute pancreatitis - is higher after CCABG than after 
OPCAB (66). This study, however, excluded patients needing grafts to the circumflex 
territory. This selection can be expected to favour OPCAB. Other, larger, randomized trials 
either do not find this difference or do not report this endpoint (6-7, 12-14). 
3.8 Inflammatory response 
A generalized inflammatory response is activated by any sort of surgery, but is aggravated 
by cardio-pulmonary by-pass. The blood–air interface and the contact between the blood 
and the artificial surfaces of the CPB circuit play important roles. Cooling and heating as 
well as ischemia and reperfusion of the myocardium are other factors that tend to activate a 
systemic inflammatory response.  
The inflammatory response includes both humoral and cellular elements. Randomized 
comparisons between CCABG and OPCAB shows the CCABG patients to have increased 
serum-levels of a multitude of different substances including tumor necrosis factor-alpha, 
interleukins 6 and 8, selectin, c-reactive protein, intracellular adhesion molecule – 1, and 
vascular endothelial growth factor (39,67-72). Also, the expression of a scavenger molecule 
on monocytes is significantly higher in “on-pump” patients (73). It has been proposed that 
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this inflammatory over-activation can be harmful and lead to organ failure and infections. 
No definitive coupling has, however been made in coronary artery by-pass patients between 
inflammatory markers and clinical outcome.  
Similarly, oxidative stress is known to be higher in patients undergoing cardiopulmonary 
by-pass. Theoretically, this may cause tissue damage, but no practical clinical consequence 
has been proven in patients (74). 
3.9 Blood loss and coagulation 
Transfusions have been shown to be associated with substantial incremental increases in 
risks of mortality and morbidity for patients undergoing cardiac surgery. There is good 
evidence from a number of large, randomized trials that blood loss and need for 
transfusions is lower after OPCAB than after CCABG (7,15, 24, 45, 74-76). This finding is 
often explained by the activation and subsequent deactivation of platelets and humoral 
coagulation factors by the non-biological surfaces of the cardiopulmonary by-pass circuit. 
The alpha granules of the platelets are being depleted and the platelet count is reduced by 
dilution. Also fibrinolytic cascades are activated. 
Some characteristics of the study protocols may, however, influence these results. Typically, 
different protocols for heparinization and reversion with protamine are used for the study 
groups, increasing bleeding tendency in the CCABG-groups. In addition, some studies 
apply a fixed value of haematocrit as an indication for transfusion. Because of dilution 
caused by the priming volume of the cardiopulmonary by-pass circuit this will increase the 
risk of transfusion in the CCABG-group compared to the OPCAB-group, even if this 
dilution were better treated using diuretics. 
3.10 Cost-effectiveness 
Some of the clinical trials have covered heath economic analyses up to twelve months after 
surgery. All these studies find OPCAB to be less costly while providing a similar gain of 
Quality Adjusted Life Years (12-13, 24, 29, 50). As an example, the Octopus study (24) found 
costs of OPCAB to be $13.069 versus $14.908 (P<0,01) at one year follow up for a one year 
QALY of 0,83 in the CCABG group versus 0,82 in the OPCAB group. Long term data on 
health economics are not available.  
4. Summary 
In conclusion, this review of currently published randomized controlled trials comparing 
outcomes after OPCAB and CCABG resulted in the following findings: 
- There is no strong evidence that one treatment is superior with regard to preventing 
death from any cause, chest pain or reintervention for ischemia. There is evidence from 
one large, well performed study that the risk of cardiovascular death is higher at one 
year follow-up after OPCAB compared to CCABG. There is some evidence from large 
trials that patients undergoing OPCAB receive fewer grafts than patients undergoing 
CCABG, but this tendency is very small in studies performed in centres with a large 
experience in OPCAB. There is strong evidence that graft patency is lower after 
OPCAB, but not in very experienced centres. 
- There is no evidence of a difference in peri-operative risk of mortality between the two 
treatments. There is strong evidence of a larger release of biochemical markers of 
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undergone cardiac surgery are prone to develop atelectasis. Theoretically, this may be 
prevented by OPCAB where the lungs are continuously ventilated. 
Most of the authors addressing this question, found that postoperative ventilation times were 
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good evidence from a meta-analysis for a lower incidence of chest infections and shorter 
postoperative need for ventilator assistance after OPCAB (21), although one study of low-risk 
patients contradicts this finding (23). Most of these studies may be biased by the fact that the 
staff members deciding the time when the patients should be weaned from the ventilator were 
not blinded with regard to the type of operation that had been performed. On the other hand, 
evidence is strengthened by the fact that the one study in which the staff was indeed blinded 
also found a shorter postoperative need of ventilation in the OPCAB group (12). 
In two trials, patients with chronic obstructive pulmonary disease were studied specifically. 
In one of these studies, a significantly higher postoperative decrease in lung function was 
found among post-CCABG patients (62). In the other study, a shorter time to extubation and 
shorter stay in intensive care unit was found among OPCAB patients (63). Also, in a study 
of patients with recent myocardial infarction, a shorter ventilation time was documented for 
OPCAB-patients compared to CCABG-patients (32). 
It has been suggested, that the mechanism behind impaired lung function after CCABG was 
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comparable in OPCAB and CCABG-patients and most significant during the first few 
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double-vessel disease, a significantly higher veno-arterial shunting was found after cardio-
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patients with triple vessel disease where the OPCAB-technique is complicated by the need 
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OPCAB (66). This study, however, excluded patients needing grafts to the circumflex 
territory. This selection can be expected to favour OPCAB. Other, larger, randomized trials 
either do not find this difference or do not report this endpoint (6-7, 12-14). 
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A generalized inflammatory response is activated by any sort of surgery, but is aggravated 
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well as ischemia and reperfusion of the myocardium are other factors that tend to activate a 
systemic inflammatory response.  
The inflammatory response includes both humoral and cellular elements. Randomized 
comparisons between CCABG and OPCAB shows the CCABG patients to have increased 
serum-levels of a multitude of different substances including tumor necrosis factor-alpha, 
interleukins 6 and 8, selectin, c-reactive protein, intracellular adhesion molecule – 1, and 
vascular endothelial growth factor (39,67-72). Also, the expression of a scavenger molecule 
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this inflammatory over-activation can be harmful and lead to organ failure and infections. 
No definitive coupling has, however been made in coronary artery by-pass patients between 
inflammatory markers and clinical outcome.  
Similarly, oxidative stress is known to be higher in patients undergoing cardiopulmonary 
by-pass. Theoretically, this may cause tissue damage, but no practical clinical consequence 
has been proven in patients (74). 
3.9 Blood loss and coagulation 
Transfusions have been shown to be associated with substantial incremental increases in 
risks of mortality and morbidity for patients undergoing cardiac surgery. There is good 
evidence from a number of large, randomized trials that blood loss and need for 
transfusions is lower after OPCAB than after CCABG (7,15, 24, 45, 74-76). This finding is 
often explained by the activation and subsequent deactivation of platelets and humoral 
coagulation factors by the non-biological surfaces of the cardiopulmonary by-pass circuit. 
The alpha granules of the platelets are being depleted and the platelet count is reduced by 
dilution. Also fibrinolytic cascades are activated. 
Some characteristics of the study protocols may, however, influence these results. Typically, 
different protocols for heparinization and reversion with protamine are used for the study 
groups, increasing bleeding tendency in the CCABG-groups. In addition, some studies 
apply a fixed value of haematocrit as an indication for transfusion. Because of dilution 
caused by the priming volume of the cardiopulmonary by-pass circuit this will increase the 
risk of transfusion in the CCABG-group compared to the OPCAB-group, even if this 
dilution were better treated using diuretics. 
3.10 Cost-effectiveness 
Some of the clinical trials have covered heath economic analyses up to twelve months after 
surgery. All these studies find OPCAB to be less costly while providing a similar gain of 
Quality Adjusted Life Years (12-13, 24, 29, 50). As an example, the Octopus study (24) found 
costs of OPCAB to be $13.069 versus $14.908 (P<0,01) at one year follow up for a one year 
QALY of 0,83 in the CCABG group versus 0,82 in the OPCAB group. Long term data on 
health economics are not available.  
4. Summary 
In conclusion, this review of currently published randomized controlled trials comparing 
outcomes after OPCAB and CCABG resulted in the following findings: 
- There is no strong evidence that one treatment is superior with regard to preventing 
death from any cause, chest pain or reintervention for ischemia. There is evidence from 
one large, well performed study that the risk of cardiovascular death is higher at one 
year follow-up after OPCAB compared to CCABG. There is some evidence from large 
trials that patients undergoing OPCAB receive fewer grafts than patients undergoing 
CCABG, but this tendency is very small in studies performed in centres with a large 
experience in OPCAB. There is strong evidence that graft patency is lower after 
OPCAB, but not in very experienced centres. 
- There is no evidence of a difference in peri-operative risk of mortality between the two 
treatments. There is strong evidence of a larger release of biochemical markers of 
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myocardial injury and of increased incidence of atrial fibrillation after CCABG but no 
difference in the incidence of clinically important myocardial infarctions. 
There is conflicting evidence of increased need of inotropic or pressor drugs and of 
intra-aortic balloon pump after CCABG. There is strong evidence of increased release of 
biochemical markers of renal insufficiency after CCABG but not of postoperative need 
of dialysis.  
There is conflicting evidence of differences in incidence of perioperative stroke. Limited 
evidence suggests that neuro-cognitive dysfunction is larger early after CCABG than 
after OPCAB. However, no difference is detected later than three months after the 
operation. 
There is strong evidence of fewer chest infections and shorter ventilation times after 
OPCAB. Risk of peri-operative bleeding and need for transfusions is higher after 
CCABG than after OPCAB. There is conflicting evidence regarding increased risk of 
gastro-intestinal complications after CCABG. 
There is strong evidence from a number of randomized, controlled trials that the 
inflammatory response and the oxidative stress is higher after CCABG than after 
OPCAB. However, the clinical significance of these findings remain unclear. 
Finally, there is strong evidence that OPCAB is more cost-effective than CCABG at up 
to twelve months follow-up. Long term data on cost-effectiveness are not available. 
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myocardial injury and of increased incidence of atrial fibrillation after CCABG but no 
difference in the incidence of clinically important myocardial infarctions. 
There is conflicting evidence of increased need of inotropic or pressor drugs and of 
intra-aortic balloon pump after CCABG. There is strong evidence of increased release of 
biochemical markers of renal insufficiency after CCABG but not of postoperative need 
of dialysis.  
There is conflicting evidence of differences in incidence of perioperative stroke. Limited 
evidence suggests that neuro-cognitive dysfunction is larger early after CCABG than 
after OPCAB. However, no difference is detected later than three months after the 
operation. 
There is strong evidence of fewer chest infections and shorter ventilation times after 
OPCAB. Risk of peri-operative bleeding and need for transfusions is higher after 
CCABG than after OPCAB. There is conflicting evidence regarding increased risk of 
gastro-intestinal complications after CCABG. 
There is strong evidence from a number of randomized, controlled trials that the 
inflammatory response and the oxidative stress is higher after CCABG than after 
OPCAB. However, the clinical significance of these findings remain unclear. 
Finally, there is strong evidence that OPCAB is more cost-effective than CCABG at up 
to twelve months follow-up. Long term data on cost-effectiveness are not available. 
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Re-Engineering in OPCAB Surgery 




Coronary artery bypass surgery is a procedure that started off with the first implantation of 
the internal mammary artery to the cardiac muscle in 1946 by Vineberg [Vineberg AM, 
1954]. Later, the coronary anastomosis distal to the occlusion using the saphenous vein graft 
(SVG) or the internal mammary artery (IMA) was experimentally conceived by Murray 
[Murray et al, 1954]. Bailey et al [Bailey et al, 1957] were the first group to approach the 
problem of coronary occlusion in 1957. Though the pioneers of OPCAB were Goetz and 
colleagues [Goetz et al, 1961] and Kolessov [Kolessov VL, 1967] who performed the 
procedure in isolated cases. The first clinical series of consecutive patients was by Trapp and 
Bisarya [Trapp WG, Bisarya R,1975] and Ankeney [Ankeney JL,1975]. 
Then, with the development of direct coronary surgery, under the leadership of Favaloro 
[Favaloro RG,1968] and Green and coworkers [Green GE, Stertzer SH 1968], with 
procedures being performed in an arrested heart with the use of extracorporeal circulation, 
off-pump coronary surgery was abandoned. Thus the surgeons all over the world started 
performing CABG on the heart lung machine , and that became the standard of care for 
patients with coronary artery disease. 
 In 1981 Enio Buffolo [Buffolo E ,et.al,1985]from Brazil and Benneti [Benetti FJ,1985] from 
Argentina had started experimenting on this technique of Direct Myocardial 
revascularization. Both of them published their series around 1985 which rekindled the idea 
of OPCAB in the western world. It was probably the idea of minimally invasive direct 
coronary artery bypass graft (MIDCABG), introduced in the mid-1990s by Benneti [Benetti 
FJ ,1985,1995], that called attention to the possibility and advantages of not using CPB. 
Calafiore's [Calafiore AM,et al,1996,1998] publications re- enforced the advantages of the 
LAST(left anterior small thoracotomy) operation. The LIMA stitch was acclaimed as an 
extraordinary step in the development of off-pump coronary surgery, which allowed 
grafting of posterior branches of the coronary arteries. The introduction of stabilizers in the 
mid 1990s further facilitated the procedure[Borst C,1996]. Eric Jansen, was one of those 
surgeon in the mid nineties who was probably the man who had made the word -Octopus- 
so very popular in the rest of the world. The article published in 1991 by Benetti [Benetti F.J 
et al,1991] in Chest, gave confidence to the Cardiac surgeons around the world to perform 
OPCAB in all anterior vessels. But even then the circumflex territory became a danger zone 
for most surgeons to perform a safe coronary anastomoses. Though LIMA stitch was used 
quite often, it was the availability of the Positioners that that made the process of 
Verticalisation of the heart more comfortable. 
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By the end of the 90's, most of the surgeons in India and in the far east had been performing 
OPCAB in 90% of their Coronary artery patients, but by early 2000, there was a sharp 
decline in the numbers, as most of the surgeons did not find the comfort zone in OPCAB 
surgery, and that their patency rates were being questioned. In the 1990s the visibility of 
coronary anastomosis was again a doubtful proposition, and also converting, and going on 
to the pump became a recipe for disaster. Then came the comparative trials of OPCAB and 
ONCAB , which obviously brought in results which showed that both the techniques 
produce nearly the same results, and that the patency was a question of concern[Kim KB,et 
al,2001&.Puskas JD.et al,2001] The Rooby trial showed that, at 1 year of follow-up, patients 
in the off-pump group had worse composite outcomes and poorer graft patency than did 
patients in the on-pump group[A. Laurie Shroyer,et al,NEJM,2009]. The surgeons had then 
come to a conclusion that OPCAB is good in experienced hands and the results in that group 
of people have been outstanding. 
The appeal of avoiding cardiopulmonary bypass with its direct and indirect physiological 
insult, the prospect of improved clinical outcomes, and the favorable economic impact gives 
OPCAB the potential of preference that may mark the dawn of a new era in our search for 
the optimal surgical strategy for the treatment of coronary artery disease. 
OPCAB has been performed in many different ways. It’s like different ways of skinning a 
cat. Ultimately, the gold standard of a perfect patent coronary anastomosis remains the 
corner stone of a good surgeon and a good operation. It is to be emphasized here that 
Coronary artery bypass surgery has a come a long way from performing them off pump, 
then on pump and now going back to off pump. But the most important point, one has to 
bear in mind is that , the surgeon has to do what he is most comfortable with and by which 
he would be able to give the best result. 
The topic of Re-engineering in OPCAB came up , because, there was an engineering that 
was done during the early phase of OPCAB by the great pioneers of this procedure. But 
what happened along the way was that these procedures were not reproducible by lesser 
mortals like us and hence we had to re-engineer this procedure to suit us. 
2. Theorotical reason of avoiding the pump 
It is logical to suppose that avoiding CPB would abolish the SIRS (systemic inflammatory 
response syndrome)and its untoward physiological impact. [Gu Y.J, 1999]. Gu Y.J, 
investigated the inflammatory response with OPCAB, and found that complement 
activation and consequently systemic inflammatory response occurred (due to surgical 
trauma) but the extent and severity were curtailed.  
Comparison with on-pump CABG confirms a limited and less severe form of inflammatory 
response. Strüber [Strüber M.,et al,1999&, Matata B.M.et al,2000] and Matata  and their 
coworkers reported significant increases in the levels of specific biological markers of 
inflammation following on-pump CABG compared to OPCAB. The inflammatory indicators 
that were evaluated in both studies and their results are summarized: 
 Activated complement factor 3a (C3a) demonstrated between 5- and 12-fold rise over 
the preoperative level after commencement of CPB, and minimal rise in the OPCAB 
patients.  
 Proinflammatory interleukin 8 (IL-8) increased 5-folds with CPB whilst the level was 
only slightly altered with OPCAB.  
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 Tumor necrosis factor (TNF-) peaked 24–48 h after CPB at a significantly higher value 
compared to OPCAB patients who had no increase. Tumor necrosis factor receptors 1 
and 2 were elevated to three times their preoperative level only with CPB.  
 Different markers tested in each study (interleukin 6 and plasma elastase) were 
significantly elevated with CPB. OPCAB patients showed a blunted response.  
The other variables of CPB such as haemodilution, non-pulsatile flow, and aortic cross-
clamping, which may act in concert with SIRS to increase postoperative morbidity, are 
eliminated by the avoidance of CPB. 
Thus avoiding the heart lung machine would be a logical solution in performing coronary 
artery bypass surgery 
3. Myocardial preservation 
Adequate myocardial preservation is crucial in CABG operations. Preoperative resuscitation 
of ischemic myocardium enables recruitment of hibernating myocardium and forms an 
important component of any myocardial protection strategy. The intraoperative strategy 
varies (within physiological boundaries) as much from patient to patient as it is from 
surgeon to surgeon, to the extent that a good clinical outcome becomes the ultimate 
determinant of the optimal strategy. Even with the same surgeon, the strategy is adapted to 
the patient and clinical scenario that a prescriptive regimen is not standard. The objective of 
intraoperative myocardial preservation is to enable efficient myocardial energy 
management by reducing cardiac metabolic demands on the one hand, while improving 
myocardial oxygen supply and utilization on the other [Buckberg G.D et.al,1996].  
In on-pump CABG, cardioplegia or cross-clamp fibrillation are conventional methods of 
intraoperative myocardial protection. Cardioplegia favorably affects myocardial energy 
metabolism but results in the alteration of both the intra- and extracellular milieu and, 
together with CPB can precipitate changes in cardiac performance postoperatively 
[Mehlhorn U.,1995]. Cross-clamp fibrillation can increase the endocardial viability ratio and 
lead to similar changes in cardiac function. In both strategies of myocardial protection, a 
period of global myocardial ischemia is followed by reperfusion with oxygen-rich blood 
predisposing to reperfusion injury which manifests as myocardial stunning and 
arrhythmias in the early postoperative period.  
Since deliberate induction of global ischemia is unnecessary in OPCAB, it is logical to 
suppose that iatrogenic biochemical injury to the myocardium would not occur. More so, 
the blunted inflammatory response with avoidance of CPB is characterised by low 
production of IL-8 which is involved in myocardial injury . In fact, Atkins et al. first 
suggested that OPCAB preserved cardiac function in 1984 [Atkins C.W .et al,1984]. In 
different prospective randomized studies, Ascione [Ascione R.et al,1999], Penttilä [Penttilä 
H.J.,et al,2001], Van Dijk [Van Dijk D..et al,2001], Czerny [Czerny M.,et al 2001], Bennetts 
[Bennetts J.S.et al,2002], and Masuda [Masuda M.et al,2002], and their collaborators reported 
minimal change in the biochemical markers of myocardial injury (troponin T and/or 
creatinine kinase-MB isoenzyme), and in some cases, better myocardial function after 
OPCAB compared to on-pump CABG. Changes in myocardial metabolism indicative of 
oxidative stress due to local ischemia when the target coronary artery is occluded to enable 
visualization for distal anastomoses have been reported in OPCAB [Matata B.M. et al 2002]. 
Compared to on-pump CABG, OPCAB is associated with better myocardial energy 
preservation, less oxidative stress and minimal myocardial damage [Penttilä H.J et al.2001]. 
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However, emerging evidence suggests that intraoperative myocardial protection in OPCAB 
can provide an added advantage [.Guyton R.A. Et al,200 & Muraki S.et al.2001]. In their 
pioneering report, Trapp and Bisarya  gave an exquisite description of coronary perfusion 
and the instantaneous improvement in the ECG and blood pressure during OPCAB. 
Vassiliades et al. [Vassiliades T.A .et al,2002] compared active coronary perfusion using a 
perfusion pump, with passive perfusion by a cannula connected from the aorta to the graft, 
and no coronary perfusion, after the distal anastomosis in a randomized clinical trial. They 
found lower troponin I levels with active and passive coronary perfusion, but cardiac 
performance was better with active coronary perfusion. The use of intracoronary shunt 
during OPCAB has also been shown to preclude left ventricular dysfunction [Yeatman M.et 
al 2002].  
Reperfusion injury can occur from regional ischemia due to a combination of underlying 
coronary obstructive pathology, stabilization and anastomotic techniques, compounded by 
episodes of hypotension which precede revascularisation. The precarious normoxic and 
normothermic passive coronary perfusion may be insufficient to protect against myocardial 
damage in such clinical scenarios.  
The concept of myocardial protection in OPCAB is less tedious. In most cases passive 
coronary perfusion with intracoronary shunts will suffice, but in the presence of heightened 
cardiac risk such as recent acute myocardial ischemia or infarction, and severely impaired 
left ventricular function active coronary perfusion is advantageous especially in multi-vessel 
revascularization.  
The role of Intra-aortic balloon pump  (IABP)in patients with Ischemic myocardium and in 
low ejection fraction would be discussed later in the chapter. As of today, apart from using 
intra coronary shunt, the use of aorto-coronnary shunts in some instances have been a 
disposable worth remembering. 
Hemodynamic instability has been the major concern in performing OPCAB even today. 
Though we have been able to master the technique of positioning the heart by the use of 
various technique and devices, this still remains a major concern. Exposure of the coronary 
artery target sites requires the heart to be lifted, rotated, dislocated and displaced producing 
a distortion of cardiac geometry and consequently hemodynamic fluctuations frequently 
occur. As a result, the early reports of OPCAB described single or double grafts limited to 
anterior target sites. The corrective measures for these hemodynamic changes include 
volume loading, trendelenberg positioning, and displacement of the heart into the opened 
right pleura, use of inotropes, vasopressors, vasodilators, intra-aortic balloon pump, and 
right heart circulatory support [Mathison M.et al, 2000 &, Kim K.B. et al, 2001]. 
What we had re-engineered over the last five years is to avoid the Trendelenberg position. 
And  we practice  an anti-Trendelenberg position of the patient, where the patient lies on 
the table with the head end up. This is very useful in patients with ischemia, where the 
pulmonary artery (PA) pressure is high. This maneuver reduces the PA pressure, and there 
by reduces the left ventricular end diastolic pressure (LVEDP). This is exactly what the 
patient would do when he develops chest pain in his room. He sits up and tries to catch his 
breath. That is what we help him do in the operation theater as he is anaesthetised. 
If the CVP is low and the right ventricle looks empty, then we give a fluid challenge to 
improve his preload. But we always try to avoid the Trendelenberg position.  
In late nineties, the principle of OPCAB was to perform the coronary anastomosis at a heart 
rate of less than 60 per minute. Hence, the patients coming for surgery used to be well beta 
blocked, so that it would be easy to perform the anastomosis. But, most of these patients  
 




Fig. 1. Photo showing the operation table with the head end elevated and tilted to the side of 
the surgeon. 
ended up having inotropes and vasoconstrictors to maintain hemodynamics. Ischemic 
patients when given either of them, they develop further ischemia and become bad. 
What we had re-engineered here, was to increase the heart rate .To attain that, we use 
intermittent boluses of Injection Atropine (0.6mgs per milliliter), which is only a 
Chronotropic agent and not an Inotrope. Thus, avoiding unnecessary strain on the 
myocardium. We aim at a rate above 100 per minute and this keeps the heart briskly 
contracting and avoiding the usual hemodynamic collapse seen in the early days. 
We do not use vasopressors or vasodilators in any of our patients undergoing OPCAB.The 
only drug the patient would be given intermittently is the Atropine injection. We use 
Glycerol trinitrate(GTN) in our patients after the distal anastomosis, and that too as an 
antihypertensive only. 
Mueller et al. found no change in the hemodynamics during exposure of the posterior and 
anterior wall arteries, and only marginal change for the lateral wall artery with a ‘no 
compression’ technique [Mueller X.M  et al,2002]. It has been suggested that the use of left 
ventricular apical suction device for cardiac positioning provokes less hemodynamic 
instability compared with pericardial retraction sutures [Sepic J.et al,2002].  
The technique which we have developed is to cut down the pericardium on the right side, down 
to the inferior vena cava, and to leave the right pleura opened. We routinely open the left pleura 
to help in the mammary dissection. Hence, in all our patients we have all the three chambers- the 
mediastinum and both the pleural cavity, remaining in continuity with  each other.  
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Fig. 2. Showing the Positioner verticalising the heart and the stabilizer used on the marginal 
circumflex. 
We too routinely use the Positioner for lifting the apex of the heart. The suction pressure 
used is not more than 150-200 mm of Hg. The positioner is always used in an off apex 
position, so as to avoid sucking the Left anterior descending (LAD) coronary artery. We use 
this pressure to avoid excessive damage to the apex. We also watch the suction tube, to see if 
any blood is being sucked. In such cases , the positioner is removed and repositioned in a 
different place. In case of grafting of the circumflex and the Posterior descending artery 
(PDA) this heart is only Verticalized and not tilted to the right side. This lifting of the apex, 
increases the left and the right ventricular volume. And in case the PDA, is being grafted, 
then we tilt the head end down, so as to increase the visibility of the PDA. This probably 
would be the only time when the Trendelenberg position is used. By this time the LAD is 
already perfused, and this has relieved the ischemia. If the visibility of the circumflex is bad, 
then the table is dropped down to its maximum and the positioner moved to right a bit. 
With this maneuver, even  the Atrioventricular groove could be visualized. 
 




Fig. 3. Showing the heart totally verticalized by the use of the positioner, and the stabilizer 
in position around the PDA. 
4. Quality of distal anastamosis 
Performing vascular anastomoses on small arteries on a beating heart can be a daunting and 
frustrating adventure, and so far, no available method of target vessel stabilization can 
achieve a steady bloodless field comparable to an  arrested heart. This was a major concern 
with OPCAB. The beating heart with a bloody operating field poses a major challenge to 
delicate tissue handling, and casts a shadow of uncertainty about the quality of the distal 
anastomosis. However, with the application of effective target vessel stabilization, and 
efficient visualization systems the early and mid-term patency of OPCAB has been 
encouraging  
The stabilizers we use are the suction stabilizers. The position of the stabilizer is very. 
important to achieve a very stable anastomotic site to perform a good coronary anastomosis. 
We have tried all types of suction stabilizers, from the Medtronic -Octopus II, III and the 
Octopus IV. We are now using the Maquet, which was the previous Guidant – Acrobat  
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Fig. 4. Photograph showing the positioner on the RV free wall to graft the distal RCA or the 
acute marginal. 
stabilizer. The Re- engineering in this is the pressure used for suction of these stabilizers. We 
use 100-150 mm of Hg on these stabilizers. The stabilizer is positioned according to the 
convenience of the surgeon. The position of our stabilizer is shown in the photographs. We 
do not use any suction while stabilizing the lateral wall, as the heart is allowed to fall on the 
stabilizer pods. 
In order to achieve a stable bloodless field while accessing the coronary artery, we use the 
following technique. After stabilizing the coronary artery by using the acrobat stabilizer, we 
use a 5.0 polypropelene suture to run around the proximal part of the coronary artery, 
proximal to where the arteriotomy is planned to be made. The two ends of the 5.0 
polypropylene are suspended using rubber shod . They are tightened just before the 
coronary arteriotomy is made. This is made using the bevel of a 18 gauge needle on a 2 ml 
syringe. After the nick is made on the coronary artery, the forward or the backward cutting 
scissors is used to open the coronary artery. A Castroveijo scissors is used to open the 
arteriotomy. The arteriotomy is usually one centimeter long. Then the intra-coronary shunt 
is inserted according to the size of the coronary artery. The shunt is to be deaired after 
inserting the proximal end first, then the snare is released and the then the distal end is 
inserted. Then the anastomosis of the coronary is performed using the conduits as preferred. 
We use shunts in nearly all the distal anastomosis. 
 




Fig. 5. Showing the clarity of the coronary anastamosis, while performing LIMA to LAD 
anastamosis. 
5. Incomplete myocardial revascularisation 
Early reports of OPCAB in the literature were uniformly consistent in the low number of 
grafts per patient [6,10]. The selection of patients with mainly single-vessel disease may, in 
part, explain this finding. But the persistence of lower average number of grafts in later 
comparative studies [Gundry S.R et al,1998 &Arom K.V.et al,2000] places OPCAB in a 
contentious position which detracts from its potential benefits. In their retrospective study, 
Gundry and colleagues reported a significantly lower mean number of grafts, and a two-
fold increase in cardiac re-intervention rate during a 7-year period with off-pump 
performed without cardiac stabilization, compared to on-pump CABG. This finding has 
been corroborated by other reports , and exemplifies incomplete revascularization with 
OPCAB. Effective cardiac retraction, stabilization and visualization systems with patient 
positioning enables grafting of all graftable targets, making complete myocardial 
revascularization (CMR) attainable in OPCAB [Calafiore A.M et al 1995 & Cartier R et al, 
2000], and this has been demonstrated in a recent prospective randomized study [Puskas J.D 
et al,2003]. However, incomplete myocardial revascularization with OPCAB is still reported 
in retrospective studies . Technical difficulties due to small caliber of target vessels or their 
intramyocardial course, poor exposure of target sites, precarious intraoperative 
hemodynamic state, electrophysiological instability and inexperience of the surgeon are 
some of the reasons for incomplete myocardial revascularization.  
Today we have no contraindications for OPCAB , the intramyocardial coronary arteries, 
small coronary arteries and diffuse coronary arteries [Anil D Prabhu et al, 2007&2008], have  
 






Fig. 4. Photograph showing the positioner on the RV free wall to graft the distal RCA or the 
acute marginal. 
stabilizer. The Re- engineering in this is the pressure used for suction of these stabilizers. We 
use 100-150 mm of Hg on these stabilizers. The stabilizer is positioned according to the 
convenience of the surgeon. The position of our stabilizer is shown in the photographs. We 
do not use any suction while stabilizing the lateral wall, as the heart is allowed to fall on the 
stabilizer pods. 
In order to achieve a stable bloodless field while accessing the coronary artery, we use the 
following technique. After stabilizing the coronary artery by using the acrobat stabilizer, we 
use a 5.0 polypropelene suture to run around the proximal part of the coronary artery, 
proximal to where the arteriotomy is planned to be made. The two ends of the 5.0 
polypropylene are suspended using rubber shod . They are tightened just before the 
coronary arteriotomy is made. This is made using the bevel of a 18 gauge needle on a 2 ml 
syringe. After the nick is made on the coronary artery, the forward or the backward cutting 
scissors is used to open the coronary artery. A Castroveijo scissors is used to open the 
arteriotomy. The arteriotomy is usually one centimeter long. Then the intra-coronary shunt 
is inserted according to the size of the coronary artery. The shunt is to be deaired after 
inserting the proximal end first, then the snare is released and the then the distal end is 
inserted. Then the anastomosis of the coronary is performed using the conduits as preferred. 
We use shunts in nearly all the distal anastomosis. 
 




Fig. 5. Showing the clarity of the coronary anastamosis, while performing LIMA to LAD 
anastamosis. 
5. Incomplete myocardial revascularisation 
Early reports of OPCAB in the literature were uniformly consistent in the low number of 
grafts per patient [6,10]. The selection of patients with mainly single-vessel disease may, in 
part, explain this finding. But the persistence of lower average number of grafts in later 
comparative studies [Gundry S.R et al,1998 &Arom K.V.et al,2000] places OPCAB in a 
contentious position which detracts from its potential benefits. In their retrospective study, 
Gundry and colleagues reported a significantly lower mean number of grafts, and a two-
fold increase in cardiac re-intervention rate during a 7-year period with off-pump 
performed without cardiac stabilization, compared to on-pump CABG. This finding has 
been corroborated by other reports , and exemplifies incomplete revascularization with 
OPCAB. Effective cardiac retraction, stabilization and visualization systems with patient 
positioning enables grafting of all graftable targets, making complete myocardial 
revascularization (CMR) attainable in OPCAB [Calafiore A.M et al 1995 & Cartier R et al, 
2000], and this has been demonstrated in a recent prospective randomized study [Puskas J.D 
et al,2003]. However, incomplete myocardial revascularization with OPCAB is still reported 
in retrospective studies . Technical difficulties due to small caliber of target vessels or their 
intramyocardial course, poor exposure of target sites, precarious intraoperative 
hemodynamic state, electrophysiological instability and inexperience of the surgeon are 
some of the reasons for incomplete myocardial revascularization.  
Today we have no contraindications for OPCAB , the intramyocardial coronary arteries, 
small coronary arteries and diffuse coronary arteries [Anil D Prabhu et al, 2007&2008], have  
 




Fig. 6. Showing the dissection on the buried intramuscular coronary artery on the lateral 
wall of the heart. 
been a thing of the past. Any patient who needs to undergo CABG would be able to have his 
coronary artery bypass surgery using the OPCAB technique. 
6. High risk surgical patients 
OPCAB has been demonstrated to offer prognostic advantage over on-pump CABG in 
patients with exaggerated surgical risk from complicated coronary artery disease and/or 
debilitating co-morbidities [Tashiro T et al,1996,Akiyama K.et al,1999,Yokoyama T. et 
al,2000 & Prifti E et al,2000]. More importantly, the preoperative optimization of high risk 
patients plays a crucial role in determining the clinical outcome for both methods of 
myocardial revascularization. 
Acute myocardial infarction and depressed left ventricular function constitute a high 
surgical risk with on-pump CABG, because the myocardial damaging effects of CPB and the 
often cumbersome and, inefficient intraoperative myocardial protection do not prevent 
immediate postoperative cardiac dysfunction [Buckberg Get al,1996,Christenson J.T..et 
al,1997 &.D'Ancona G,2001]. OPCAB achieves comparatively better outcomes in patients 
who have myocardial revascularization soon after recent AMI [Locker C,2001]. Mohr et al. 
[Mohr R et al 1999] reported a mortality of 1.7% with 1- and 5-year actuarial survival rates of 
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Fig. 7. Showing the vein graft  after anastomosis on the coronary artery. 
within 48 hr of acute myocardial infarction and some were in cardiogenic shock. OPCAB 
decreases the operative risk in the presence of impaired left ventricular function [Nakayama 
Y.et al,2003] 
Preoperative renal impairment is an independent predictor of poor prognosis after on-pump 
CABG [Ascione R et al 1999]]. OPCAB preserves renal function better than on-pump CABG 
[Ascione R.et al,2001], and available evidence favors the preferential use of OPCAB for 
patients with chronic renal for a better early clinical outcome.  
Patients with coexisting chronic obstructive airway disease derive better early clinical 
benefit from CABG performed without CPB compared with on-pump surgery [Güler M et 
al,2001], although in low-risk patients, OPCAB induces impairment of the mechanics of the 
respiratory system, lung and chest wall similar to on-pump CABG [Roosens C et al,2002].  
Elderly patients are considered high risk surgical patients because of their reduced 
functional capacity and the presence of co-morbidities. Correspondingly, the outcome of on-
pump CABG in this group is characterized by increased morbidity and mortality [Montague 
N.T et al,,1985,,Mullany C.J et al,1980 & Hirose H,2000]. Interestingly, OPCAB has been 
shown to improve the clinical outcome in this growing population of surgical patients [Boyd 
W.D et al, 1999, Stamou S.C et al, 2000, Al-Ruzzeh S et al, 2001 & Hoff S.J.et al, 2002]. 
Specifically, the incidence of stroke, perioperative myocardial infarction, duration of 
mechanical ventilation, blood transfusion, length of intensive care and hospital stay, and 
mortality are decreased.  
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7. Vettath's anastamotic obturator 
In patients with diffusely diseased coronary arteries and in patients with diseased aortas, 
OPCAB has remained a life saver. We had developed the Vettaths anastomotic  obturator 
(VAO) (Murali.P.Vettath,2003,2004) – which , is is an aortic anastomosis enabling  device. 
This allows the surgeon to avoid the side clamp on the aorta, when a no touch technique is 
required in cases of diseased aorta. In patients with plaquey aortas, where a saphenous vein 
top end is to be connected, this could be used to make an anastomosis on a no plaquey zone 
in the aorta. The technique is to identify a soft spot and make two purse string sutures with 
3.0 polypropylene around the intended zone of anastomosis. The purse strings are about a 
centimeter in diameter. A stab wound is made using a no.11 blade and an aortic punch is 
used to make a punch hole on the aorta. The VAO is then inserted into the hole and one of 
the 3.0 purse strings are used to snare the bleeding around the VAO if it persists. The aortic 
systolic pressure may be maintained at around 100 mm of Hg. The advantage is that this 
allows the surgeon to perform a hand sewn anastomosis on the vein graft. This is like the 
devices that are available in the market, like the Heartstring and the Enclose device. This is 
like an instrument and is made of steel and can be reused and could help in avoiding a 
stroke in elderly patients. We have performed more than 500 top ends using this device and 
is a good one to have in the armamentarium of a cardiac surgeon. This is also a good tool to 
use in redo CABG, when a proximal anastomosis could be made on the hood of the old vein 
graft. 
The VAO is also a useful tool in cases where a combined aortic valve replacement is done 
with a CABG. Here it is useful when the side clamp needs to be avoided.  
8. Diffusely diseased coronary arteries 
The diffusely diseased coronary arteries have been a curse in the south East-Asian 
population, and more so in patients with Indian origin. This is seen in these patients in the 
younger age group and they are usually termed inoperable. The disease is so diffuse that 
grafting area in the coronary arteries are studded with plaques. We had developed our own 
technique of Vettath's technique of long mammary patch on LAD without endarterectomy 
on beating heart. We had performed this on more than 200 patients since the last 9 years. We 
have also published the same (Murali Vettath,2008 ) in couple of journals. In fact we have 
been reviewing these patients with coronary angiograms and the results have been quite 
gratifying. 
9. Vettath's technique of long mammary patch 
A single stabilizer is used if the arteriotomy is <4 cm. If it exceeds >4 cm, two stabilizers 
(one facing each other)  are used for coronary stabilization. The arteriotomy extends distally 
to reach the normal lumen of LAD. Proximal extent of arteriotomy is kept just short of the 
most severe proximal lesion to avoid competitive flow from native LAD. 
Distal coronary perfusion during anastomosis is maintained using conventional 
intracoronary shunts (Clearview, Medtronic Inc, Minneapolis, MN, USA). If the arteriotomy 
exceeds 3-4 cm, cut ends of aorto- coronary shunts (Quickflow, Medtronic Inc, Minneapolis, 
MN, USA) are used. These may be tailored to use in arteriotomies upto 6-7 cms. In this 
technique, hither to undescribed (Vettath’s modification of aorto-coronary shunts), the distal 
perfusion tips of aorto- coronary shunts are cut and inserted into the coronary artery. The  
 


















Fig. 8. Shows the Vettath's anastomotic obturator , the whole length of the device and the 
working end of the piece that goes into the aorta. 
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Fig. 9. Shows the close up of the top end anastomosis in progress using the VAO 
bulb is inserted into the end from where the blood flows (i.e., into distal coronary lumen if 
the flow is retrograde and vice-verse). If the shunt does not sit inside the coronary (or it 
bowstrings), it is tacked down with a tacking suture taken in the midpoint of arteriotomy. 
This tacking suture is taken out at the end of anastomosis, along with the shunt. We use 7-0 
polypropylene for this tacking suture. Occasionally, when native coronary flow is negligible 
and/or coronary lumen is <1 mm, the LAD is snared proximally with circumferential suture 
and LIMA to LAD anastomose was done. LIMA is slit to match the coronary arteriotomy 
and LIMA to LAD anastomosis is performed using 7-0 polypropylene. The plaques are 
excluded from the lumen of the reconstructed LAD. Diagonals and perforators are included 
in the new lumen. Posterior 25% of reconstructed coronary artery is formed by native 
coronary artery and anterior 75% by LIMA . Approximately 10 minutes were taken to 
construct a 2cm patch and an additional 5 minute per each added centimeter of patch was 
taken for anastomosis. 
The advantage of this technique is that the intima is left intact and no injury is made on it. 
The avoidance of endarterectomy is a definite reason for the patency in our study. We also 
do not add any anticoagulants or anything other medications, than those used for the 
normal CABG patients. Also that in spite of our long anastomosis, patients remain quite 
stable all along the anastomotic time.This technique of long patch has also been described by 
Takanashi [S.Takanashi,2003.] 
 




Fig. 10. Shows: 
(a) The VAO is inserted into the vein hood of the blocked vein graft. In a re do CABG- On pump. 
(b) The suturing being done on the top end of the vein graft. 
(c) The anastomosed vein graft s in position. 
(d) The top end of the vein graft in a CABG plus AVR done without using side clamp 
10. Role of IABP in OPCAB 
The use of intra-aortic balloon pump (IABP) either preoperatively or intraoperatively, to 
reduce operative risk and to facilitate posterior vessel OPCAB has been well documented. 
IABP has been useful in high-risk patients with left main coronary artery disease (> 75% 
stenosis), intractable resting angina, post infarction angina, left ventricular dysfunction 
(ejection fraction < 35%), or unstable angina.  
Preoperative IABP counterpulsation has been shown to have better outcomes compared 
with perioperative or postoperative insertion in critical patients, and off-pump surgical 
procedures have been advocated to reduce mortality in high-risk patients. 
In patients with high risk factors, higher mortality and morbidity rates have been 
demonstrated in spite of massive pharmacologic support combined with postoperative 
IABP support. IABP therapy results in a more favorable myocardial blood supply, increased 
stroke volume and cardiac output through augmentation of the diastolic pressure, and 
afterload reduction (Christenson, 1997, 1999).Intraoperative or postoperative IABP insertion 
has been reported to be associated with higher operative mortality rate and device-related 
complication rate, as compared with preoperative use of IABP.  
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Fig. 11. Shows the Coronary angiograms of patients, showing diffusely diseased coronary 
arteries. 
 
Fig. 12. Showing the Double stabilizer technique while performing the long mammary patch 
anastomosis of LIMA on the LAD without enadarterectomy. 
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Any patient who has a hemodynamic compromise or has an inclination to crash, gets an 
IABP inserted sheath less.(8 or &7 Fr). We had the IABP inserted in the early days when we 
had the patient included in one of the high risk group like- left main coronary artery disease 
(> 75% stenosis), intractable resting angina, ST depression more than 2.5mm,Post-infarction 
angina, Left ventricular dysfunction (ejection fraction < 35%), or unstable angina. 
We had noticed that the use of IABP was not high in the left main disease group and low 
ejection fraction group, but was high in patients with ongoing ischemia. Hence we re-
engineered our use of IABP such that every patient undergoing OPCAB gets a femoral 
arterial line and this is used for monitoring along with the radial arterial line. When a 
patient becomes ischemic during lifting the heart and while positioning for lateral wall 
grafting, then the heart is repositioned, and a sheathless IABP inserted. This is then used till 
the distal anastomosis is over. Once the anastomosis is complete and the heart repositioned 
for top end anastomosis, then the IABP is kept on standby mode. Then after the top end 
anastomosis is over, the heparin is reversed. Once the reversal is over and when the patient 
remains hemodynamically stable, we remove the IABP on the table, after inserting another 
femoral arterial line in the other groin. This technique has been very useful and we have 
been following this for the past four years, with excellent results. In fact this technique is 
being sent for publication. We have not had to reintroduce any IABP in any of these patients 




We had analyzed the results of our last 2000 OPCAB patients. It was noticed that we had a 
higher rate of conversion onto the heart lung machine in our first thousand, when compared 
the second thousand. Probably, that was our initial learning curve which was seen in our 
technique, which we have developed and standardized. The use of IABP had been low in the 
early years, and probably the reason for the increased conversion on to the Heart lung 
machine. But as we understood the use of IABP, we found it more user friendly. Also the need 
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for the balloon pump only for distal anastomosis did come as a surprise to us. In the last 1600 
odd patients, we had to convert only one patient on to the heart lung patient (That too when 
the patient developed intractable Ventricular arrhythmia). The mortality of the second 
thousand patients had come down by half and we have been able to maintain that result. 
Our results of the different parameters like the use of ionotropes, number of grafts, Renal 
failure, perioperative Myocardial infarction etc, in comparison with our two groups of 




The advance that has been made in the surgical management of coronary artery disease has 
placed us in a vantage position of judging the outcome of our management techniques not 
only by morbidity and mortality incurred, but also by the potential of our treatment 
modality to cause harm. This is why OPCAB has generated renewed, widespread and 
sustained interest. The resurgence of OPCAB has also ignited a keen enthusiasm in the 
refinement of CPB techniques and the management of on-pump CABG patients. In most 
practices, OPCAB is paradoxically dependent on, and guaranteed by the presence of the 
CPB machine. We would like to stress here that OPCAB is not for everyone. It is definitely 
not for the faint hearted surgeon, It needs a Team with a MINDSET. And the team has to 
gear itself from being able to perform CABG on full Cardiopulmonary bypass, with cross 
clamp and cardoplegia, to performing CABG on pump with a beating heart, and then going 
on to just cannulating the aorta, and then stabilizing the heart and performing OPCAB, to 
doing a full OPCAB. This should be a slow transition, than a sudden change. Then the 
results would be good. There has been numerous article comparing OPCAB with ONCAB, 
but in our opinion, a surgeon performing OPCAB would not have to perform ONCAB, what 
ever the coronary anatomy is, if he sets his mind to it. 
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In our last 12 years of OPCAB experience and over 2500 OPCABs, we have been able to 
perform the last 1600 OPCABs with only one conversion to the heart lung machine. That 
was when patient developed intractable arrhythmia. Hence in our opinion, intractable 
arrhythmia is the only reason for conversion. The mortality in the first one thousand 
patients have been 0.8% and in the second thousand is 0.4%.This proves to say that OPCAB 
has definitely reduced the mortality in coronary surgery. And if trained well we would be 
able to perform the same in patients with any ejection fraction. 
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practices, OPCAB is paradoxically dependent on, and guaranteed by the presence of the 
CPB machine. We would like to stress here that OPCAB is not for everyone. It is definitely 
not for the faint hearted surgeon, It needs a Team with a MINDSET. And the team has to 
gear itself from being able to perform CABG on full Cardiopulmonary bypass, with cross 
clamp and cardoplegia, to performing CABG on pump with a beating heart, and then going 
on to just cannulating the aorta, and then stabilizing the heart and performing OPCAB, to 
doing a full OPCAB. This should be a slow transition, than a sudden change. Then the 
results would be good. There has been numerous article comparing OPCAB with ONCAB, 
but in our opinion, a surgeon performing OPCAB would not have to perform ONCAB, what 
ever the coronary anatomy is, if he sets his mind to it. 
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In our last 12 years of OPCAB experience and over 2500 OPCABs, we have been able to 
perform the last 1600 OPCABs with only one conversion to the heart lung machine. That 
was when patient developed intractable arrhythmia. Hence in our opinion, intractable 
arrhythmia is the only reason for conversion. The mortality in the first one thousand 
patients have been 0.8% and in the second thousand is 0.4%.This proves to say that OPCAB 
has definitely reduced the mortality in coronary surgery. And if trained well we would be 
able to perform the same in patients with any ejection fraction. 
13. References 
Akiyama K., Ogasawara K., Inoue T., Shindou S., Okumura H., Negishi N., Sezai Y. 
Myocardial revascularization without     cardiopulmonary bypass in patients with 
operative risk factors. Ann Thorac Cardiovasc Surg 1999;5:31-35 
Al-Ruzzeh S., George S., Yacoub M., Amrani M. The clinical outcome of off-pump coronary 
artery bypass surgery in the elderly patients. Eur J Cardiothorac Surg 2001;20:1152-
1156. 
A. Laurie Shroyer, Ph.D., Frederick L. Grover, M.D., Brack Hattler, M.D., Joseph F. Collins, 
Sc.D., Gerald O. McDonald, M.D., Elizabeth Kozora, Ph.D., John C. Lucke, M.D., 
Janet H. Baltz, R.N., and Dimitri Novitzky, M.D., Ph.D. for the Veterans Affairs 
Randomized  On-Pump versus Off-Pump Coronary-Artery Bypass Surgery.On/Off 
Bypass (ROOBY) Study Group.N Engl J Med 2009; 361:1827-1837. 
Anil D Prabhu, MCh, Ismail E Thazhkuni, PhD, Sunil Rajendran, MRCS, Ranjish A 
Thamaran, MS, Kannan A Vellachamy, MD, Murali P Vettath, MD. Mammary 
patch reconstruction of left anterior descending coronary artery.Asian Cardiovasc 
Thorac Ann 2008;16:313-317 
Anil D. Prabhu, MCh, Rafeek A. Karim, MCh, Sunil Rajendran, FRCS, Ismail E. Thazhkuni, 
PhD, Ranjish A. Thamaran, MS, Kannan A. Vellachami, MD,Murali P.Vettath, 
MCh. Vettath’s technique of long mammary patch reconstruction of a diffusely 
diseased left anterior descending coronaryartery without endarterectomy on the 
beating heart.The Heart Surgery Forum #2007-1155  11 (2) P 64-67, 2008  doi: 
10.1532/HSF98.20071155 http://cardenjennings.metapress.com 
Ankeney JL. To use or not use the pump oxygenator in coronary bypass operations Ann 
Thorac Surg 1975;19:108-109. 
Arom K.V., Flavin T.F., Emery R.W., Kshettry V.R., Janey P.A., Petersen R.J. Safety and 
efficacy of off-pump coronary artery bypass grafting. Ann Thorac Surg 2000;69:704-
710. 
Ascione R., Lloyd C.T., Gomes W.J., Caputo M., Bryan A.J., Angelini G.D. Beating versus 
arrested heart revascularization: evaluation of myocardial function in a prospective 
randomized study. Eur J Cardiothorac Surg 1999;15:685-690.  
Ascione R., Lloyd C.T., Underwood M.J., Gomes W.J., Angelini G.D. On-pump versus off-
pump coronary revascularization: evaluation of renal function. Ann Thorac Surg 
1999;68:493-498.  
Ascione R., Nason G., Al-Ruzzeh S., Ko C., Ciulli F., Angelini G.D. Coronary 
revascularization with or without cardiopulmonary bypass in patients with 
preoperative nondialysis-dependent renal insufficiency. Ann Thorac Surg 
2001;72:2020-2025 
 
Special Topics in Cardiac Surgery 
 
200 
Atkins C.W., Boucher C.A., Pohot G.M. Preservation of interventricular septal function in 
patient having coronary artery bypass grafts without cardiopulmonary bypass. Am 
Heart J 1984;107:304-309. 
Bailey CP, May A, Lemon WM. Survival after coronary endarterectomy I men . JAMA 
1957;167:641. 
Benetti FJ. Direct coronary surgery with saphenous vein bypass without either 
cardiopulmonary bypass or cardiac arrest J Cardiovasc Surg 1985;26:217-222. 
Benetti FJ. Video assisted coronary bypass surgery J Cardiovasc Surg 1995;10:620-625. 
Benetti F.J., Naselli C., Wood M., Geffner L. Direct myocardial revascularization without 
extracorporeal circulation. Experience in 700 patients. Chest 1991;100:312-316 
Bennetts J.S., Baker R., Ross I.K., Knight J.L. Assessment of myocardial injury by troponin T 
in off-pump coronary artery grafting and conventional coronary artery graft 
surgery. ANZ J Surg 2002;72:105-109. 
Borst C, Jansen EW, Tulleken CA, et al. Coronary artery bypass grafting without 
cardiopulmonary bypass and without interruption of native coronary flow using a 
novel anastomosis site restraining device ("Octopus") J Am Coll Cardiol 
1996;27:1356-1364. 
Boyd W.D., Desai N.D., Del Rizzo D.F., Novick R.J., McKenzie F.N., Menkis A.H. Off-pump 
surgery decreases postoperative complications and resource utilization in the 
elderly. Ann Thorac Surg 1999;68:1490-1493 
Buckberg G.D., Allen B.S. Myocardilal protection management during adult cardiac 
operations. In: Baue A.E., Geha A.S., Hammond G.L., Laks H., Naunheim K.S., eds. 
Glenn's thoracic and cardiovascular surgery. Stamford: Apple & Lange, 1996:1653-
1687.  
Buckberg G.D., Allen B.S. Myocardilal protection management during adult cardiac 
operations. In: Baue A.E., Geha A.S., Hammond G.L., Laks H., Naunheim K.S., eds. 
Glenn's thoracic and cardiovascular surgery. Stamford: Apple & Lange, 1996:1653-
1687.  
Buffolo E, Andrade JCS, Succi JE, et al. Direct myocardial revascularization without 
cardiopulmonary bypass Thorac Cardiovasc Surg 1985;33:26-29 
Calafiore AM, Gianmarco GD, Teodori G, et al. Left anterior descending coronary artery 
grafting via left anterior small thoracotomy without cardiopulmonary bypass Ann 
Thorac Surg 1996;61:1658-1665. 
Calafiore AM, Vitolla G, Mazzei V, et al. The Last operation technique and results before 
and after stabilization era. Ann Thorac Surg 1998;66:998-1001. 
Calafiore A.M., Di Giammarco G., Teodori G., Mazzei V., Vitolla G. Recent advances in 
multivessel coronary grafting without cardiopulmonary bypass. Heart Surg Forum 
1998;1:20-25. 
Cartier R., Brann S., Dagenais F., Martineau R., Couturier A. Systematic off-pump coronary 
artery revascularization in multivessel disease: experience of three hundred cases. J 
Thorac Cardiovasc Surg 2000;119:221-229. 
Christenson J.T., Simonet F., Badel P., Schmuziger M. Evaluation of preoperative intra-aortic 
balloon pump support in high risk coronary patients. Eur J Cardiothorac Surg 
1997;11:1097-1103. 
Christenson J., Simonet F., Badel P., Schmuziger M. The effect of preoperative intra-aortic 
balloon pump support in patients with coronary artery disease, poor left-
 
Re-Engineering in OPCAB Surgery 
 
201 
ventricular function (LVEF < 40%) and hypertensive LV hypertrophy. Thorac 
Cardiovasc Surg 1997;45:60-64. 
Christenson J., Simonet F., Badel P., Schmuziger M. Optimal timing of preoperative 
intraaortic balloon pump support in high-risk coronary patients. Ann Thorac Surg 
1999;68:934-939 
Czerny M., Baumer H., Kilo J., Zuckermann A., Grubhofer G., Chevtchik O., Wolner E., 
Grimm M. Complete revascularization in coronary artery bypass grafting with and 
without cardiopulmonary bypass. Ann Thorac Surg 2001;71:165-169. 
D'Ancona G., Karamanoukian H., Ricci M., Kawaguchi A., Bergsland J., Salerno T. 
Myocardial revascularization on the beating heart after recent onset of acute 
myocardial infarction. Heart Surg Forum 2001;4:74-79. 
Favaloro RG. Saphenous vein graft in the surgical treatment of coronary artery disease J 
Thorac Cardiovasc Surg 1968;58:178-185. 
Goetz RH, Rohman M, Haller JD, et al. Internal mammary-coronary anastomosis. A 
nonsuture method employing tantalum rings J Thorac Cardiovasc Surg 
1961;41:378-386. 
Green GE, Stertzer SH, Reppert EH. Coronary artery bypass graft Ann Thoracic Surg 
1968;5:443-450 
Güler M., Kirali K., Toker M.E., Bozbuga N., Ömeroglu S.N., Akinci E., Yakut C. Different 
CABG methods in patients with chronic obstructive pulmonary disease. Ann 
Thorac Surg 2001;71:152-157. 
Gundry S.R., Romano M.A., Shattuck O.H., Razzouk A.J., Bailey L.L. Seven-year follow-up 
of coronary artery bypasses performed with and without cardiopulmonary bypass. 
J Thorac Cardiovasc Surg 1998;115:1273-1278.  
Gu Y.J., Mariani M.A., Boonstra P.W., Grandjean J.G., Oeveren W.V. Complement activation 
in coronary artery bypass grafting patients without cardiopulmonary bypass: the 
role of tissue injury by surgical incision. Chest 1999;116:892-898. 
Guyton R.A., Thourani V.H., Puskas J.D., Shanewise J.S., Steele M.A., Palmer-Steele C.L., 
Vinten-Johansen J. Perfusion-assisted direct coronary artery bypass: selective graft 
perfusion in off-pump cases. Ann Thorac Surg 2000;69:171-175. 
Hoff S.J., Ball S.K., Coltharp W.H., Glassford D.M., Jr., Lea J.W., IV, Petracek M.R. Coronary 
artery bypass in patients 80 years and over: is off-pump the operation of choice?. 
Ann Thorac Surg 2002;74:S1340-S1343. 
Kim KB, Lim C, Lee C, et al. Off-pump coronary artery bypass may decrease the patency of 
saphenous vein grafts Ann Thorac Surg 2001;72:1033-1037. 
Kim K.B., Lim C., Ahn H., Yang J.K. Intraaortic ballon pump therapy facilitates posterior 
vessel off-pump coronary artery bypass grafting in high-risk patients. Ann Thorac 
Surg 2001;71:1964-1968. 
Kolessov VL. Mammary artery coronary anastomosis as method of treatment for angina 
pectoris J Thorac Cardiovasc Surg 1967;54:535-544. 
Locker C., Shapira I., Paz Y., Kramer A., Gurevitch J., Matsa M., Pevni D., Mohr R. 
Emergency myocardial revascularization for acute myocardial infarction: survival 
benefits of avoiding cardiopulmonary bypass. Eur J Cardiothorac Surg 2000;17:234-
2385.  
 
Special Topics in Cardiac Surgery 
 
200 
Atkins C.W., Boucher C.A., Pohot G.M. Preservation of interventricular septal function in 
patient having coronary artery bypass grafts without cardiopulmonary bypass. Am 
Heart J 1984;107:304-309. 
Bailey CP, May A, Lemon WM. Survival after coronary endarterectomy I men . JAMA 
1957;167:641. 
Benetti FJ. Direct coronary surgery with saphenous vein bypass without either 
cardiopulmonary bypass or cardiac arrest J Cardiovasc Surg 1985;26:217-222. 
Benetti FJ. Video assisted coronary bypass surgery J Cardiovasc Surg 1995;10:620-625. 
Benetti F.J., Naselli C., Wood M., Geffner L. Direct myocardial revascularization without 
extracorporeal circulation. Experience in 700 patients. Chest 1991;100:312-316 
Bennetts J.S., Baker R., Ross I.K., Knight J.L. Assessment of myocardial injury by troponin T 
in off-pump coronary artery grafting and conventional coronary artery graft 
surgery. ANZ J Surg 2002;72:105-109. 
Borst C, Jansen EW, Tulleken CA, et al. Coronary artery bypass grafting without 
cardiopulmonary bypass and without interruption of native coronary flow using a 
novel anastomosis site restraining device ("Octopus") J Am Coll Cardiol 
1996;27:1356-1364. 
Boyd W.D., Desai N.D., Del Rizzo D.F., Novick R.J., McKenzie F.N., Menkis A.H. Off-pump 
surgery decreases postoperative complications and resource utilization in the 
elderly. Ann Thorac Surg 1999;68:1490-1493 
Buckberg G.D., Allen B.S. Myocardilal protection management during adult cardiac 
operations. In: Baue A.E., Geha A.S., Hammond G.L., Laks H., Naunheim K.S., eds. 
Glenn's thoracic and cardiovascular surgery. Stamford: Apple & Lange, 1996:1653-
1687.  
Buckberg G.D., Allen B.S. Myocardilal protection management during adult cardiac 
operations. In: Baue A.E., Geha A.S., Hammond G.L., Laks H., Naunheim K.S., eds. 
Glenn's thoracic and cardiovascular surgery. Stamford: Apple & Lange, 1996:1653-
1687.  
Buffolo E, Andrade JCS, Succi JE, et al. Direct myocardial revascularization without 
cardiopulmonary bypass Thorac Cardiovasc Surg 1985;33:26-29 
Calafiore AM, Gianmarco GD, Teodori G, et al. Left anterior descending coronary artery 
grafting via left anterior small thoracotomy without cardiopulmonary bypass Ann 
Thorac Surg 1996;61:1658-1665. 
Calafiore AM, Vitolla G, Mazzei V, et al. The Last operation technique and results before 
and after stabilization era. Ann Thorac Surg 1998;66:998-1001. 
Calafiore A.M., Di Giammarco G., Teodori G., Mazzei V., Vitolla G. Recent advances in 
multivessel coronary grafting without cardiopulmonary bypass. Heart Surg Forum 
1998;1:20-25. 
Cartier R., Brann S., Dagenais F., Martineau R., Couturier A. Systematic off-pump coronary 
artery revascularization in multivessel disease: experience of three hundred cases. J 
Thorac Cardiovasc Surg 2000;119:221-229. 
Christenson J.T., Simonet F., Badel P., Schmuziger M. Evaluation of preoperative intra-aortic 
balloon pump support in high risk coronary patients. Eur J Cardiothorac Surg 
1997;11:1097-1103. 
Christenson J., Simonet F., Badel P., Schmuziger M. The effect of preoperative intra-aortic 
balloon pump support in patients with coronary artery disease, poor left-
 
Re-Engineering in OPCAB Surgery 
 
201 
ventricular function (LVEF < 40%) and hypertensive LV hypertrophy. Thorac 
Cardiovasc Surg 1997;45:60-64. 
Christenson J., Simonet F., Badel P., Schmuziger M. Optimal timing of preoperative 
intraaortic balloon pump support in high-risk coronary patients. Ann Thorac Surg 
1999;68:934-939 
Czerny M., Baumer H., Kilo J., Zuckermann A., Grubhofer G., Chevtchik O., Wolner E., 
Grimm M. Complete revascularization in coronary artery bypass grafting with and 
without cardiopulmonary bypass. Ann Thorac Surg 2001;71:165-169. 
D'Ancona G., Karamanoukian H., Ricci M., Kawaguchi A., Bergsland J., Salerno T. 
Myocardial revascularization on the beating heart after recent onset of acute 
myocardial infarction. Heart Surg Forum 2001;4:74-79. 
Favaloro RG. Saphenous vein graft in the surgical treatment of coronary artery disease J 
Thorac Cardiovasc Surg 1968;58:178-185. 
Goetz RH, Rohman M, Haller JD, et al. Internal mammary-coronary anastomosis. A 
nonsuture method employing tantalum rings J Thorac Cardiovasc Surg 
1961;41:378-386. 
Green GE, Stertzer SH, Reppert EH. Coronary artery bypass graft Ann Thoracic Surg 
1968;5:443-450 
Güler M., Kirali K., Toker M.E., Bozbuga N., Ömeroglu S.N., Akinci E., Yakut C. Different 
CABG methods in patients with chronic obstructive pulmonary disease. Ann 
Thorac Surg 2001;71:152-157. 
Gundry S.R., Romano M.A., Shattuck O.H., Razzouk A.J., Bailey L.L. Seven-year follow-up 
of coronary artery bypasses performed with and without cardiopulmonary bypass. 
J Thorac Cardiovasc Surg 1998;115:1273-1278.  
Gu Y.J., Mariani M.A., Boonstra P.W., Grandjean J.G., Oeveren W.V. Complement activation 
in coronary artery bypass grafting patients without cardiopulmonary bypass: the 
role of tissue injury by surgical incision. Chest 1999;116:892-898. 
Guyton R.A., Thourani V.H., Puskas J.D., Shanewise J.S., Steele M.A., Palmer-Steele C.L., 
Vinten-Johansen J. Perfusion-assisted direct coronary artery bypass: selective graft 
perfusion in off-pump cases. Ann Thorac Surg 2000;69:171-175. 
Hoff S.J., Ball S.K., Coltharp W.H., Glassford D.M., Jr., Lea J.W., IV, Petracek M.R. Coronary 
artery bypass in patients 80 years and over: is off-pump the operation of choice?. 
Ann Thorac Surg 2002;74:S1340-S1343. 
Kim KB, Lim C, Lee C, et al. Off-pump coronary artery bypass may decrease the patency of 
saphenous vein grafts Ann Thorac Surg 2001;72:1033-1037. 
Kim K.B., Lim C., Ahn H., Yang J.K. Intraaortic ballon pump therapy facilitates posterior 
vessel off-pump coronary artery bypass grafting in high-risk patients. Ann Thorac 
Surg 2001;71:1964-1968. 
Kolessov VL. Mammary artery coronary anastomosis as method of treatment for angina 
pectoris J Thorac Cardiovasc Surg 1967;54:535-544. 
Locker C., Shapira I., Paz Y., Kramer A., Gurevitch J., Matsa M., Pevni D., Mohr R. 
Emergency myocardial revascularization for acute myocardial infarction: survival 
benefits of avoiding cardiopulmonary bypass. Eur J Cardiothorac Surg 2000;17:234-
2385.  
 
Special Topics in Cardiac Surgery 
 
202 
Masuda M., Morita S., Tomita H., Kurisu K., Nishida T., Tominaga R., Yasui H. Off-pump 
attenuates myocardial enzyme leakage but not postoperative brain natriuretic 
peptide secretion. Ann Thorac Cardiovasc Surg 2002;8:139-144. 
Matata B.M., Sosnowski A.W., Galiñanes M. Off-pump bypass graft operation significantly 
reduces oxidative stress and inflammation. Ann Thorac Surg 2000;69:785-791.  
Mathison M., Buffolo E., Jatene A.D., Jatene F., Reichenspurner H., Matheny R.G., Shennib 
H., Akin J.J., Mack M.J. Right heart circulatory support facilitates coronary artery 
bypass without cardiopulmonary bypass. Ann Thorac Surg 2000;70:1083-1085. 
Mehlhorn U., Allen S.J., Adams D.L., Davies K.L., Gogola G.R., de Vivie R., Laine G.A. 
Normothermic continuous antegrade blood cardioplegia does not prevent 
myocardial edema and cardiac dysfunction. Circulation 1995;92:1940-1946. 
Mohr R., Moshkovitch Y., Shapira I., Amir G., Hod H., Gurevitch J. Coronary artery bypass 
without cardiopulmonary bypass for patients with acute myocardial infarction. J 
Thorac Cardiovasc Surg 1999;118:50-56. 
Montague N.T., Kouchoukos N.T., Wilson T.A., Bennett A.L., Knott H.W., Lochridge S.K., 
Erath H.G., Clayton O.W. Morbidity and mortality of coronary bypass grafting in 
patients 70 years of age and older. Ann Thorac Surg 1985;39:552-557. 
Mueller X.M., Chassot G., Zhou J., Eisa K.M., Chappuis C., Tevaearai H.T., von Seggesser 
L.K. Hemodynamics optimization during off-pump coronary artery bypass: the ‘no 
compression’ technique. Eur J Cardiothorac Surg 2002;22:249-254. 
Mullany C.J., Darling G.E., Pluth J.R., Orszulak T.A., Schaff H.V., Ilstrup D.M., Gersh B.J. 
Early and late results after isolated coronary artery bypass surgery in 159 patients 
aged 80 years and older. Circulation 1990;82(5 Suppl):IV229-IV236.  
Hirose H. Coronoary artery bypass grafting in the elderly. Chest 2000;117:1262-1270 
Muraki S., Morris C.D., Budde J.M., Velez D.A., Zhao Z., Guyton R., Vinten-Johanson J. 
Experimental off-pump coronary artery revascularization with adenosine-
enhanced reperfusion. J Thorac Cardiovasc Surg 2001;121:570-579. 
Murray G,Porcheron R, Hilario J, Rosemblau W. Anastamosis of a systemic artery to the 
coronary artery. Can Med Assoc J 1954;594:71. 
Nakayama Y., Sakata R., Ura M., Itoh T. Long-term results of coronary artery bypass 
grafting in patients with renal insufficiency. Ann Thorac Surg 2003;75:496-500. 
Penttilä H.J., Lepojärvi M.V.K., Kiviluoma K.T., Kaukoranta P.K., Hassinen I.E., 
Peuhkurinen K.J. Myocardial preservation during coronary surgery with and 
without cardiopulmonary bypass. Ann Thorac Surg 2001;71:565-571. 
Prifti E., Bonacchi M., Giunti G., Frati G., Proietti P., Leacche M., Salica A., Sani G., 
Brancaccio G. Does on-pump/beating-heart coronary artery bypass grafting offer 
better outcome in end-stage coronary artery disease patients?. J Card Surg 
2000;15:403-410. 
Puskas JD, Thourani VH, Marshall JJ, et al. Clinical outcomes, angiographic patency and 
resource utilization in 200 consecutive off-pump coronary bypass patients Ann 
Thorac Surg 2001;71:1477-1484. 
Puskas J.D., Williams W.H., Duke P.G., Staples J.R., Glas K.E., Marshall J.J., Leimbach M., 
Huber P., Garas S., Sammons B.H., McCall S.A., Petersen R.J., Bailey D.E., Chu H., 
Mahoney E.M., Weintraub W.S., Guyton R.A. Off-pump coronary artery bypass 
grafting provides complete revascularization with reduced myocardial injury, 
transfusion requirements, and length of stay: a prospective randomized 
 
Re-Engineering in OPCAB Surgery 
 
203 
comparison of two hundred unselected patients undergoing off-pump versus 
conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg 
2003;125:797-808 
Roosens C., Heerman J., De Somer F., Caes F., Van Belleghem Y., Poelaert J.I. Effects of off-
pump coronary surgery on the mechanics of the respiratory system, lung, and chest 
wall: comparison with extracorporeal circulation. Crit Care Med 2002;30:2430-2437. 
Sepic J., Wee J.O., Soltesz E.G., Hsin M.K., Cohn L.H., Laurence R.G., Aklog L. Cardiac 
positioning using an apical suction device maintains beating heart hemodynamics. 
Heart Surg Forum 2002;5/volume-nr>:279-284 
Stamou S.C., Dangas G., Dullum M.K., Pfister A.J., Boyce S.W., Bafi A.S., Garcia J.M., Corso 
P.J. Beating heart surgery in octogenarians: perioperative outcome and comparison 
with younger age groups. Ann Thorac Surg 2000;69:1140-1145.  
Strüber M., Cremer J.T., Gohrbandt B., Hagl C., Jankowski M., Völker B., Rückoldt H., 
Martin M., Haverich A. Human cytokine responses to coronary artery bypass 
grafting with and without cardiopulmonary bypass. Ann Thorac Surg 1999;68:1330-
1335.  
Shuichiro Takanashi, Toshihiro Fukui, Yasuyuki Hosoda, and Yoshihiro Shimizu. Off-pump 
long onlay bypass grafting using left internal mammary artery for diffusely 
diseased coronary artery.Ann. Thorac. Surg., Aug 2003; 76: 635 – 637. 
Svedjeholm R., Huljebrant I., Hkanson E., Vanhanen I. Glutamate and high dose glucose–
insulin–potassium (GIK) in the treatment of severe cardiac failure after cardiac 
operations. Ann Thorac Surg 1995;59:S23-S30. 
Tashiro T., Todo K., Haruta Y., Yasunaga H., Tachikawa Y. Coronary artery bypass grafting 
without cardiopulmonary bypass for high-risk patients. Cardiovasc Surg 
1996;4:207-211. 
Trapp WG, Bisarya R. Placement of coronary artery bypass graft without pump-oxygenator 
Ann Thorac Surg 1975;19:1-9. 
Van Dijk D., Nierich A.P., Jansen E.W.L., Nathoe H.M., Suyker W.J.L., Diephuis J.C., van 
Boven W., Borst C., Buskens E., Grobbee D.E., de Medina E.O.R., de Jaegere P.P.T. 
Early outcome after off-pump versus on pump coronary bypass surgery. 
Circulation 2001;104:1761-1766. 
Vassiliades T.A., Nielsen J.L., Lonquist J.L. Coronary perfusion methods during off-pump 
coronary bypass: results of a randomized clinical trial. Ann Thorac Surg 
2002;74:S1383-S1389. 
Vettath, Murali P; Kannan, A.V.; Sheen Peecheeyen, C.S.; Baburajan, A.K.; Vahab, Abdul 
and Sujith, M.P.  
Vettath’s anastamotic obturator: A simple proximal anastamotic device. Murali P Vettath. 
The heart surgery forum #2003-73305 6 (5), 2003 Online address: 
www.hsforum.com/vol6/issue5/2003-73305.html 
Vettath P Murali. Vettath’s anastamotic obturator — our experience of 269 proximal 
anastamosis.(2004). Heart Lung and Circulation, 13. pp. 288-290. Heart Lung and 
Circulation 2004; 13:288–290 
Vineberg AM  . Development of anastomosis between coronary vessels and transplanted 
mammary artery: Med Assoc J 1954;594:71 
 
Special Topics in Cardiac Surgery 
 
202 
Masuda M., Morita S., Tomita H., Kurisu K., Nishida T., Tominaga R., Yasui H. Off-pump 
attenuates myocardial enzyme leakage but not postoperative brain natriuretic 
peptide secretion. Ann Thorac Cardiovasc Surg 2002;8:139-144. 
Matata B.M., Sosnowski A.W., Galiñanes M. Off-pump bypass graft operation significantly 
reduces oxidative stress and inflammation. Ann Thorac Surg 2000;69:785-791.  
Mathison M., Buffolo E., Jatene A.D., Jatene F., Reichenspurner H., Matheny R.G., Shennib 
H., Akin J.J., Mack M.J. Right heart circulatory support facilitates coronary artery 
bypass without cardiopulmonary bypass. Ann Thorac Surg 2000;70:1083-1085. 
Mehlhorn U., Allen S.J., Adams D.L., Davies K.L., Gogola G.R., de Vivie R., Laine G.A. 
Normothermic continuous antegrade blood cardioplegia does not prevent 
myocardial edema and cardiac dysfunction. Circulation 1995;92:1940-1946. 
Mohr R., Moshkovitch Y., Shapira I., Amir G., Hod H., Gurevitch J. Coronary artery bypass 
without cardiopulmonary bypass for patients with acute myocardial infarction. J 
Thorac Cardiovasc Surg 1999;118:50-56. 
Montague N.T., Kouchoukos N.T., Wilson T.A., Bennett A.L., Knott H.W., Lochridge S.K., 
Erath H.G., Clayton O.W. Morbidity and mortality of coronary bypass grafting in 
patients 70 years of age and older. Ann Thorac Surg 1985;39:552-557. 
Mueller X.M., Chassot G., Zhou J., Eisa K.M., Chappuis C., Tevaearai H.T., von Seggesser 
L.K. Hemodynamics optimization during off-pump coronary artery bypass: the ‘no 
compression’ technique. Eur J Cardiothorac Surg 2002;22:249-254. 
Mullany C.J., Darling G.E., Pluth J.R., Orszulak T.A., Schaff H.V., Ilstrup D.M., Gersh B.J. 
Early and late results after isolated coronary artery bypass surgery in 159 patients 
aged 80 years and older. Circulation 1990;82(5 Suppl):IV229-IV236.  
Hirose H. Coronoary artery bypass grafting in the elderly. Chest 2000;117:1262-1270 
Muraki S., Morris C.D., Budde J.M., Velez D.A., Zhao Z., Guyton R., Vinten-Johanson J. 
Experimental off-pump coronary artery revascularization with adenosine-
enhanced reperfusion. J Thorac Cardiovasc Surg 2001;121:570-579. 
Murray G,Porcheron R, Hilario J, Rosemblau W. Anastamosis of a systemic artery to the 
coronary artery. Can Med Assoc J 1954;594:71. 
Nakayama Y., Sakata R., Ura M., Itoh T. Long-term results of coronary artery bypass 
grafting in patients with renal insufficiency. Ann Thorac Surg 2003;75:496-500. 
Penttilä H.J., Lepojärvi M.V.K., Kiviluoma K.T., Kaukoranta P.K., Hassinen I.E., 
Peuhkurinen K.J. Myocardial preservation during coronary surgery with and 
without cardiopulmonary bypass. Ann Thorac Surg 2001;71:565-571. 
Prifti E., Bonacchi M., Giunti G., Frati G., Proietti P., Leacche M., Salica A., Sani G., 
Brancaccio G. Does on-pump/beating-heart coronary artery bypass grafting offer 
better outcome in end-stage coronary artery disease patients?. J Card Surg 
2000;15:403-410. 
Puskas JD, Thourani VH, Marshall JJ, et al. Clinical outcomes, angiographic patency and 
resource utilization in 200 consecutive off-pump coronary bypass patients Ann 
Thorac Surg 2001;71:1477-1484. 
Puskas J.D., Williams W.H., Duke P.G., Staples J.R., Glas K.E., Marshall J.J., Leimbach M., 
Huber P., Garas S., Sammons B.H., McCall S.A., Petersen R.J., Bailey D.E., Chu H., 
Mahoney E.M., Weintraub W.S., Guyton R.A. Off-pump coronary artery bypass 
grafting provides complete revascularization with reduced myocardial injury, 
transfusion requirements, and length of stay: a prospective randomized 
 
Re-Engineering in OPCAB Surgery 
 
203 
comparison of two hundred unselected patients undergoing off-pump versus 
conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg 
2003;125:797-808 
Roosens C., Heerman J., De Somer F., Caes F., Van Belleghem Y., Poelaert J.I. Effects of off-
pump coronary surgery on the mechanics of the respiratory system, lung, and chest 
wall: comparison with extracorporeal circulation. Crit Care Med 2002;30:2430-2437. 
Sepic J., Wee J.O., Soltesz E.G., Hsin M.K., Cohn L.H., Laurence R.G., Aklog L. Cardiac 
positioning using an apical suction device maintains beating heart hemodynamics. 
Heart Surg Forum 2002;5/volume-nr>:279-284 
Stamou S.C., Dangas G., Dullum M.K., Pfister A.J., Boyce S.W., Bafi A.S., Garcia J.M., Corso 
P.J. Beating heart surgery in octogenarians: perioperative outcome and comparison 
with younger age groups. Ann Thorac Surg 2000;69:1140-1145.  
Strüber M., Cremer J.T., Gohrbandt B., Hagl C., Jankowski M., Völker B., Rückoldt H., 
Martin M., Haverich A. Human cytokine responses to coronary artery bypass 
grafting with and without cardiopulmonary bypass. Ann Thorac Surg 1999;68:1330-
1335.  
Shuichiro Takanashi, Toshihiro Fukui, Yasuyuki Hosoda, and Yoshihiro Shimizu. Off-pump 
long onlay bypass grafting using left internal mammary artery for diffusely 
diseased coronary artery.Ann. Thorac. Surg., Aug 2003; 76: 635 – 637. 
Svedjeholm R., Huljebrant I., Hkanson E., Vanhanen I. Glutamate and high dose glucose–
insulin–potassium (GIK) in the treatment of severe cardiac failure after cardiac 
operations. Ann Thorac Surg 1995;59:S23-S30. 
Tashiro T., Todo K., Haruta Y., Yasunaga H., Tachikawa Y. Coronary artery bypass grafting 
without cardiopulmonary bypass for high-risk patients. Cardiovasc Surg 
1996;4:207-211. 
Trapp WG, Bisarya R. Placement of coronary artery bypass graft without pump-oxygenator 
Ann Thorac Surg 1975;19:1-9. 
Van Dijk D., Nierich A.P., Jansen E.W.L., Nathoe H.M., Suyker W.J.L., Diephuis J.C., van 
Boven W., Borst C., Buskens E., Grobbee D.E., de Medina E.O.R., de Jaegere P.P.T. 
Early outcome after off-pump versus on pump coronary bypass surgery. 
Circulation 2001;104:1761-1766. 
Vassiliades T.A., Nielsen J.L., Lonquist J.L. Coronary perfusion methods during off-pump 
coronary bypass: results of a randomized clinical trial. Ann Thorac Surg 
2002;74:S1383-S1389. 
Vettath, Murali P; Kannan, A.V.; Sheen Peecheeyen, C.S.; Baburajan, A.K.; Vahab, Abdul 
and Sujith, M.P.  
Vettath’s anastamotic obturator: A simple proximal anastamotic device. Murali P Vettath. 
The heart surgery forum #2003-73305 6 (5), 2003 Online address: 
www.hsforum.com/vol6/issue5/2003-73305.html 
Vettath P Murali. Vettath’s anastamotic obturator — our experience of 269 proximal 
anastamosis.(2004). Heart Lung and Circulation, 13. pp. 288-290. Heart Lung and 
Circulation 2004; 13:288–290 
Vineberg AM  . Development of anastomosis between coronary vessels and transplanted 
mammary artery: Med Assoc J 1954;594:71 
 
Special Topics in Cardiac Surgery 
 
204 
Yeatman M., Caputo M., Narayan P., Ghosh A.K., Ascione R., Ryder I., Angelini G.D. 
Intracoronary shunts reduce transient intraoperative myocardial dysfunction 
during off-pump coronary operations. Ann Thorac Surg 2002;73:1411-1417. 
Yokoyama T., Baumgartner F.J., Gheissari A., Capouya E.R., Panagiotides G.P., Declusin R.J. 
Off-pump versus on-pump coronary bypass in high-risk subgroups. Ann Thorac 
Surg 2000;70:1546-1550. 
9 
Strategies for the Prevention of Postoperative 
Atrial Fibrillation in Cardiac Surgery 
Estella M. Davis1, Kathleen A. Packard1, Jon T. Knezevich1, 
 Thomas M. Baker2 and Thomas J. Langdon2  
1Creighton University School of Pharmacy and Health Professions 
2Alegent Health, Cardiovascular and Thoracic Surgery 
USA 
1. Introduction 
Atrial fibrillation (AF) occurs in 15% to 50% of patients after cardiac surgery (Bradley et al., 
2005; Dunning et al., 2006). Postoperative atrial fibrillation (POAF) most often develops 
between the second and fifth postoperative day, with a peak incidence in the first two to 
three days. While POAF can be self-limiting, it may also be associated with hemodynamic 
compromise, postoperative stroke, perioperative myocardial infarction (MI), ventricular 
arrhythmias, and heart failure (Echahidi et al., 2008; Kaireviciute et al., 2009). The 
development of POAF is associated with, on average, an additional hospital length of stay 
(LOS) of 1 to 1.5 days (Kim et al., 2001; Zimmer et al., 2003). Some studies, however, report 
that POAF increases hospital LOS by almost 5 days (Aranski et al., 1996; Gillespie et al., 
2006). POAF is also associated with higher hospital costs with an average increase of 
$10,000-$12,600 per hospitalization (Gillespie et al., 2006; Aranski et al., 1996).  
Practice guidelines for the prevention of POAF in patients undergoing cardiac surgery exist 
which include the American College of Chest Physicians (ACCP) 2005 POAF Guidelines, the 
ACCP 2005 Recommendations for the Role of Cardiac Pacing for POAF, the American College 
of Cardiology (ACC)/American Heart Association (AHA)/European Society of Cardiology 
(ESC) 2006 Atrial Fibrillation Guidelines, the ACC/AHA 2004 Coronary Artery Bypass Graft 
Surgery (CABG) Guidelines, the Canadian Cardiovascular Society (CCS) Consensus 
Conference Statements on AF, and the European Association for Cardio-Thoracic Surgery 
(EACTS) 2006 POAF Guidelines and updated ESC/EACTS 2010 AF Guidelines (Bradley et al., 
2005; Maisel & Epstein 2005; Dunning et al., 2006; Fuster et al., 2006; Eagle et al., 2004; Mitchell 
et al., 2005; Kerr & Roy, 2004; European Society of Cardiology ([ESC], 2010) (Table 1). 
The guidelines are consistent in that they all strongly recommend using beta-blockers to 
reduce POAF incidence (ACCP 2005 POAF Guidelines Strength A, ACC/AHA/ESC 2006 AF 
Guidelines and ACC/AHA 2004 CABG Guidelines Class I, Canadian Cardiovascular Society 
AF/POAF Consensus Class I, and ESC 2010 AF Guidelines Class I). The Surgical Care 
Improvement Project (SCIP) National Quality Measures also state that all patients undergoing 
cardiac surgery should receive a beta-blocker during the perioperative period if they were on a 
beta-blocker prior to arrival (Surgical Care Improvement Project [SCIP] Version 3.0a,  
2009). Most institutions have incorporated this requirement into their prospective  
preoperative order sets for all patients without contraindications to beta-blockers. 
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ACCP= American College of Chest Physicians, ACC= American College of Cardiology, AHA= American 
Heart Association, ESC= European Society of Cardiology AF = atrial fibrillation, BB = beta-blocker, CABG = 
coronary artery bypass graft, CV = cardiovascular, EACTS = European Association for Cardiothoracic 
Surgery, POAF= postoperative atrial fibrillation, pts = patients 
Table 1. International Guideline Recommendations for Therapies for the Prevention of 
POAF in Patients Undergoing Cardiac Surgery 
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Though there are no studies examining POAF prophylaxis for patients intolerant of beta-
blockers, effective alternatives include sotalol and amiodarone, depending upon the 
contraindication. The guidelines further specify that amiodarone may be given as an 
alternative or considered in patients at high risk for POAF (Fuster et al., 2006; Eagle et al., 
2004; ESC, 2010; Mitchell et al., 2005a; Kerr & Roy, 2004). Only the previous 2006 EACTS and 
Canadian guidelines support the use of magnesium and state that it may be given in 
addition to other strategies to reduce POAF(Dunning et al., 2006; Mitchell et al., 2005a; Kerr 
& Roy, 2004). Additionally, the most recent ESC guidelines include consideration of 
corticosteroids for the prevention of POAF (ESC, 2010). 
The practice guidelines also recommend utilization of non-pharmacologic strategies for the 
prevention of POAF in cardiac surgery patients (Table 1). The most common strategy 
referred to in the guidelines is cardiac pacing. The most recent 2010 ESC AF guidelines and 
ACCP statement from 2005 recommend that biatrial pacing should be considered for 
prophylaxis (ESC, 2010, Maisel & Epstein, 2005). The CCS statement also recommends that 
atrial pacing with or without a ventricular lead should be considered in patients with 
symptomatic bradycardia (Class 2A recommendation based on Level A evidence) and that 
atrial pacing should be considered if a patient is not on a beta-blocker before surgery (Class 
2A recommendation based on Level B evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004). 
Lastly, the CVS guidelines strongly recommend placing temporary ventricular epicardial 
pacing electrode wires at the time of surgery to allow for backup pacing as necessary (Class 
1 recommendation based on Level C evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004). 
Other non-pharmacologic strategies mentioned in the guidelines include the use of off-
pump CABG, posterior pericardiotomy, and introperative maze ablation (Mitchell et al., 
2005a; Kerr & Roy, 2004; ESC, 2010). 
2. Pathogenesis of POAF 
The underlying mechanisms for the development of POAF after cardiac surgery are not 
precisely known, but are thought to be multifactorial (Figure 1) (Banach et al., 2010). It has 
been proposed that certain causative mechanisms alter atrial refractoriness and slow atrial 
conduction which results in multiple reentry wavelets circulating within the atria (Baker & 
White, 2007a). Some of these mechanisms include pericardial inflammation, excessive 
production of catecholamines, and volume and pressure changes. Numerous predisposing 
factors such as advanced age, hypertension, diabetes, left atrial enlargement, left ventricular 
hypertrophy, intraoperative and postoperative factors such as atrial injury or ischemia, are 
all thought to impact the development of POAF. Once these conditions exist, a triggering 
event such as premature atrial contraction, electrolyte imbalance, and/or enhanced 
adrenergic or vagal stimulation initiates POAF. Neurohormonal activation is more widely 
recognized as a cause of POAF based on studies linking elevated norepinephrine and 
epinephrine concentrations to the development of POAF (Baker & White, 2007a; Kalman et 
al., 1995). Hence, the majority of interventions that reduce the incidence of POAF modulate 
sympathetic and parasympathetic systems or alter cardiac conduction (Table 1). 
While the mechanisms involved in the development of POAF are multifactorial, there is 
increasing evidence that inflammation also plays a role. Such inflammation may be induced 
by extracorporeal circulation or cardiopulmonary bypass (CPB) with subsequent elevations of 
C-reactive protein (CRP), interleukin-6 (IL-6), and the complement system (Echahidi et al., 
2008; Gaudino et al., 2003; Bruins et al., 1997; Canbaz et al., 2008). Angiotensin II has been 
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HR= heart rate, SD= standard deviation, NADPH= nicotinomide adenine dinucleotide phosphate, 
CABG= coronary artery bypass grafting, ECM= extracellular matrix, CRP= C-reactive protein, IL-6= 
interleukin-6, HSP= heat shock protein, PAI= plasminogen activator inhibitor 
Fig. 1. Pathogenesis of postoperative atrial fibrillation (Banach et al., 2010) 
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shown to increase the production of proinflammatory cytokines, adhesion molecules, and 
selectins (Erlich et al., 2006; Boos et al., 2006). White blood cell count may also be a predictor of 
POAF (Lamm et al., 2006). The degree of inflammation postoperatively can negatively affect 
atrial conduction and duration of atrial fibrillation (Ishii et al., 2005; Tselentakis et al., 2006).  
Oxidative stress has also been implicated in the pathogenesis of atrial fibrillation as the atrial 
tissue undergoes oxidative challenge during CPB (Rodrigo et al., 2008). Patients with POAF 
have been shown to have increased acute myocardial oxidation when compared to patients 
that did not experience POAF (Ramlawi et al., 2007). Specifically, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, an enzyme associated with the formation of the 
reactive oxygen species, superoxide, was found to be independently associated with increased 
risk of POAF (Kim et al., 2008). This may be due to damage of cardiac myocytes through lipid 
peroxidation, breakdown of cell membrane, decreased mitochondrial function, calcium 
overload, and apoptosis (Elahi et al., 2008). Because NADPH is activated by numerous 
mediators including tumor necrosis factor- α (TNF-α) (Griendling et al., 2000), it has been 
proposed as a link between inflammation and oxidative stress in POAF.  
Based on these newly identified pathways, emerging pharmacologic therapies for the 
prevention of POAF have been under investigation including HMG Co-A reductase inhibitors 
(statins), renin-angiotensin-aldosterone-system modulators (including angiotensin converting 
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)), corticosteroids, omega-
3 fatty acids, ascorbic acid, N-acetylcysteine, and sodium nitroprusside.  
The guidelines suggest additive therapies can be considered for patients at high risk of 
developing POAF. Risk factors that have been identified to increase the risk of POAF 
include advanced age, history of atrial fibrillation, COPD, valvular surgery, hypertension, 
poor left ventricular function, chronic renal insufficiency, diabetes mellitus, rheumatic heart 
disease, withdrawal of preoperative beta-blockers or ACEIs, and increased aortic cross-
clamp and CPB time (Mathew et al., 2004; Baker et al., 2007b; Nisanoglu et al., 2007). No 
simple criteria exist that allow patients to be classified as high risk for the development of 
POAF. A risk index model (Multicenter Study of Perioperative Ischemia Atrial Fibrillation 
Risk Index) (Table 2) was developed to identify subjects at high risk for POAF (Mathew et 
al., 2004). Patients receiving a risk score less than 14 were considered low risk, 14-31 were 
considered medium risk, and greater than 31 were considered high risk for developing 
POAF. Comparison of the predictive ability of the model revealed that the incidence of atrial 
fibrillation was similar in the derivation and validation cohorts across the three risk groups, 
and the area under the receiver operating characteristic curve applied to the final model was 
0.77 (where >0.75 represents a model with good discriminate power). This risk scoring tool 
has been used to stratify patients into risk groups that may benefit from add-on prophylactic 
therapy (Barnes et al., 2006). 
3. Pharmacologic therapies for the prevention of POAF in cardiac surgery 
3.1 Established pharmacologic therapies 
3.1.1 Beta-blockers 
Beta-blockers work at the myocardium antagonizing the effects of catecholamines and have 
been studied extensively for the prevention of POAF. Meta-analyses have shown significant 
reduction in POAF incidence with the use of beta-blocker therapy, resulting in 
recommendation for their use as first-line therapy (Bradley et al., 2005; Dunning et al.; 2006, 
Fuster et al., 2006; Eagle et al., 2004, Kerr & Roy, 2004; [ESC], 2010). The largest meta- 
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Predictor of POAF after CABG Risk Score Point Assignment 
Age (Y)  
      <30 6 
      30-39 12 
      40-49 18 
      50-59 24 
      60-69 30 
      70-79 36 
      ≥80 42 
History of AF 7 
History of COPD 4 
Concurrent valve surgery 6 
Withdrawal of postoperative treatment  
      ΒB 6 
      ACEI 5 
BB treatment  
      Preoperative and postoperative -7 
      Postoperative -11 
Preoperative and postoperative ACEI treatment -5 
Postoperative treatment  
      Potassium supplementation -5 
      NSAIDs -7 
 = aTotal Points 
aRisk Groups based on summative total point assignment using predictors from table:  
Low risk = Score < 14, Medium risk = Score 14-31, High risk = Score >31 
ACEI = angiotensin converting enzyme inhibitor, AF = atrial fibrillation, BB = beta-blocker, CABG = 
coronary artery bypass graft, COPD = chronic obstructive pulmonary disease, NSAIDs = non-steroidal 
anti-inflammatory drugs, POAF = postoperative atrial fibrillation   
Table 2. Multicenter Study of Perioperative Ischemia Atrial Fibrillation Risk Index (Mathew 
et al., 2004)   
analysis was published in 2002 by Crystal et al. that included 27 randomized controlled 
trials with 3,840 patients (Crystal et al., 2002). Use of beta-blocker therapy decreased the 
incidence of POAF from 33% in the control group compared to 19% in the group receiving 
beta-blockade. This corresponded to a number needed to treat (NNT) of seven patients. A 
large retrospective analysis of the Society of Thoracic Surgeons (STS) database containing 
629,877 patients, demonstrated a reduction in mortality rate with use of peri-operative beta-
blockers (Ferguson et al., 2002). It has been shown that patients receiving perioperative beta-
blockers have reduced mortality compared to control (3.4% versus 2.8%, OR 0.8, 95% CI 0.78 
– 0.82; p<0.001). Efficacy of beta-blockade in the prevention of POAF has been theorized to 
decrease hospital LOS. However, two beta-blocker trials reporting effect on LOS 
demonstrated a non-significant reduction in LOS (-0.66 days; 95% CI, -2.04-0.72) (Cybulsky 
et al., 2000; Wenke et al., 1999).  
The importance of beta-blockers is also affirmed by the two to five-fold increase in the 
incidence of POAF when beta-blockers are discontinued postoperatively (Kalman et al., 
1995; Jideus et al., 2000; Ali et al., 1997). The increase in POAF is thought to be caused by 
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prevention of POAF have been under investigation including HMG Co-A reductase inhibitors 
(statins), renin-angiotensin-aldosterone-system modulators (including angiotensin converting 
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)), corticosteroids, omega-
3 fatty acids, ascorbic acid, N-acetylcysteine, and sodium nitroprusside.  
The guidelines suggest additive therapies can be considered for patients at high risk of 
developing POAF. Risk factors that have been identified to increase the risk of POAF 
include advanced age, history of atrial fibrillation, COPD, valvular surgery, hypertension, 
poor left ventricular function, chronic renal insufficiency, diabetes mellitus, rheumatic heart 
disease, withdrawal of preoperative beta-blockers or ACEIs, and increased aortic cross-
clamp and CPB time (Mathew et al., 2004; Baker et al., 2007b; Nisanoglu et al., 2007). No 
simple criteria exist that allow patients to be classified as high risk for the development of 
POAF. A risk index model (Multicenter Study of Perioperative Ischemia Atrial Fibrillation 
Risk Index) (Table 2) was developed to identify subjects at high risk for POAF (Mathew et 
al., 2004). Patients receiving a risk score less than 14 were considered low risk, 14-31 were 
considered medium risk, and greater than 31 were considered high risk for developing 
POAF. Comparison of the predictive ability of the model revealed that the incidence of atrial 
fibrillation was similar in the derivation and validation cohorts across the three risk groups, 
and the area under the receiver operating characteristic curve applied to the final model was 
0.77 (where >0.75 represents a model with good discriminate power). This risk scoring tool 
has been used to stratify patients into risk groups that may benefit from add-on prophylactic 
therapy (Barnes et al., 2006). 
3. Pharmacologic therapies for the prevention of POAF in cardiac surgery 
3.1 Established pharmacologic therapies 
3.1.1 Beta-blockers 
Beta-blockers work at the myocardium antagonizing the effects of catecholamines and have 
been studied extensively for the prevention of POAF. Meta-analyses have shown significant 
reduction in POAF incidence with the use of beta-blocker therapy, resulting in 
recommendation for their use as first-line therapy (Bradley et al., 2005; Dunning et al.; 2006, 
Fuster et al., 2006; Eagle et al., 2004, Kerr & Roy, 2004; [ESC], 2010). The largest meta- 
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Predictor of POAF after CABG Risk Score Point Assignment 
Age (Y)  
      <30 6 
      30-39 12 
      40-49 18 
      50-59 24 
      60-69 30 
      70-79 36 
      ≥80 42 
History of AF 7 
History of COPD 4 
Concurrent valve surgery 6 
Withdrawal of postoperative treatment  
      ΒB 6 
      ACEI 5 
BB treatment  
      Preoperative and postoperative -7 
      Postoperative -11 
Preoperative and postoperative ACEI treatment -5 
Postoperative treatment  
      Potassium supplementation -5 
      NSAIDs -7 
 = aTotal Points 
aRisk Groups based on summative total point assignment using predictors from table:  
Low risk = Score < 14, Medium risk = Score 14-31, High risk = Score >31 
ACEI = angiotensin converting enzyme inhibitor, AF = atrial fibrillation, BB = beta-blocker, CABG = 
coronary artery bypass graft, COPD = chronic obstructive pulmonary disease, NSAIDs = non-steroidal 
anti-inflammatory drugs, POAF = postoperative atrial fibrillation   
Table 2. Multicenter Study of Perioperative Ischemia Atrial Fibrillation Risk Index (Mathew 
et al., 2004)   
analysis was published in 2002 by Crystal et al. that included 27 randomized controlled 
trials with 3,840 patients (Crystal et al., 2002). Use of beta-blocker therapy decreased the 
incidence of POAF from 33% in the control group compared to 19% in the group receiving 
beta-blockade. This corresponded to a number needed to treat (NNT) of seven patients. A 
large retrospective analysis of the Society of Thoracic Surgeons (STS) database containing 
629,877 patients, demonstrated a reduction in mortality rate with use of peri-operative beta-
blockers (Ferguson et al., 2002). It has been shown that patients receiving perioperative beta-
blockers have reduced mortality compared to control (3.4% versus 2.8%, OR 0.8, 95% CI 0.78 
– 0.82; p<0.001). Efficacy of beta-blockade in the prevention of POAF has been theorized to 
decrease hospital LOS. However, two beta-blocker trials reporting effect on LOS 
demonstrated a non-significant reduction in LOS (-0.66 days; 95% CI, -2.04-0.72) (Cybulsky 
et al., 2000; Wenke et al., 1999).  
The importance of beta-blockers is also affirmed by the two to five-fold increase in the 
incidence of POAF when beta-blockers are discontinued postoperatively (Kalman et al., 
1995; Jideus et al., 2000; Ali et al., 1997). The increase in POAF is thought to be caused by 
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beta-blocker withdrawal and mediated by an upregulation of beta adrenergic receptors and 
sympathetic stimulation (Kalman et al., 1995). Beta-blocker withdrawal is significantly 
associated with a greater than two-fold risk of developing POAF in cardiac surgery patients 
(Adjusted OR 2.17, 95% CI 1.11-4.25, p=0.04) (Lertsburapa et al., 2008). Thus, timing of beta-
blocker administration appears play an important role and evidence supports the 
continuation of beta-blocker therapy from the preoperative stage through postoperative 
management. The guidelines emphasize the importance of reinitiating beta-blockers 
postoperatively without delay (Bradley et al., 2005).  
In addition, the mode of administration of beta-blocker therapy has been evaluated in the 
prevention of POAF. Intravenous administration of metoprolol has demonstrated 
superiority to oral administration when accessing for the prevention of POAF. This is 
theorized to be a result of diminished gastrointestinal absorption with oral administration 
early after surgery. This phenomenon has been demonstrated by Halonen et al., when a 
significant reduction (p=0.036) of POAF occurrence by 11.3% was noted to occur in patients 
assigned to receive intravenous metoprolol therapy compared to patients assigned oral 
therapy (Halonen et al., 2006).  
Controversy exists around selection of the most effective beta-blocker in reducing POAF. 
Two studies have demonstrated improved efficacy of carvedilol when compared to 
metoprolol (Acikel et al., 2008; Haghjoo et al., 2007). This was confirmed by approximately 
18%-20.4% less episodes of POAF in those patients assigned to receive carvedilol.  
Despite the overwhelming evidence to support beta-blocker therapy in the prevention of 
POAF, contraindications to this therapy exist. Alternative pharmacologic and non-
pharmacologic modalities are warranted for patients who cannot tolerate or have the 
following contraindications to beta-blockers: bradycardia (<45 bpm), heart block, cardiac 
failure, severe peripheral edema, sick-sinus syndrome, bronchospastic disease (non-selective 
beta-blockers), and hypotension (SBP < 100 mmHg) with myocardial infarction.  
3.1.2 Amiodarone 
Amiodarone, a class III antiarrhythmic agent, has shown efficacy in the prevention of POAF. 
Its activity is demonstrated through blockade of alpha and beta-adrenergic receptors as well 
as sodium, calcium and potassium channels. Only beta-blockers have more safety and 
efficacy data to support their effectiveness in the prevention of POAF. Most randomized, 
controlled trials have supported the efficacy of amiodarone over placebo in the prevention 
of POAF by showing reduction of occurrence between 12% to 51% (Auer et al., 2004a; 
Barnes et al., 2006; Daoud et al., 1997;  Guarnieri et al., 1999; Giri et al., 2001; White et al., 
2002; Yazigi et al., 2002; Tokmakoglu et al., 2002; White et al., 2003; Mitchell et al., 2005a; 
Budeus et al., 2006; Zebis et al., 2007). Therefore, amiodarone has been granted a class IIa 
recommendation for POAF prophylaxis, behind beta-blockers, according to the 
ACC/AHA/ESC 2006 AF Guidelines, ACC/AHA 2004 CABG Guidelines, 2004 CCS 
AF/POAF Consensus statement, and ESC 2010 (Fuster et al., 2006; Eagle et al., 2004; Kerr & 
Roy, 2004; ESC, 2010). Additionally, the guidelines support amiodarone as prophylactic 
therapy in patients unable to tolerate beta-blockers or in high-risk patients with or without 
beta-blocker therapy (Bradley et al., 2005).  
Two trials evaluating amiodarone versus placebo have demonstrated clear reduction of 
POAF occurrence (Mitchell et al., 2005b; Daoud et al., 1997). Compared to placebo, 
amiodarone reduced POAF incidence by 13.4%-19%. Effectiveness between amiodarone 
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versus other pharmacological agents has been established. Two meta-analysis have been 
conducted evaluating the efficacy of amiodarone in POAF in which a statistically significant 
decrease in incidence was established (Bagshaw et al., 2006; Haan et al., 2002). Comparisons 
of amiodarone effectiveness have been made with agents such as beta-blockers (propranolol, 
metoprolol, and bisoprolol), sotalol, digoxin, and diltiazem. No clear superiority has been 
established amongst comparative trials. Amiodarone has been given in direct combination 
with metoprolol, magnesium, and atrial septal pacing in Bachmanns’s Bundle (Auer et al., 
2004a; Cagli et al.; 2006, White et al., 2003). All of these studies showed amiodarone in direct 
combination with the previous pharmacologic and non-pharmacologic options to be 
superior than that of placebo, with absolute reductions in the incidence of POAF by 20% to 
24% (Auer et al., 2004a; Cagli et al., 2006; White et al., 2003). Combination therapy with 
amiodarone and beta-blockers has been well validated. A meta-analysis also found that 
amiodarone also significantly reduces the LOS by 0.91 days (95% CI, -1.59- -0.24) (Crystal et 
al., 2002). 
Various dosing regimens using IV and/or oral amiodarone with varying administration 
times have been used in the POAF prevention trials. A meta-analysis evaluating 14 
randomized, controlled trials in 2,864 patients, stratified into low (<3 g), medium (3-5 g), or 
high (>5 g) and timing was divided into preoperative or postoperative administration, 
found that cumulative doses of >3 g may be more effective than lower doses and 
preoperative initiation of amiodarone may be unnecessary (Buckley et al., 2007). 
Amiodarone is effective for the prevention of POAF, however it has a complex side effect 
profile that includes QTc interval prolongation, pulmonary and liver toxicity, thyroid 
abnormalities, and visual disturbances. Patients with any of these pre-existing conditions 
may be placed at more risk with the addition of amiodarone for the prevention of POAF 
and the risk versus benefit must be evaluated for each patient. Side effects of amiodarone 
are typically associated with large cumulative doses and prolonged use. However, dosing 
regimens for prophylaxis tend to be short in duration, use lower cumulative dosing, and 
may use more convenient oral doses with or without a short course of IV amiodarone to 
avoid side effects associated with IV administration. The safety of amiodarone in patients 
undergoing cardiac surgery has been evaluated in a meta-analysis reviewing 18 
randomized controlled trials (Patel et al., 2006). Results showed that amiodarone use was 
significantly associated with increased risk of hypotension (OR 1.79; 95% CI 1.04-3.09) and 
bradycardia (OR 2.33; 95% CI 1.41-3.61), especially when the intravenous formulation was 
utilized in high doses (greater than 1 gram). Therefore, clinicians should be cautious using 
amiodarone, especially in combination therapy with beta-blockers or other therapies that 
may cause bradycardia or hypotension. Finally, if amiodarone therapy is added to a 
patient’s medication profile, physical and laboratory exams should be conducted and 
evaluated for the presence of drug-drug interactions or medication side effects.  
3.1.3 Sotalol 
Sotalol, a class III antiarrhythmic that possess beta-blocking activity, has been shown to be 
an effective pharmacological agent for the prevention of POAF. Within the primary 
literature, sotalol has demonstrated absolute reductions in the incidence of POAF between 
13% - 16% (Auer et al., 2004a; Janssen et al., 1986; Suttorp et al., 1991; Weber et al., 1998; 
Evrard et al., 2000). Despite its demonstrated effectiveness, sotalol is contraindicated in 
patients with severe renal insufficiency and should be avoided in patients with heart failure. 
Furthermore, because of its propensity to cause torsades de pointes, it should be avoided in 
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beta-blocker withdrawal and mediated by an upregulation of beta adrenergic receptors and 
sympathetic stimulation (Kalman et al., 1995). Beta-blocker withdrawal is significantly 
associated with a greater than two-fold risk of developing POAF in cardiac surgery patients 
(Adjusted OR 2.17, 95% CI 1.11-4.25, p=0.04) (Lertsburapa et al., 2008). Thus, timing of beta-
blocker administration appears play an important role and evidence supports the 
continuation of beta-blocker therapy from the preoperative stage through postoperative 
management. The guidelines emphasize the importance of reinitiating beta-blockers 
postoperatively without delay (Bradley et al., 2005).  
In addition, the mode of administration of beta-blocker therapy has been evaluated in the 
prevention of POAF. Intravenous administration of metoprolol has demonstrated 
superiority to oral administration when accessing for the prevention of POAF. This is 
theorized to be a result of diminished gastrointestinal absorption with oral administration 
early after surgery. This phenomenon has been demonstrated by Halonen et al., when a 
significant reduction (p=0.036) of POAF occurrence by 11.3% was noted to occur in patients 
assigned to receive intravenous metoprolol therapy compared to patients assigned oral 
therapy (Halonen et al., 2006).  
Controversy exists around selection of the most effective beta-blocker in reducing POAF. 
Two studies have demonstrated improved efficacy of carvedilol when compared to 
metoprolol (Acikel et al., 2008; Haghjoo et al., 2007). This was confirmed by approximately 
18%-20.4% less episodes of POAF in those patients assigned to receive carvedilol.  
Despite the overwhelming evidence to support beta-blocker therapy in the prevention of 
POAF, contraindications to this therapy exist. Alternative pharmacologic and non-
pharmacologic modalities are warranted for patients who cannot tolerate or have the 
following contraindications to beta-blockers: bradycardia (<45 bpm), heart block, cardiac 
failure, severe peripheral edema, sick-sinus syndrome, bronchospastic disease (non-selective 
beta-blockers), and hypotension (SBP < 100 mmHg) with myocardial infarction.  
3.1.2 Amiodarone 
Amiodarone, a class III antiarrhythmic agent, has shown efficacy in the prevention of POAF. 
Its activity is demonstrated through blockade of alpha and beta-adrenergic receptors as well 
as sodium, calcium and potassium channels. Only beta-blockers have more safety and 
efficacy data to support their effectiveness in the prevention of POAF. Most randomized, 
controlled trials have supported the efficacy of amiodarone over placebo in the prevention 
of POAF by showing reduction of occurrence between 12% to 51% (Auer et al., 2004a; 
Barnes et al., 2006; Daoud et al., 1997;  Guarnieri et al., 1999; Giri et al., 2001; White et al., 
2002; Yazigi et al., 2002; Tokmakoglu et al., 2002; White et al., 2003; Mitchell et al., 2005a; 
Budeus et al., 2006; Zebis et al., 2007). Therefore, amiodarone has been granted a class IIa 
recommendation for POAF prophylaxis, behind beta-blockers, according to the 
ACC/AHA/ESC 2006 AF Guidelines, ACC/AHA 2004 CABG Guidelines, 2004 CCS 
AF/POAF Consensus statement, and ESC 2010 (Fuster et al., 2006; Eagle et al., 2004; Kerr & 
Roy, 2004; ESC, 2010). Additionally, the guidelines support amiodarone as prophylactic 
therapy in patients unable to tolerate beta-blockers or in high-risk patients with or without 
beta-blocker therapy (Bradley et al., 2005).  
Two trials evaluating amiodarone versus placebo have demonstrated clear reduction of 
POAF occurrence (Mitchell et al., 2005b; Daoud et al., 1997). Compared to placebo, 
amiodarone reduced POAF incidence by 13.4%-19%. Effectiveness between amiodarone 
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versus other pharmacological agents has been established. Two meta-analysis have been 
conducted evaluating the efficacy of amiodarone in POAF in which a statistically significant 
decrease in incidence was established (Bagshaw et al., 2006; Haan et al., 2002). Comparisons 
of amiodarone effectiveness have been made with agents such as beta-blockers (propranolol, 
metoprolol, and bisoprolol), sotalol, digoxin, and diltiazem. No clear superiority has been 
established amongst comparative trials. Amiodarone has been given in direct combination 
with metoprolol, magnesium, and atrial septal pacing in Bachmanns’s Bundle (Auer et al., 
2004a; Cagli et al.; 2006, White et al., 2003). All of these studies showed amiodarone in direct 
combination with the previous pharmacologic and non-pharmacologic options to be 
superior than that of placebo, with absolute reductions in the incidence of POAF by 20% to 
24% (Auer et al., 2004a; Cagli et al., 2006; White et al., 2003). Combination therapy with 
amiodarone and beta-blockers has been well validated. A meta-analysis also found that 
amiodarone also significantly reduces the LOS by 0.91 days (95% CI, -1.59- -0.24) (Crystal et 
al., 2002). 
Various dosing regimens using IV and/or oral amiodarone with varying administration 
times have been used in the POAF prevention trials. A meta-analysis evaluating 14 
randomized, controlled trials in 2,864 patients, stratified into low (<3 g), medium (3-5 g), or 
high (>5 g) and timing was divided into preoperative or postoperative administration, 
found that cumulative doses of >3 g may be more effective than lower doses and 
preoperative initiation of amiodarone may be unnecessary (Buckley et al., 2007). 
Amiodarone is effective for the prevention of POAF, however it has a complex side effect 
profile that includes QTc interval prolongation, pulmonary and liver toxicity, thyroid 
abnormalities, and visual disturbances. Patients with any of these pre-existing conditions 
may be placed at more risk with the addition of amiodarone for the prevention of POAF 
and the risk versus benefit must be evaluated for each patient. Side effects of amiodarone 
are typically associated with large cumulative doses and prolonged use. However, dosing 
regimens for prophylaxis tend to be short in duration, use lower cumulative dosing, and 
may use more convenient oral doses with or without a short course of IV amiodarone to 
avoid side effects associated with IV administration. The safety of amiodarone in patients 
undergoing cardiac surgery has been evaluated in a meta-analysis reviewing 18 
randomized controlled trials (Patel et al., 2006). Results showed that amiodarone use was 
significantly associated with increased risk of hypotension (OR 1.79; 95% CI 1.04-3.09) and 
bradycardia (OR 2.33; 95% CI 1.41-3.61), especially when the intravenous formulation was 
utilized in high doses (greater than 1 gram). Therefore, clinicians should be cautious using 
amiodarone, especially in combination therapy with beta-blockers or other therapies that 
may cause bradycardia or hypotension. Finally, if amiodarone therapy is added to a 
patient’s medication profile, physical and laboratory exams should be conducted and 
evaluated for the presence of drug-drug interactions or medication side effects.  
3.1.3 Sotalol 
Sotalol, a class III antiarrhythmic that possess beta-blocking activity, has been shown to be 
an effective pharmacological agent for the prevention of POAF. Within the primary 
literature, sotalol has demonstrated absolute reductions in the incidence of POAF between 
13% - 16% (Auer et al., 2004a; Janssen et al., 1986; Suttorp et al., 1991; Weber et al., 1998; 
Evrard et al., 2000). Despite its demonstrated effectiveness, sotalol is contraindicated in 
patients with severe renal insufficiency and should be avoided in patients with heart failure. 
Furthermore, because of its propensity to cause torsades de pointes, it should be avoided in 
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patients with congenital long QT syndrome or a baseline corrected QT interval greater than 
440 msec. Due to its beta-blocking properties, sotalol is contraindicated in patients intolerant 
of beta-blockers. Because of the aforementioned limitations of this agent, sotalol has been 
granted a class IIb recommendation for POAF prophylaxis behind beta-blockers according 
to the ACC/AHA/ESC 2006 AF Guidelines and the ACC/AHA 2004 CABG Guidelines 
(Fuster et al., 2006; Eagle et al., 2004). The most recent 2010 ESC guidelines have assigned a 
Class IIb recommendation for sotalol due to its proarrhythmic risk (ESC, 2010). However, 
the earlier 2006 EACTS guidelines gave sotalol a stronger grade A recommendation based 
upon its comparative efficacy trials versus beta-blockers (Dunning et al., 2006) similar to 
ACC recommendations. 
Patel and Dunning evaluated seven different randomized trials comparing sotalol to 
conventional beta blockers (Patel et al., 2005). Out of the seven trials evaluated, five studies 
demonstrated a statistically significant reduction in POAF for those patients assigned to 
sotalol compared to conventional beta-blockade. The number of patients needed to be 
treated with sotalol to prevent POAF over that of conventional beta-blocker therapy was 
found to be 10. Conversely, because of the pro-arrythmic properties of sotalol, conventional 
beta-blocker therapy may be a safer option.  
3.1.4 Magnesium 
POAF has been associated with decreased postoperative magnesium levels (Kalman et al., 
1995). In fact, plasma magnesium concentration levels less that 0.9 mmol have been found to 
be an independent predictor of POAF (OR 6.7) when using multivariate logistic regression 
models (Treggiari-Venzi et al., 2000). Multiple large, randomized, controlled trials with 
magnesium have failed to demonstrate superiority to usual care with no magnesium in the 
prevention of POAF. These trials included various delivery forms of magnesium including: 
IV infusion (Treggiari-Venzi et al., 2000; Serafimovski et al., 2008; Caspie et al., 1995; Bert et 
al., 2001; Zangrillo et al., 2005), IV infusion based on serum levels (Wilkes et al., 2002), 
magnesium supplementation in maintenance fluids (Colquhoun et al., 1993) and in 
supplementation through cardioplegia solution (Shakerinia et al., 1996). Surprising lower 
cumulative doses of magnesium supplementation (mean cumulative dose 8.2 g) have shown 
to be more effective in reducing the incidence of POAF (OR 0.36, 95% CI 0.23-0.56), 
compared to higher doses (mean cumulative dose 15 g) (OR 0.99, 95% CI 0.70-1.41) (Henyan 
et al., 2005). Results from the same meta-analysis found that preoperative administration of 
magnesium was more effective at decreasing the incidence of POAF (OR 0.46, 95% CI 0.31-
0.67) compared to intraoperative or postoperative administration. Results from several 
meta-analysis (Woodend et al., 1998; Burgess et al., 2006; Shiga et al., 2004; Miller et al., 2005; 
Alghamdi et al., 2005; Henyan et al., 2005; Shepard et al., 2008) have shown inconsistent 
efficacy with magnesium use. A few studies have demonstrated a significant benefit of 
magnesium when compared to usual care with absolute reductions in the incidence of 
POAF by 16% to 34% (Nurozler et al., 1996; Maslow et al., 2000; Kohno et al., 2005). 
However, at this time there is a lack of statistically significant data to support magnesium 
supplementation as monotherapy compared to that of beta-blocker, amiodarone, or sotalol 
therapy in the treatment of POAF (Bert et al., 2001; Solomon et al., 2000; Cagli et al., 2006). 
Only the CCS consensus statement includes magnesium as a Class IIa recommendation, 
however no other guidelines strongly recommend its use for the prevention POAF (Kerr & 
Roy, 2004). Magnesium therapy may be considered in combination with amiodarone and/or 
B-blocker therapy for those patients deemed at high risk or intolerant to the latter 
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medications. If magnesium is utilized in the prevention of POAF, doses of 2.5-5 g have been 
most commonly utilized (Nurozler et al., 1996; Maslow et al., 2000; Kohno et al., 2005). 
When utilized in combination with B-blockers, clinicians should monitor for hypotension as 
combination therapy has been shown to significantly increase the risk of hypotension 
compared to B-blocker therapy alone (24.4% versus 43.5%, p=0.01) (Solomon et al., 2000). 
Finally, it should be noted that magnesium levels need to be monitored carefully 
throughout cardiac surgery and postoperatively regardless if magnesium is being utilized as 
a pharmacological agent for the prophylaxis of POAF. 
4. Emerging pharmacologic therapies for the prevention of POAF in cardiac 
surgery 
4.1 HMG Co-A reductase inhibitors 
HMG Co-A reductase inhibitors (statins) may possess pleiotropic activity beyond lipid 
lowering effects and may be protective against POAF. They have been shown to reduce 
oxidative stress by inhibiting oxidant enzymes, up-regulate antioxidant enzymes, and 
enhance nitric oxide bioavailability (Paraskevas, 2008). It is also proposed that they possess 
direct antiarrhythmic effects mediated through cell membrane stabilization, down-
regulation of the renin-angiotensin-aldosterone-system (RAAS), and protection of ischemic 
myocardium (Howard & Barnes, 2008). They also have been shown to reduce the expression 
of inflammatory mediators (i.e. interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis 
factor- α (TNF-α), C-reactive protein (CRP), cyclooxygenase 2) and decrease the expression 
of CD11b with consequential decreased adherence to endothelial cells of vein grafts (Chello 
et al., 2006; Patel et al., 2007). Therefore, statins may favorably impact the acute 
inflammatory response and alter atrial refractoriness or sympathetic activation that could 
lead to POAF after cardiac surgical procedures.  
Many trials have evaluated the effect of statins on the incidence of POAF in cardiac surgery 
patients. Prospective, randomized trials found an absolute reduction in the incidence of 
POAF of 14% to 22% with statins compared to placebo or usual care (Chello et al., 2006; Patti 
et al, 2006; Song et al., 2008; Ji et al., 2009). The largest and most robust of these three trials 
was the Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study 
(ARMYDA-3) in which a significant reduction in POAF of 22% and a reduction in LOS of 0.6 
days was observed with a statin compared to placebo (Patti et al., 2006). This study enrolled 
only patients who had no previous history of statin use and these patients could have less 
risk of pre-existing atherosclerotic disease and subsequently been at lower risk for 
developing POAF.  
Other statin trials in CABG patients are observational, cohort studies with conflicting results 
of no benefit (Thielmann et al., 2007; Mithani et al., 2009) or a significant reduction in the 
incidence of POAF (Lertsburapa et al., 2008; Subramaniam et al., Mariscalco et al., Ozaydin 
et al., 2007; Miceli et al., 2009a;  Kinoshita et al., 2010).  
One study evaluated the combination of a statin and beta-blocker on the incidence of POAF. 
Monotherapy with atorvastatin or a beta-blocker reduced the risk of POAF by 61% (OR 0.39; 
95% CI 0.18-0.85) and 82% (OR 0.19; 95% CI 0.08-0.44), respectively. However, the 
combination of atorvastatin plus a beta-blocker performed better by reducing the risk of 
POAF by 90% (OR 0.10; 95% CI 0.02-0.25) (Patti et al., 2006). The combination of 
preoperative and postoperative beta-blocker and amiodarone prophylaxis in 40% of patients 
may have also influenced the positive results in the statin group (Lertsburapa et al., 2008). 
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patients with congenital long QT syndrome or a baseline corrected QT interval greater than 
440 msec. Due to its beta-blocking properties, sotalol is contraindicated in patients intolerant 
of beta-blockers. Because of the aforementioned limitations of this agent, sotalol has been 
granted a class IIb recommendation for POAF prophylaxis behind beta-blockers according 
to the ACC/AHA/ESC 2006 AF Guidelines and the ACC/AHA 2004 CABG Guidelines 
(Fuster et al., 2006; Eagle et al., 2004). The most recent 2010 ESC guidelines have assigned a 
Class IIb recommendation for sotalol due to its proarrhythmic risk (ESC, 2010). However, 
the earlier 2006 EACTS guidelines gave sotalol a stronger grade A recommendation based 
upon its comparative efficacy trials versus beta-blockers (Dunning et al., 2006) similar to 
ACC recommendations. 
Patel and Dunning evaluated seven different randomized trials comparing sotalol to 
conventional beta blockers (Patel et al., 2005). Out of the seven trials evaluated, five studies 
demonstrated a statistically significant reduction in POAF for those patients assigned to 
sotalol compared to conventional beta-blockade. The number of patients needed to be 
treated with sotalol to prevent POAF over that of conventional beta-blocker therapy was 
found to be 10. Conversely, because of the pro-arrythmic properties of sotalol, conventional 
beta-blocker therapy may be a safer option.  
3.1.4 Magnesium 
POAF has been associated with decreased postoperative magnesium levels (Kalman et al., 
1995). In fact, plasma magnesium concentration levels less that 0.9 mmol have been found to 
be an independent predictor of POAF (OR 6.7) when using multivariate logistic regression 
models (Treggiari-Venzi et al., 2000). Multiple large, randomized, controlled trials with 
magnesium have failed to demonstrate superiority to usual care with no magnesium in the 
prevention of POAF. These trials included various delivery forms of magnesium including: 
IV infusion (Treggiari-Venzi et al., 2000; Serafimovski et al., 2008; Caspie et al., 1995; Bert et 
al., 2001; Zangrillo et al., 2005), IV infusion based on serum levels (Wilkes et al., 2002), 
magnesium supplementation in maintenance fluids (Colquhoun et al., 1993) and in 
supplementation through cardioplegia solution (Shakerinia et al., 1996). Surprising lower 
cumulative doses of magnesium supplementation (mean cumulative dose 8.2 g) have shown 
to be more effective in reducing the incidence of POAF (OR 0.36, 95% CI 0.23-0.56), 
compared to higher doses (mean cumulative dose 15 g) (OR 0.99, 95% CI 0.70-1.41) (Henyan 
et al., 2005). Results from the same meta-analysis found that preoperative administration of 
magnesium was more effective at decreasing the incidence of POAF (OR 0.46, 95% CI 0.31-
0.67) compared to intraoperative or postoperative administration. Results from several 
meta-analysis (Woodend et al., 1998; Burgess et al., 2006; Shiga et al., 2004; Miller et al., 2005; 
Alghamdi et al., 2005; Henyan et al., 2005; Shepard et al., 2008) have shown inconsistent 
efficacy with magnesium use. A few studies have demonstrated a significant benefit of 
magnesium when compared to usual care with absolute reductions in the incidence of 
POAF by 16% to 34% (Nurozler et al., 1996; Maslow et al., 2000; Kohno et al., 2005). 
However, at this time there is a lack of statistically significant data to support magnesium 
supplementation as monotherapy compared to that of beta-blocker, amiodarone, or sotalol 
therapy in the treatment of POAF (Bert et al., 2001; Solomon et al., 2000; Cagli et al., 2006). 
Only the CCS consensus statement includes magnesium as a Class IIa recommendation, 
however no other guidelines strongly recommend its use for the prevention POAF (Kerr & 
Roy, 2004). Magnesium therapy may be considered in combination with amiodarone and/or 
B-blocker therapy for those patients deemed at high risk or intolerant to the latter 
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medications. If magnesium is utilized in the prevention of POAF, doses of 2.5-5 g have been 
most commonly utilized (Nurozler et al., 1996; Maslow et al., 2000; Kohno et al., 2005). 
When utilized in combination with B-blockers, clinicians should monitor for hypotension as 
combination therapy has been shown to significantly increase the risk of hypotension 
compared to B-blocker therapy alone (24.4% versus 43.5%, p=0.01) (Solomon et al., 2000). 
Finally, it should be noted that magnesium levels need to be monitored carefully 
throughout cardiac surgery and postoperatively regardless if magnesium is being utilized as 
a pharmacological agent for the prophylaxis of POAF. 
4. Emerging pharmacologic therapies for the prevention of POAF in cardiac 
surgery 
4.1 HMG Co-A reductase inhibitors 
HMG Co-A reductase inhibitors (statins) may possess pleiotropic activity beyond lipid 
lowering effects and may be protective against POAF. They have been shown to reduce 
oxidative stress by inhibiting oxidant enzymes, up-regulate antioxidant enzymes, and 
enhance nitric oxide bioavailability (Paraskevas, 2008). It is also proposed that they possess 
direct antiarrhythmic effects mediated through cell membrane stabilization, down-
regulation of the renin-angiotensin-aldosterone-system (RAAS), and protection of ischemic 
myocardium (Howard & Barnes, 2008). They also have been shown to reduce the expression 
of inflammatory mediators (i.e. interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis 
factor- α (TNF-α), C-reactive protein (CRP), cyclooxygenase 2) and decrease the expression 
of CD11b with consequential decreased adherence to endothelial cells of vein grafts (Chello 
et al., 2006; Patel et al., 2007). Therefore, statins may favorably impact the acute 
inflammatory response and alter atrial refractoriness or sympathetic activation that could 
lead to POAF after cardiac surgical procedures.  
Many trials have evaluated the effect of statins on the incidence of POAF in cardiac surgery 
patients. Prospective, randomized trials found an absolute reduction in the incidence of 
POAF of 14% to 22% with statins compared to placebo or usual care (Chello et al., 2006; Patti 
et al, 2006; Song et al., 2008; Ji et al., 2009). The largest and most robust of these three trials 
was the Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study 
(ARMYDA-3) in which a significant reduction in POAF of 22% and a reduction in LOS of 0.6 
days was observed with a statin compared to placebo (Patti et al., 2006). This study enrolled 
only patients who had no previous history of statin use and these patients could have less 
risk of pre-existing atherosclerotic disease and subsequently been at lower risk for 
developing POAF.  
Other statin trials in CABG patients are observational, cohort studies with conflicting results 
of no benefit (Thielmann et al., 2007; Mithani et al., 2009) or a significant reduction in the 
incidence of POAF (Lertsburapa et al., 2008; Subramaniam et al., Mariscalco et al., Ozaydin 
et al., 2007; Miceli et al., 2009a;  Kinoshita et al., 2010).  
One study evaluated the combination of a statin and beta-blocker on the incidence of POAF. 
Monotherapy with atorvastatin or a beta-blocker reduced the risk of POAF by 61% (OR 0.39; 
95% CI 0.18-0.85) and 82% (OR 0.19; 95% CI 0.08-0.44), respectively. However, the 
combination of atorvastatin plus a beta-blocker performed better by reducing the risk of 
POAF by 90% (OR 0.10; 95% CI 0.02-0.25) (Patti et al., 2006). The combination of 
preoperative and postoperative beta-blocker and amiodarone prophylaxis in 40% of patients 
may have also influenced the positive results in the statin group (Lertsburapa et al., 2008). 
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A few studies have been conducted to determine the optimal prophylactic dose of statins. 
Kourlioros et al found that simvastatin 40 mg and atorvastatin 40 mg had the greatest effect on 
POAF (Kourlioros et al., 2008). Simvastatin 20 mg and atorvastatin 20 mg maintained efficacy 
compared to control, but no difference was found at 10 mg or 80 mg of either drug. 
Lertsburapa et al analyzed patients by converting their statin dose to atorvastatin equivalents. 
Relative statin doses ≥40 mg of atorvastatin resulted in the greatest reduction in POAF by 55% 
(OR 0.45; 95% CI 0.21-0.99) (Lertsburapa et al., 2008). The 20 mg atorvastatin dose still showed 
a significant benefit (OR 0.6; 95% CI 0.23-0.99), while the < 20 mg dose showed no significant 
benefit (OR 0.75; 95% CI  0.47-1.20). Mithani et al found in their multivariate analysis that 
POAF was less common among patients taking higher doses of statins compared to those 
taking simvastatin < 20 mg/day (28% versus 34%, p=0.03). (Mithani et al., 2009)  Comparing 
statins, only one prospective, observational study found that POAF was less frequent in 
patients receiving pravastatin compared to atorvastatin (9.5% versus 34.9%, p=0.0257) or no 
statins (9.5% versus 34.2%, p=0.0025). (Tamura et al., 2010) 
A long-term study found that statins’ benefit may extend beyond the immediate postoperative 
period and in outcomes other than POAF. Statins reduced the composite endpoint of death, 
MI, and unstable angina at both 60 days (OR 0.09; 95% CI 0.01-0.70, p=0.02) and one year post-
CABG (OR 0.26; 95% CI 0.015-0.4, p<0.0001) (Dotani et al., 2000). Kaplan-Meier 30 day atrial 
fibrillation-free survival curves also indicated benefit with statins (Patti et al., 2006; Mariscalco 
et al., 2007; Ozaydin et al., 2007; Song et al., 2008). One meta-analysis confirmed the protective 
benefit of preoperative statins for POAF and early all cause mortality. This study also found a 
significant reduction in the risk of stroke by 26% with statins when compared to controls (OR 
0.74; 95% CI 0.60-0.91) (Laikopoulos et al., 2008, Chen et al., 2010). While statins appear to 
reduce POAF in the short term setting in cardiac surgery patients, a recent meta-analysis 
found that longer term (≥ 6 months of follow-up) use of statins in cardiac patients was not 
associated with a significant reduction in AF (OR 0.95; 95% CI 0.88-1.03, p=0.24), however only 
one of the 22 studies was in CABG patients (Rahimi et al., 2011).  
Statins have shown benefit in reducing the risk of POAF, LOS, mortality, and 30 day atrial 
fibrillation-free survival. It is less clear which statin, what dose, and for what duration will 
achieve the greatest benefit. While the combination of statins and standard beta-blocker 
therapy is safe, certain statins, such as simvastatin, should only be used in reduced doses 
with the combination of amiodarone due to risk of myalgias or rhabdomyolysis (FDA Alert 
2008). Larger, prospective, randomized control trials are necessary to confirm that statins are 
effective in reducing the occurrence of POAF in addition to beta-blockers.  
4.2 Renin-angiotensin-aldosterone-system (RAAS) modulators 
An increasing number of investigations are being conducted to evaluate the association 
between the RAAS, the inflammatory process, and atrial fibrillation. Interruption of the 
RAAS by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 
prevents the production of the regulatory hormone angiotensin II, which plays a key role in 
controlling blood pressure, vascular smooth muscle tone, aldosterone release, and sodium 
resorption from the renal tubules (Boos et al., 2006). Beyond these actions, angiotensin II has 
been implicated in increasing the production of pro-inflammatory cytokines (i.e. IL-6, IL-8, 
TNF-α), adhesion molecules, selectins, and the recruitment of neutrophils (Boos et al., 2006). 
Histologic evidence exists that persistent and paroxysmal atrial fibrillation leads to altered 
angiotensin II receptor expression (Erlich et al., 2006; Boos et al., 2006). Genetic 
polymorphisms in the angiotensinogen gene are also two to three times more likely to have 
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non-familial atrial fibrillation (Tsai et al., 2004), further supporting the role RAAS plays in 
the development of atrial fibrillation. ACEIs and ARBs have been shown to reduce the 
incidence of atrial fibrillation in patients with congestive heart failure, hypertension, or post 
MI (Makkar et al., 2009).  
Three potential mechanisms have been suggested to explain the antiarrhythmic benefits of 
ACEIs and ARBs against atrial fibrillation. It is proposed that they improve left ventricular 
hemodynamics, reduce atrial stretch, suppress angiotensin-induced fibrosis, and direct 
modulation of potassium and calcium ion channel function. These ACEI/ARB-induced 
changes decrease atrial vulnerability and may diminish the initiation of atrial fibrillation 
(Erlich et al., 2006).  
Few prospective, controlled studies have been conducted to assess the efficacy of ACEIs or 
ARBs in reducing the incidence of POAF in cardiac surgery patients (White et al., 2007a; 
Ozaydin et al., 2008a). One study randomized patients to an active intervention of ACEI or 
combination of ACEI/ARB and then compared these two treatment groups to a historical 
control. Greater than 85% of patients randomized to ACEI or combination were also on beta-
blockers preoperatively and 97% of patients in the historical control group were on beta-
blockers (Ozaydin et al., 2008a). Despite the high percentage of preoperative beta-blocker 
use in the control group, the combination of an ACEI/ARB or an ACEI alone proved 
superior to usual care with absolute reductions in the incidence of POAF compared to 
controls by 23% and 21%, respectively. There was no difference in the magnitude of the 
reduction of the incidence of POAF using the combination of an ACEI/ARB compared to an 
ACEI alone. The authors also found that both the combination ACEI/ARB or ACEI alone 
significantly reduced the risk of POAF by 72% and 66%, respectively (RR 0.28; 95% CI 0.09-
0.83 and RR 0.34; 95% CI 0.12-0.93, respectively). The other study examined the effect of 
ACEI or ARBs on development of POAF from a nested cohort of patients from the AFIST II 
and III trials (White et al., 2007a). This study also found that preoperative use of ACEIs or 
ARBs were protective in reducing the risk of POAF by 29%, however the magnitude of the 
reduction was not statistically significant (adjusted OR 0.71; 95% CI 0.42-1.20). The clinical 
reduction in risk of POAF in patients on ACEIs or ARBs could have been influenced by 84% 
of the total population of patients receiving postoperative beta-blockade and 38% receiving 
amiodarone for POAF prophylaxis, therefore it remains unclear from that study the 
independent effect ACEIs or ARBs on POAF. Multivariate logistic regression analysis found 
that postoperative beta-blocker (adjusted OR 0.47, 95%CI 0.24-0.89) and prophylactic 
amiodarone (adjusted OR 0.32, 95%CI 0.18-0.57) were both negative predictors of POAF, 
thus decreasing the risk for POAF by 53% and 68%, respectively (White et al., 2007a). 
Cohort studies conducted to evaluate the risk factors associated with the development of 
POAF in cardiac surgery patients found that preoperative and postoperative use of ACEIs 
or ARBs decreased the risk of POAF by 38% (OR 0.62; 95% CI 0.48-0.79; p<0.001) and that 
withdrawal of ACEI or ARB increases the risk of POAF by 1.7 times (OR 1.69; 95% CI 1.38-
2.08; p<0.001) (Mathew et al., 2004)  while another study in cardiac surgery patients with EF 
≤ 50% confirmed this association that both ACEIs decreased the risk of POAF by 73% (OR 
0.27, 95% CI 0.12-0.62, p=0.002) and ARBs by 79% (OR 0.21; 95% CI 0.07-0.62, p=0.005) 
(Ozaydin et al., 2010). Unfortunately, three other cohort studies did not confirm a protective 
effect of ACEIs or ARBs with no significant reduction in the risk of POAF compared to 
controls (Coleman et al., 2007; Miceli et al., 2009b; Rader et al., 2010). The largest of these 
cohort studies, evaluating over 10,000 patients, found that preoperative ACEI doubled the 
risk of death (OR 2.00, 95% CI 1.17-3.42; p= 0.013) and that preoperative ACEIs were an 
independent predictor of mortality (p = 0.04), postoperative renal dysfunction (p=  0.0002), 
use of inotropic drugs (p < 0.0001), and new onset POAF (p < 0.0001). (Miceli et al., 2009b) A 
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A few studies have been conducted to determine the optimal prophylactic dose of statins. 
Kourlioros et al found that simvastatin 40 mg and atorvastatin 40 mg had the greatest effect on 
POAF (Kourlioros et al., 2008). Simvastatin 20 mg and atorvastatin 20 mg maintained efficacy 
compared to control, but no difference was found at 10 mg or 80 mg of either drug. 
Lertsburapa et al analyzed patients by converting their statin dose to atorvastatin equivalents. 
Relative statin doses ≥40 mg of atorvastatin resulted in the greatest reduction in POAF by 55% 
(OR 0.45; 95% CI 0.21-0.99) (Lertsburapa et al., 2008). The 20 mg atorvastatin dose still showed 
a significant benefit (OR 0.6; 95% CI 0.23-0.99), while the < 20 mg dose showed no significant 
benefit (OR 0.75; 95% CI  0.47-1.20). Mithani et al found in their multivariate analysis that 
POAF was less common among patients taking higher doses of statins compared to those 
taking simvastatin < 20 mg/day (28% versus 34%, p=0.03). (Mithani et al., 2009)  Comparing 
statins, only one prospective, observational study found that POAF was less frequent in 
patients receiving pravastatin compared to atorvastatin (9.5% versus 34.9%, p=0.0257) or no 
statins (9.5% versus 34.2%, p=0.0025). (Tamura et al., 2010) 
A long-term study found that statins’ benefit may extend beyond the immediate postoperative 
period and in outcomes other than POAF. Statins reduced the composite endpoint of death, 
MI, and unstable angina at both 60 days (OR 0.09; 95% CI 0.01-0.70, p=0.02) and one year post-
CABG (OR 0.26; 95% CI 0.015-0.4, p<0.0001) (Dotani et al., 2000). Kaplan-Meier 30 day atrial 
fibrillation-free survival curves also indicated benefit with statins (Patti et al., 2006; Mariscalco 
et al., 2007; Ozaydin et al., 2007; Song et al., 2008). One meta-analysis confirmed the protective 
benefit of preoperative statins for POAF and early all cause mortality. This study also found a 
significant reduction in the risk of stroke by 26% with statins when compared to controls (OR 
0.74; 95% CI 0.60-0.91) (Laikopoulos et al., 2008, Chen et al., 2010). While statins appear to 
reduce POAF in the short term setting in cardiac surgery patients, a recent meta-analysis 
found that longer term (≥ 6 months of follow-up) use of statins in cardiac patients was not 
associated with a significant reduction in AF (OR 0.95; 95% CI 0.88-1.03, p=0.24), however only 
one of the 22 studies was in CABG patients (Rahimi et al., 2011).  
Statins have shown benefit in reducing the risk of POAF, LOS, mortality, and 30 day atrial 
fibrillation-free survival. It is less clear which statin, what dose, and for what duration will 
achieve the greatest benefit. While the combination of statins and standard beta-blocker 
therapy is safe, certain statins, such as simvastatin, should only be used in reduced doses 
with the combination of amiodarone due to risk of myalgias or rhabdomyolysis (FDA Alert 
2008). Larger, prospective, randomized control trials are necessary to confirm that statins are 
effective in reducing the occurrence of POAF in addition to beta-blockers.  
4.2 Renin-angiotensin-aldosterone-system (RAAS) modulators 
An increasing number of investigations are being conducted to evaluate the association 
between the RAAS, the inflammatory process, and atrial fibrillation. Interruption of the 
RAAS by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 
prevents the production of the regulatory hormone angiotensin II, which plays a key role in 
controlling blood pressure, vascular smooth muscle tone, aldosterone release, and sodium 
resorption from the renal tubules (Boos et al., 2006). Beyond these actions, angiotensin II has 
been implicated in increasing the production of pro-inflammatory cytokines (i.e. IL-6, IL-8, 
TNF-α), adhesion molecules, selectins, and the recruitment of neutrophils (Boos et al., 2006). 
Histologic evidence exists that persistent and paroxysmal atrial fibrillation leads to altered 
angiotensin II receptor expression (Erlich et al., 2006; Boos et al., 2006). Genetic 
polymorphisms in the angiotensinogen gene are also two to three times more likely to have 
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non-familial atrial fibrillation (Tsai et al., 2004), further supporting the role RAAS plays in 
the development of atrial fibrillation. ACEIs and ARBs have been shown to reduce the 
incidence of atrial fibrillation in patients with congestive heart failure, hypertension, or post 
MI (Makkar et al., 2009).  
Three potential mechanisms have been suggested to explain the antiarrhythmic benefits of 
ACEIs and ARBs against atrial fibrillation. It is proposed that they improve left ventricular 
hemodynamics, reduce atrial stretch, suppress angiotensin-induced fibrosis, and direct 
modulation of potassium and calcium ion channel function. These ACEI/ARB-induced 
changes decrease atrial vulnerability and may diminish the initiation of atrial fibrillation 
(Erlich et al., 2006).  
Few prospective, controlled studies have been conducted to assess the efficacy of ACEIs or 
ARBs in reducing the incidence of POAF in cardiac surgery patients (White et al., 2007a; 
Ozaydin et al., 2008a). One study randomized patients to an active intervention of ACEI or 
combination of ACEI/ARB and then compared these two treatment groups to a historical 
control. Greater than 85% of patients randomized to ACEI or combination were also on beta-
blockers preoperatively and 97% of patients in the historical control group were on beta-
blockers (Ozaydin et al., 2008a). Despite the high percentage of preoperative beta-blocker 
use in the control group, the combination of an ACEI/ARB or an ACEI alone proved 
superior to usual care with absolute reductions in the incidence of POAF compared to 
controls by 23% and 21%, respectively. There was no difference in the magnitude of the 
reduction of the incidence of POAF using the combination of an ACEI/ARB compared to an 
ACEI alone. The authors also found that both the combination ACEI/ARB or ACEI alone 
significantly reduced the risk of POAF by 72% and 66%, respectively (RR 0.28; 95% CI 0.09-
0.83 and RR 0.34; 95% CI 0.12-0.93, respectively). The other study examined the effect of 
ACEI or ARBs on development of POAF from a nested cohort of patients from the AFIST II 
and III trials (White et al., 2007a). This study also found that preoperative use of ACEIs or 
ARBs were protective in reducing the risk of POAF by 29%, however the magnitude of the 
reduction was not statistically significant (adjusted OR 0.71; 95% CI 0.42-1.20). The clinical 
reduction in risk of POAF in patients on ACEIs or ARBs could have been influenced by 84% 
of the total population of patients receiving postoperative beta-blockade and 38% receiving 
amiodarone for POAF prophylaxis, therefore it remains unclear from that study the 
independent effect ACEIs or ARBs on POAF. Multivariate logistic regression analysis found 
that postoperative beta-blocker (adjusted OR 0.47, 95%CI 0.24-0.89) and prophylactic 
amiodarone (adjusted OR 0.32, 95%CI 0.18-0.57) were both negative predictors of POAF, 
thus decreasing the risk for POAF by 53% and 68%, respectively (White et al., 2007a). 
Cohort studies conducted to evaluate the risk factors associated with the development of 
POAF in cardiac surgery patients found that preoperative and postoperative use of ACEIs 
or ARBs decreased the risk of POAF by 38% (OR 0.62; 95% CI 0.48-0.79; p<0.001) and that 
withdrawal of ACEI or ARB increases the risk of POAF by 1.7 times (OR 1.69; 95% CI 1.38-
2.08; p<0.001) (Mathew et al., 2004)  while another study in cardiac surgery patients with EF 
≤ 50% confirmed this association that both ACEIs decreased the risk of POAF by 73% (OR 
0.27, 95% CI 0.12-0.62, p=0.002) and ARBs by 79% (OR 0.21; 95% CI 0.07-0.62, p=0.005) 
(Ozaydin et al., 2010). Unfortunately, three other cohort studies did not confirm a protective 
effect of ACEIs or ARBs with no significant reduction in the risk of POAF compared to 
controls (Coleman et al., 2007; Miceli et al., 2009b; Rader et al., 2010). The largest of these 
cohort studies, evaluating over 10,000 patients, found that preoperative ACEI doubled the 
risk of death (OR 2.00, 95% CI 1.17-3.42; p= 0.013) and that preoperative ACEIs were an 
independent predictor of mortality (p = 0.04), postoperative renal dysfunction (p=  0.0002), 
use of inotropic drugs (p < 0.0001), and new onset POAF (p < 0.0001). (Miceli et al., 2009b) A 
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significant reduction may not have been observed in these studies as patients were 
propensity score matched for common predictors of atrial fibrillation. Thus groups could 
have been at high risk for the development of POAF (Coleman et al., 2007; Rader et al., 
2010). 
Further prospective, controlled trials are needed evaluate the impact of ACEIs or ARBs on 
the development of POAF. These studies will provide more definitive evidence concerning 
the effectiveness of ACEIs and ARBs in the prevention of POAF following cardiac surgical 
procedures. If ACIEs or ARBs are used in combination with standard therapies for the 
prevention of POAF, they must be used with caution or avoided in patients with renal 
dysfunction or electrolyte abnormalties, specifically hyperkalemia.  
4.3 Corticosteroids 
Corticosteroids have been traditionally utilized in cardiac surgeries to reduce inflammation 
in an effort to achieve early extubation, enhance pulmonary function recovery, or decrease 
postoperative nausea and vomiting. Inflammatory biomarkers increase in patients 
undergoing cardiothoracic surgery and inflammation appears to play a role in the 
development of POAF. 
Studies evaluating corticosteroids have used various types of intravenous (IV) steroids, 
doses, and regimens. Two studies used beta-blockers postoperatively in all of their patients 
found that corticosteroids were superior to placebo with absolute reductions in the 
incidence of POAF of 18% to 30% (Prasongsukarn et al., 2005; Halonen et al., 2007). 
However other trials failed to show a significant benefit (Chaney et al., 1998; Halvorsen et 
al., 2003) in reducing incidence of POAF compared to placebo or usual care. Halonen et al 
further reported that after adjusting for potential unbalanced confounders, that 
hydrocortisone continued to be effective in reducing the risk of POAF by 46% (HR 0.54; 95% 
CI 0.35-0.83) with treatment of only 5.6 patients needed to prevent one occurrence of POAF 
(Halonen et al., 2007). The authors further performed a meta-analysis combining results 
from their trial with two other similar trials for a total of 621 patients (Prasongsukarn et al., 
2005; Halvorsen et al., 2003). They found that corticosteroid therapy significantly reduced 
the risk of POAF by 33% (OR 0.67; 95% CI 0.54-0.84) (Halonen et al., 2007). Two other meta-
analyses confirmed this finding where corticosteroids significantly reduced the risk of POAF 
by 29% (OR 0.71; 95% CI 0.59-0.87) and 45% (OR 0.55; 95% CI 0.39-0.78) and show a 
significant decrease in LOS with steroids of 0.6 days and 1.6 days (Whitlock et al., 2008; 
Baker et al., 2007b). 
At this time, specific dosing of corticosteroids that may confer optimal protection against 
POAF is unkown. Baker et al converted the steroid dosing to dexamethasone equivalence 
based on total cumulative dose and relative potencies and found that reduction in POAF 
appeared greatest in patients receiving intermediate doses of corticosteroids (50-120 mg 
dexamethasone equivalent), while lower (≤ 8 mg dexamethasone equivalent) and higher 
(236-2850 mg dexamethasone equivalent) dosing resulted in blunted effects (Baker et al., 
2007b). The most recent meta-analysis by Ho et al converted steroid dosing to 
hydrocortisone equivalence and found a significant reduction of POAF in patients receiving 
low (< 1,000 mg hydrocortisone equivalent) and intermediate (1,000-10,000 mg 
hydrocortisone equivalent) doses of steroids (Ho & Tan, 2009). 
While corticosteroids can attenuate biomarkers shown to regulate the inflammatory 
response leading to the development of POAF, they are also associated with side effects that 
may inhibit their widespread use. Cardiac surgery patients who have received 
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corticosteroids have been shown to have peak white blood cell counts were higher up to 14 
days postoperatively, higher blood glucose and larger insulin requirements (Sano et al., 
2006), greater risk of wound and infectious complications (Whitlock et al., 2008). Therefore it 
may be necessary to avoid corticosteroids in patients with uncontrolled hyperglycemia, 
infection, or edema. 
Corticosteroids can target the inflammatory process for the prevention of POAF in patients 
undergoing cardiac surgery. While some studies found a reduction in the incidence of POAF 
using corticosteroids as prophylaxis in cardiac surgery patients receiving standard beta-
blocker therapy, there is no consensus on which steroid, dose, and duration has the greatest 
benefit. Only the 2010 European guidelines recommend corticosteroids for prophylaxis of 
POAF in cardiac surgery patients and include suggested dosing in dexamethasone equivalent 
for the prevention of POAF with a Class 2B recommendation, stating however that there is risk 
associated with using them (ESC, 2010). The most relevant risk in hospitalized patients after 
cardiac surgery includes steroid-induced hyperglycemia or leukocytosis. Corticosteroids may 
play a future role in targeting the inflammatory process in patients undergoing cardiothoracic 
surgery, however larger clinical trials are necessary to confirm if corticosteroids are effective in 
reducing the occurrence of POAF in addition to beta-blockers. 
4.4 Omega-3 fatty acids 
The ability of omega-3 fatty acids to reduce the occurrence of POAF is thought to result from 
a stabilizing effect on the myocardium, anti-inflammatory properties, and possibly 
antioxidant activity (Kris-Etherton et al., 2002; Korantzopoulos et al., 2006). Calo et al 
performed a prospective, randomized, open label study in 160 patients assessing the impact 
of N-3 polyunsaturated fatty acids (PUFA) 2 g/day on the incidence of POAF in cardiac 
surgery patients (Calo et al., 2005). Approximately 60% of patients in both groups were on 
preoperative beta-blockers. They found a significant reduction in incidence of POAF (15.2% 
versus 33.3%, respectively, p=0.013) and mean LOS (7.3 + 2.1 days versus 8.2 + 2.6 days, 
respectively, p=0.017) in patients receiving PUFA compared to control patients. Another 
small prospective, randomized study found that administration of IV PUFA at 100 mg fish 
oil/kg/day significantly reduced the incidence of POAF compared to control (17.3% vs. 
30.6%, p<0.05) however this study did not mention the percentage of patients on beta-
blocker therapy (Heidt, et al., 2009). Similar to other new agents showing studies with 
conflicting results for the prevention of POAF in cardiac surgery patients, two small, 
prospective, randomized, double blind, placebo controlled studies found no benefit using 
PUFA ~ 2 g/day therapy (Heidarsdottir et al., 2010;  Saravanan et al., 2010). Further studies 
are warranted to determine if omega-3 fatty acids are viable add-on prophylactic therapy or 
alternative for patients unable to take beta-blockers. 
4.5 Ascorbic acid 
The ability of ascorbic acid (vitamin C) to prevent POAF is thought to occur due its antioxidant 
properties and potential to attenuate inflammation and electrical remodeling (Korantzopoulos 
et al., 2005). Vitamin C has been studied in prospective trials for the prevention of POAF in 
cardiac surgery patients (Carnes et al., 2001; Eslami et al., 2007). Both studies demonstrated 
significant benefit using vitamin C compared to usual care with an absolute reduction in 
POAF between 19-22%, but no reduction in mean LOS. Both studies also had substantial rates 
of both pre- and postoperative beta-blocker utilization. Due to the low cost and relative safety 
of this drug, larger placebo-controlled trials appear to be warranted. 
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significant reduction may not have been observed in these studies as patients were 
propensity score matched for common predictors of atrial fibrillation. Thus groups could 
have been at high risk for the development of POAF (Coleman et al., 2007; Rader et al., 
2010). 
Further prospective, controlled trials are needed evaluate the impact of ACEIs or ARBs on 
the development of POAF. These studies will provide more definitive evidence concerning 
the effectiveness of ACEIs and ARBs in the prevention of POAF following cardiac surgical 
procedures. If ACIEs or ARBs are used in combination with standard therapies for the 
prevention of POAF, they must be used with caution or avoided in patients with renal 
dysfunction or electrolyte abnormalties, specifically hyperkalemia.  
4.3 Corticosteroids 
Corticosteroids have been traditionally utilized in cardiac surgeries to reduce inflammation 
in an effort to achieve early extubation, enhance pulmonary function recovery, or decrease 
postoperative nausea and vomiting. Inflammatory biomarkers increase in patients 
undergoing cardiothoracic surgery and inflammation appears to play a role in the 
development of POAF. 
Studies evaluating corticosteroids have used various types of intravenous (IV) steroids, 
doses, and regimens. Two studies used beta-blockers postoperatively in all of their patients 
found that corticosteroids were superior to placebo with absolute reductions in the 
incidence of POAF of 18% to 30% (Prasongsukarn et al., 2005; Halonen et al., 2007). 
However other trials failed to show a significant benefit (Chaney et al., 1998; Halvorsen et 
al., 2003) in reducing incidence of POAF compared to placebo or usual care. Halonen et al 
further reported that after adjusting for potential unbalanced confounders, that 
hydrocortisone continued to be effective in reducing the risk of POAF by 46% (HR 0.54; 95% 
CI 0.35-0.83) with treatment of only 5.6 patients needed to prevent one occurrence of POAF 
(Halonen et al., 2007). The authors further performed a meta-analysis combining results 
from their trial with two other similar trials for a total of 621 patients (Prasongsukarn et al., 
2005; Halvorsen et al., 2003). They found that corticosteroid therapy significantly reduced 
the risk of POAF by 33% (OR 0.67; 95% CI 0.54-0.84) (Halonen et al., 2007). Two other meta-
analyses confirmed this finding where corticosteroids significantly reduced the risk of POAF 
by 29% (OR 0.71; 95% CI 0.59-0.87) and 45% (OR 0.55; 95% CI 0.39-0.78) and show a 
significant decrease in LOS with steroids of 0.6 days and 1.6 days (Whitlock et al., 2008; 
Baker et al., 2007b). 
At this time, specific dosing of corticosteroids that may confer optimal protection against 
POAF is unkown. Baker et al converted the steroid dosing to dexamethasone equivalence 
based on total cumulative dose and relative potencies and found that reduction in POAF 
appeared greatest in patients receiving intermediate doses of corticosteroids (50-120 mg 
dexamethasone equivalent), while lower (≤ 8 mg dexamethasone equivalent) and higher 
(236-2850 mg dexamethasone equivalent) dosing resulted in blunted effects (Baker et al., 
2007b). The most recent meta-analysis by Ho et al converted steroid dosing to 
hydrocortisone equivalence and found a significant reduction of POAF in patients receiving 
low (< 1,000 mg hydrocortisone equivalent) and intermediate (1,000-10,000 mg 
hydrocortisone equivalent) doses of steroids (Ho & Tan, 2009). 
While corticosteroids can attenuate biomarkers shown to regulate the inflammatory 
response leading to the development of POAF, they are also associated with side effects that 
may inhibit their widespread use. Cardiac surgery patients who have received 
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corticosteroids have been shown to have peak white blood cell counts were higher up to 14 
days postoperatively, higher blood glucose and larger insulin requirements (Sano et al., 
2006), greater risk of wound and infectious complications (Whitlock et al., 2008). Therefore it 
may be necessary to avoid corticosteroids in patients with uncontrolled hyperglycemia, 
infection, or edema. 
Corticosteroids can target the inflammatory process for the prevention of POAF in patients 
undergoing cardiac surgery. While some studies found a reduction in the incidence of POAF 
using corticosteroids as prophylaxis in cardiac surgery patients receiving standard beta-
blocker therapy, there is no consensus on which steroid, dose, and duration has the greatest 
benefit. Only the 2010 European guidelines recommend corticosteroids for prophylaxis of 
POAF in cardiac surgery patients and include suggested dosing in dexamethasone equivalent 
for the prevention of POAF with a Class 2B recommendation, stating however that there is risk 
associated with using them (ESC, 2010). The most relevant risk in hospitalized patients after 
cardiac surgery includes steroid-induced hyperglycemia or leukocytosis. Corticosteroids may 
play a future role in targeting the inflammatory process in patients undergoing cardiothoracic 
surgery, however larger clinical trials are necessary to confirm if corticosteroids are effective in 
reducing the occurrence of POAF in addition to beta-blockers. 
4.4 Omega-3 fatty acids 
The ability of omega-3 fatty acids to reduce the occurrence of POAF is thought to result from 
a stabilizing effect on the myocardium, anti-inflammatory properties, and possibly 
antioxidant activity (Kris-Etherton et al., 2002; Korantzopoulos et al., 2006). Calo et al 
performed a prospective, randomized, open label study in 160 patients assessing the impact 
of N-3 polyunsaturated fatty acids (PUFA) 2 g/day on the incidence of POAF in cardiac 
surgery patients (Calo et al., 2005). Approximately 60% of patients in both groups were on 
preoperative beta-blockers. They found a significant reduction in incidence of POAF (15.2% 
versus 33.3%, respectively, p=0.013) and mean LOS (7.3 + 2.1 days versus 8.2 + 2.6 days, 
respectively, p=0.017) in patients receiving PUFA compared to control patients. Another 
small prospective, randomized study found that administration of IV PUFA at 100 mg fish 
oil/kg/day significantly reduced the incidence of POAF compared to control (17.3% vs. 
30.6%, p<0.05) however this study did not mention the percentage of patients on beta-
blocker therapy (Heidt, et al., 2009). Similar to other new agents showing studies with 
conflicting results for the prevention of POAF in cardiac surgery patients, two small, 
prospective, randomized, double blind, placebo controlled studies found no benefit using 
PUFA ~ 2 g/day therapy (Heidarsdottir et al., 2010;  Saravanan et al., 2010). Further studies 
are warranted to determine if omega-3 fatty acids are viable add-on prophylactic therapy or 
alternative for patients unable to take beta-blockers. 
4.5 Ascorbic acid 
The ability of ascorbic acid (vitamin C) to prevent POAF is thought to occur due its antioxidant 
properties and potential to attenuate inflammation and electrical remodeling (Korantzopoulos 
et al., 2005). Vitamin C has been studied in prospective trials for the prevention of POAF in 
cardiac surgery patients (Carnes et al., 2001; Eslami et al., 2007). Both studies demonstrated 
significant benefit using vitamin C compared to usual care with an absolute reduction in 
POAF between 19-22%, but no reduction in mean LOS. Both studies also had substantial rates 
of both pre- and postoperative beta-blocker utilization. Due to the low cost and relative safety 
of this drug, larger placebo-controlled trials appear to be warranted. 
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4.6 N-Acetylcysteine 
N-acetylcysteine (NAC) has been theorized to prevent POAF based on its antioxidant activity 
as a free radical scavenger and ability to reduce cellular damage in the atrium (Carnes et al., 
2007). Two recent studies, which were randomized and placebo-controlled, found conflicting 
results with NAC in the prophylaxis of POAF (El-Hamamsy et al, 2007; Ozaydin et al., 2008b). 
The first study failed to demonstrate a significant reduction in the incidence of POAF (7% with 
NAC versus 12% with placebo, p=0.7). A more recent study, which included valve surgeries, 
did show a significant benefit with NAC compared to placebo (5% versus 21%, p=0.01). After 
controlling for perioperative beta-blocker use, NAC was still associated with a significant 
reduction in POAF (OR 0.17, 95% CI 0.04-0.69, p=0.01). Neither study found a significant 
reduction in LOS. Both studies reported substantial preoperative beta-blocker use while 
Ozaydin et al also reported substantial postoperative beta-blocker utilization. Two conflicting 
meta-analyses have been recently published, one that found a statistically significant reduction 
in POAF with NAC use (36%, 95% CI 2-58%, total n=1,338) and one larger one that did not (OR 
0.67, 95% CI 0.37-1.22, p=0.19, total n=1,407) (Baker et al., 2009; Wang et al., 2011). Large, 
prospective, randomized clinical trials are necessary to determine if NAC is effective in 
reducing the occurrence of POAF in addition to beta-blockers.  
4.7 Sodium nitroprusside 
One pilot study evaluated sodium nitroprusside as an agent for POAF prophylaxis 
compared to placebo (Cavolli et al., 2008). This study demonstrated a significant reduction 
in the incidence of POAF when compared to placebo (12% versus 36%, p=0.005) and a 
significant reduction in mean LOS (7.3 + 0.7 days versus 9.1 + 1.2 days, p<0.001). The 
authors suggest that nitric oxide (NO) function may be disrupted due to ischemia-
reperfusion injury and that administration of NO donors such as nSNP could recover this 
function. SNP may also reduce POAF by reducing left atrial stretching due to preload and 
afterload reduction. This study also showed a significant reduction in serum CRP levels in 
patients given SNP when compared to placebo (p<0.05), suggesting some possible effects on 
inflammation. Though not significant, more patients randomized to SNP received 
preoperative beta-blockers when compared to the placebo group (68% versus 58% p=0.303). 
Postoperative beta-blocker use was not addressed. Likewise, patients in this study had 
relative preserved ejection fractions (60-61%). Currently, SNP is routinely used in 
institutions for the management of postoperative hypertension. Patients receiving this 
medication may also experience an additional benefit of arrhythmia prevention. 
4.8 Dofetilide 
Dofetilide has been compared to placebo for postoperative atrial tachycardia (POAT) 
prophylaxis in one study (Serafimovski et al., 2008). The investigators found that patients 
receiving dofetilide prophylaxis experienced a significant reduction in the incidence of 
POAT, including atrial fibrillation and atrial flutter, when compared to placebo (18% versus 
36%, p<0.017). There was no significant decrease in mean LOS. Although the use of 
postoperative beta-blockers was not reported, the authors conclude that the dofetilide group 
experienced a significant decrease in POAT independent of concomitant beta-blocker use 
based on multivariate logistic regression accounting for preoperative beta-blocker use. Due 
to cost, stringent prescribing and monitoring guidelines, and lack of robust head to head 
trials, dofetilide is not currently recommended as first line POAF prophylaxis. Like sotalol, 
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it also carries a greater risk of Torsades and should be avoided in patients with prolonged 
QT intervals. It could be considered for add on therapy in high risk patients or in patients 
intolerant of beta-blockers but should first be compared to other traditional class III 
antiarrhythmics such as amiodarone or sotalol in head to head trials. 
4.9 Levosimendan 
Levosimendan is an intravenous calcium sensitizer agent that is used for the treatment of 
acute decompensated heart failure. It increases myocardial contraction without increasing 
myocardial oxygen consumption and produces coronary and peripheral vasodilation 
(Lilleberg et al., 1998). While the drug is not approved and will not be pursued for FDA 
approval in the US, it has been shown in one study to significantly reduce the incidence of 
POAF and increase stroke volume in patients with ejection fraction <30% when compared to 
milrinone (50% for milrinone, 5% for levosimendan started post anesthesia, and 35% for 
levosimendan started after cross clamp release, p<0.01) (De Hert et al., 2008). Very few 
patients in this study, however, were taking preoperative beta-blockers (~13-14%) and all 
patients received dobutamine after the release of the cross clamp. 
5. Unestablished pharmacologic therapies for the prevention of POAF in 
cardiac surgery 
5.1 Propafenone, procainamide, digoxin and calcium channel blockers  
Given the availability of just a few trials with inconsistent results, propafenone is not 
currently recommended as first-line for POAF prophylaxis (Bradley et al., 2005; Dunning et 
al., 2006; Fuster et al., 2006; Eagle et al., 2004). Its use may be limited by its proarrhythmic 
effects in patients with structural heart disease. Current available evidence also does not 
support the use of procainamide for POAF prophylaxis. Although based on limited 
evidence, preoperative “digitalization” was historically used to prevent POAF. Currently, 
digoxin does not have an indication for POAF prophylaxis but can be used for rate control 
once atrial fibrillation occurs (Bradley et al., 2005). Only the non-dihydropyridine calcium 
channel blockers (non-DHP-CCB) diltiazem and verapamil, have evidence supporting their 
effectiveness for POAF prophylaxis from a meta-analysis evaluating twelve small studies 
encompassing 719 patients (Wijeysundera et al., 2003). However, two other meta-analyses 
found a non-significant reduction (Andrews et al., 1991) and even an increase in the risk of 
POAF (Woodend et al., 1998) with the CCBs. Because of this and the risk of atrioventricular 
block and low-output syndrome, especially in combination with beta-blockers, the 
guidelines recommend against routine use of CCBs for POAF prophylaxis and that the non-
DHP-CCBs, diltiazem or verapamil, be reserved for rate control only once POAF has 
occurred (Bradley et al., 2005; Eagle et al., 2004). 
5.2 Thiazolidinediones 
Thiazolidinediones (TZDs) may affect POAF through pleiotropic anti-inflammatory activity 
against macrophage activation and pro-inflammatory cytokines (Consoli & Devangelio, 
2005; Ricote et al., 1998). One study evaluated a nested cohort study of diabetic patients 
from the AFIST I, II, and III trials (Giri et al., 2001; White et al., 2003; White et al., 2007a) 
assessed whether the use of TZDs affected the incidence of POAF in diabetic patients who 
were also receiving beta- blockers and amiodarone (Anglade et al., 2007). In addition to 
substantial pre- and postoperative beta-blocker use, 43.8% of control patients and 35% of 
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4.6 N-Acetylcysteine 
N-acetylcysteine (NAC) has been theorized to prevent POAF based on its antioxidant activity 
as a free radical scavenger and ability to reduce cellular damage in the atrium (Carnes et al., 
2007). Two recent studies, which were randomized and placebo-controlled, found conflicting 
results with NAC in the prophylaxis of POAF (El-Hamamsy et al, 2007; Ozaydin et al., 2008b). 
The first study failed to demonstrate a significant reduction in the incidence of POAF (7% with 
NAC versus 12% with placebo, p=0.7). A more recent study, which included valve surgeries, 
did show a significant benefit with NAC compared to placebo (5% versus 21%, p=0.01). After 
controlling for perioperative beta-blocker use, NAC was still associated with a significant 
reduction in POAF (OR 0.17, 95% CI 0.04-0.69, p=0.01). Neither study found a significant 
reduction in LOS. Both studies reported substantial preoperative beta-blocker use while 
Ozaydin et al also reported substantial postoperative beta-blocker utilization. Two conflicting 
meta-analyses have been recently published, one that found a statistically significant reduction 
in POAF with NAC use (36%, 95% CI 2-58%, total n=1,338) and one larger one that did not (OR 
0.67, 95% CI 0.37-1.22, p=0.19, total n=1,407) (Baker et al., 2009; Wang et al., 2011). Large, 
prospective, randomized clinical trials are necessary to determine if NAC is effective in 
reducing the occurrence of POAF in addition to beta-blockers.  
4.7 Sodium nitroprusside 
One pilot study evaluated sodium nitroprusside as an agent for POAF prophylaxis 
compared to placebo (Cavolli et al., 2008). This study demonstrated a significant reduction 
in the incidence of POAF when compared to placebo (12% versus 36%, p=0.005) and a 
significant reduction in mean LOS (7.3 + 0.7 days versus 9.1 + 1.2 days, p<0.001). The 
authors suggest that nitric oxide (NO) function may be disrupted due to ischemia-
reperfusion injury and that administration of NO donors such as nSNP could recover this 
function. SNP may also reduce POAF by reducing left atrial stretching due to preload and 
afterload reduction. This study also showed a significant reduction in serum CRP levels in 
patients given SNP when compared to placebo (p<0.05), suggesting some possible effects on 
inflammation. Though not significant, more patients randomized to SNP received 
preoperative beta-blockers when compared to the placebo group (68% versus 58% p=0.303). 
Postoperative beta-blocker use was not addressed. Likewise, patients in this study had 
relative preserved ejection fractions (60-61%). Currently, SNP is routinely used in 
institutions for the management of postoperative hypertension. Patients receiving this 
medication may also experience an additional benefit of arrhythmia prevention. 
4.8 Dofetilide 
Dofetilide has been compared to placebo for postoperative atrial tachycardia (POAT) 
prophylaxis in one study (Serafimovski et al., 2008). The investigators found that patients 
receiving dofetilide prophylaxis experienced a significant reduction in the incidence of 
POAT, including atrial fibrillation and atrial flutter, when compared to placebo (18% versus 
36%, p<0.017). There was no significant decrease in mean LOS. Although the use of 
postoperative beta-blockers was not reported, the authors conclude that the dofetilide group 
experienced a significant decrease in POAT independent of concomitant beta-blocker use 
based on multivariate logistic regression accounting for preoperative beta-blocker use. Due 
to cost, stringent prescribing and monitoring guidelines, and lack of robust head to head 
trials, dofetilide is not currently recommended as first line POAF prophylaxis. Like sotalol, 
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it also carries a greater risk of Torsades and should be avoided in patients with prolonged 
QT intervals. It could be considered for add on therapy in high risk patients or in patients 
intolerant of beta-blockers but should first be compared to other traditional class III 
antiarrhythmics such as amiodarone or sotalol in head to head trials. 
4.9 Levosimendan 
Levosimendan is an intravenous calcium sensitizer agent that is used for the treatment of 
acute decompensated heart failure. It increases myocardial contraction without increasing 
myocardial oxygen consumption and produces coronary and peripheral vasodilation 
(Lilleberg et al., 1998). While the drug is not approved and will not be pursued for FDA 
approval in the US, it has been shown in one study to significantly reduce the incidence of 
POAF and increase stroke volume in patients with ejection fraction <30% when compared to 
milrinone (50% for milrinone, 5% for levosimendan started post anesthesia, and 35% for 
levosimendan started after cross clamp release, p<0.01) (De Hert et al., 2008). Very few 
patients in this study, however, were taking preoperative beta-blockers (~13-14%) and all 
patients received dobutamine after the release of the cross clamp. 
5. Unestablished pharmacologic therapies for the prevention of POAF in 
cardiac surgery 
5.1 Propafenone, procainamide, digoxin and calcium channel blockers  
Given the availability of just a few trials with inconsistent results, propafenone is not 
currently recommended as first-line for POAF prophylaxis (Bradley et al., 2005; Dunning et 
al., 2006; Fuster et al., 2006; Eagle et al., 2004). Its use may be limited by its proarrhythmic 
effects in patients with structural heart disease. Current available evidence also does not 
support the use of procainamide for POAF prophylaxis. Although based on limited 
evidence, preoperative “digitalization” was historically used to prevent POAF. Currently, 
digoxin does not have an indication for POAF prophylaxis but can be used for rate control 
once atrial fibrillation occurs (Bradley et al., 2005). Only the non-dihydropyridine calcium 
channel blockers (non-DHP-CCB) diltiazem and verapamil, have evidence supporting their 
effectiveness for POAF prophylaxis from a meta-analysis evaluating twelve small studies 
encompassing 719 patients (Wijeysundera et al., 2003). However, two other meta-analyses 
found a non-significant reduction (Andrews et al., 1991) and even an increase in the risk of 
POAF (Woodend et al., 1998) with the CCBs. Because of this and the risk of atrioventricular 
block and low-output syndrome, especially in combination with beta-blockers, the 
guidelines recommend against routine use of CCBs for POAF prophylaxis and that the non-
DHP-CCBs, diltiazem or verapamil, be reserved for rate control only once POAF has 
occurred (Bradley et al., 2005; Eagle et al., 2004). 
5.2 Thiazolidinediones 
Thiazolidinediones (TZDs) may affect POAF through pleiotropic anti-inflammatory activity 
against macrophage activation and pro-inflammatory cytokines (Consoli & Devangelio, 
2005; Ricote et al., 1998). One study evaluated a nested cohort study of diabetic patients 
from the AFIST I, II, and III trials (Giri et al., 2001; White et al., 2003; White et al., 2007a) 
assessed whether the use of TZDs affected the incidence of POAF in diabetic patients who 
were also receiving beta- blockers and amiodarone (Anglade et al., 2007). In addition to 
substantial pre- and postoperative beta-blocker use, 43.8% of control patients and 35% of 
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TZD patients received amiodarone. Despite this, the study was unable to show a significant 
reduction in POAF. This may have been due to a lack of power due to small sample size, 
dilution of effect from concomitant beta-blocker and/or amiodarone use, or increased fluid 
retention associated with TZD use. In this same analysis, statins did demonstrate a 
significant reduction in POAF (28% versus 37%, p<0.05). This suggests that the most likely 
reason TZDs were of no benefit is due to their risk of fluid accumulation thereby attenuating 
any anti-inflammatory effect (Lertsburapa K, 2008). At this time, TZDs can not be 
recommended as an option for POAF prophylaxis, either alone or in combination with beta-
blockers. 
5.3 Triiodothyronine 
The rationale behind the use of triiodothyronine (T3) for POAF prophylaxis lies in the 
observation that CPB results in a euthyroid sick or low T3 state (Klemperer et al., 1996). The 
mechanism by which T3 may prevent POAF is unknown (Reichert & Verzino, 2001). 
Interestingly, it has been shown that POAF is more common in patients with subclinical 
hypothyroidism when compared to those with normal thyroid function, after adjustments 
for other variables (Park et al., 2009). One demonstrated that intravenous administration of 
T3 starting at the time of cross clamp removal significantly decreases the incidence of POAF 
when compared to placebo (24% versus 46%, p=0.009) (Klemperer et al., 1996). All patients 
had a left ventricular ejection fraction of less than 40%. While T3 administration was 
associated with significantly higher postoperative cardiac indices and lower systemic 
vascular resistance, there was no significant difference in LOS (Klemperer et al., 1995). The 
authors previously reported data from this same study but included those patients with a 
history of preoperative atrial fibrillation (Klemperer et al., 1995). In this earlier study, there 
were no significant differences in the incidence of SVT between the two treatment groups. 
The authors do not report postoperative beta-blocker use but suggest that because the study 
population was more ill (ejection fraction <40%), beta-blockade may not be as effective and 
add-on therapy would be warranted. None of the guidelines currently recommend the use 
of T3 due to low quality of evidence (Bradley et al., 2005). Until more data becomes available 
supporting its for POAF prophylaxis, it should not be routinely utilized.  
6. Non-pharmacologic strategies for the prevention of POAF in cardiac 
surgery 
6.1 Pacing 
The use of right atrial, left atrial, bi-atrial and pacing of the Bachman’s bundle all have been 
evaluated in their merit in reducing post-operative supraventricular arrhythmias. The 
mechanism of atrial fibrillation is in part believed to be related to changes in the substrate on 
a temporary basis which causes lengthening of the P-R interval thereby allowing re-entrant 
POAF (Fan et al., 2003). There is evidence that bi-atrial pacing is beneficial especially in the 
age group over 70 (Gerstenfeld et al., 2001). While bi-atrial pacing has demonstrated some 
success it is noted the right atrial pacing alone is less favorable (Chung et al., 1996). Pacing 
thresholds and stability of the pacing wire has become problematic and alternate sources of 
pacing locations have been sought out (Goette et al., 2002). Bachman’s bundle, a thick 
fibrous strip of muscle at the roof of both atria that crosses the intra-atrial septum has been 
demonstrated to have low pacing thresholds for at least five days post-operatively. This site 
may reduce intra-atrial conduction times thus reducing POAF (Goette et al., 2002). 
 
Strategies for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery 223 
In a meta-analysis of 10 clinical trials it was demonstrated that atrial pacing at the right 
atrium, left atrium or Bachman’s bundle produced a decrease in atrial fibrillation (Fan et al., 
2003). These 10 studies are limited by multiple pacing protocols, including using complex 
algorithms, fixed pacing and flexible algorithms. Eight of these studies demonstrated that 
bi-atrial pacing reduced the odds of POAF by 54% (OR=0.46; 95% CI 0.3-0.71). There was a 
significant lack of use of beta-adrenergic blocking drugs used in the post-operative phase in 
the meta-analysis at 56%. In a small group of patients (n=80) who underwent valvular 
surgery it was found that bi-atrial synchronous pacing for 72 hours decreased atrial 
fibrillation from 45% in the control group to 20% in the paced group (p=0.02) (Debrunner et 
al., 2004). It is noted that only 30% of this small group were exposed to pre-operative beta-
adrenergic blockade, and post-operative use was not collected.  
Pacing of the atria is not without risk. In a randomized trial of 100 patients it was found that 
atrial fibrillation occurred in 27.5% of the paced patients and 28.6% of the control group 
(Chung, 2003). There was an increase in atrial ectopy (10 fold increase) in the group of 
patients whom developed atrial fibrillation (Chung, 2003). It was hypothesized that 
inconsistent pacing in the atria, under sensing and intermittent loss of capture were factors 
in the increase in ectopy (Chung, 2003). A sub-analysis of patients paced at a lower rate (80 
bpm) and use of an algorithm that maintained the atrial rate 50 ms above the intrinsic rate, 
demonstrated no difference in atrial fibrillation rates (Chung, 2003).  
The most recent 2010 European AF guidelines recommend that biatrial pacing should be 
considered for prophylaxis (Class 2B recommendation based on Level A evidence) (ESC, 
2010). Earlier publication in 2006 by EACTS for the guidelines for POAF after cardiothoracic 
surgery in 2006 (Grade A recommendation based on Level 1B studies) and in 2005 by the 
American College of Chest Physicians (ACCP) (Strength: B, Evidence: good, Net Benefit: 
small/weak) both similarly recommend biatrial pacing for prophylaxis (Dunning et al., 
2006; Maisel & Epstein, 2005). (Table 1) Specifically, the 2005 ACCP guideline specifically 
recommends not using unilateral pacing of the right or left atrium. (Strength: I, Evidence: 
fair, Net Benefit: small/weak) (Maisel & Epstein, 2005). Furthermore, the 2006 EACTS 
guidelines recommend that temporary pacing should be used in high risk patients receiving 
beta-blockers and amiodarone for prophylaxis as protection from complications of 
bradycardia (Grade A recommendation based of Level 1B studies). The CCS guideline also 
recommends considering atrial pacing with or without a ventricular lead in patients with 
symptomatic bradycardia (Class 2A recommendation based on Level A evidence) and those 
patients who are not on a beta-blocker before surgery (Class 2A recommendation based on 
Level B evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004). Last, the CCS guidelines 
strongly recommend placing temporary ventricular epicardial pacing electrode wires at the 
time of surgery to allow for backup pacing as necessary (Class 1 recommendation based on 
Level C evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004).  
6.2 Posterior pericardiotomy 
The pathophysiology of posterior pericardiotomy is based upon adequate drainage of the 
pericardial space thereby reducing pericardial effusion (Biancari, 2010). Only the earlier 
European guidelines do include posterior pericardiotomy as a non-pharmacologic option 
for the prevention of POAF (Grade B recommendation based on Level 1B studies) (Dunning 
et al., 2006). A recent meta-analysis evaluating 763 patients found that patients who had a 
posterior pericardiotomy significantly reduced POAF (10.8% versus 28.1%, p=0.003; OR. 
0.33, 95% CI 0.16–0.69) and early (6.9% versus 46.2% p<.0001) or late (0% versus 11.3%, 
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TZD patients received amiodarone. Despite this, the study was unable to show a significant 
reduction in POAF. This may have been due to a lack of power due to small sample size, 
dilution of effect from concomitant beta-blocker and/or amiodarone use, or increased fluid 
retention associated with TZD use. In this same analysis, statins did demonstrate a 
significant reduction in POAF (28% versus 37%, p<0.05). This suggests that the most likely 
reason TZDs were of no benefit is due to their risk of fluid accumulation thereby attenuating 
any anti-inflammatory effect (Lertsburapa K, 2008). At this time, TZDs can not be 
recommended as an option for POAF prophylaxis, either alone or in combination with beta-
blockers. 
5.3 Triiodothyronine 
The rationale behind the use of triiodothyronine (T3) for POAF prophylaxis lies in the 
observation that CPB results in a euthyroid sick or low T3 state (Klemperer et al., 1996). The 
mechanism by which T3 may prevent POAF is unknown (Reichert & Verzino, 2001). 
Interestingly, it has been shown that POAF is more common in patients with subclinical 
hypothyroidism when compared to those with normal thyroid function, after adjustments 
for other variables (Park et al., 2009). One demonstrated that intravenous administration of 
T3 starting at the time of cross clamp removal significantly decreases the incidence of POAF 
when compared to placebo (24% versus 46%, p=0.009) (Klemperer et al., 1996). All patients 
had a left ventricular ejection fraction of less than 40%. While T3 administration was 
associated with significantly higher postoperative cardiac indices and lower systemic 
vascular resistance, there was no significant difference in LOS (Klemperer et al., 1995). The 
authors previously reported data from this same study but included those patients with a 
history of preoperative atrial fibrillation (Klemperer et al., 1995). In this earlier study, there 
were no significant differences in the incidence of SVT between the two treatment groups. 
The authors do not report postoperative beta-blocker use but suggest that because the study 
population was more ill (ejection fraction <40%), beta-blockade may not be as effective and 
add-on therapy would be warranted. None of the guidelines currently recommend the use 
of T3 due to low quality of evidence (Bradley et al., 2005). Until more data becomes available 
supporting its for POAF prophylaxis, it should not be routinely utilized.  
6. Non-pharmacologic strategies for the prevention of POAF in cardiac 
surgery 
6.1 Pacing 
The use of right atrial, left atrial, bi-atrial and pacing of the Bachman’s bundle all have been 
evaluated in their merit in reducing post-operative supraventricular arrhythmias. The 
mechanism of atrial fibrillation is in part believed to be related to changes in the substrate on 
a temporary basis which causes lengthening of the P-R interval thereby allowing re-entrant 
POAF (Fan et al., 2003). There is evidence that bi-atrial pacing is beneficial especially in the 
age group over 70 (Gerstenfeld et al., 2001). While bi-atrial pacing has demonstrated some 
success it is noted the right atrial pacing alone is less favorable (Chung et al., 1996). Pacing 
thresholds and stability of the pacing wire has become problematic and alternate sources of 
pacing locations have been sought out (Goette et al., 2002). Bachman’s bundle, a thick 
fibrous strip of muscle at the roof of both atria that crosses the intra-atrial septum has been 
demonstrated to have low pacing thresholds for at least five days post-operatively. This site 
may reduce intra-atrial conduction times thus reducing POAF (Goette et al., 2002). 
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In a meta-analysis of 10 clinical trials it was demonstrated that atrial pacing at the right 
atrium, left atrium or Bachman’s bundle produced a decrease in atrial fibrillation (Fan et al., 
2003). These 10 studies are limited by multiple pacing protocols, including using complex 
algorithms, fixed pacing and flexible algorithms. Eight of these studies demonstrated that 
bi-atrial pacing reduced the odds of POAF by 54% (OR=0.46; 95% CI 0.3-0.71). There was a 
significant lack of use of beta-adrenergic blocking drugs used in the post-operative phase in 
the meta-analysis at 56%. In a small group of patients (n=80) who underwent valvular 
surgery it was found that bi-atrial synchronous pacing for 72 hours decreased atrial 
fibrillation from 45% in the control group to 20% in the paced group (p=0.02) (Debrunner et 
al., 2004). It is noted that only 30% of this small group were exposed to pre-operative beta-
adrenergic blockade, and post-operative use was not collected.  
Pacing of the atria is not without risk. In a randomized trial of 100 patients it was found that 
atrial fibrillation occurred in 27.5% of the paced patients and 28.6% of the control group 
(Chung, 2003). There was an increase in atrial ectopy (10 fold increase) in the group of 
patients whom developed atrial fibrillation (Chung, 2003). It was hypothesized that 
inconsistent pacing in the atria, under sensing and intermittent loss of capture were factors 
in the increase in ectopy (Chung, 2003). A sub-analysis of patients paced at a lower rate (80 
bpm) and use of an algorithm that maintained the atrial rate 50 ms above the intrinsic rate, 
demonstrated no difference in atrial fibrillation rates (Chung, 2003).  
The most recent 2010 European AF guidelines recommend that biatrial pacing should be 
considered for prophylaxis (Class 2B recommendation based on Level A evidence) (ESC, 
2010). Earlier publication in 2006 by EACTS for the guidelines for POAF after cardiothoracic 
surgery in 2006 (Grade A recommendation based on Level 1B studies) and in 2005 by the 
American College of Chest Physicians (ACCP) (Strength: B, Evidence: good, Net Benefit: 
small/weak) both similarly recommend biatrial pacing for prophylaxis (Dunning et al., 
2006; Maisel & Epstein, 2005). (Table 1) Specifically, the 2005 ACCP guideline specifically 
recommends not using unilateral pacing of the right or left atrium. (Strength: I, Evidence: 
fair, Net Benefit: small/weak) (Maisel & Epstein, 2005). Furthermore, the 2006 EACTS 
guidelines recommend that temporary pacing should be used in high risk patients receiving 
beta-blockers and amiodarone for prophylaxis as protection from complications of 
bradycardia (Grade A recommendation based of Level 1B studies). The CCS guideline also 
recommends considering atrial pacing with or without a ventricular lead in patients with 
symptomatic bradycardia (Class 2A recommendation based on Level A evidence) and those 
patients who are not on a beta-blocker before surgery (Class 2A recommendation based on 
Level B evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004). Last, the CCS guidelines 
strongly recommend placing temporary ventricular epicardial pacing electrode wires at the 
time of surgery to allow for backup pacing as necessary (Class 1 recommendation based on 
Level C evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004).  
6.2 Posterior pericardiotomy 
The pathophysiology of posterior pericardiotomy is based upon adequate drainage of the 
pericardial space thereby reducing pericardial effusion (Biancari, 2010). Only the earlier 
European guidelines do include posterior pericardiotomy as a non-pharmacologic option 
for the prevention of POAF (Grade B recommendation based on Level 1B studies) (Dunning 
et al., 2006). A recent meta-analysis evaluating 763 patients found that patients who had a 
posterior pericardiotomy significantly reduced POAF (10.8% versus 28.1%, p=0.003; OR. 
0.33, 95% CI 0.16–0.69) and early (6.9% versus 46.2% p<.0001) or late (0% versus 11.3%, 
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p=0.0001) pleural effusion (Biancari & Mahar, 2010). The authors noted several limitations to 
the studies favoring pericardiotomy, including no data regarding hemodynamic instability, 
re-operation for bleeding and use of drugs for prevention of POAF (Biancari & Mahar, 
2010). Posterior pericardiotomy however is not risk free. Potential risks include cardiac 
herniation as well as compromise of grafts protruding thought the pericardiotomy (Biancari 
& Mahar, 2010).  
6.3 Coronary bypass surgery without the use of cardiopulmonary bypass  
(“Off-pump” CABG) 
The introduction of cardiac surgery without the use of cardiopulmonary bypass, also referred 
to as “off-pump”, has been hypothesized to lower the incidence of POAF. The multiple 
mechanisms hypothesized to cause POAF may all be avoided when coronary bypass surgery 
is completed without the use of the cardiopulmonary bypass circuit. Salamon et al evaluated a 
series of over 2500 patients with 252 undergoing “off-pump” coronary bypass surgery 
(Salamon et al., 2003). Patient on cardiopulmonary bypass had higher rates of atrial fibrillation 
and concluded that avoiding cardiopulmonary bypass did not aid in the reduction of AF. 
Another retrospective analysis by Enc and colleagues in 670 patients undergoing conventional 
compared to “off-pump” coronary bypass surgery, found a lower, but non-significant 
reduction in POAF respectively (16.1% versus 14.6%) (Enc et al., 2004).  
Elimination of the use of cardiopulmonary bypass in cardiac surgery has shown inconsistent 
results from meta-analyses and studies. Only the European EACTS 2006 guidelines supports 
its use as a non-pharmacologic option are the 2006 EACTS guidelines and include earlier meta-
analysis that show conflicting results (Dunning et al., 2006). Focus for the prevention of POAF 
in cardiac surgery patients should focus on the use more standard prophylactic regimens 
including beta-blockers, rather than explicit avoidance of cardiopulmonary bypass. 
6.4 Pericardial fat pad 
Two other novel non-pharmacologic options that have been studied include preservation of 
pericardial fat pad and regulation of body temperature during cardiac surgery which targets 
disruption of AV node and inflammation, respectively. The anterior fat pad is commonly 
disrupted to provide clear field of view while applying the cross clamp during cardiac 
surgery. The anterior fat pad is known to possess parasympathetic ganglia as well as vagal 
pathways (Singh et al., 1996). The fat pads located at the superior vena cava-atrial junction 
contain post ganglionic fibers that lead to the sino-atrial node (Carlson et al., 1992). The fat 
pads located at the pulmonary vein-left atrium contain post ganglionic fibers that innervate 
the atrio-ventricular node (Quan et al., 2001). These fat pads are analogous to dog 
physiology and has been determined that ablation of these fibers in dogs reduces 
susceptibility of POAF. In a study of 55 patients where the fat pad was preserved, a 
significant reduction of POAF was observed (Cummings et al., 2004). A significant 
limitation of this research includes a small sample size and not accounting for the use of 
beta-adrenergic blocking drugs. Secondarily the rate of atrial fibrillation in “off-pump” 
cardiac surgery remains a significant problem despite no manipulation of the epicardial fat 
pads (Salamon et al., 2003). 
6.5 Regulation of body temperature during surgery 
The other novel non-pharmacologic strategy is to regulate body temperature to limit 
systemic effects of the inflammatory cascade during cardiac surgery. Adams and colleagues 
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identified that hypothermia decreases sympathetic activation which lowers plasma 
norepinephrine levels and neuropeptide Y levels (Adams et al., 2000). A study randomized 
patients into two groups including mild hypothermia (34 C) and moderate hypothermia 
(28 C) and found no difference in the incidence of POAF between the groups, thus did not 
validate this pathophysiologic basis of POAF (Adams et al., 2000). The study was completed 
without benefit of knowledge regarding use of beta blockers or other adjunct measures to 
prevent POAF which could  influence the outcome of that study.. It should be noted that 
POAF is still common in beating heart surgery with normothermia, therefore negating the 
use of hypothermia as a valid tool in prevention of POAF. 
6.6 Maze procedure during open-heart surgery 
The surgical maze procedure, or Cox-maze procedure, uses surgical incisions in the atria to 
form scar tissue to interrupt possible macroreentrant circuits (Cox et al., 1991). Alternative 
energy sources including radiofrequency or cryothermia have been incorporated to create 
lesions blocking atrial conduction without surgical incision into the atria. These procedures 
can be effective in restoring sinus rhythm, however when it is combined with other open 
heart operations to treat chronic AF, operative morbidity is consistently increased (Banach, 
et al., 2010). It is usually only performed on patients needing open-heart surgery for other 
issues, such as valve replacement or repair or CABG. The Canadian and most recent 
European guidelines both mention surgical ablation, however it should only be considered 
in patients with symptomatic AF already undergoing cardiac surgery (Kerr & Roy, 2004; 
ESC, 2010). The Canadian guidelines additionally mention that it should be considered in 
patients with previous AF who are undergoing mitral valve surgery, who may be at higher 
risk of POAF (Kerr & Roy, 2004) 
7. Conclusion 
For the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgery, 
pharmacologic prophylaxis with beta-blockers and amiodarone are widely utilized. 
Evidence based guidelines also support the use of sotalol, magnesium, and atrial pacing. 
While these agents reduce the incidence of POAF, they do not eliminate it. Thus, there is a 
need for additional effective therapies. Other strategies that may be beneficial for 
prophylaxis include dofetilide, renin-angiotensin-aldosterone-system modulators, statins, 
corticosteroids, omega-3 fatty acids, ascorbic acid, N-acetylcysteine, sodium nitroprusside, 
levosimendan or intraoperative maze procedure in symptomatic AF patients undergoing 
cardiac surgery. For most of these strategies, there is a need for additional large scale, 
adequately powered, clinical studies to determine the benefit before they can be considered 
for routine use. Identification of high risk patients undergoing cardiac surgery and use of 
appropriate pharmacologic and non-pharmacologic therapies may further reduce the 
incidence of POAF and lead to improvements in the overall morbidity and burden to the 
health care system.  
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p=0.0001) pleural effusion (Biancari & Mahar, 2010). The authors noted several limitations to 
the studies favoring pericardiotomy, including no data regarding hemodynamic instability, 
re-operation for bleeding and use of drugs for prevention of POAF (Biancari & Mahar, 
2010). Posterior pericardiotomy however is not risk free. Potential risks include cardiac 
herniation as well as compromise of grafts protruding thought the pericardiotomy (Biancari 
& Mahar, 2010).  
6.3 Coronary bypass surgery without the use of cardiopulmonary bypass  
(“Off-pump” CABG) 
The introduction of cardiac surgery without the use of cardiopulmonary bypass, also referred 
to as “off-pump”, has been hypothesized to lower the incidence of POAF. The multiple 
mechanisms hypothesized to cause POAF may all be avoided when coronary bypass surgery 
is completed without the use of the cardiopulmonary bypass circuit. Salamon et al evaluated a 
series of over 2500 patients with 252 undergoing “off-pump” coronary bypass surgery 
(Salamon et al., 2003). Patient on cardiopulmonary bypass had higher rates of atrial fibrillation 
and concluded that avoiding cardiopulmonary bypass did not aid in the reduction of AF. 
Another retrospective analysis by Enc and colleagues in 670 patients undergoing conventional 
compared to “off-pump” coronary bypass surgery, found a lower, but non-significant 
reduction in POAF respectively (16.1% versus 14.6%) (Enc et al., 2004).  
Elimination of the use of cardiopulmonary bypass in cardiac surgery has shown inconsistent 
results from meta-analyses and studies. Only the European EACTS 2006 guidelines supports 
its use as a non-pharmacologic option are the 2006 EACTS guidelines and include earlier meta-
analysis that show conflicting results (Dunning et al., 2006). Focus for the prevention of POAF 
in cardiac surgery patients should focus on the use more standard prophylactic regimens 
including beta-blockers, rather than explicit avoidance of cardiopulmonary bypass. 
6.4 Pericardial fat pad 
Two other novel non-pharmacologic options that have been studied include preservation of 
pericardial fat pad and regulation of body temperature during cardiac surgery which targets 
disruption of AV node and inflammation, respectively. The anterior fat pad is commonly 
disrupted to provide clear field of view while applying the cross clamp during cardiac 
surgery. The anterior fat pad is known to possess parasympathetic ganglia as well as vagal 
pathways (Singh et al., 1996). The fat pads located at the superior vena cava-atrial junction 
contain post ganglionic fibers that lead to the sino-atrial node (Carlson et al., 1992). The fat 
pads located at the pulmonary vein-left atrium contain post ganglionic fibers that innervate 
the atrio-ventricular node (Quan et al., 2001). These fat pads are analogous to dog 
physiology and has been determined that ablation of these fibers in dogs reduces 
susceptibility of POAF. In a study of 55 patients where the fat pad was preserved, a 
significant reduction of POAF was observed (Cummings et al., 2004). A significant 
limitation of this research includes a small sample size and not accounting for the use of 
beta-adrenergic blocking drugs. Secondarily the rate of atrial fibrillation in “off-pump” 
cardiac surgery remains a significant problem despite no manipulation of the epicardial fat 
pads (Salamon et al., 2003). 
6.5 Regulation of body temperature during surgery 
The other novel non-pharmacologic strategy is to regulate body temperature to limit 
systemic effects of the inflammatory cascade during cardiac surgery. Adams and colleagues 
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identified that hypothermia decreases sympathetic activation which lowers plasma 
norepinephrine levels and neuropeptide Y levels (Adams et al., 2000). A study randomized 
patients into two groups including mild hypothermia (34 C) and moderate hypothermia 
(28 C) and found no difference in the incidence of POAF between the groups, thus did not 
validate this pathophysiologic basis of POAF (Adams et al., 2000). The study was completed 
without benefit of knowledge regarding use of beta blockers or other adjunct measures to 
prevent POAF which could  influence the outcome of that study.. It should be noted that 
POAF is still common in beating heart surgery with normothermia, therefore negating the 
use of hypothermia as a valid tool in prevention of POAF. 
6.6 Maze procedure during open-heart surgery 
The surgical maze procedure, or Cox-maze procedure, uses surgical incisions in the atria to 
form scar tissue to interrupt possible macroreentrant circuits (Cox et al., 1991). Alternative 
energy sources including radiofrequency or cryothermia have been incorporated to create 
lesions blocking atrial conduction without surgical incision into the atria. These procedures 
can be effective in restoring sinus rhythm, however when it is combined with other open 
heart operations to treat chronic AF, operative morbidity is consistently increased (Banach, 
et al., 2010). It is usually only performed on patients needing open-heart surgery for other 
issues, such as valve replacement or repair or CABG. The Canadian and most recent 
European guidelines both mention surgical ablation, however it should only be considered 
in patients with symptomatic AF already undergoing cardiac surgery (Kerr & Roy, 2004; 
ESC, 2010). The Canadian guidelines additionally mention that it should be considered in 
patients with previous AF who are undergoing mitral valve surgery, who may be at higher 
risk of POAF (Kerr & Roy, 2004) 
7. Conclusion 
For the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgery, 
pharmacologic prophylaxis with beta-blockers and amiodarone are widely utilized. 
Evidence based guidelines also support the use of sotalol, magnesium, and atrial pacing. 
While these agents reduce the incidence of POAF, they do not eliminate it. Thus, there is a 
need for additional effective therapies. Other strategies that may be beneficial for 
prophylaxis include dofetilide, renin-angiotensin-aldosterone-system modulators, statins, 
corticosteroids, omega-3 fatty acids, ascorbic acid, N-acetylcysteine, sodium nitroprusside, 
levosimendan or intraoperative maze procedure in symptomatic AF patients undergoing 
cardiac surgery. For most of these strategies, there is a need for additional large scale, 
adequately powered, clinical studies to determine the benefit before they can be considered 
for routine use. Identification of high risk patients undergoing cardiac surgery and use of 
appropriate pharmacologic and non-pharmacologic therapies may further reduce the 
incidence of POAF and lead to improvements in the overall morbidity and burden to the 
health care system.  
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Post Operative Arrhythmias 
Rama Dilip Gajulapalli and Florian Rader 
Case Western Reserve University 
USA 
1. Introduction 
Heart rhythm disturbances are being increasingly recognized during the postoperative 
period. While many are transient and short lived without altering the recovery phase after 
cardiac or non-cardiac surgery, they do have the potential to pose a threat to patient’s 
health, prolong hospital stay, and in a minority of patients may even cause death. 
Continuous monitoring is becoming the standard of care after surgery and therefore rhythm 
disturbances are being more frequently diagnosed during the postoperative recovery 
period. While cardiology consultation may be required, surgeons and anesthesiologists are 
often the first responders and are expected to be able to recognize the rhythm disturbance 
and treat them appropriately.  
2. Normal physiology 
Normal sinus rhythm is when the heart beats in an orderly predetermined sequence. The 
atria contract initially in response to the firing of an impulse by the Sino-Atrial (SA) node 
located at the junction of the superior vena cava and the right atrium. The SA node 
contains specialized tissue with ‘pacemaker cells’, which can initiate repetitive rhythmic 
action potentials. These potentials then travel via internodal atrial pathways to the 
AtrioVentricular (AV) node located at the right posterior portion of the interatrial septum. 
The AV node slows conduction into the bundle of HIS which then leads to its right and 
left branches. The left bundle branch further divides into anterior and posterior fascicles. 
The final pathway of conduction is the Purkinje system, which consists of a network  
of fibers that transmit the electrical impulse to the myocardium near the apex of the  
heart. (1) 
The Electrocardiogram (ECG) is a reliable and practical way to document the underlying 
cardiac rhythm. It essentially consists of a recording obtained by 12 surface leads which 
trace the electrical activity of the heart from different directions. The 12 leads include 6 limb 
and 6 precordial leads. The limb leads include 3 bipolar leads (I, II, III) meaning they have 2 
electrodes of opposite polarity. The other limb leads are aVR, aVL, aVF which are the 
unipolar leads meaning they have only one electrode connecting to a central terminal. The 
precordial leads are all unipolar and include V1-V6. 
The limb leads are the frontal plane leads representing electrical current along the coronal 
plane of the heart, i.e. right/left and superior/inferior. The precordial leads represent the 
horizontal plane of the heart measuring transverse currents, i.e. right/left and 
anterior/posterior. Lead I traces currents from right shoulder to left shoulder, lead II from 
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right shoulder to left leg, and lead III from left arm to left leg. Lead aVF traces from central 
terminal, which corresponds to zero potential to the left leg, aVL from centre to left arm and 
aVR from centre to right arm. The precordial leads work in a similar fashion in that leads V1 
– V6 trace their axis center out from right to left respectively, so that V1 represents right of 
the interventricular septum, V2 and V3 the interventricular septum (anterior wall), V4 the 
apex (anterolateral), V5 and V6 the lateral ventricular wall. Any current flowing towards the 
lead causes a positive deflection and current flowing away from the lead causes a negative 
deflection and vice versa. The strength of the deflection depends on the amount of potential 
recorded and is affected by cardiac and extracardiac structures. To understand the 
electrophysiological basis of the 12-lead tracings on an ECG is important, because it gives 
clues about the origin of an arrhythmia and sometimes guides their therapies. 
The first deflection on an ECG is the P wave which represents atrial depolarization. In sinus 
rhythm without any discernable atrial pathology, P wave is an upright, smooth, rounded 
wave with relatively low voltage. The PR interval consists of the P wave and the normally 
isoelectric segment up to the initial deflection of the QRS complex. The PR interval represents 
the conduction through atria, AV node, bundle branches and Purkinje system. The QRS 
complex follows the PR segment. The initial negative deflection is the Q wave, a positive 
deflection which can occur either initially or after the Q is the R wave while any negative 
deflection which follows the R is the S wave. QRS complex represents intraventricular 
conduction and depolarization. The J point represents the junction between QRS and the ST 
segment. The ST segment corresponds with the end of ventricular depolarization and start of 
the ventricular repolarization. The T wave, which follows the ST segment, represents 
ventricular repolarization. As such the QT interval represents the complete ventricular 
depolarization and repolarization period. Occasionally a small hump-like U wave follows the 
T wave, and is felt to be due to repolarization of the purkinje system. (2,3)  
The bedside monitors which are routinely used for continuous cardiac monitoring are 
typically wireless, i.e. telemetry systems. These can be either 5 lead wire or 3 lead wire 
systems. The 5 lead wire system allows for monitoring all of the limb leads or the precordial 
leads while the 3 lead wire system allows monitoring one lead at a time, usually lead II, 
because the P wave is best visible in this lead. Depending on the monitoring system 
available it is essential for health care providers to be able to recognize the cardiac rhythm 
changes based only on a few select leads seen on the monitor as there may be no time to 
record a 12 lead ECG. 
3. Recognition of arrhythmias 
Postoperative arrhythmias though transient are usually sudden in onset. It is essential to 
recognize a rhythm disturbance and institute treatment as quickly as possible in most cases. 
A 12 lead ECG is recommended but may be impractical if the rhythm disturbance is an 
immediate threat to the patient’s life. The wave forms visible on the telemonitor or a rhythm 
strip in one lead tracing may be the only available clue.  
It is worthwhile to note some salient points early. Is the patient stable as assessed by the 
blood pressure, oxygen saturation or mental status? If deemed unstable then more 
aggressive steps are warranted.  
A rapid and accurate interpretation of the ECG can be tricky and readers are advised to 
develop a personal strategy to identify any given cardiac tracing so that a quick diagnosis 
can be made. One approach is to identify and describe 5 basic features of the 
electrocardiogram (2): 
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Step 1.  Determine the ventricular rate – tachycardia is >100 / Bradycardia is < 60 
Step 2.  Measure the QRS complex – Narrow is < 0.12ms / Broad is > 0.12 ms  
Step 3.  Determine the regularity of the QRS complex – Regular/irregular 
Step 4. Identify the P waves – upright in lead II and III and negative in aVR usually 
identifies sinus rhythm, P waves are absent in atrial fibrillation, saw tooth 
appearance at an atrial rate of 300 bpm may indicate atrial flutter 
Step 5:  Measure the PR interval – helps identify AV delay 
The above steps should help one to identify the salient features of any rhythm and place it in 
one of the following mentioned categories. (Figure 1) We would like to point out that this 
scheme is only one of many and sometimes more than one arrhythmia can be present in a 
patient. This scheme also, at times over simplifies natural heart rhythms. For example, a 
heart rate of 40 beats per minute (bpm) during sleep or in an athletic patient can be normal, 
while patients with an abnormal conduction system can have supraventricular arrhythmias 
with heart rates less than 100 bpm. 
 
                                                                      Rate  
                                                      <60           │         >100 
                                      │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│ 
                            Bradycardia                                         Tachycardia 
                                      │                                              <0.12ms │  >0.12ms 
           │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ │                 │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│ 
      Regular                                Irregular     Narrow                                   Broad  
            ↓                                            ↓                                                                
   Sinus Brady                        Heart blocks                                                  
                                                 Sinus pause                                                     
                                             Atrial Fibrillation                                               
                                                                                                                            
                                                                                                                            
                                                     │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│           │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│ 
                                                Regular                         Irregular     Regular            Irregular 
                                                      ↓                                   ↓               ↓                             ↓ 
                                             Sinus tach                          AF            VT                          VF 
                                            A Flutter**                        MAT         SVT *                    AF * 
                                            AVRT                                                                                        
                                            AVNRT 
                                            AT 
(AF – Atrial Fibrillation, AT – Atrial tachycardia, MAT – Multifocal atria tachycardia, SVT – Supra 
ventricular tachycardia, VF – Ventricular Fibrillation, VT – Ventricular tachycardia) 
*With Aberrancy 
** Flutter can be irregular occasionally when the AV block is variable 
Fig. 1. Various cardiac rhythm disturbances noted in clinical practice 
The Brugada criteria can be used to identify any broad complex tachycardia (4) 
Step 1. Are there RS complexes in any of the chest leads?  
Step 2. Is the onset of the R wave to the nadir of S > 100 ms? 
Step 3. Is there any AV dissociation? 
Step 4. Is there any typical bundle branch morphology in leads V1 or V6? 
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wave with relatively low voltage. The PR interval consists of the P wave and the normally 
isoelectric segment up to the initial deflection of the QRS complex. The PR interval represents 
the conduction through atria, AV node, bundle branches and Purkinje system. The QRS 
complex follows the PR segment. The initial negative deflection is the Q wave, a positive 
deflection which can occur either initially or after the Q is the R wave while any negative 
deflection which follows the R is the S wave. QRS complex represents intraventricular 
conduction and depolarization. The J point represents the junction between QRS and the ST 
segment. The ST segment corresponds with the end of ventricular depolarization and start of 
the ventricular repolarization. The T wave, which follows the ST segment, represents 
ventricular repolarization. As such the QT interval represents the complete ventricular 
depolarization and repolarization period. Occasionally a small hump-like U wave follows the 
T wave, and is felt to be due to repolarization of the purkinje system. (2,3)  
The bedside monitors which are routinely used for continuous cardiac monitoring are 
typically wireless, i.e. telemetry systems. These can be either 5 lead wire or 3 lead wire 
systems. The 5 lead wire system allows for monitoring all of the limb leads or the precordial 
leads while the 3 lead wire system allows monitoring one lead at a time, usually lead II, 
because the P wave is best visible in this lead. Depending on the monitoring system 
available it is essential for health care providers to be able to recognize the cardiac rhythm 
changes based only on a few select leads seen on the monitor as there may be no time to 
record a 12 lead ECG. 
3. Recognition of arrhythmias 
Postoperative arrhythmias though transient are usually sudden in onset. It is essential to 
recognize a rhythm disturbance and institute treatment as quickly as possible in most cases. 
A 12 lead ECG is recommended but may be impractical if the rhythm disturbance is an 
immediate threat to the patient’s life. The wave forms visible on the telemonitor or a rhythm 
strip in one lead tracing may be the only available clue.  
It is worthwhile to note some salient points early. Is the patient stable as assessed by the 
blood pressure, oxygen saturation or mental status? If deemed unstable then more 
aggressive steps are warranted.  
A rapid and accurate interpretation of the ECG can be tricky and readers are advised to 
develop a personal strategy to identify any given cardiac tracing so that a quick diagnosis 
can be made. One approach is to identify and describe 5 basic features of the 
electrocardiogram (2): 
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Step 1.  Determine the ventricular rate – tachycardia is >100 / Bradycardia is < 60 
Step 2.  Measure the QRS complex – Narrow is < 0.12ms / Broad is > 0.12 ms  
Step 3.  Determine the regularity of the QRS complex – Regular/irregular 
Step 4. Identify the P waves – upright in lead II and III and negative in aVR usually 
identifies sinus rhythm, P waves are absent in atrial fibrillation, saw tooth 
appearance at an atrial rate of 300 bpm may indicate atrial flutter 
Step 5:  Measure the PR interval – helps identify AV delay 
The above steps should help one to identify the salient features of any rhythm and place it in 
one of the following mentioned categories. (Figure 1) We would like to point out that this 
scheme is only one of many and sometimes more than one arrhythmia can be present in a 
patient. This scheme also, at times over simplifies natural heart rhythms. For example, a 
heart rate of 40 beats per minute (bpm) during sleep or in an athletic patient can be normal, 
while patients with an abnormal conduction system can have supraventricular arrhythmias 
with heart rates less than 100 bpm. 
 
                                                                      Rate  
                                                      <60           │         >100 
                                      │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│ 
                            Bradycardia                                         Tachycardia 
                                      │                                              <0.12ms │  >0.12ms 
           │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ │                 │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│ 
      Regular                                Irregular     Narrow                                   Broad  
            ↓                                            ↓                                                                
   Sinus Brady                        Heart blocks                                                  
                                                 Sinus pause                                                     
                                             Atrial Fibrillation                                               
                                                                                                                            
                                                                                                                            
                                                     │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│           │¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯│ 
                                                Regular                         Irregular     Regular            Irregular 
                                                      ↓                                   ↓               ↓                             ↓ 
                                             Sinus tach                          AF            VT                          VF 
                                            A Flutter**                        MAT         SVT *                    AF * 
                                            AVRT                                                                                        
                                            AVNRT 
                                            AT 
(AF – Atrial Fibrillation, AT – Atrial tachycardia, MAT – Multifocal atria tachycardia, SVT – Supra 
ventricular tachycardia, VF – Ventricular Fibrillation, VT – Ventricular tachycardia) 
*With Aberrancy 
** Flutter can be irregular occasionally when the AV block is variable 
Fig. 1. Various cardiac rhythm disturbances noted in clinical practice 
The Brugada criteria can be used to identify any broad complex tachycardia (4) 
Step 1. Are there RS complexes in any of the chest leads?  
Step 2. Is the onset of the R wave to the nadir of S > 100 ms? 
Step 3. Is there any AV dissociation? 
Step 4. Is there any typical bundle branch morphology in leads V1 or V6? 
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If the answer to any of questions 1-3 is yes or to question 4 is no, the rhythm is probably 
ventricular tachycardia. There are several additional ways to distinguish between supra 
ventricular and ventricular arrhythmias, which exceed the objectives of this review. 
4. Types of arrhythmias 
The conduction system of the heart has to be intact anatomically and physiologically for 
synchronized contraction of the heart in a regular and coordinated fashion. Arrhythmias are 
caused when there is disturbance in the working of the conduction system for any reason.  
The accepted mechanisms include abnormality of conduction (i.e. blocking or Re-entry of 
the impulse), abnormality of impulse initiation (i.e. altered automaticity or triggered 
activity). The underlying causes can include ischemia, electrolyte imbalances, scarring or 
fibrosis of atrial and ventricular tissue, increased or decreased excitability for various 
reasons including changes in autonomic nervous system, action of drugs and others.  
Disturbances of the normal cardiac rhythm can be of many types. A universal hierarchical 
classification which can encompass all the salient arrhythmias is difficult to conceive. 
Arrhythmias are usually classified based on morphology, rate or origin. They can be divided 
into fast or slow based on the rate- Tachyarrhythmias when heart rate is faster than 100 bpm 
and bradyarrhythmias when rate is slower than 60 bpm. The QRS duration which defines 
the ventricular depolarization is usually less than 0.12 seconds (or 3 small boxes on the ECG 
at 25 mm/sec paper speed). If it is more than 0.12 seconds it represents delayed 
depolarization and can be used as a feature to divide the tachyarrhythmias into narrow 
complex and wide complex tachycardia. Another classification of arrhythmias describes 
regular versus irregular rhythms. Finally arrhythmias can generally be classified based on 
various anatomical substrates of the heart, which initiate these rhythm changes like atrial (or 
supraventricular) or ventricular arrhythmias. As mentioned above these classifications are 
an attempt, far from perfect, to distinguish normal from abnormal and define categories 
with different underlying pathophysiology and treatment options.  
The following chapter will discuss Atrial Fibrillation (AF) after cardiac surgery initially as 
this seems to be the most common and most extensively studied arrhythmia.  
5. Postoperative AF  
Incidence: 
The incidence of any arrhythmia postoperatively can be up to 85% (5). The Multi center 
anesthesia outcomes study quotes that postoperative arrhythmias can complicate about 70% of 
the operations. (6) AF seems to be the most common arrhythmia in the post operative period 
(7). Goldman concluded as early as 1978 utilizing a prospective registry that the incidence of 
postoperative AF was nearly 3% after non-cardiac surgeries. (8)  While AF is certainly more 
frequent after cardiac surgery, incidence varies between studies. Reasons for these variations 
seem to be different ascertainment methods between studies (12 lead ECG vs. continuous 
telemetry monitoring etc). Mathew et al document an incidence of up to 34% with similar 
incidences in North America and Europe but lower incidence in Asia at 16 %. (13) The 
incidence also varies depending on the type of cardiac surgery undertaken. AF seems to occur 
60% of the time post mitral valve surgery, 36% of the time post aortic valve surgery, (10) and 
25% post cardiac transplants. (11) The combination of coronary artery bypass graft surgery 
(CABG) with valve surgery seems to increase the risk for AF as well. (12) Often times the 
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definition for postoperative AF includes the need of medical treatment or electrical 
cardioversion (14) or confirmation on a 12 lead ECG (13) altering the incidence rates further.  
The peak incidence of postoperative AF (POAF) has been consistently described on day 2 
and 3 after surgery. (10) It usually is transient with 80% of the patients converting to sinus 
rhythm within 24 hours. The recurrence rate has been quoted to be as much as 50% but 
still only 10% of patients are still in AF at 6 weeks post operation. (13) Late Postoperative 
AF is less frequent but was seen in nearly 5% of the postoperative patients after discharge 
from the hospital. This was found when patients were being followed for cardiac 
rehabilitation and documented in the ISYDE and ICAROS registries in Italy. (15) Despite 
better coordinated postoperative care and advances in cardiothoracic surgical and 
anesthetic practices, the incidence of AF seems stable with no reduction over the last 2 
decades.  
Pathophysiology of Postoperative AF: 
AF is generally due to reentry of multiple wavelets circling the atria. It is likely that a pre-
existing substrate is needed to allow peri-operative triggers to initiate AF. It is thus a specific 
interaction of preexisting and perioperative risk factors which can lead to AF.  
Preexisting factors:  
Age is the most consistent risk factor seen in past studies. Advancing age increases the risk 
with each decade. The incidence of POAF is around 6% when less than 40y of age, 18% in 
less than 60y olds and increasing to as much as 50% in patients older than 80 years. 
(13,14,16) Other risk factors include male gender, history of prior AF, heart valve disease 
(especially if the mitral valve is affected), prior cardiac surgery, prior cardiac structural 
changes like increased left atrial size and left ventricular hypertrophy. Preexisting medical 
conditions like obesity, chronic lung disease, peripheral vascular disease, hypertension, 
prior stroke are associated with increased incidence of POAF. However certain other morbid 
factors like preexisting diabetes, chronic kidney disease, hyperlipidemia, smoking have not 
been shown to be individual risk factors for POAF in some studies. (17) Pericarditis which is 
usually a consequence of the cardiac surgery itself is mechanistically involved. Other unique 
factors such as preoperative use of Digoxin or Dopamine, raised Brain natriuretic peptide 
(BNP) and right-sided coronary artery disease have been associated as well. ECG features 
like increased P wave duration of more than 140 ms, which is suggestive of atrial conduction 
delay can increase the susceptibility to AF. (18) Withdrawal of preoperative Angiotensin 
converting enzyme inhibitor (ACE I) or Beta blocker therapy is also contributory if not 
immediately initiated after the surgery. (13)  
Intraoperative factors:  
Certain operative features like aortic cross clamping, pulmonary venting, bicaval venous 
cannulation, increased length of cardiopulmonary bypass time and mitral valve surgery can 
increase the propensity for POAF. It has also been noted that at times cardioplegia via 
coronary sinus does not stun the atria completely and may be associated with occurrence of 
POAF(19) Direct cardiac injury due to operative techniques causing inflammation is 
perceived as plausible cause as well.  
Postoperative features:  
The postoperative period is a critical stage as the body is yet to recover from the operative 
stress completely. Many proarrhythmic features such as pericardial inflammation, acute 
blood pressure or volume changes, acute cardiac ischemia, electrolyte imbalances, 
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If the answer to any of questions 1-3 is yes or to question 4 is no, the rhythm is probably 
ventricular tachycardia. There are several additional ways to distinguish between supra 
ventricular and ventricular arrhythmias, which exceed the objectives of this review. 
4. Types of arrhythmias 
The conduction system of the heart has to be intact anatomically and physiologically for 
synchronized contraction of the heart in a regular and coordinated fashion. Arrhythmias are 
caused when there is disturbance in the working of the conduction system for any reason.  
The accepted mechanisms include abnormality of conduction (i.e. blocking or Re-entry of 
the impulse), abnormality of impulse initiation (i.e. altered automaticity or triggered 
activity). The underlying causes can include ischemia, electrolyte imbalances, scarring or 
fibrosis of atrial and ventricular tissue, increased or decreased excitability for various 
reasons including changes in autonomic nervous system, action of drugs and others.  
Disturbances of the normal cardiac rhythm can be of many types. A universal hierarchical 
classification which can encompass all the salient arrhythmias is difficult to conceive. 
Arrhythmias are usually classified based on morphology, rate or origin. They can be divided 
into fast or slow based on the rate- Tachyarrhythmias when heart rate is faster than 100 bpm 
and bradyarrhythmias when rate is slower than 60 bpm. The QRS duration which defines 
the ventricular depolarization is usually less than 0.12 seconds (or 3 small boxes on the ECG 
at 25 mm/sec paper speed). If it is more than 0.12 seconds it represents delayed 
depolarization and can be used as a feature to divide the tachyarrhythmias into narrow 
complex and wide complex tachycardia. Another classification of arrhythmias describes 
regular versus irregular rhythms. Finally arrhythmias can generally be classified based on 
various anatomical substrates of the heart, which initiate these rhythm changes like atrial (or 
supraventricular) or ventricular arrhythmias. As mentioned above these classifications are 
an attempt, far from perfect, to distinguish normal from abnormal and define categories 
with different underlying pathophysiology and treatment options.  
The following chapter will discuss Atrial Fibrillation (AF) after cardiac surgery initially as 
this seems to be the most common and most extensively studied arrhythmia.  
5. Postoperative AF  
Incidence: 
The incidence of any arrhythmia postoperatively can be up to 85% (5). The Multi center 
anesthesia outcomes study quotes that postoperative arrhythmias can complicate about 70% of 
the operations. (6) AF seems to be the most common arrhythmia in the post operative period 
(7). Goldman concluded as early as 1978 utilizing a prospective registry that the incidence of 
postoperative AF was nearly 3% after non-cardiac surgeries. (8)  While AF is certainly more 
frequent after cardiac surgery, incidence varies between studies. Reasons for these variations 
seem to be different ascertainment methods between studies (12 lead ECG vs. continuous 
telemetry monitoring etc). Mathew et al document an incidence of up to 34% with similar 
incidences in North America and Europe but lower incidence in Asia at 16 %. (13) The 
incidence also varies depending on the type of cardiac surgery undertaken. AF seems to occur 
60% of the time post mitral valve surgery, 36% of the time post aortic valve surgery, (10) and 
25% post cardiac transplants. (11) The combination of coronary artery bypass graft surgery 
(CABG) with valve surgery seems to increase the risk for AF as well. (12) Often times the 
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definition for postoperative AF includes the need of medical treatment or electrical 
cardioversion (14) or confirmation on a 12 lead ECG (13) altering the incidence rates further.  
The peak incidence of postoperative AF (POAF) has been consistently described on day 2 
and 3 after surgery. (10) It usually is transient with 80% of the patients converting to sinus 
rhythm within 24 hours. The recurrence rate has been quoted to be as much as 50% but 
still only 10% of patients are still in AF at 6 weeks post operation. (13) Late Postoperative 
AF is less frequent but was seen in nearly 5% of the postoperative patients after discharge 
from the hospital. This was found when patients were being followed for cardiac 
rehabilitation and documented in the ISYDE and ICAROS registries in Italy. (15) Despite 
better coordinated postoperative care and advances in cardiothoracic surgical and 
anesthetic practices, the incidence of AF seems stable with no reduction over the last 2 
decades.  
Pathophysiology of Postoperative AF: 
AF is generally due to reentry of multiple wavelets circling the atria. It is likely that a pre-
existing substrate is needed to allow peri-operative triggers to initiate AF. It is thus a specific 
interaction of preexisting and perioperative risk factors which can lead to AF.  
Preexisting factors:  
Age is the most consistent risk factor seen in past studies. Advancing age increases the risk 
with each decade. The incidence of POAF is around 6% when less than 40y of age, 18% in 
less than 60y olds and increasing to as much as 50% in patients older than 80 years. 
(13,14,16) Other risk factors include male gender, history of prior AF, heart valve disease 
(especially if the mitral valve is affected), prior cardiac surgery, prior cardiac structural 
changes like increased left atrial size and left ventricular hypertrophy. Preexisting medical 
conditions like obesity, chronic lung disease, peripheral vascular disease, hypertension, 
prior stroke are associated with increased incidence of POAF. However certain other morbid 
factors like preexisting diabetes, chronic kidney disease, hyperlipidemia, smoking have not 
been shown to be individual risk factors for POAF in some studies. (17) Pericarditis which is 
usually a consequence of the cardiac surgery itself is mechanistically involved. Other unique 
factors such as preoperative use of Digoxin or Dopamine, raised Brain natriuretic peptide 
(BNP) and right-sided coronary artery disease have been associated as well. ECG features 
like increased P wave duration of more than 140 ms, which is suggestive of atrial conduction 
delay can increase the susceptibility to AF. (18) Withdrawal of preoperative Angiotensin 
converting enzyme inhibitor (ACE I) or Beta blocker therapy is also contributory if not 
immediately initiated after the surgery. (13)  
Intraoperative factors:  
Certain operative features like aortic cross clamping, pulmonary venting, bicaval venous 
cannulation, increased length of cardiopulmonary bypass time and mitral valve surgery can 
increase the propensity for POAF. It has also been noted that at times cardioplegia via 
coronary sinus does not stun the atria completely and may be associated with occurrence of 
POAF(19) Direct cardiac injury due to operative techniques causing inflammation is 
perceived as plausible cause as well.  
Postoperative features:  
The postoperative period is a critical stage as the body is yet to recover from the operative 
stress completely. Many proarrhythmic features such as pericardial inflammation, acute 
blood pressure or volume changes, acute cardiac ischemia, electrolyte imbalances, 
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hypothyroidism are present at this juncture. (20, 21, 22) Increased sympathetic activation 
causing exaggerated adrenergic responses could be a factor as well. (23) 
The assumption is that non-uniform disruption of the electric conduction properties leads to 
changes in the resistance between adjacent cells in the atria. This causes decreased atrial 
conduction and creation of micro reentry loops causing AF. (24) Various factors mentioned 
above change the atrial refractoriness/transmembrane potentials causing increased local 
reentry and subsequent AF. (25) The suggestion that expression of connexin 40, a gap 
junction protein in the atria is altered during the postoperative period lends credence to the 
theory that the gap junction function in the atria is altered. (26) 
Clinical Significance:  
POAF is usually transient as the underlying mechanical and metabolic changes are usually 
reversible and not long lasting. However it is associated with significant morbidity and 
mortality even when it occurs briefly. POAF can increase the risk of stroke by 3-4 folds. (27) 
Cresswell et al noted that the occurrence of stroke postoperatively with AF was at 3.3 vs.1.2% 
without AF. (12) However, other features such as increased age, prior stroke, length of cardiac 
bypass time seem to be playing additional role in the additive risk of stroke postoperatively.  
AF has been shown to increase overall health care cost. The hospitalization time is increased 
by an average of 2 to 5 days. (13, 14) The costs were higher by as much as $10,000 per patient 
if AF occurred postoperatively. The chances that the patient will suffer infection, renal 
failure, and mechanical ventilation also seem to be higher when AF is present. There has 
been suspicion that cognition of the patients can be affected as evidenced by a fall in the 
Mini Mental Score postoperatively when AF occurred. (10, 17, 28) 
AF remains the leading cause for readmission after hospital discharge following cardiac 
surgery. It is estimated that AF contributed to nearly 23% of readmissions in one series. (9) 
So it would seem AF is a problem even after discharge and it would argue for continued 
monitoring of the patient as an outpatient preferably in a cardiac rehabilitation program.  
AF seems to be associated with increased mortality both early and late after operation even 
after correction for many important confounding variables. It is estimated that the mortality 
associated with postoperative AF is around 5% compared to around 2% without AF. (13)  
Management: 
Given the morbidity and mortality associated with POAF it has long been a target for 
preventive as well as suppressive therapy. A variety of interventions have been studied and 
validated. We would like to clarify that our list does not claim to be complete, but only gives 
an overview of some of the most important therapies available. In most cases consultation 
with a Cardiologist is recommended. Multiple studies (29) have shown that AF can be 
suppressed in the postoperative period and various meta analyses confirmed their findings. 
Incidence of AF was reduced by as much as 50%. (30, 31) We categorize preventative 
measures into preoperative, operative and postoperative measures. 
Preoperative measures: 
The main thrust has been to reduce the sympathetic drive and Beta blockers seem to be the 
mainstay of this preventive approach. The 2004 ACC/AHA guidelines give a class I 
recommendation for preoperative and early postoperative beta blockade to prevent POAF. (32) 
Amiodarone which blocks Potassium and Calcium ion channels, and has both alpha and 
beta blockade properties has been assessed in various trials such as AFIST, ARCH, AFIST 2, 
GAP and PapaBear for prevention of POAF and has been summarized in a meta analysis 
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(33). It can reduce postoperative AF by 50% - 70% and evidence suggests that ventricular 
arrhythmias are also reduced. However, there is concern about possible complications 
including proarrhythmia, sudden respiratory distress or bradycardia requiring pacing 
following Amiodarone prophylaxis or treatment. Therefore, Amiodarone therapy needs to 
be closely monitored.  
Digoxin has also been studied but seems to be better only when used along with beta 
blockers and is currently not recommended. (34)  
Magnesium has been studied as a preventive strategy and while hypomagnesaemia does 
definitely portend arrhythmias (20) supplementation does not seem to be helpful in 
reducing rhythm disturbances. One meta analysis (35) has shown a positive outcome but 
another study (36) has cast a doubt on the utility of Magnesium supplementation in 
preventing POAF.  
Sotalol which has beta blocker as well as potassium channel blocking properties has been 
shown in certain studies (37) to be useful in preventing AF with relative risk reduction of up 
to 90%. However, studies generally involved small sample sizes. (29) There may not be an 
incremental effect of Sotalol along with Beta blocker therapy to prevent POAF.  
Angiotensin Converting Enzyme inhibitor (ACE I) therapy did not consistently reduce 
POAF, but incidence may be increased if the ACE inhibitor therapy is withdrawn in patients 
who were receiving it before surgery.  
Statins appear to have a beneficial effect in preventing AF. The ARMYDA 3 trial showed that 
taking a  statin two weeks prior to surgery significantly reduces the incidence of POAF, although 
there were concerns about the relatively high incidence of AF in the control group. (38)  
Various other agents like Non steroidal anti inflammatory agents (NSAID), Ascorbic acid, 
N-acetyl cysteine, Nitroprusside, Glucocorticoids, Fish oil have been tried on the premise 
that they reduce the oxidative stress and help modify the inflammatory process that seems 
to be present postoperatively and thereby contributing to lower the risk of POAF. However 
despite positive results in small trials, larger randomized controlled trials are necessary to 
ascertain any true benefit. (39)  
Pacing via epicardial wires introduced at the time of the surgery has been recognized as an 
effective method in controlling AF in as much as 63% of the cases. (40) Pacing is done either 
at the sinus rate or faster with overdrive pacing. Studies have showed that bi atrial pacing 
(BAP) seems to be better than pacing in only one atrium. The American College of Chest 
Physicians (ACCP) guide recommends BAP over either right or left single atrial pacing. (41) 
Beta blockers seem to provide additive benefits along with pacing in preventing POAF.  
The odds ratios of various agents used in POAF prevention are given below: (21) 
Beta blockers – 0.35 
Sotalol – 0.36 
Amiodarone – 0.54 
Pacing – 0.57 
Potassium – 0.53 
NSAID – 0.49 
ACE inhibition – 0.62 
The ACC/AHA/ESC 2006 guidelines recommend using a beta blocker routinely to prevent 
POAF and using Amiodarone or pacing only if the patient is intolerant of beta blockers or in 
high risk cases such as when the patient is undergoing mitral valve surgery or if they have 
had prior history of AF. (32) 
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hypothyroidism are present at this juncture. (20, 21, 22) Increased sympathetic activation 
causing exaggerated adrenergic responses could be a factor as well. (23) 
The assumption is that non-uniform disruption of the electric conduction properties leads to 
changes in the resistance between adjacent cells in the atria. This causes decreased atrial 
conduction and creation of micro reentry loops causing AF. (24) Various factors mentioned 
above change the atrial refractoriness/transmembrane potentials causing increased local 
reentry and subsequent AF. (25) The suggestion that expression of connexin 40, a gap 
junction protein in the atria is altered during the postoperative period lends credence to the 
theory that the gap junction function in the atria is altered. (26) 
Clinical Significance:  
POAF is usually transient as the underlying mechanical and metabolic changes are usually 
reversible and not long lasting. However it is associated with significant morbidity and 
mortality even when it occurs briefly. POAF can increase the risk of stroke by 3-4 folds. (27) 
Cresswell et al noted that the occurrence of stroke postoperatively with AF was at 3.3 vs.1.2% 
without AF. (12) However, other features such as increased age, prior stroke, length of cardiac 
bypass time seem to be playing additional role in the additive risk of stroke postoperatively.  
AF has been shown to increase overall health care cost. The hospitalization time is increased 
by an average of 2 to 5 days. (13, 14) The costs were higher by as much as $10,000 per patient 
if AF occurred postoperatively. The chances that the patient will suffer infection, renal 
failure, and mechanical ventilation also seem to be higher when AF is present. There has 
been suspicion that cognition of the patients can be affected as evidenced by a fall in the 
Mini Mental Score postoperatively when AF occurred. (10, 17, 28) 
AF remains the leading cause for readmission after hospital discharge following cardiac 
surgery. It is estimated that AF contributed to nearly 23% of readmissions in one series. (9) 
So it would seem AF is a problem even after discharge and it would argue for continued 
monitoring of the patient as an outpatient preferably in a cardiac rehabilitation program.  
AF seems to be associated with increased mortality both early and late after operation even 
after correction for many important confounding variables. It is estimated that the mortality 
associated with postoperative AF is around 5% compared to around 2% without AF. (13)  
Management: 
Given the morbidity and mortality associated with POAF it has long been a target for 
preventive as well as suppressive therapy. A variety of interventions have been studied and 
validated. We would like to clarify that our list does not claim to be complete, but only gives 
an overview of some of the most important therapies available. In most cases consultation 
with a Cardiologist is recommended. Multiple studies (29) have shown that AF can be 
suppressed in the postoperative period and various meta analyses confirmed their findings. 
Incidence of AF was reduced by as much as 50%. (30, 31) We categorize preventative 
measures into preoperative, operative and postoperative measures. 
Preoperative measures: 
The main thrust has been to reduce the sympathetic drive and Beta blockers seem to be the 
mainstay of this preventive approach. The 2004 ACC/AHA guidelines give a class I 
recommendation for preoperative and early postoperative beta blockade to prevent POAF. (32) 
Amiodarone which blocks Potassium and Calcium ion channels, and has both alpha and 
beta blockade properties has been assessed in various trials such as AFIST, ARCH, AFIST 2, 
GAP and PapaBear for prevention of POAF and has been summarized in a meta analysis 
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(33). It can reduce postoperative AF by 50% - 70% and evidence suggests that ventricular 
arrhythmias are also reduced. However, there is concern about possible complications 
including proarrhythmia, sudden respiratory distress or bradycardia requiring pacing 
following Amiodarone prophylaxis or treatment. Therefore, Amiodarone therapy needs to 
be closely monitored.  
Digoxin has also been studied but seems to be better only when used along with beta 
blockers and is currently not recommended. (34)  
Magnesium has been studied as a preventive strategy and while hypomagnesaemia does 
definitely portend arrhythmias (20) supplementation does not seem to be helpful in 
reducing rhythm disturbances. One meta analysis (35) has shown a positive outcome but 
another study (36) has cast a doubt on the utility of Magnesium supplementation in 
preventing POAF.  
Sotalol which has beta blocker as well as potassium channel blocking properties has been 
shown in certain studies (37) to be useful in preventing AF with relative risk reduction of up 
to 90%. However, studies generally involved small sample sizes. (29) There may not be an 
incremental effect of Sotalol along with Beta blocker therapy to prevent POAF.  
Angiotensin Converting Enzyme inhibitor (ACE I) therapy did not consistently reduce 
POAF, but incidence may be increased if the ACE inhibitor therapy is withdrawn in patients 
who were receiving it before surgery.  
Statins appear to have a beneficial effect in preventing AF. The ARMYDA 3 trial showed that 
taking a  statin two weeks prior to surgery significantly reduces the incidence of POAF, although 
there were concerns about the relatively high incidence of AF in the control group. (38)  
Various other agents like Non steroidal anti inflammatory agents (NSAID), Ascorbic acid, 
N-acetyl cysteine, Nitroprusside, Glucocorticoids, Fish oil have been tried on the premise 
that they reduce the oxidative stress and help modify the inflammatory process that seems 
to be present postoperatively and thereby contributing to lower the risk of POAF. However 
despite positive results in small trials, larger randomized controlled trials are necessary to 
ascertain any true benefit. (39)  
Pacing via epicardial wires introduced at the time of the surgery has been recognized as an 
effective method in controlling AF in as much as 63% of the cases. (40) Pacing is done either 
at the sinus rate or faster with overdrive pacing. Studies have showed that bi atrial pacing 
(BAP) seems to be better than pacing in only one atrium. The American College of Chest 
Physicians (ACCP) guide recommends BAP over either right or left single atrial pacing. (41) 
Beta blockers seem to provide additive benefits along with pacing in preventing POAF.  
The odds ratios of various agents used in POAF prevention are given below: (21) 
Beta blockers – 0.35 
Sotalol – 0.36 
Amiodarone – 0.54 
Pacing – 0.57 
Potassium – 0.53 
NSAID – 0.49 
ACE inhibition – 0.62 
The ACC/AHA/ESC 2006 guidelines recommend using a beta blocker routinely to prevent 
POAF and using Amiodarone or pacing only if the patient is intolerant of beta blockers or in 
high risk cases such as when the patient is undergoing mitral valve surgery or if they have 
had prior history of AF. (32) 
 




Certain operative practices and techniques have shown to be of some benefit in reducing the 
incidence of POAF. Off pump surgery may decrease occurrence of AF, even when taking 
age into account. (42, 43) The anterior fat pad present in the mediastinum is considered to 
have parasympathetic nerves, which may play a role in initiating POAF. One study showed 
that preservation of the fat pad was protective but it could not be replicated in other studies. 
(44,45) Other factors include inducing hypothermia during Cardio Pulmonary Bypass 
(CPB), using posterior pericardiotomy and Heparin coated CPB circuit etc. (27)  
Postoperative measures:  
The only postoperative preventative measure may be early reinitiation of beta blockers and 
ACE-inhibitors. (13) There was a suggestion in a recent study that early statin use post 
operatively may be beneficial in preventing POAF after cardiac surgery as well. (46) 
If AF does occur and is persistent despite the prophylactic measures, treatment should be 
initiated. There are two general approaches to AF treatment, Rate control or Rhythm control 
with both being acceptable as to preferred outcomes. (47) Whatever approach is taken, 
initial efforts need to be made to try and correct any obvious precipitating or co-existent 
mitigating factors. Meticulous attention needs to be paid to pain control, volume status, 
electrolyte balance, correcting anemia and hypoxia. Anticoagulation needs to be initiated as 
well if the AF is persistent for more than 48 hours.  
Rhythm control where in AF is converted to sinus rhythm is preferred when the patient is 
deemed unstable such as if there is hypotension, ongoing ischemia, co-existing heart failure, if 
pre excitation is suspected or if the patient is very symptomatic. It is also preferred if 
anticoagulation is not an option for any reason. Rhythm control can be achieved either with 
pharmacological cardioversion or electrical cardioversion. Various anti arrhythmic agents can 
be used to convert AF, Amiodarone is typically preferred, because it can be transitioned to oral 
route, has comparatively lower proarrhythmic potential and may be better at ventricular rate 
control. Also as most patients have some underlying left ventricular dysfunction or coronary 
artery disease, Amiodarone is a safer choice in such patients. It is usually given as an initial 
bolus at 5 mg/Kg body weight over 30 minutes and then continued as an infusion at a dose of 
25 mg /Hr.  Various other pharmacological rhythm control agents used include 
Disopyramide, Procainamide, Flecainide, Ibutilide and Dofetilide. (10)  
Direct current (DC) cardioversion is a quick and safe way to attempt rhythm control. Initial 
shock is attempted at 100 - 200 joules with synchronization when monophasic waveforms 
are used and 50 – 100 joules when biphasic waveforms are used. As usually the POAF has 
been present only for a short time DC cardioversion can successfully convert the AF to sinus 
in up to 95% of the cases. If it is not successful, intra venous Ibutilide can be given before 
repeat electrical cardioversion. However, significant pauses and risk for Torsades make 
Ibutilide less attractive for most practitioners. The transvenous electrodes or epicardial wires 
placed during surgery can be used for cardioversion or patient can be shocked by two pairs 
of external patch electrodes. 
Rate control can be achieved with a variety of agents such as beta blockers including 
Metoprolol, Esmolol, Atenolol or Calcium channel antagonists like Diltiazem. Digoxin, 
Amiodarone or the newer agent Dronedarone are also popular choices at rate control. (48) 
Anticoagulation with warfarin is recommended if the AF is persisting for more than 48 
hours. (32, 48) Heparin bridging is not recommended unless high risk features are present 
such as Mitral valve disease, prior stroke. (49) The criteria for anti coagulation per ESC are 
based on the CHADS2 – VASc score. Risk factors including increased Age > 75y and prior 
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Stroke, transient ischemic attack (TIA) or thrombo embolism are given 2 points each. Factors 
including Hypertension, Congestive heart failure, Diabetes, Ages 65-74y, female Sex and co 
existent Vascular disease are scored 1 point each. Anticoagulation is indicated if the 
combined score is > 2. (48) Newer agents like Dabigatran are available on the market but 
studies will need to be done to assess its value specifically in the postoperative period.  
Not much significant data is available as to the management of patients after discharge. 
They are usually reassessed 4-6 weeks after discharge and often times Holter monitoring is 
employed. Most of the patients can stop their anti arrhythmic medications and anti 
coagulation if they are deemed to be in sinus rhythm without intermittent AF, 3-6 months 
after hospital discharge.  
In spite of all studies and evidence regarding preventing and treating POAF, doubts still 
exist whether any real benefit is obtained. Some evidence suggests that AF prevention does 
not or only minimally reduces the length of stay or the overall cost. (50) It is also noted that 
there is no actual decrease in the stroke incidence post operatively even if the AF is 
suppressed. It is unclear if the mortality and morbidity are improved if the AF is indeed 
suppressed. (51) It seems that stroke may be an epiphenomenon and not directly related to 
the occurrence of POAF. However a large Meta analysis does seem to suggest some overall 
benefit with prophylaxis measures and prevention of POAF. (52) 
6. Post cardiac surgery ventricular arrhythmias 
These include the more common benign isolated ectopic beats or Non sustained ventricular 
tachycardia (NSVT) and the more dangerous ventricular tachycardia or ventricular 
fibrillation (VT/VF) which fortunately are less common. The incidence of sustained 
ventricular arrhythmias has been quoted at around 0.4 – 1.4% (53) to 0.7 – 3% (54). The 
benign rhythm changes including ectopic ventricular beats and NSVT can occur in up to 
60% of patients (55) but are not known to portend the more malignant rhythms like VT/VF 
(56) nor do they portend any rise in mortality risk (55, 57) if no underlying structural heart 
disease is suspected. The mortality of sustained VT is high at around 50% in hospital and a 
further 10% die within 2 years. (53)  
The risk factors for the occurrence of VT/VF seem to correlate with factors associated in 
general cardiology practice. Any underlying structural heart disease, prior myocardial 
infarction, reduced left ventricular ejection fraction or congestive heart failure increase the 
risk of life threatening ventricular arrhythmias. Immediate postoperative features which set 
off the rhythm disturbance include any hemodynamic instability, electrolyte or acid base 
disturbances, hypoxia, anemia, new onset ischemia etc. An occasional cause can be acute 
graft closure after bypass grafting. Any inotropes used in the postoperative phase can also 
be pro arrhythmic.  
Treatment:  
Even though frequent ectopics and NSVT are considered benign it would be prudent to look 
for any reversible factors mentioned before in the acute phase. Lidocaine and pacing have 
been studied to suppress these rhythm disturbances but no actual benefit was observed. (53, 
58) Sustained Ventricular arrhythmia is invariably quite unstable and quick remedial 
measures need to be instituted to treat the patient. Electrical cardioversion with 200 – 360 
Joules is usually the first line option to convert the arrhythmia. If Direct Current 
cardioversion is not an option or if medications are preferred as per the clinical situation, 
various drugs like Lidocaine, Amiodarone, Procainamide can be considered. Emergency 
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pacing via epicardial leads placed during surgery can be used sometimes to provide 
overdrive pacing to get the heart out of the arrhythmia. Emergency bypass surgery can be 
considered in some situations. (59) Readers are also referred to the American Heart 
Association (AHA) 2010 guidelines on advanced cardiovascular life support (ACLS) for 
dealing with unstable tachycardia. (75) 
If the patient does survive and is back in sinus it is prudent to initiate them on long term 
beta blocker and ACE inhibitor therapy according to current ACC guidelines. For those who 
sustained VT/VF and have recovered, if there are no underlying risk factors mentioned 
prior, a cardiac electrophysiological study can be considered and an implantable cardiac 
defibrillator (ICD) is advised if there is any inducible VT or VF. If the patient is deemed to 
have an underlying heart disease that is unlikely to respond to medical therapy, an ICD may 
be indicated without electrophysiological study.  
7. Bradyarrhythmias after cardiac surgery 
Bradyarrhythmias include sinus pauses, sinus bradycardia and various blocks depending 
on the site of abnormal conduction including SA node, AV node or parts of HIS bundle. 
Bundle branch blocks are common and are not only transient but also harmless in most 
cases. Various bundle branch blocks can occur in up to 50 – 60% of cases after CABG but 
are usually transient. (60, 61, 62, 63) Symptomatic blocks needing permanent pacemaker 
(PPM) insertion complicate 0.8 – 3.4% of CABG operations and up to 2 – 4% of valve 
surgeries. (64, 65) The incidence of symptomatic bradyarrhythmias is higher after aortic or 
tricuspid valve surgeries. Repeat surgeries are complicated by blocks needing pacing 
more often. (65) Heart transplantation is complicated by sinus node dysfunction needing a 
pacemaker in 21% of cases while AV node blocks needing pacemaker can happen in 4-5% 
of cases. (53)  
Risk factors include increased age, prior Left bundle branch block (LBBB), valve 
calcification, left main coronary blockage, longer cardiopulmonary bypass time, higher 
number of bypassed arteries during surgery, associated Left Ventricular aneurysmectomy 
etc. Valve surgeries seem to be more of a risk than CABG. Increased vagal tone due to 
surgery, the type of anesthesia used or occurrence of postoperative pain seem to be 
important underlying factor as well. 
Specific factors involved in increasing the risk of bradyarrhythmias after heart 
transplantation include Biatrial rather than bicaval transplant, older donor age, longer donor 
ischemic time, longer aortic cross clamp time.  
Treatment:  
It is prudent to stop all unnecessary medications that can cause increased AV block like beta 
blockers or calcium channel blockers. Atropine can reverse symptomatic bradycardia. 
Aminophylline and Theophylline can be used to increase the heart rate during sinus node 
dysfunction or high grade AV blocks. (66, 67) Readers are also referred to the AHA 2010 
guidelines on advanced ACLS for dealing with unstable bradycardia. (75) 
Patients with complete heart block, symptomatic AV block or sinus node dysfunction need 
to have a temporary pacer inserted. It is advisable to wait for 5 – 7 days post op so that any 
possible edema of the conduction system of the heart resolves before a permanent 
pacemaker is inserted if still indicated. (68) 
Patients who already have a permanent pacemaker or ICD prior to surgery pose a challenge 
for the surgeons and anesthetists. Electrocautery-induced electromagnetic interference can 
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cause problems during the surgery. The cautery can inhibit the pacer and may cause 
inappropriate discharge of the ICD if the sensing function is not disabled. A comprehensive 
evaluation of the patient prior to surgery by an electrophysiologist is indicated. A magnet 
can be placed on top to disable the devices during the surgery so as to not cause any 
interference. Another option is to switch the pacer/ICD to asynchronous mode so that the 
cautery does not influence its function. However, patients need to be continuously 
monitored while the devices are in asynchronous mode as any malignant arrhythmias need 
to be treated via external defibrillator. (76) 
8. Postoperative arrhythmias after non cardiac surgery  
Arrhythmias complicate postoperative period after non cardiac surgery in up to 5 -20 % of 
the times. (69) Again, AF seems to be the most common arrhythmia making up about 68% of 
the documented arrhythmias. (8) Benign ventricular rhythms like ectopics or NSVT occur in 
up to 5 -25% of the patients and sustained VT is rather rare occurring in less than 1% of the 
cases. (70) 
The rate of incidence after non-cardiac surgery also seems to depend on the type of surgery. 
Non vascular abdominal surgery, especially colorectal surgery seems more prone with rates 
of around 20%. The incidence seems increased after any instance of thoracotomy (10%) as 
well. In other instances the rate is around 0.01% after ophthalmologic surgery and 4% after 
orthopedic surgery.  
The risk factors seem to be similar to those implicated in post cardiac surgery including 
male sex, increased age > 70y, heart valve disease, prior history of arrhythmia, co existing 
asthma, congestive heart failure, and hypertension. (71) Post operative causes include 
electrolyte imbalances, hypoxia, and hypercarbia. (72) Sepsis seems to be a recurring factor 
implicated as a causative factor of arrhythmias. In fact all kinds of stress inducing causes 
like stroke, Gastrointestinal bleed, Pulmonary Embolism, Myocardial Infarction, pulmonary 
edema and others have been implicated. Some specific factors noted to cause postoperative 
arrhythmias also include anastomotic leak (77) or acute alcohol withdrawal. (69) Increased 
vagal tone due to anesthetic practices like laryngoscopy is also a risk factor for any 
bradyarrhythmia.  
Apart from associated morbidity similar to post cardiac surgery arrhythmias, post non-
cardiac surgery arrhythmias can also cause mortality of around 12 – 50%. (72, 73, 74) 
Management:  
No large scale randomized trials validating the treatment of post non-cardiac surgery 
arrhythmias are available. However the management can be closely extrapolated from both 
post cardiac surgery treatment and non-surgical related general cardiology treatment 
protocols. Initial priority is to assess the physiological impact and stabilize the patient 
hemodynamically while searching for the specific causes that initiated the rhythm 
disturbance. One needs to rectify these issues while simultaneously initiating specific 
therapy to halt the arrhythmia.  Specific treatment methods for individual rhythms are 
similar to the approach already explained for post cardiac surgery arrhythmias.  
In conclusion, postoperative arrhythmias, especially AF are common and are associated 
with significant morbidity and mortality but can be prevented to some extent. Further 
research is required to completely understand causes of such arrhythmias and to improve 
their prevention and treatment. 
 
Special Topics in Cardiac Surgery 
 
250 
pacing via epicardial leads placed during surgery can be used sometimes to provide 
overdrive pacing to get the heart out of the arrhythmia. Emergency bypass surgery can be 
considered in some situations. (59) Readers are also referred to the American Heart 
Association (AHA) 2010 guidelines on advanced cardiovascular life support (ACLS) for 
dealing with unstable tachycardia. (75) 
If the patient does survive and is back in sinus it is prudent to initiate them on long term 
beta blocker and ACE inhibitor therapy according to current ACC guidelines. For those who 
sustained VT/VF and have recovered, if there are no underlying risk factors mentioned 
prior, a cardiac electrophysiological study can be considered and an implantable cardiac 
defibrillator (ICD) is advised if there is any inducible VT or VF. If the patient is deemed to 
have an underlying heart disease that is unlikely to respond to medical therapy, an ICD may 
be indicated without electrophysiological study.  
7. Bradyarrhythmias after cardiac surgery 
Bradyarrhythmias include sinus pauses, sinus bradycardia and various blocks depending 
on the site of abnormal conduction including SA node, AV node or parts of HIS bundle. 
Bundle branch blocks are common and are not only transient but also harmless in most 
cases. Various bundle branch blocks can occur in up to 50 – 60% of cases after CABG but 
are usually transient. (60, 61, 62, 63) Symptomatic blocks needing permanent pacemaker 
(PPM) insertion complicate 0.8 – 3.4% of CABG operations and up to 2 – 4% of valve 
surgeries. (64, 65) The incidence of symptomatic bradyarrhythmias is higher after aortic or 
tricuspid valve surgeries. Repeat surgeries are complicated by blocks needing pacing 
more often. (65) Heart transplantation is complicated by sinus node dysfunction needing a 
pacemaker in 21% of cases while AV node blocks needing pacemaker can happen in 4-5% 
of cases. (53)  
Risk factors include increased age, prior Left bundle branch block (LBBB), valve 
calcification, left main coronary blockage, longer cardiopulmonary bypass time, higher 
number of bypassed arteries during surgery, associated Left Ventricular aneurysmectomy 
etc. Valve surgeries seem to be more of a risk than CABG. Increased vagal tone due to 
surgery, the type of anesthesia used or occurrence of postoperative pain seem to be 
important underlying factor as well. 
Specific factors involved in increasing the risk of bradyarrhythmias after heart 
transplantation include Biatrial rather than bicaval transplant, older donor age, longer donor 
ischemic time, longer aortic cross clamp time.  
Treatment:  
It is prudent to stop all unnecessary medications that can cause increased AV block like beta 
blockers or calcium channel blockers. Atropine can reverse symptomatic bradycardia. 
Aminophylline and Theophylline can be used to increase the heart rate during sinus node 
dysfunction or high grade AV blocks. (66, 67) Readers are also referred to the AHA 2010 
guidelines on advanced ACLS for dealing with unstable bradycardia. (75) 
Patients with complete heart block, symptomatic AV block or sinus node dysfunction need 
to have a temporary pacer inserted. It is advisable to wait for 5 – 7 days post op so that any 
possible edema of the conduction system of the heart resolves before a permanent 
pacemaker is inserted if still indicated. (68) 
Patients who already have a permanent pacemaker or ICD prior to surgery pose a challenge 
for the surgeons and anesthetists. Electrocautery-induced electromagnetic interference can 
 
Post Operative Arrhythmias 
 
251 
cause problems during the surgery. The cautery can inhibit the pacer and may cause 
inappropriate discharge of the ICD if the sensing function is not disabled. A comprehensive 
evaluation of the patient prior to surgery by an electrophysiologist is indicated. A magnet 
can be placed on top to disable the devices during the surgery so as to not cause any 
interference. Another option is to switch the pacer/ICD to asynchronous mode so that the 
cautery does not influence its function. However, patients need to be continuously 
monitored while the devices are in asynchronous mode as any malignant arrhythmias need 
to be treated via external defibrillator. (76) 
8. Postoperative arrhythmias after non cardiac surgery  
Arrhythmias complicate postoperative period after non cardiac surgery in up to 5 -20 % of 
the times. (69) Again, AF seems to be the most common arrhythmia making up about 68% of 
the documented arrhythmias. (8) Benign ventricular rhythms like ectopics or NSVT occur in 
up to 5 -25% of the patients and sustained VT is rather rare occurring in less than 1% of the 
cases. (70) 
The rate of incidence after non-cardiac surgery also seems to depend on the type of surgery. 
Non vascular abdominal surgery, especially colorectal surgery seems more prone with rates 
of around 20%. The incidence seems increased after any instance of thoracotomy (10%) as 
well. In other instances the rate is around 0.01% after ophthalmologic surgery and 4% after 
orthopedic surgery.  
The risk factors seem to be similar to those implicated in post cardiac surgery including 
male sex, increased age > 70y, heart valve disease, prior history of arrhythmia, co existing 
asthma, congestive heart failure, and hypertension. (71) Post operative causes include 
electrolyte imbalances, hypoxia, and hypercarbia. (72) Sepsis seems to be a recurring factor 
implicated as a causative factor of arrhythmias. In fact all kinds of stress inducing causes 
like stroke, Gastrointestinal bleed, Pulmonary Embolism, Myocardial Infarction, pulmonary 
edema and others have been implicated. Some specific factors noted to cause postoperative 
arrhythmias also include anastomotic leak (77) or acute alcohol withdrawal. (69) Increased 
vagal tone due to anesthetic practices like laryngoscopy is also a risk factor for any 
bradyarrhythmia.  
Apart from associated morbidity similar to post cardiac surgery arrhythmias, post non-
cardiac surgery arrhythmias can also cause mortality of around 12 – 50%. (72, 73, 74) 
Management:  
No large scale randomized trials validating the treatment of post non-cardiac surgery 
arrhythmias are available. However the management can be closely extrapolated from both 
post cardiac surgery treatment and non-surgical related general cardiology treatment 
protocols. Initial priority is to assess the physiological impact and stabilize the patient 
hemodynamically while searching for the specific causes that initiated the rhythm 
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1. Introduction 
Atrial Fibrillation (AF) is characterised by rapid and disorganised depolarisation of the atria 
resulting in uncoordinated atrial contraction. It is the most common cardiac arrhythmia 
encountered in clinical practice increasing in prevalence with age and the presence of heart 
disease1 It is estimated that it affects 2.5 million people in the United States and 4.5 million in 
the European Union.2,3 The actual incidence of the arrhythmia may be much higher owing to 
undetected or asymptomatic patients within the population.  Since it is an age-associated 
arrhythmia its incidence has steadily risen over the past decade and will continue to 
increase due to a growing population of the elderly in the western world. Contributing risk 
factors include hypertension, diabetes, coronary artery disease, valvular disease, electrolyte 
imbalance.4 Patients with atrial fibrillation have a higher risk for stroke, heart failure and 
death.5Given the significant morbidity and mortality associated with AF and its associated 
economic burden, it is not surprising that there has been great interest in developing 
effective treatments for it. 
Atrial fibrillation is a supraventricular arrhythmia where uncoordinated rapid atrial 
contractions produce an irregular ventricular response. The atria may discharge between 
300-600 beats per minute but not all these impulses are conducted by the AV node. 
Ventricular response can be between 100-160 beats per minute in untreated patients with 
normal AV conduction.  This chaotic rhythm disrupts normal movement of blood through 
the heart reducing cardiac output and increasing the risk for thromboembolism such as 
stroke as a consequence of stasis of blood in the atria.6 
The serious morbidity and mortality associated with AF are attributed to three detrimental 
consequences: 
 Palpitations causing significant patient discomfort and anxiety  
 Loss of the coordinated atrioventricular contraction and “atrial kick” compromising 
cardiac haemodynamics and can lead to varying levels of ventricular dysfunction 
 Stasis and pooling of stagnant blood that can lead to intra-atrial thrombus formation 
and resulting in increased risk of thromboembolism 
Medical therapy remains the most common and first line treatment for patients with AF but 
frequently ineffective at restoring sinus rhythm leaving the patient susceptible to 
cardiovascular morbidity and mortality. Therefore, the goal of pharmacological therapy is 
often shifted from rhythm control (maintenance of sinus rhythm) to rate control (slowing 
the ventricular response to AF).7 
The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial 
demonstrated no survival benefit of rhythm control strategy over a rate control strategy. 
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the ventricular response to AF).7 
The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial 
demonstrated no survival benefit of rhythm control strategy over a rate control strategy. 
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Although rate control slows the ventricular response to AF, preventing tachycardia induced 
cardiomyopathy, it does not reduce the rates of thromboembolism or congestive heart 
failure. The atria are still in fibrillation and there is loss of the atrial “kick” resulting in 
worsening of congestive heart failure and requires indefinite anticoagulation with warfarin 
to counter the risk for developing thromboembolism. Although warfarin reduces the annual 
risk of ischaemic stroke and systemic thromboembolism to approximately 2%, its use is 
associated with significant morbidity with a 2% annual risk of drug associated 
haemorrhage.8,9,10 Anticoagulation may reduce lifetime relative risk of stroke by 60% but 
does not eliminate it11 
Although the results of the AFFIRM trial demonstrated no long-term benefit of rhythm 
versus rate control, some patients may still have advantages of being in sinus rhythm. These 
include freedom from palpitations, increased exercise tolerance and prevention of atrial 
remodelling. 12,13 
Ineffective results with rate and rhythm control strategies have helped to encourage the 
development of new interventional catheter and surgical treatments. Although catheter 
ablation is an established therapeutic option, the highest success rates are typically seen in 
patients with paroxysmal AF and minimal structural heart disease.14 
Therefore it is limited to a small number of patients treated by highly skilled 
electrophysiologists. On the other hand, almost all cardiac surgeons are capable of 
performing surgical ablation of AF. 
2. Classification of atrial fibrillation 
The terms used to classify and describe AF categorise it as paroxysmal, persistent, 
longstanding or permanent (figure 1). Paroxysmal AF is defined as at least two episodes of 
AF that terminate spontaneously within 7 days. If this is sustained beyond 7 days it is 
described as persistent. Another category of persistent AF includes longstanding AF, 
defined by duration of greater than one year. This usually leads to permanent atrial 
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3. Electrophysiology of AF 
In recent years there has been considerable progress in understanding the pathophysiology 
of AF. It was initially thought that AF was caused by random, multiple wavelets generated 
throughout the atria that propagated new wavelets to cause re-entry mechanism. In the 
1980s, several procedures were developed aimed at curing atrial fibrillation. However, most 
of these were abandoned due to their inability to address all three detrimental sequelae of 
atrial fibrillation. It was discovered that electrical impulses were incapable of crossing areas 
of the heart that had been incised and sutured.16,17 
This fostered the development of the Maze procedure, designed and first reported by Cox 
and colleagues in which multiple incisions were made and sutured in a manner that blocked 
the aberrant impulses within the atrium (figure 2). These incisions directed the SA node 
impulse to initiate and propagate throughout the atria to the AV node along a specified 
route created by the Maze incisional lesions18. However, recently studies have demonstrated 
that the initiation of paroxysmal but not necessarily persistent or permanent AF are 
generated by electrical waves from focal sources, particularly near the pulmonary veins. 
Haissaguerre et al.19 mapped the triggers of paroxysmal AF to originate around the orifices 
of the pulmonary veins in 94% of patients with atrial diameters of less than 5cm. These 
findings have directed the development of more precisely targeted procedures that can be 
performed less invasively with less destruction of normal tissue. 
 
 
Fig. 2. The pathway taken in the atria by the aberrant impulses in atrialfibrillation (arrows). 
The thick lines are the ablation lesions used in the Maze procedure. Key-  SAN: sino-atrial 
node, AVN: atrio-ventricular node,  RAA: right atrial appendage, LAA: left atrial 
appendage, SVC: superior vena cava, IVC: inferior vena cava, PVs: pulmonary veins. 
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A key concept in understanding the development of persistent atrial fibrillation is that the 
atria undergo electrical remodelling. Atrial electrical remodelling results in shortening of the 
atrial refractory period, myocyte calcium overload, decreased conduction velocity, 
dispersion of conduction and increased sensitivity to catecholamines4,20,21,22. This 
phenomenon may be reversed after maintenance of sinus rhythm23. The more a patient 
experiences AF, the more susceptible they are to continue fibrillating as a result of 
remodelling. Therefore AF can become a self-sustaining arrhythmia once atrial remodelling 
has occurred. Micro-reentrant triggers are then no longer necessary and limited to 
pulmonary venous impulse-triggering sites.24 Therefore, treatment for persistent or 
longstanding AF directed at the pulmonary veins only is likely to be unsuccessful. 
4. Non pharmacological therapy 
When pharmacological intervention is unsuccessful or contraindicated in patients, non-
pharmacological therapy may be attempted. These include synchronised electrical 
cardioversion, catheter based ablation techniques or surgical intervention.25,26,27. Direct-
current cardioversion differs from defibrillation whereby the shock is synchronised to the R 
wave in the patient’s ECG. The patient must be adequately anticoagulated during electrical 
cardioversion in order to prevent disruption of a pre-existing intra cardiac thrombus which 
will cause it to embolize to the brain or systemic circulation. The risks of electrical 
cardioversion include hypotension, bradycardia, pulmonary oedema, systemic 
embolization, skin burns and ventricular arrhythmias.28 Risks of emboli range from 0.5% to 
3% and is further multiplied in patients who experience recurrence and treated with serial 
cardioversions.29,30 
Catheter based ablation techniques were initially developed following Cox’s pioneering 
work with the Maze procedure. These techniques were further influenced by research that 
demonstrated ectopic foci surrounding pulmonary veins. Isolation of the pulmonary veins 
remains the cornerstone of most AF catheter ablation procedures.  Following heparinization, 
a percutaneous catheter placed into the femoral vein is advanced to the right atrium. The left 
atrium is accessed via an interatrial septal puncture. Lesions are created around the 
pulmonary veins using cryoenergy or radio-frequency energy. These techniques have 
shown a higher success in treating patients with paroxysmal AF compared to those with 
enlarged left atrium and persistent or permanent AF.31,32 Complications of catheter ablation 
include cardiac tamponade, atrioesophageal fistula and stroke33 
5. Surgical treatment 
Surgery is indicated in patients undergoing elective cardiac surgery that have symptomatic 
AF or those with asymptomatic AF with low operative risk.34 It is advised that patients with 
persistent or permanent AF scheduled for elective cardiac surgery should be considered for 
concomitant ablation procedure that may increase both short-term and long-term freedom 
from AF, in addition to lowering the risk of thromboembolism and improving long term 
survival and cardiac function35. Surgery for lone AF may be considered in certain 
circumstances where patients have failed to respond to catheter ablation or in whom 
catheter ablation is contraindicated such as a mural thrombus. Patients that develop 
tachycardia-induced cardiomyopathy will also benefit from surgery. It results in atrial or 
ventricular dysfunction as a result of increased heart rates in an otherwise structurally 
normal heart.36 If left untreated it can lead to heart failure and is reversible if sinus rhythm is 
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restored.37 In addition patients in whom anticoagulation is contraindicated may also be 
suitable candidates that may benefit from surgical intervention following failure of catheter 
based ablation. Patients that continue to experience thromboembolic events despite 
adequate anticoagulation may also benefit from surgery.38  
Several procedures were developed in the 1980s aimed at finding a cure to atrial fibrillation. 
Hoewever, most of these procedures were subsequently abandoned due to their inability to 
address all three of the detrimental sequelae of AF. Early attempts at surgical treatment of 
AF attempted to isolate and confine AF to a specific region of the atria and thereby stopping 
it from propagating its effects upon the ventricles. The left atrial isolation procedure 
developed by Williams and colleagues was successful in confining AF to the left atrium and 
thus restoring sinus rhythm to the rest of the heart.39 It also removed two of the 3 
detrimental consequences attributed to AF namely, irregular heart rate and compromised 
haemodynamics. The latter was achieved because restoring sinus rhythm on the right side 
permitted a normal right-sided cardiac output that was delivered to the left side of the heart. 
The left ventricle responded to the normal cardiac output on the right side by delivering a 
normal cardiac output. Since the left atrium continued to fibrillate this procedure did not 
reduce the risk of thromboembolism. The ‘Corridor’ procedure was introduced in 1985 that 
isolated a strip of atrium that contained both the SA node and AV node from the rest of the 
atria to create a continuous pathway (corridor) directing the impulses from the SA node to 
the AV node to maintain sinus rhythm.  Since parts of the right and left atrial were free to 
fibrillate it did not eliminate the risk of thromboembolism and nor did it restore 
atrioventricular synchrony.  
Cox and colleagues described a series of experiments that attempted to cure AF in dogs. A 
single incision across both atria successfully prevented AF and atrial flutter. Further 
investigations by Cox and colleagues led to the Cox-Maze procedure in 1987.16,17,40 The 
procedure itself was based upon a cut and sew technique whereby multiple incisions were 
made in the atria. This created lines of scar that interrupted the conduction routes of the 
most common re-entrant circuits, thus preventing AF or atrial flutter by directing the sinus 
node impulses along a specified route. It was based around the concept of a maze and as a 
result was called the Cox-Maze procedure. In contrast to the previous surgical techniques, 
this was the first that addressed all three sequelae of AF and restored sinus rhythm, AV 
synchrony and thus significantly reducing the risk of thromboembolism and stroke.41 The 
original procedure, known as Cox-Maze I was complicated with a high incidence of heart 
block requiring pacemaker implantation. It also resulted in the late incidence of two 
problems. Firstly it led to the frequent inability of patients to generate an appropriate sinus 
tachycardia and secondly left atrial dysfunction. This was modified to the Cox Maze II 
procedure which despite decreased incidence of conduction system injury was technically 
difficult. It was therefore modified to the Cox-Maze III procedure that was associated with a 
higher incidence of sinus rhythm and improved long-term sinus node function and atrial 
transport function.40 In this procedure several dead-end “alleyways “create a maze-like 
pathway and permit the depolarization of all the atrial tissue. The Cox Maze III procedure 
can be performed both through median sternotomy as well as a partial lower sternotomy. 
The patient is fully heparinized and the surgeon cannulates the patient for cardiopulmonary 
bypass after dividing the sternum. Bicaval cannulation is achieved. The right atrial 
appendage is excised and a series of incisions are made to the right atrium including a 
cryolesion. The aorta is occluded preparing for the left atrial portions of the operation. Cold 
blood potassium cardioplegia is administered via retrograde perfusion of the coronary 
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sinus. The left atrium is exposed by an incision posterior to the interatrial groove close to the 
orifices of the right pulmonary veins. A number of incisions are made across the left atrium 
and the left atrial appendage is excised at its base. The incisions to the left atrium interatrial 
septum and right atrium are closed. Despite its complexity, the Cox-Maze III procedure 
became the gold standard for surgical treatment of AF. It has been performed in hundreds 
of patients and proven to be highly successful in ablating any form of AF irrespective of 
whether patients had concomitant heart disease or not.42,43 Although it adds to 
cardiopulmonary bypass and cardiac arrest time it does not increase the operative 
mortality.44,45 
Sinus rhythm was reported in 97% at late follow-up and it was equally effective in patients 
with lone AF as those undergoing concomitant cardiac surgery.44,46 Similar results were 
reproduced by other institutions across the world.47,48Early postoperative AF is common 
following a maze procedure and usually abates by 3 months.44,46 In addition to restoring 
sinus rhythm the maze procedure is associated with additional clinical benefits for the 
patients. In those with mitral valve disease restoration of sinus rhythm improves survival. 
Risks for stroke, systemic thromboembolism and anticoagulant-related haemorrhage are 
also reduced.41,49The freedom from late stroke is likely to be from restoration of sinus 
rhythm as well as excision of the left atrial appendage, an integral part of the maze 
procedure.50 
Despite the excellent results of the cut and sew maze procedure, few surgeons adopted the 
procedure due to its technical difficulty and is almost obsolete today. Advances in the 
understanding the pathophysiology of AF and newer ablation technologies fostered the 
development of novel strategies aimed at simplifying the procedure to make it more 
accessible to the average surgeon without compromising the results.  
Use of ablative energy sources has enabled to replace most of Cox III incisions with a variety 
of energy sources including radiofrequency, cryoablation and high frequency ultrasound.  
The development of these technologies has rendered a technically difficult and time-
consuming operation easy for all cardiac surgeons to perform. Ablation technologies have 
also helped foster the development of less invasive procedures through a small incision or 
port. In order to replace the incision in AF surgery, ablation technology must meet several 
requirements. It must reliably produce transmural lesion either from the epicardial or 
endocardial surface to ensure bidirectional conduction block. It should also be safe  and 
render AF surgery simpler and less time consuming to perform. It would also be adaptable 
to minimally invasive approach. Melby and colleagues51 described procedure that replaced 
with cut-and-sew lesions with bipolar radiofrequency lines as the Cox-Maze IV. In this 
technique, the atrial septal lesion was not performed and an independent isolation of the 
pulmonary veins was made with a connecting lesion. Although bipolar radiofrequency may 
reliably produce transmural lines and applied minimally invasively for pulmonary veins, it 
does not permit secure performance of connecting lines in the left atrial isthmus or inside 
the right atrium.53,54  
Early follow-up suggests that the Cox-Maze IV procedure is similar in efficacy  with 91% of 
patients having freedom from AF at 6 months.55 There was no operative mortality and the 
group had significantly shorter cross clamp time compared to the Cox Maze III group. Cox 
also suggested another simplified procedure to cure most patients of AF.56 This involved three 
essential lesions that include 1.an incision encircling the pulmonary veins, 2.left atrial isthmus 
and companion coronary sinus lesions and 3.right atrial isthmus lesion. This modified Cox-
Maze procedure has been shown to be nearly as effective as the Cox-Maze III.57  
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6. Lesion sets for the surgical treatment of atrial fibrillation 
Three general categories of lesion sets exist for the surgical treatment of AF in adults: 
 Pulmonary vein isolation 
 Left atrial lesion set 
 Biatrial lesion set 
Pulmonary vein isolation is only an ideal choice for those who have new onset paroxysmal 
AF Lesions can be created using a variety of different approaches that include beating heart 
epicardial techniques or on pump endocardial approaches that use energy devices or the cut 
and sew technique. Pulmonary vein isolation can be achieved through either a single lesion 
encircling all pulmonary veins or two lesions encompassing the left and right pulmonary 
veins. Left atrial lesion sets are advised in patients with recent-onset or paroxysmal AF 
undergoing elective surgery with no justification to open the right atrium. This includes 
pulmonary vein isolation with the addition of linear lesions extending to the mitral annulus 
and left atrial appendage that is usually excised or excluded. This is because more than 90% 
of left atrial thrombi originate from the left atrial appendage in patients with non-rheumatic 
AF.58 Biatrial lesion sets are the most effective treatment option for AF59. Patients with 
longstanding or symptomatic AF, young patients or those undergoing right heart surgery 
would benefit from this procedure60  
The Cox maze IV procedure is performed with the patient on CPB with bicaval cannulation. 
Using blunt dissection, the right and left PVs are dissected. If the patient is in AF, they are 
cardioverted. Pacing thresholds are obtained from all PVs. The bipolar ablation is performed 
around the cuff of atrial tissue surrounding the right and left pulmonary veins.  Pacing is 
used to confirm block from both the superior and inferior PVs. Following PVI, the right 
atrial lesions are performed with the heart beating. An incision is created in the right atrial 
appendage as shown in figure 3. The bipolar device is used to make a right atrial free wall 
lesion. Following this a vertical right atriotomy is made around 2cm from the free wall 
ablation that extends from the crista terminalis toward the intra-atrial septum. The incision 
is then extended superiorly toward the AV groove. Two cryolesions are placed at the 
tricuspid annulus using cryoprobe. The bipolar clamp is used to create linear ablation lines 
from the SVC down to the IVC. The SVC ablation is made as laterally as possible to avoid 
damage to the SA node. The left sided atrial lesions are performed through a standard left 
atriotomy. This extends superiorly onto the dome of the left atrium and inferiorly around 
the orifice of the right inferior pulmonary vein. A lesion is made with the bipolar RF device 
to create a connecting lesion between the left atrial incision inferiorly to the ablation line 
encircling left inferior pulmonary vein. In atria greater than 5cm in diameter,  a second 
connecting ablation is placed from the superior aspect of the incision into the left superior 
pulmonary vein. Finally, a bipolar radiofrequency ablation line is performed from the 
inferior aspect of the left atrial incision across the mitral valve annulus at a point between 
the circumflex and right coronary artery circulation. A cryolesion is placed at the mitral 
valve annulus. The left atrial appendage is amputated and a bipolar RF ablation is 
performed between the amputated left atrial appendage and superior PV. The left atrial 
appendage is oversewn. The aorta is unclamped and the right atrial incision is closed. 
Patients with lone atrial fibrillation can choose between a catheter based approach or a 
minimally invasive surgical technique. Minimally invasive surgery to treat lone atrial 
fibrillation also can benefit patients who have a contraindication to warfarin, antiarrhythmic 
medications, or a history of cerebrovascular events. The procedure involves groin  
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Fig. 3. Cox-Maze IV procedure 
cannulation to connect the patient to CPB. The right sided lesions can be completed on a 
beating heart with or without cardiopulmonary support. After cross clamping the aorta, left 
sided lesions are created in a similar pattern to the Cox-Maze II procedure, creating a box 
lesion around all the pulmonary veins with a connecting lesion to the left atrial appendage 
and to the mitral valve isthmus. The left atrial orifice is closed from the endocardial side. 
When performed correctly, the results of the minimally invasive approach are excellent.61  
Minimally invasive surgical techniques have been an area of interest as an alternative to 
catheter based pulmonary vein isolation. Bilateral thoracotomies or mini sternotomy can be 
used to isolate the pulmonary veins62,63. Its major advantage is that it can be performed in 
the absence of cardiopulmonary bypass and in many cases left atrial appendage 
disarticulation can also be offered.  However, since AF does not always originate in the 
pulmonary veins this is not suitable in all patients, particularly those with non-paroxysmal 
AF.  
Surgery for AF reduces medical costs successfully. When performed in conjunction with 
elective cardiac surgery it is cheaper and more effective than medical or catheter based 
therapy at a later time and cost effective in patients with a good prognosis64,65 In summary, 
surgery for AF has evolved during the previous 2 decades to include several different 
approaches, lesion sets and energy sources. All patients undergoing concomitant cardiac 
surgery with AF should undergo surgical treatment for their AF. Ablation technology has 
simplified the procedure to make it easy for all surgeons to adopt and pave way towards 
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1. Introduction  
Infective endocarditis (IE) is a threatening disease associated with a high risk of morbidity 
and mortality. The most etiologic agents are the bacteria followed by fungi. Fungal 
Endocarditis (FE) is an uncommon occurrence and the most severe form of IE, however, its 
rate has increased in recent decades.  The first report of FE after a mitral valve replacement 
was in 1964 (1) but there have been many cases reported in recent years indicating the 
importance of such infections (2-4).  Fungal endocarditis accounts for 1.3% to 6% of all IE 
cases (5-8).  Ranges between 1.7 to 3.8 per 100,000 person-years have been reported in 
different studies for mean annual incidence (5, 9). Increase in the number of cases of 
fungemia and FE has been seen during the last 2 decades (10, 11). Men are more at risk of 
infections than women (7, 12, 13), and younger persons (third to fourth decades of life) are 
in more risk factor. The incidence of FE varies based on the criteria and methods of 
diagnosis (5) and population under survey; in liver transplants (14) the incidence of FE after 
transplantation was 1.7%. The mortality rate was 72% (15) but is still high (about 50%) 
despite the treatments (7). In an international multicenter prospective cohort study that 
included 33 cases of Candida endocarditis treated between 2000 and 2005, the mortality rate 
was 30 % (16),  and in post-surgical invasive aspergillosis (17) and Aspergillus endocarditis 
the rate was too high (100%) even with combined medical and surgical therapy (2).  
Fungi are important causes of prosthetic valve endocarditis, responsible for 1%–10% of these 
infections (18). Also, there are reports that fungi are responsible for 9.6% of the early cases of 
prosthetic valve endocarditis (60 days after the insertion of prosthesis) and for 4.3% of late 
cases (>60 days after the insertion of prosthesis) (19, 20). The incidence of FE in culture- 
documented cases has been reported to range from 12% to 20% (21) or to 37.5% (22). 
Many fungal species cause FE, of which the most important are Candida albicans 60%-67% 
and filamentous Aspergillus spp. 20–30% (ratio rate 2/1) (7, 15, 23), In addition, non-albicans 
species of Candida, Torulopsis glabrata, Candida tropicalis, and other filamentus fungi like 
Aspergillus spp., Curvularia genuculata, Hormondendrum dermatitidis, Mucoracae, Scopulariopsis 
spp., Trichosporon spp. and Blastoschizomyces capitatus have been reported in the literature (10, 
15, 22, 24, 25). In some studies, the most common etiologic agent was different, as in 
Rubinstein E et al. Candida parapsilosis accounts for half of the culture-documented patients, 
whereas C. albicans and Candida stellatoidea account for 12%-15% only (21). Pneumocystis 
jiroveci caused fungal infection in 9% to 11% of all heart transplant recipients in the past, 
with a mortality rate of 11% to 38% (26) but with use of prophylaxis, the rate of this infection 
has decreased. 
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The source of infection can be internal or external, the former usually with Candida spp. This 
organism is the normal flora of the patient’s body and causes contamination during the 
surgery, and is recognized as the catheter-related blood stream infection (27). However, 
conidia of the external agents could contaminate the tissues during the surgery or post 
operative contamination by environmental isolates present in high counts (17).   
Time of presenting of infection is different and maybe during the first 2 weeks in hospital 
period to months after heart surgery at home, and in some cases 12 years later (15). 
Diagnosis should be prompt because the time interval between the first symptom and 
hospital admission in some cases is long and may be one year (15). Early diagnosis could be 
helpful for the patients' survival. The onset of symptoms is usually about 2 weeks or less 
from the initiating bacteremia. 
Anatomical cardiac condition diseases (cardiac abnormality), intravenous drug abusers and 
open heart cardiac surgery are the top risk factors for the infections. There are many risk 
factors for progressive FE, including the use of multiple immunosuppressive drugs such as 
azathioprine, corticosteroids, cyclosporine A, and cyclophosphamide (12, 13, 15). 
Malignancy, exposure to multiple broad-spectrum antibiotics, prolonged use of intravenous 
catheters (28), use of high glucose concentrations intravenous catheters especially in 
premature neonates (29), rheumatic heart disease (22), previous bacterial endocarditis, prior 
surgery, prolonged intravenous hyper alimentation, pacemaker implantation, and 
reconstructive cardiovascular surgery are other risk factors (15,30-32). In some cases no 
predisposing factor has been identified (7, 33) 
The mechanism of endocarditis includes high turbulent blood flow due to cardiac 
abnormality or other risk factors (e.g., particulate material in the repeated injections of drugs 
in IV drug abusers) which disrupt the surface of endocardia and endothelium. The response 
of the body is repairing the damaged tissue with platelet-fibrin meshwork which is sticky 
and proper site for infection. After temporary bacteremia, it sticks to this meshwork and 
proliferation of organism causes the infection that invades the cardiac valves.  
Infective endocarditis is classified into definite, probable, and possible according to Pelletier 
and Petersdorf (34). Other classifications include definite, probable, possible and rejected by 
von Reyn (35) and definitive, possible and rejected by Duke criteria (36) (Table 1). Briefly, 
proven FE is defined as the isolation of fungi from the normally sterile sites, the blood or 
heart biopsy or vegetation, by culture and/or the evidence of fungal invasion of tissue by 
histopathological methods. Probable FE is defined as when the culture is negative for the 
infective agents, and clinical conditions of the respective patients are not recovered despite 
the administration of standard antibacterial therapy. Role of echocardiography, definition of 
rejected IE and major and minor clinical criteria were added to the previous definition in 
1994 (37).  According to Duke criteria, the diagnosis of definitive IE requires the presence of 
either two major criteria, one major and three minor criteria, or five minor criteria. 
2. Clinical manifestations 
The clinical manifestations of acute or sub-acute IE are related to the underlying 
pathophysiology of embolization, bacteremia/ candidemia, immunologic response, and 
valvulitis (30). Common clinical features are changing heart murmur, fever, and major 
peripheral emboli (common in fungal endocarditis) (10, 33). Some cases presented with the 
systemic symptoms associated with bacteremia include fever, tachycardia, septic shock; and 
the general symptoms and signs of cardiac involvement including chest pain, arrhythmias,  
 





















-Histologic evidence of vegetation on tissue from surgery or autopsy 
 
- Positive blood cultures with known underlying valvular heart disease 
and evidence of emboli to viscera or skin  
- OR fever >38ºC with negative blood cultures in individuals, embolic 
phenomena and new regurgitant valvular heart murmurs  
 
- Positive blood cultures with known underlying heart disease 
- Embolic phenomena; or negative blood cultures with fever, known 
underlying valvular heart disease, and embolic episodes. 
  
- Many patients with clinical features of infective endocarditis did not 
meet the above criteria due to lack of sensitivity. 


































- Histologic evidence from surgery or autopsy 
- Positive bacteriology evidence of valvular vegetation or peripheral 
embolus (staining or culture). 
 
-Persistently positive blood cultures plus one of the following: New 
regurgitant murmur and predisposing heart disease, vascular 
phenomena, negative or intermittently positive blood cultures,  plus three 
of the following: new regurgitant murmur, fever, vascular phenomena - 
petechiae, Roth spots, Osler's nodes, Janeway lesions, splinter 
hemorrhages, aseptic meningitis,  conjunctival hemorrhages, 
glomerulonephritis, or central nervous system, pulmonary, coronary or 
peripheral emboli.  
 
-Persistently positive blood cultures plus one of the following: 
predisposing heart disease - definite valvular or congenital heart disease, 
or a cardiac prosthesis (excluding permanent pacemakers) , vascular 
phenomena  
-Negative or intermittently positive blood cultures with all three of the 
following: fever, predisposing heart disease, vascular phenomena.   
-Only for viridans streptococcal endocarditis: fever with at least two 
positive blood cultures without an extra cardiac source 
 
-Endocarditis unlikely, alternative diagnosis generally apparent or 
endocarditis likely, empiric antibiotic therapy warranted  
- Culture negative diagnosed clinically as endocarditis, but excluded by 
postmortem 
 
- Lacked prospective validation, but improved the specificity of the 
classification system, a large proportion of cases being classified as 
probable or possible (most patients do not require valve surgery). 
 
Special Topics in Cardiac Surgery 
 
270 
The source of infection can be internal or external, the former usually with Candida spp. This 
organism is the normal flora of the patient’s body and causes contamination during the 
surgery, and is recognized as the catheter-related blood stream infection (27). However, 
conidia of the external agents could contaminate the tissues during the surgery or post 
operative contamination by environmental isolates present in high counts (17).   
Time of presenting of infection is different and maybe during the first 2 weeks in hospital 
period to months after heart surgery at home, and in some cases 12 years later (15). 
Diagnosis should be prompt because the time interval between the first symptom and 
hospital admission in some cases is long and may be one year (15). Early diagnosis could be 
helpful for the patients' survival. The onset of symptoms is usually about 2 weeks or less 
from the initiating bacteremia. 
Anatomical cardiac condition diseases (cardiac abnormality), intravenous drug abusers and 
open heart cardiac surgery are the top risk factors for the infections. There are many risk 
factors for progressive FE, including the use of multiple immunosuppressive drugs such as 
azathioprine, corticosteroids, cyclosporine A, and cyclophosphamide (12, 13, 15). 
Malignancy, exposure to multiple broad-spectrum antibiotics, prolonged use of intravenous 
catheters (28), use of high glucose concentrations intravenous catheters especially in 
premature neonates (29), rheumatic heart disease (22), previous bacterial endocarditis, prior 
surgery, prolonged intravenous hyper alimentation, pacemaker implantation, and 
reconstructive cardiovascular surgery are other risk factors (15,30-32). In some cases no 
predisposing factor has been identified (7, 33) 
The mechanism of endocarditis includes high turbulent blood flow due to cardiac 
abnormality or other risk factors (e.g., particulate material in the repeated injections of drugs 
in IV drug abusers) which disrupt the surface of endocardia and endothelium. The response 
of the body is repairing the damaged tissue with platelet-fibrin meshwork which is sticky 
and proper site for infection. After temporary bacteremia, it sticks to this meshwork and 
proliferation of organism causes the infection that invades the cardiac valves.  
Infective endocarditis is classified into definite, probable, and possible according to Pelletier 
and Petersdorf (34). Other classifications include definite, probable, possible and rejected by 
von Reyn (35) and definitive, possible and rejected by Duke criteria (36) (Table 1). Briefly, 
proven FE is defined as the isolation of fungi from the normally sterile sites, the blood or 
heart biopsy or vegetation, by culture and/or the evidence of fungal invasion of tissue by 
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infective agents, and clinical conditions of the respective patients are not recovered despite 
the administration of standard antibacterial therapy. Role of echocardiography, definition of 
rejected IE and major and minor clinical criteria were added to the previous definition in 
1994 (37).  According to Duke criteria, the diagnosis of definitive IE requires the presence of 
either two major criteria, one major and three minor criteria, or five minor criteria. 
2. Clinical manifestations 
The clinical manifestations of acute or sub-acute IE are related to the underlying 
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valvulitis (30). Common clinical features are changing heart murmur, fever, and major 
peripheral emboli (common in fungal endocarditis) (10, 33). Some cases presented with the 
systemic symptoms associated with bacteremia include fever, tachycardia, septic shock; and 
the general symptoms and signs of cardiac involvement including chest pain, arrhythmias,  
 





















-Histologic evidence of vegetation on tissue from surgery or autopsy 
 
- Positive blood cultures with known underlying valvular heart disease 
and evidence of emboli to viscera or skin  
- OR fever >38ºC with negative blood cultures in individuals, embolic 
phenomena and new regurgitant valvular heart murmurs  
 
- Positive blood cultures with known underlying heart disease 
- Embolic phenomena; or negative blood cultures with fever, known 
underlying valvular heart disease, and embolic episodes. 
  
- Many patients with clinical features of infective endocarditis did not 
meet the above criteria due to lack of sensitivity. 


































- Histologic evidence from surgery or autopsy 
- Positive bacteriology evidence of valvular vegetation or peripheral 
embolus (staining or culture). 
 
-Persistently positive blood cultures plus one of the following: New 
regurgitant murmur and predisposing heart disease, vascular 
phenomena, negative or intermittently positive blood cultures,  plus three 
of the following: new regurgitant murmur, fever, vascular phenomena - 
petechiae, Roth spots, Osler's nodes, Janeway lesions, splinter 
hemorrhages, aseptic meningitis,  conjunctival hemorrhages, 
glomerulonephritis, or central nervous system, pulmonary, coronary or 
peripheral emboli.  
 
-Persistently positive blood cultures plus one of the following: 
predisposing heart disease - definite valvular or congenital heart disease, 
or a cardiac prosthesis (excluding permanent pacemakers) , vascular 
phenomena  
-Negative or intermittently positive blood cultures with all three of the 
following: fever, predisposing heart disease, vascular phenomena.   
-Only for viridans streptococcal endocarditis: fever with at least two 
positive blood cultures without an extra cardiac source 
 
-Endocarditis unlikely, alternative diagnosis generally apparent or 
endocarditis likely, empiric antibiotic therapy warranted  
- Culture negative diagnosed clinically as endocarditis, but excluded by 
postmortem 
 
- Lacked prospective validation, but improved the specificity of the 
classification system, a large proportion of cases being classified as 
probable or possible (most patients do not require valve surgery). 
 






















Possible IE  
 
Rejected IE  
 
 
- Persistently positive blood cultures for organisms, new or partial 
dehiscence of a prosthetic valve or an abscess in the tissues surrounding a 
heart valve, presented of vegetation or other typical findings of 
endocarditis in echocardiography; new regurgitate murmur, serological 
or culture evidence of infection with Coxiella burnetii.  
 
- Positive blood cultures that do not meet the strict definitions of a major 
criterion, fever, predisposing valvular conditiona 
- OR intravenous drug abuse, elevated erythrocyte sedimentation rate and 
C-reactive protein hematuria and splenomegaly. 
 
 - Pathological criterion: vegetation or intracardiac abscess, confirmed by 
histology showing active   endocarditis, positive Gram stain results or 
cultures of specimens obtained from surgery or autopsy 
- Clinical criteria: 2 major criteria OR 1 major and 3 minor criteria OR 5 
minor criteria  
 
- 1 major criterion and 1 minor criterion OR 3 minor criteria 
 
- Firm alternate diagnosis for manifestations of endocarditis  
- Resolution of manifestations of endocarditis, or no pathologic evidence 
of infective endocarditis at surgery or autopsy after antibiotic therapy for 
four days or less  
- Does not meet criteria for possible infective endocarditis, as above 
a Prosthetic heart valve or a valve lesion that leads to significant regurgitation or turbulence of blood 
flow; Vascular phenomenon like emboli to the brain or organs, hemorrhages in the mucous membranes 
around the eyes; Immunologic phenomenon include lesions such as Roth's spots or "Osler's nodes and 
glomerulonephritis. 
Table 1. Definition of three criteria for the diagnosis of infective endocarditis 
edema, dyspnea, murmur on examination, cardiac failure, and persistent sepsis would also 
present. Other symptoms include abdominal pain, malaise, weight loss, night sweats, 
arthritis, finger clubbing, cough, hemoptysis, sudden death, coagulopathy, jaundice, nausea, 
hypotension, and renal failure.  Candida spp. is the most etiologic agent of FE; therefore, 
patients can present endophthalmitis, meningitis, osteomyelitis and other complications of 
candidemia. The more specific cutaneous or mucocutaneous lesions of IE include  Osler’s 
nodes, Roth spots (rare), and Janeway lesions  are more specific signs but less common and 
not diagnostic . Petechiae and splinter hemorrhages (nonblanching, linear reddish-brown 
lesions found under the nail bed) are not specific but are common skin manifestations. They 
may be present on the extremities of skin, or on mucous membranes. Other organs may be 
involved due to embolic events such as splenic or renal infarcts, or immune reactions like 
arthritis and glomerulonephritis, or spread by the blood passing to other organs like soft 
tissues, vertebral osteomyelitis, and the brain causing meningitis and/or encephalitis.  
3. Diagnosis of fungal endocarditis 
The diagnosis of IE is based upon high index of suspicion, careful history and physical 
examination, echocardiographic or histopathological findings, laboratory results, and chest 
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radiography. Gold standard tests for the detection of documented infections are the 
isolation of fungi from the blood, heart biopsy or vegetation by culture and the presence of 
tissue invasion by histopathology. Isolation of fungi from blood samples is difficult due to 
non-growth of fungal etiologic agents in blood culture. The rate of culture positive of 
Candida spp. in the blood is about 50% of the documented cases and positive blood culture 
for Aspergillus is rare (38-40). Fungi are cleared rapidly, due to large size, in the blood by the 
host’s reticuloendothelial system; therefore, the blood culture results are negative in many 
suspicious patients. The use of lysis-centrifugation system (41), or Bactec blood culture (42), 
may help the isolation of fungal agents but none is recommend as a standard method. Heart 
tissue is the best sample for the isolation of fungal agents. As resistance to the antifungal 
agents has been reported in many studies (43-45), in case of positive culture, sensitivity test 
of the isolated fungi to antifungal agents can contribute to the best management of 
infections.  
Another definitive microbiologic diagnosis depends upon the evidence of fungal tissue 
invasion with histopathologic investigation. The samples (tissue valve or emboli) are stained 
with specific stains like Gomori methenamine silver or Periodic acid-Schiff. With 
histopathology examination, morphological differentiation between Aspergillus spp. and 
other fungi is not completely available. 
Given the frequent negative blood cultures, and difficulty in obtaining the material from the 
surgical sites in the operating rooms, echocardiography, either transthoracic 
echocardiography (TTE) or transesophageal echocardiography (TEE), are used as the 
diagnosis tools with the sensitivity of about 77% (15) for the evaluation of FE and the 
presence of vegetation, based on the major diagnostic Duke criterion. Echocardiography can 
also detect intra cardiac abscess, new or progressive valvular regurgitation, the size and 
location of vegetation.  The size of vegetation may be small, medium, or large and anatomic 
site of the vegetation may be aortic valve, on tricuspid, mitral or endocardium, or on the 
previous aortic valvular surgery.  
Transesophageal echocardiography should be considered as the standard diagnostic 
procedure for IE (46). This method is able to evaluate the prosthetic valves, intracardiac 
complications, inadequate TTE, fungemia or bacteremia, and has superior sensitivity (47), 
compared to TTE, but significantly more invasive and expensive than it. Transthoracic 
echocardiography is the first line procedure for the detection of FE especially in native valve 
and prosthetic valve vegetations, and local extension of infection. The sensitivity of TTE in 
infants and younger children is about 80 percent (48, 49), therefore, the negative result of it 
cannot definitively rule out FE and examination should be repeated in respective patients. If 
there is a high clinical suspicion for FE and the TTE is negative, we should turn to TEE. 
Once treatment is completed, repeated evaluation may be necessary to establish a new 
baseline of valvular and myocardial functions for the patient. Unfortunately, both TTE and 
TEE may yield false negative results if the vegetations are small, or large size of the 
vegetation suspected as a mural thrombus, vegetation is attached to the mural endocardium 
and if embolization of the vegetation has occurred. 
Chest radiography and echocardiography are not useful in the diagnosis of IE; x-ray may 
present the septic pulmonary emboli (Minor Duke’s Criteria) and echocardiography may 
show evidence of some complications.  
Over the last several decades, non-culture laboratory methods have been directed at the 
development for the diagnosis of systemic fungal infections such as FE. Serological 
diagnostic methods can serve as the non-invasive methods for detecting the circulating 
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heart valve, presented of vegetation or other typical findings of 
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- Resolution of manifestations of endocarditis, or no pathologic evidence 
of infective endocarditis at surgery or autopsy after antibiotic therapy for 
four days or less  
- Does not meet criteria for possible infective endocarditis, as above 
a Prosthetic heart valve or a valve lesion that leads to significant regurgitation or turbulence of blood 
flow; Vascular phenomenon like emboli to the brain or organs, hemorrhages in the mucous membranes 
around the eyes; Immunologic phenomenon include lesions such as Roth's spots or "Osler's nodes and 
glomerulonephritis. 
Table 1. Definition of three criteria for the diagnosis of infective endocarditis 
edema, dyspnea, murmur on examination, cardiac failure, and persistent sepsis would also 
present. Other symptoms include abdominal pain, malaise, weight loss, night sweats, 
arthritis, finger clubbing, cough, hemoptysis, sudden death, coagulopathy, jaundice, nausea, 
hypotension, and renal failure.  Candida spp. is the most etiologic agent of FE; therefore, 
patients can present endophthalmitis, meningitis, osteomyelitis and other complications of 
candidemia. The more specific cutaneous or mucocutaneous lesions of IE include  Osler’s 
nodes, Roth spots (rare), and Janeway lesions  are more specific signs but less common and 
not diagnostic . Petechiae and splinter hemorrhages (nonblanching, linear reddish-brown 
lesions found under the nail bed) are not specific but are common skin manifestations. They 
may be present on the extremities of skin, or on mucous membranes. Other organs may be 
involved due to embolic events such as splenic or renal infarcts, or immune reactions like 
arthritis and glomerulonephritis, or spread by the blood passing to other organs like soft 
tissues, vertebral osteomyelitis, and the brain causing meningitis and/or encephalitis.  
3. Diagnosis of fungal endocarditis 
The diagnosis of IE is based upon high index of suspicion, careful history and physical 
examination, echocardiographic or histopathological findings, laboratory results, and chest 
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radiography. Gold standard tests for the detection of documented infections are the 
isolation of fungi from the blood, heart biopsy or vegetation by culture and the presence of 
tissue invasion by histopathology. Isolation of fungi from blood samples is difficult due to 
non-growth of fungal etiologic agents in blood culture. The rate of culture positive of 
Candida spp. in the blood is about 50% of the documented cases and positive blood culture 
for Aspergillus is rare (38-40). Fungi are cleared rapidly, due to large size, in the blood by the 
host’s reticuloendothelial system; therefore, the blood culture results are negative in many 
suspicious patients. The use of lysis-centrifugation system (41), or Bactec blood culture (42), 
may help the isolation of fungal agents but none is recommend as a standard method. Heart 
tissue is the best sample for the isolation of fungal agents. As resistance to the antifungal 
agents has been reported in many studies (43-45), in case of positive culture, sensitivity test 
of the isolated fungi to antifungal agents can contribute to the best management of 
infections.  
Another definitive microbiologic diagnosis depends upon the evidence of fungal tissue 
invasion with histopathologic investigation. The samples (tissue valve or emboli) are stained 
with specific stains like Gomori methenamine silver or Periodic acid-Schiff. With 
histopathology examination, morphological differentiation between Aspergillus spp. and 
other fungi is not completely available. 
Given the frequent negative blood cultures, and difficulty in obtaining the material from the 
surgical sites in the operating rooms, echocardiography, either transthoracic 
echocardiography (TTE) or transesophageal echocardiography (TEE), are used as the 
diagnosis tools with the sensitivity of about 77% (15) for the evaluation of FE and the 
presence of vegetation, based on the major diagnostic Duke criterion. Echocardiography can 
also detect intra cardiac abscess, new or progressive valvular regurgitation, the size and 
location of vegetation.  The size of vegetation may be small, medium, or large and anatomic 
site of the vegetation may be aortic valve, on tricuspid, mitral or endocardium, or on the 
previous aortic valvular surgery.  
Transesophageal echocardiography should be considered as the standard diagnostic 
procedure for IE (46). This method is able to evaluate the prosthetic valves, intracardiac 
complications, inadequate TTE, fungemia or bacteremia, and has superior sensitivity (47), 
compared to TTE, but significantly more invasive and expensive than it. Transthoracic 
echocardiography is the first line procedure for the detection of FE especially in native valve 
and prosthetic valve vegetations, and local extension of infection. The sensitivity of TTE in 
infants and younger children is about 80 percent (48, 49), therefore, the negative result of it 
cannot definitively rule out FE and examination should be repeated in respective patients. If 
there is a high clinical suspicion for FE and the TTE is negative, we should turn to TEE. 
Once treatment is completed, repeated evaluation may be necessary to establish a new 
baseline of valvular and myocardial functions for the patient. Unfortunately, both TTE and 
TEE may yield false negative results if the vegetations are small, or large size of the 
vegetation suspected as a mural thrombus, vegetation is attached to the mural endocardium 
and if embolization of the vegetation has occurred. 
Chest radiography and echocardiography are not useful in the diagnosis of IE; x-ray may 
present the septic pulmonary emboli (Minor Duke’s Criteria) and echocardiography may 
show evidence of some complications.  
Over the last several decades, non-culture laboratory methods have been directed at the 
development for the diagnosis of systemic fungal infections such as FE. Serological 
diagnostic methods can serve as the non-invasive methods for detecting the circulating 
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fungal antigens, fungal metabolites, or antibody in the blood (50, 51). The major limitation of 
these methods is unavailability to detect some fungi like Mucor spp. 
Galactomannan (GM) is a more promising circulating fungal antigen used to detect fungal 
infections especially invasive aspergillosis, but it is an exoantigen released from the tip of 
mycelium of many fungi spp. during growth (52), therefore, cross-reactivity has been 
described with other fungi (53-55). False negative reactivity without any known reason (56) 
and false positive reactivity with use of some drugs and foods have been reported (57-61). 
Sensitivity range of GM test, for the diagnosis of documented invasive aspergillosis cases 
was reported to be between 50.0% (62) and 90.6% (63).  There are limited studies using this 
method for the diagnosis of FE. In one study, GM test to establish the diagnosis of invasive 
aspergillosis was only positive (≥1 ng/mL) in 2/7 patients with endocarditis and 
mediastinitis(17) and four out of nine cases in another study (33).  To diagnose systemic 
candidiasis, enolase (64), phospholipase and proteinase enzymes (65), Candida mannan 
antigen (66, 67), and β-D-glucan (68-71) have been detected in some studies. However, there 
are a few reports on the use of such antigens in patients with FE. 
Antibody assays can be helpful for some species of fungi which are not the normal flora but 
there are problems with both specificity and sensitivity when Candida spp. is responsible for 
infections, since it is a part of the body normal flora. Immunosuppressed hosts may be 
unable to produce strong antibodies; therefore, the sensitivity of the assay in this high-risk 
population is decreased.  
The current focus of non-culture methods is on the development of a polymerase chain 
reaction (PCR) assay for the detection of fungal infections (72, 73). Panfungal PCR with 
universal primers (74), nested PCR (75, 76) and real-time PCR (77, 78) can serve as sensitive 
and quantitative methods to detect fungal DNA in the human blood specimens (74, 79). The 
sensitivity and specificity of nested PCR for invasive aspergillosis in the blood are 92.8% and 
94%, respectively (55). Although these methods have not been standardized and are not 
widely used, limited studies indicate a good sensitivity for FE diagnosis and close to blood 
cultures (33, 80). Using the molecular methods with reduced PCR steps like real time- PCR, 
the result can be released within 6 hours (81). Due to the inhibitory factors in human blood 
samples, PCR may yield false negative (82) and for the abundant conidia of fungi in the 
environment, false positive may also be seen, which is rare and limited.  The significance of 
PCR tests is their ability to detect fungal infections in early stages (83).  
Other nonspecific laboratory outcomes include: a normochromic normocytic anemia, 
elevated erythrocyte sedimentation rate and C-reactive protein indicative of inflammation, 
elevated rheumatoid factor titers (minor Duke criteria), hematuria and proteinuria (minor 
Duke criteria). 
Totally, in patients suspicious to FE, microscopy examination and culture of tissue materials 
obtained from heart surgery, with antifungal susceptibility test on the isolated fungi are the 
best methods for the diagnosis and management of FE. In patients with suspected FE in 
early stage of infection, use of nonaggressive method (i.e., serologic or molecular) is 
recommended. Combination of serological and microbiological tests is more useful if we are 
to avoid over-treatment.  
4. Treatment  
The high mortality rate, difficulty in sterilizing large fungal vegetation or abscesses, and 
the risk of embolization associated with medical therapy alone (84) are the reasons for the 
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recommendation of combined surgical and medical treatment in patients with FE for 
better prognosis (7, 8, 85). It is also the suggestion of the 2009 Infectious Diseases Society 
of America guidelines for the treatment of native and prosthetic valve Candida 
endocarditis (86). However, there are some reports of Candida endocarditis in which 
medical treatment alone proved successful (85, 87-89) with either caspofungin alone or in 
combination with flucytosine or fluconazole (87-90). The higher dose of antifungal agents 
than normal dose is recommended for treatment (86). In critically ill patients for whom 
surgical resection cannot be done, antifungal therapy is recommended for months and 
even life-long. In combination therapy a minimum of 6 weeks medication after surgery is 
advocated (91), but the treatment should be continued till signs and symptoms of the 
infection disappear and radiographic abnormalities are stabilized, and life-long 
prophylactic therapy is recommended.  Relapses are common either with medical or 
combined therapy (37, 92, 93) and may appear early or late; mean 25 months (92). Due to 
high relapse rates, patients should receive life-long therapy (92, 93) and careful follow-up 
is also essential for successful therapy.  
Treatment of FE in immunocompromised patients needs to take into account the 
underlying disease of patients and the intervention of antifungal agents with the patient's 
condition. For example, use of amphotericin B deoxycholate, in patients with renal 
insufficiency or those who are on multiple nephrotoxic drugs is not suggested and for 
fewer adverse effects, lipid formulations of amphotericin B are recommended (94). Many 
studies have  reported the resistance of some fungi to this antifungal agent (44, 45, 95), 
therefore,  to limit the use of amphotericin B, current treatment options including azole 
due to its broad antifungal activity, and echinocandins as a new class of antifungal drugs, 
are recommended (96).  
In transplant recipients and HIV patients, use of triazoles which have interaction with 
human P450 cytochromes (97),  can block the metabolism of certain anti-HIV drugs and also 
some drugs such as cyclosporine, statins, and benzodiazepines (98). Therefore, close 
monitoring of drug levels needs to be calibrated with the dose of immunosuppressive drugs 
(99, 100). Physicians should prescribe triazole agents in consultation with a pharmacist 
because inhibitory activities among triazoles are different and fluconazole is of less active 
inhibition of P450 than other azole agents such as itraconazole, voriconazole, and 
posaconazole. In patients receiving these antifungals, monitoring of drug levels in respective 
sera is suggested (96).  
Echinocandins; caspofungin, micafungin, and anidulafungin; are new antifungal agents 
which damage the fungal cell walls by inhibiting the b-(1, 3)-glucan synthesis. Drug–drug 
interactions between echinocandins such as caspofungin are observed with tacrolimus and 
cyclosporine, certain anti-HIV drugs and rifampin (96). Use of caspofungin in patients with 
impaired liver function and those receiving cyclosporine should be carefully considered, 
because of the common side effects of this agent including increased liver enzymes, 
pruritus, facial swelling, headache and nausea. They have fungicidal activity against Candida 
biofilm (101) and most isolates of Candida species including C. glabrata in vitro and in vivo 
with benign toxicity profile (102).  
If the patients are not responsive to their initial mono-antifungal therapy regimen, the use 
of the combination antifungal regimen is recommended that include an echinocandins 
with voriconazole or liposomal amphotericin B. Combination therapy by amphotericin 
B and a triazole is not suggested in the literature (103). The function of combination 
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fungal antigens, fungal metabolites, or antibody in the blood (50, 51). The major limitation of 
these methods is unavailability to detect some fungi like Mucor spp. 
Galactomannan (GM) is a more promising circulating fungal antigen used to detect fungal 
infections especially invasive aspergillosis, but it is an exoantigen released from the tip of 
mycelium of many fungi spp. during growth (52), therefore, cross-reactivity has been 
described with other fungi (53-55). False negative reactivity without any known reason (56) 
and false positive reactivity with use of some drugs and foods have been reported (57-61). 
Sensitivity range of GM test, for the diagnosis of documented invasive aspergillosis cases 
was reported to be between 50.0% (62) and 90.6% (63).  There are limited studies using this 
method for the diagnosis of FE. In one study, GM test to establish the diagnosis of invasive 
aspergillosis was only positive (≥1 ng/mL) in 2/7 patients with endocarditis and 
mediastinitis(17) and four out of nine cases in another study (33).  To diagnose systemic 
candidiasis, enolase (64), phospholipase and proteinase enzymes (65), Candida mannan 
antigen (66, 67), and β-D-glucan (68-71) have been detected in some studies. However, there 
are a few reports on the use of such antigens in patients with FE. 
Antibody assays can be helpful for some species of fungi which are not the normal flora but 
there are problems with both specificity and sensitivity when Candida spp. is responsible for 
infections, since it is a part of the body normal flora. Immunosuppressed hosts may be 
unable to produce strong antibodies; therefore, the sensitivity of the assay in this high-risk 
population is decreased.  
The current focus of non-culture methods is on the development of a polymerase chain 
reaction (PCR) assay for the detection of fungal infections (72, 73). Panfungal PCR with 
universal primers (74), nested PCR (75, 76) and real-time PCR (77, 78) can serve as sensitive 
and quantitative methods to detect fungal DNA in the human blood specimens (74, 79). The 
sensitivity and specificity of nested PCR for invasive aspergillosis in the blood are 92.8% and 
94%, respectively (55). Although these methods have not been standardized and are not 
widely used, limited studies indicate a good sensitivity for FE diagnosis and close to blood 
cultures (33, 80). Using the molecular methods with reduced PCR steps like real time- PCR, 
the result can be released within 6 hours (81). Due to the inhibitory factors in human blood 
samples, PCR may yield false negative (82) and for the abundant conidia of fungi in the 
environment, false positive may also be seen, which is rare and limited.  The significance of 
PCR tests is their ability to detect fungal infections in early stages (83).  
Other nonspecific laboratory outcomes include: a normochromic normocytic anemia, 
elevated erythrocyte sedimentation rate and C-reactive protein indicative of inflammation, 
elevated rheumatoid factor titers (minor Duke criteria), hematuria and proteinuria (minor 
Duke criteria). 
Totally, in patients suspicious to FE, microscopy examination and culture of tissue materials 
obtained from heart surgery, with antifungal susceptibility test on the isolated fungi are the 
best methods for the diagnosis and management of FE. In patients with suspected FE in 
early stage of infection, use of nonaggressive method (i.e., serologic or molecular) is 
recommended. Combination of serological and microbiological tests is more useful if we are 
to avoid over-treatment.  
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The high mortality rate, difficulty in sterilizing large fungal vegetation or abscesses, and 
the risk of embolization associated with medical therapy alone (84) are the reasons for the 
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recommendation of combined surgical and medical treatment in patients with FE for 
better prognosis (7, 8, 85). It is also the suggestion of the 2009 Infectious Diseases Society 
of America guidelines for the treatment of native and prosthetic valve Candida 
endocarditis (86). However, there are some reports of Candida endocarditis in which 
medical treatment alone proved successful (85, 87-89) with either caspofungin alone or in 
combination with flucytosine or fluconazole (87-90). The higher dose of antifungal agents 
than normal dose is recommended for treatment (86). In critically ill patients for whom 
surgical resection cannot be done, antifungal therapy is recommended for months and 
even life-long. In combination therapy a minimum of 6 weeks medication after surgery is 
advocated (91), but the treatment should be continued till signs and symptoms of the 
infection disappear and radiographic abnormalities are stabilized, and life-long 
prophylactic therapy is recommended.  Relapses are common either with medical or 
combined therapy (37, 92, 93) and may appear early or late; mean 25 months (92). Due to 
high relapse rates, patients should receive life-long therapy (92, 93) and careful follow-up 
is also essential for successful therapy.  
Treatment of FE in immunocompromised patients needs to take into account the 
underlying disease of patients and the intervention of antifungal agents with the patient's 
condition. For example, use of amphotericin B deoxycholate, in patients with renal 
insufficiency or those who are on multiple nephrotoxic drugs is not suggested and for 
fewer adverse effects, lipid formulations of amphotericin B are recommended (94). Many 
studies have  reported the resistance of some fungi to this antifungal agent (44, 45, 95), 
therefore,  to limit the use of amphotericin B, current treatment options including azole 
due to its broad antifungal activity, and echinocandins as a new class of antifungal drugs, 
are recommended (96).  
In transplant recipients and HIV patients, use of triazoles which have interaction with 
human P450 cytochromes (97),  can block the metabolism of certain anti-HIV drugs and also 
some drugs such as cyclosporine, statins, and benzodiazepines (98). Therefore, close 
monitoring of drug levels needs to be calibrated with the dose of immunosuppressive drugs 
(99, 100). Physicians should prescribe triazole agents in consultation with a pharmacist 
because inhibitory activities among triazoles are different and fluconazole is of less active 
inhibition of P450 than other azole agents such as itraconazole, voriconazole, and 
posaconazole. In patients receiving these antifungals, monitoring of drug levels in respective 
sera is suggested (96).  
Echinocandins; caspofungin, micafungin, and anidulafungin; are new antifungal agents 
which damage the fungal cell walls by inhibiting the b-(1, 3)-glucan synthesis. Drug–drug 
interactions between echinocandins such as caspofungin are observed with tacrolimus and 
cyclosporine, certain anti-HIV drugs and rifampin (96). Use of caspofungin in patients with 
impaired liver function and those receiving cyclosporine should be carefully considered, 
because of the common side effects of this agent including increased liver enzymes, 
pruritus, facial swelling, headache and nausea. They have fungicidal activity against Candida 
biofilm (101) and most isolates of Candida species including C. glabrata in vitro and in vivo 
with benign toxicity profile (102).  
If the patients are not responsive to their initial mono-antifungal therapy regimen, the use 
of the combination antifungal regimen is recommended that include an echinocandins 
with voriconazole or liposomal amphotericin B. Combination therapy by amphotericin 
B and a triazole is not suggested in the literature (103). The function of combination 
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antifungal therapy is controversial due to probable increase in side effects and toxicity 
level (104, 105). 
5. Prevention 
Fungal endocarditis may be caused by endogenous or exogenous fungi. The prevention of 
FE could be through adopting two strategies; one is general and useful for all infections like 
hand-washing, personal hygiene, and indwelling central venous catheters care, and the 
other is especially for fungal infections. Practical ways to achieve this goal is use of non-
drug or drug prevention (prophylaxis). Avoiding opportunistic endogenous agents like 
Candida spp. which colonize in the human body sites is difficult. The best strategy for the 
management of Candida endocarditis is the evaluation of colonization pre-surgery to 
determine the susceptibility pattern of the isolated organisms, which may cause  infection 
after surgery and enhance the success of management of systemic or endocarditis 
candidiasis. Care of central venous catheters is important for reducing candidemia and 
Candida endocarditis; and the removal of all existing central venous catheters for the 
reduction of morbidity and mortality (106-108) is helpful. However, in patients with obligate 
central venous access, new sites should be obtained (109, 110).  
Fungal spores are abundant in the environment, and unfiltered air, dust, and contaminated 
materials are full of fungal conidia (111, 112). In many cases, fungal infections may occur 
during the surgery, via contaminated air, surgical site or equipment with conidia. To 
prevent the contamination, use of high-efficiency particulate air filters for air sterility (113), 
and sterile equipment in the operation room are recommended.   
Antifungal prophylaxis could be used to avoid the development of fungal infections in high 
risk patients (114), based on the susceptibility patterns of the etiologic agents in each region. 
Empiric therapy (antifungal treatment of febrile patients at risk for infections) was first 
introduced to prevent invasive fungal infections in the 1980s in patients with undiagnosed 
fevers, particularly invasive candidiasis (115). To prevent the relapse in patients with history 
of fungal infections who have received complete antifungal therapy, clinicians can turn to 
secondary prophylaxis. 
6. Conclusion 
Fungal endocarditis is one of the most serious manifestations of invasive fungal infections. 
The first line of prevention is decreasing fungal conidia transition during surgery in 
operating rooms by using high-efficiency particulate air filters and sterile equipment. Early 
diagnosis and immediate appropriate antifungal therapy are critical for the survival of the 
respective patients. For high quality care of the patients, echocardiography with non-
cultural methods such as GM assay and PCR which can detect infection in early stages 
should be performed. In patients with suspected FE and positive test results, it is 
recommended that they receive antifungal agents pre-operation and also the clinical 
management be continued once the documented diagnosis is made based on the sample 
obtained in the operation room. As high relapses are common, treatment should be followed 
by careful review of the clinical, mycological (serum GM level and DNA load) and 
echocardiography sign and symptoms of the infections.  
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1. Introduction 
Median sternotomy is a commonly performed incision with distinct advantages for 
exposure of mediastinal and pulmonary hilar structures [1]. However, a well-defined 
incidence of wound complications is associated with sternotomy, which are costly and 
potentially lethal in cases of deep sternal wound infection (DSWI) or mediastinitis [2-13]. 
Not only is DSWI associated with significant perioperative mortality, but historically even 
successfully treated DSWI is associated with reduced mid- and long-term survival 
compared with matched cardiac surgical patients without this dreaded postoperative 
complication [7-12].  
In the past 10 years, we have accumulated extensive experience with managing DSWI as a 
referral center for these difficult problems. We and others have formalized a protocol for 
managing mediastinal infection utilizing negative pressure wound therapy which allows 
sternal salvage and improved outcomes in the majority of cases of DSWI [14-16]. This report 
describes our protocol for managing mediastinitis and presents our results for the past 18 
years. 
2. Background 
Median sternotomy was originally introduced by Milton in 1897 and was performed 
infrequently for various conditions of the mediastinum until cardiac surgery as a field 
blossomed in the 1950s [17]. Shumacker first suggested median sternotomy as the procedure 
of choice for approaches to the heart and great vessels [18] since it avoided the significant 
pain and other complications, primarily pulmonary- or pleural-based, of the bilateral 
anterior thoracotomy (“clamshell”) incision, which was most frequently used up to that 
point. However, not until Julian and colleagues demonstrated discrete advantages of the 
median sternotomy incision for cardiac surgery, particularly improved surgical efficiency, 
excellent exposure the heart, great vessels, and pulmonary hila, and reduced pulmonary 
trauma, was a convincing argument for median sternotomy as the incision of choice for 
cardiac surgical procedures put forth [19 Table 1]. The utility of this incision, the ease and 
speed of performance, and the common nature of surgically-treated cardiovascular and  
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RIGHT ATRIUM +++ ++ 0 
RIGHT VENTRICLE +++ + + 
LEFT ATRIUM +++ + + 
LEFT VENTRICLE ++ 0 +++ 
SVC +++ ++ 0 
IVC +++ ++ 0 
ASC AORTA/root +++ + + 
RIGHT SCA ++ ++ 0 
INNOMINATE +++ ++ 0 
LEFT SCA + 0 +++ 
DESC AORTA 0 0 +++ 
Main PA +++ 0 ++ 
RIGHT PA ++ +++ 0 
LEFT PA ++ 0 +++ 
PROX TRACHEA ++ + + 
ESOPHAGUS 0 +++ ++ 
HEMIDIAPHRAGM ++ + + 
MAIN STEM 
BRONCHI 
0 +++ ++ 
Table 1. Comparison of exposure of various intrathoracic anatomic structures through 
median sternotomy, right thoracotomy, or left thoracotomy. (+++ denotes excellent, reliable 
exposure; 0 denotes no reliable exposure) 
thoracic diseases in multiple populations approached through this incision are factors 
which combine to make median sternotomy the most commonly performed osteotomy 
worldwide [20]. Recently, several alternatives to median sternotomy have been promoted, 
including thoracoscopic and robotic approaches to cardiac and thoracic procedures [21, 
22]. These approaches are possible as a result of high fidelity instrumentation and video 
platforms but are limited by steep learning curves and expense. Therefore, for most 
hospital systems performing cardiac surgical procedures, median sternotomy remains the 
mainstay incision.  
3. Definition and classification 
There is still no universally accepted method for treatment of DSWI or other sternal wound 
complication. One possible explanation for this is that until relatively recently, thorough 
classification schemes providing specific criteria for assignment as deep sternal infection, 
mediastinitis, superficial infection, or sterile sternal dehiscence were lacking. However, it is 
important to distinguish between these individual entities since each demands a different 
management strategy. Furthermore, results of reported series which include a variety of 
wound complications will differ from those that report a homogenous population. For 
example, sternal wound infections that are limited to the superficial soft tissues obviously 
demand less aggressive intervention for treatment and will generally respond more readily 
to treatment than deep sternal infection with higher likelihood for success. Therefore, when 
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comparing different treatment modalities for sternal wound infection, it is important to be 
clear about the extent of infection, since heterogeneity could skew reported results. 
Two prominent classification schemes have been proposed and are in use. Mediastinal 
dehiscence or the more chronic form, sternal nonunion, is defined as sternal wound 
disruption without any evidence for infection either clinically or pathologically [23, 24]. 
These entities will not be discussed in any detail. In contrast, mediastinitis, as characterized 
by the U.S. Centers for Disease Control and Prevention (CDC), is an infection of the 
mediastinum diagnosed by isolation of pathogenic organisms from the mediastinal fluid or 
tissue especially when there is obvious evidence of infection at the time of sternal 
exploration [25]. Alternatively, a combination of clinical features including chest pain, 
sternal drainage with bony instability, fevers, radiographic findings such as widened 
mediastinum, and bacterial isolation may also warrant a diagnosis of mediastinitis. 
Obviously, from the surgical perspective, these definitions are somewhat lacking since 
either superficial infections, confined to the soft tissues, or deep infections, involving the 
bone and/or retrosternal space could produce bacteremia and clinical signs of severe 
infection [23].  
Fortunately, more descriptive classification schemes have been introduced and provide 
more specific insight into the pathologic involvement of the sternal tissues and the clinical 
consequences and course [23, 26, 27]. For example, the classification scheme introduced by 
El Oakley and Wright is based on the time at which the patient presents with 
mediatiastinitis relative to the initial surgical procedure [23]. Schulman et al have advocated 
a similar classification system [27]. In addition, the El Oakley description also accounts for 
relevant risk factors underlying the clinical scenario and whether or not previous attempts 
to treat the sternal wound infection have been made and failed [Table 2]. Therefore, five 
distinct categories of infection are described, each with important treatment implications. 
For example, the subtypes I and II appear to respond well to primary sternal closure with 
mediatinal irrigation, while subtypes III-V appear to require more aggressive sternal 
debridement and repair techniques [23]. 
 
Classification Description of Infection 
Type 1 Mediastinitis within 2 weeks of operation 
without risk factors 
Type 2 Mediastinitis between 2 and 6 weeks of 
operation without risk factors 
Type 3a Type 1 with one or more risk factors 
Type 3b Type 2 with one or more risk factors 
Type 4a Type 1, 2, or 3 after one failed therapy 
Type 4b Type 1, 2, or 3 after more than one failed 
therapy 
Type 5 Mediastinitis presenting 6 weeks or more 
after operation 
Table 2. Classification scheme of mediastinitis introduced by El Oakley and Wright based on 
the time at which the patient presents with mediatiastinitis relative to the initial surgical 
procedure (modified from El Oakley and Wright [23]).  
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example, sternal wound infections that are limited to the superficial soft tissues obviously 
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comparing different treatment modalities for sternal wound infection, it is important to be 
clear about the extent of infection, since heterogeneity could skew reported results. 
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exploration [25]. Alternatively, a combination of clinical features including chest pain, 
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infection [23].  
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more specific insight into the pathologic involvement of the sternal tissues and the clinical 
consequences and course [23, 26, 27]. For example, the classification scheme introduced by 
El Oakley and Wright is based on the time at which the patient presents with 
mediatiastinitis relative to the initial surgical procedure [23]. Schulman et al have advocated 
a similar classification system [27]. In addition, the El Oakley description also accounts for 
relevant risk factors underlying the clinical scenario and whether or not previous attempts 
to treat the sternal wound infection have been made and failed [Table 2]. Therefore, five 
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Classification Description of Infection 
Type 1 Mediastinitis within 2 weeks of operation 
without risk factors 
Type 2 Mediastinitis between 2 and 6 weeks of 
operation without risk factors 
Type 3a Type 1 with one or more risk factors 
Type 3b Type 2 with one or more risk factors 
Type 4a Type 1, 2, or 3 after one failed therapy 
Type 4b Type 1, 2, or 3 after more than one failed 
therapy 
Type 5 Mediastinitis presenting 6 weeks or more 
after operation 
Table 2. Classification scheme of mediastinitis introduced by El Oakley and Wright based on 
the time at which the patient presents with mediatiastinitis relative to the initial surgical 
procedure (modified from El Oakley and Wright [23]).  
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The classification by Jones et al differs from that of El Oakley and Wright in that it is more 
descriptive anatomically and physiologically [26, TABLE 3]. Three different “types” of 
sternal infection are described, encompassing both superficial and deep infections, and 
based on the degree of underlying tissue involvement with infection. We have preferred the 
use of this classification system as it is simpler to use since it based strictly on features 
observed or encountered at the time of initial sternal exploration. In addition, Type 3b is 
physiologically meaningful since it denotes the patient who is systemically ill from the 
sternal wound process. In our own institutional experience of 222 adult cardiac surgical 
patients treated for postoperative DSWI, approximately 50% of patients exhibited 
septicemia (Jones 3b) upon initial presentation [14]. 
 
Class Depth of Involvement Description 
1a Superficial Skin/subcutaneous tissue dehiscence 
1b Superficial Exposed deep fascia, sutures intact 
2a Deep Exposed bone, stable wired sternotomy 
2b Deep Exposed bone, unstable wired 
sternotomy 
3a Deep Exposed necrotic or fractured bone, 
unstable, heart exposed 
3b Deep Types 2 or 3 with septicemia 
Table 3. Mediastinal wound classification system modified from Jones et al [26]. Although 
anatomic involvement by infection in distinguished, the presence of septicemia is the most 
important feature clinically. 
4. Risk factors and pathophysiology 
Multiple different etiologies for development of DSWI have been invoked over time. For 
example, most infections were traditionally thought to arise as a result of breaks in proper 
surgical technique, prompting strict guidelines for sterile surgical technique. In addition, 
secondary involvement the mediastinum from remote sites such as leg incisions or the 
pulmonary tree has also been suggested as a mechanism for DSWI. The “endogenous 
pathway,” seeding of the mediastinum from other host sources, does appear to be important 
in the development of S. aureus mediastinitis. To illustrate, Jakob et al showed that nasal 
carriage of S. aureus was an independent predictor of sternal infection postoperatively [28], 
while others have demonstrated that application of mupirocin to the nares of S. aureus 
colonized individuals can help reduce postoperative infection [29]. More recently, other factors 
have been recognized as important contributors to cardiac surgical site infections. For instance, 
the appropriate timing of perioperative antibiotics and strict perioperative glucose control are 
both associated with reduced surgical wound infectious complications [30, 31].  
Several different patient-related factors have been repeatedly implicated in the development of 
DSWI, most consistently obesity and diabetes mellitus [5, 6, 32, TABLE 4]. Eklund et al and 
others have observed that increasing severity of obesity elevates the risk for surgical site 
infection in a step-wise fashion [6, 13, 33]. Furthermore, when obesity is described in terms of 
percentage body fat, the relationship between obesity and surgical site infection is nearly linear 
and appears more accurate than use of body mass index as a descriptor of obesity [34]. 
Potential explanations for relationship between obesity and DSWI include technical problems  
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Study # Patients Identified Risk Factors 
Milano CA, et al. 
Circulation 1995 [9] 
6,459 Obesity, NYHA class, redo surgery, CPB duration 
Toumpoulis IK, et al. 
Chest 2005 [55] 
3,760 Diabetes, preoperative hemodynamic instability, 
renal failure, bilateral IMA, sepsis and/or 
endocarditis  
Immer FF, et al. Ann 
Thorac Surg 2005 [94] 
5,690 Obesity, diabetes mellitus, COPD, bilateral IMA 
Fowler G, et al. 
Circulation 2005 [13] 
300,000 Obesity (BMI of 30-40 kg/m2), diabetes, previous 
MI, urgent operative status, hypertension 
Prabhakar G, et al. Ann 
Thorac Surg 2002 [32] 
559,004 Obesity 
Sjorgren J, et al. Ann 
Thorac Surg 2005 [90] 
4,826 Diabetes, obesity, reduced EF, renal failure, multi-
vessel CAD 
Olsen MA, et al. J Thorac 
Cardiovasc Surg 2002 
[10]  
1,980 Obesity (BMI>30 kg/m2), diabetes, > 4 units RBC 
transfusion, IABP, current smoking 
Cayci C,et al. Ann Plast 
Surg 2008 [52] 
7,978 Obesity (BMI>30 kg/m2), diabetes, urgent 
operation, recent smoking; h/o CVA, total HLOS, 
sepsis/endocarditis postop 
Risnes I, et al. Ann 
Thorac Surg 2010 [12] 
18,352 COPD, obesity (BMI > 30 kg/m2), blood 
transfusion, advanced age, male sex, diabetes 
Table 4. Compiled analyses for underlying risk factors associated with sternal wound 
infection. Obesity and diabetes mellitus are consistently shown to be independent predictors 
of poststernotomy mediastinitis. 
during surgery owing to the patient’s size, increased bleeding, increased deadspace in the 
wound, and ineffective or inadequate dosing of perioperative antibiotics [6, 9]. 
Although multiple mechanisms for sternal wound complications are proposed, it is widely 
accepted that reduced sternal perfusion, often by virtue of internal mammary artery (IMA) 
harvesting for use as a vascular conduit in coronary artery revascularization, is one of the 
most important causes of sternal nonhealing and infection [1-6, 8, 26], especially when both 
IMAs are harvested for bypass graft surgery [5]. Therefore, more cases of DSWI appear to 
occur after coronary artery bypass grafting or after combined procedures that include 
coronary artery surgery [7, 35]. Other viable explanations for DSWI etiology include poor 
bone stock from osteoporosis, malnutrition, and other factors; poorly performed sternotomy 
leading to sternal fractures and/or costosternal disassociation; and other patient related 
factors including peripheral vascular disease and lung disease [8, 36]. Several other factors 
have been implicated in the development of DSWI but may not be manifest in the context of 
a retrospective review or randomized trial because the numbers are too low. For example, it 
is generally accepted that postoperative steroids or chronic immunosuppression increases 
risk for DSWI, but this has been difficult to demonstrate in even large database reviews [13, 
37]. Finally, Risnes et al have demonstrated in a review of over 18,000 consecutive patients 
undergoing coronary artery surgery in Norway, the major preventable risk factor associated 
with the development of DSWI was the amount of blood product transfusion 
perioperatively [12]. 
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in the development of S. aureus mediastinitis. To illustrate, Jakob et al showed that nasal 
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have been recognized as important contributors to cardiac surgical site infections. For instance, 
the appropriate timing of perioperative antibiotics and strict perioperative glucose control are 
both associated with reduced surgical wound infectious complications [30, 31].  
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during surgery owing to the patient’s size, increased bleeding, increased deadspace in the 
wound, and ineffective or inadequate dosing of perioperative antibiotics [6, 9]. 
Although multiple mechanisms for sternal wound complications are proposed, it is widely 
accepted that reduced sternal perfusion, often by virtue of internal mammary artery (IMA) 
harvesting for use as a vascular conduit in coronary artery revascularization, is one of the 
most important causes of sternal nonhealing and infection [1-6, 8, 26], especially when both 
IMAs are harvested for bypass graft surgery [5]. Therefore, more cases of DSWI appear to 
occur after coronary artery bypass grafting or after combined procedures that include 
coronary artery surgery [7, 35]. Other viable explanations for DSWI etiology include poor 
bone stock from osteoporosis, malnutrition, and other factors; poorly performed sternotomy 
leading to sternal fractures and/or costosternal disassociation; and other patient related 
factors including peripheral vascular disease and lung disease [8, 36]. Several other factors 
have been implicated in the development of DSWI but may not be manifest in the context of 
a retrospective review or randomized trial because the numbers are too low. For example, it 
is generally accepted that postoperative steroids or chronic immunosuppression increases 
risk for DSWI, but this has been difficult to demonstrate in even large database reviews [13, 
37]. Finally, Risnes et al have demonstrated in a review of over 18,000 consecutive patients 
undergoing coronary artery surgery in Norway, the major preventable risk factor associated 
with the development of DSWI was the amount of blood product transfusion 
perioperatively [12]. 
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Several risk analyses are available to estimate the individual patient’s propensity for 
developing DSWI. For example, using Society of Thoracic Surgery National Cardiac 
Database information, Fowler et al created a model to estimate the risk for systemic infection 
after coronary artery bypass surgery using patient characteristics available preoperatively 
[13]. The Fowler model also provides for inclusion of important intraoperative details 
known to influence postoperative infection including the need for intra-aortic balloon 
counterpulsation and prolonged cardiopulmonary bypass times [13]. Although the model 
devised by Fowler et al was based on various cases of major infection after coronary artery 
surgery, including DSWI, the authors did validate the model as predictive of infection in a 
test population from the STS Database, and the model was also recently validated in a 
different cohort of patients from the UK as being predictive of DSWI [38]. The EuroSCORE 
system also has been shown to predict infection and associated mortality with acceptable 
discrimination [39]. 
5. Incidence 
Despite advancements in most aspects of perioperative care, rates of sternal wound 
complications, including mediastinitis, following adult cardiac surgery have varied little 
over the past 30 years [2-6], although incremental reduction in single center rates of DSWI 
have been noted and attributed to adjunctive measures such as strict perioperative glucose 
control [40]. As noted previously, rates of DSWI vary with regard to the specific definition 
used to describe the pathology encountered and the patient population studied. In general, 
reported rates of DSWI are relatively low, ranging from 0.25% to 3.6 % [2-9, 38, 39, 41, 42]. 
However, the incidence of superficial sternal infection excedes that of deep sternal infection 
by as many as three times [10, 41, 43], and Francel has stated that as many as 70% of patients 
with poststernotomy infection will have superficial tissue involvement [44]. 
6. Diagnosis 
Depending on the virulent nature of the sternal wound infection, patients typically present 
within 30 days of cardiac surgery. The most common symptoms include sternal wound 
drainage, sternal instability, fever, and malaise. In many cases, a high index of suspicion is 
required to establish the diagnosis, especially when classic signs and symptoms are absent. 
In addition, it is often difficult to distinguish on physical examination the difference 
between deep sternal wound infection (infection present beneath the sternum) and 
superficial sternal infection. Therefore, early wound opening and inspection with 
appropriate sampling of tissue for bacteriologic assessment is strongly encouraged when 
sufficient clinical suspicion exists. 
One of the most reliable signs of DSWI is sternal instability, which frequently implies a 
deeper problem than can be appreciated at the superficial level [44]. While sternal instability 
can be tested on physical examination, we have often noted that the patient themselves will 
typically report sternal clicking with inspiration, cough, or various other physical 
maneuvers, so this information should be thoughtfully considered if DSWI diagnosis is 
being entertained.  
The use of various radiographic examinations is often encouraged when evaluating for DSWI, 
and, in fact, is included as part of the CDC guidelines for defining mediastinitis [25]. Formerly, 
PA and lateral chest radiograph was the investigative procedure of choice, where details such 
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as a “sternal stripe” indicated present of air between the two sternal halves. The lateral 
displacement of one or more sternal wires, secondary to tearing of the wire through one side of 
the sternum, has been a frequently noted finding in the case of poststernotomy infection [37]. 
More recently, chest computed tomography has been suggested as the procedure of choice for 
assessing sternal wound infection when a diagnosis cannot be established by clinical 
examination alone [45, 46]. Mediastial fluid collections, free gas bubbles, soft tissue swelling, 
pleural effusions, sternal dehiscence, and subcutaneous fluid collections have been the 
predominant CT findings in cases of DSWI [47], but these features appear to be more specific 
and sensitive for DSWI presenting more than 3 weeks after surgery [48]. 
7. Morbidity and mortality 
Mediastinal infection negatively impacts early, mid-term, and long-term survival after adult 
heart surgery [2, 7-12]. While it is intuitive that clinically serious DSWI reduces 30-day 
and/or in-hospital survival relative to similar patients not suffering this complications, the 
effect of DSWI on long-term survival is especially insulting since many patients referred for 
heart surgery expect to gain a survival advantage compared with other treatment options 
for their underlying heart disease [49].  
Prior to the development of modern protocols for DSWI management, which include 
thorough sternal debridement and use of vascularized flaps to repair the mediastinal defect 
resulting from debridement, early mortality from DSWI exceeded 50% [50]. In the “modern 
era,” reported rates of in-hospital or 30-day DSWI mortality for range from 7% to over 30% 
[11,14, 35, 42, 51, 52]. In our own recent experience, early mortality for DSWI is 
approximately 16% [14]. Therefore, despite many advancements in intensive care medicine, 
DSWI continues to be a deadly complication. Death in the early period is typicaly the result 
of sepsis or other infectious complications including multiorgan failure [12]. Morisaki et al. 
recently demonstrated methicillin-resistent S. aureus infection to be an independent risk 
factor for in-hospital mortality in their cohort of poststernotomy DSWI patients [53].  
Patients surviving infectious complications and the acute insult of DSWI exhibit reduced 
mid-term survival compared with controls. For example, one-year mortality for DSWI 
following CABG is significantly increased compared with similar patients who did not 
develop DSWI [2, 8, 10]. Milano et al and Braxton et al both demonstrated a doubling of 
mid-term mortality among patients with DSWI after CABG compared with controls [9, 54]. 
Karra et al examined predictors of one-year mortality after treatment for DSWI and found 
that delay in closing the mediastinal defect; age over 65 years; need for ICU care prior to 
sternal debridement; and methicillin-resistent S. aureus infections were each independently 
associated with mortality [7]. 
Long-term survival has consistently been demonstrated to suffer in patients with a history 
of poststernotomy DSWI [5, 8, 9, 12, 35, 52, 54-56, Figure 1]. For example, Filsoufi et al 
reviewed nearly 5,800 adult heart surgery patients at a single institution over 8 years and 
found DSWI to be associated with significantly reduced 5-year survival compared with 
patients who did not develop DSWI [35]. Similarly, Risnes et al reviewed their experience of 
over 18,000 cardiac surgical patients with a mean follow-up of over 10 years. Long-term 
survival for patients whose course was complicated by DSWI was <50% compared with 
>70% for patients without DSWI, and DSWI was independently associated with reduced 
long-term survival after cardiac surgery [HR 1.59; 95% CI 1.16 – 2.70, p = 0.003] [12]. Similar 
data have been also been reported by Toumpoulis et al. [55].  
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as a “sternal stripe” indicated present of air between the two sternal halves. The lateral 
displacement of one or more sternal wires, secondary to tearing of the wire through one side of 
the sternum, has been a frequently noted finding in the case of poststernotomy infection [37]. 
More recently, chest computed tomography has been suggested as the procedure of choice for 
assessing sternal wound infection when a diagnosis cannot be established by clinical 
examination alone [45, 46]. Mediastial fluid collections, free gas bubbles, soft tissue swelling, 
pleural effusions, sternal dehiscence, and subcutaneous fluid collections have been the 
predominant CT findings in cases of DSWI [47], but these features appear to be more specific 
and sensitive for DSWI presenting more than 3 weeks after surgery [48]. 
7. Morbidity and mortality 
Mediastinal infection negatively impacts early, mid-term, and long-term survival after adult 
heart surgery [2, 7-12]. While it is intuitive that clinically serious DSWI reduces 30-day 
and/or in-hospital survival relative to similar patients not suffering this complications, the 
effect of DSWI on long-term survival is especially insulting since many patients referred for 
heart surgery expect to gain a survival advantage compared with other treatment options 
for their underlying heart disease [49].  
Prior to the development of modern protocols for DSWI management, which include 
thorough sternal debridement and use of vascularized flaps to repair the mediastinal defect 
resulting from debridement, early mortality from DSWI exceeded 50% [50]. In the “modern 
era,” reported rates of in-hospital or 30-day DSWI mortality for range from 7% to over 30% 
[11,14, 35, 42, 51, 52]. In our own recent experience, early mortality for DSWI is 
approximately 16% [14]. Therefore, despite many advancements in intensive care medicine, 
DSWI continues to be a deadly complication. Death in the early period is typicaly the result 
of sepsis or other infectious complications including multiorgan failure [12]. Morisaki et al. 
recently demonstrated methicillin-resistent S. aureus infection to be an independent risk 
factor for in-hospital mortality in their cohort of poststernotomy DSWI patients [53].  
Patients surviving infectious complications and the acute insult of DSWI exhibit reduced 
mid-term survival compared with controls. For example, one-year mortality for DSWI 
following CABG is significantly increased compared with similar patients who did not 
develop DSWI [2, 8, 10]. Milano et al and Braxton et al both demonstrated a doubling of 
mid-term mortality among patients with DSWI after CABG compared with controls [9, 54]. 
Karra et al examined predictors of one-year mortality after treatment for DSWI and found 
that delay in closing the mediastinal defect; age over 65 years; need for ICU care prior to 
sternal debridement; and methicillin-resistent S. aureus infections were each independently 
associated with mortality [7]. 
Long-term survival has consistently been demonstrated to suffer in patients with a history 
of poststernotomy DSWI [5, 8, 9, 12, 35, 52, 54-56, Figure 1]. For example, Filsoufi et al 
reviewed nearly 5,800 adult heart surgery patients at a single institution over 8 years and 
found DSWI to be associated with significantly reduced 5-year survival compared with 
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over 18,000 cardiac surgical patients with a mean follow-up of over 10 years. Long-term 
survival for patients whose course was complicated by DSWI was <50% compared with 
>70% for patients without DSWI, and DSWI was independently associated with reduced 
long-term survival after cardiac surgery [HR 1.59; 95% CI 1.16 – 2.70, p = 0.003] [12]. Similar 
data have been also been reported by Toumpoulis et al. [55].  
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Fig. 1. From Braxton et al with permission [8], patients suffering mediastinal infection after 
coronary artery bypass grafting have worse overall long-term survival compared with 
similar patients not experiencing the complication.  
It is unclear as to the specific reasons for worse long-term survival after DSWI is successfully 
treated, but cardiac-related deaths or progression of cardiovascular disease appears to be a 
common cause of death for those with DSWI [8, 12]. In addition, Chu et al recently reported 
that patients with peripheral vascular disease had worse outcomes long-term after coronary 
artery surgery [57]. We recently evaluated long-term survival in a cohort of 222 adult 
cardiac surgical patients treated at Duke University Hospital for poststernotomy 
mediastinitis. Using multivariable regression analysis and at a mean follow-up of 5.5 years, 
the following variables were noted to be independently associated with survival: heart 
failure [Hazard ratio (HR) 1.58, p = 0.029]; sepsis [HR 2.38, p <0.001]; peripheral vascular 
disease [HR 2.06, p = 0.001], age > 65 years [HR 1.61, p = 0.037]; and take back for bleeding 
[HR 2.96; p = 0.007] (unpublished data).  
Not only does DSWI lead to increased mortality among post-surgical patients, it is also 
closely associated with other types of postoperative complications. For example, in a recent 
review of morbidity following coronary surgery from the Virginia Cardiac Surgery Quality 
Initiative, DSWI was the not only the most expensive complication, but it was also 
associated with a longer length of hospital stay, by more than two full weeks, than any other 
single postoperative complication, including perioperative stroke and renal failure [4]. Other 
reports have corroborated the impact of DSWI on overall hospital length of stay [2, 6, 52]. 
Speir et al also demonstrated that DSWI was the most likely form of postoperative 
morbidity to be associated with other complications such as prolonged ventilation, bleeding, 
renal failure, and atrial fibrillation [4]. DSWI has also been associated with increased rates of 
stroke, need for inotropic or mechanical cardiac support, and perioperative myocardial 
infarction, renal failure, and prolonged mechanical ventilation [12, 51].  
8. Microbiology 
Numerous bacterial pathogens may contribute to DSWI, but the most commonly isolated 
organisms are Staphylococcus, either coagulase-negative Staphylococcus (CNS) or S. aureus 
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[58]. In our own recently described experience, methicillin-sensitive and methicillin-resistent 
S. aureus each accounted for 35% of wound isolates, while CNS was present in 12%, and 
gram negative organisms were found in 18% [14]. It is noteworthy that our protocols for 
preoperative preparation of the cardiac surgical patient do not routinely incorporate 
mupirocin treatment. Additionally, many patients included in our cohort of patients treated 
for DSWI underwent primary cardiac surgery at referring facilities. Therefore, specific 
details in these patients predisposing to a certain pathogen were often lacking. Risk factors 
for the development of methicillin-resistent S. aureus poststernotomy mediastinitis include 
previous hospitalization and takeback for bleeding after the original cardiac surgical 
procedure [59]. Gardlund et al have attributed the development of S. aureus infection to the 
development of bacteremia [60], which is corroborated by our own data in which 50% of 
patients treated for DSWI had evidence of bacteremia or septicemia (Jones classification 3b) 
at the time of clinical presentation with DSWI [14]. Finally, it has been demonstrated that 
methicillin-resistent strains of S. aureus are more virulent and deadly than methicillin-
sensitive strains, and, in fact, methicillin resistance was the only independent predictor of 
early mortality in one analysis [61].  
In contrast, S. epidermidis often presents with a rather indolent course, often not manifesting 
clinically until 3 weeks or more postoperatively [62]. CNS is frequently isolated in cases of 
sternal instability or nonunion, which may itself arise from obesity or acute or chronic 
pulmonary disease [60]. CNS has recently been noted to of increasing incidence and has 
been reported to be present in roughly 50% of sternal infections in some series [6, 11, 60].  
Gram negative organisms contribute less commonly to the pathogenesis of DSWI. Gram-
negative infections of the mediastinum classically arise in the setting of other postoperative 
infectious complications such pneumonia, urinary tract infections, intra-abdominal 
infections, or other nosocomial infections [58, 60]. Mekontso-Dessap et al reviewed their 
experience with DSWI after cardiac surgery and found that Enterococcus species were the 
most common isolates in early cases of DSWI (<14 days), which likely arise from 
translocation of these bacteria from other sources in the host [63]. In contrast, Staphylococcus 
species, often CNS, were the most common isolates in cases presenting more remotely from 
the original surgery [63]. 
9. Cost of DSWI 
One of the most impactful consequences of DSWI is the costs incurred in its management, in 
part due to the multiple associated conditions that frequently complicate the clinical picture of 
these sick patients [4, 12]. The average hospital costs for patients treated for DSWI is 
approximately 2.5 to 3 times that of similarly matched patients who enjoy an uncomplicated 
postoperative course [23, 64, 65]. As noted, increased costs are primarily attributed to 
associated comorbid conditions that arise during the treatment of mediastinitis, increased 
length of hospital stays, including frequent need for ICU services, and the need for multiple 
surgical procedures when using traditional approaches to DSWI [4, 23]. For example, 
Hollenbeak et al found that patients with DSWI remained hospitalized an average of 3 weeks 
longer than noninfected patients after coronary artery surgery [2]. Interestingly, in the same 
study it was noted that DSWI patients who ultimately expired incurred nearly $61,000 US 
dollars more in costs than other DSWI patients who ultimately survived, presumably 
secondary to the multiple comorbidities associated with clinically aggressive mediastinitis [2]. 
Using more recently acquired information, Speir et al found that mediastinitis was the single 
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Fig. 1. From Braxton et al with permission [8], patients suffering mediastinal infection after 
coronary artery bypass grafting have worse overall long-term survival compared with 
similar patients not experiencing the complication.  
It is unclear as to the specific reasons for worse long-term survival after DSWI is successfully 
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common cause of death for those with DSWI [8, 12]. In addition, Chu et al recently reported 
that patients with peripheral vascular disease had worse outcomes long-term after coronary 
artery surgery [57]. We recently evaluated long-term survival in a cohort of 222 adult 
cardiac surgical patients treated at Duke University Hospital for poststernotomy 
mediastinitis. Using multivariable regression analysis and at a mean follow-up of 5.5 years, 
the following variables were noted to be independently associated with survival: heart 
failure [Hazard ratio (HR) 1.58, p = 0.029]; sepsis [HR 2.38, p <0.001]; peripheral vascular 
disease [HR 2.06, p = 0.001], age > 65 years [HR 1.61, p = 0.037]; and take back for bleeding 
[HR 2.96; p = 0.007] (unpublished data).  
Not only does DSWI lead to increased mortality among post-surgical patients, it is also 
closely associated with other types of postoperative complications. For example, in a recent 
review of morbidity following coronary surgery from the Virginia Cardiac Surgery Quality 
Initiative, DSWI was the not only the most expensive complication, but it was also 
associated with a longer length of hospital stay, by more than two full weeks, than any other 
single postoperative complication, including perioperative stroke and renal failure [4]. Other 
reports have corroborated the impact of DSWI on overall hospital length of stay [2, 6, 52]. 
Speir et al also demonstrated that DSWI was the most likely form of postoperative 
morbidity to be associated with other complications such as prolonged ventilation, bleeding, 
renal failure, and atrial fibrillation [4]. DSWI has also been associated with increased rates of 
stroke, need for inotropic or mechanical cardiac support, and perioperative myocardial 
infarction, renal failure, and prolonged mechanical ventilation [12, 51].  
8. Microbiology 
Numerous bacterial pathogens may contribute to DSWI, but the most commonly isolated 
organisms are Staphylococcus, either coagulase-negative Staphylococcus (CNS) or S. aureus 
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[58]. In our own recently described experience, methicillin-sensitive and methicillin-resistent 
S. aureus each accounted for 35% of wound isolates, while CNS was present in 12%, and 
gram negative organisms were found in 18% [14]. It is noteworthy that our protocols for 
preoperative preparation of the cardiac surgical patient do not routinely incorporate 
mupirocin treatment. Additionally, many patients included in our cohort of patients treated 
for DSWI underwent primary cardiac surgery at referring facilities. Therefore, specific 
details in these patients predisposing to a certain pathogen were often lacking. Risk factors 
for the development of methicillin-resistent S. aureus poststernotomy mediastinitis include 
previous hospitalization and takeback for bleeding after the original cardiac surgical 
procedure [59]. Gardlund et al have attributed the development of S. aureus infection to the 
development of bacteremia [60], which is corroborated by our own data in which 50% of 
patients treated for DSWI had evidence of bacteremia or septicemia (Jones classification 3b) 
at the time of clinical presentation with DSWI [14]. Finally, it has been demonstrated that 
methicillin-resistent strains of S. aureus are more virulent and deadly than methicillin-
sensitive strains, and, in fact, methicillin resistance was the only independent predictor of 
early mortality in one analysis [61].  
In contrast, S. epidermidis often presents with a rather indolent course, often not manifesting 
clinically until 3 weeks or more postoperatively [62]. CNS is frequently isolated in cases of 
sternal instability or nonunion, which may itself arise from obesity or acute or chronic 
pulmonary disease [60]. CNS has recently been noted to of increasing incidence and has 
been reported to be present in roughly 50% of sternal infections in some series [6, 11, 60].  
Gram negative organisms contribute less commonly to the pathogenesis of DSWI. Gram-
negative infections of the mediastinum classically arise in the setting of other postoperative 
infectious complications such pneumonia, urinary tract infections, intra-abdominal 
infections, or other nosocomial infections [58, 60]. Mekontso-Dessap et al reviewed their 
experience with DSWI after cardiac surgery and found that Enterococcus species were the 
most common isolates in early cases of DSWI (<14 days), which likely arise from 
translocation of these bacteria from other sources in the host [63]. In contrast, Staphylococcus 
species, often CNS, were the most common isolates in cases presenting more remotely from 
the original surgery [63]. 
9. Cost of DSWI 
One of the most impactful consequences of DSWI is the costs incurred in its management, in 
part due to the multiple associated conditions that frequently complicate the clinical picture of 
these sick patients [4, 12]. The average hospital costs for patients treated for DSWI is 
approximately 2.5 to 3 times that of similarly matched patients who enjoy an uncomplicated 
postoperative course [23, 64, 65]. As noted, increased costs are primarily attributed to 
associated comorbid conditions that arise during the treatment of mediastinitis, increased 
length of hospital stays, including frequent need for ICU services, and the need for multiple 
surgical procedures when using traditional approaches to DSWI [4, 23]. For example, 
Hollenbeak et al found that patients with DSWI remained hospitalized an average of 3 weeks 
longer than noninfected patients after coronary artery surgery [2]. Interestingly, in the same 
study it was noted that DSWI patients who ultimately expired incurred nearly $61,000 US 
dollars more in costs than other DSWI patients who ultimately survived, presumably 
secondary to the multiple comorbidities associated with clinically aggressive mediastinitis [2]. 
Using more recently acquired information, Speir et al found that mediastinitis was the single 
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most costly complication in Virginia after coronary artery surgery, raising the cost of care by 
over $62,000 US dollars, or more than 240% increase, on average, [4].  
Therefore, it is apparent that treatment of these critically ill patients is extremely 
expensive to the hospital system, even if the complication is uncommonly encountered. 
As a result, and based on increased scrutiny of various hospital-associated conditions, the 
US Center for Medicare and Medicaid Services no longer reimburses for hospital costs 
incurred in treatment of DSWI following coronary artery bypass surgery [66]. 
Interestingly, however, it appears that use of negative pressure therapy in the treatment 
of DSWI contains associated costs. For example, Mokhtari et al reported the use of VAC 
therapy to be cost effective and efficacious in eradicating mediastinal infection [65]. In our 
own experience, patients treated with negative pressure therapy for DSWI had costs that 
were $150,000 US dollars less than the average Medicare charges for treatment required 
for DSWI ($152,00 vs. $ 300,000) [67].  
10. Treatment of DSWI 
Upon establishing the diagnosis of sternal wound infection, the immediate goal of treatment 
is complete eradication of infection followed by stabilization of the sternum and chest wall. 
Multiple strategies for managing mediastinitis have been proposed and range from open 
mediastinal packing to debridement with closure over drains, to placement of vascularized 
tissue flaps. In addition, negative pressure therapy (NPT) has been used to aide in the 
treatment of mediastinal infection, as first reported in 1999 [68]. Several initial series 
described the use of NPT for treating mediastinitis and outlined potential benefits of this 
approach to controlling mediastinal infection [15, 16, 45, 69, 70]. However, a consensus as to 
best treatment for mediastinal infection has yet to be established. For example, Schimmer et 
al recently surveyed 79 cardiac surgery programs in Germany to query DSWI management 
strategies [71]. They found that approximately 1/3 of the centers preferentially used NPT for 
controlling mediastinal contamination, while another 1/3 use closed chest irrigation, and 
another 1/3 combine management approaches [71]. Other groups continue to advocate 
more aggressive surgical therapy in addressing infected sternal wounds [7, 72].  
Initially, the primary treatment for DSWI was open packing followed by secondary closure 
[73]. This method was labor intensive, cumbersome, and was characterized by significant 
rates of recurrent infection and other complications [58]. Shortly thereafter, Schumaker and 
Mandelbaum proposed early closure over drains [74], which allowed continual irrigation of 
the infected mediastinum [73, 74]. Although this approach represented an improvement 
relative to open packing procedure, the latter procedure was still associated with failure 
rates of at least 25% [73].  
Omental flap repair of the infected mediastinum was originally reported in 1976 by Lee [75] 
and has been shown to have distinct advantages over continuous antiobiotic irrigation 
through drains [76] and over muscle flaps for sternal wound defect repair [9, 14]. This is 
thought to occur by obliterating dead space, a mechanism that can also be credited to 
muscle flap repair of the open mediastinum [26]. However, the omentum may have 
angiogenic and immunologic properties that stimulate more complete sternal defect healing 
[58]. Other advantages of using the greater omentum to flap the sternal defect include 
superior malleability and excellent blood flow. As originally described, traditional omental 
flap repair of the mediastinum involves a laparotomy to mobilize and place the graft 
through the anterior portion of the diaphragm [Figure 2]. More recently, harvesting the  
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Fig. 2. Preparation of the omental flap graft for transfer to the mediastinum from Milano et 
al with permission [80]. After preparation of the mediastinum [A], a laparotomy is 
performed and the greater omental graft is prepared by mobilizing it from the transverse 
colon [B]. Once the graft is tunneled through an anterior diaphragm incision, it is secured in 
the mediastinum to fill the defect. Care is taken to avoid twisting or kinking the omental 
graft as it is delivered from the abdomen into the mediastinum [C]. The mediastinum is then 
closed over drains with retention sutures. The drains are placed to bulb suction [D]. 
omental pedicle using a laparoscopic approach may have advantages over open abdominal 
procedures and has been utilized successfully [77].  
Jurkiewicz et al first reported on the successful use of muscle flaps in DSWI in 1980 [78], 
while the Emory groups’ experience with muscle flap repair of the infected mediastinum 
refined approaches and clarified advantages of these techniques [26]. As with omental 
flap repair, discrete advantages of complete mediastinal repair with vascularized muscle 
flaps were demonstrated as compared with closed chest irrigation [26, 79]. Milano et al 
compared omental and pectoralis muscle flap repairs for the infected mediastinum and 
found that procedural details, early complications, and hospital length of stay were all 
improved with omental flap repair [80]. Omental flap repair also trended towards 
improved survival and reduced chronic pain when compared with pectoralis flap 
procedures [80]. In fact, significant long-term complications can be associated with muscle 
flap repair of the mediastinum including paresthesias, sternal instability, truncal 
weakness, and prolonged pain syndromes [9, 26, 81, 82]. Reporting on the long term 
results of muscle flap coverage of the mediastinum, Ringelman noted persistent pain in 
over 50% of patients, numbness and paresthesias in 44%, sternal instability in over 40%, 
and shoulder weakness in 1/3 of patients [82]. It is worth noting, however, that 
unfavorable outcomes with open packing and/or mediastinal irrigation prompted 
recommendations for aggressive mediastinal debridement including radical sternectomy 
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most costly complication in Virginia after coronary artery surgery, raising the cost of care by 
over $62,000 US dollars, or more than 240% increase, on average, [4].  
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As a result, and based on increased scrutiny of various hospital-associated conditions, the 
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were $150,000 US dollars less than the average Medicare charges for treatment required 
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tissue flaps. In addition, negative pressure therapy (NPT) has been used to aide in the 
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described the use of NPT for treating mediastinitis and outlined potential benefits of this 
approach to controlling mediastinal infection [15, 16, 45, 69, 70]. However, a consensus as to 
best treatment for mediastinal infection has yet to be established. For example, Schimmer et 
al recently surveyed 79 cardiac surgery programs in Germany to query DSWI management 
strategies [71]. They found that approximately 1/3 of the centers preferentially used NPT for 
controlling mediastinal contamination, while another 1/3 use closed chest irrigation, and 
another 1/3 combine management approaches [71]. Other groups continue to advocate 
more aggressive surgical therapy in addressing infected sternal wounds [7, 72].  
Initially, the primary treatment for DSWI was open packing followed by secondary closure 
[73]. This method was labor intensive, cumbersome, and was characterized by significant 
rates of recurrent infection and other complications [58]. Shortly thereafter, Schumaker and 
Mandelbaum proposed early closure over drains [74], which allowed continual irrigation of 
the infected mediastinum [73, 74]. Although this approach represented an improvement 
relative to open packing procedure, the latter procedure was still associated with failure 
rates of at least 25% [73].  
Omental flap repair of the infected mediastinum was originally reported in 1976 by Lee [75] 
and has been shown to have distinct advantages over continuous antiobiotic irrigation 
through drains [76] and over muscle flaps for sternal wound defect repair [9, 14]. This is 
thought to occur by obliterating dead space, a mechanism that can also be credited to 
muscle flap repair of the open mediastinum [26]. However, the omentum may have 
angiogenic and immunologic properties that stimulate more complete sternal defect healing 
[58]. Other advantages of using the greater omentum to flap the sternal defect include 
superior malleability and excellent blood flow. As originally described, traditional omental 
flap repair of the mediastinum involves a laparotomy to mobilize and place the graft 
through the anterior portion of the diaphragm [Figure 2]. More recently, harvesting the  
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Fig. 2. Preparation of the omental flap graft for transfer to the mediastinum from Milano et 
al with permission [80]. After preparation of the mediastinum [A], a laparotomy is 
performed and the greater omental graft is prepared by mobilizing it from the transverse 
colon [B]. Once the graft is tunneled through an anterior diaphragm incision, it is secured in 
the mediastinum to fill the defect. Care is taken to avoid twisting or kinking the omental 
graft as it is delivered from the abdomen into the mediastinum [C]. The mediastinum is then 
closed over drains with retention sutures. The drains are placed to bulb suction [D]. 
omental pedicle using a laparoscopic approach may have advantages over open abdominal 
procedures and has been utilized successfully [77].  
Jurkiewicz et al first reported on the successful use of muscle flaps in DSWI in 1980 [78], 
while the Emory groups’ experience with muscle flap repair of the infected mediastinum 
refined approaches and clarified advantages of these techniques [26]. As with omental 
flap repair, discrete advantages of complete mediastinal repair with vascularized muscle 
flaps were demonstrated as compared with closed chest irrigation [26, 79]. Milano et al 
compared omental and pectoralis muscle flap repairs for the infected mediastinum and 
found that procedural details, early complications, and hospital length of stay were all 
improved with omental flap repair [80]. Omental flap repair also trended towards 
improved survival and reduced chronic pain when compared with pectoralis flap 
procedures [80]. In fact, significant long-term complications can be associated with muscle 
flap repair of the mediastinum including paresthesias, sternal instability, truncal 
weakness, and prolonged pain syndromes [9, 26, 81, 82]. Reporting on the long term 
results of muscle flap coverage of the mediastinum, Ringelman noted persistent pain in 
over 50% of patients, numbness and paresthesias in 44%, sternal instability in over 40%, 
and shoulder weakness in 1/3 of patients [82]. It is worth noting, however, that 
unfavorable outcomes with open packing and/or mediastinal irrigation prompted 
recommendations for aggressive mediastinal debridement including radical sternectomy 
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[78, 83]. While effective in removing devitalized and infected tissue, the resulting sternal 
defect required large-volume vascularized tissue such as muscle flaps or large omental 
flaps to obliterate deadspace. As a result, many of the negative long-term consequences 
often experienced and attributed to muscle flap repair may actually have originated with 
radical sternal debridement. After the introduction of NPT management of mediastinal 
sepsis/infection, radical sternal debridement has been de-emphasized [14, 16, 83, 84]. 
Stated differently, the use of NPT to treat the infected mediastinum helps to avoid radical 
sternal debridement and likely avoids chronic syndromes previously seen and perhaps 
erroneously attributed to treatment methods.  
Obdeijn et al introduced the use of negative pressure therapy (NPT) for treatment of the 
infected mediastinum after median sternotomy [68]. The introduction of vacuum-assisted 
closure (VAC®) technology [Kinetic Concepts Inc. USA San Antonio, TX], based on the 
application of negative or subatmospheric pressure to the wound, has improved 
management of DSWI, as demonstrated by several groups including our own, and is now 
considered a cornerstone in the management of these complex clinical scenarios [14, 15, 70, 
73]. Negative pressure therapy appears to induce effective proliferation of the effectors of 
wound healing [85] removes wound exudates, improves regional blood flow [86], and 
reduces accumulation of inflammatory mediators such that earlier and more complete 
wound healing results [70]. Laboratory studies also show that NPT induces early wound 
healing through microdeformations within the wound, stimulating cell division, 
proliferation, and angiogenesis [73, 87]. One distinct advantage of the mechanisms of NPT is 
more thorough eradication of infection, stimulation of vigorous wound granulation, and the 
subsequent promotion of safe and effective sternal closure either primarily or with rigid 
osteosynthesis [11, 14, 88]. Wound treatment with NPT appears to be significantly lower 
rates of recurrent wound complications such as reinfection, seromas, or hematomas [14, 89, 
90]. However, there is a recognized tendency for recurrent infection when MRSA is the 
inciting organism or with prolonged mechanical ventilation [91].  
Clinically, NPT has been associated with significantly lower mortality rates in the acute 
management of mediastinitis [11, 89]. For instance, Petzina et al recently compared 118 
patients with poststernotomy DSWI and demonstrated that patients treated with NPT had 
better survival and less sternal re-infection compared with patients in whom NPT was not 
used [89]. In addition, as may have been expected, shorter hospital stays were noted within 
the NPT group. Baillot et al reported similar results by, while documenting a reduction in 
acute DSWI mortality from 14.1% to less than 5% when NPT was incorporated into 
treatment regimens [11]. Finally, De Feo et al evaluated 157 patients with poststernotomy 
DSWI at a single institution over 15 years. Patients in whom NPT was incorporated in the 
treatment regimen had reduced early mortality rates and, reduced reinfection rates, and 
slightly reduced overall hospital stays [92].  
As noted previously, long term mortality among patients with DSWI has been historically 
poor compared with similar patients not suffering the complication, but recent evidence 
suggests this may be changing. The first evidence for this phenomenon was reported by 
Sjogren et al, who compared 46 patients with poststernotomy mediastinitis managed with 
NPT with a matched cohort of cardiac surgical patients not experiencing postoperative 
mediastinitis [93]. Actuarial and adjusted 5-year survival was not different between groups, 
demonstrating for the first time that long-term results of heart surgery were not negatively 
impacted by DSWI [Figure 3].  
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Fig. 3. Actuarial (panel A) and adjusted (panel B) survival curves for patients with 
poststernotomy mediastinitis treated with vacuum-assisted closure (VAC) as compared to 
control subjects who did not experience mediastinitis after heart surgery. No difference in 
long-term survival was demonstrated between the groups. From Sjogren et al [93], with 
permission. 
Another study from the UK demonstrated that midterm survival for patients with 
postoperative mediastinitis was similar to patients not suffering the complication [51]. 
Similar results have been reported by Cayci et al from Columbia University, who found 
that DSWI was associated with increased early mortality but long-term survival was not 
different from controls. Furthermore, DSWI was not an independent predictor of 
mortality in their single-center experience [52]. It is unclear as to why this may be the 
case, but it is notable that NPT was used in over 80% of patients with mediastinitis as a 
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[78, 83]. While effective in removing devitalized and infected tissue, the resulting sternal 
defect required large-volume vascularized tissue such as muscle flaps or large omental 
flaps to obliterate deadspace. As a result, many of the negative long-term consequences 
often experienced and attributed to muscle flap repair may actually have originated with 
radical sternal debridement. After the introduction of NPT management of mediastinal 
sepsis/infection, radical sternal debridement has been de-emphasized [14, 16, 83, 84]. 
Stated differently, the use of NPT to treat the infected mediastinum helps to avoid radical 
sternal debridement and likely avoids chronic syndromes previously seen and perhaps 
erroneously attributed to treatment methods.  
Obdeijn et al introduced the use of negative pressure therapy (NPT) for treatment of the 
infected mediastinum after median sternotomy [68]. The introduction of vacuum-assisted 
closure (VAC®) technology [Kinetic Concepts Inc. USA San Antonio, TX], based on the 
application of negative or subatmospheric pressure to the wound, has improved 
management of DSWI, as demonstrated by several groups including our own, and is now 
considered a cornerstone in the management of these complex clinical scenarios [14, 15, 70, 
73]. Negative pressure therapy appears to induce effective proliferation of the effectors of 
wound healing [85] removes wound exudates, improves regional blood flow [86], and 
reduces accumulation of inflammatory mediators such that earlier and more complete 
wound healing results [70]. Laboratory studies also show that NPT induces early wound 
healing through microdeformations within the wound, stimulating cell division, 
proliferation, and angiogenesis [73, 87]. One distinct advantage of the mechanisms of NPT is 
more thorough eradication of infection, stimulation of vigorous wound granulation, and the 
subsequent promotion of safe and effective sternal closure either primarily or with rigid 
osteosynthesis [11, 14, 88]. Wound treatment with NPT appears to be significantly lower 
rates of recurrent wound complications such as reinfection, seromas, or hematomas [14, 89, 
90]. However, there is a recognized tendency for recurrent infection when MRSA is the 
inciting organism or with prolonged mechanical ventilation [91].  
Clinically, NPT has been associated with significantly lower mortality rates in the acute 
management of mediastinitis [11, 89]. For instance, Petzina et al recently compared 118 
patients with poststernotomy DSWI and demonstrated that patients treated with NPT had 
better survival and less sternal re-infection compared with patients in whom NPT was not 
used [89]. In addition, as may have been expected, shorter hospital stays were noted within 
the NPT group. Baillot et al reported similar results by, while documenting a reduction in 
acute DSWI mortality from 14.1% to less than 5% when NPT was incorporated into 
treatment regimens [11]. Finally, De Feo et al evaluated 157 patients with poststernotomy 
DSWI at a single institution over 15 years. Patients in whom NPT was incorporated in the 
treatment regimen had reduced early mortality rates and, reduced reinfection rates, and 
slightly reduced overall hospital stays [92].  
As noted previously, long term mortality among patients with DSWI has been historically 
poor compared with similar patients not suffering the complication, but recent evidence 
suggests this may be changing. The first evidence for this phenomenon was reported by 
Sjogren et al, who compared 46 patients with poststernotomy mediastinitis managed with 
NPT with a matched cohort of cardiac surgical patients not experiencing postoperative 
mediastinitis [93]. Actuarial and adjusted 5-year survival was not different between groups, 
demonstrating for the first time that long-term results of heart surgery were not negatively 
impacted by DSWI [Figure 3].  
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Fig. 3. Actuarial (panel A) and adjusted (panel B) survival curves for patients with 
poststernotomy mediastinitis treated with vacuum-assisted closure (VAC) as compared to 
control subjects who did not experience mediastinitis after heart surgery. No difference in 
long-term survival was demonstrated between the groups. From Sjogren et al [93], with 
permission. 
Another study from the UK demonstrated that midterm survival for patients with 
postoperative mediastinitis was similar to patients not suffering the complication [51]. 
Similar results have been reported by Cayci et al from Columbia University, who found 
that DSWI was associated with increased early mortality but long-term survival was not 
different from controls. Furthermore, DSWI was not an independent predictor of 
mortality in their single-center experience [52]. It is unclear as to why this may be the 
case, but it is notable that NPT was used in over 80% of patients with mediastinitis as a 
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means for clearing infection, and nearly 50% of patients in their cohort were managed 
with vac therapy alone or vac + secondary sternal closure. In our own series, we found 
that use of NPT for controlling mediastinal infection was an independent predictor of 
survival on multivariable analysis [unpublished data], and that patients managed with 
NPT had significantly improved long term survival compared with patients not treated 





Fig. 4. Kaplan Meier survival curves for patients with poststernotomy mediastinitis treated 
with negative pressure therapy (NPT) or by traditional means for controlling mediastinal 
infection (controls). Patients treated with NPT had significantly improved long-term 
survival by log rank analysis. 
11. Suggested treatment algorithms for DSWI 
While accumulating extensive experience with DSWI management as a referral center for 
these difficult problems. We and others have formalized protocols for managing mediastinal 
infection utilizing NPT which allows sternal salvage and improved outcomes in the majority 
of cases of DSWI [14-16, Figure 5].  
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Fig. 5. Suggested algorithm for management of mediastinal infection after cardiac surgery 
via median sternotomy, with permission from Sjogren et al [15]. Emphasis is placed on 
gentle sternal debridement, negative pressure therapy to the mediastinum, and closure 
based on monitored serum C-reactive protein levels. 
As noted previously, successful treatment of DSWI begins with recognition of signs and 
symptoms of sternal infection, which may occasionally be subtle. Sternal wound exploration 
to ensure a prompt and accurate diagnosis is warranted when signs of mediastinitis are 
present. This approach also helps to distinguish between superficial and deep sternal 
infections. At the time of initial sternal exploration, tissues and fluid should be obtained for 
bacteriologic analysis. Targeted antibiotic therapy for 4-6 weeks duration is prescribed and 
is determined by the culture results [14, 15]. If the infectious process extends beneath the 
facial layer, all sternal hardware should be removed. The sternum itself is then gently 
debrided of grossly devitalized tissue, but wide excision of the sternum is not necessary and 
may be injurious and counterproductive. Limited sternal debridement is now preferred and 
good results have been seen with this approach [14, 16, 83, 93, 94]. Negative pressure 
therapy is then instituted on the opened incision after limited sternal debridement. The 
polyurethane foam is subsequently changed in the operating room or at the bedside every 2-
3 days. During this time, assessment as to the state of the sternum is made to determine if 
mediastinal flap repair is required or if secondary sternal closure is possible. Our general 
approach for determining when the sternum can reliably be reapproximated is based on the 
state of the sternum after several days of NPT. Wound characteristics precluding secondary 
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sternal reapproximation include multiple transverse sternal fractures, poor bone stock, 
costosternal separation, or the requirement for such extensive sternal debridement that 
reapproximation of the sternal halves is not feasible. Gustafsson en et al have advocated use 
of serum C-reactive protein levels to guide wound closure timing [95, Figure 6]. C-reactive 
protein levels less than 70 mg/L corresponded with successful sternal reapproximation [95]. 
Successes have also been reported with sternal plating as a treatment for the fractured 
sternum [11, 96], but our approach has been conservative in this regard since any residual 
infectious process could contaminate the implanted hardware [91].  
Numerous clinical advantages for DSWI management protocols incorporating NPT have 
been observed, many centered upon the sternal stabilization achieved when vacuum-
assisted clousure is engaged [70]. The sternal stability afforded by NPT improves pain 
compared with open packing or other approaches for addressing the infected mediastinum 
[88]. In addition, the stabilized sternum yields several pulmonary benefits, the first of which 
is the ability to successfully separate from mechanical ventilation. This promotes earlier and 
more effective patient mobilization and prevents the patient from being confined to bed, 
where other complications common to DSWI therapy are often incurred [70]. Negative 
pressure therapy also improves ventilation and overall pulmonary function and leads to 
more effective chest physiotherapy [70, 97]. Importantly, no deleterious hemodynamic 
effects of NPT have been documented although this has been speculated [70].  
12. Complications of treating mediastinitis 
It has been estimated that approximately 15% of patients develop recurrent infection [98]. 
In the experience of Bapat et al, this has included recurrent infection with the same 
organism associated with the original sternal infection [99], and we speculate that if the 
polyurethane foam required for NPT is not adequately inserted with each dressing 
change, small, isolated spaces may arise within the wound that can become superinfected. 
We recently reported rates of recurrent wound complications associated with various 
mediastinal flap coverages. For example, muscle flap repair of the treated mediastinum, 
consisting predominantly of pectoralis muscle flaps, was associated with increased rates 
of recurrent wound complications such as hematoma, seromas, and recurrent infection 
[14]. Conversely, use of NPT prior to definitive repair of the sternal wound defect was 
associated with increased rates of successful secondary sternal closure without the need 
for any flap transfer, and with shortened length of hospital stay after definitive repair. 
Excellent results have been reported elsewhere when NPT is incorporated into 
management protocols for DSWI [65]. 
Petzina et al recently reported a 7.2% rate of “major complications” associated with NPT for 
DSWI in a cohort of 69 patients. Most complications were bleeding-related [100]. On the 
other hand, cardiac function and hemodynamics appear to be stable during NPT to the open 
mediastinal wound [101, 102]. 
When NPT is used, caution should be exercised with regard to the length of therapy. In our 
own experience, prolonged use of NPT leads to a “frozen” mediastinum, making 
subsequent closure by vascularized flaps or other technique difficult to perform and places 
the cardiac structures at risk for injury during subsequent sternal repair. Others have noted 
the similar difficultiess [99]. In such cases, continued application of NPT to closure by 
secondary intent may be the best therapeutic option rather than to place the mediastinal 
structures at risk for injury during attempted flap repair. 
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13. Can mediastinitis be prevented? 
Loop has stated: “prevention and better treatment of sternal wound complications must be a 
major goal in assuring the highest quality of cardiovascular care…[5]. Although most efforts 
towards DSWI have focused on the treatment of DSWI, several methods to reduce rates of 
mediastinitis have been proposed and validated recently. As a result, efforts to prevent 
mediastinal infection may already be working. For instance, investigators from Boston 
recently reported on their experience with DSWI between 1992 and 2006, separating analysis 
into early and late time periods. They noted that DSWI had decreased from 1.57% to 0.88% 
over the last 5 years of their analysis and attributed the positive findings to adoption of strict 
glucose control algorithms [40]. Tight glycemic control appears to be effective in 
significantly reducing rates of DSWI. [30, 103]. In addition, Lazar et al demonstrated 
improved coronary surgery outcomes with a strategy for strict glucose control (125 – 200 
mg/dL) using glucose-insulin-potassium solution, including reduced ischemic events and 
improved rates of wound infection in a cohort of diabetic patients undergoing CABG [31]. 
Antimicrobial therapy has also positively impacted rates of DSWI. Most notably, 
appropriate timing and selection of preoperative antibiotics has been associated with 
reduced rates of sugical site infection [6, 104]. Furthermore, use of nasal mupirocin in 
patients undergoing cardiac surgery via median sternotomy eradicates 95 – 100% of S. 
aureus for up to one year postoperatively [105], and sternal wound infections are also 
reduced by nearly 2/3 in some series with the use of mupirocin in patients colonized with S. 
aureus [106, 107]. 
Technical details of the median sternotomy incision and closure almost certainly impact the 
likelihood for DSWI postoperatively. Baskett et al have argued that assiduously following 
technical details and proper surgical and aseptic techniques can also dramatically reduce 
rates of poststernotomy infection [42]. They emphasize the importance of accurate 
reapproximation of the sternal halves and caution against the use of bone wax to gain 
sternal hemostasis [42]. Since sternal instability is often evoked as one mechanism 
contributing to the development of sternal infection, evaluation of the most effective sternal 
closure methods has been undertaken. For example, Schimmer et al compared standard 
closure techniques by transsternal or peristernal wiring with techniques using additional 
lateral wire reinforcement in the method described by Robicsek in a cohort of 815 high-risk 
patients [108]. There were no differences observed in the rates of sternal dehiscence or 
superficial or deep sternal wound infections, but they did show that more sternal wires 
placed for closure was associated with significantly reduced rates of DSWI [108]. Others 
have emphasized that rigid sternal closure techniques are preferred, particularly in those 
considered at high risk for sternal wound complications such as dehiscence and infection. 
These techniques are widely used in most surgical practices that incorporate osteotomy 
incisions. In fact, cardiac surgery is now the only discipline not routinely repairing 
osteotomies with rigid plating techniques [109]. Lee et al recently reported their experience 
with titanium plate fixation of the sternum in 750 patients at high risk for sternal wound 
complications, noting 97.6% freedom from sternal infection or dehiscence [110]. Levin et al 
have also introduced another form of rigid sternal closure as an alterntive to wire circlage 
and highlighted advantages to this approach [111]. Although rigid sternal closure 
techniques have not been compared prospectively with wire circlage, cadaveric studies have 
shown rigid plate fixation techniques to be superior to wire circlage by providing increased 
stiffness to the wound closure and less lateral displacement of the sternal halves [112]. 
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Other suggested techniques for reducing the incidence of DSWI include ensuring true 
midline sternotomy as this is thought to preserve periosteal blood flow and limits 
transverse sternal fractures which contribute to sternal nonunionn and instability [42, 44]. 
Since sternal ischemia is thought to play an important role in most cases of DSWI, limiting 
the length of internal mammary artery harvested for use as a coronary artery bypass 
conduit or avoiding its use altogether in prohibitively high risk patients may help to 
reduce DSWI [44]. Harvesting the internal mammary artery as a skeletonized conduit is 
also preferable to harvesting the graft as a pedicle since this preserves more peristernal 
blood flow [113]. Finally, sternal foreign bodies that may impede bony union, especially 
bone wax, should be avoided [42, 44]. In contrast, vancomycin paste or gentamicin-soaked 
absorbable sponges applied to the sternum upon closure have been shown to reduce rates 
of sternal bacterial contamination [114, 115]. However a more recent randomized 
controlled trial evaluating the impact of gentamicin-soaked collagen sponge on 
poststernotomy wound infection did not show an advantage of this approach over 
controls [116]. 
Based on the aforementioned successes with NPT in the treatment of documented DSWI we 
and others have recently evaluated the application of NPT to clean, closed incisions as a 
method to prevent complications in high-risk wounds [117, 118]. We initially applied this 
form of “well wound therapy” in a cohort of 57 adult cardiac surgery patients known to be 
at increased risk for DSWI based on a validated risk stratification model [13]. No cases of 
superficial or deep sternal wound infections were noted although the group had an 
estimated 6% risk for DSWI [118]. This form of NPT was noted to be easy to apply, well-
tolerated by the patients, and was also judged to be cost-effective when utilized in patients 
with increased demonstrated risk for DSWI [117]. Since the time of the original report, we 
have used this novel wound treatment system in over 200 high risk patients and continue to 
observe reduce rates of sternal wound complications (unpublished data). However, residual 
problems have been encountered with gross technical errors including off-center sternal 
incisions, sternal fractures, and costo-sternal separation.  
The mechanisms underlying such positive clinical findings are not well understood, but 
based on well described mechanisms of vacuum-assisted therapy in open incisions, it is 
hypothesized that applying NPT to the closed incision also favorably affects wound 
perfusion. Therefore, we assessed peristernal perfusion after median sternotomy and under 
various degrees of reduced native sternal perfusion as a result of mammary artery 
harvesting using laser Doppler flowmetry, demonstrating that after median sternotomy and 
IMA harvesting, peristernal perfusion is significantly reduced and recovers little in the first 
4 postoperative days [119]. However, NPT applied to the closed incision increases 
peristernal perfusion compared with controls regardless of the status of the ipsilateral IMA, 
providing a rare piece of physiologic evidence for the efficacy of NPT and supports use of 
NPT as a form of “well wound therapy,” particularly in patients at high-risk for sternotomy 
complications [119] These findings are clinically important and relevant, implying that NPT 
can augment peristernal soft tissue perfusion made relatively ischemic by IMA harvesting. 
Although this study does not address bony perfusion, per se, Fokin et al proposed that 
substrate diffusion through peristernal tissues may be an important mechanism to maintain 
perfusion in sternal wounds rendered ischemic by mammary artery harvesting until 
collateral blood supply to the sternum is well-established [120, 121]. If so, NPT may indeed 
augment sternal and/or periosteal perfusion via improved peristernal “diffusion” through 
improved soft tissue perfusion. 
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14. Conclusions 
Deep sternal wound infections remain dreaded and deadly complications associated with 
cardiac surgery. However, incremental improvements have been made recently with regard 
to lowering rates of observed infections due to a variety of measures. In addition, it appears 
that management of DSWI with negative pressure therapy alleviates the impact of this 
condition on short- and long-term survival. Further investigation is needed to determine the 
potential impact of negative pressure therapy on closed incisions as a novel method to 
prevent sternal wound complications. 
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